# ::tok Results
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 0-1.1 0-1.1.r
# ::id pmid_1177_7939.30
# ::preferred 
(t2 / thing~e.0
      :ARG2-of~e.0 (r / result-01~e.0))

# ::tok The S/E/E8 complex exists under physiological conditions
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1 3-1 5-1.2 6-1.2.r
# ::id pmid_1177_7939.31
# ::preferred 
(e / exist-01~e.3
      :ARG1 (m / macro-molecular-complex~e.2
            :part (s / slash
                  :op1 (p / protein
                        :name (n / name :op1 "S"))
                  :op2 (p2 / protein
                        :name (n2 / name :op1 "E"))
                  :op2 (e2 / enzyme
                        :name (n3 / name :op1 "E8"))))
      :condition~e.6 (p4 / physiology~e.5))

# ::tok In previous studies , we showed that Sos @-@ 1 , E3b1 , and Eps8 could form a trimeric complex in vivo upon concomitant overexpression of the three proteins .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.4 1-1.3.1 2-1.3 4-1.1 5-1 7-1.2.1.1.1.1 9-1.2.1.1.1.1 11-1.2.1.2.1.1 13-1.2.1 14-1.2.1.3.1.1 15-1.2.3 16-1.2 18-1.2.2.1 19-1.2.2 20-1.2.4 21-1.2.4 23-1.2.5.2 28-1.2.5.1
# ::id pmid_1177_7939.32
# ::preferred 
(s / show-01~e.5
      :ARG0 (w / we~e.4)
      :ARG1 (f / form-01~e.16
            :ARG0 (a / and~e.13
                  :op1 (p2 / protein
                        :name (n / name :op1 "Sos-1"~e.7,9))
                  :op2 (p3 / protein
                        :name (n2 / name :op1 "E3b1"~e.11))
                  :op3 (e2 / enzyme
                        :name (n3 / name :op1 "Eps8"~e.14)))
            :ARG1 (m / macro-molecular-complex~e.19
                  :mod (t / trimeric~e.18))
            :mod (p / possible~e.15)
            :manner (i / in-vivo~e.0,20,21)
            :condition (o / overexpress-00
                  :ARG2 a~e.28
                  :manner (c / concomitant~e.23)))
      :medium (s2 / study~e.2
            :time (p5 / previous~e.1)))

# ::tok However , we failed to detect the existence of an endogenous S/E/E8 complex ( <xref ref-type="bibr" rid="bib40"> Scita et al. , 1999 </xref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 2-1.1.1 3-1.1 5-1.1.2 7-1.1.2.2 8-1.1.2.2.1.r 10-1.1.2.2.1.1 12-1.1.2.2.1 17-1.2.1.1.1.1.1 18-1.2.1.1 19-1.2.1.1.2.1 21-1.2.1.2.1
# ::id pmid_1177_7939.33
# ::preferred 
(c / contrast-01~e.0
      :ARG2 (f / fail-01~e.3
            :ARG1 (w / we~e.2)
            :ARG2 (d / detect-01~e.5
                  :ARG0 w
                  :ARG1 (e / exist-01~e.7
                        :ARG1~e.8 (m / macro-molecular-complex~e.12
                              :mod (e2 / endogenous~e.10)
                              :part (s / slash
                                    :op1 (p / protein
                                          :name (n / name :op1 "S"))
                                    :op2 (p2 / protein
                                          :name (n2 / name :op1 "E"))
                                    :op3 (e3 / enzyme
                                          :name (n3 / name :op1 "E8")))))))
      :ARG1-of (d2 / describe-01
            :ARG0 (p4 / publication-91
                  :ARG0 (a / and~e.18
                        :op1 (p5 / person
                              :name (n4 / name :op1 "Scita"~e.17))
                        :op2 (p6 / person
                              :mod (o / other~e.19)))
                  :time (d3 / date-entity :year "1999"~e.21))))

# ::tok We reasoned that this could be due to the low efficiency of the immunoprecipitating antibodies used .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1 2-1.2.r 3-1.2.1.2 4-1.2 5-1.2.1.r 6-1.2.1 7-1.2.1 9-1.2.1.1.2 10-1.2.1.1 14-1.2.1.1.1 15-1.2.1.1.1.1
# ::id pmid_1177_7939.34
# ::preferred 
(r / reason-01~e.1
      :ARG0 (w / we~e.0)
      :ARG1~e.2 (p2 / possible~e.4
            :domain~e.5 (c / cause-01~e.6,7
                  :ARG0 (e / efficient-01~e.10
                        :ARG1 (a / antibody~e.14
                              :ARG1-of (u / use-01~e.15
                                    :ARG2 (i2 / immunoprecipitate-00)))
                        :ARG1-of (l / low-04~e.9))
                  :ARG1 (t / this~e.3))))

# ::tok We thus sought to exploit the availability of eps8 @<sup> −/− </sup> fibroblasts to circumvent this problem .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1.3 2-1 3-1.3 4-1.2 6-1.2.2 7-1.2.2.1.r 8-1.2.2.1.1.1.1.1 10-1.2.2.1.1.1.2.1 12-1.2.2.1 14-1.2.3 15-1.2.3.2.1 16-1.2.3.2
# ::id pmid_1177_7939.35
# ::preferred 
(s / seek-01~e.2
      :ARG0 (w / we~e.0)
      :ARG1 (e / exploit-01~e.4
            :ARG0 w
            :ARG1 (a / available~e.6
                  :domain~e.7 (f2 / fibroblast~e.12
                        :ARG0-of (c3 / contain-01
                              :ARG1 (e2 / enzyme
                                    :name (n2 / name :op1 "eps8"~e.8)
                                    :ARG2-of (m / mutate-01 :mod "−/−"~e.10)))))
            :purpose (c2 / circumvent-01~e.14
                  :ARG0 w
                  :ARG1 (p / problem~e.16
                        :mod (t / this~e.15))))
      :ARG0-of (c / cause-01~e.1,3))

# ::tok To this end , we performed immunoprecipitation experiments using eps8 @<sup> −/− </sup> fibroblasts in which the expression of Eps8 was restored , to physiological levels , with an expression vector encoding a myc epitope @-@ tagged Eps8 (−/− [Eps8 myc] cells ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3 4-1.1 5-1 7-1.2 8-1.3.r 9-1.2.1.1.1.1.1.1.1 9-1.2.1.1.2.1.1.1 11-1.2.1.1.2.1.2.1 13-1.2.1.1 17-1.2.1.1.1.1 18-1.2.1.1.1.1.1.r 19-1.2.1.1.1.1.1.1.1 21-1.2.1.1.1 23-1.2.1.1.1.2.r 24-1.2.1.1.1.2.1 25-1.2.1.1.1.2 27-1.2.1.1.1.3.r 29-1.2.1.1.1.3.2 30-1.2.1.1.1.3 31-1.2.1.1.1.3.1 33-1.2.1.1.1.3.1.1.2.1.1.1 34-1.2.1.1.1.3.1.1.2.1 36-1.2.1.1.1.3.1.1.2 37-1.2.1.1.1.3.1.1.1.1 37-1.2.1.1.2.1.1.1
# ::id pmid_1177_7939.36
# ::preferred 
(p / perform-01~e.5
      :ARG0 (w / we~e.4)
      :ARG1 (e / experiment-01~e.7
            :ARG2 (i / immunoprecipitate-00
                  :ARG2 (f / fibroblast~e.13
                        :location-of (r / restore-01~e.21
                              :ARG1 (e2 / express-03~e.17
                                    :ARG2~e.18 (e4 / enzyme
                                          :name (n2 / name :op1 "Eps8"~e.9,19)))
                              :ARG2~e.23 (l / level~e.25
                                    :mod (p3 / physiology~e.24))
                              :instrument~e.27 (v / vector~e.30
                                    :ARG0-of (e3 / encode-01~e.31
                                          :ARG1 (e6 / enzyme
                                                :name (n / name :op1 "Eps8"~e.37)
                                                :ARG1-of (t2 / tag-01~e.36
                                                      :ARG2 (e7 / epitope~e.34
                                                            :name (n3 / name :op1 "myc"~e.33)))))
                                    :ARG2-of (e8 / express-03~e.29)))
                        :ARG0-of (c2 / contain-01
                              :ARG1 (e5 / enzyme
                                    :name (n4 / name :op1 "eps8"~e.9,37)
                                    :ARG2-of (m / mutate-01 :mod "−/−"~e.11))))))
      :purpose~e.8 (t / this~e.1))

# ::tok We selected transfected clones in which the levels of expression of Eps8 myc were very similar to those present in wild @-@ type fibroblasts ( <xref ref-type="fig" rid="fig1"> Fig . 1 </xref> A ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1 2-1.2.1 3-1.2 7-1.2.2.2 7-1.2.2.2.1.1 9-1.2.2 14-1.2.2.2.1.2 15-1.2.2.2.1 19-1.2.2.2.1.1.1.r 20-1.2.2.2.1.1.1.1 22-1.2.2.2.1.1.1.1 23-1.2.2.2.1.1.1
# ::id pmid_1177_7939.37
# ::preferred 
(s / select-01~e.1
      :ARG0 (w / we~e.0)
      :ARG1 (c / clone~e.3
            :ARG1-of (t / transfect-00~e.2)
            :ARG3-of (e / express-03~e.9
                  :ARG2 (e2 / enzyme
                        :name (n2 / name :op1 "Eps8myc"))
                  :degree (l / level~e.7
                        :ARG1-of (r / resemble-01~e.15
                              :ARG2 (l2 / level~e.7
                                    :location~e.19 (f / fibroblast~e.23
                                          :mod (w2 / wild-type~e.20,22)))
                              :degree (v / very~e.14)))
                  :ARG1-of (d / describe-01
                        :ARG0 (f2 / figure :mod "1A")))))

# ::tok Endogenous Sos @-@ 1 and E3b1 could be detected in anti @-@ myc immunoprecipitates from lysates of Eps8 myc @-@ reconstituted , but not from eps8 @<sup> −/− </sup> fibroblasts ( <xref ref-type="fig" rid="fig1"> Fig . 1 </xref> B ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.3 1-1.1.1.1.1.1 3-1.1.1.1.1.1 4-1.1.1 5-1.1.1.2.1.1 6-1 7-1.1.r 8-1.1 8-1.1.2.1 9-1.1.3.r 10-1.1.3.1.2 12-1.1.3.1.2.1.1.1 14-1.1.3.1.1.1.r 16-1.1.2.1.3.r 16-1.1.2.r 17-1.1.2.1.3.1.1.1.1.1.1 18-1.1.3.1.2.1.1.1 20-1.1.3.1.1.1.1.1.2 22-1.1.2 23-1.1.2.1.1 23-1.1.2.1.1.r 24-1.1.3.1.1.1.r 25-1.1.2.1.3.1.1.1.1.1.1 27-1.1.2.1.3.1.1.1.1.2.1 29-1.1.2.1.3.1.1 29-1.1.3.1.1.1 36-1.1.1.1.1.1
# ::id pmid_1177_7939.38
# ::preferred 
(p / possible~e.6
      :domain~e.7 (d / detect-01~e.8
            :ARG1 (a / and~e.4
                  :op1 (p3 / protein
                        :name (n / name :op1 "Sos-1"~e.1,3,36))
                  :op2 (p4 / protein
                        :name (n2 / name :op1 "E3b1"~e.5))
                  :mod (e / endogenous~e.0))
            :ARG1-of~e.16 (c4 / contrast-01~e.22
                  :ARG2 (d2 / detect-01~e.8
                        :polarity~e.23 "-"~e.23
                        :ARG1 a
                        :location~e.16 (p6 / protein
                              :ARG1-of (i / immunoprecipitate-00
                                    :ARG2 (f / fibroblast~e.29
                                          :ARG0-of (c2 / contain-01
                                                :ARG1 (e3 / enzyme
                                                      :name (n4 / name :op1 "eps8"~e.17,25)
                                                      :ARG2-of (m / mutate-01 :mod "−/−"~e.27))))))))
            :location~e.9 (p5 / protein
                  :ARG1-of (i3 / immunoprecipitate-00
                        :ARG2 (l / lysate
                              :source~e.14,24 (f3 / fibroblast~e.29
                                    :ARG0-of (c5 / contain-01
                                          :ARG1 (e2 / enzyme
                                                :name (n7 / name :op1 "Eps8myc")
                                                :ARG1-of (r / reconstitute-01~e.20)))))
                        :ARG0-of (c / counter-01~e.10
                              :ARG1 (p2 / protein
                                    :name (n3 / name :op1 "myc"~e.12,18))))))
      :ARG1-of (d3 / describe-01
            :ARG0 (f2 / figure :mod "1B")))

# ::tok To determine whether E3b1 mediates the interaction between Eps8 and Sos @-@ 1 , as it would be expected according to the tricomplex model , we performed coimmunoprecipitation experiments under conditions in which the association between Eps8 and E3b1 was disrupted .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3 3-1.3.2.1 4-1.3.2 6-1.3.2.2 8-1.3.2.2.1 10-1.3.2.2.2.1.1 12-1.3.2.2.2.1.1 18-1.3.2.3 19-1.3.2.3.1 20-1.3.2.3.1 22-1.3.2.3.1.1.1 23-1.3.2.3.1.1 25-1.1 26-1 28-1.2 30-1.2.2.r 34-1.2.2.1 36-1.2.2.1.1.1.1 38-1.2.2.1.2.1.1 40-1.2.2
# ::id pmid_1177_7939.39
# ::preferred 
(p / perform-01~e.26
      :ARG0 (w / we~e.25)
      :ARG1 (e / experiment-01~e.28
            :ARG2 (c / coimmunoprecipitate-00)
            :condition~e.30 (d / disrupt-01~e.40
                  :ARG1 (a / associate-01~e.34
                        :ARG1 (e3 / enzyme
                              :name (n / name :op1 "Eps8"~e.36))
                        :ARG2 (p3 / protein
                              :name (n2 / name :op1 "E3b1"~e.38)))))
      :purpose (d2 / determine-01~e.1
            :ARG0 w
            :ARG1 (m / mediate-01~e.4
                  :ARG0 p3~e.3
                  :ARG1 (i / interact-01~e.6
                        :ARG0 e3~e.8
                        :ARG1 (p4 / protein
                              :name (n3 / name :op1 "Sos-1"~e.10,12)))
                  :ARG1-of (e2 / expect-01~e.18
                        :ARG1-of (s / say-01~e.19,20
                              :ARG0 (m2 / model~e.23
                                    :mod (t / tricomplex~e.22)))))))

# ::tok The binding site of E3b1 to the SH3 domain of Eps8 was previously mapped to the amino acid sequence , PPPPPVDYTEDEE , where the D and the Y residues are critical for efficient binding ( <xref ref-type="bibr" rid="bib28"> Mongiovi et al. , 1999 </xref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.2 2-1.1 3-1.1.1.r 4-1.1.1.1.1 5-1.1.2.1.r 7-1.1.2.1.1.1 8-1.1.2.1.1.2 10-1.1.2.1.2.1.1 13-1 14-1.2.r 16-1.2.3 17-1.2.3 18-1.2 20-1.2.1.1 24-1.2.2.1.1.1.1.1 25-1.2.2.1 27-1.2.2.1.2.1.1.1 28-1.2.2.1.1 28-1.2.2.1.2 30-1.2.2.1.3 31-1.2.2.1.3.1.r 32-1.2.2.1.3.1 33-1.2.2.1.3.1.1 38-1.3.1.1.1.1.1 39-1.3.1.1 40-1.3.1.1.2.1 42-1.3.1.2.1
# ::id pmid_1177_7939.40
# ::preferred 
(m / map-02~e.13
      :ARG1 (p / protein-segment~e.2
            :part-of~e.3 (p3 / protein
                  :name (n8 / name :op1 "E3b1"~e.4))
            :ARG1-of (b / bind-01~e.1
                  :ARG2~e.5 (p2 / protein-segment
                        :name (n2 / name :op1 "SH3"~e.7 :op2 "domain"~e.8)
                        :part-of (e / enzyme
                              :name (n3 / name :op1 "Eps8"~e.10)))))
      :ARG2~e.14 (s3 / sequence~e.18
            :name (n / name :op1 "PPPPPVDYTEDEE"~e.20)
            :ARG2-of (i / include-91
                  :ARG1 (a2 / and~e.25
                        :op1 (r3 / residue~e.28
                              :mod (a4 / amino-acid
                                    :name (n5 / name :op1 "D"~e.24)))
                        :op2 (r / residue~e.28
                              :mod (a5 / amino-acid
                                    :name (n6 / name :op1 "Y"~e.27)))
                        :mod (c / critical~e.30
                              :topic~e.31 (e2 / efficient-01~e.32
                                    :ARG2 b~e.33))))
            :mod (a / amino-acid~e.16,17))
      :ARG1-of (d / describe-01
            :ARG0 (p4 / publication-91
                  :ARG0 (a3 / and~e.39
                        :op1 (p5 / person
                              :name (n7 / name :op1 "Mongiovi"~e.38))
                        :op2 (p6 / person
                              :mod (o / other~e.40)))
                  :time (d2 / date-entity :year "1999"~e.42))))

# ::tok Thus , a peptide encompassing this region should specifically disrupt the Eps8–E3b1 association .
# ::amr-annotator SDL-AMR-09
# ::alignments 3-1.1.1.1 4-1.1.1.1.1 5-1.1.1.1.1.1.1 6-1.1.1.1.1.1 7-1.1 8-1.1.1.3 9-1.1.1 12-1.1.1.2
# ::id pmid_1177_7939.41
# ::preferred 
(i / infer-01
      :ARG1 (r / recommend-01~e.7
            :ARG1 (d / disrupt-01~e.9
                  :ARG0 (p / peptide~e.3
                        :ARG0-of (e / encompass-01~e.4
                              :ARG1 (r2 / region~e.6
                                    :mod (t / this~e.5))))
                  :ARG1 (a / associate-01~e.12
                        :ARG1 (e2 / enzyme
                              :name (n / name :op1 "Eps8"))
                        :ARG2 (p3 / protein
                              :name (n2 / name :op1 "E3b1")))
                  :manner (s / specific~e.8))))

# ::tok Indeed , no E3b1 could be recovered in anti @-@ myc immunoprecipitates from lysates of Eps8 myc @-@ reconstituted cells , when the immunoprecipitation was performed in the presence of an excess of the competing peptide .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3 2-1.1 2-1.1.r 3-1.2.1.1.1 4-1 5-1.2.r 6-1.2 7-1.2.2.r 8-1.2.2.1.2 10-1.2.2.1.2.1.1.1 12-1.2.2.1.1.1.r 16-1.2.2.1.2.1.1.1 18-1.2.2.1.1.1.1.1.2 19-1.2.2.1.1.1 24-1.2.r 25-1.4 29-1.4.2.r 31-1.4.2 32-1.4.2.1.r 34-1.4.2.1.1 35-1.4.2.1
# ::id pmid_1177_7939.42
# ::preferred 
(p / possible~e.4
      :polarity~e.2 "-"~e.2
      :domain~e.5,24 (r / recover-02~e.6
            :ARG1 (p2 / protein
                  :name (n / name :op1 "E3b1"~e.3))
            :location~e.7 (p6 / protein
                  :ARG1-of (i3 / immunoprecipitate-00
                        :ARG2 (l / lysate
                              :source~e.12 (c5 / cell~e.19
                                    :ARG0-of (c6 / contain-01
                                          :ARG1 (e2 / enzyme
                                                :name (n5 / name :op1 "Eps8myc")
                                                :ARG1-of (r2 / reconstitute-01~e.18)))))
                        :ARG0-of (c3 / counter-01~e.8
                              :ARG1 (p4 / protein
                                    :name (n4 / name :op1 "myc"~e.10,16))))))
      :mod (i2 / indeed~e.0)
      :condition (p3 / perform-01~e.25
            :ARG1 (i / immunoprecipitate-00)
            :condition~e.29 (e / exceed-01~e.31
                  :ARG0~e.32 (p5 / peptide~e.35
                        :ARG0-of (c4 / compete-01~e.34)))))

# ::tok The association was , however , preserved when a control peptide , bearing a Y→A substitution and unable to bind to Eps8 ( <xref ref-type="bibr" rid="bib28"> Mongiovi et al. , 1999 </xref> ) , was used ( <xref ref-type="fig" rid="fig1"> Fig . 1 </xref> C ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1 4-1 6-1.1 7-1.1.3.1.2.r 8-1.1.2.1.2.1.1.1.1 9-1.1.2.1.1 10-1.1.2.1 12-1.1.2.1.2 13-1.1.2.1.2.1.1.1.1 15-1.1.2.1.2.1 17-1.1.2.1.3.2 17-1.1.2.1.3.2.1 17-1.1.2.1.3.2.1.r 19-1.1.2.1.3 20-1.1.2.1.3.1.r 21-1.1.2.1.3.1.1.1 26-1.1.3.1.1.1.1.1 27-1.1.3.1.1 28-1.1.3.1.1.2.1 30-1.1.3.1.2.1 35-1.1.2
# ::id pmid_1177_7939.43
# ::preferred 
(c / contrast-01~e.4
      :ARG2 (p / preserve-01~e.6
            :ARG1 (a / associate-01~e.1)
            :condition (u / use-01~e.35
                  :ARG1 (p2 / peptide~e.10
                        :purpose (c2 / control-01~e.9)
                        :ARG0-of (b / bear-01~e.12
                              :ARG1 (s / substitute-01~e.15
                                    :ARG1 (a3 / amino-acid
                                          :name (n2 / name :op1 "A"~e.8,13))
                                    :ARG2 (a2 / amino-acid
                                          :name (n / name :op1 "Y"))))
                        :ARG1-of (b2 / bind-01~e.19
                              :ARG2~e.20 (e / enzyme
                                    :name (n3 / name :op1 "Eps8"~e.21))
                              :mod (p4 / possible~e.17 :polarity~e.17 "-"~e.17)))
                  :ARG1-of (d3 / describe-01
                        :ARG0 (f / figure :mod "1C")))
            :ARG1-of (d / describe-01
                  :ARG0 (p5 / publication-91
                        :ARG0 (a4 / and~e.27
                              :op1 (p6 / person
                                    :name (n4 / name :op1 "Mongiovi"~e.26))
                              :op2 (p7 / person
                                    :mod (o / other~e.28)))
                        :time~e.7 (d2 / date-entity :year "1999"~e.30)))))

# ::tok Similarly , no Sos @-@ 1 could be recovered in anti @-@ myc immunoprecipitates in the presence of the competing , but not of the control , peptide ( <xref ref-type="fig" rid="fig1"> Fig . 1 </xref> C ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2 2-1.1 2-1.1.r 3-1.3.1.1.1 5-1.3.1.1.1 6-1 6-1.5.1 7-1.3.r 8-1.3 9-1.3.2.r 10-1.3.2 10-1.3.2.1 10-1.3.2.1.r 12-1.3.2.1.1.1.1 19-1.6.1 21-1.5 22-1.1.r 25-1.5.1.2.1 27-1.5.1.2 27-1.6 34-1.3.1.1.1
# ::id pmid_1177_7939.44
# ::preferred 
(p / possible~e.6
      :polarity~e.2,22 "-"~e.2
      :ARG1-of (r / resemble-01~e.0)
      :domain~e.7 (r2 / recover-02~e.8
            :ARG1 (p2 / protein
                  :name (n / name :op1 "Sos-1"~e.3,5,34))
            :location~e.9 (p5 / protein~e.10
                  :ARG0-of~e.10 (c / counter-01~e.10
                        :ARG1 (p3 / protein
                              :name (n2 / name :op1 "myc"~e.12)))
                  :ARG1-of (i / immunoprecipitate-00)))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "1C"))
      :ARG1-of (c4 / contrast-01~e.21
            :ARG2 (p7 / possible~e.6
                  :domain r2
                  :condition (p6 / peptide~e.27
                        :ARG0-of (c3 / control-01~e.25))))
      :condition (p4 / peptide~e.27
            :ARG0-of (c2 / compete-01~e.19)))

# ::tok Thus , under physiological conditions , the coimmunoprecipitation of Eps8 and Sos @-@ 1 depends on the integrity of the Eps8–E3b1 interaction , pointing to the existence of a physiological S/E/E8 complex .
# ::amr-annotator SDL-AMR-09
# ::alignments 3-1.1.3 4-1.1.3.r 9-1.1.1.1.1.1.1 10-1.1.1.1 11-1.1.1.1.2.1.1 13-1.1.1.1.2.1.1 14-1.1 15-1.1.2.r 17-1.1.2 21-1.1.2.1 23-1.1.4 24-1.1.4.1.r 26-1.1.4.1 27-1.1.4.1.1.r 29-1.1.4.1.1.1 31-1.1.4.1.1
# ::id pmid_1177_7939.45
# ::preferred 
(i / infer-01
      :ARG1 (d / depend-01~e.14
            :ARG0 (c / coimmunoprecipitate-00
                  :ARG1 (a / and~e.10
                        :op1 (e2 / enzyme
                              :name (n / name :op1 "Eps8"~e.9))
                        :op2 (p3 / protein
                              :name (n2 / name :op1 "Sos-1"~e.11,13))))
            :ARG1~e.15 (i2 / integrity~e.17
                  :mod (i3 / interact-01~e.21
                        :ARG0 e2
                        :ARG1 (p4 / protein
                              :name (n3 / name :op1 "E3b1"))))
            :condition~e.4 (p / physiology~e.3)
            :ARG0-of (p2 / point-01~e.23
                  :ARG1~e.24 (e / exist-01~e.26
                        :ARG1~e.27 (m / macro-molecular-complex~e.31
                              :mod (p5 / physiology~e.29)
                              :part (s / slash
                                    :op1 (p6 / protein
                                          :name (n4 / name :op1 "S"))
                                    :op2 (p7 / protein
                                          :name (n5 / name :op1 "E"))
                                    :op3 (e3 / enzyme
                                          :name (n6 / name :op1 "E8"))))))))

# ::tok It cannot be formally excluded that Eps8 , E3b1 , and Sos @-@ 1 associate after cell lysis , thus allowing coimmunoprecipitation .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1 1-1.1 1-1.1.r 2-1.2.r 3-1.2.2 4-1.2 5-1.2.1.r 6-1.2.1.1.1.1.1 8-1.2.1.1.2.1.1 10-1.2.1.1 11-1.2.1.2.1.1 13-1.2.1.2.1.1 14-1.2.1 15-1.2.1.3 16-1.2.1.3.1.1 19-1.2.1.4
# ::id pmid_1177_7939.46
# ::preferred 
(p / possible~e.1
      :polarity~e.1 "-"~e.1
      :domain~e.2 (e / exclude-01~e.4
            :ARG1~e.5 (a / associate-01~e.14
                  :ARG1 (a2 / and~e.10
                        :op1 (e2 / enzyme
                              :name (n / name :op1 "Eps8"~e.6))
                        :op2 (p3 / protein
                              :name (n2 / name :op1 "E3b1"~e.8)))
                  :ARG2 (p4 / protein
                        :name (n3 / name :op1 "Sos-1"~e.11,13))
                  :time (a3 / after~e.15
                        :op1 (l2 / lyse-00
                              :ARG1 (c / cell~e.16)))
                  :ARG1-of (c2 / cause-01~e.19
                        :ARG0 (c3 / coimmunoprecipitate-00
                              :ARG1 a2)))
            :mod (f / formal~e.3)))

# ::tok However , we have previously demonstrated ( <xref ref-type="bibr" rid="bib42"> Scita et al. , 2001 </xref> ) that the three endogenous proteins also colocalize in vivo in dynamic actin structures .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 2-1.1.1 4-1.1.3 5-1.1 10-1.1.4.1.1.1.1.1 11-1.1.4.1.1 12-1.1.4.1.1.2.1 14-1.1.4.1.2.1 17-1.1.2.r 19-1.1.2.1.1 20-1.1.2.1.2 21-1.1.2.1 22-1.1.2.2 23-1.1.2 24-1.1.2.3 25-1.1.2.3 26-1.1.2.3 26-1.1.2.4.r 27-1.1.2.4.1 28-1.1.2.4.2 29-1.1.2.4
# ::id pmid_1177_7939.47
# ::preferred 
(c / contrast-01~e.0
      :ARG2 (d / demonstrate-01~e.5
            :ARG0 (w / we~e.2)
            :ARG1~e.17 (c2 / colocalize-00~e.23
                  :ARG0 (p5 / protein~e.21
                        :quant "3"~e.19
                        :mod (e / endogenous~e.20))
                  :mod (a2 / also~e.22)
                  :manner (i / in-vivo~e.24,25,26)
                  :location~e.26 (s / structure~e.29
                        :mod (d4 / dynamic~e.27)
                        :mod (a3 / actin~e.28)))
            :time (p / previous~e.4)
            :ARG1-of (d2 / describe-01
                  :ARG0 (p2 / publication-91
                        :ARG0 (a / and~e.11
                              :op1 (p3 / person
                                    :name (n / name :op1 "Scita"~e.10))
                              :op2 (p4 / person
                                    :mod (o / other~e.12)))
                        :time (d3 / date-entity :year "2001"~e.14)))))

# ::tok Thus , the sum of our results strongly argues in favor of the existence of a physiological S/E/E8 complex .
# ::amr-annotator SDL-AMR-09
# ::alignments 3-1.1.1 4-1.1.1.1.r 5-1.1.1.1.2 5-1.1.1.1.2.r 6-1.1.1.1 6-1.1.1.1.1 6-1.1.1.1.1.r 7-1.1.3 7-1.1.3.r 8-1.1 11-1.1.2.r 13-1.1.2 14-1.1.2.1.r 16-1.1.2.1.1 18-1.1.2.1
# ::id pmid_1177_7939.48
# ::preferred 
(i / infer-01
      :ARG1 (a / argue-01~e.8
            :ARG0 (s3 / sum~e.3
                  :mod~e.4 (t / thing~e.6
                        :ARG2-of~e.6 (r / result-01~e.6)
                        :poss~e.5 (w / we~e.5)))
            :ARG1~e.11 (e / exist-01~e.13
                  :ARG1~e.14 (m / macro-molecular-complex~e.18
                        :mod (p / physiology~e.16)
                        :part (s2 / slash
                              :op1 (p2 / protein
                                    :name (n / name :op1 "S"))
                              :op2 (p3 / protein
                                    :name (n2 / name :op1 "E"))
                              :op3 (e2 / enzyme
                                    :name (n3 / name :op1 "E8")))))
            :manner~e.7 (s / strong~e.7)))

# ::tok Similarly , it cannot be formally excluded that other interactors of the SH3 domain of Eps8 , besides E3b1 , mediate the formation of the endogenous trimeric complex .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2 3-1 3-1.1 3-1.1.r 4-1.3.r 5-1.3.2 6-1.3 7-1.3.1.r 8-1.3.1.1.2 12-1.3.1.1.1.1.1 13-1.3.1.1.1.1.2 15-1.3.1.1.1.2.1.1 18-1.3.1.1.3.1.1.1 20-1.3.1 22-1.3.1.2 23-1.3.1.2.1.r 25-1.3.1.2.1.2 26-1.3.1.2.1.1 27-1.3.1.2.1
# ::id pmid_1177_7939.49
# ::preferred 
(p / possible~e.3
      :polarity~e.3 "-"~e.3
      :ARG1-of (r / resemble-01~e.0)
      :domain~e.4 (e / exclude-01~e.6
            :ARG1~e.7 (m / mediate-01~e.20
                  :ARG0 (i / interact-01
                        :ARG0 (p4 / protein-segment
                              :name (n3 / name :op1 "SH3"~e.12 :op2 "domain"~e.13)
                              :part-of (e4 / enzyme
                                    :name (n2 / name :op1 "Eps8"~e.15)))
                        :mod (o / other~e.8)
                        :ARG2-of (e2 / except-01
                              :ARG1 (p2 / protein
                                    :name (n / name :op1 "E3b1"~e.18))))
                  :ARG1 (f2 / form-01~e.22
                        :ARG1~e.23 (m2 / macro-molecular-complex~e.27
                              :mod (t / trimeric~e.26)
                              :mod (e3 / endogenous~e.25))))
            :mod (f / formal~e.5)))

# ::tok This is , however , unlikely since no coimmunoprecipitation between Eps8 and Sos @-@ 1 could be detected when the two proteins were overexpressed in cell lines with relative low levels of E3b1 ( <xref ref-type="bibr" rid="bib40"> Scita et al. , 1999 </xref> ; unpublished data ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2 1-1.1.2.r 3-1 5-1.1 5-1.1.1 5-1.1.1.r 6-1.1.3 7-1.1.3.1.1 7-1.1.3.1.1.r 10-1.1.3.1.2.1.1.1.1 11-1.1.3.1.2.1 12-1.1.3.1.2.1.2.1.1 14-1.1.3.1.2.1.2.1.1 17-1.1.3.1 18-1.2.1.1.2.r 21-1.1.3.1.2.1.2 21-1.1.3.1.3.2.1 25-1.1.3.1.3.2 26-1.1.3.1.3.2 27-1.1.3.1.3.2.1.2.r 28-1.1.3.1.3.2.1.2.1.1 29-1.1.3.1.3.2.1.2.1 30-1.1.3.1.3.2.1.2 32-1.1.3.1.3.2.1.1.1 37-1.2.1.1.1.1.1.1 38-1.2.1 38-1.2.1.1.1 39-1.2.1.1.1.2.1 41-1.2.1.1.2.1 44-1.2.1.2.1.1 45-1.2.1.2
# ::id pmid_1177_7939.50
# ::preferred 
(c / contrast-01~e.3
      :ARG2 (l3 / likely~e.5
            :polarity~e.5 "-"~e.5
            :domain~e.1 (t / this~e.0)
            :ARG1-of (c2 / cause-01~e.6
                  :ARG0 (d / detect-01~e.17
                        :polarity~e.7 "-"~e.7
                        :ARG1 (c3 / coimmunoprecipitate-00
                              :ARG1 (a / and~e.11
                                    :op1 (e2 / enzyme
                                          :name (n / name :op1 "Eps8"~e.10))
                                    :op2 (p3 / protein~e.21
                                          :name (n2 / name :op1 "Sos-1"~e.12,14))))
                        :condition (e / express-03
                              :ARG2 a
                              :ARG3 (c4 / cell-line~e.25,26
                                    :part (p4 / protein~e.21
                                          :name (n3 / name :op1 "E3b1"~e.32)
                                          :quant~e.27 (l / level~e.30
                                                :ARG1-of (l2 / low-04~e.29
                                                      :mod (r / relative~e.28)))))
                              :degree (o / over)))))
      :ARG1-of (d2 / describe-01
            :ARG0 (a3 / and~e.38
                  :op1 (p5 / publication-91
                        :ARG0 (a2 / and~e.38
                              :op1 (p6 / person
                                    :name (n4 / name :op1 "Scita"~e.37))
                              :op2 (p7 / person
                                    :mod (o2 / other~e.39)))
                        :time~e.18 (d3 / date-entity :year "1999"~e.41))
                  :op2 (d4 / data~e.45
                        :ARG1-of (p8 / publish-01 :polarity "-"~e.44)))))

# ::tok Moreover , neither RN @-@ tre , nor JIK , two other known interactors of the SH3 domain of Eps8 ( <xref ref-type="bibr" rid="bib5"> Biesova et al. , 1997 </xref> ; <xref ref-type="bibr" rid="bib28"> Mongiovi et al. , 1999 </xref> ) , were able to bind to Sos @-@ 1 ( unpublished data ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.2.1 2-1.2.1.r 3-1.1.2.1.1.1.1 5-1.1.2.1.1.1.1 7-1.1.1.r 8-1.1.2.1.2.1.1 11-1.1.2.1.3.2 11-1.1.2.1.4.1.1.1.2.1 12-1.1.2.1.3.3 16-1.1.2.1.3.1.1.1 17-1.1.2.1.3.1.1.2 19-1.1.2.1.3.1.2.1.1 24-1.1.2.1.4.1.1.1.1.1.1 25-1.1.2.1.4.1.1.1 26-1.1.2.1.4.1.1.1.2.1 28-1.1.2.1.4.1.1.2.1 34-1.1.2.1.4.1.2.1.1.1.1 35-1 35-1.1.2.1 35-1.1.2.1.4.1 35-1.1.2.1.4.1.2.1 36-1.1.2.1.4.1.2.1.2.1 38-1.1.2.1.4.1.2.2.1 42-1.1.2.r 43-1.1 45-1.1.2 46-1.1.2.2.r 47-1.1.2.2.1.1 49-1.1.2.2.1.1 51-1.1.1 51-1.2.1
# ::id pmid_1177_7939.51
# ::preferred 
(a / and~e.35
      :op2 (p / possible~e.43
            :polarity~e.7 "-"~e.51
            :domain~e.42 (b / bind-01~e.45
                  :ARG1 (a2 / and~e.35
                        :op1 (p4 / protein
                              :name (n3 / name :op1 "RN-tre"~e.3,5))
                        :op2 (p5 / protein
                              :name (n4 / name :op1 "JIK"~e.8))
                        :ARG0-of (i2 / interact-01
                              :ARG1 (p3 / protein-segment
                                    :name (n2 / name :op1 "SH3"~e.16 :op2 "domain"~e.17)
                                    :part-of (e / enzyme
                                          :name (n5 / name :op1 "Eps8"~e.19)))
                              :mod (o / other~e.11)
                              :ARG1-of (k / know-01~e.12))
                        :ARG1-of (d / describe-01
                              :ARG0 (a3 / and~e.35
                                    :op1 (p7 / publication-91
                                          :ARG0 (a4 / and~e.25
                                                :op1 (p8 / person
                                                      :name (n6 / name :op1 "Biesova"~e.24))
                                                :op2 (p9 / person
                                                      :mod (o2 / other~e.11,26)))
                                          :time (d2 / date-entity :year "1997"~e.28))
                                    :op2 (p10 / publication-91
                                          :ARG0 (a5 / and~e.35
                                                :op1 (p11 / person
                                                      :name (n7 / name :op1 "Mongiovi"~e.34))
                                                :op2 (p12 / person
                                                      :mod (o3 / other~e.36)))
                                          :time (d3 / date-entity :year "1999"~e.38)))))
                  :ARG2~e.46 (p2 / protein
                        :name (n / name :op1 "Sos-1"~e.47,49))))
      :ARG1-of (p13 / publish-01 :polarity~e.2 "-"~e.2,51))

# ::tok The adaptor molecules , E3b1 and Grb2 , compete for binding to Sos @-@ 1 both in vitro and in vivo
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1.3 4-1.1.1.1.1.1 5-1.1.1 6-1.1.1.2.1.1 8-1.1 8-1.2 9-1.1.2.r 10-1.1.2 11-1.1.2.2.r 12-1.1.2.2.1.1 14-1.1.2.2.1.1 16-1.1.3 17-1.1.3 19-1.1.3 19-1.2.3.r 20-1.2.3
# ::id pmid_1177_7939.52
# ::preferred 
(a3 / and
      :op1 (c / compete-01~e.8
            :ARG0 (a2 / and~e.5
                  :op1 (p3 / protein
                        :name (n3 / name :op1 "E3b1"~e.4))
                  :op2 (p4 / protein
                        :name (n4 / name :op1 "Grb2"~e.6))
                  :mod (a4 / adaptor~e.1))
            :ARG2~e.9 (b2 / bind-01~e.10
                  :ARG1 a2
                  :ARG2~e.11 (p / protein
                        :name (n / name :op1 "Sos-1"~e.12,14)))
            :manner (i / in-vitro~e.16,17,19))
      :op2 (c2 / compete-01~e.8
            :ARG0 a2
            :ARG1 b2
            :manner~e.19 (i2 / in-vivo~e.20)))

# ::tok Sos @-@ 1 has been shown to be part of a signaling complex with Grb2 , which mediates the activation of Ras upon RTK stimulation .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2.1.1 2-1.1.2.1.1 3-1.1 5-1 8-1.1 11-1.1.1.1 12-1.1.1 13-1.1.1.2.r 14-1.1.1.2.1.1 17-1.1.1.2 17-1.1.1.2.2 17-1.1.1.2.2.r 19-1.1.1.2.2.1 20-1.1.1.2.2.1.1.r 21-1.1.1.2.2.1.1.1.1 23-1.1.1.2.2.1.2.1.1.1 24-1.1.1.2.2.1.2
# ::id pmid_1177_7939.53
# ::preferred 
(s / show-01~e.5
      :ARG1 (h / have-part-91~e.3,8
            :ARG1 (m / macro-molecular-complex~e.12
                  :ARG0-of (s2 / signal-07~e.11)
                  :part~e.13 (p2 / protein~e.17
                        :name (n2 / name :op1 "Grb2"~e.14)
                        :ARG0-of~e.17 (m2 / mediate-01~e.17
                              :ARG1 (a / activate-01~e.19
                                    :ARG1~e.20 (e / enzyme
                                          :name (n3 / name :op1 "Ras"~e.21))
                                    :condition (s3 / stimulate-01~e.24
                                          :ARG1 (e2 / enzyme
                                                :name (n4 / name :op1 "RTK"~e.23)))))))
            :ARG2 (p / protein
                  :name (n / name :op1 "Sos-1"~e.0,2))))

# ::tok Our finding that , under physiological conditions , Sos @-@ 1 also participates in a complex with Eps8 and E3b1 raises the question of the physical and functional relationships between these two Sos @-@ 1–containing complexes .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 0-1.1.1.r 1-1.1 5-1.1.2.2 6-1.1.2.2.r 8-1.1.2.1.1.1.1 10-1.1.2.1.1.1.1 11-1.1.2.1.1.2 15-1.1.2 16-1.1.2.1.r 17-1.1.2.1.2.1.1 18-1.1.2.1 19-1.1.2.1.3.1.1 20-1 22-1.2 25-1.2.1.2.1 26-1.2.1.2 27-1.2.1.2.2 32-1.2.1.3.1.1 35-1.2.1.3
# ::id pmid_1177_7939.54
# ::preferred 
(r / raise-01~e.20
      :ARG0 (f / find-01~e.1
            :ARG0~e.0 (w / we~e.0)
            :ARG1 (m / macro-molecular-complex~e.15
                  :part~e.16 (a / and~e.18
                        :op1 (p2 / protein
                              :name (n / name :op1 "Sos-1"~e.8,10)
                              :mod (a2 / also~e.11))
                        :op2 (e / enzyme
                              :name (n2 / name :op1 "Eps8"~e.17))
                        :op3 (p4 / protein
                              :name (n3 / name :op1 "E3b1"~e.19)))
                  :condition~e.6 (p / physiology~e.5)))
      :ARG1 (q / question-01~e.22
            :ARG1 (r2 / relation-03
                  :ARG0 a
                  :ARG1 (a5 / and~e.26
                        :op1 (p5 / physical~e.25)
                        :op2 (f2 / functional~e.27))
                  :ARG2 (m2 / macro-molecular-complex~e.35
                        :part (a3 / and
                              :op1 p2~e.32
                              :op2 (p6 / protein
                                    :name (n4 / name :op1 "Grb2")))))))

# ::tok To gain insight into this issue , we initially mapped the region of E3b1 responsible for the interaction with Sos @-@ 1 by using a series of deletion mutants of E3b1 fused to glutathione <i> S </i>@ -@ transferase ( GST ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3 3-1.3.2.r 4-1.3.2.1 5-1.3.2 7-1.1 8-1.4 9-1 11-1.2 12-1.2.1.r 13-1.2.1.1.1 15-1.2.2.r 17-1.2.2 18-1.2.2.1.r 19-1.2.2.1.1.1 21-1.2.2.1.1.1 22-1.2.2.2.r 23-1.2.2.2 25-1.2.2.2.2.3 26-1.2.2.2.2.3.r 27-1.2.2.2.2.4.1 28-1.2.2.2.2 28-1.2.2.2.2.4 28-1.2.2.2.2.4.r 30-1.2.2.2.2.1.1 31-1.2.2.2.2.2 32-1.2.2.2.2.2.1.r 33-1.2.2.2.2.2.1.1.1 35-1.2.2.2.2.2.1.1.2 38-1.2.2.2.2.2.1.1.2
# ::id pmid_1177_7939.55
# ::preferred 
(m / map-01~e.9
      :ARG0 (w / we~e.7)
      :ARG1 (r2 / region~e.11
            :part-of~e.12 (p / protein
                  :name (n / name :op1 "E3b1"~e.13))
            :ARG0-of~e.15 (i2 / interact-01~e.17
                  :ARG1~e.18 (p2 / protein
                        :name (n2 / name :op1 "Sos-1"~e.19,21))
                  :manner~e.22 (u2 / use-01~e.23
                        :ARG0 w
                        :ARG1 (p3 / protein~e.28
                              :name (n3 / name :op1 "E3b1"~e.30)
                              :ARG1-of (f / fuse-01~e.31
                                    :ARG3~e.32 (e2 / enzyme
                                          :name (n5 / name :op1 "glutathione"~e.33 :op2 "S-transferase"~e.35,38)))
                              :quant~e.26 (s / series~e.25)
                              :ARG2-of~e.28 (m2 / mutate-01~e.28
                                    :manner (d3 / delete-01~e.27))))))
      :purpose (u / understand-01~e.0
            :ARG0 w
            :ARG1~e.3 (i3 / issue~e.5
                  :mod (t / this~e.4)))
      :time (i / initial~e.8))

# ::tok Native Sos @-@ 1 could be efficiently recovered onto GST @-@ E3b1 full length ( <xref ref-type="fig" rid="fig2"> Fig . 2 </xref> A , amino acids [aa] 2–480 ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.2 1-1.1.1.1.1 3-1.1.1.1.1 4-1 5-1.1.r 6-1.1.2 7-1.1 9-1.1.3.2.1.1 11-1.1.3.2.1.1 12-1.1.3.1 13-1.1.3 20-1.2.1.2.1.1 24-1.2.1.2.1 24-1.2.1.2.2 25-1.2.1.2.1 25-1.2.1.2.2
# ::id pmid_1177_7939.56
# ::preferred 
(p2 / possible~e.4
      :domain~e.5 (r / recover-02~e.7
            :ARG1 (p / protein
                  :name (n / name :op1 "Sos-1"~e.1,3)
                  :mod (n2 / native~e.0))
            :ARG2-of (e / efficient-01~e.6)
            :location (l / length~e.13
                  :degree (f / full~e.12)
                  :poss (p3 / protein
                        :name (n3 / name :op1 "GST-E3b1"~e.9,11))))
      :ARG1-of (d / describe-01
            :ARG0 (f2 / figure
                  :mod "2A"
                  :mod (b / between
                        :op1 (a2 / amino-acid~e.24,25 :value "2"~e.20)
                        :op2 (a3 / amino-acid~e.24,25 :value "480")))))

# ::tok Further mapping revealed that the SH3 domain of E3b1 ( aa 416–480 ) was necessary and sufficient for binding ( <xref ref-type="fig" rid="fig2"> Fig . 2 </xref> A ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1 2-1 3-1.2.r 5-1.2.1.2.1.1 8-1.2.1.2.2.1.1 14-1.2.1 15-1.2 15-1.2.1.2.3 16-1.2.2 17-1.2.1.1.r 18-1.2.1.1
# ::id pmid_1177_7939.57
# ::preferred 
(r / reveal-01~e.2
      :ARG0 (m / map-01~e.1
            :degree (f / further~e.0))
      :ARG1~e.3 (a / and~e.15
            :op1 (n / need-01~e.14
                  :ARG0~e.17 (b / bind-01~e.18
                        :ARG2 (p / protein-segment
                              :name (n2 / name :op1 "SH3"~e.5)
                              :part-of (p2 / protein
                                    :name (n3 / name :op1 "E3b1"~e.8))
                              :consist-of (b2 / between~e.15
                                    :op1 (a3 / amino-acid :value "416")
                                    :op2 (a4 / amino-acid :value "480"))))
                  :ARG1 p)
            :op2 (s / suffice-01~e.16
                  :ARG0 p
                  :ARG1 b))
      :ARG1-of (d / describe-01
            :ARG0 (f2 / figure :mod "2A")))

# ::tok We have previously shown that E3b1 binds to the proline @-@ rich , COOH @-@ terminal tail of Sos @-@ 1 ( aa 1131–1333 ) ( <xref ref-type="bibr" rid="bib40"> Scita et al. , 1999 </xref> ) , which also binds to the SH3 of Grb2 ( <xref ref-type="bibr" rid="bib24"> Li et al. , 1993 </xref> ; <xref ref-type="bibr" rid="bib12"> Cussac et al. , 1994 </xref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 2-1.3 3-1 4-1.2.r 5-1.2.1.1.1 6-1.2 7-1.2.2.r 9-1.2.2.1.2.1.1.1 11-1.2.2.1.2 13-1.2.2.1.1.1 15-1.2.2.1.1.1 16-1.2.2 18-1.2.2.1.3.1.1 20-1.2.2.1.3.1.1 29-1.2.3.1.1.1.1.1 30-1.2.3.1.1 31-1.2.3.1.1.2.1 33-1.2.3.1.2.1 38-1.2.2.1.4.2 39-1.2.2.1 39-1.2.2.1.4 39-1.2.2.1.4.r 40-1.2.2.1.4.1.r 42-1.2.2.1.4.1.1.1 44-1.2.2.1.4.1.2.1.1 49-1.2.2.1.4.3.1.1.1.1.1.1 50-1.2.2.1.4.3.1.1.1 51-1.2.2.1.4.3.1.1.1.2.1 53-1.2.2.1.4.3.1.1.2.1 59-1.2.2.1.4.3.1.2.1.1.1.1 60-1.2.2.1.4.3.1 60-1.2.2.1.4.3.1.2.1 61-1.2.2.1.4.3.1.2.1.2.1 63-1.2.2.1.4.3.1.2.2.1
# ::id pmid_1177_7939.58
# ::preferred 
(s / show-01~e.3
      :ARG0 (w / we~e.0)
      :ARG1~e.4 (b / bind-01~e.6
            :ARG1 (p / protein
                  :name (n / name :op1 "E3b1"~e.5))
            :ARG2~e.7 (t / tail~e.16
                  :part-of (p2 / protein-segment~e.39
                        :name (n2 / name :op1 "COOH-terminus"~e.13,15)
                        :mod (r / rich~e.11
                              :topic (a / amino-acid
                                    :name (n3 / name :op1 "proline"~e.9)))
                        :part-of (p3 / protein
                              :name (n4 / name :op1 "Sos-1"~e.18,20))
                        :ARG1-of~e.39 (b2 / bind-01~e.39
                              :ARG2~e.40 (p7 / protein-segment
                                    :name (n6 / name :op1 "SH3"~e.42)
                                    :part-of (p8 / protein
                                          :name (n7 / name :op1 "Grb2"~e.44)))
                              :mod (a3 / also~e.38)
                              :ARG1-of (d5 / describe-01
                                    :ARG0 (a4 / and~e.60
                                          :op1 (p9 / publication-91
                                                :ARG0 (a5 / and~e.50
                                                      :op1 (p10 / person
                                                            :name (n8 / name :op1 "Li"~e.49))
                                                      :op2 (p11 / person
                                                            :mod (o2 / other~e.51)))
                                                :time (d2 / date-entity :year "1993"~e.53))
                                          :op2 (p12 / publication-91
                                                :ARG0 (a6 / and~e.60
                                                      :op1 (p13 / person
                                                            :name (n9 / name :op1 "Cussac"~e.59))
                                                      :op2 (p14 / person
                                                            :mod (o3 / other~e.61)))
                                                :time (d3 / date-entity :year "1994"~e.63)))))
                        :ARG1-of (m / mean-01
                              :ARG2 (b3 / between
                                    :op1 (a8 / amino-acid :value "1131")
                                    :op2 (a9 / amino-acid :value "1333")))))
            :ARG1-of (d4 / describe-01
                  :ARG0 (p4 / publication-91
                        :ARG0 (a2 / and~e.30
                              :op1 (p5 / person
                                    :name (n5 / name :op1 "Scita"~e.29))
                              :op2 (p6 / person
                                    :mod (o / other~e.31)))
                        :time (d / date-entity :year "1999"~e.33))))
      :time (p15 / previous~e.2))

# ::tok Thus , Grb2 and E3b1 might compete for binding to Sos @-@ 1 .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1.1.1.1.1 3-1.1.1.3.1 4-1.1.1.2.1.1 5-1.1 6-1.1.1 7-1.1.1.3.r 8-1.1.1.3 9-1.1.1.3.2.r 10-1.1.1.3.2.1.1 12-1.1.1.3.2.1.1
# ::id pmid_1177_7939.59
# ::preferred 
(i / infer-01
      :ARG1 (p / possible~e.5
            :domain (c / compete-01~e.6
                  :ARG0 (p2 / protein
                        :name (n / name :op1 "Grb2"~e.2))
                  :ARG1 (p3 / protein
                        :name (n2 / name :op1 "E3b1"~e.4))
                  :ARG2~e.7 (b / bind-01~e.8
                        :ARG1 (a / and~e.3
                              :op1 p2
                              :op2 p3)
                        :ARG2~e.9 (p4 / protein
                              :name (n3 / name :op1 "Sos-1"~e.10,12))))))

# ::tok This hypothesis was validated by a series of experiments performed both in vitro and in vivo .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.2 1-1.2 1-1.2.1 1-1.2.1.r 3-1 4-1.1.r 6-1.1 7-1.1.1.r 8-1.1.1 9-1.1.1.1 11-1.1.1.1.1.1 12-1.1.1.1.1.1 13-1.1.1.1.1 14-1.1.1.1.1.1 14-1.1.1.1.1.2 15-1.1.1.1.1.2
# ::id pmid_1177_7939.60
# ::preferred 
(v / validate-01~e.3
      :ARG0~e.4 (s / series~e.6
            :consist-of~e.7 (e / experiment-01~e.8
                  :ARG1-of (p / perform-01~e.9
                        :manner (a / and~e.13
                              :op1 (i / in-vitro~e.11,12,14)
                              :op2 (i2 / in-vivo~e.14,15)))))
      :ARG1 (t / thing~e.1
            :ARG1-of~e.1 (h / hypothesize-01~e.1)
            :mod (t2 / this~e.0)))

# ::tok We could demonstrate that <bold> ( </bold>@ a ) the SH3 of Grb2 , but not of Eps8 , efficiently competed with the SH3 of E3b1 for binding to the proline @-@ rich COOH @-@ terminal tail of Sos @-@ 1 in vitro ( <xref ref-type="fig" rid="fig2"> Fig . 2 </xref> B ) ; ( b ) the Sos @-@ 1 peptide VPVPPPVPPRRR , known to constitute a Grb2 @-@ SH3 binding site ( <xref ref-type="bibr" rid="bib24"> Li et al. , 1993 </xref> ; <xref ref-type="bibr" rid="bib12"> Cussac et al. , 1994 </xref> ) , competed equally well the binding of the COOH @-@ terminal tail of Sos @-@ 1 to the SH3s of Grb2 or E3b1 ( <xref ref-type="fig" rid="fig2"> Fig . 2 </xref> C ) ; ( c ) the binding constants of the interaction between the proline rich COOH @-@ terminal tail of Sos @-@ 1 and the SH3 domains of Grb2 and E3b1 were very similar ( <xref ref-type="fig" rid="fig2"> Fig . 2 </xref> D ) ; ( d ) overexpression of Grb2 abolished the ability of GST @-@ E3b1 to bind to native Sos @-@ 1 ( <xref ref-type="fig" rid="fig3"> Fig . 3 </xref> A ) ; and ( e ) overexpression of E3b1 significantly decreased the coimmunoprecipitation between Grb2 and Sos @-@ 1 ( <xref ref-type="fig" rid="fig3"> Fig . 3 </xref> B ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1 2-1.1 7-1.1.2.1.6 10-1.1.2.1.1.1.1 10-1.1.2.1.2.1.1 11-1.1.2.1.4.1 12-1.1.2.1.4.1 13-1.1.2.1.4.1 14-1.1.2.1.4.1 15-1.1.2.1.4.1 16-1.1.2.1.4.1 17-1.1.2.1.4.1 19-1.1.2.1.4 20-1.1.2.1 23-1.1.2.1.1.1.1 23-1.1.2.1.1.3.1.1.1 23-1.1.2.1.2.1.1 24-1.1.2.1.1.3 24-1.1.2.1.2.r 25-1.1.2.1.2.2.1.1 26-1.1.2.1.3.r 27-1.1.2.1.3 28-1.1.2.1.3.1.r 30-1.1.2.1.3.1.1.3.1.1.1 32-1.1.2.1.3.1.1.3 33-1.1.2.1.3.1.1.1.1 35-1.1.2.1.3.1.1.1.1 36-1.1.2.1.3.1 38-1.1.2.1.3.1.1.2.1.1 40-1.1.2.1.3.1.1.2.1.1 41-1.1.2.1.3.2 42-1.1.2.1.3.2 51-1.1.2.2.5 55-1.1.2.2.5 58-1.1.2.1.3.1.1.2.1.1 60-1.1.2.1.3.1.1.2.1.1 61-1.1.2.1.1.3.1 61-1.1.2.1.3.1.1 61-1.1.2.2.1 62-1.1.2.2.1.1.1 64-1.1.2.2.1.3.3 66-1.1.2.2.1.3 67-1.1.2.1.6 68-1.1.2.1.1.2.1.1 70-1.1.2.1.1.1.1 70-1.1.2.1.1.3.1.1.1 70-1.1.2.1.2.1.1 71-1.1.2.2.1.3.1.1 72-1.1.2.2.1.3.1 77-1.1.2.2.1.3.2.1.1.1.1.1.1 78-1.1.2.2.1.3.2.1.1.1 79-1.1.2.2.1.3.2.1.1.1.2.1 81-1.1.2.2.1.3.2.1.1.2.1 87-1.1.2.2.1.3.2.1.2.1.1.1.1 88-1.1.2.2.1.3.2.1.2.1 89-1.1.2.2.1.3.2.1.2.1.2.1 91-1.1.2.2.1.3.2.1.2.2.1 95-1.1.2.2 96-1.1.2.2.3.1 97-1.1.2.2.3 99-1.1.2.2.2 100-1.1.2.1.1.3 100-1.1.2.2.2.1.r 102-1.1.2.2.2.1 103-1.1.2.2.2.1 104-1.1.2.2.2.1 105-1.1.2.2.2.1 106-1.1.2.2.2.1 107-1.1.2.2.2.1 108-1.1.2.2.2.1 109-1.1.2.2.2.1 113-1.1.2.2.2.2.1 114-1.1.2.2.2.2.1 115-1.1.2.2.2.2 116-1.1.2.2.2.2.2 125-1.1.2.3.5 129-1.1.2.3.5 132-1.1.2.3.1.1.3 132-1.1.2.3.2.1.3 133-1.1.2.3.1 133-1.1.2.3.2 136-1.1.2.3.1.1 136-1.1.2.3.2.1 139-1.1.2.1.3.1.1.3.1.1.1 140-1.1.2.1.3.1.1.3 141-1.1.2.1.3.1.1.1.1 143-1.1.2.1.3.1.1.1.1 144-1.1.2.1.3.1 145-1.1.2.1.1.3 145-1.1.2.r 146-1.1.2.4.2.2.1.1.1 148-1.1.2.4.2.2.1.1.1 151-1.1.2.1.1.1.1 151-1.1.2.1.1.3.1.1.1 151-1.1.2.1.2.1.1 153-1.1.2.1.1.3 154-1.1.2.1.1.2.1.1 155-1.1.2 155-1.1.2.2.1.3.2.1 156-1.1.2.1.2.2.1.1 158-1.1.2.3.3 159-1.1.2.3 168-1.1.2.4.4 172-1.1.2.4.4 174-1.1.2.4.1 175-1.1.2.1.1.3 175-1.1.2.4.1.1.r 176-1.1.2.4.1.1 177-1.1.2.4 179-1.1.2.4.2 180-1.1.2.4.2.1.r 181-1.1.2.4.2.1.1.1 183-1.1.2.4.2.1.1.1 185-1.1.2.4.2.2 187-1.1.2.4.2.2.1.2 188-1.1.2.4.2.2.1.1.1 190-1.1.2.4.2.2.1.1.1 199-1.1.2.1.6 202-1.1.2 202-1.1.2.2.1.3.2.1 204-1.1.2.5.5 206-1.1.2.5.1 207-1.1.2.1.1.3 207-1.1.2.5.1.1.r 208-1.1.2.5.1.1 209-1.1.2.5.3 210-1.1.2.5 214-1.1.2.1.1.2.1.1 215-1.1.2 215-1.1.2.2.1.3.2.1 216-1.1.2.4.2.2.1.1.1 218-1.1.2.4.2.2.1.1.1 227-1.1.2.2.5
# ::id pmid_1177_7939.61
# ::preferred 
(p / possible~e.1
      :domain (d3 / demonstrate-01~e.2
            :ARG0 (w / we~e.0)
            :ARG1~e.145 (a2 / and~e.155,202,215
                  :op1 (c / compete-01~e.20
                        :ARG0 (p2 / protein-segment
                              :name (n2 / name :op1 "SH3"~e.10,23,70,151)
                              :part-of (p3 / protein
                                    :name (n3 / name :op1 "Grb2"~e.68,154,214))
                              :ARG1-of (i / instead-of-91~e.24,100,145,153,175,207
                                    :ARG2 (p4 / protein-segment~e.61
                                          :name (n4 / name :op1 "SH3"~e.23,70,151)
                                          :part-of (p5 / protein
                                                :name (n5 / name :op1 "Eps8")))))
                        :ARG1~e.24 (p6 / protein-segment
                              :name (n6 / name :op1 "SH3"~e.10,23,70,151)
                              :part-of (p7 / protein
                                    :name (n7 / name :op1 "E3b1"~e.25,156)))
                        :ARG2~e.26 (b / bind-01~e.27
                              :ARG2~e.28 (t2 / tail~e.36,144
                                    :part-of (p8 / protein-segment~e.61
                                          :name (n8 / name :op1 "COOH-terminus"~e.33,35,141,143)
                                          :part-of (p19 / protein
                                                :name (n9 / name :op1 "Sos-1"~e.38,40,58,60))
                                          :mod (r2 / rich~e.32,140
                                                :topic (a3 / amino-acid
                                                      :name (n10 / name :op1 "proline"~e.30,139)))))
                              :manner (i2 / in-vitro~e.41,42))
                        :ARG2-of (e / efficient-01~e.19
                              :ARG1 p2~e.11,12,13,14,15,16,17)
                        :ARG1-of (d4 / describe-01
                              :ARG0 (f / figure :mod "2B"))
                        :li (a8 / a~e.7,67,199))
                  :op2 (c2 / compete-01~e.95
                        :ARG0 (p10 / peptide~e.61
                              :name (n15 / name :op1 "VPVPPPVPPRRR"~e.62)
                              :part-of p19
                              :ARG0-of (c3 / constitute-01~e.66
                                    :ARG1 (p9 / protein-segment~e.72
                                          :ARG1-of (b2 / bind-01~e.71
                                                :ARG2 p2))
                                    :ARG1-of (d5 / describe-01
                                          :ARG0 (a5 / and~e.155,202,215
                                                :op1 (p11 / publication-91
                                                      :ARG0 (a4 / and~e.78
                                                            :op1 (p12 / person
                                                                  :name (n11 / name :op1 "Li"~e.77))
                                                            :op2 (p13 / person
                                                                  :mod (o / other~e.79)))
                                                      :time (d / date-entity :year "1993"~e.81))
                                                :op2 (p14 / publication-91
                                                      :ARG0 (a6 / and~e.88
                                                            :op1 (p15 / person
                                                                  :name (n12 / name :op1 "Cussac"~e.87))
                                                            :op2 (p16 / person
                                                                  :mod (o2 / other~e.89)))
                                                      :time (d2 / date-entity :year "1994"~e.91))))
                                    :ARG1-of (k / know-01~e.64)))
                        :ARG1 (b3 / bind-01~e.99
                              :ARG1~e.100 t2~e.102,103,104,105,106,107,108,109
                              :ARG2 (o3 / or~e.115
                                    :op1 p2~e.113,114
                                    :op2 p6~e.116))
                        :mod (w2 / well~e.97
                              :degree (e2 / equal~e.96))
                        :ARG1-of (d6 / describe-01
                              :ARG0 (f2 / figure :mod "2C"))
                        :li (b7 / b~e.51,55,227))
                  :op3 (r / resemble-01~e.159
                        :ARG1 (c4 / constant~e.133
                              :value-of (i3 / interact-01~e.136
                                    :ARG0 t2
                                    :ARG1 p2
                                    :ARG0-of (b4 / bind-01~e.132)))
                        :ARG2 (c5 / constant~e.133
                              :value-of (i4 / interact-01~e.136
                                    :ARG0 t2
                                    :ARG1 p6
                                    :ARG0-of (b5 / bind-01~e.132)))
                        :degree (v / very~e.158)
                        :ARG1-of (d7 / describe-01
                              :ARG0 (f3 / figure :mod "2D"))
                        :li (c6 / c~e.125,129))
                  :op4 (a / abolish-01~e.177
                        :ARG0 (e3 / express-03~e.174
                              :ARG2~e.175 p3~e.176
                              :degree (t / too))
                        :ARG1 (c7 / capable-01~e.179
                              :ARG1~e.180 (p18 / protein
                                    :name (n / name :op1 "GST-E3b1"~e.181,183))
                              :ARG2 (b6 / bind-01~e.185
                                    :ARG2 (p20 / protein
                                          :name (n13 / name :op1 "Sos-1"~e.146,148,188,190,216,218)
                                          :mod (n14 / native~e.187))))
                        :ARG1-of (d8 / describe-01
                              :ARG0 (f4 / figure :mod "3A"))
                        :li (d11 / d~e.168,172))
                  :op5 (d9 / decrease-01~e.210
                        :ARG0 (e4 / express-03~e.206
                              :ARG2~e.207 p7~e.208
                              :degree t)
                        :ARG1 (p17 / precipitate-01
                              :ARG0 (a7 / antibody)
                              :ARG1 (m / macro-molecular-complex
                                    :part p3
                                    :part p19))
                        :ARG2 (s / significant-02~e.209)
                        :ARG1-of (d10 / describe-01
                              :ARG0 (f5 / figure :mod "3B"))
                        :li (e5 / e~e.204)))))

# ::tok Thus , Sos @-@ 1 binds either E3b1 or Grb2 , in a mutually exclusive fashion , suggesting that two distinct pools of Sos @-@ 1 exist in the cells .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1.1.1.1 4-1.1.1.1.1 5-1.1 7-1.1.2.1.1.1 8-1.1.2 9-1.1.2.2.1.1 11-1.1.3.r 13-1.1.3.1 14-1.1.3 17-1.1.4 19-1.1.4.1.1.1 20-1.1.4.1.1.3 21-1.1.4.1.1 22-1.1.4.1.1.2.r 23-1.1.4.1.1.2 24-1.1.4.1.1.2 25-1.1.4.1.1.2 29-1.1.4.1.2
# ::id pmid_1177_7939.62
# ::preferred 
(i / infer-01
      :ARG1 (b / bind-01~e.5
            :ARG1 (p / protein
                  :name (n / name :op1 "Sos-1"~e.2,4))
            :ARG2 (o / or~e.8
                  :op1 (p2 / protein
                        :name (n2 / name :op1 "E3b1"~e.7))
                  :op2 (p3 / protein
                        :name (n3 / name :op1 "Grb2"~e.9)))
            :manner~e.11 (e3 / exclusive~e.14
                  :mod (m / mutual~e.13))
            :ARG0-of (s / suggest-01~e.17
                  :ARG1 (b2 / be-located-at-91
                        :ARG1 (p4 / pool~e.21
                              :quant "2"~e.19
                              :consist-of~e.22 p~e.23,24,25
                              :mod (d / distinct~e.20))
                        :ARG2 (c / cell~e.29)))))

# ::tok To test this possibility in vivo , we set out to perturb the equilibrium between the Sos @-@ 1–E3b1 ( S/E ) and Sos @-@ 1–Grb2 ( S/G ) complexes , by increasing the levels of E3b1 within the cell .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3 2-1.3.2.1 3-1.3.2 4-1.3.3 5-1.3.3 7-1.1 8-1 9-1 11-1.2 16-1.2.2.1.1.1.1.1 23-1.2.2.1.1.1.1.1 29-1.2.2.1.1 29-1.2.2.1.2 31-1.2.3.r 32-1.2.3 34-1.2.3.2 35-1.2.2.1.1.2.r 36-1.2.2.1.1.2.1.1 39-1.2.3.3
# ::id pmid_1177_7939.63
# ::preferred 
(s / set-out-07~e.8,9
      :ARG0 (w / we~e.7)
      :ARG1 (p / perturb-01~e.11
            :ARG0 w
            :ARG1 (e / equilibrate-01
                  :ARG1 (a / and
                        :op1 (m / macro-molecular-complex~e.29
                              :part (p2 / protein
                                    :name (n / name :op1 "Sos-1"~e.16,23))
                              :part~e.35 (p3 / protein
                                    :name (n2 / name :op1 "E3b1"~e.36)))
                        :op2 (m2 / macro-molecular-complex~e.29
                              :part p2
                              :part (p4 / protein
                                    :name (n3 / name :op1 "Grb2")))))
            :instrument~e.31 (i / increase-01~e.32
                  :ARG0 w
                  :ARG1 (l / level~e.34
                        :quant-of p3)
                  :location (c / cell~e.39)))
      :purpose (t / test-01~e.1
            :ARG0 w
            :ARG1 (p5 / possible~e.3
                  :domain (t2 / this~e.2))
            :manner (i2 / in-vivo~e.4,5)))

# ::tok If the two complexes are functionally distinct , then the overexpression of E3b1 , by competing the S/G interaction , should result in ( a ) reduced Sos @-@ 1 recruitment in vivo to active EGFR , ( b ) consequent reduction in Ras activation , as measured by reduced Ras @-@ GTP levels , ( c ) reduced activation of Ras @-@ dependent pathways , as measured by activation of MAPK , and finally ( d ) reduced proliferative response .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.r 2-1.2.1.1 3-1.1.2.2.3.1.1 3-1.2.1 5-1.2 6-1.2.2 12-1.1.1.1.1.1 15-1.1.3 18-1.1.3.2 20-1 21-1.1 22-1.1.2.1.4 24-1.1.2.1.5 26-1.1.2.1.3 27-1.1.3.2.1.1.1 29-1.1.3.2.1.1.1 30-1.1.2.1 31-1.1.2.1.4 32-1.1.2.1.4 35-1.1.2.1.2.1.1 38-1.1.2.2.4 40-1.1.2.2.2 41-1.1.2.2 42-1.1.2.1.4 43-1.1.2.2.1.1.1.1 44-1.1.2.3 46-1.1.2.4.3.r 47-1.1.2.2.3 49-1.1.2.2 49-1.1.2.2.3.1.2 50-1.1.2.2.3.1.1.1 52-1.1.2.2.3.1.1.2.1.1 53-1.1.2.2.3.1 56-1.1.2.3.4 58-1.1.2.2 58-1.1.2.3.2 59-1.1.2.2.1 59-1.1.2.3 60-1.1.2.3.1.r 61-1.1.2.3.1.1.1 63-1.1.2.3.1.1 64-1.1.2.3.1 66-1.1.2.3.3.r 66-1.1.2.4.3.r 67-1.1.2.3.3 69-1.1.2.1.2 69-1.1.2.1.2.2 69-1.1.2.1.2.2.r 69-1.1.2.3.3.1 70-1.1.2.3.3.1.1.r 71-1.1.2.3.3.1.1.1.1 73-1.1.2 74-1.1.2.4.3 76-1.1.2.4.4 78-1.1.2.4.1 80-1.1.2.4
# ::id pmid_1177_7939.64
# ::preferred 
(r / recommend-01~e.20
      :ARG1 (r2 / result-01~e.21
            :ARG1 (o / overexpress-00
                  :ARG2 (p2 / protein
                        :name (n4 / name :op1 "E3b1"~e.12)))
            :ARG2 (a / and~e.73
                  :op1 (r3 / recruit-01~e.30
                        :ARG1 (p3 / protein
                              :name (n5 / name :op1 "Sos-1"~e.27,29))
                        :ARG2 (e / enzyme~e.69
                              :name (n / name :op1 "EGFR"~e.35)
                              :ARG1-of~e.69 (a2 / activate-01~e.69))
                        :ARG1-of (r4 / reduce-01~e.26)
                        :manner (i2 / in-vivo~e.22,31,32,42)
                        :li (a6 / a~e.24))
                  :op2 (r5 / reduce-01~e.41,49,58
                        :ARG1 (a3 / activate-01~e.59
                              :ARG1 (e2 / enzyme
                                    :name (n2 / name :op1 "Ras"~e.43)))
                        :ARG1-of (c2 / cause-01~e.40
                              :ARG0 r3)
                        :ARG1-of (m / measure-01~e.47
                              :ARG2 (l / level~e.53
                                    :quant-of (m2 / macro-molecular-complex~e.3
                                          :part e2~e.50
                                          :part (s / small-molecule
                                                :name (n7 / name :op1 "GTP"~e.52)))
                                    :ARG1-of (r6 / reduce-01~e.49)))
                        :li (b / b~e.38))
                  :op3 (a4 / activate-01~e.44,59
                        :ARG1~e.60 (p5 / pathway~e.64
                              :ARG0-of (d / depend-01~e.63
                                    :ARG1 e2~e.61))
                        :ARG1-of (r7 / reduce-01~e.58)
                        :ARG1-of~e.66 (m3 / measure-01~e.67
                              :ARG2 (a5 / activate-01~e.69
                                    :ARG1~e.70 (p / pathway
                                          :name (n3 / name :op1 "MAPK"~e.71))))
                        :li (c3 / c~e.56))
                  :op4 (r8 / respond-01~e.80
                        :ARG1-of (r9 / reduce-01~e.78)
                        :mod (p6 / proliferate-01)
                        :time~e.46,66 (f / final~e.74)
                        :li (d3 / d~e.76)))
            :manner (c / compete-01~e.15
                  :ARG0 o
                  :ARG1 (i / interact-01~e.18
                        :ARG0 p3
                        :ARG1 (p4 / protein
                              :name (n6 / name :op1 "Grb2")))))
      :condition~e.0 (f2 / function-01~e.5
            :ARG0 (m4 / macro-molecular-complex~e.3 :quant "2"~e.2)
            :mod (d2 / distinct~e.6)))

# ::tok All of these predictions were confirmed experimentally ( <xref ref-type="fig" rid="fig4"> Fig . 4 </xref> , A–C ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2 2-1.1.3 3-1.1 3-1.1.1 3-1.1.1.r 5-1 6-1.2
# ::id pmid_1177_7939.65
# ::preferred 
(c / confirm-01~e.5
      :ARG1 (t / thing~e.3
            :ARG1-of~e.3 (p / predict-01~e.3)
            :mod (a / all~e.0)
            :mod (t2 / this~e.2))
      :manner (e / experiment-01~e.6)
      :ARG1-of (d / describe-01
            :ARG0 (f / figure
                  :mod (v / value-interval :op1 "A" :op2 "C"))))

# ::tok We note that our mapping data are at variance with those recently reported by <xref ref-type="bibr" rid="bib16"> Fan and Goff ( 2000 ) </xref> , who concluded that , in vivo @<i> , </i> the interaction between Sos @-@ 1 and E3b1–Abi @-@ 1 is mediated by the NH @<sub> 2 </sub>@ -@ terminal portion of the latter .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1 2-1.2.2.1 3-1.2.1.2 3-1.2.1.2.r 4-1.2.1.1 5-1.2.1 5-1.2.2 8-1.2 10-1.2.2.1 11-1.2.2.2.2 12-1.2.2.2 17-1.2.2.2.1.1.1.1.1 18-1.2.2.2.1.1 19-1.2.2.2.1.1.2.1.1 21-1.2.2.2.1.2.1 26-1.2.2.2.1.1.3 27-1.2.2.1 29-1.2.2.2.1.1.3.1.3 30-1.2.2.2.1.1.3.1.3 35-1.2.2.2.1.1.3.1.2 37-1.2.2.2.1.1.3.1.2.1.1.1 39-1.2.2.2.1.1.3.1.2.1.1.1 39-1.2.2.2.1.1.3.1.2.2.1.1 41-1.2.2.2.1.1.3.1.2.2.1.1 43-1.2.2.2.1.1.3.1.2.1.1.1 43-1.2.2.2.1.1.3.1.2.2.1.1 45-1.2.2.2.1.1.3.1 53-1.2.2.2.1.1.3.1.1.1.1
# ::id pmid_1177_7939.66
# ::preferred 
(n2 / note-02~e.1
      :ARG0 (w / we~e.0)
      :ARG1 (v / vary-01~e.8
            :ARG1 (d3 / data~e.5
                  :topic (m / map-01~e.4)
                  :poss~e.3 w~e.3)
            :compared-to (d4 / data~e.5
                  :mod (t / that~e.2,10,27)
                  :ARG1-of (r / report-01~e.12
                        :ARG0 (p / publication-91
                              :ARG0 (a / and~e.18
                                    :op1 (p2 / person
                                          :name (n / name :op1 "Fan"~e.17))
                                    :op2 (p3 / person
                                          :name (n3 / name :op1 "Goff"~e.19))
                                    :ARG0-of (c / conclude-01~e.26
                                          :ARG1 (m2 / mediate-01~e.45
                                                :ARG0 (p6 / protein-segment
                                                      :name (n7 / name :op1 "NH2-terminus"~e.53)
                                                      :part-of (p4 / protein
                                                            :name (n5 / name :op1 "E3b1–Abi-1"~e.39,41,43)))
                                                :ARG1 (i / interact-01~e.35
                                                      :ARG0 (p5 / protein
                                                            :name (n4 / name :op1 "Sos-1"~e.37,39,43))
                                                      :ARG1 p4)
                                                :manner (i2 / in-vivo~e.29,30))))
                              :time (d / date-entity :year "2000"~e.21))
                        :time (r2 / recent~e.11)))))

# ::tok Consistently , <xref ref-type="bibr" rid="bib16"> Fan and Goff ( 2000 ) </xref> did not observe competition in vivo between Grb2 and E3b1 for binding to Sos @-@ 1 .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.4 5-1.2.1.1.1 6-1.2 7-1.2.2.1.1 9-1.2.3.1.1 13-1.1 13-1.1.r 14-1 15-1.3 16-1.5 17-1.5 19-1.3.1.1.1 21-1.3.2.1.1 22-1.3.3.r 23-1.3.3 24-1.3.3.1.r 25-1.3.3.1.1.1 27-1.3.3.1.1.1
# ::id pmid_1177_7939.67
# ::preferred 
(o / observe-01~e.14
      :polarity~e.13 "-"~e.13
      :ARG0 (a / and~e.6
            :op1 (p2 / person
                  :name (n / name :op1 "Fan"~e.5))
            :op2 (p3 / person
                  :name (n2 / name :op1 "Goff"~e.7))
            :ARG0-of (p / publication-91
                  :time (d / date-entity :year "2000"~e.9)))
      :ARG1 (c / compete-01~e.15
            :ARG0 (p4 / protein
                  :name (n3 / name :op1 "Grb2"~e.19))
            :ARG1 (p5 / protein
                  :name (n4 / name :op1 "E3b1"~e.21))
            :ARG2~e.22 (b / bind-01~e.23
                  :ARG2~e.24 (p6 / protein
                        :name (n5 / name :op1 "Sos-1"~e.25,27))))
      :ARG1-of (c2 / consistent-01~e.0)
      :manner (i / in-vivo~e.16,17))

# ::tok Although we cannot exclude that the NH @<sub> 2 </sub>@ -@ terminal region of E3b1–Abi @-@ 1 participates in binding , in vivo @<i> , </i> we were not able to observe a high @-@ affinity binding surface in that region by in vitro binding experiments ( <xref ref-type="fig" rid="fig2"> Fig . 2 </xref> A ; <xref ref-type="bibr" rid="bib40"> Scita et al. , 1999 </xref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3.r 1-1.2.1 2-1 2-1.1 2-1.1.r 2-1.3 2-1.3.1 2-1.3.1.r 3-1.3.2 4-1.2.3.1 11-1.3.2.2.1.1.1 12-1.2.3 14-1.3.2.2.1.2.1.1 16-1.3.2.2.1.2.1.1 17-1.3.2.2 18-1.3.2.2.2.r 18-1.3.2.2.3 19-1.3.2.2.2 21-1.3.2.2.3 22-1.3.2.2.3 26-1.3.2.1 27-1.2.r 27-1.3.2.r 28-1.1 28-1.1.r 29-1 31-1.2 33-1.2.2.2.1 35-1.2.2.2 36-1.2.2.1 37-1.2.2 38-1.2.4.2 39-1.2.3.1 40-1.2.3 42-1.2.4.2 43-1.2.4.2 44-1.2.4.1 45-1.2.4 59-1.4.1.1.1.1.1.1 60-1.4.1 60-1.4.1.1.1 61-1.4.1.1.1.2.1 63-1.4.1.1.2.1
# ::id pmid_1177_7939.68
# ::preferred 
(p / possible~e.2,29
      :polarity~e.2,28 "-"~e.2,28
      :domain~e.27 (o / observe-01~e.31
            :ARG0 (w / we~e.1)
            :ARG1 (s / surface~e.37
                  :location-of (b / bind-01~e.36)
                  :mod (a / affinity~e.35
                        :degree (h / high~e.33)))
            :location (r / region~e.12,40
                  :mod (t / that~e.4,39))
            :manner (e / experiment-01~e.45
                  :ARG1 (b2 / bind-01~e.44)
                  :manner (i / in-vitro~e.38,42,43)))
      :concession~e.0 (p2 / possible~e.2
            :polarity~e.2 "-"~e.2
            :domain~e.27 (e2 / exclude-01~e.3
                  :ARG0 w~e.26
                  :ARG1 (p3 / participate-01~e.17
                        :ARG0 (p4 / protein-segment
                              :name (n / name :op1 "NH2-terminus"~e.11)
                              :part-of (p5 / protein
                                    :name (n2 / name :op1 "E3b1–Abi-1"~e.14,16)))
                        :ARG1~e.18 (b3 / bind-01~e.19)
                        :manner (i2 / in-vivo~e.18,21,22))))
      :ARG1-of (d2 / describe-01
            :ARG0 (a3 / and~e.60
                  :op1 (p6 / publication-91
                        :ARG0 (a2 / and~e.60
                              :op1 (p7 / person
                                    :name (n4 / name :op1 "Scita"~e.59))
                              :op2 (p8 / person
                                    :mod (o2 / other~e.61)))
                        :time (d / date-entity :year "1999"~e.63))
                  :op2 (f / figure :mod "2A"))))

# ::tok Conversely , under our conditions of analysis , the efficient competition of the SH3 domains of Grb2 and E3b1 for binding to the same Sos @-@ 1 peptide , coupled to the readily detectable biological competition , strongly suggests that the SH3 @-@ mediated contact is the major determinant of the interaction between Sos @-@ 1 and E3b1 .
# ::amr-annotator SDL-AMR-09
# ::alignments 3-1.5.2 3-1.5.2.r 4-1.5 4-1.5.r 5-1.5.1.r 6-1.5.1 9-1.1.4 10-1.1 13-1.1.1.1.1 13-1.1.2.1.1 14-1.1.1.1.2 14-1.1.2.1.2 15-1.1.1.r 16-1.1.1.2.1.1 17-1.1.2.r 18-1.1.2.2.1.1 19-1.1.3.r 20-1.1.3 21-1.1.3.1.r 23-1.1.3.1.1 24-1.1.3.1.2.1.1 26-1.1.3.1.2.1.1 27-1.1.3.1 29-1.1.5 30-1.1.5.1.r 32-1.1.5.1.2.2 32-1.1.5.1.2.2.r 34-1.1.5.1.1 35-1.1.5.1 37-1.3 37-1.3.r 38-1 41-1.2.1.1.1.1.1 43-1.2.1.1 44-1.2.1 47-1.2.3 51-1.2.2 53-1.2.2.1 54-1.2.2.1 55-1.2.2.1 57-1.1.2.2.1.1
# ::id pmid_1177_7939.69
# ::preferred 
(s / suggest-01~e.38
      :ARG0 (c / compete-01~e.10
            :ARG0~e.15 (p8 / protein-segment
                  :name (n6 / name :op1 "SH3"~e.13 :op2 "domain"~e.14)
                  :part-of (p3 / protein
                        :name (n3 / name :op1 "Grb2"~e.16)))
            :ARG1~e.17 (p / protein-segment
                  :name (n / name :op1 "SH3"~e.13 :op2 "domain"~e.14)
                  :part-of (p4 / protein
                        :name (n4 / name :op1 "E3b1"~e.18,57)))
            :ARG2~e.19 (b / bind-01~e.20
                  :ARG2~e.21 (p5 / peptide~e.27
                        :ARG1-of (s3 / same-01~e.23)
                        :part-of (p6 / protein
                              :name (n5 / name :op1 "Sos-1"~e.24,26))))
            :ARG2-of (e / efficient-01~e.9
                  :ARG1 p)
            :ARG1-of (c2 / couple-01~e.29
                  :ARG2~e.30 (c3 / compete-01~e.35
                        :mod (b2 / biology~e.34)
                        :ARG1-of (d / detect-01
                              :mod (p7 / possible)
                              :manner~e.32 (r / ready~e.32)))))
      :ARG1 (d2 / determine-01
            :ARG0 (c4 / contact~e.44
                  :ARG1-of (m / mediate-01~e.43
                        :ARG0 (p2 / protein-segment
                              :name (n8 / name :op1 "SH3"~e.41))))
            :ARG1 (i / interact-01~e.51
                  :ARG0 p6~e.53,54,55
                  :ARG1 p4)
            :mod (m2 / major~e.47))
      :manner~e.37 (s2 / strong~e.37)
      :ARG2-of (c6 / contrast-01)
      :condition~e.4 (c5 / condition~e.4
            :mod~e.5 (a / analyze-01~e.6)
            :poss~e.3 (w / we~e.3)))

# ::tok E3b1 is a limiting factor in Rac activation
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.1.1 1-1.2.r 3-1.1 4-1 5-1.1.1.r 6-1.1.1.1.1.1 7-1.1.1
# ::id pmid_1177_7939.70
# ::preferred 
(f / factor~e.4
      :ARG0-of (l / limit-01~e.3
            :ARG1~e.5 (a / activate-01~e.7
                  :ARG1 (e / enzyme
                        :name (n2 / name :op1 "Rac"~e.6))))
      :domain~e.1 (p / protein
            :name (n / name :op1 "E3b1"~e.0)))

# ::tok The competition between E3b1 and Grb2 for the same binding site on Sos @-@ 1 implies that an individual Sos @-@ 1 molecule can only be part of one GEF complex at a time .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1 3-1.1.1.1.1 5-1.1.2.1.1 6-1.1.3.r 8-1.1.3.1 9-1.1.3.2 10-1.1.3 11-1.1.3.3.r 12-1.1.3.3.1.1 14-1.1.3.3.1.1 15-1 16-1.2.r 18-1.2.1.2.2 19-1.2.1.2.1 21-1.1.3.3.1.1 21-1.2.1.1.1 22-1.2.1.1 22-1.2.1.2 23-1.2 24-1.2.1.4 25-1.2.1.r 26-1.2.1 26-1.2.1.1.2.r 28-1.2.1.1.1 29-1.2.1.1.2.1.1 30-1.2.1.1 31-1.2.1.3 32-1.2.1.3 33-1.2.1.3
# ::id pmid_1177_7939.71
# ::preferred 
(i / imply-01~e.15
      :ARG0 (c / compete-01~e.1
            :ARG0 (p / protein
                  :name (n / name :op1 "E3b1"~e.3))
            :ARG1 (p2 / protein
                  :name (n2 / name :op1 "Grb2"~e.5))
            :ARG2~e.6 (p7 / protein-segment~e.10
                  :ARG1-of (s2 / same-01~e.8)
                  :ARG1-of (b / bind-01~e.9)
                  :part-of~e.11 (p3 / protein
                        :name (n3 / name :op1 "Sos-1"~e.12,14,21))))
      :ARG1~e.16 (p4 / possible~e.23
            :domain~e.25 (h / have-part-91~e.26
                  :ARG1 (m / macro-molecular-complex~e.22,30
                        :quant "1"~e.21,28
                        :part~e.26 (p6 / protein
                              :name (n4 / name :op1 "GEF"~e.29)))
                  :ARG2 (m2 / molecule~e.22
                        :mod p3~e.19
                        :mod (i2 / individual~e.18))
                  :manner (a / at-a-time~e.31,32,33)
                  :mod (o / only~e.24))))

# ::tok However , different pools of Sos @-@ 1 , either bound to Grb2 or to E3b1 , could exist in vivo .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 2-1.1.1.1.1 3-1.1.1.1 4-1.1.1.1.2.r 5-1.1.1.1.2.1.1 7-1.1.1.1.2.1.1 10-1.1.1.1.2 10-1.1.1.1.2.2 10-1.1.1.1.2.2.r 11-1.1.1.1.2.2.1.r 12-1.1.1.1.2.2.1.1.1.1 13-1.1.1.1.2.2.1 15-1.1.1.1.2.2.1.2.1.1 17-1.1 18-1.1.1 19-1.1.2 20-1.1.2
# ::id pmid_1177_7939.72
# ::preferred 
(c2 / contrast-01~e.0
      :ARG2 (p / possible~e.17
            :domain (e / exist-01~e.18
                  :ARG1 (p2 / pool~e.3
                        :ARG1-of (d / differ-02~e.2)
                        :consist-of~e.4 (e2 / enzyme~e.10
                              :name (n / name :op1 "Sos-1"~e.5,7)
                              :ARG1-of~e.10 (b / bind-01~e.10
                                    :ARG2~e.11 (o / or~e.13
                                          :op1 (p4 / protein
                                                :name (n2 / name :op1 "Grb2"~e.12))
                                          :op2 (p5 / protein
                                                :name (n3 / name :op1 "E3b1"~e.15)))))))
            :manner (i / in-vivo~e.19,20)))

# ::tok We tried to gain insight into this issue .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1 3-1.2 4-1.2.2 5-1.2.2.1.r 6-1.2.2.1.1 7-1.2.2.1
# ::id pmid_1177_7939.73
# ::preferred 
(t2 / try-01~e.1
      :ARG0 (w / we~e.0)
      :ARG1 (g / gain-02~e.3
            :ARG0 w
            :ARG1 (i2 / insight~e.4
                  :topic~e.5 (i / issue~e.7
                        :mod (t / this~e.6)))))

# ::tok We showed that BIAcore measurements revealed similar kinetic parameters for the SH3 @-@ mediated S/G and S/E interactions ( <xref ref-type="fig" rid="fig2"> Fig . 2 </xref> D ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1 2-1.2.r 3-1.2.1.1.1.1.1 4-1.2.1 4-1.2.1.1 4-1.2.1.1.r 5-1.2 6-1.2.2.1 7-1.2.2.2 8-1.2.2 11-1.2.2.3.3.1.1.1 13-1.2.2.3.3 17-1.2.2.1.1 17-1.2.2.3
# ::id pmid_1177_7939.74
# ::preferred 
(s / show-01~e.1
      :ARG0 (w / we~e.0)
      :ARG1~e.2 (r2 / reveal-01~e.5
            :ARG0 (t / thing~e.4
                  :ARG1-of~e.4 (m / measure-01~e.4
                        :ARG0 (c / company
                              :name (n / name :op1 "BIAcore"~e.3))))
            :ARG1 (p / parameter~e.8
                  :ARG1-of (r / resemble-01~e.6
                        :ARG2 (i2 / interact-01~e.17
                              :ARG0 (p5 / protein
                                    :name (n3 / name :op1 "Sos-1"))
                              :ARG1 (p4 / protein
                                    :name (n5 / name :op1 "E3b1"))
                              :ARG1-of (m2 / mediate-01~e.13
                                    :ARG0 (p2 / protein-segment
                                          :name (n2 / name :op1 "SH3"~e.11)))))
                  :mod (k / kinetic~e.7)
                  :topic (i / interact-01~e.17
                        :ARG0 p5
                        :ARG1 (p3 / protein
                              :name (n4 / name :op1 "Grb2"))
                        :ARG1-of m2)))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "2D")))

# ::tok However , when we measured the relative abundance of S/G and S/E complexes within the cell , we found a 10 @-@ fold excess of the former ( <xref ref-type="fig" rid="fig5"> Fig . 5 </xref> A ) , under conditions in which quantitative immunoprecipitation of the adaptor molecules , Grb2 and E3b1 , was achieved ( <xref ref-type="fig" rid="fig5"> Fig . 5 </xref> A ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 2-1.1.3.r 3-1.1.1 4-1.1.3 6-1.1.3.1.3 7-1.1.3.1 12-1.1.2.2 15-1.1.3.1.2 17-1.1.1 18-1.1 20-1.1.2.3.1 23-1.1.2 24-1.1.2.3 39-1.1.2.5.r 42-1.1.2.5.1.2 46-1.1.2.5.1.1.3 47-1.1.2.1 49-1.1.2.1.2.1.1 50-1.1.2.5.1.1 51-1.1.2.2.1.1.1 54-1.1.2.5
# ::id pmid_1177_7939.75
# ::preferred 
(c3 / contrast-01~e.0
      :ARG2 (f / find-01~e.18
            :ARG0 (w / we~e.3,17)
            :ARG1 (e / exceed-01~e.23
                  :ARG0 (m / macro-molecular-conplex~e.47
                        :part (p5 / protein
                              :name (n / name :op1 "Sos-1"))
                        :part (p / protein
                              :name (n2 / name :op1 "Grb2"~e.49)))
                  :ARG1 (m2 / macro-molecular-complex~e.12
                        :part (p2 / protein
                              :name (n3 / name :op1 "E3b1"~e.51))
                        :part p5)
                  :ARG2 (p3 / product-of~e.24 :op1 "10"~e.20)
                  :ARG1-of (d / describe-01
                        :ARG0 (f2 / figure :mod "5A"))
                  :condition~e.39 (a2 / achieve-01~e.54
                        :ARG1 (i / immunoprecipitate-00
                              :ARG1 (a5 / and~e.50
                                    :op1 p
                                    :op2 p2
                                    :mod (a4 / adaptor~e.46))
                              :mod (q / quantity~e.42))
                        :ARG1-of (d2 / describe-01
                              :ARG0 (f3 / figure :mod "5A"))))
            :time~e.2 (m3 / measure-01~e.4
                  :ARG1 (a / abound-01~e.7
                        :ARG1 (a6 / and
                              :op1 m
                              :op2 m2)
                        :ARG2 (c / cell~e.15)
                        :degree (r / relative~e.6)))))

# ::tok Thus , the data indicate that two pools of Sos @-@ 1 , associated with different adaptors , exist simultaneously in the cell .
# ::amr-annotator SDL-AMR-09
# ::alignments 3-1.1.1 4-1.1 5-1.1.2.r 6-1.1.2.1.1 7-1.1.2.1 8-1.1.2.1.2.r 9-1.1.2.1.2.1.1 11-1.1.2.1.2.1.1 13-1.1.2.1.3 14-1.1.2.1.3.1.r 15-1.1.2.1.3.1.1 16-1.1.2.1.3.1 18-1.1.2 19-1.1.2.2 19-1.1.2.2.r 20-1.1.2.3.r 22-1.1.2.3
# ::id pmid_1177_7939.76
# ::preferred 
(i / infer-01
      :ARG1 (i2 / indicate-01~e.4
            :ARG0 (d / data~e.3)
            :ARG1~e.5 (e / exist-01~e.18
                  :ARG1 (p / pool~e.7
                        :quant "2"~e.6
                        :consist-of~e.8 (p2 / protein
                              :name (n / name :op1 "Sos-1"~e.9,11))
                        :ARG1-of (a / associate-01~e.13
                              :ARG2~e.14 (a2 / adaptor~e.16
                                    :ARG1-of (d2 / differ-02~e.15))))
                  :manner~e.19 (s / simultaneous~e.19)
                  :location~e.20 (c / cell~e.22))))

# ::tok They further suggest that the pool of E3b1 , available for binding to Sos @-@ 1 , is reduced relative to that of Grb2 , and may be rate @-@ limiting .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1.3 2-1 3-1.2.r 5-1.2.1.1 5-1.2.1.2 6-1.2.1.1.1.r 7-1.2.1.1.1.1.1 9-1.2.1.1.1.2 10-1.2.1.1.1.2.1.r 11-1.2.1.1.1.2.1 12-1.2.1.1.1.2.1.2.r 13-1.2.1.1.1.2.1.2.1.1 15-1.2.1.1.1.2.1.2.1.1 18-1.2.1 22-1.2.1.2.1.r 23-1.2.1.2.1.1.1 25-1.2 26-1.2.2 27-1.2.2.1.r 28-1.2.2.1.2 30-1.2.2.1
# ::id pmid_1177_7939.77
# ::preferred 
(s / suggest-01~e.2
      :ARG0 (t / they~e.0)
      :ARG1~e.3 (a3 / and~e.25
            :op1 (r / reduce-01~e.18
                  :ARG1 (p / pool~e.5
                        :consist-of~e.6 (p3 / protein
                              :name (n / name :op1 "E3b1"~e.7)
                              :mod (a / available~e.9
                                    :purpose~e.10 (b / bind-01~e.11
                                          :ARG1 p
                                          :ARG2~e.12 (p4 / protein
                                                :name (n2 / name :op1 "Sos-1"~e.13,15))))))
                  :compared-to (p5 / pool~e.5
                        :consist-of~e.22 (p6 / protein
                              :name (n3 / name :op1 "Grb2"~e.23))))
            :op2 (p2 / possible~e.26
                  :domain~e.27 (l / limit-01~e.30
                        :ARG0 p
                        :ARG1 (r2 / rate~e.28))))
      :degree (f / further~e.1))

# ::tok Indeed , overexpression of E3b1 resulted in increased PAK65 activity , an indicator of Rac activation ( <xref ref-type="bibr" rid="bib27"> Manser et al. , 1994 </xref> ) ( <xref ref-type="fig" rid="fig5"> Fig . 5 </xref> B ) , which was abrogated by a dominant negative Rac mutant ( <xref ref-type="fig" rid="fig5"> Fig . 5 </xref> B ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.4 4-1.1.1.1.1 5-1 6-1.2.r 7-1.2.2 8-1.2.1.1.1 9-1.2 12-1.2.3 13-1.2.3.1.r 14-1.2.3.1.1.1.1 15-1.2.3.1 20-1.3.1.1.1.1.1.1 21-1.3.1 21-1.3.1.1.1 22-1.3.1.1.1.2.1 24-1.3.1.1.2.1 40-1.2.3.1.2 41-1.2.3.1.2.1.r 43-1.2.3.1.2.1 43-1.2.3.1.2.1.2 43-1.2.3.1.2.1.2.r 44-1.2.3.1.2.1.4 45-1.2.3.1.2.1.1.1 46-1.2.3.1.2.1.3
# ::id pmid_1177_7939.78
# ::preferred 
(r / result-01~e.5
      :ARG1 (o3 / overexpress-00
            :ARG2 (p4 / protein
                  :name (n / name :op1 "E3b1"~e.4)))
      :ARG2~e.6 (a / act-02~e.9
            :ARG0 (e4 / enzyme
                  :name (n2 / name :op1 "PAK65"~e.8))
            :ARG1-of (i2 / increase-01~e.7)
            :ARG0-of (i / indicate-01~e.12
                  :ARG1~e.13 (a2 / activate-01~e.15
                        :ARG1 (e2 / enzyme
                              :name (n3 / name :op1 "Rac"~e.14))
                        :ARG1-of (a3 / abrogate-01~e.40
                              :ARG2~e.41 (e3 / enzyme~e.43
                                    :name (n5 / name :op1 "Rac"~e.45)
                                    :ARG0-of~e.43 (d4 / dominate-01~e.43)
                                    :ARG1-of (m / mutate-01~e.46)
                                    :mod (n6 / negative~e.44))
                              :ARG1-of (d5 / describe-01
                                    :ARG0 (f2 / figure :mod "5B"))))))
      :ARG1-of (d2 / describe-01
            :ARG0 (a5 / and~e.21
                  :op1 (p / publication-91
                        :ARG0 (a4 / and~e.21
                              :op1 (p2 / person
                                    :name (n4 / name :op1 "Manser"~e.20))
                              :op2 (p5 / person
                                    :mod (o2 / other~e.22)))
                        :time (d3 / date-entity :year "1994"~e.24))
                  :op2 f2))
      :mod (i3 / indeed~e.0))

# ::tok On the other hand , overexpression of Sos @-@ 1 did not lead to increased PAK65 activity .
# ::amr-annotator SDL-AMR-09
# ::alignments 7-1.1.2.1.1.1 9-1.1.2.1.1.1 11-1.1.1 11-1.1.1.r 12-1.1 13-1.1.3.r 14-1.1.3.2 15-1.1.3.1.1.1 16-1.1.3
# ::id pmid_1177_7939.79
# ::preferred 
(c / contrast-01
      :ARG2 (l / lead-03~e.12
            :polarity~e.11 "-"~e.11
            :ARG0 (o2 / overexpress-00
                  :ARG2 (p / protein
                        :name (n / name :op1 "Sos-1"~e.7,9))
                  :degree (o / over))
            :ARG2~e.13 (a / act-02~e.16
                  :ARG0 (e2 / enzyme
                        :name (n2 / name :op1 "PAK65"~e.15))
                  :ARG1-of (i2 / increase-01~e.14))))

# ::tok An additional corollary of this hypothesis is that the overexpression of E3b1 , by facilitating the formation of a trimeric complex with Eps8 and Sos @-@ 1 , should directly lead to activation of Rac .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1 4-1.2.1.2 5-1.2.1 5-1.2.1.1 5-1.2.1.1.r 6-1.1.r 11-1.1.1.1.1.1.1 14-1.1.1.4 16-1.1.1.4.2 20-1.1.1.4.2.1 21-1.1.1.4.2.1.2.r 22-1.1.1.4.2.1.2.1.1 24-1.1.1.4.2.1.3.1.1 26-1.1.1.4.2.1.3.1.1 28-1.1 29-1.1.1.3 29-1.1.1.3.r 30-1.1.1 31-1.1.1.2.r 32-1.1.1.2 33-1.1.1.2.1.r 34-1.1.1.2.1.1.1
# ::id pmid_1177_7939.80
# ::preferred 
(c / corollary~e.2
      :domain~e.6 (r / recommend-01~e.28
            :ARG1 (l / lead-03~e.30
                  :ARG0 (o2 / overexpress-00
                        :ARG2 (p2 / protein
                              :name (n2 / name :op1 "E3b1"~e.11)))
                  :ARG2~e.31 (a / activate-01~e.32
                        :ARG1~e.33 (p / protein
                              :name (n / name :op1 "Rac"~e.34)))
                  :manner~e.29 (d / direct~e.29)
                  :manner (f / facilitate-01~e.14
                        :ARG0 o2
                        :ARG1 (f2 / form-01~e.16
                              :ARG1 (m / macro-molecular-complex~e.20
                                    :part p2
                                    :part~e.21 (e2 / enzyme
                                          :name (n3 / name :op1 "Eps8"~e.22))
                                    :part (p3 / protein
                                          :name (n4 / name :op1 "Sos-1"~e.24,26)))))))
      :ARG0-of (a2 / add-01
            :ARG1 (t2 / thing~e.5
                  :ARG1-of~e.5 (h / hypothesize-01~e.5)
                  :mod (t / this~e.4))))

# ::tok To test this prediction E3b1 or a mutant of E3b1 ( E3b1 @-@ DY ) , bearing alanine substitutions of the DY residues critical for the interaction with Eps8 ( <xref ref-type="bibr" rid="bib28"> Mongiovi et al. , 1999 </xref> ) , were used to infect wild @-@ type and eps8 @<sup> −/− </sup> fibroblasts .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.2.2 2-1.2.2.1.2 3-1.2.2.1 3-1.2.2.1.1 3-1.2.2.1.1.r 4-1.1.1.1.1 5-1.1 7-1.1.2 7-1.1.2.2 7-1.1.2.2.r 7-1.2.1.2.1 9-1.1.1.1.1 11-1.1.1.1.1 13-1.1.2.1.1 16-1.1.2.3 17-1.1.2.3.1.1.1.1 18-1.1.2.3.1 19-1.1.2.3.1.2.r 21-1.1.2.3.1.2.1.1.1 22-1.1.2.3.1.2 23-1.1.2.3.1.3 24-1.1.2.3.1.2.2.r 26-1.1.2.3.1.2.2 27-1.1.2.3.1.2.2.2.r 28-1.1.2.3.1.2.2.2.1.1 33-1.2.2.2.1.1.1.1.1 34-1.2.2.2.1.1 35-1.2.2.2.1.1.2.1 37-1.2.2.2.1.2.1 42-1 42-1.2.2.r 44-1.2 45-1.2.1.1.1 47-1.2.1.1.1 48-1.2.1 49-1.1.2.3.1.2.2.2.1.1 53-1.2.1.1 53-1.2.1.2
# ::id pmid_1177_7939.81
# ::preferred 
(u / use-01~e.42
      :ARG1 (o / or~e.5
            :op1 (p / protein
                  :name (n2 / name :op1 "E3b1"~e.4,9,11))
            :op2 (p2 / protein~e.7
                  :name (n3 / name :op1 "E3b1-DY"~e.13)
                  :ARG2-of~e.7 (m / mutate-01~e.7
                        :ARG1 p)
                  :ARG0-of (b / bear-01~e.16
                        :ARG1 (s / substitute-01~e.18
                              :ARG1 (a / amino-acid
                                    :name (n / name :op1 "alanine"~e.17))
                              :ARG2~e.19 (r / residue~e.22
                                    :mod (p8 / protein-segment
                                          :name (n4 / name :op1 "DY"~e.21))
                                    :purpose~e.24 (i / interact-01~e.26
                                          :ARG0 p2
                                          :ARG1~e.27 (e2 / enzyme
                                                :name (n5 / name :op1 "Eps8"~e.28,49))))
                              :mod (c / critical~e.23)))))
      :ARG2 (i2 / infect-01~e.44
            :ARG1 (a2 / and~e.48
                  :op1 (f / fibroblast~e.53
                        :mod (w / wild-type~e.45,47))
                  :op2 (f2 / fibroblast~e.53
                        :ARG0-of (m2 / mutate-01~e.7
                              :ARG1 e2)))
            :purpose~e.42 (t2 / test-01~e.1
                  :ARG1 (t3 / thing~e.3
                        :ARG1-of~e.3 (p3 / predict-01~e.3)
                        :mod (t4 / this~e.2))
                  :ARG1-of (d2 / describe-01
                        :ARG0 (p4 / publication-91
                              :ARG0 (a3 / and~e.34
                                    :op1 (p6 / person
                                          :name (n7 / name :op1 "Mongiovi"~e.33))
                                    :op2 (p7 / person
                                          :mod (o2 / other~e.35)))
                              :time (d3 / date-entity :year "1999"~e.37))))))

# ::tok The levels of GTP @-@ bound Rac were then determined by in vitro binding assays using the immobilized CRIB domain of PAK65 ( <xref ref-type="bibr" rid="bib27"> Manser et al. , 1994 </xref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1 2-1.1.1.r 3-1.1.1.2.1.1.1 5-1.1.1 5-1.1.1.2 5-1.1.1.2.r 6-1.1.1.1.1 8-1.4 9-1 10-1.2.r 11-1.2.3 12-1.2.3 13-1.2.1 14-1.2 15-1.2.2 18-1.2.2.1.1.1 19-1.2.2.1.1.2 21-1.2.2.1.3.1.1 26-1.3.1.1.1.1.1 27-1.3.1.1 28-1.3.1.1.2.1 30-1.3.1.2.1
# ::id pmid_1177_7939.82
# ::preferred 
(d2 / determine-01~e.9
      :ARG1 (l / level~e.1
            :quant-of~e.2 (p / protein~e.5
                  :name (n / name :op1 "Rac"~e.6)
                  :ARG2-of~e.5 (b / bind-01~e.5
                        :ARG1 (s / small-molecule
                              :name (n2 / name :op1 "GTP"~e.3)))))
      :ARG2~e.10 (a / assay-00~e.14
            :manner (b2 / bind-01~e.13)
            :ARG0-of (u / use-01~e.15
                  :ARG1 (p5 / protein-segment
                        :name (n6 / name :op1 "CRIB"~e.18 :op2 "domain"~e.19)
                        :ARG1-of (m / mobilize-01 :polarity "-")
                        :part-of (e3 / enzyme
                              :name (n4 / name :op1 "PAK65"~e.21))))
            :manner (i / in-vitro~e.11,12))
      :ARG1-of (d4 / describe-01
            :ARG0 (p2 / publication-91
                  :ARG0 (a2 / and~e.27
                        :op1 (p4 / person
                              :name (n3 / name :op1 "Manser"~e.26))
                        :op2 (p6 / person
                              :mod (o / other~e.28)))
                  :time (d5 / date-entity :year "1994"~e.30)))
      :time (t / then~e.8))

# ::tok E3b1 , but not the E3b1 mutant impaired in Eps8 binding , caused a readily detectable increase in Rac @-@ GTP levels in wild type , but not in eps8 @<sup> −/− </sup> fibroblasts ( <xref ref-type="fig" rid="fig5"> Fig . 5 </xref> C ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1.1 0-1.2.2.1.1 2-1 3-1.2.1 3-1.2.1.r 5-1.1.1.1.1 5-1.2.2.1.1 6-1.1.2.3.2.1.3.1 6-1.1.2.3.2.1.3.1.2 6-1.1.2.3.2.1.3.1.2.r 6-1.2.2 6-1.2.2.2 6-1.2.2.2.r 7-1.2.2.3 8-1.2.2.3.1.r 9-1.2.2.3.1.2.1.1 10-1.2.2.3.1 12-1.1 12-1.2 14-1.1.2.2.2 16-1.1.2 17-1.1.2.1.r 18-1.1.2.1.1.1.1.1 20-1.1.2.1.1.2.1.1 21-1.1.2.1 23-1.1.2.3.1.1 24-1.1.2.3.1.1 26-1.1.2.3.2 27-1.1.2.3.2.1.1 27-1.1.2.3.2.1.1.r 29-1.1.2.3.2.1.3.1.1.1 31-1.1.2.3.2.1.3.1.2.1 33-1.1.2.3.1 33-1.1.2.3.2.1.3
# ::id pmid_1177_7939.83
# ::preferred 
(c3 / contrast-01~e.2
      :ARG1 (c / cause-01~e.12
            :ARG0 (p / protein
                  :name (n / name :op1 "E3b1"~e.0,5))
            :ARG1 (i / increase-01~e.16
                  :ARG1~e.17 (l / level~e.21
                        :quant-of (m3 / macro-molecular-complex
                              :part (p2 / protein
                                    :name (n2 / name :op1 "Rac"~e.18))
                              :part (s / small-molecule
                                    :name (n6 / name :op1 "GTP"~e.20))))
                  :ARG1-of (d3 / detect-01
                        :mod (p3 / possible)
                        :mod (r / ready~e.14))
                  :ARG1-of (b2 / be-located-at-91
                        :ARG2 (f4 / fibroblast~e.33
                              :mod (w2 / wild-type~e.23,24))
                        :ARG1-of (c2 / contrast-01~e.26
                              :ARG2 (b3 / be-located-at-91
                                    :polarity~e.27 "-"~e.27
                                    :ARG1 i
                                    :ARG2 (f3 / fibroblast~e.33
                                          :mod (e / enzyme~e.6
                                                :name (n3 / name :op1 "eps8"~e.29)
                                                :ARG2-of~e.6 (m2 / mutate-01~e.6 :mod "−/−"~e.31))))))))
      :ARG2 (c4 / cause-01~e.12
            :polarity~e.3 "-"~e.3
            :ARG0 (e2 / enzyme~e.6
                  :name (n4 / name :op1 "E3b1"~e.0,5)
                  :ARG1-of~e.6 (m / mutate-01~e.6)
                  :ARG1-of (i2 / impair-01~e.7
                        :ARG0~e.8 (b / bind-01~e.10
                              :ARG1 e2
                              :ARG2 (e3 / enzyme
                                    :name (n5 / name :op1 "Eps8"~e.9)))))
            :ARG1 i)
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure :mod "5C")))

# ::tok Thus , the overexpression of E3b1 is sufficient to activate Rac and this effect is strictly dependent on Eps8 @<bold> . </bold>
# ::amr-annotator SDL-AMR-09
# ::alignments 5-1.1.1.1.1.1.1 7-1.1.1 9-1.1.1.2 10-1.1.1.2.2.1.1 11-1.1 12-1.1.2.1.1 13-1.1.2.1 15-1.1.2.3 16-1.1.2 17-1.1.2.2.r 18-1.1.2.2.1.1
# ::id pmid_1177_7939.84
# ::preferred 
(i2 / infer-01
      :ARG1 (a2 / and~e.11
            :op1 (s / suffice-01~e.7
                  :ARG0 (o2 / overexpress-00
                        :ARG2 (p / protein
                              :name (n / name :op1 "E3b1"~e.5))
                        :degree (o / over))
                  :ARG1 (a / activate-01~e.9
                        :ARG0 o2
                        :ARG1 (p2 / protein
                              :name (n2 / name :op1 "Rac"~e.10))))
            :op2 (d / depend-01~e.16
                  :ARG0 (e2 / effect~e.13
                        :mod (t / this~e.12))
                  :ARG1~e.17 (e3 / enzyme
                        :name (n3 / name :op1 "Eps8"~e.18))
                  :mod (s2 / strict~e.15))))

# ::tok The indispensability of E3b1 in the cascade of events leading to Rac activation and Rac @-@ dependent actin reorganization was further analyzed at the biological level .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1 3-1.1.2.1.1 6-1.1.3 7-1.1.3.1.r 8-1.1.3.1 9-1.1.3.1.1 10-1.1.3.1.1.1.r 11-1.1.3.1.1.1.1.1.1.1 12-1.1.3.1.1.1.1 14-1.1.3.1.1.1.1.1.1.1 16-1.1.3.1.1.1.2.1 16-1.1.3.1.1.1.2.1.2 16-1.1.3.1.1.1.2.1.2.r 17-1.1.3.1.1.1.2.1.1.1 18-1.1.3.1.1.1.2 20-1.2 21-1 22-1.3.r 24-1.3.1 25-1.3
# ::id pmid_1177_7939.85
# ::preferred 
(a / analyze-01~e.21
      :ARG1 (d / dispense-01
            :polarity "-"~e.1
            :ARG1 (e / enzyme
                  :name (n / name :op1 "E3b1"~e.3))
            :purpose (c / cascade-01~e.6
                  :subevent~e.7 (e2 / event~e.8
                        :ARG0-of (l / lead-03~e.9
                              :ARG2~e.10 (a4 / and
                                    :op1 (a2 / activate-01~e.12
                                          :ARG1 (p / protein
                                                :name (n2 / name :op1 "Rac"~e.11,14)))
                                    :op2 (r / reorganize-01~e.18
                                          :ARG1 (p2 / protein~e.16
                                                :name (n3 / name :op1 "actin"~e.17)
                                                :ARG0-of~e.16 (d2 / depend-01~e.16
                                                      :ARG1 p)))))))
            :mod (p3 / possible))
      :time (f / further~e.20)
      :manner~e.22 (l2 / level~e.25
            :mod (b / biology~e.24)))

# ::tok We have previously shown that interference with E3b1 functions , by microinjection of anti @-@ E3b1 antibodies , inhibited PDGF @-@ induced ruffles ( <xref ref-type="bibr" rid="bib40"> Scita et al. 1999 </xref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 2-1.3 3-1 4-1.2.r 5-1.2.1 6-1.2.1.1.r 7-1.2.1.1.1.1.1 8-1.2.1.1 13-1.2.1.2.1.1 15-1.2.1.2.1.1.1 16-1.2.1.2.1 18-1.2 19-1.2.2.1.1.1.1 21-1.2.2.1 22-1.2.2 27-1.4.1.1.1.1.1 28-1.4.1.1 29-1.4.1.1.2.1 30-1.4.1.2.1
# ::id pmid_1177_7939.86
# ::preferred 
(s / show-01~e.3
      :ARG0 (w2 / we~e.0)
      :ARG1~e.4 (i3 / inhibit-01~e.18
            :ARG0 (i / interfere-01~e.5
                  :ARG1~e.6 (f / function-01~e.8
                        :ARG0 (p6 / protein
                              :name (n / name :op1 "E3b1"~e.7)))
                  :manner (m2 / microinject-00
                        :ARG1 (a / antibody~e.16
                              :ARG0-of (c / counter-01~e.13
                                    :ARG1 f~e.15))
                        :ARG2 f))
            :ARG1 (r / ruffle-02~e.22
                  :ARG1-of (i4 / induce-01~e.21
                        :ARG0 (s2 / small-molecule
                              :name (n3 / name :op1 "PDGF"~e.19)))))
      :time (p / previous~e.2)
      :ARG1-of (d2 / describe-01
            :ARG0 (p4 / publication-91
                  :ARG0 (a2 / and~e.28
                        :op1 (p2 / person
                              :name (n2 / name :op1 "Scita"~e.27))
                        :op2 (p3 / person
                              :mod (o / other~e.29)))
                  :time (d3 / date-entity :year "1999"~e.30))))

# ::tok We also showed that in eps8 @<sup> −/− </sup> cells , ruffling induced by PDGF and activated Ras , but not by activated Rac , was inhibited .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1.3 2-1 4-1.4.r 5-1.4.1.1.1 7-1.4.1.2.1 9-1.4 11-1.2.1 12-1.2.1.1 12-1.2.1.1.2.1 13-1.2.1.1.1.r 14-1.2.1.1.1.1.1.1 15-1.2.1.1.1 16-1.2.1.1.1.2.2 17-1.2.1.1.1.2.1.1 19-1.2.1.1.2 20-1.2.1.1.2.1.1 20-1.2.1.1.2.1.1.r 21-1.2.1.1.2.1.2.r 22-1.2.1.1.2.1.2.2 23-1.2.1.1.2.1.2.1.1 26-1.2
# ::id pmid_1177_7939.87
# ::preferred 
(s / show-01~e.2
      :ARG0 (w / we~e.0)
      :ARG1 (i / inhibit-01~e.26
            :ARG1 (r / ruffle-02~e.11
                  :ARG1-of (i2 / induce-01~e.12
                        :ARG0~e.13 (a2 / and~e.15
                              :op1 (s2 / small-molecule
                                    :name (n3 / name :op1 "PDGF"~e.14))
                              :op2 (e2 / enzyme
                                    :name (n4 / name :op1 "Ras"~e.17)
                                    :ARG1-of (a3 / activate-01~e.16)))
                        :ARG1-of (c2 / contrast-01~e.19
                              :ARG2 (i3 / induce-01~e.12
                                    :polarity~e.20 "-"~e.20
                                    :ARG0~e.21 (e3 / enzyme
                                          :name (n5 / name :op1 "Rac"~e.23)
                                          :ARG1-of a3~e.22)
                                    :ARG1 r)))))
      :mod (a / also~e.1)
      :location~e.4 (c / cell~e.9
            :part (e / enzyme
                  :name (n / name :op1 "eps8"~e.5)
                  :ARG2-of (m / mutate-01 :mod "−/−"~e.7))))

# ::tok Ruffling , however , could be restored upon reexpression of Eps8 , but not of an Eps8 mutant unable to bind to E3b1 ( <xref ref-type="bibr" rid="bib40"> Scita et al. , 1999 </xref> ) , suggesting that the Eps8–E3b1 @-@ based complex is implicated in the transmission of signal between Ras and Rac .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.2 2-1 4-1.1 4-1.1.1.1.1.2.1 5-1.1.1.r 6-1.1.1 6-1.1.1.1.1.2.1.2 10-1.1.1.1.1.1.1 12-1.1.1.1.1 12-1.1.1.1.1.2 12-1.1.1.1.1.2.r 13-1.1.1.1.1.2.1.1.r 16-1.1.1.1.1.2.1.2.1.1.1.1 17-1.1.1.1.1.2.1.2.1.1 17-1.1.1.1.1.2.1.2.1.1.2 17-1.1.1.1.1.2.1.2.1.1.2.r 18-1.1.1.1.1.2.1.1 18-1.1.1.1.1.2.1.2.1.1.3.2 18-1.1.1.1.1.2.1.2.1.1.3.2.1 18-1.1.1.1.1.2.1.2.1.1.3.2.1.r 20-1.1.1.1.1.2.1.2.1.1.3 21-1.1.1.1.1.2.1.2.1.1.3.1.r 22-1.1.1.1.1.2.1.2.1.1.3.1.1.1 27-1.2.1.1.1.1.1 28-1.2.1.1 29-1.2.1.1.2.1 31-1.2.1.2.1 35-1.1.2 40-1.1.2.1.1.1 41-1.1.2.1.1 43-1.1.2.1 44-1.1.2.1.2.r 46-1.1.2.1.2 47-1.1.2.1.2.2.r 48-1.1.2.1.2.2 50-1.1.2.1.2.1.1.1 52-1.1.2.1.2.3.1.1
# ::id pmid_1177_7939.88
# ::preferred 
(c2 / contrast-01~e.2
      :ARG2 (p / possible~e.4
            :domain~e.5 (r / restore-01~e.6
                  :ARG0 (e2 / express-03
                        :ARG2 (e5 / enzyme~e.12
                              :name (n2 / name :op1 "Eps8"~e.10)
                              :ARG1-of~e.12 (c4 / contrast-01~e.12
                                    :ARG2 (p6 / possible~e.4
                                          :polarity~e.13 "-"~e.18
                                          :domain (r3 / restore-01~e.6
                                                :ARG0 (e6 / express-03
                                                      :ARG2 (e7 / enzyme~e.17
                                                            :name (n3 / name :op1 "Eps8"~e.16)
                                                            :ARG1-of~e.17 (m / mutate-01~e.17)
                                                            :ARG1-of (b / bind-01~e.20
                                                                  :ARG2~e.21 (e3 / enzyme
                                                                        :name (n4 / name :op1 "E3b1"~e.22))
                                                                  :mod (p4 / possible~e.18 :polarity~e.18 "-"~e.18))))
                                                :ARG1 (r2 / ruffle-02~e.0)
                                                :mod (a4 / again)))))
                        :mod (a2 / again))
                  :ARG1 r2)
            :ARG0-of (s / suggest-01~e.35
                  :ARG1 (i / implicate-01~e.43
                        :ARG1 (c / complex~e.41
                              :ARG1-of (b2 / base-02~e.40
                                    :ARG2 (a / and
                                          :op1 e5
                                          :op2 e3)))
                        :ARG2~e.44 (t / transmit-01~e.46
                              :ARG0 (e / enzyme
                                    :name (n / name :op1 "Ras"~e.50))
                              :ARG1~e.47 (s2 / signal~e.48)
                              :ARG2 (e4 / enzyme
                                    :name (n6 / name :op1 "Rac"~e.52))))))
      :ARG1-of (d2 / describe-01
            :ARG0 (p5 / publication-91
                  :ARG0 (a3 / and~e.28
                        :op1 (p2 / person
                              :name (n7 / name :op1 "Scita"~e.27))
                        :op2 (p3 / person
                              :mod (o / other~e.29)))
                  :time (d3 / date-entity :year "1999"~e.31))))

# ::tok Thus , one might predict that a mutant of E3b1 unable to associate to Eps8 should function as a dominant negative on Ras @-@ induced Rac @-@ dependent ruffling .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1.1.1 3-1.1 4-1.1.1 5-1.1.1.2.r 7-1.1.1.2.1.1 7-1.1.1.2.1.1.2 7-1.1.1.2.1.1.2.r 9-1.1.1.2.1.1.1.1 10-1.1.1.2.1.1.3.2 10-1.1.1.2.1.1.3.2.1 10-1.1.1.2.1.1.3.2.1.r 12-1.1.1.2.1.1.3 13-1.1.1.2.1.1.3.1.r 14-1.1.1.2.1.1.3.1.1.1 15-1.1.1.2 16-1.1.1.2.1 17-1.1.1.2.1.2.2.r 19-1.1.1.2.1.2.1 20-1.1.1.2.1.2 22-1.1.1.2.1.2.2.1.1.1.1 24-1.1.1.2.1.2.2.1 25-1.1.1.2.1.2.2.2.1.1.1 27-1.1.1.2.1.2.2.2 28-1.1.1.2.1.2.2
# ::id pmid_1177_7939.89
# ::preferred 
(i2 / infer-01
      :ARG1 (p5 / possible~e.3
            :domain (p6 / predict-01~e.4
                  :ARG0 (o / one~e.2)
                  :ARG1~e.5 (r2 / recommend-01~e.15
                        :ARG1 (f / function-01~e.16
                              :ARG0 (e / enzyme~e.7
                                    :name (n / name :op1 "E3b1"~e.9)
                                    :ARG1-of~e.7 (m / mutate-01~e.7)
                                    :ARG1-of (a / associate-01~e.12
                                          :ARG2~e.13 (e2 / enzyme
                                                :name (n2 / name :op1 "Eps8"~e.14))
                                          :mod (p / possible~e.10 :polarity~e.10 "-"~e.10)))
                              :ARG1 (n6 / negative~e.20
                                    :ARG0-of (d / dominate-01~e.19)
                                    :time~e.17 (r3 / ruffle-02~e.28
                                          :ARG1-of (i / induce-01~e.24
                                                :ARG0 (e3 / enzyme
                                                      :name (n4 / name :op1 "Ras"~e.22)))
                                          :ARG0-of (d2 / depend-01~e.27
                                                :ARG1 (e4 / enzyme
                                                      :name (n5 / name :op1 "Rac"~e.25))))))))))

# ::tok To test this , we cotransfected the activated versions of either Ras or Rac , together with E3b1 or the E3b1DY mutant .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.4 2-1.4.2 4-1.1 7-1.2.1.1 7-1.2.2.2 8-1.2.1 8-1.2.2 11-1.2.1.2.1.1 12-1.2 13-1.2.2.1.1.1 17-1.3.1.1.1 18-1.3 20-1.3.2.1.1 21-1.3.1 21-1.3.1.2 21-1.3.1.2.r 21-1.3.2 21-1.3.2.2 21-1.3.2.2.r
# ::id pmid_1177_7939.90
# ::preferred 
(c / cotransfect-00
      :ARG0 (w / we~e.4)
      :ARG1 (o2 / or~e.12
            :op1 (v / version~e.8
                  :ARG1-of (a / activate-01~e.7)
                  :mod (e4 / enzyme
                        :name (n5 / name :op1 "Ras"~e.11)))
            :op2 (v2 / version~e.8
                  :mod (e3 / enzyme
                        :name (n2 / name :op1 "Rac"~e.13))
                  :ARG1-of (a2 / activate-01~e.7)))
      :ARG2 (o / or~e.18
            :op1 (p / protein~e.21
                  :name (n3 / name :op1 "E3b1"~e.17)
                  :ARG1-of~e.21 (m / mutate-01~e.21))
            :op2 (p2 / protein~e.21
                  :name (n4 / name :op1 "E3b1DY"~e.20)
                  :ARG1-of~e.21 (m2 / mutate-01~e.21)))
      :purpose (t3 / test-01~e.1
            :ARG0 w
            :ARG1 (t4 / this~e.2)))

# ::tok RasV12 @-@ induced , but not RacQL @-@ induced , ruffles were efficiently inhibited by the coexpression of E3b1DY , but not of E3b1 wild type ( <xref ref-type="fig" rid="fig6"> Fig . 6 </xref> ) , supporting the contention that the ability of E3b1 to form a complex with Eps8 is required to transmit signals from Ras to Rac .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.1.1.1.1 2-1.2.1.1.2.1 4-1.2.1.1 4-1.2.1.1.2 4-1.2.1.1.2.r 5-1.2.1.1.2.1.1.1 5-1.2.1.1.2.1.1.1.r 6-1.2.1.1.2.1.1.2.1 8-1.2.1 10-1.2 12-1.3 13-1 13-1.6.1 18-1.1.1.1.1 20-1.6 21-1.6.1.1 21-1.6.1.1.r 21-1.6.1.2.1 21-1.6.1.2.1.r 23-1.6.1.2.2.1.1 24-1.6.1.2.2.2 25-1.6.1.2.2.2 32-1.4.1.1 36-1.5 38-1.5.1 43-1.6.1.2.2.1.1 44-1.5.1.1.r 45-1.5.1.1.1.1 47-1.5.1.1.1.1.1 48-1.5.1.1.1.1.1.2.r 49-1.5.1.1.1.1.1.2.1.1 50-1.5.1.1.1.1.r 51-1.5.1.1 53-1.5.1.1.2 54-1.5.1.1.2.2 55-1.5.1.1.2.1.r 56-1.5.1.1.2.1.1.1 57-1.5.1.1.2.3.r 58-1.5.1.1.2.3.1.1
# ::id pmid_1177_7939.91
# ::preferred 
(i / inhibit-01~e.13
      :ARG0 (c / coexpress-00
            :ARG1 (p / protein
                  :name (n4 / name :op1 "E3b1DY"~e.18)))
      :ARG1 (r / ruffle-02~e.10
            :ARG1-of (i2 / induce-01~e.8
                  :ARG0 (e3 / enzyme~e.4
                        :name (n2 / name :op1 "RasV12"~e.0)
                        :ARG1-of~e.4 (c2 / contrast-01~e.4
                              :ARG2 (i4 / induce-01~e.2
                                    :ARG0 (e4 / enzyme
                                          :polarity~e.5 "-"~e.5
                                          :name (n3 / name :op1 "RacQL"~e.6)))))))
      :ARG2-of (e / efficient-01~e.12
            :ARG1 c)
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "6"~e.32))
      :ARG0-of (s / support-01~e.36
            :ARG1 (c4 / contend-01~e.38
                  :ARG1~e.44 (r2 / require-01~e.51
                        :ARG1 (p3 / possible
                              :domain~e.50 (f2 / form-01~e.45
                                    :ARG1 (m / macro-molecular-complex~e.47
                                          :part p
                                          :part~e.48 (e2 / enzyme
                                                :name (n6 / name :op1 "Eps8"~e.49)))))
                        :purpose (t2 / transmit-01~e.53
                              :ARG0~e.55 (e6 / enzyme
                                    :name (n7 / name :op1 "Ras"~e.56))
                              :ARG1 (s2 / signal~e.54)
                              :ARG2~e.57 (e7 / enzyme
                                    :name (n8 / name :op1 "Rac"~e.58))))))
      :ARG1-of (c3 / contrast-01~e.20
            :ARG2 (i3 / inhibit-01~e.13
                  :polarity~e.21 "-"~e.21
                  :ARG0 (c5 / coexpress-00
                        :polarity~e.21 "-"~e.21
                        :ARG2 (p2 / protein
                              :name (n5 / name :op1 "E3b1"~e.23,43)
                              :mod (w / wild-type~e.24,25))))))

# ::tok In conclusion , our data show that two pools of Sos @-@ 1 exist in the cell , coupled respectively to Grb2 or E3b1 .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1 3-1.1.1.1 3-1.1.1.1.r 4-1.1.1 5-1.1 7-1.1.2.1.1 8-1.1.2.1 9-1.1.2.1.2.r 10-1.1.2.1.2.1.1 12-1.1.2.1.2.1.1 16-1.1.2.2 18-1.1.2.1.3 19-1.1.2.1.3.2 20-1.1.2.1.3.1.r 21-1.1.2.1.3.1.1.1.1 22-1.1.2.1.3.1 23-1.1.2.1.3.1.2.1.1
# ::id pmid_1177_7939.92
# ::preferred 
(c / conclude-02~e.1
      :ARG1 (s / show-01~e.5
            :ARG0 (d / data~e.4
                  :poss~e.3 (w / we~e.3))
            :ARG1 (b / be-located-at-91
                  :ARG1 (p / pool~e.8
                        :quant "2"~e.7
                        :consist-of~e.9 (p2 / protein
                              :name (n / name :op1 "Sos-1"~e.10,12))
                        :ARG1-of (c3 / couple-01~e.18
                              :ARG2~e.20 (o / or~e.22
                                    :op1 (p4 / protein
                                          :name (n2 / name :op1 "Grb2"~e.21))
                                    :op2 (p3 / protein
                                          :name (n3 / name :op1 "E3b1"~e.23)))
                              :mod (r / respective~e.19)))
                  :ARG2 (c2 / cell~e.16))))

# ::tok In addition , the availability of E3b1 , but not of Sos @-@ 1 , is indispensable and rate limiting in the pathway leading to Rac activation .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 0-1.1 0-1.1.r 1-1 1-1.1 1-1.1.r 4-1.1.1.2 4-1.1.1.3.1.1 4-1.1.2.3.1.2 5-1.1.1.2.1.r 6-1.1.1.2.1.1.1 8-1.1.1.3 8-1.1.2.3 9-1.1.1.1 9-1.1.1.1.r 10-1.1.1.3.1.1.1.r 11-1.1.1.3.1.1.1.1.1 13-1.1.1.3.1.1.1.1.1 15-1.1.2.3.1.2.1.r 16-1.1.1.1 16-1.1.2.3.1.1 17-1.1 18-1.1.2.2 19-1.1.2 19-1.1.2.3.1 20-1.1.2.4.r 22-1.1.2.4 23-1.1.2.4.1 24-1.1.2.4.1.1.r 25-1.1.2.4.1.1.1.1.1 26-1.1.2.4.1.1
# ::id pmid_1177_7939.93
# ::preferred 
(a / and~e.0,1
      :op2~e.0,1 (a2 / and~e.0,1,17
            :op1 (d2 / dispense-01
                  :polarity~e.9 "-"~e.9,16
                  :ARG1 (a6 / available~e.4
                        :domain~e.5 (p / protein
                              :name (n / name :op1 "E3b1"~e.6)))
                  :ARG1-of (c2 / contrast-01~e.8
                        :ARG2 (d / dispense-01
                              :ARG1 (a3 / available~e.4
                                    :domain~e.10 (p2 / protein
                                          :name (n2 / name :op1 "Sos-1"~e.11,13))))))
            :op2 (l / limit-01~e.19
                  :ARG0 a6
                  :ARG1 (r / rate~e.18)
                  :ARG1-of (c / contrast-01~e.8
                        :ARG2 (l3 / limit-01~e.19
                              :polarity "-"~e.16
                              :ARG0 (a7 / available~e.4
                                    :domain~e.15 p2)
                              :ARG1 r))
                  :location~e.20 (p3 / pathway~e.22
                        :ARG0-of (l2 / lead-03~e.23
                              :ARG2~e.24 (a4 / activate-01~e.26
                                    :ARG1 (e / enzyme
                                          :name (n3 / name :op1 "Rac"~e.25))))))))

# ::tok The dual GEF activity of Sos @-@ 1 depends on its presence in distinct complexes
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.3 2-1.1.2.1.1 5-1.1.1.1.1 7-1.1.1.1.1 8-1 10-1.2.2 10-1.2.2.r 13-1.2.1.1 14-1.2.1
# ::id pmid_1177_7939.94
# ::preferred 
(d / depend-01~e.8
      :ARG0 (a / act-01
            :ARG0 (p / protein
                  :name (n / name :op1 "Sos-1"~e.5,7))
            :ARG1 (e / enzyme
                  :name (n2 / name :op1 "GEF"~e.2))
            :mod (d2 / dual~e.1))
      :ARG1 (h / have-part-91
            :ARG1 (c / complex~e.14
                  :mod (d3 / distinct~e.13))
            :ARG2~e.10 p~e.10))

# ::tok The existence of Sos @-@ 1 in two physically and functionally distinct pools suggests the hypothesis that its presence in a S/G or a S/E/E8 complex could dictate its Ras @- or Rac @-@ specific GEF activities , respectively .
# ::amr-annotator SDL-AMR-09
# ::alignments 3-1.1.1.1.1 5-1.1.1.1.1 7-1.1.2.1 8-1.1.2.3 10-1.1.2.2 11-1.1.2.2.1 12-1.1.2 13-1 15-1.2 16-1.2.1.r 17-1.2.1.1.1.1 17-1.2.1.1.1.1.r 22-1.2.1.1.1.2 25-1.2.1.1.1.2.1 25-1.2.1.1.1.2.2 26-1.2.1 27-1.2.1.1 28-1.2.1.1.2.1 28-1.2.1.1.2.1.r 29-1.2.1.1.2.4.1.1.1.1 31-1.2.1.1.2.4.1 32-1.2.1.1.2.4.1.2.1.1 34-1.2.1.1.2.4 35-1.2.1.1.2.2.1.1 38-1.2.1.1.2.3
# ::id pmid_1177_7939.95
# ::preferred 
(s / suggest-01~e.13
      :ARG0 (b / be-located-at-91
            :ARG1 (p / protein
                  :name (n / name :op1 "Sos-1"~e.3,5))
            :ARG2 (p2 / pool~e.12
                  :quant "2"~e.7
                  :ARG0-of (f / function-01~e.10
                        :manner (d / distinct~e.11))
                  :mod (p3 / physical~e.8)))
      :ARG1 (h / hypothesize-01~e.15
            :ARG1~e.16 (p4 / possible~e.26
                  :domain (d2 / dictate-01~e.27
                        :ARG0 (b2 / be-located-at-91
                              :ARG1~e.17 p~e.17
                              :ARG2 (o / or~e.22
                                    :op1 (m / macro-molecular-complex~e.25
                                          :part p
                                          :part (p5 / protein
                                                :name (n2 / name :op1 "Grb2")))
                                    :op2 (m2 / macro-molecular-complex~e.25
                                          :part p
                                          :part (p6 / protein
                                                :name (n3 / name :op1 "E3b1"))
                                          :part (e / enzyme
                                                :name (n4 / name :op1 "Eps8")))))
                        :ARG1 (a / act-01
                              :ARG0~e.28 p~e.28
                              :ARG1 (e2 / enzyme
                                    :name (n5 / name :op1 "GEF"~e.35))
                              :mod (r / respective~e.38)
                              :mod (s3 / specific~e.34
                                    :topic (o2 / or~e.31
                                          :op1 (e3 / enzyme
                                                :name (n6 / name :op1 "Ras"~e.29))
                                          :op2 (e4 / enzyme
                                                :name (n7 / name :op1 "Rac"~e.32)))))))))

# ::tok To explore this possibility , we used an in vitro assay that can score GEF activities in Sos @-@ 1–containing immunoprecipitates .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3 2-1.3.2.1 3-1.3.2 5-1.1 6-1 8-1.2.3 9-1.2.3 10-1.2 12-1.2.2.2 13-1.2.2 14-1.2.2.1.2.1.1 16-1.2.3 17-1.2.1.2.1.1
# ::id pmid_1177_7939.96
# ::preferred 
(u / use-01~e.6
      :ARG0 (w / we~e.5)
      :ARG1 (a / assay-00~e.10
            :ARG1 (c / contain-01
                  :ARG0 (m / molecular-physical-entity
                        :ARG1-of (i / immunoprecipitate-00))
                  :ARG1 (p / protein
                        :name (n2 / name :op1 "Sos-1"~e.17)))
            :ARG0-of (s / score-01~e.13
                  :ARG1 (a2 / act-01
                        :ARG0 p
                        :ARG1 (e / enzyme
                              :name (n / name :op1 "GEF"~e.14)))
                  :mod (p2 / possible~e.12))
            :manner (i2 / in-vitro~e.8,9,16))
      :ARG2 (e2 / explore-01~e.1
            :ARG0 w
            :ARG1 (p3 / possible~e.3
                  :mod (t / this~e.2))))

# ::tok Cells were transfected with either Sos @-@ 1 alone ( SosTfx ) or a combination of S/E/E8 ( Triple Tfx ) ( <xref ref-type="fig" rid="fig7"> Fig . 7 </xref> A ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 2-1 5-1.2.1.1.1 7-1.2.1.1.1 8-1.2.1.2 12-1.2 14-1.2.2
# ::id pmid_1177_7939.97
# ::preferred 
(t / transfect-00~e.2
      :ARG1 (c / cell~e.0)
      :ARG2 (o / or~e.12
            :op1 (p / protein
                  :name (n / name :op1 "Sos-1"~e.5,7)
                  :mod (a / alone~e.8))
            :op2 (c2 / combine-01~e.14
                  :ARG3 (m / macro-molecular-complex
                        :part p
                        :part (p2 / protein
                              :name (n2 / name :op1 "E3b1"))
                        :part (e / enzyme
                              :name (n3 / name :op1 "Eps8")))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "7A")))

# ::tok When Sos @-@ 1 was immunoprecipitated from SosTfx , it displayed Ras @-@ GEF , but not Rac @-@ GEF , activity ( <xref ref-type="fig" rid="fig7"> Fig . 7 </xref> B ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.2.1.1 3-1.1.2.1.1 7-1.1.1.1.1 9-1.2.1.1 11-1.2.1.3.1.1 13-1.2.1.2.1.1 15-1.2 16-1.2.2.1 16-1.2.2.1.r 17-1.2.2.4.1.1 19-1.2.2.3
# ::id pmid_1177_7939.98
# ::preferred 
(c / cause-01
      :ARG0 (i / immunoprecipitate-00
            :ARG1 (p2 / protein
                  :name (n2 / name :op1 "SosTfx"~e.7))
            :ARG3 (p / protein
                  :name (n / name :op1 "Sos-1"~e.1,3)))
      :ARG1 (c2 / contrast-01~e.15
            :ARG1 (a / act-01
                  :ARG0 p~e.9
                  :ARG1 (e / enzyme
                        :name (n4 / name :op1 "GEF"~e.13))
                  :beneficiary (e2 / enzyme
                        :name (n5 / name :op1 "Ras"~e.11)))
            :ARG2 (a2 / act-01
                  :polarity~e.16 "-"~e.16
                  :ARG0 p
                  :ARG1 e~e.19
                  :beneficiary (e3 / enzyme
                        :name (n7 / name :op1 "Rac"~e.17))))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure :mod "7B")))

# ::tok Of note , little E3b1 and no Eps8 could be detected in Sos @-@ 1 immunoprecipitates ( <xref ref-type="fig" rid="fig7"> Fig . 7 </xref> A ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3 3-1.1.1.1.2 4-1.1.1.1.1.1 5-1 6-1.2.1 6-1.2.1.r 7-1.2.2.1.1.1 8-1.1 8-1.2 9-1.1.1.r 9-1.2.2.r 10-1.1.1 10-1.2.2 11-1.1.1.2.r 12-1.1.1.2.1.1.1.1 14-1.1.1.2.1.1.1.1
# ::id pmid_1177_7939.99
# ::preferred 
(a2 / and~e.5
      :op1 (p / possible~e.8
            :domain~e.9 (d / detect-01~e.10
                  :ARG1 (p2 / protein
                        :name (n / name :op1 "E3b1"~e.4)
                        :quant (l / little~e.3))
                  :location~e.11 (m / molecular-physical-entity
                        :ARG1-of (i / immunoprecipitate-00
                              :ARG3 (p3 / protein
                                    :name (n4 / name :op1 "Sos-1"~e.12,14))))))
      :op2 (p4 / possible~e.8
            :polarity~e.6 "-"~e.6
            :domain~e.9 (d3 / detect-01~e.10
                  :ARG1 (e / enzyme
                        :name (n2 / name :op1 "Eps8"~e.7))
                  :location m))
      :ARG1-of (n3 / note-01~e.1
            :ARG1-of (r / recommend-01))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure :mod "7A")))

# ::tok Conversely , Grb2 was readily recovered from the same immunoprecipitates ( unpublished data ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1.1.1.1 4-1.1.3 4-1.1.3.r 5-1.1 6-1.1.2.r 8-1.1.2 8-1.1.2.2 8-1.1.2.2.r 11-1.1.4.1.1 12-1.1.4
# ::id pmid_1177_7939.100
# ::preferred 
(c / contrast-01
      :ARG2 (r / recover-02~e.5
            :ARG1 (p / protein
                  :name (n / name :op1 "Grb2"~e.2))
            :ARG2~e.6 (m / molecular-physical-entity~e.8
                  :ARG1-of (i / immunoprecipitate-00)
                  :ARG1-of~e.8 (s / same-01~e.8))
            :manner~e.4 (r2 / ready~e.4)
            :mod (d / data~e.12
                  :ARG1-of (p2 / publish-01 :polarity "-"~e.11))))

# ::tok We then used the Triple Tfx and coimmunoprecipitated Sos @-@ 1 with anti @-@ Eps8 antibodies ( <xref ref-type="fig" rid="fig7"> Fig . 7 , A and B </xref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1.3 2-1.1 8-1.1.2.1.1.1 10-1.1.2.1.1.1 12-1.2.2.1 14-1.1.2.3.1.1 15-1.2.2 25-1 25-1.3.1
# ::id pmid_1177_7939.101
# ::preferred 
(a / and~e.25
      :op1 (u / use-01~e.2
            :ARG0 (w / we~e.0)
            :ARG1 (m / macro-molecular-complex
                  :part (p / protein
                        :name (n / name :op1 "Sos-1"~e.8,10))
                  :part (p2 / protein
                        :name (n2 / name :op1 "E3b1"))
                  :part (e / enzyme
                        :name (n4 / name :op1 "Eps8"~e.14))
                  :ARG2-of (t2 / transfect-00))
            :time (t / then~e.1))
      :op2 (c / coimmunoprecipitate-00
            :ARG1 p
            :ARG2 (a2 / antibody~e.15
                  :ARG0-of (c2 / counter-01~e.12
                        :ARG1 e)))
      :ARG1-of (d / describe-01
            :ARG0 (a3 / and~e.25
                  :op1 (f / figure :mod "7A")
                  :op2 (f2 / figure :mod "7B"))))

# ::tok Under these conditions , all of the coimmunoprecipitated Sos @-@ 1 is present in the S/E/E8 tricomplex ( <xref ref-type="bibr" rid="bib40"> Scita et al. , 1999 </xref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.2 2-1 4-1.1.1.2 8-1.1.1.1.1 10-1.1.1.1.1 11-1.1 21-1.3.1.1.1.1.1 22-1.3.1.1 23-1.3.1.1.2.1 25-1.3.1.2.1
# ::id pmid_1177_7939.102
# ::preferred 
(h / have-condition-91~e.2
      :ARG1 (b / be-located-at-91~e.11
            :ARG1 (p / protein
                  :name (n / name :op1 "Sos-1"~e.8,10)
                  :mod (a / all~e.4)
                  :ARG3-of (c / coimmunoprecipitate-00))
            :ARG2 (m / macro-molecular-complex
                  :part p
                  :part (p2 / protein
                        :name (n2 / name :op1 "E3b1"))
                  :part (e / enzyme
                        :name (n3 / name :op1 "Eps8"))))
      :ARG2 (t / this~e.1)
      :ARG1-of (d / describe-01
            :ARG0 (p3 / publication-91
                  :ARG0 (a2 / and~e.22
                        :op1 (p4 / person
                              :name (n4 / name :op1 "Scita"~e.21))
                        :op2 (p5 / person
                              :mod (o / other~e.23)))
                  :time (d2 / date-entity :year "1999"~e.25))))

# ::tok Despite lower levels of Sos @-@ 1 in the coimmunoprecipitate ( with respect to a Sos @-@ 1 immunoprecipitate from SosTfx ) , Rac @-@ GEF activity was now present ( <xref ref-type="fig" rid="fig7"> Fig . 7 </xref> B ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.5.r 1-1.5 1-1.5.2 1-1.5.2.r 2-1.5.1 3-1.5.1.1.r 4-1.5.1.1 5-1.5.1.1 6-1.5.1.1 7-1.5.1.2.r 9-1.5.1.2 9-1.5.1.2.1 9-1.5.1.2.1.r 15-1.1.1.1.1 17-1.1.1.1.1 18-1.3 19-1.3.1.r 20-1.3.1.1.1 23-1.1.3.1.1 25-1.1.2.1.1 27-1.1.r 28-1.2 29-1
# ::id pmid_1177_7939.103
# ::preferred 
(p / present~e.29
      :domain~e.27 (a / act-01
            :ARG0 (p2 / protein
                  :name (n / name :op1 "Sos-1"~e.15,17))
            :ARG1 (e / enzyme
                  :name (n2 / name :op1 "GEF"~e.25))
            :beneficiary (e2 / enzyme
                  :name (n3 / name :op1 "Rac"~e.23)))
      :time (n4 / now~e.28)
      :topic (i / immunoprecipitate-00~e.18
            :ARG1~e.19 (p3 / protein
                  :name (n5 / name :op1 "SosTfx"~e.20))
            :ARG3 p2)
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "7B"))
      :concession~e.0 (l2 / low-04~e.1
            :ARG1 (l / level~e.2
                  :quant-of~e.3 p2~e.4,5,6
                  :location~e.7 (m2 / molecular-physical-entity~e.9
                        :ARG1-of~e.9 (c / coimmunoprecipitate-00~e.9)))
            :degree~e.1 (m / more~e.1)))

# ::tok Conversely , no Ras @-@ GEF activity could be detected ( <xref ref-type="fig" rid="fig7"> Fig . 7 </xref> B ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1.1 2-1.1.1.r 3-1.1.2.1.3.1.1 5-1.1.2.1.2.1.1 7-1.1 8-1.1.2.r 9-1.1.2
# ::id pmid_1177_7939.104
# ::preferred 
(c / contrast-01
      :ARG2 (p / possible~e.7
            :polarity~e.2 "-"~e.2
            :domain~e.8 (d / detect-01~e.9
                  :ARG1 (a / act-01
                        :ARG0 (p2 / protein
                              :name (n / name :op1 "Sos-1"))
                        :ARG1 (e / enzyme
                              :name (n2 / name :op1 "GEF"~e.5))
                        :beneficiary (e2 / enzyme
                              :name (n3 / name :op1 "Ras"~e.3)))
                  :ARG1-of (d2 / describe-01
                        :ARG0 (f / figure :mod "7B")))))

# ::tok The lack of Ras @-@ GEF activity was not due to the low levels of Sos @-@ 1 .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3 3-1.3.1.3.1.1 5-1.3.1.2.1.1 8-1.1 8-1.1.r 9-1 10-1 12-1.2.1 13-1.2 14-1.2.1.1.r 15-1.2.1.1.1.1 17-1.2.1.1.1.1
# ::id pmid_1177_7939.105
# ::preferred 
(c / cause-01~e.9,10
      :polarity~e.8 "-"~e.8
      :ARG0 (l / level~e.13
            :ARG1-of (l2 / low-04~e.12
                  :quant-of~e.14 (p / protein
                        :name (n / name :op1 "Sos-1"~e.15,17))))
      :ARG1 (l3 / lack-01~e.1
            :ARG1 (a / act-01
                  :ARG0 p
                  :ARG1 (e / enzyme
                        :name (n3 / name :op1 "GEF"~e.5))
                  :beneficiary (e2 / enzyme
                        :name (n4 / name :op1 "Ras"~e.3)))))

# ::tok To prove this point , we immunoprecipitated from SosTfx an amount of Sos @-@ 1 comparable to that present in anti @-@ Eps8 immunoprecipitates from Triple Tfx ( <xref ref-type="fig" rid="fig7"> Fig . 7 , A and B </xref> , lanes SosTfx1 @/@ 10 ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.4 2-1.4.2.1 3-1.4.2 3-1.4.r 5-1.1 7-1.3.2.1.1.2.1.1.3.r 8-1.2.1.1 10-1.3.2 10-1.3.2.1.1.2 12-1.3.2.1.1.1.1 14-1.3.1.1 14-1.3.2.1.1.1.1 17-1.3.2.1.1.2.1.1.4 20-1.3.2.1.1.2.1.1 20-1.3.2.1.1.2.1.1.2 20-1.3.2.1.1.2.1.1.2.r 22-1.3.2.1.1.2.1.1.2.1.1.1 24-1.3.2.1.1.2.1.1.3.r 36-1.5.1.2 40-1.5.1 41-1.5.1.1.1 43-1.5.1.1.1
# ::id pmid_1177_7939.106
# ::preferred 
(i / immunoprecipitate-00
      :ARG0 (w / we~e.5)
      :ARG1 (p / protein
            :name (n / name :op1 "SosTfx"~e.8))
      :ARG3 (p2 / protein
            :name (n2 / name :op1 "Sos-1"~e.14)
            :quant (a / amount~e.10
                  :ARG1-of (c / compare-01
                        :ARG2 (p3 / protein
                              :name (n3 / name :op1 "Sos-1"~e.12,14)
                              :quant-of (a2 / amount~e.10
                                    :ARG1-of (b / be-located-at-91
                                          :ARG2 (m / molecular-physical-entity~e.20
                                                :ARG1-of (i2 / immunoprecipitate-00)
                                                :ARG0-of~e.20 (c2 / counter-01~e.20
                                                      :ARG1 (e / enzyme
                                                            :name (n4 / name :op1 "Eps8"~e.22)))
                                                :source~e.7,24 (m2 / macro-molecular-complex
                                                      :part p3
                                                      :part (p4 / protein
                                                            :name (n5 / name :op1 "E3b1"))
                                                      :part e
                                                      :ARG2-of (t3 / transfect-00))
                                                :mod (t / that~e.17)))))
                        :mod (p5 / possible))))
      :purpose~e.3 (p6 / prove-01~e.1
            :ARG0 w
            :ARG1 (p7 / point~e.3
                  :mod (t2 / this~e.2)))
      :ARG1-of (d / describe-01
            :ARG0 (l2 / lane~e.40
                  :ARG1-of (l / label-01 :ARG2 "SosTfx1/10"~e.41,43)
                  :part-of (a3 / and~e.36
                        :op1 (f / figure :mod "7A")
                        :op2 (f2 / figure :mod "7B")))))

# ::tok Under these conditions , Ras @-@ GEF activity was readily detectable ( <xref ref-type="fig" rid="fig7"> Fig . 7 </xref> B ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.2 2-1 4-1.1.4.1.1 6-1.1.2.1.1 9-1.1.3.2 9-1.1.3.2.r
# ::id pmid_1177_7939.107
# ::preferred 
(h / have-condition-91~e.2
      :ARG1 (a / act-01
            :ARG0 (p / protein
                  :name (n / name :op1 "Sos-1"))
            :ARG1 (e / enzyme
                  :name (n2 / name :op1 "GEF"~e.6))
            :ARG1-of (d / detect-01
                  :mod (p2 / possible)
                  :manner~e.9 (r / ready~e.9))
            :beneficiary (e2 / enzyme
                  :name (n3 / name :op1 "Ras"~e.4)))
      :ARG2 (t / this~e.1)
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure :mod "7B")))

# ::tok The detection of Rac @-@ specific GEF activity in anti @-@ Eps8 immunoprecipitates strictly required the presence of Sos @-@ 1 , since no GEF activity was detected in Eps8 immunoprecipitates , in the absence of coexpressed Sos @-@ 1 ( <xref ref-type="bibr" rid="bib40"> Scita et al. , 1999 </xref> ; unpublished data ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1 1-1.4.1 3-1.1.1.4.1.1.1 5-1.1.1.4 6-1.1.1.2.1.1 7-1.4.1.2 9-1.1.1.3 9-1.1.1.3.2 9-1.1.1.3.2.r 11-1.1.1.3.2.1.1.1 13-1.3 13-1.3.r 14-1 16-1.2 18-1.2.1 19-1.2.1 20-1.2.1 22-1.4 23-1.4.1.1 23-1.4.1.1.r 24-1.4.1.2.1 25-1.4.1.2 26-1.2.1.r 27-1.1 27-1.4.1 29-1.1.1.3.2.1.1.1 32-1.4.1.4.r 34-1.4.1.4 37-1.4.1.4.1 38-1.4.1.4.1 39-1.4.1.4.1 44-1.5.1.1.1.1.1.1 45-1.5.1 45-1.5.1.1.1 46-1.5.1.1.1.2.1 48-1.5.1.1.2.1 51-1.5.1.2.1.1 52-1.5.1.2
# ::id pmid_1177_7939.108
# ::preferred 
(r / require-01~e.14
      :ARG0 (d / detect-01~e.1,27
            :ARG1 (a / act-01
                  :ARG0 (p / protein
                        :name (n / name :op1 "Sos-1")
                        :ARG1-of (c3 / coexpress-00))
                  :ARG1 (e / enzyme
                        :name (n2 / name :op1 "GEF"~e.6))
                  :location (m / molecular-physical-entity~e.9
                        :ARG1-of (i / immunoprecipitate-00)
                        :ARG0-of~e.9 (c / counter-01~e.9
                              :ARG1 (e3 / enzyme
                                    :name (n4 / name :op1 "Eps8"~e.11,29))))
                  :mod (s3 / specific~e.5
                        :topic (e2 / enzyme
                              :name (n3 / name :op1 "Rac"~e.3)))))
      :ARG1 (p2 / present~e.16
            :domain~e.26 p~e.18,19,20)
      :manner~e.13 (s2 / strict~e.13)
      :ARG1-of (c2 / cause-01~e.22
            :ARG0 (d2 / detect-01~e.1,27
                  :polarity~e.23 "-"~e.23
                  :ARG1 (a2 / act-02~e.7,25
                        :ARG0 e~e.24)
                  :location (m2 / molecular-physical-entity
                        :ARG1-of (i2 / immunoprecipitate-00
                              :ARG3 e3))
                  :manner~e.32 (a3 / absent-01~e.34
                        :ARG1 p~e.37,38,39)))
      :ARG1-of (d3 / describe-01
            :ARG0 (a4 / and~e.45
                  :op1 (p3 / publication-91
                        :ARG0 (a5 / and~e.45
                              :op1 (p4 / person
                                    :name (n6 / name :op1 "Scita"~e.44))
                              :op2 (p5 / person
                                    :mod (o / other~e.46)))
                        :time (d4 / date-entity :year "1999"~e.48))
                  :op2 (d5 / data~e.52
                        :ARG1-of (p6 / publish-01 :polarity "-"~e.51)))))

# ::tok Furthermore , no Rac @-@ GEF activity could be detected in Eps8 immunoprecipitates from lysates of cells transfected with Sos @-@ 1 , E3b1 , and an Eps8 mutant that is impaired in its ability to bind E3b1 and thereby cannot form a trimeric complex ( <xref ref-type="bibr" rid="bib40"> Scita et al. , 1999 </xref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1.1.r 3-1.1.2.1.3.1.1 5-1.1.2.1.2.1.1 7-1.1 8-1.1.2.r 9-1.1.2 10-1.1.2.2.r 11-1.1.2.2.1.1.1.1 13-1.1.2.3.r 16-1.1.2.3.1 17-1.1.2.3.2 19-1.1.2.1.1.1.1 21-1.1.2.1.1.1.1 23-1.1.2.3.2.1.2.1.1 25-1.1.2.3.2.1 27-1.1.2.3.2.1.3.1.1 28-1.1.2.3.2.1.3 28-1.1.2.3.2.1.3.2 28-1.1.2.3.2.1.3.2.r 30-1.1.2.3.2.1.3.3.2.1.1.1.2.r 31-1.1.2.3.2.1.3.3.2.1 35-1.1.2.3.2.1.3.3.2.1.1 36-1.1.2.3.2.1.3.3 37-1.1.2.3.2.1.2.1.1 40-1.1.1 40-1.1.2.3.2.1.3.3.2 40-1.1.2.3.2.1.3.3.2.1.1.1 40-1.1.2.3.2.1.3.3.2.1.1.1.1 40-1.1.2.3.2.1.3.3.2.1.1.1.1.r 41-1.1.2.3.2.1.3.3.2.1.1.1.2 44-1.1.2.3.2.1.3.3.2.1.1.1.2.2 49-1.1.2.4.1.1.1.1.1 50-1 50-1.1.2.4.1.1 51-1.1.2.4.1.1.2.1 53-1.1.2.4.1.2.1
# ::id pmid_1177_7939.109
# ::preferred 
(a / and~e.50
      :op2 (p / possible~e.7
            :polarity~e.2 "-"~e.40
            :domain~e.8 (d / detect-01~e.9
                  :ARG1 (a2 / act-01
                        :ARG0 (p2 / protein
                              :name (n / name :op1 "Sos-1"~e.19,21))
                        :ARG1 (e / enzyme
                              :name (n2 / name :op1 "GEF"~e.5))
                        :beneficiary (e2 / enzyme
                              :name (n3 / name :op1 "Rac"~e.3)))
                  :location~e.10 (m / molecular-physical-entity
                        :ARG1-of (i / immunoprecipitate-00
                              :ARG3 (e3 / enzyme
                                    :name (n4 / name :op1 "Eps8"~e.11))))
                  :source~e.13 (l / lysate
                        :domain (c / cell~e.16)
                        :ARG1-of (t / transfect-00~e.17
                              :ARG2 (a3 / and~e.25
                                    :op1 p2
                                    :op2 (p3 / protein
                                          :name (n5 / name :op1 "E3b1"~e.23,37))
                                    :op3 (e4 / enzyme~e.28
                                          :name (n6 / name :op1 "Eps8"~e.27)
                                          :ARG1-of~e.28 (m2 / mutate-01~e.28)
                                          :ARG0-of (b / bind-01~e.36
                                                :ARG1 p3
                                                :mod (p4 / possible~e.40
                                                      :ARG1-of (i2 / impair-01~e.31
                                                            :ARG0-of (c2 / cause-01~e.35
                                                                  :ARG1 (p5 / possible~e.40
                                                                        :polarity~e.40 "-"~e.40
                                                                        :domain~e.30 (f / form-01~e.41
                                                                              :ARG0 e4
                                                                              :ARG1 (m3 / macro-molecular-complex~e.44
                                                                                    :mod (t2 / trimer))))))))))))
                  :ARG1-of (d2 / describe-01
                        :ARG0 (p6 / publication-91
                              :ARG0 (a4 / and~e.50
                                    :op1 (p7 / person
                                          :name (n7 / name :op1 "Scita"~e.49))
                                    :op2 (p8 / person
                                          :mod (o / other~e.51)))
                              :time (d3 / date-entity :year "1999"~e.53))))))

# ::tok At this stage , we cannot formally exclude that an unknown GEF , coprecipitating with Sos @-@ 1 , is responsible for the observed activity .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.2.3.1 2-1.2.3 4-1.2.1 5-1 5-1.1 5-1.1.r 5-1.2.2.1.2.1.r 6-1.2.4 6-1.2.4.r 7-1.2 8-1.2.2.r 10-1.2.2.1.2 10-1.2.2.1.2.1 11-1.2.2.1.1.1 15-1.2.2.1.3.1.1.1 17-1.2.2.1.3.1.1.1 20-1.2.2 21-1.2.2.2.r 23-1.2.2.2.1 24-1.2.2.2
# ::id pmid_1177_7939.110
# ::preferred 
(p / possible~e.5
      :polarity~e.5 "-"~e.5
      :domain (e / exclude-01~e.7
            :ARG0 (w / we~e.4)
            :ARG1~e.8 (r / responsible-01~e.20
                  :ARG0 (e2 / enzyme
                        :name (n2 / name :op1 "GEF"~e.11)
                        :mod (k / know-02~e.10 :polarity~e.5 "-"~e.10)
                        :ARG1-of (c / coprecipitate-00
                              :ARG2 (p2 / protein
                                    :name (n3 / name :op1 "Sos-1"~e.15,17))))
                  :ARG1~e.21 (a / act-02~e.24
                        :ARG1-of (o / observe-01~e.23)))
            :time (s / stage~e.2
                  :mod (t / this~e.1))
            :manner~e.6 (f / formal~e.6)))

# ::tok However , such a hypothetical protein should not only be associated with Sos @-@ 1 , but also be active only in the presence of Eps8 and E3b1 , which are both required for the formation of the trimeric complex endowed with Rac @-@ specific GEF activity ( <xref ref-type="bibr" rid="bib40"> Scita et al. , 1999 </xref> ) , making this possibility unlikely .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 2-1.1.1.1.1.2 5-1.1.1.1.1 6-1.1.1 7-1.1.3.1.1.r 8-1.1.1.1.3 10-1.1.1.1 11-1.1.1.1.2.r 12-1.1.1.1.2.1.1 14-1.1.1.1.2.1.1 16-1 17-1.1.2.2 20-1.1.1.1.3 23-1.1.2.3 25-1.1.2.3.1.1.1.1 26-1.1.2.3.1 27-1.1.2.3.1.2.1.1 30-1.1.2.3.1.r 32-1.1.2.3.1.3 33-1.1.2.3.1.3.1.r 35-1.1.2.3.1.3.1 39-1.1.2.3.1.3.1.1 40-1.1.2.3.1.3.1.1.2 42-1.1.2.3.1.3.1.1.2.1.3.1.1.1 44-1.1.2.3.1.3.1.1.2.1.3 45-1.1.2.3.1.3.1.1.2.1.2.1.1 51-1.2.1.1.1.1.1 52-1.1 52-1.2.1.1 53-1.2.1.1.2.1 55-1.2.1.2.1 59-1.1.3 60-1.1.3.1.2.2 61-1.1.3.1.2 62-1.1.3.1 62-1.1.3.1.1
# ::id pmid_1177_7939.111
# ::preferred 
(c / contrast-01~e.0,16
      :ARG2 (a / and~e.52
            :op1 (r / recommend-01~e.6
                  :ARG1 (a2 / associate-01~e.10
                        :ARG1 (p / protein~e.5
                              :ARG1-of (h / hypothesize-01)
                              :mod (s / such~e.2))
                        :ARG2~e.11 (p2 / protein
                              :name (n / name :op1 "Sos-1"~e.12,14))
                        :mod (o / only~e.8,20)))
            :op2 (a3 / activate-01
                  :ARG1 p
                  :mod (a4 / also~e.17)
                  :condition (p3 / present~e.23
                        :domain~e.30 (a5 / and~e.26
                              :op1 (e / enzyme
                                    :name (n2 / name :op1 "Eps8"~e.25))
                              :op2 (p4 / protein
                                    :name (n3 / name :op1 "E3b1"~e.27))
                              :ARG1-of (r2 / require-01~e.32
                                    :purpose~e.33 (f / form-01~e.35
                                          :ARG1 (m / macro-molecular-complex~e.39
                                                :mod (t / trimer)
                                                :ARG2-of (e2 / endow-01~e.40
                                                      :ARG1 (a6 / act-01
                                                            :ARG0 p2
                                                            :ARG1 (e3 / enzyme
                                                                  :name (n4 / name :op1 "GEF"~e.45))
                                                            :mod (s3 / specific~e.44
                                                                  :topic (e4 / enzyme
                                                                        :name (n5 / name :op1 "Rac"~e.42)))))))))))
            :ARG0-of (m2 / make-02~e.59
                  :ARG1 (l / likely~e.62
                        :polarity~e.7 "-"~e.62
                        :domain (p5 / possible~e.61
                              :domain p
                              :mod (t2 / this~e.60)))))
      :ARG1-of (d / describe-01
            :ARG0 (p6 / publication-91
                  :ARG0 (a7 / and~e.52
                        :op1 (p7 / person
                              :name (n6 / name :op1 "Scita"~e.51))
                        :op2 (p8 / person
                              :mod (o2 / other~e.53)))
                  :time (d2 / date-entity :year "1999"~e.55))))

# ::tok It is reasonable , therefore , to propose that Sos @-@ 1 alone ( or complexed with proteins , such as Grb2 ) is endowed with Ras @-@ GEF activity .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1.r 2-1.1 4-1 6-1 7-1.1.1 9-1.1.1.1.1.1.1.1 11-1.1.1.1.1.1.1.1 12-1.1.1.1.1.1.2 14-1.1.1.1.1 17-1.1.1.1.1.2.2 19-1.1.1.1.1.2.2.1.r 20-1.1.1.1.1.2.2.1.r 21-1.1.1.1.1.2.2.1.1.1 26-1.1.1.1.3.1.1 28-1.1.1.1.2.1.1
# ::id pmid_1177_7939.112
# ::preferred 
(c / cause-01~e.4,6
      :ARG1 (r / reasonable~e.2
            :domain~e.1 (p / propose-01~e.7
                  :ARG1 (a / act-01
                        :ARG0 (o / or~e.14
                              :op1 (p2 / protein
                                    :name (n / name :op1 "Sos-1"~e.9,11)
                                    :mod (a2 / alone~e.12))
                              :op2 (m / macro-molecular-complex
                                    :part p2
                                    :part (p3 / protein~e.17
                                          :example~e.19,20 (p4 / protein
                                                :name (n2 / name :op1 "Grb2"~e.21)))))
                        :ARG1 (e / enzyme
                              :name (n3 / name :op1 "GEF"~e.28))
                        :beneficiary (e2 / enzyme
                              :name (n4 / name :op1 "Ras"~e.26))))))

# ::tok However , upon interaction with Eps8 and E3b1 , its specificity is switched toward Rac .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 3-1.2 4-1.2.2.r 5-1.2.2.1.1.1 6-1.2.2 7-1.2.2.2.1.1 9-1.1.1.1 9-1.1.1.1.r 10-1.1.1 12-1.1 14-1.1.2.1.1
# ::id pmid_1177_7939.113
# ::preferred 
(h / have-concession-91~e.0
      :ARG1 (s / switch-01~e.12
            :ARG1 (s2 / specificity~e.10
                  :poss~e.9 (i2 / it~e.9))
            :ARG2 (e3 / enzyme
                  :name (n3 / name :op1 "Rac"~e.14)))
      :time (i / interact-01~e.3
            :ARG0 i2
            :ARG1~e.4 (a / and~e.6
                  :op1 (e / enzyme
                        :name (n / name :op1 "Eps8"~e.5))
                  :op2 (p3 / protein
                        :name (n2 / name :op1 "E3b1"~e.7)))))

# ::tok A common feature of proteins endowed with GEF catalytic activity is their ability to bind to their specific nucleotide @-@ depleted GTPase with relative high affinities .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1 2-1 4-1.2.1 5-1.2.1.1 7-1.2.1.1.1.1.1.1 8-1.2.1.1.1.2 10-1.2.r 12-1.2 14-1.2.2 15-1.2.2.2.r 16-1.2.2.2.4 16-1.2.2.2.4.r 17-1.2.2.2.2 18-1.2.2.2.3.1 20-1.2.2.2.3 21-1.2.2.2.1.1 22-1.2.2.3.r 23-1.2.2.3.1.1 24-1.2.2.3.1 25-1.2.2.3
# ::id pmid_1177_7939.114
# ::preferred 
(f / feature~e.2
      :ARG1-of (s2 / share-01~e.1
            :ARG0 (p / protein~e.4
                  :ARG2-of (e2 / endow-01~e.5
                        :ARG1 (a / act-01
                              :ARG0 (s / small-molecule
                                    :name (n2 / name :op1 "GEF"~e.7))
                              :ARG1 (c2 / catalysis~e.8)))))
      :domain~e.10 (c / capable-01~e.12
            :ARG1 p
            :ARG2 (b / bind-01~e.14
                  :ARG1 p
                  :ARG2~e.15 (e / enzyme
                        :name (n / name :op1 "GTPase"~e.21)
                        :mod (s3 / specific~e.17)
                        :ARG1-of (d / deplete-01~e.20
                              :ARG2 (n3 / nucleotide~e.18))
                        :poss~e.16 p~e.16)
                  :manner~e.22 (a2 / affinity~e.25
                        :mod (h / high~e.24
                              :mod (r / relative~e.23))))))

# ::tok Thus , one might postulate that Sos @-@ 1 associates with the nucleotide @-@ free form of Rac exclusively when engaged in the S/E/E8 complex .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 2-1.1.1.2.1.1.1 3-1.1 4-1.1.1 6-1.1.1.2.1.1.1 8-1.1.1.2.1.1.1 9-1.1.1.2 10-1.1.1.2.2.r 12-1.1.1.2.2.1.1 14-1.1.1.2.2.1 15-1.1.1.2.2 16-1.1.1.2.2.2.r 17-1.1.1.2.2.2.1.1 18-1.1.1.2.3 18-1.1.1.2.3.r 19-1.1.1.2.4.r 20-1.1.1.2.4 24-1.1.1.2.4.2
# ::id pmid_1177_7939.115
# ::preferred 
(c / cause-01~e.0
      :ARG1 (p8 / possible~e.3
            :domain (p5 / postulate-01~e.4
                  :ARG0 (p6 / person)
                  :ARG1 (a / associate-01~e.9
                        :ARG1 (p7 / protein
                              :name (n / name :op1 "Sos-1"~e.2,6,8))
                        :ARG2~e.10 (f / form~e.15
                              :ARG1-of (f2 / free-04~e.14
                                    :ARG2 (n2 / nucleotide~e.12))
                              :mod~e.16 (e / enzyme
                                    :name (n3 / name :op1 "Rac"~e.17)))
                        :manner~e.18 (e2 / exclusive~e.18)
                        :time~e.19 (e3 / engage-01~e.20
                              :ARG1 p7
                              :ARG2 (m / macro-molecular-complex~e.24
                                    :part (p / protein
                                          :name (n4 / name :op1 "S"))
                                    :part (p3 / protein
                                          :name (n5 / name :op1 "E"))
                                    :part (p4 / protein
                                          :name (n6 / name :op1 "E8"))))))))

# ::tok Purified and nucleotide depleted , GST @-@ Rac and GST @-@ Cdc42 proteins were therefore used to test their ability to interact with Sos @-@ 1 .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.3 1-1.1.1 2-1.1.1.4.1 3-1.1.1.4 5-1.1.1.1.1.1 5-1.1.1.2.1.1 7-1.1.1.1.1.1 8-1.1.1 9-1.1.1.1.1.1 9-1.1.1.2.1.1 11-1.1.1.2.1.1 12-1.1.1.1 12-1.1.1.2 12-1.1.2.1.2.2 14-1 15-1.1 17-1.1.2 18-1.1.2.1.1 18-1.1.2.1.1.r 19-1.1.2.1 21-1.1.2.1.2 23-1.1.2.1.2.2.1.1 25-1.1.2.1.2.2.1.1
# ::id pmid_1177_7939.116
# ::preferred 
(c2 / cause-01~e.14
      :ARG1 (u2 / use-01~e.15
            :ARG1 (a / and~e.1,8
                  :op1 (p2 / protein~e.12
                        :name (n2 / name :op1 "GST-Rac"~e.5,7,9))
                  :op2 (p3 / protein~e.12
                        :name (n3 / name :op1 "GST-Cdc42"~e.5,9,11))
                  :ARG1-of (p / purify-01~e.0)
                  :ARG1-of (d / deplete-01~e.3
                        :ARG2 (n / nucleotide~e.2)))
            :ARG2 (t2 / test-01~e.17
                  :ARG1 (c / capable-01~e.19
                        :ARG1~e.18 a~e.18
                        :ARG2 (i / interact-01~e.21
                              :ARG0 a
                              :ARG1 (p4 / protein~e.12
                                    :name (n4 / name :op1 "Sos-1"~e.23,25)))))))

# ::tok Native Sos @-@ 1 , present in lysates of −/− [Eps8 myc] fibroblasts , could be specifically recovered with nucleotide @-@ depleted immobilized GST @-@ Rac , but not with GST @-@ Cdc42 or GST alone ( <xref ref-type="fig" rid="fig7"> Fig . 7 </xref> C ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1.2 1-1.1.1.1.1.1 3-1.1.1.1.1.1 9-1.1.1.1.3.1.1.1.2.1 12-1.1.1.1.3.1.1 14-1 15-1.1.1.1.3 15-1.1.r 16-1.1.1.3 17-1.1.1 17-1.1.2 18-1.1.1.2.r 19-1.1.1.2.3.1 21-1.1.1.2.3 22-1.1.1.2.2 23-1.1.1.2.1.1 25-1.1.1.2.1.1 27-1.1 28-1.1.2.1 28-1.1.2.1.r 29-1.1.2.3.r 30-1.1.2.3.2.1.1 32-1.1.2.3.1.1.1 33-1.1.2.3 34-1.1.2.3.2.1.1 35-1.1.2.3.3
# ::id pmid_1177_7939.117
# ::preferred 
(p / possible~e.14
      :domain~e.15 (c / contrast-01~e.27
            :ARG1 (r / recover-01~e.17
                  :ARG1 (p2 / protein
                        :name (n / name :op1 "Sos-1"~e.1,3)
                        :mod (n2 / native~e.0)
                        :ARG1-of (b / be-located-at-91~e.15
                              :ARG2 (l / lysate
                                    :mod (f / fibroblast~e.12
                                          :mod (p5 / protein
                                                :name (n3 / name :op1 "Eps8myc")
                                                :ARG2-of (m / mutate-01 :mod "−/−"~e.9))))))
                  :instrument~e.18 (p4 / protein
                        :name (n4 / name :op1 "GST-Rac"~e.23,25)
                        :ARG1-of (i / immobilize-01~e.22)
                        :ARG1-of (d / deplete-01~e.21
                              :ARG2 (n7 / nucleotide~e.19)))
                  :manner (s / specific~e.16))
            :ARG2 (r2 / recover-01~e.17
                  :polarity~e.28 "-"~e.28
                  :ARG1 p2
                  :instrument~e.29 (o / or~e.33
                        :op1 (p3 / protein
                              :name (n5 / name :op1 "GST-Cdc42"~e.32))
                        :op2 (e2 / enzyme
                              :name (n12 / name :op1 "GST"~e.30,34))
                        :mod (a / alone~e.35))))
      :ARG1-of (d2 / describe-01
            :ARG0 (f2 / figure :mod "7C")))

# ::tok Conversely , no Sos @-@ 1 could be recovered with GST @-@ Rac from lysates of eps8 @<sup> −/− </sup> cells .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2 0-1.2.r 2-1.1.1.1 2-1.1.1.1.r 3-1.1.1.2.1 5-1.1.1.2.1 6-1 7-1.1.r 8-1.1 9-1.1.3.r 10-1.1.3.1.1 12-1.1.3.1.1 16-1.1.2.1.1.1.1 18-1.1.2.1.1.2.1 20-1.1.2.1
# ::id pmid_1177_7939.118
# ::preferred 
(p / possible~e.6
      :domain~e.7 (r / recover-02~e.8
            :ARG1 (p2 / protein
                  :polarity~e.2 "-"~e.2
                  :name (n / name :op1 "Sos-1"~e.3,5))
            :ARG2 (l / lysate
                  :mod (c2 / cell~e.20
                        :mod (e / enzyme
                              :name (n3 / name :op1 "eps8"~e.16)
                              :ARG2-of (m / mutate-01 :mod "−/−"~e.18))))
            :instrument~e.9 (p3 / protein
                  :name (n2 / name :op1 "GST-Rac"~e.10,12)))
      :manner~e.0 (c / converse~e.0))

# ::tok Thus , Eps8 is required for the association between Sos @-@ 1 and nucleotide @-@ free Rac .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 2-1.1.1.1.1 4-1.1 5-1.1.2.r 7-1.1.2 9-1.1.2.1.1.1 11-1.1.2.1.1.1 13-1.1.2.2.2.1 15-1.1.2.2 15-1.1.2.2.2 15-1.1.2.2.2.r 16-1.1.2.2.1.1
# ::id pmid_1177_7939.119
# ::preferred 
(c / cause-01~e.0
      :ARG1 (r / require-01~e.4
            :ARG1 (e / enzyme
                  :name (n / name :op1 "Eps8"~e.2))
            :purpose~e.5 (a / associate-01~e.7
                  :ARG1 (p / protein
                        :name (n2 / name :op1 "Sos-1"~e.9,11))
                  :ARG2 (e2 / enzyme~e.15
                        :name (n3 / name :op1 "Rac"~e.16)
                        :ARG1-of~e.15 (f / free-04~e.15
                              :ARG2 (n4 / nucleotide~e.13))))))

# ::tok Furthermore , under conditions in which the Eps8–E3b1 or the E3b1–Sos @-@ 1 interactions were disrupted by specifically competing peptides , a reduction of >80 % in the amount of Sos @-@ 1 bound to nucleotide @-@ depleted Rac was observed ( <xref ref-type="fig" rid="fig7"> Fig . 7 </xref> C ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 3-1.1.2.r 8-1.1.2.2 12-1.1.1.1.1.1.1 13-1.1.2.2.1 13-1.1.2.2.2 15-1.1.2 16-1.1.2.1.r 17-1.1.2.1.1.1 18-1.1.2.1.1 19-1.1.2.1 22-1.1.1 25-1.1.1.2 28-1.1.1.1 30-1.1.1.1.1.1.1 32-1.1.1.1.1.1.1 33-1.1.1.1.1 33-1.1.1.1.1.2 33-1.1.1.1.1.2.r 34-1.1.1.1.1.2.1.r 35-1.1.1.1.1.2.1.2.1 37-1.1.1.1.1.2.1.2 38-1.1.1.1.1.2.1.1.1 40-1.1
# ::id pmid_1177_7939.120
# ::preferred 
(a2 / and
      :op2 (o / observe-01~e.40
            :ARG1 (r / reduce-01~e.22
                  :ARG1 (a / amount~e.28
                        :quant-of (p3 / protein~e.33
                              :name (n / name :op1 "Sos-1"~e.12,30,32)
                              :ARG1-of~e.33 (b / bind-01~e.33
                                    :ARG2~e.34 (e / enzyme
                                          :name (n2 / name :op1 "Rac"~e.38)
                                          :ARG1-of (d / deplete-01~e.37
                                                :ARG2 (n3 / nucleotide~e.35))))))
                  :ARG2 (p / percentage-entity~e.25
                        :value "80"
                        :degree (m / more)))
            :condition~e.3 (d2 / disrupt-01~e.15
                  :ARG0~e.16 (p2 / peptide~e.19
                        :ARG0-of (c / compete-01~e.18
                              :manner (s / specific~e.17)))
                  :ARG1 (o2 / or~e.8
                        :op1 (i / interact-01~e.13
                              :ARG0 (e2 / enzyme
                                    :name (n4 / name :op1 "Eps8"))
                              :ARG1 (p5 / protein
                                    :name (n5 / name :op1 "E3b1")))
                        :op2 (i2 / interact-01~e.13
                              :ARG0 p5
                              :ARG1 p3))))
      :ARG1-of (d3 / describe-01
            :ARG0 (f / figure :mod "7C")))

# ::tok This latter result strongly suggests that an intact S/E/E8 complex is required for binding to Rac , providing a molecular basis for the catalytic specificity of the complex .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.3 1-1.1.2 2-1.1 2-1.1.1 2-1.1.1.r 3-1.3 3-1.3.r 4-1 5-1.2.r 7-1.2.1.4 9-1.2.1 11-1.2 12-1.2.2.r 13-1.2.2 14-1.2.2.1.r 15-1.2.2.1.1.1 17-1.2.1.5 19-1.2.1.5.1.1 20-1.2.1.5.1 21-1.2.1.5.2.r 23-1.2.1.5.2.1 24-1.2.1.5.2 27-1.2.1
# ::id pmid_1177_7939.121
# ::preferred 
(s / suggest-01~e.4
      :ARG0 (t / thing~e.2
            :ARG2-of~e.2 (r / result-01~e.2)
            :mod (l / latter~e.1)
            :mod (t2 / this~e.0))
      :ARG1~e.5 (r2 / require-01~e.11
            :ARG1 (m2 / macro-molecular-complex~e.9,27
                  :part (p2 / protein
                        :name (n / name :op1 "S"))
                  :part (p3 / protein
                        :name (n2 / name :op1 "E"))
                  :part (p4 / protein
                        :name (n3 / name :op1 "E8"))
                  :mod (i / intact~e.7)
                  :ARG0-of (p / provide-01~e.17
                        :ARG1 (b2 / basis~e.20
                              :mod (m / molecule~e.19))
                        :ARG2~e.21 (s3 / specificity~e.24
                              :mod (c / catalysis~e.23)
                              :poss m2)))
            :purpose~e.12 (b / bind-01~e.13
                  :ARG2~e.14 (e / enzyme
                        :name (n4 / name :op1 "Rac"~e.15))))
      :manner~e.3 (s2 / strong~e.3))

# ::tok RTK activation differentially regulates the S/G and S/E/E8 complexes
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1.1 1-1.1 2-1.3 2-1.3.r 3-1 6-1.2 8-1.2.1 8-1.2.2
# ::id pmid_1177_7939.122
# ::preferred 
(r / regulate-01~e.3
      :ARG0 (a / activate-01~e.1
            :ARG0 (e / enzyme
                  :name (n / name :op1 "RTK"~e.0)))
      :ARG1 (a2 / and~e.6
            :op1 (m / macro-molecular-complex~e.8
                  :part (p / protein
                        :name (n2 / name :op1 "S"))
                  :part (p2 / protein
                        :name (n3 / name :op1 "G")))
            :op2 (m2 / macro-molecular-complex~e.8
                  :part p
                  :part (p3 / protein
                        :name (n4 / name :op1 "E"))
                  :part (p4 / protein
                        :name (n5 / name :op1 "E8"))))
      :manner~e.2 (d / differential~e.2))

# ::tok Since S/G and S/E complexes are present in the cells simultaneously , then both Sos @-@ 1 @-@ dependent Ras @- and Rac @-@ GEF activities are present at the same time .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3 2-1.3.1 4-1.1.1 4-1.2.1 4-1.3.1.1 5-1.3.1.2 9-1.3.1.2.1 10-1.3.1.2.2 14-1.1.1.3.1.1.1 16-1.1.1.3.1.1.1 18-1.1.1.3 19-1.1.1.1.1.1 21-1.3.1 22-1.2.1.1.1.1 24-1.1.1.2.1.1 26-1.3.1.2 28-1.4 30-1.4.1.1 31-1.3.1.2.2.r 31-1.4.1 31-1.4.1.r
# ::id pmid_1177_7939.123
# ::preferred 
(a5 / and
      :op1 (a2 / act-01
            :ARG0 (m / macro-molecular-complex~e.4
                  :part (e / enzyme
                        :name (n / name :op1 "Ras"~e.19))
                  :part (s2 / small-molecule
                        :name (n2 / name :op1 "GEF"~e.24))
                  :ARG0-of (d / depend-01~e.18
                        :ARG1 (g / gene
                              :name (n3 / name :op1 "Sos-1"~e.14,16)))))
      :op2 (a / act-01
            :ARG0 (m2 / macro-molecular-complex~e.4
                  :part (e3 / enzyme
                        :name (n4 / name :op1 "Rac"~e.22))
                  :part s2))
      :ARG1-of (c / cause-01~e.0
            :ARG0 (a4 / and~e.2,21
                  :op1 (m3 / macro-molecular-complex~e.4
                        :part (p / protein
                              :name (n6 / name :op1 "S"))
                        :part (p2 / protein
                              :name (n7 / name :op1 "G")))
                  :ARG1-of (b / be-located-at-91~e.5,26
                        :ARG2 (c2 / cell~e.9)
                        :time~e.31 (s / simultaneous~e.10))))
      :ARG1-of (b2 / be-located-at-91~e.28
            :time~e.31 (t / time~e.31
                  :ARG1-of (s3 / same-01~e.30))))

# ::tok The question remains as to how these two complexes , and the ensuing Ras and Rac activities , are coordinated to achieve propagation of signals .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1 2-1.2 4-1.1.r 5-1.1.1.r 6-1.1.1.1.1.2 7-1.1.1.1.1.1 8-1.1.1.1.1 10-1.1.1.1 10-1.1.1.1.2 10-1.1.1.1.2.r 12-1.1.1.1.2.3 13-1.1.1.1.2.1.1.1.1 14-1.1.1.1.2 15-1.1.1.1.2.2.1.1.1 16-1.1.1.1.2.2 19-1.1.1 21-1.1.1.2 22-1.1.1.2.2 23-1.1.1.2.2.1.r 24-1.1.1.2.2.1
# ::id pmid_1177_7939.124
# ::preferred 
(q / question-01~e.1
      :ARG1~e.4 (t / thing
            :manner-of~e.5 (c / coordinate-01~e.19
                  :ARG1 (a2 / and~e.10
                        :op1 (m / macro-molecular-complex~e.8
                              :quant "2"~e.7
                              :mod (t2 / this~e.6))
                        :op2~e.10 (a3 / and~e.10,14
                              :op1 (a5 / act-01
                                    :ARG0 (e3 / enzyme
                                          :name (n2 / name :op1 "Ras"~e.13)))
                              :op2 (a4 / act-02~e.16
                                    :ARG0 (e4 / enzyme
                                          :name (n3 / name :op1 "Rac"~e.15)))
                              :ARG1-of (e2 / ensue-01~e.12)))
                  :purpose (a / achieve-01~e.21
                        :ARG0 m
                        :ARG1 (p / propagate-01~e.22
                              :ARG1~e.23 (s / signal~e.24)))))
      :ARG1-of (r / remain-01~e.2))

# ::tok We therefore looked for evidence of differential regulation of the S/G and S/E complex upon RTK stimulation .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1 2-1.1 3-1.1.2.r 4-1.1.2 5-1.1.2.1.r 6-1.1.2.1.2 7-1.1.2.1 11-1.1.2.1.1 13-1.1.2.1.1.1 13-1.1.2.1.1.2 15-1.1.2.1.3.1.1.1 16-1.1.2.1.3
# ::id pmid_1177_7939.125
# ::preferred 
(c / cause-01~e.1
      :ARG1 (l2 / look-01~e.2
            :ARG0 (w / we~e.0)
            :ARG1~e.3 (e / evidence-01~e.4
                  :ARG1~e.5 (r / regulate-01~e.7
                        :ARG1 (a / and~e.11
                              :op1 (m / macro-molecular-complex~e.13
                                    :part (p / protein
                                          :name (n / name :op1 "S"))
                                    :part (p2 / protein
                                          :name (n2 / name :op1 "G")))
                              :op2 (m2 / macro-molecular-complex~e.13
                                    :part (p4 / protein
                                          :name (n5 / name :op1 "E"))
                                    :part p))
                        :mod (d / differential~e.6)
                        :condition (s / stimulate-01~e.16
                              :ARG2 (e4 / enzyme
                                    :name (n3 / name :op1 "RTK"~e.15)))))))

# ::tok Upon PDGF stimulation , we observed decreased coimmunoprecipitation between Grb2 and Sos @-@ 1 and consequently between PDGFR and Sos @-@ 1 ( <xref ref-type="fig" rid="fig8"> Fig . 8 , A and B </xref> ) , which correlated with the appearance of a mobility @-@ retarded form of Sos @-@ 1 .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3.1.1.1 2-1.3 4-1.1 5-1 6-1.2.2.2.1 7-1.2.2.2.1 8-1.2.2.2.1 9-1.2.2.2.1 10-1.2.2.2.1 11-1.2.2.2.1 12-1.2.2.2.1 13-1.2.2.2.1 14-1.2 14-1.2.1.1 14-1.2.4.1 15-1.2.2.2 17-1.2.2.1.1.1.1 18-1.2 18-1.2.1.1 18-1.2.2.1 18-1.2.4.1 19-1.2.2.1.2 20-1.2.2.1.2 21-1.2.2.1.2 31-1.2 31-1.2.1.1 31-1.2.2.1 31-1.2.4.1 37-1.2.3 38-1.2.3.1.r 40-1.2.3.1 41-1.2.3.1.1.r 43-1.2.3.1.1.2.1 45-1.2.3.1.1.2 46-1.2.3.1.1 47-1.2.3.1.1.1.r 48-1.2.3.1.1.1 49-1.2.3.1.1.1 50-1.2.3.1.1.1
# ::id pmid_1177_7939.126
# ::preferred 
(o / observe-01~e.5
      :ARG0 (w / we~e.4)
      :ARG1 (a / and~e.14,18,31
            :op1 (c / coimmunoprecipitate-00
                  :ARG1 (a4 / and~e.14,18,31
                        :op1 (e / enzyme
                              :name (n / name :op1 "Grb2"))
                        :op2 (p3 / protein
                              :name (n2 / name :op1 "Sos-1")))
                  :ARG1-of (d / decrease-01))
            :op2 (c3 / coimmunoprecipitate-00
                  :ARG1 (a5 / and~e.18,31
                        :op1 (p / protein
                              :name (n3 / name :op1 "PDGFR"~e.17))
                        :op2 p3~e.19,20,21)
                  :ARG1-of (c2 / cause-01~e.15
                        :ARG0 c~e.6,7,8,9,10,11,12,13))
            :ARG1-of (c4 / correlate-01~e.37
                  :ARG2~e.38 (a2 / appear-01~e.40
                        :ARG1~e.41 (f4 / form~e.46
                              :mod~e.47 p3~e.48,49,50
                              :ARG0-of (r / retard-01~e.45
                                    :ARG1 (m / mobility~e.43)))))
            :ARG1-of (d2 / describe-01
                  :ARG0 (a3 / and~e.14,18,31
                        :op1 (f / figure :mod "8A")
                        :op2 (f2 / figure :mod "8B"))))
      :condition (s / stimulate-01~e.2
            :ARG0 (p2 / protein
                  :name (n4 / name :op1 "PDGF"~e.1))))

# ::tok This likely represents a hyperphosphorylated form of Sos @-@ 1 , as previously demonstrated ( <xref ref-type="bibr" rid="bib1"> Baltensperger et al. , 1993 </xref> ; <xref ref-type="bibr" rid="bib10"> Cherniack et al. , 1994 </xref> ; <xref ref-type="bibr" rid="bib31"> Pronk et al. , 1994 </xref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1 2-1.1 4-1.1.2.1 5-1.1.2 6-1.1.2.2.r 7-1.1.2.2.1.1 9-1.1.2.2.1.1 11-1.1.3.2.r 12-1.1.3.2 13-1.1.3 18-1.2.1.1.1.1.1.1 19-1.2.1.1.1 20-1.2.1.1.1.2.1 22-1.2.1.1.2.1 28-1.2.1.2.1.1.1.1 29-1.2.1 29-1.2.1.2.1 29-1.2.1.3.1 30-1.2.1.2.1.2.1 30-1.2.1.3.1.2.1 32-1.2.1.2.2.1 32-1.2.1.3.2.1 38-1.2.1.3.1.1.1.1 39-1.2.1 39-1.2.1.2.1 39-1.2.1.3.1 40-1.2.1.2.1.2.1 40-1.2.1.3.1.2.1 42-1.2.1.2.2.1 42-1.2.1.3.2.1
# ::id pmid_1177_7939.127
# ::preferred 
(l / likely~e.1
      :domain (r / represent-01~e.2
            :ARG0 (t / this~e.0)
            :ARG1 (f / form~e.5
                  :ARG1-of (h / hyperphosphorylate-00~e.4)
                  :mod~e.6 (p / protein
                        :name (n / name :op1 "Sos-1"~e.7,9)))
            :compared-to (d3 / demonstrate-01~e.13
                  :ARG1 r
                  :time~e.11 (p2 / previous~e.12)))
      :ARG1-of (d4 / describe-01
            :ARG0 (a / and~e.29,39
                  :op1 (p3 / publication-91
                        :ARG0 (a2 / and~e.19
                              :op1 (p6 / person
                                    :name (n2 / name :op1 "Baltensperger"~e.18))
                              :op2 (p9 / person
                                    :mod (o / other~e.20)))
                        :time (d / date-entity :year "1993"~e.22))
                  :op2 (p4 / publication-91
                        :ARG0 (a3 / and~e.29,39
                              :op1 (p7 / person
                                    :name (n3 / name :op1 "Cherniack"~e.28))
                              :op2 (p10 / person
                                    :mod (o2 / other~e.30,40)))
                        :time (d2 / date-entity :year "1994"~e.32,42))
                  :op3 (p5 / publication-91
                        :ARG0 (a4 / and~e.29,39
                              :op1 (p8 / person
                                    :name (n4 / name :op1 "Pronk"~e.38))
                              :op2 (p11 / person
                                    :mod (o3 / other~e.30,40)))
                        :time (d5 / date-entity :year "1994"~e.32,42)))))

# ::tok Conversely , under identical conditions , the coimmunoprecipitation between E3b1 and Sos @-@ 1 was not affected ( <xref ref-type="fig" rid="fig8"> Fig . 8 </xref> A ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.4 3-1.5.1 4-1.5 4-1.5.r 9-1.2.1.1.1.1 10-1.2.1 11-1.2.1.2.1.1 13-1.2.1.2.1.1 15-1.1 15-1.1.r 16-1
# ::id pmid_1177_7939.128
# ::preferred 
(a / affect-01~e.16
      :polarity~e.15 "-"~e.15
      :ARG1 (c4 / coimmunoprecipitate-00
            :ARG1 (a2 / and~e.10
                  :op1 (p3 / protein
                        :name (n / name :op1 "E3b1"~e.9))
                  :op1 (p2 / protein
                        :name (n2 / name :op1 "Sos-1"~e.11,13))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "8A"))
      :mod (c / converse~e.0)
      :condition~e.4 (c3 / condition~e.4
            :ARG1-of (i / identical-01~e.3)))

# ::tok Similarly , the stability of the endogenous trimeric complex , Sos @-@ 1/Eps8/E3b1 was not affected by treatment of cells with growth factors ( <xref ref-type="fig" rid="fig8"> Fig . 8 </xref> C ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.5 3-1.2 4-1.2.1.r 6-1.2.1.2 7-1.2.1.1 8-1.2.1 10-1.2.1.3.1.1 14-1.1 14-1.1.r 15-1 16-1.3.r 17-1.3 18-1.3.1.r 19-1.3.1 20-1.3.2.r 21-1.3.2.1.1 22-1.3.2.1.2
# ::id pmid_1177_7939.129
# ::preferred 
(a / affect-01~e.15
      :polarity~e.14 "-"~e.14
      :ARG1 (s2 / stable-02~e.3
            :ARG1~e.4 (m / macro-molecular-complex~e.8
                  :mod (t2 / trimeric~e.7)
                  :mod (e / endogenous~e.6)
                  :part (p / protein
                        :name (n / name :op1 "Sos-1"~e.10))
                  :part (e2 / enzyme
                        :name (n2 / name :op1 "Eps8"))
                  :part (p3 / protein
                        :name (n3 / name :op1 "E3b1"))))
      :ARG2~e.16 (t / treat-04~e.17
            :ARG1~e.18 (c / cell~e.19)
            :ARG2~e.20 (s / small-molecule
                  :name (n4 / name :op1 "growth"~e.21 :op2 "factor"~e.22)))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "8C"))
      :ARG1-of (r / resemble-01~e.0))

# ::tok The above data indicate that , as a consequence of activation of RTKs , the S/G complex is disrupted , whereas the S/E/E8 complex persists in the cell .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1 2-1.1 3-1 6-1.2.3 7-1.2.3 8-1.2.3 9-1.2.3.1.r 10-1.2.3.1 16-1.2.1.1 18-1.2.1 20-1.2 23-1.2.2.1 24-1.2.2 25-1.2.2.2.r 27-1.2.2.2
# ::id pmid_1177_7939.130
# ::preferred 
(i / indicate-01~e.3
      :ARG0 (d / data~e.2
            :location (a / above~e.1))
      :ARG1 (c / contrast-01~e.20
            :ARG1 (d2 / disrupt-01~e.18
                  :ARG1 (m / macro-molecular-complex~e.16
                        :part (p / protein
                              :name (n / name :op1 "S"))
                        :part (p2 / protein
                              :name (n2 / name :op1 "G"))))
            :ARG2 (p3 / persist-01~e.24
                  :ARG1 (m2 / macro-molecular-complex~e.23
                        :part (p5 / protein
                              :name (n4 / name :op1 "E"))
                        :part (p6 / protein
                              :name (n5 / name :op1 "E8"))
                        :part p)
                  :location~e.25 (c2 / cell~e.27))
            :ARG1-of (c3 / cause-01~e.6,7,8
                  :ARG0~e.9 (a2 / activate-01~e.10
                        :ARG1 (e / enzyme
                              :name (n6 / name :op1 "RTK"))))))

# ::tok This might lead to a transient peak in Ras activity vis a vis a more prolonged activation of Rac .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1 2-1.1 5-1.1.2.2 6-1.1.2 8-1.1.2.1.1.1.1 14-1.1.3.2.1 15-1.1.3.2 16-1.1.3 17-1.1.3.1.r 18-1.1.3.1.1.1
# ::id pmid_1177_7939.131
# ::preferred 
(p / possible~e.1
      :domain (l / lead-03~e.2
            :ARG0 (t / this~e.0)
            :ARG2 (p2 / peak-01~e.6
                  :ARG1 (a / act-01
                        :ARG0 (e / enzyme
                              :name (n / name :op1 "Ras"~e.8)))
                  :mod (t2 / transient~e.5))
            :purpose (a2 / activate-01~e.16
                  :ARG1~e.17 (e2 / enzyme
                        :name (n2 / name :op1 "Rac"~e.18))
                  :ARG1-of (p3 / prolong-01~e.15
                        :degree (m / more~e.14)))))

# ::tok Therefore , we measured the kinetic of RTK @-@ induced activation of Ras and Rac .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 2-1.1.1 3-1.1 7-1.1.2.1.2.1.1.1 9-1.1.2.1.2 10-1.1.2.1 11-1.1.2.1.1.r 12-1.1.2.1.1.1.1.1 13-1.1.2.1.1 14-1.1.2.1.1.2.1.1
# ::id pmid_1177_7939.132
# ::preferred 
(c / cause-01~e.0
      :ARG1 (m / measure-01~e.3
            :ARG0 (w / we~e.2)
            :ARG1 (k / kinetics
                  :mod (a / activate-01~e.10
                        :ARG1~e.11 (a2 / and~e.13
                              :op1 (e / enzyme
                                    :name (n / name :op1 "Ras"~e.12))
                              :op2 (e2 / enzyme
                                    :name (n2 / name :op1 "Rac"~e.14)))
                        :ARG1-of (i / induce-01~e.9
                              :ARG0 (k2 / kinase
                                    :name (n3 / name :op1 "RTK"~e.7)))))))

# ::tok As shown in <xref ref-type="fig" rid="fig8"> Fig . 8 </xref> D , activation of Ras was rapid and short lived , whereas activation of Rac was sustained over a longer period of time , compatible with the differential regulation of the corresponding activating complexes , S/G and S/E/E8 .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3 12-1.1.1.1 13-1.1.1.1.1.r 14-1.1.1.1.1.1.1 15-1.1.1.1.r 16-1.1.1 17-1.1 18-1.1.2.2 19-1.1.2 21-1 22-1.2.1 23-1.2.1.1.r 24-1.2.1.1.1.1 26-1.2 29-1.2.2.1 29-1.2.2.1.1 29-1.2.2.1.1.r 30-1.2.2 34-1.2.2.2 35-1.2.2.2.1.r 37-1.2.2.2.1.2 38-1.2.2.2.1 39-1.2.2.2.1.1.r 41-1.2.2.2.1.1.3.1 42-1.2.2.2.1.1.3 43-1.2.2.2.1.1.1 43-1.2.2.2.1.1.2 46-1.2.2.2.1.1
# ::id pmid_1177_7939.133
# ::preferred 
(c / contrast-01~e.21
      :ARG1 (a / and~e.17
            :op1 (r / rapid~e.16
                  :domain~e.15 (a2 / activate-01~e.12
                        :ARG1~e.13 (e / enzyme
                              :name (n / name :op1 "Ras"~e.14))))
            :op2 (l / live-01~e.19
                  :ARG0 a2
                  :duration (s / short~e.18)))
      :ARG2 (s2 / sustain-01~e.26
            :ARG1 (a3 / activate-01~e.22
                  :ARG1~e.23 (e2 / enzyme
                        :name (n2 / name :op1 "Rac"~e.24)))
            :duration (p / period~e.30
                  :mod (l2 / long~e.29
                        :degree~e.29 (m / more~e.29))
                  :mod (c2 / compatible~e.34
                        :prep-with~e.35 (r2 / regulate-01~e.38
                              :ARG1~e.39 (a4 / and~e.46
                                    :op1 (m2 / macro-molecular-complex~e.43
                                          :part (p2 / protein
                                                :name (n3 / name :op1 "S"))
                                          :part (p3 / protein
                                                :name (n5 / name :op1 "G")))
                                    :op2 (m3 / macro-molecular-complex~e.43
                                          :part (p5 / protein
                                                :name (n6 / name :op1 "E"))
                                          :part (p6 / protein
                                                :name (n7 / name :op1 "E8"))
                                          :part p2)
                                    :ARG0-of (a5 / activate-01~e.42
                                          :ARG1-of (c3 / correspond-02~e.41)))
                              :ARG1-of (d / differ-02~e.37)))))
      :ARG1-of (s3 / show-01~e.1
            :ARG0 (f / figure :mod "8D")))

# ::tok Figure 1 .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.1
# ::id pmid_1177_7939.198
# ::preferred 
(f / figure~e.0 :mod "1"~e.1)

# ::tok <bold> The S/E/E8 complex exists under physiological conditions . </bold>
# ::amr-annotator SDL-AMR-09
# ::alignments 3-1.1 4-1 6-1.2 7-1.2.r
# ::id pmid_1177_7939.199
# ::preferred 
(e / exist-01~e.4
      :ARG1 (m / macro-molecular-complex~e.3
            :part (p2 / protein
                  :name (n / name :op1 "S"))
            :part (p3 / protein
                  :name (n2 / name :op1 "E"))
            :part (p4 / protein
                  :name (n3 / name :op1 "E8")))
      :condition~e.7 (p / physiology~e.6))

# ::tok ( A ) Eps8 @<sup> −/− </sup> cells were transfected with a control vector (−/− lanes ) or a vector coding a myc epitope–tagged Eps8 (−/− [Eps8 myc] lanes ) , both carrying a hygromicin resistance gene .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3 3-1.1.1.1.1.1 5-1.2.1.2.1.1.1 7-1.1 7-1.2.2.1.1 9-1 12-1.2.1.1 13-1.2.1 15-1.2.2.2.1 17-1.2 19-1.2.2 20-1.2.2.1 22-1.2.2.1.1.2.1.1.1 24-1.2.2.1.1.1.1.1.1 28-1.2.1.2.1 28-1.2.2.2.1 32-1.2.3 34-1.2.3.1.1.1.1.1 35-1.2.3.1.1 36-1.2.3.1
# ::id pmid_1177_7939.200
# ::preferred 
(t / transfect-00~e.9
      :ARG1 (c / cell~e.7
            :ARG0-of (c6 / contain-01
                  :ARG1 (e2 / enzyme
                        :name (n / name :op1 "Eps8"~e.3)
                        :ARG2-of (m4 / mutate-01 :mod "−/−"~e.5))))
      :ARG2 (o / or~e.17
            :op1 (v / vector~e.13
                  :ARG0-of (c2 / control-01~e.12)
                  :ARG1-of (d / describe-01
                        :ARG2 (l / lane~e.28
                              :ARG2-of m4)))
            :op2 (v2 / vector~e.19
                  :ARG0-of (c3 / code-01~e.20
                        :ARG1 (c4 / cell~e.7
                              :ARG0-of (c7 / contain-01
                                    :ARG1 (e3 / enzyme
                                          :name (n2 / name :op1 "Eps8"~e.24)))
                              :ARG1-of (t2 / tag-01
                                    :ARG0 (e / epitope
                                          :name (n3 / name :op1 "myc"~e.22)))))
                  :ARG1-of (m2 / mean-01
                        :ARG2 (l2 / lane~e.15,28
                              :mod (e4 / enzyme
                                    :name (n5 / name :op1 "Eps8myc")
                                    :ARG2-of m4))))
            :ARG0-of (c5 / carry-01~e.32
                  :ARG1 (g / gene~e.36
                        :ARG0-of (r / resist-01~e.35
                              :ARG1 (m3 / molecular-physical-entity
                                    :name (n4 / name :op1 "hygromicin"~e.34))))))
      :li (a / A~e.1))

# ::tok Hygromicin @-@ resistant single @-@ cell clones were established after 10 d of selection with hygromicin ( 0.2 mg/ml ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2.1.1.1 2-1.1.2 3-1.1.1 5-1.1 6-1.1.3 8-1 9-1.2 10-1.2.1.1 12-1.2.2.r 13-1.2.2 14-1.2.2.2.r 15-1.2.2.2.2.1 17-1.2.2.2.1 17-1.2.2.2.3.1
# ::id pmid_1177_7939.201
# ::preferred 
(e / establish-01~e.8
      :ARG1 (c2 / cell~e.5
            :mod (s / single~e.3)
            :ARG0-of (r / resist-01~e.2
                  :ARG1 (m / molecular-physical-entity
                        :name (n / name :op1 "hygromicin"~e.0)))
            :ARG1-of (c / clone-01~e.6))
      :time (a / after~e.9
            :op1 (t / temporal-quantity
                  :quant "10"~e.10
                  :unit (d / day))
            :duration-of~e.12 (s2 / select-01~e.13
                  :ARG1 c2
                  :instrument~e.14 (m2 / molecular-physical-entity
                        :quant "0.2"~e.17
                        :name (n2 / name :op1 "hygromicin"~e.15)
                        :quant (c3 / concentration-quantity
                              :quant "0.2"~e.17
                              :unit (m3 / milligram-per-milliliter))))))

# ::tok The levels of Eps8 , PDGFR , and EGFR in individual clones of eps8 @<sup> −/− </sup> , −/− [Eps8 myc], or in wild @-@ type ( WT ) cells were determined by immunoblotting analysis of equal amounts of total cellular lysates ( 50 μg ) using the indicated antibodies ( WB ) , and clones with levels of expression of Eps8 , PDGFR , and EGFR similar to wild @-@ type fibroblasts were used .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.2.1 2-1.1.2.1.1.r 3-1.1.2.1.1.1.1 5-1.1.2.2.1.1.1 7-1.1.2 8-1.1.2.3.1.1.1 10-1.1.2.4.1.2 11-1.1.2.4.1 11-1.1.2.4.2 11-1.1.2.4.3 13-1.1.2.4.1.1.1.1.1.1 15-1.1.2.4.1.1.1.1.2.1 18-1.1.2.4.1.1.1.1.2.1 21-1.1.2.4 23-1.1.2.4.3.1.1 25-1.1.2.4.3.1.1 27-1.1.2.4.3.1.1 27-1.1.2.4.3.1.1.1.1.1 29-1.1.2.4.1.1 29-1.1.2.4.2.1 29-1.1.2.4.3.1 31-1.1 34-1.1.1 35-1.1.1.1.r 36-1.1.1.1.1 37-1.1.1.1 39-1.1.1.1.2.2 40-1.1.1.1.2.1 43-1.1.1.1.2.2.1.1 46-1.1.1.3 48-1.1.1.3.1.1 49-1.1.1.3.1 51-1.1.1.3.1.2.1.1 54-1 54-1.1.2 55-1.2.1 57-1.1.2.2 57-1.1.2.3 57-1.2.1.1.1 57-1.2.1.1.2 57-1.2.1.1.3 59-1.2.1.1.1.1 59-1.2.1.1.2.1 59-1.2.1.1.3.1 61-1.1.2.1.1.1.1 61-1.1.2.4.1.1.1.1.1.1 63-1.1.2.2.1.1.1 66-1.1.2.3.1.1.1 67-1.2.1.1.4 68-1.2.1.1.4.1.r 69-1.2.1.1.4.1.1 70-1.2.1.1.4.1.1 71-1.2.1.1.4.1.1 72-1.2.1.1.4.1 74-1.2
# ::id pmid_1177_7939.202
# ::preferred 
(a / and~e.54
      :op1 (d / determine-01~e.31
            :ARG0 (a3 / analyze-01~e.34
                  :ARG1~e.35 (a4 / amount~e.37
                        :ARG1-of (e2 / equal-01~e.36)
                        :quant-of (l4 / lysate
                              :mod (c3 / cell~e.40)
                              :ARG1-of (t / total-01~e.39
                                    :ARG2 (m / mass-quantity
                                          :quant "50"~e.43
                                          :unit (m2 / microgram)))))
                  :mod (i2 / immunoblot-00)
                  :manner (u / use-01~e.46
                        :ARG1 (a5 / antibody~e.49
                              :ARG1-of (i3 / indicate-01~e.48)
                              :ARG1-of (d3 / describe-01
                                    :ARG2 (n6 / name :op1 "WB"~e.51)))))
            :ARG1 (a2 / and~e.7,54
                  :op1 (l / level~e.1
                        :quant-of~e.2 (e8 / enzyme
                              :name (n2 / name :op1 "Eps8"~e.3,61)))
                  :op2 (l2 / level~e.57
                        :quant-of (e4 / enzyme
                              :name (n3 / name :op1 "PDGFR"~e.5,63)))
                  :op3 (l3 / level~e.57
                        :quant-of (e3 / enzyme
                              :name (n4 / name :op1 "EGFR"~e.8,66)))
                  :location (o / or~e.21
                        :op1 (c / clone-01~e.11
                              :ARG1 (c5 / cell~e.29
                                    :ARG0-of (c6 / contain-01
                                          :ARG1 (e7 / enzyme
                                                :name (n5 / name :op1 "Eps8"~e.13,61)
                                                :ARG2-of (m3 / mutate-01 :mod "−/−"~e.15,18))))
                              :mod (i / individual~e.10))
                        :op2 (c7 / clone-01~e.11
                              :ARG1 (c8 / cell~e.29
                                    :ARG0-of (c9 / contain-01
                                          :ARG1 (p / protein
                                                :name (n / name :op1 "Eps8myc")
                                                :ARG2-of m3))))
                        :op3 (c10 / clone-01~e.11
                              :ARG1 (c2 / cell~e.29
                                    :mod (w / wild-type~e.23,25,27
                                          :ARG1-of (d2 / describe-01
                                                :ARG2 (n7 / name :op1 "WT"~e.27))))))))
      :op2 (u2 / use-01~e.74
            :ARG1 (c4 / clone~e.55
                  :poss-of (a6 / and
                        :op1 (l5 / level~e.57
                              :degree-of (e / express-01~e.59
                                    :ARG1 e8))
                        :op2 (l6 / level~e.57
                              :degree-of (e5 / express-01~e.59
                                    :ARG1 e4))
                        :op3 (l7 / level~e.57
                              :degree-of (e6 / express-01~e.59
                                    :ARG1 e3))
                        :ARG1-of (r / resemble-01~e.67
                              :ARG2~e.68 (f / fibroblast~e.72
                                    :mod w~e.69,70,71))))))

# ::tok ( B ) Total cellular lysates ( 10 mg ) , obtained from the transfectants described in A , were immunoprecipitated ( IP ) with the antibody indicated at the bottom ( ctr , irrelevant antibody ) , followed by immunoblot with indicated antibodies ( WB ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.4 3-1.1.2 4-1.1.1 7-1.1.2.1.1 11-1.1.3 15-1.1.3.1.2 15-1.2.3 15-1.3.1.1.2 15-1.5 16-1.1.3.1.2.1.r 16-1.1.3.1.r 17-1.1.3.1.2.1 22-1.5.1.1 26-1.2 27-1.2.1 28-1.2.1.1.r 30-1.2.1.1 32-1.2.3.1.1 34-1.2.2 34-1.2.2.1 34-1.2.2.1.r 35-1.2 38-1.3 39-1.3.1.r 40-1.3.1 41-1.3.1.1.r 42-1.3.1.1.1 43-1.3.1.1 45-1.3.1.1.2.1.1
# ::id pmid_1177_7939.203
# ::preferred 
(i / immunoprecipitate-00
      :ARG1 (l / lysate
            :mod (c / cell~e.4)
            :ARG1-of (t / total-01~e.3
                  :ARG2 (m / mass-quantity
                        :quant "10"~e.7
                        :unit (m2 / milligram)))
            :ARG1-of (o / obtain-01~e.11
                  :ARG2~e.16 (m3 / molecular-physical-entity
                        :ARG1-of (t2 / transfect-00)
                        :ARG1-of (d / describe-01~e.15
                              :ARG0~e.16 (a / A~e.17)))))
      :ARG2 (a2 / antibody~e.26,35
            :ARG1-of (i2 / indicate-01~e.27
                  :location~e.28 (b / bottom~e.30))
            :ARG1-of (r / relevant-01~e.34 :polarity~e.34 "-"~e.34)
            :ARG1-of (d3 / describe-01~e.15
                  :ARG2 (n2 / name
                        :op1 (c2 / ctr~e.32))))
      :ARG2-of (f / follow-01~e.38
            :ARG1~e.39 (i3 / immunoblot-00~e.40
                  :ARG2~e.41 (a3 / antibody~e.43
                        :ARG1-of (i4 / indicate-01~e.42)
                        :ARG1-of (d4 / describe-01~e.15
                              :ARG2 (n3 / name :op1 "WB"~e.45)))))
      :li (b2 / B~e.1)
      :ARG1-of (d2 / describe-01~e.15
            :ARG2 (n / name :op1 "IP"~e.22)))

# ::tok The indicated lanes ( lysates ) were loaded with 100 μg of total cellular lysates .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1 2-1.1 7-1 9-1.2.2.1.1 12-1.2.2 13-1.2.1
# ::id pmid_1177_7939.204
# ::preferred 
(l / load-01~e.7
      :ARG1 (l2 / lane~e.2
            :ARG1-of (i / indicate-01~e.1)
            :ARG1-of (d / describe-01
                  :ARG2 (l4 / lysate)))
      :ARG2 (l3 / lysate
            :mod (c / cell~e.13)
            :ARG1-of (t / total-01~e.12
                  :ARG2 (m / mass-quantity
                        :quant "100"~e.9
                        :unit (m2 / microgram)))))

# ::tok ( C ) Total cellular lysates ( 10 mg ) obtained from −/− [Eps8 myc] cells were immunoprecipitated ( IP ) with the antibody indicated at the top ( ctr , irrelevant antibody ) in the presence or absence (−) of 40 ng @/@ ml of the indicated peptides ( peptides ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.4 3-1.1.2 4-1.1.1 7-1.1.2.1.1 10-1.1.3 12-1.1.3.1.1.1.2.1 15-1.1.1 15-1.1.3.1 16-1.3.1 19-1.5.1.1 23-1.2 24-1.2.1 25-1.2.1.1.r 25-1.3.1 27-1.2.1.1 29-1.2.3.1.1 31-1.2.2 31-1.2.2.1 31-1.2.2.1.r 32-1.2 37-1.3 38-1.3.2 41-1.3.1.1.2.1 47-1.3.1.1.1 48-1.3.1.1 48-1.3.1.1.3.1 50-1.3.1.1 50-1.3.1.1.3.1
# ::id pmid_1177_7939.205
# ::preferred 
(i / immunoprecitipate-00
      :ARG1 (l / lysate
            :mod (c / cell~e.4,15)
            :ARG1-of (t / total-01~e.3
                  :ARG2 (m / mass-quantity
                        :quant "10"~e.7
                        :unit (m2 / milligram)))
            :ARG1-of (o / obtain-01~e.10
                  :ARG2 (c2 / cell~e.15
                        :ARG0-of (c4 / contain-01
                              :ARG1 (p2 / protein
                                    :name (n / name :op1 "EPS8myc")
                                    :ARG2-of (m3 / mutate-01 :mod "−/−"~e.12))))))
      :ARG2 (a / antibody~e.23,32
            :ARG1-of (i2 / indicate-01~e.24
                  :location~e.25 (t2 / top~e.27))
            :ARG1-of (r / relevant-01~e.31 :polarity~e.31 "-"~e.31)
            :ARG1-of (d2 / describe-01
                  :ARG2 (n2 / name
                        :op1 (c5 / ctr~e.29))))
      :condition (o2 / or~e.37
            :op1 (b / be-located-at-91~e.16,25
                  :ARG1 (p / peptide~e.48,50
                        :ARG1-of (i3 / indicate-01~e.47)
                        :quant (c6 / concentration-quantity
                              :quant "40"~e.41
                              :unit (n3 / nanogram-per-milliliter))
                        :ARG1-of (d3 / describe-01
                              :ARG2 (p3 / peptide~e.48,50))))
            :op2 (a2 / absent-01~e.38
                  :ARG1 p))
      :li (c3 / C~e.1)
      :ARG1-of (d / describe-01
            :ARG2 (n4 / name :op1 "IP"~e.19)))

# ::tok The peptides used were PPPPPVD @<bold> Y </bold>@ TEDEE ( PXXDY ) and PPPPPVD @<bold> A </bold>@ TEDEE ( PXXDA , used as a control ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1 1-1.1.2 2-1.1.2.2 10-1.1.1.2.1.1 12-1.1 19-1.1.2.3.1.1 21-1 21-1.1.2.2 22-1.1.2.2.1.r 24-1.1.2.2.1
# ::id pmid_1177_7939.206
# ::preferred 
(u / use-01~e.21
      :ARG1 (a / and~e.12
            :op1 (p / peptide~e.1
                  :name (n / name :op1 "PPPPPVDYTEDEE")
                  :ARG1-of (d / describe-01
                        :ARG2 (n3 / name :op1 "PXXDY"~e.10)))
            :op2 (p2 / peptide~e.1
                  :name (n2 / name :op1 "PPPPPVDATEDEE")
                  :ARG1-of (u2 / use-01~e.2,21
                        :ARG2~e.22 (c / control-01~e.24
                              :ARG0 p2))
                  :ARG1-of (d2 / describe-01
                        :ARG2 (n4 / name :op1 "PXXDA"~e.19)))))

# ::tok Immunoblotting was with the indicated antibodies ( WB ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 4-1.1.1 5-1.1 7-1.1.2.1.1
# ::id pmid_1177_7939.207
# ::preferred 
(i / immunoblot-00
      :ARG2 (a / antibody~e.5
            :ARG1-of (i2 / indicate-01~e.4)
            :ARG1-of (d / describe-01
                  :ARG2 (n / name :op1 "WB"~e.7))))

# ::tok The indicated lanes ( lysates ) were loaded with 100 μg of total cellular lysates .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1 2-1.1 7-1 9-1.2.1.1.1 12-1.2.1 13-1.2.2
# ::id pmid_1177_7939.208
# ::preferred 
(l / load-01~e.7
      :ARG1 (l2 / lane~e.2
            :ARG1-of (i / indicate-01~e.1)
            :ARG1-of (d / describe-01
                  :ARG2 (l4 / lysate)))
      :ARG2 (l3 / lysate
            :ARG1-of (t / total-01~e.12
                  :ARG2 (m / mass-quantity
                        :quant "100"~e.9
                        :unit (m2 / microgram)))
            :mod (c / cell~e.13)))

# ::tok Figure 2 .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.1
# ::id pmid_1177_7939.209
# ::preferred 
(f / figure~e.0 :mod "2"~e.1)

# ::tok <bold> In vitro competition between E3b1 and Grb2 for binding to Sos @-@ 1. </bold>
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.4 2-1.4 3-1 5-1.1.1.1 7-1.2.1.1 8-1.3.r 9-1.3 10-1.3.1.r 11-1.3.1.1.1
# ::id pmid_1177_7939.210
# ::preferred 
(c / compete-01~e.3
      :ARG0 (p / protein
            :name (n / name :op1 "E3b1"~e.5))
      :ARG1 (p2 / protein
            :name (n2 / name :op1 "Grb2"~e.7))
      :ARG2~e.8 (b / bind-01~e.9
            :ARG2~e.10 (p3 / protein
                  :name (n3 / name :op1 "Sos-1"~e.11)))
      :manner (i / in-vitro~e.1,2))

# ::tok ( A , Top ) schematic of E3b1 .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.2.1.1 3-1.2.1.2 5-1 6-1.1.r 7-1.1.1.1
# ::id pmid_1177_7939.211
# ::preferred 
(s / schematic~e.5
      :poss~e.6 (p / protein
            :name (n / name :op1 "E3b1"~e.7))
      :ARG1-of (d / describe-01
            :location (f / figure
                  :mod (a / A~e.1)
                  :location (t / top~e.3))))

# ::tok The ruler shows amino acid positions .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1 2-1 3-1.2.1.1 4-1.2.1.1 5-1.2 5-1.2.1 5-1.2.1.r
# ::id pmid_1177_7939.212
# ::preferred 
(s / show-01~e.2
      :ARG0 (r / ruler~e.1)
      :ARG1 (l / location~e.5
            :ARG2-of~e.5 (p / position-01~e.5
                  :ARG1 (a / amino-acid~e.3,4))))

# ::tok ( Bottom ) In vitro binding of various fragments of E3b1 ( all engineered as GST fusions , amino acid boundaries are indicated on the top ) to Sos @-@ 1 from lysates of Sos @-@ 1–transfected Cos @-@ 7 cells .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.3 3-1.1.4 4-1.1.4 5-1.1 6-1.1.1.r 7-1.1.1.2 10-1.1.1.1.1.1 12-1.2.1.1 13-1.2.1 14-1.2.1.2.r 15-1.2.1.2.1.1 16-1.2.1.2.1.2 18-1.2.2.1.1 19-1.2.2.1.1 20-1.2.2.1 22-1.2.2 23-1.2.2.2.r 25-1.2.2.2 27-1.1.2.r 28-1.1.2.1.1 30-1.1.2.1.1 31-1.1.2.2.r 34-1.1.2.1.1 37-1.1.2.2.1.1.1 39-1.1.2.2.1.1.1 40-1.1.2.2.1
# ::id pmid_1177_7939.213
# ::preferred 
(m / multi-sentence
      :snt1 (b / bind-01~e.5
            :ARG1~e.6 (p2 / protein-segment
                  :part-of (p / protein
                        :name (n / name :op1 "E3b1"~e.10))
                  :mod (v / various~e.7))
            :ARG2~e.27 (p4 / protein
                  :name (n3 / name :op1 "Sos-1"~e.28,30,34)
                  :source~e.31 (l / lysate
                        :mod (c / cell~e.40
                              :name (n4 / name :op1 "Cos-7"~e.37,39)
                              :ARG1-of (t / transfect-00
                                    :ARG2 p4))))
            :location (b2 / bottom~e.1)
            :manner (i / in-vitro~e.3,4))
      :snt2 (a2 / and
            :op1 (e / engineer-01~e.13
                  :ARG1 (a / all~e.12)
                  :ARG2~e.14 (p3 / protein
                        :name (n2 / name :op1 "GST"~e.15 :op2 "fusion"~e.16)))
            :op2 (i2 / indicate-01~e.22
                  :ARG1 (b3 / boundary~e.20
                        :poss (a3 / amino-acid~e.18,19))
                  :location~e.23 (t2 / top~e.25))))

# ::tok Detection was with anti–Sos @-@ 1 antibody .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 5-1.1.1.1.1.1 6-1.1
# ::id pmid_1177_7939.214
# ::preferred 
(d / detect-01~e.0
      :ARG2 (a / antibody~e.6
            :ARG0-of (c / counter-01
                  :ARG1 (p / protein
                        :name (n / name :op1 "Sos-1"~e.5)))))

# ::tok The lane “ lysate ” was loaded with 50 μg of total cellular lysates .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1 3-1.1.1.1 3-1.2 6-1 7-1.2.2.r 8-1.2.2.1.1 11-1.2.2 12-1.2.1
# ::id pmid_1177_7939.215
# ::preferred 
(l / load-01~e.6
      :ARG1 (l2 / lane~e.1
            :ARG1-of (d / describe-01
                  :ARG2 (l4 / lysate~e.3)))
      :ARG2 (l3 / lysate~e.3
            :mod (c / cell~e.12)
            :ARG1-of~e.7 (t / total-01~e.11
                  :ARG2 (m / mass-quantity
                        :quant "50"~e.8
                        :unit (m2 / microgram)))))

# ::tok P Rich , proline rich region ; SH3 , SH3 domain .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1.2 1-1.1.3.1 3-1.1.3.1.3.1.1 4-1.1.3.1 5-1.1.3.1.2 7-1.2.1 9-1.2.2.1.1.1 10-1.2.2.1.1.2
# ::id pmid_1177_7939.216
# ::preferred 
(a2 / and
      :op1 (n4 / name
            :op1 "P"~e.0
            :op2 "Rich"~e.1
            :ARG2-of (d / describe-01
                  :ARG1 (r2 / rich~e.1,4
                        :mod (a / amino-acid
                              :name (n / name :op1 "proline"~e.3))
                        :domain (r3 / region~e.5)
                        :mod a)))
      :op2 (n5 / name
            :op1 "SH3"~e.7
            :ARG2-of (d2 / describe-01
                  :ARG1 (p2 / protein-segment
                        :name (n3 / name :op1 "SH3"~e.9 :op2 "domain"~e.10)))))

# ::tok ( B ) A His @-@ tagged COOH @-@ terminal fragment ( His @-@ Sos , aa 1131–1333 ) of Sos @-@ 1 ( 10 pmoles ) was bound to 60 pmoles of either immobilized GST ( GST ) or GST @-@ E3b1–331–480 in the presence of increasing concentrations of the NH @<sub> 2 </sub>@ -@ terminal SH3 domain of Grb2 or of Eps8 ( SH3s , 0 , 10 , 100 , 1,000 pmoles , as indicated on the top ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.4 6-1.1.1.3 7-1.1.1.1.1 9-1.1.1.1.1 14-1.1.1.2.1.1 20-1.1.1.2.1.1 22-1.1.1.2.1.1 24-1.1.1.4.1 27-1.1.3 28-1.1 29-1.1.2.r 30-1.1.2.1.3.1 35-1.1.2.1.1.1 37-1.1.2.1.1.1 39-1.1.2 40-1.1.2.1.1.1 47-1.1.3.1.2 48-1.1.3.1 56-1.1.3.1.1.1.2.1.1 56-1.1.3.1.1.2.2.1.1 57-1.1.3.1.1.1.1.1 57-1.1.3.1.1.2.1.1 57-1.2.1.1.1 58-1.1.3.1.1.1.1.2 58-1.1.3.1.1.2.1.2 59-1.1.3.1.1.r 60-1.1.3.1.1.1.2.2.1.1 61-1.1.3.1.1 63-1.1.3.1.1.2.2.2.1.1 67-1.2.2.1 69-1.2.3.1 71-1.2.4.1 73-1.2.5.1 77-1.2.6 78-1.2.6.1.r 80-1.2.6.1
# ::id pmid_1177_7939.217
# ::preferred 
(m4 / multi-sentence
      :snt1 (b / bind-01~e.28
            :ARG1 (p / protein-segment
                  :name (n / name :op1 "COOH-terminus"~e.7,9)
                  :part-of (p2 / protein
                        :name (n2 / name :op1 "Sos-1"~e.14,20,22))
                  :ARG1-of (t / tag-01~e.6
                        :ARG2 (a / amino-acid
                              :name (n3 / name :op1 "histidine")))
                  :quant (m / mass-quantity
                        :quant "10"~e.24
                        :unit (p3 / picomole))
                  :consist-of (a2 / amino-acid
                        :mod (b2 / between :op1 "1131" :op2 "1333")))
            :ARG2~e.29 (o / or~e.39
                  :op1 (e / enzyme
                        :name (n4 / name :op1 "GST"~e.35,37,40)
                        :ARG1-of (m2 / mobilize-01 :polarity "-")
                        :quant (m3 / mass-quantity
                              :quant "60"~e.30
                              :unit (p4 / picomole)))
                  :op2 (p5 / protein
                        :name (n5 / name :op1 "GST-E3b1")
                        :consist-of (a3 / amino-acid
                              :mod (b3 / between :op1 "331" :op2 "480"))))
            :manner (b4 / be-located-at-91~e.27
                  :ARG1 (c / concentrate-02~e.48
                        :ARG1~e.59 (o2 / or~e.61
                              :op1 (p15 / protein-segment
                                    :name (n11 / name :op1 "SH3"~e.57 :op2 "domain"~e.58)
                                    :part-of (p6 / protein-segment
                                          :name (n6 / name :op1 "NH2-terminus"~e.56)
                                          :part-of (p7 / protein
                                                :name (n7 / name :op1 "Grb2"~e.60))))
                              :op2 (p16 / protein-segment
                                    :name (n12 / name :op1 "SH3"~e.57 :op2 "domain"~e.58)
                                    :part-of (p8 / protein-segment
                                          :name (n8 / name :op1 "NH2-terminus"~e.56)
                                          :part-of (e2 / enzyme
                                                :name (n9 / name :op1 "Eps8"~e.63)))))
                        :ARG1-of (i / increase-01~e.47)))
            :li (b5 / B~e.1))
      :snt2 (a4 / and
            :op1 (p10 / protein-segment
                  :name (n10 / name :op1 "SH3"~e.57))
            :op2 (m5 / mass-quantity
                  :quant "0"~e.67
                  :unit (p11 / picomole))
            :op3 (m6 / mass-quantity
                  :quant "10"~e.69
                  :unit (p12 / picomole))
            :op4 (m7 / mass-quantity
                  :quant "100"~e.71
                  :unit (p13 / picomole))
            :op5 (m8 / mass-quantity
                  :quant "1000"~e.73
                  :unit (p14 / picomole))
            :ARG1-of (i2 / indicate-01~e.77
                  :location~e.78 (t2 / top~e.80))))

# ::tok Detection was with antihistidine antibody .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 4-1.1
# ::id pmid_1177_7939.218
# ::preferred 
(d / detect-01~e.0
      :ARG2 (a / antibody~e.4
            :ARG0-of (c / counter-01
                  :ARG1 (a2 / amino-acid
                        :name (n / name :op1 "histidine")))))

# ::tok I , input , 10 pmoles of His @-@ Sos @-@ 1 .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.1.1 2-1 4-1.1.3.1 9-1.1.1.1 11-1.1.1.1
# ::id pmid_1177_7939.219
# ::preferred 
(i / input~e.2
      :mod (p / protein
            :name (n / name :op1 "Sos-1"~e.9,11)
            :ARG1-of (t / tag-01
                  :ARG2 (a / amino-acid
                        :name (n2 / name :op1 "histidine")))
            :quant (m / mass-quantity
                  :quant "10"~e.4
                  :unit (p2 / picomole)))
      :ARG1-of (d / describe-01
            :ARG2 (n3 / name :op1 "I"~e.0)))

# ::tok ( C ) His @-@ Sos ( 10 pmoles ) was bound to 60 pmoles of GST fusions encompassing the SH3s of either E3b1 (○ and •) or of Grb2 (□ and ▪).
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3 5-1.1.1.1 7-1.1.3.1 11-1 12-1.2.r 13-1.2.2.1 16-1.2.1.1 17-1.2.1.2 18-1.2.3 23-1.2.3.1.1.2.1.1 27-1.2.3.1 28-1.2.3.1.r 29-1.2.3.1.2.2.1.1
# ::id pmid_1177_7939.220
# ::preferred 
(b / bind-01~e.11
      :ARG1 (p / protein
            :name (n2 / name :op1 "Sos"~e.5)
            :ARG1-of (t / tag-01
                  :ARG2 (a / amino-acid
                        :name (n / name :op1 "histidine")))
            :quant (m2 / mass-quantity
                  :quant "10"~e.7
                  :unit (p2 / picomole)))
      :ARG2~e.12 (p3 / protein
            :name (n3 / name :op1 "GST"~e.16 :op2 "fusion"~e.17)
            :quant (m3 / mass-quantity
                  :quant "60"~e.13
                  :unit (p4 / picomole))
            :ARG0-of (e / encompass-01~e.18
                  :ARG1~e.28 (o / or~e.27
                        :op1 (p5 / protein-segment
                              :name (n4 / name :op1 "SH3")
                              :part-of (p6 / protein
                                    :name (n5 / name :op1 "E3b1"~e.23)))
                        :op2 (p7 / protein-segment
                              :name (n6 / name :op1 "SH3")
                              :part-of (p8 / protein
                                    :name (n7 / name :op1 "Grb2"~e.29))))))
      :li (c / C~e.1))

# ::tok Binding was in the presence of the indicated amounts of the competing peptide NH2 @-@ VPVPPPVPPRRR @-@ COOH ( derived from the sequence of Sos @-@ 1 , • and ▪), or of a scrambled control peptide (○ and □).
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.1 7-1.1.1.3 8-1.1.1.1 8-1.1.1.2 9-1.1.1.1.1.r 11-1.1.1.1.1.2 12-1.1.1.1.1 13-1.1.1.1.1.1.1 15-1.1.1.1.1.1.1 17-1.1.1.1.1.1.1 19-1.1.1.1.1.3 20-1.1.1.1.1.3.1.r 22-1.1.1.1.1.3.1 23-1.1.1.1.1.3.1.1.r 24-1.1.1.1.1.3.1.1.1.1 26-1.1.1.1.1.3.1.1.1.1 31-1.1.1 32-1.1.1.2.1.r 34-1.1.1.2.1.2 35-1.1.1.2.1.1 36-1.1.1.2.1
# ::id pmid_1177_7939.221
# ::preferred 
(b / bind-01~e.0
      :condition (b2 / be-located-at-91~e.1
            :ARG1 (o / or~e.31
                  :op1 (a / amount~e.8
                        :quant-of~e.9 (p / peptide~e.12
                              :name (n / name :op1 "NH2-VPVPPPVPPRRR-COOH"~e.13,15,17)
                              :ARG0-of (c / compete-01~e.11)
                              :ARG1-of (d / derive-01~e.19
                                    :ARG2~e.20 (s2 / sequence~e.22
                                          :mod~e.23 (p3 / protein
                                                :name (n2 / name :op1 "Sos-1"~e.24,26))))))
                  :op2 (a2 / amount~e.8
                        :quant-of~e.32 (p4 / peptide~e.36
                              :ARG0-of (c2 / control-01~e.35)
                              :ARG1-of (s / scramble-02~e.34)))
                  :ARG1-of (i / indicate-01~e.7))))

# ::tok Detection was by immunoblot with anti @-@ His , followed by densitometric scanning .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 2-1.1.r 3-1.1 5-1.1.1.1 9-1.1.2 10-1.1.2.1.r 11-1.1.2.1.1 12-1.1.2.1
# ::id pmid_1177_7939.222
# ::preferred 
(d / detect-01~e.0
      :ARG2~e.2 (i / immunoblot-00~e.3
            :ARG2 (a / antibody
                  :ARG0-of (c / counter-01~e.5
                        :ARG1 (h / histidine)))
            :ARG2-of (f / follow-01~e.9
                  :ARG1~e.10 (s / scan-01~e.12
                        :mod (d2 / densitometric~e.11)))))

# ::tok ( D ) Kinetic analysis and rate constants for the binding of the SH3 domains of Grb2 and E3b1 to the proline @-@ rich COOH @-@ terminal of Sos @-@ 1 ( aa 1131–1333 ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.4 4-1.1 5-1 6-1.2.1 7-1.2 10-1.3 13-1.3.1.1.1.1 13-1.3.1.2.1.2 14-1.3.1.1.1.2 14-1.3.1.2.1.3 15-1.3.1.r 16-1.3.1.1.2.1.1 18-1.3.1.2.2.1.1 19-1.3.2.r 21-1.3.2.4.1.1.1 23-1.3.2.4 24-1.3.2.1.1 26-1.3.2.1.1 28-1.3.2.2.1.1 30-1.3.2.2.1.1
# ::id pmid_1177_7939.223
# ::preferred 
(a / and~e.5
      :op1 (a2 / analyze-01~e.4
            :ARG1 (k / kinetics))
      :op2 (c / constant~e.7
            :mod (r / rate~e.6))
      :purpose (b / bind-01~e.10
            :ARG1~e.15 (a3 / and
                  :op1 (p / protein-segment
                        :name (n / name :op1 "SH3"~e.13 :op2 "domain"~e.14)
                        :part-of (p2 / protein
                              :name (n2 / name :op1 "Grb2"~e.16)))
                  :op2 (p3 / protein
                        :name (n3 / name
                              :op1 "segment"
                              :op2 "SH3"~e.13
                              :op3 "domain"~e.14)
                        :part-of (p4 / protein
                              :name (n4 / name :op1 "E3b1"~e.18))))
            :ARG2~e.19 (p5 / protein-segment
                  :name (n5 / name :op1 "COOH-terminus"~e.24,26)
                  :part-of (p6 / protein
                        :name (n6 / name :op1 "Sos-1"~e.28,30))
                  :consist-of (a4 / amino-acid
                        :mod (b2 / between :op1 "1131" :op2 "1333"))
                  :mod (r2 / rich~e.23
                        :mod (a5 / amino-acid
                              :name (n7 / name :op1 "proline"~e.21)))))
      :li (d / D~e.1))

# ::tok Increasing concentrations ( 10–400 nM ) of His @-@ Sos @-@ 1 were passed over the immobilized GST fusion proteins ( GST @-@ SH3 @-@ Grb2 and GST @-@ SH3 @-@ E3b1 ) for 2.5 min at a flow rate of 50 μl/min .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1 1-1.1.3 1-1.1.3.r 9-1.1.2.1.1 11-1.1.2.1.1 11-1.4.2.1 13-1 17-1.2.1.1 18-1.2.1.2 19-1.1.2 19-1.2 19-1.2.3.1.1 19-1.2.3.1.2 23-1.2.3.1.1.1.1 23-1.2.3.1.2.1.1 25-1.2.3.1.1.1.1 26-1.2.3.1 27-1.2.3.1.1.1.1 27-1.2.3.1.2.1.1 29-1.2.3.1.1.1.1 29-1.2.3.1.2.1.1 31-1.2.3.1.2.1.1 33-1.3.r 34-1.3.1 39-1.4 41-1.4.1.1
# ::id pmid_1177_7939.224
# ::preferred 
(p / pass-08~e.13
      :ARG0 (c / concentration~e.1
            :ARG1-of (i / increase-01~e.0)
            :mod (p2 / protein~e.19
                  :name (n2 / name :op1 "Sos-1"~e.9,11)
                  :ARG1-of (t3 / tag-01
                        :ARG2 (a / amino-acid
                              :name (n / name :op1 "histidine"))))
            :quant~e.1 (c2 / concentration-quantity~e.1
                  :quant (b / between :op1 "10" :op2 "400")
                  :unit (n3 / nanomolar)))
      :ARG1 (p3 / protein~e.19
            :name (n4 / name :op1 "GST"~e.17 :op2 "fusion"~e.18)
            :ARG1-of (m2 / mobilize-01 :polarity "-")
            :ARG0-of (m3 / mean-01
                  :ARG1 (a2 / and~e.26
                        :op1 (p4 / protein~e.19
                              :name (n5 / name :op1 "GST-SH3-Grb2"~e.23,25,27,29))
                        :op2 (p5 / protein~e.19
                              :name (n6 / name :op1 "GST-SH3-E3b1"~e.23,27,29,31)))))
      :duration~e.33 (t / temporal-quantity
            :quant "2.5"~e.34
            :unit (m4 / minute))
      :frequency (r / rate-entity-91~e.39
            :ARG1 (v / volume-quantity
                  :quant "50"~e.41
                  :unit (m5 / microliter))
            :ARG2 (t2 / temporal-quantity
                  :quant "1"~e.11
                  :unit (m6 / minute))))

# ::tok The kinetics of binding are shown in the graphs .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.2 2-1.2.1.r 3-1.2.1 5-1 6-1.1.r 8-1.1
# ::id pmid_1177_7939.225
# ::preferred 
(s / show-01~e.5
      :ARG0~e.6 (g / graph~e.8)
      :ARG1 (k / kinetics~e.1
            :mod~e.2 (b / bind-01~e.3)))

# ::tok Coupling of equal amounts of the GST fusion proteins was performed with a goat anti @-@ GST antibody covalently linked to CM5 sensor chip according to the manufacturer 's instructions .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1.1.1.r 2-1.1.1.2 3-1.1.1 4-1.1.1.1.r 6-1.1.1.1.1.1 7-1.1.1.1.1.2 8-1.1.1.1 10-1 11-1.1.2.r 13-1.1.2.1.1 14-1.1.2.1.2 16-1.1.2.1.2.1.1.1 17-1.1.2.1 19-1.1.2.3 21-1.1.2.2.1.1 22-1.1.2.2.2 23-1.1.2.2 24-1.2 25-1.2 27-1.2.1.1 27-1.2.1.1.1 27-1.2.1.1.1.r 28-1.2.1.1.r 29-1.2.1
# ::id pmid_1177_7939.226
# ::preferred 
(p / perform-01~e.10
      :ARG1 (c / couple-01~e.0
            :ARG1~e.1 (a / amount~e.3
                  :quant-of~e.4 (p2 / protein~e.8
                        :name (n / name :op1 "GST"~e.6 :op2 "fusion"~e.7))
                  :ARG1-of (e / equal-01~e.2))
            :ARG2~e.11 (a3 / and
                  :op1 (a2 / antibody~e.17
                        :mod (g / goat~e.13)
                        :ARG0-of (c5 / counter-01~e.14
                              :ARG1 (e2 / enzyme
                                    :name (n2 / name :op1 "GST"~e.16))))
                  :op2 (c3 / chip~e.23
                        :name (n3 / name :op1 "CM5"~e.21)
                        :mod (s / sensor~e.22))
                  :ARG1-of (l / link-01~e.19
                        :manner (c2 / covalent))))
      :ARG1-of (s2 / say-01~e.24,25
            :ARG0 (i / instruct-01~e.29
                  :ARG0~e.28 (c4 / company~e.27
                        :ARG0-of~e.27 (m / manufacture-01~e.27)))))

# ::tok k @<sub> on </sub> and k @<sub> off </sub> kinetic rates were obtained by simple Langmuir fitting model ( biaevaluation software v2.1 ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1.1.1.1 4-1.1 7-1.1.2.1.1 10-1.1.1 10-1.1.2 12-1 13-1.2.r 14-1.2.3 15-1.2.1.1 16-1.2.2 17-1.2 19-1.3.1 20-1.3 21-1.3.2
# ::id pmid_1177_7939.227
# ::preferred 
(o / obtain-01~e.12
      :ARG1 (a / and~e.4
            :op1 (r / rate~e.10
                  :mod (k / kinetics
                        :mod (o2 / on~e.2)))
            :op2 (r2 / rate~e.10
                  :mod (k2 / kinetics
                        :mod (o3 / off~e.7))))
      :manner~e.13 (m / model~e.17
            :name (n / name :op1 "Langmuir"~e.15)
            :ARG0-of (f / fit-01~e.16)
            :mod (s / simple~e.14))
      :instrument (s2 / software~e.20
            :mod (b / biaevaluation~e.19)
            :mod (v / v2.1~e.21)))

# ::tok Figure 3 .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.1
# ::id pmid_1177_7939.228
# ::preferred 
(f / figure~e.0 :mod "3"~e.1)

# ::tok <bold> In vivo competition between E3b1 and Grb2 for binding to Sos @-@ 1. </bold>
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.4 2-1.4 3-1 5-1.1.1.1 7-1.2.1.1 8-1.3.r 9-1.3 10-1.3.1.r 11-1.3.1.1.1
# ::id pmid_1177_7939.229
# ::preferred 
(c / compete-01~e.3
      :ARG0 (p / protein
            :name (n / name :op1 "E3b1"~e.5))
      :ARG1 (p2 / protein
            :name (n2 / name :op1 "Grb2"~e.7))
      :ARG2~e.8 (b / bind-01~e.9
            :ARG2~e.10 (p3 / protein
                  :name (n3 / name :op1 "Sos-1"~e.11)))
      :manner (i / in-vivo~e.1,2))

# ::tok ( A , Top ) GST @-@ E3b1 @-@ 331–480 , or control GST , was bound to Sos @-@ 1 present in Cos @-@ 7 cells transfected ( Tfx ) with either Sos @-@ 1 or S/G .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3.1.1 3-1.3.1.2 5-1.1.1.2.1.1 5-1.1.2.1.1 7-1.1.1.3.1.1 11-1.1 12-1.1.2 12-1.1.2.2 12-1.1.2.2.r 13-1.1.1.2.1.1 13-1.1.2.1.1 16-1 17-1.2.r 18-1.2.1.1 20-1.2.1.1 23-1.2.2.1.1.1 25-1.2.2.1.1.1 26-1.2.2.1 27-1.2.2.1.2 29-1.2.2.1.3.1.1 33-1.2.2.1.2.1.1.1.1 35-1.2.2.1.2.1.1.1.1 36-1.2.2.1.2.1
# ::id pmid_1177_7939.230
# ::preferred 
(b / bind-01~e.16
      :ARG1 (o / or~e.11
            :op1 (m / macro-molecular-complex
                  :consist-of (a / amino-acid
                        :mod (b2 / between :op1 "331" :op2 "480"))
                  :part (e2 / enzyme
                        :name (n / name :op1 "GST"~e.5,13))
                  :part (p4 / protein
                        :name (n8 / name :op1 "E3b1"~e.7)))
            :op2 (e / enzyme~e.12
                  :name (n2 / name :op1 "GST"~e.5,13)
                  :ARG0-of~e.12 (c / control-01~e.12)))
      :ARG2~e.17 (p2 / protein
            :name (n3 / name :op1 "Sos-1"~e.18,20)
            :ARG1-of (b3 / be-located-at-91
                  :ARG2 (c2 / cell~e.26
                        :name (n4 / name :op1 "Cos-7"~e.23,25)
                        :ARG1-of (t / transfect-00~e.27
                              :ARG2 (o2 / or~e.36
                                    :op1 (p3 / protein
                                          :name (n5 / name :op1 "Sos-1"~e.33,35))
                                    :op2 (m2 / macro-molecular-complex
                                          :part p3
                                          :part (p / protein
                                                :name (n7 / name :op1 "Grb2")))))
                        :ARG1-of (d / describe-01
                              :ARG2 (n9 / name :op1 "Tfx"~e.29)))))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure
                  :mod (a2 / A~e.1)
                  :location (t2 / top~e.3))))

# ::tok Detection was with anti–Sos @-@ 1 .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 5-1.1.1.1.1.1
# ::id pmid_1177_7939.231
# ::preferred 
(d / detect-01~e.0
      :ARG2 (a / antibody
            :ARG0-of (c / counter-01
                  :ARG1 (p / protein
                        :name (n / name :op1 "Sos-1"~e.5)))))

# ::tok ( Bottom ) The same cellular lysates ( 50 μg ) were detected with anti @-@ Grb2 .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3 4-1.1.2 5-1.1.1 8-1.1.3.1 12-1 14-1.2.1 16-1.2.1.1.1.1
# ::id pmid_1177_7939.232
# ::preferred 
(d / detect-01~e.12
      :ARG1 (l / lysate
            :mod (c / cell~e.5)
            :ARG1-of (s / same-01~e.4)
            :quant (m / mass-quantity
                  :quant "50"~e.8
                  :unit (m2 / microgram)))
      :ARG2 (a / antibody
            :ARG0-of (c2 / counter-01~e.14
                  :ARG1 (p / protein
                        :name (n / name :op1 "Grb2"~e.16))))
      :location (b / bottom~e.1))

# ::tok ( B ) Lysates , from 293T cells transfected ( Tfx ) with E3b1 or a control vector ( ctr ) , were immunoprecipitated ( IP ) with anti @-@ Grb2 or an irrelevant antibody ( ctr ) , followed by detection ( WB ) with anti–Sos @-@ 1 ( top ) or anti @-@ Grb2 ( middle ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.4 5-1.1.1.r 6-1.1.1.1.1 7-1.1.1 8-1.1.1.2 10-1.1.1.3.1.1 12-1.1.1.2.1.r 13-1.1.1.2.1.1.1.1 14-1.1.1.2.1 16-1.1.1.2.1.2.1 17-1.1.1.2.1.2 19-1.1.1.2.1.2.2.1.1 25-1.5.1.1 28-1.2.1.1.1 28-1.3.1.2.2.1 30-1.2.1.1.1 31-1.2 33-1.2.2.1 33-1.2.2.1.1 33-1.2.2.1.1.r 34-1.2.1 34-1.2.2 34-1.3.1.2.1 34-1.3.1.2.2 36-1.1.1.2.1.2.2.1.1 39-1.3 40-1.3.1.r 41-1.3.1 43-1.3.1.3.1.1 48-1.3.1.2.1.1.1.1.1 50-1.3.1.2.1.2.1 52-1.3.1.2 53-1.3.1.2.1.1 55-1.3.1.2.2.1.1.1.1 57-1.3.1.2.2.2.1
# ::id pmid_1177_7939.233
# ::preferred 
(i / immunoprecipitate-00
      :ARG1 (l / lysate
            :source~e.5 (c / cell~e.7
                  :name (n / name :op1 "293T"~e.6)
                  :ARG1-of (t / transfect-00~e.8
                        :ARG2~e.12 (o / or~e.14
                              :op1 (p / protein
                                    :name (n2 / name :op1 "E3b1"~e.13))
                              :op2 (v / vector~e.17
                                    :ARG0-of (c2 / control-01~e.16)
                                    :ARG1-of (d3 / describe-01
                                          :ARG2 (n7 / name
                                                :op1 (c3 / ctr~e.19,36))))))
                  :ARG1-of (d2 / describe-01
                        :ARG2 (n6 / name :op1 "Tfx"~e.10))))
      :ARG2 (o2 / or~e.31
            :op1 (a / antibody~e.34
                  :name (n3 / name :op1 "anti-Grb2"~e.28,30))
            :op2 (a2 / antibody~e.34
                  :ARG1-of (r / relevant-01~e.33 :polarity~e.33 "-"~e.33)
                  :ARG1-of d3))
      :ARG2-of (f / follow-01~e.39
            :ARG1~e.40 (d / detect-01~e.41
                  :ARG1 l
                  :ARG2 (o3 / or~e.52
                        :op1 (a3 / antibody~e.34
                              :ARG0-of (c4 / counter-01~e.53
                                    :ARG1 (p2 / protein
                                          :name (n4 / name :op1 "Sos-1"~e.48)))
                              :ARG1-of (d7 / describe-01
                                    :location (t2 / top~e.50)))
                        :op2 (a4 / antibody~e.34
                              :ARG0-of (c5 / counter-01~e.28
                                    :ARG1 (p3 / protein
                                          :name (n10 / name :op1 "Grb2"~e.55)))
                              :ARG1-of (d6 / describe-01
                                    :location (m / middle~e.57))))
                  :ARG1-of (d5 / describe-01
                        :ARG2 (n9 / name :op1 "WB"~e.43))))
      :li (b / B~e.1)
      :ARG1-of (d4 / describe-01
            :ARG2 (n8 / name :op1 "IP"~e.25)))

# ::tok The expression of E3b1 ( bottom ) was detected with an anti @-@ E3b1 antibody .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1 2-1.1.1.r 3-1.1.1.1.1 5-1.1.1.2.1 8-1 9-1.2.r 11-1.2.1 13-1.2.1.1.1.1 14-1.2
# ::id pmid_1177_7939.234
# ::preferred 
(d / detect-01~e.8
      :ARG1 (e / express-03~e.1
            :ARG2~e.2 (p / protein
                  :name (n / name :op1 "E3b1"~e.3)
                  :ARG1-of (d2 / describe-01
                        :location (b / bottom~e.5))))
      :ARG2~e.9 (a / antibody~e.14
            :ARG0-of (c / counter-01~e.11
                  :ARG1 (p2 / protein
                        :name (n3 / name :op1 "E3b1"~e.13)))))

# ::tok Figure 4 .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.1
# ::id pmid_1177_7939.235
# ::preferred 
(f / figure~e.0 :mod "4"~e.1)

# ::tok <bold> The S/G and the S/E complexes are functionally distinct . </bold>
# ::amr-annotator SDL-AMR-09
# ::alignments 3-1.1 6-1.1.1 6-1.1.2 8-1 9-1.2
# ::id pmid_1177_7939.236
# ::preferred 
(f / function-01~e.8
      :ARG0 (a / and~e.3
            :op1 (m / macro-molecular-complex~e.6
                  :part (p / protein
                        :name (n / name :op1 "Sos-1"))
                  :part (p3 / protein
                        :name (n3 / name :op1 "Grb2")))
            :op2 (m2 / macro-molecular-complex~e.6
                  :part p
                  :part (p2 / protein
                        :name (n2 / name :op1 "E3b1"))))
      :mod (d / distinct~e.9))

# ::tok ( A ) Cos @-@ 7 cells were transfected with the indicated cDNAs ( Tfx ) , and treated with EGF ( 3 min , +) or mock treated (−).
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3 3-1.1.1.1.1 5-1.1.1.1.1 6-1.1.1 8-1.1 11-1.1.2.2 17-1 18-1.2.2 20-1.2.1.2.1.1 22-1.2.1.3.1 26-1.2 27-1.2.2.2 28-1.2.1 28-1.2.2
# ::id pmid_1177_7939.237
# ::preferred 
(a / and~e.17
      :op1 (t / transfect-00~e.8
            :ARG1 (c / cell-line~e.6
                  :name (n / name :op1 "Cos-7"~e.3,5))
            :ARG2 (d / DNA
                  :ARG1-of (c2 / complement-01)
                  :ARG1-of (i / indicate-01~e.11)))
      :op2 (o / or~e.26
            :op1 (t2 / treat-04~e.28
                  :ARG1 c
                  :ARG2 (s / small-molecule
                        :name (n2 / name :op1 "EGF"~e.20))
                  :duration (t3 / temporal-quantity
                        :quant "3"~e.22
                        :unit (m / minute))
                  :ARG1-of (d2 / describe-01 :ARG2 "+"))
            :op2 (t4 / treat-04~e.18,28
                  :ARG1 c
                  :mod (m2 / mock~e.27)
                  :ARG1-of (d3 / describe-01 :ARG2 "−")))
      :li (a2 / A~e.1))

# ::tok Immunoprecipitates ( IP ) with anti @-@ EGFR or preimmune sera ( ctr ) were analyzed by immunoblotting ( WB ) with anti–EGFR or HA ( for Sos @-@ 1 detection ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1.2.1.1.1 4-1.2.1.1.r 4-1.2.2.1.r 5-1.1.1.1.1.1 7-1.1.1.1.1.1.1.1.1 8-1.1.1.1 9-1.1.1.1.2.1 15-1 21-1.2.1.1.r 21-1.2.2.1.r 23-1.2 24-1.2.2.1.1.1 27-1.2.2.2.1.1.1 29-1.2.2.2.1.1.1 30-1.2.2.2
# ::id pmid_1177_7939.238
# ::preferred 
(a / analyze-01~e.15
      :ARG1 (p / protein
            :ARG1-of (i / immunoprecipitate-00
                  :ARG0 (o / or~e.8
                        :op1 (a2 / antibody
                              :ARG0-of (c2 / counter-01~e.5
                                    :ARG1 (e / enzyme
                                          :name (n / name :op1 "EGFR"~e.7))))
                        :op2 (s2 / serum
                              :mod (p2 / preimmune~e.9)
                              :ARG2-of (c / control-01))))
            :ARG1-of (m / mean-01
                  :ARG2 (p4 / protein
                        :name (n4 / name :op1 "IP"~e.2))))
      :manner (o4 / or~e.23
            :op1 (i2 / immunoblot-00
                  :instrument~e.4,21 a2
                  :ARG1-of (m2 / mean-01
                        :ARG2 (b / blot-01
                              :mod (w / west))))
            :op2 (i3 / immunoblot-00
                  :instrument~e.4,21 (a3 / antibody
                        :name (n2 / name :op1 "HA"~e.24))
                  :purpose (d / detect-01~e.30
                        :ARG1 (p3 / protein
                              :name (n3 / name :op1 "Sos-1"~e.27,29)))
                  :ARG1-of m2)))

# ::tok Lysates ( 50 μg ) were analyzed by immunoblotting with anti @-@ EGFR , anti @-@ HA ( for Sos @-@ 1 detection ) , or anti @-@ E3b1 antibody .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1.1.1 6-1 9-1.2.r 10-1.2.1.1.1 12-1.2.1.1.1.1.1.1 14-1.2.1.1.1 16-1.2.2.1.1.1.1.1 19-1.2.2.2.1.1.1 21-1.2.2.2.1.1.1 22-1.2.2.2 25-1.2 26-1.2.1.1.1 26-1.2.2.1.1 26-1.2.3.1.1 28-1.2.3.1.1.1.1.1 29-1.2.1.1 29-1.2.2.1 29-1.2.3.1
# ::id pmid_1177_7939.239
# ::preferred 
(a / analyze-01~e.6
      :ARG1 (l / lysate
            :quant (m / mass-quantity
                  :quant "50"~e.2
                  :unit (m2 / microgram)))
      :manner~e.9 (o5 / or~e.25
            :op1 (i / immunoblot-00
                  :ARG2 (a2 / antibody~e.29
                        :ARG0-of (c / counter-01~e.10,14,26
                              :ARG1 (e / enzyme
                                    :name (n / name :op1 "EGFR"~e.12)))))
            :op2 (i2 / immunoblot-00
                  :ARG2 (a3 / antibody~e.29
                        :ARG0-of (c2 / counter-01~e.26
                              :ARG1 (p / protein
                                    :name (n2 / name :op1 "HA"~e.16))))
                  :purpose (d / detect-01~e.22
                        :ARG1 (p2 / protein
                              :name (n3 / name :op1 "Sos-1"~e.19,21))))
            :op3 (i3 / immunoblot-00
                  :ARG2 (a4 / antibody~e.29
                        :ARG0-of (c3 / counter-01~e.26
                              :ARG1 (p3 / protein
                                    :name (n4 / name :op1 "E3b1"~e.28)))))))

# ::tok HA @-@ Sos , HA @-@ epitope tagged Sos @-@ 1
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.2.1.1.1.1 2-1.1.1.1 4-1.2.2.1.1.1.1 6-1.2.2.1 7-1.2.2 8-1.2.1.1 10-1.2.1.1
# ::id pmid_1177_7939.240
# ::preferred 
(m / mean-01
      :ARG1 (p / protein
            :name (n / name :op1 "HA-Sos"~e.2))
      :ARG2 (p2 / protein
            :name (n2 / name :op1 "Sos-1"~e.8,10)
            :ARG1-of (t / tag-01~e.7
                  :ARG2 (e / epitope~e.6
                        :mod (p3 / protein
                              :name (n3 / name :op1 "HA"~e.0,4))))))

# ::tok ( B ) Cos @-@ 7 cells were cotransfected ( Tfx ) with E3b1 ( or a control empty vector , ctr ) and either a myc @-@ tagged Ras ( left ) or HA @-@ tagged MAPK ( right ) , followed by treatment with EGF ( 5 min , +) or mock @-@ treatment (−).
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.4 3-1.1.1.1 5-1.1.1.1 6-1.1 13-1.2.1.1.1.1 15-1.2.1 15-1.2.2 17-1.2.1.2.2 18-1.2.1.2.1 19-1.2.1.2 23-1.2 26-1.2.2.1.2.1.1.1 28-1.2.2.1.2 29-1.2.2.1.1.1 31-1.2.2.1.3.1 33-1.3.1 34-1.2.2.2.2.1.1.1 36-1.2.2.2.2 37-1.2.2.2.1.1 39-1.2.2.2.3.1 42-1.3 44-1.3.1.2 46-1.3.1.1.1.1.1 48-1.3.1.1.2.1 52-1.3.1 53-1.3.1.2.1 55-1.3.1.1 55-1.3.1.2
# ::id pmid_1177_7939.241
# ::preferred 
(c / cotransfect-00
      :ARG1 (c2 / cell-line~e.6
            :name (n3 / name :op1 "Cos-7"~e.3,5))
      :ARG2 (a / and~e.23
            :op1 (o / or~e.15
                  :op1 (p2 / protein
                        :name (n4 / name :op1 "E3b1"~e.13))
                  :op2 (v / vector~e.19
                        :mod (e2 / empty~e.18)
                        :ARG2-of (c3 / control-01~e.17)))
            :op2 (o2 / or~e.15
                  :op1 (e / enzyme
                        :name (n / name :op1 "Ras"~e.29)
                        :ARG1-of (t / tag-01~e.28
                              :ARG2 (p / protein
                                    :name (n2 / name :op1 "myc"~e.26)))
                        :ARG1-of (d / describe-01
                              :location (l / left~e.31)))
                  :op2 (e3 / enzyme
                        :name (n5 / name :op1 "MAPK"~e.37)
                        :ARG1-of (t2 / tag-01~e.36
                              :ARG2 (p4 / protein
                                    :name (n6 / name :op1 "HA"~e.34)))
                        :ARG1-of (d2 / describe-01
                              :location (r / right~e.39)))))
      :ARG2-of (f3 / follow-01~e.42
            :ARG1 (o3 / or~e.33,52
                  :op1 (t3 / treat-04~e.55
                        :ARG2 (s / small-molecule
                              :name (n7 / name :op1 "EGF"~e.46))
                        :duration (t4 / temporal-quantity
                              :quant "5"~e.48
                              :unit (m / minute))
                        :ARG1-of (d3 / describe-01 :ARG2 "+"))
                  :op2 (t5 / treat-04~e.44,55
                        :mod (m2 / mock~e.53)
                        :ARG1-of (d4 / describe-01 :ARG2 "−"))))
      :li (b / B~e.1)
      :ARG1-of (m5 / mean-01
            :ARG2 (t6 / transfect-00
                  :ARG2 (f / factor))))

# ::tok ( Top , left ) Ras @-@ GTP was recovered with the GST @-@ RBD of Raf @-@ 1 followed by immunodetection with anti @-@ myc antibodies .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.2.1.1 3-1.2.1.2 5-1.1.1.1.1 7-1.1.2.1.1 9-1 10-1.3.r 12-1.3.1.1 14-1.3.1.1 16-1.3.2.1.1 18-1.3.2.1.1 19-1.3.3 23-1.3.3.1.1.1 25-1.3.3.1.1.1.1.1.1 26-1.3.3.1.1
# ::id pmid_1177_7939.242
# ::preferred 
(r / recover-02~e.9
      :ARG1 (m / macro-molecular-complex
            :part (e / enzyme
                  :name (n / name :op1 "Ras"~e.5))
            :part (s / small-molecule
                  :name (n2 / name :op1 "GTP"~e.7)))
      :ARG1-of (d / describe-01
            :location (a / and
                  :op1 (t / top~e.1)
                  :op2 (l / left~e.3)))
      :manner~e.10 (p / protein-segment
            :name (n3 / name :op1 "GST-RBD"~e.12,14)
            :part-of (e2 / enzyme
                  :name (n4 / name :op1 "Raf-1"~e.16,18))
            :ARG2-of (f2 / follow-01~e.19
                  :ARG1 (i2 / immunodetect-00
                        :ARG2 (a2 / antibody~e.26
                              :ARG0-of (c / counter-01~e.23
                                    :ARG1 (p2 / protein
                                          :name (n5 / name :op1 "myc"~e.25))))))))

# ::tok ( Top , right ) Anti @-@ HA immunoprecipitation , followed by immunodetection with an anti–phosphorylated MAPK antibody .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3.1.1 3-1.3.1.2 5-1.1.1 5-1.2.1.1.1 7-1.1.1.1.1.1 10-1.2 16-1.2.1.1.1.1.1.1 17-1.1 17-1.2.1.1
# ::id pmid_1177_7939.243
# ::preferred 
(i / immunoprecipitate-00
      :ARG2 (a / antibody~e.17
            :ARG0-of (c / counter-01~e.5
                  :ARG1 (p / protein
                        :name (n / name :op1 "HA"~e.7))))
      :ARG2-of (f / follow-01~e.10
            :ARG1 (i3 / immunodetect-00
                  :ARG2 (a2 / antibody~e.17
                        :ARG0-of (c2 / counter-01~e.5
                              :ARG1 (e / enzyme
                                    :name (n2 / name :op1 "MAPK"~e.16)
                                    :ARG1-of (p3 / phosphorylate-01))))))
      :ARG1-of (d2 / describe-01
            :location (a3 / and
                  :op1 (t / top~e.1)
                  :op2 (r / right~e.3))))

# ::tok The levels of expression of myc @-@ Ras and HA @-@ MAPK ( middle ) and E3b1 ( bottom ) are also shown .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1 2-1.1.1.r 3-1.1.1 4-1.1.1.1.r 5-1.1.1.1.1.1.1.1.1 7-1.1.1.1.1.1.2.1.1 8-1.1.1.1.1 9-1.1.1.1.1.2.1.1.1 11-1.1.1.1.1.2.2.1.1 13-1.1.1.1.1.3.1 15-1.1.1.1 15-1.1.1.1.1 15-1.1.1.1.1.r 16-1.1.1.1.2.1.1 18-1.1.1.1.2.2.1 21-1.2 22-1
# ::id pmid_1177_7939.244
# ::preferred 
(s / show-01~e.22
      :ARG1 (l / level~e.1
            :mod~e.2 (e / express-03~e.3
                  :ARG2~e.4 (a / and~e.15
                        :op1~e.15 (a3 / and~e.8,15
                              :op1 (m / macro-molecular-complex
                                    :part (p / protein
                                          :name (n / name :op1 "myc"~e.5))
                                    :part (e2 / enzyme
                                          :name (n2 / name :op1 "Ras"~e.7)))
                              :op2 (m2 / macro-molecular-complex
                                    :part (p2 / protein
                                          :name (n3 / name :op1 "HA"~e.9))
                                    :part (e3 / enzyme
                                          :name (n4 / name :op1 "MAPK"~e.11)))
                              :ARG1-of (d / describe-01
                                    :location (m3 / middle~e.13)))
                        :op2 (p4 / protein
                              :name (n5 / name :op1 "E3b1"~e.16)
                              :ARG1-of (d2 / describe-01
                                    :location (b / bottom~e.18))))))
      :mod (a2 / also~e.21))

# ::tok ( C ) Quiescent NIH @-@ 3T3 fibroblasts were microinjected with an empty vector together with rabbit IgG ( left ) or with an HA @-@ tagged E3b1 expression vector ( right ) followed by treatment with 10 % serum .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3 3-1.1.2 4-1.1.1.1.1 6-1.1.1.1.1 7-1.1 9-1 10-1.2.1.2.r 12-1.2.1.1 13-1.2.1 15-1.2.1.2.r 16-1.2.1.2.2 17-1.2.1.2.1.1 19-1.2.1.3.1 21-1.2 22-1.2.1.2.r 22-1.2.r 24-1.2.2.1.1.2.1.1.1 26-1.2.2.1.1.2 27-1.2.2.1.1.1.1 28-1.2.2.1 29-1.2.2 31-1.2.2.2.1 33-1.2.2.3 34-1.2.2.3.1.r 35-1.2.2.3.1 36-1.2.1.2.r 36-1.2.2.3.1.1.r 37-1.2.2.3.1.1.1.1 38-1.2.2.3.1.1.1 39-1.2.2.3.1.1
# ::id pmid_1177_7939.245
# ::preferred 
(m2 / microinject-00~e.9
      :ARG1 (f / fibroblast~e.7
            :mod (c / cell-line
                  :name (n / name :op1 "NIH-3T3"~e.4,6))
            :mod (q / quiescent~e.3))
      :ARG2~e.22 (o / or~e.21
            :op1 (v / vector~e.13
                  :mod (e / empty~e.12)
                  :accompanier~e.10,15,22,36 (p2 / protein
                        :name (n2 / name :op1 "IgG"~e.17)
                        :mod (r / rabbit~e.16))
                  :ARG1-of (d / describe-01
                        :location (l / left~e.19)))
            :op2 (v2 / vector~e.29
                  :ARG1-of (e2 / express-03~e.28
                        :ARG2 (p3 / protein
                              :name (n3 / name :op1 "E3b1"~e.27)
                              :ARG1-of (t / tag-01~e.26
                                    :ARG2 (p4 / protein
                                          :name (n4 / name :op1 "HA"~e.24)))))
                  :ARG1-of (d2 / describe-01
                        :location (r2 / right~e.31))
                  :ARG2-of (f2 / follow-01~e.33
                        :ARG1~e.34 (t2 / treat-04~e.35
                              :ARG2~e.36 (s / serum~e.39
                                    :mod (p / percentage-entity~e.38 :value "10"~e.37))))))
      :li (c2 / C~e.1))

# ::tok After 15 h , BrdU was added and 3 h later the cells were fixed and stained to detect BrdU incorporation ( top ) , E3b1 ( anti @-@ HA ) , or control ( anti @-@ IgG ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2 1-1.1.2.1.1 4-1.1.1.1.1 6-1.1 7-1 8-1.2.4.1.1 10-1.2.4 10-1.2.4.2 10-1.2.4.2.r 12-1.2.1.1 14-1.2.1 15-1.2 16-1.2.2 18-1.2.3 19-1.2.3.1.1.1 20-1.2.3.1.1 22-1.2.3.1.1.2.1 25-1.2.3.1.2.1.1 27-1.2.3.1.2 27-1.2.3.1.2.2 27-1.2.3.1.2.2.r 29-1.2.3.1.2.2.1.1.1 32-1.2.3.1 33-1.2.3.1.3 35-1.2.3.1.3.1 37-1.2.3.1.3.1.1.1.1
# ::id pmid_1177_7939.246
# ::preferred 
(a / and~e.7
      :op1 (a2 / add-02~e.6
            :ARG1 (p / protein
                  :name (n / name :op1 "BrdU"~e.4))
            :time (a4 / after~e.0
                  :op1 (t / temporal-quantity
                        :quant "15"~e.1
                        :unit (h / hour))))
      :op2 (a3 / and~e.15
            :op1 (f / fix-02~e.14
                  :ARG1 (c / cell~e.12))
            :op2 (s / stain-00~e.16
                  :ARG1 c)
            :purpose (d / detect-01~e.18
                  :ARG1 (o / or~e.32
                        :op1 (i / incorporate-02~e.20
                              :ARG1 p~e.19
                              :ARG1-of (d2 / describe-01
                                    :location (t2 / top~e.22)))
                        :op2 (p2 / protein~e.27
                              :name (n2 / name :op1 "E3b1"~e.25)
                              :ARG0-of~e.27 (c3 / counter-01~e.27
                                    :ARG1 (p3 / protein
                                          :name (n3 / name :op1 "HA"~e.29))))
                        :op3 (c2 / control-01~e.33
                              :ARG0-of (c4 / counter-01~e.35
                                    :ARG1 (p4 / protein
                                          :name (n4 / name :op1 "IgG"~e.37))))))
            :time (l2 / late~e.10
                  :op1 (t3 / temporal-quantity
                        :quant "3"~e.8
                        :unit (h2 / hour))
                  :degree~e.10 (m2 / more~e.10))))

# ::tok Nuclei were counterstained with Dapi ( bottom ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 4-1.2.1.1 6-1.4.1
# ::id pmid_1177_7939.247
# ::preferred 
(s / stain-00
      :ARG1 (n / nucleus~e.0)
      :ARG2 (m / molecular-physical-entity
            :name (n2 / name :op1 "Dapi"~e.4))
      :ARG1-of (c / counter-01)
      :ARG1-of (d / describe-01
            :location (b / bottom~e.6)))

# ::tok A quantitative analysis of BrdU incorporation into control ( empty bar ) and E3b1 ( closed bar ) injected cells is shown on the right .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.2 2-1.1 3-1.1.1.r 4-1.1.1.1.1.1 5-1.1.1 6-1.1.1.2.r 7-1.1.1.2.1.1 9-1.1.1.2.1.2.1.1 10-1.1.1.2.1.2.1 12-1.1.1.2 13-1.1.1.2.2.2.1.1.1 15-1.1.1.2.2.1.1.1 16-1.1.1.2.2.1.1 18-1.1.1.2.2.2 19-1.1.1.2.1 19-1.1.1.2.2 21-1 22-1.2.r 24-1.2
# ::id pmid_1177_7939.248
# ::preferred 
(s / show-01~e.21
      :ARG1 (a / analyze-01~e.2
            :ARG1~e.3 (i / incorporate-02~e.5
                  :ARG1 (p / protein
                        :name (n / name :op1 "BrdU"~e.4))
                  :ARG2~e.6 (a2 / and~e.12
                        :op1 (c / cell~e.19
                              :mod (c3 / control-01~e.7)
                              :ARG1-of (m / mean-01
                                    :ARG2 (b / bar~e.10
                                          :mod (e / empty~e.9))))
                        :op2 (c2 / cell~e.19
                              :ARG1-of (m2 / mean-01
                                    :ARG2 (b2 / bar~e.16
                                          :ARG1-of (c4 / close-01~e.15)))
                              :ARG2-of (i2 / inject-01~e.18
                                    :ARG1 (p2 / protein
                                          :name (n2 / name :op1 "E3b1"~e.13))))))
            :mod (q / quantity~e.1))
      :location~e.22 (r / right~e.24))

# ::tok The data are the mean ± SEM of three independent experiments .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1 4-1.2.1.1.1.1 7-1.2.1.1.1.1.1.r 8-1.2.1.1.1.1.1.1 9-1.2.1.1.1.1.1.2 9-1.2.1.1.1.1.1.2.1 9-1.2.1.1.1.1.1.2.1.r 10-1.2.1.1.1.1.1
# ::id pmid_1177_7939.249
# ::preferred 
(e4 / equal-01
      :ARG1 (d / data~e.1)
      :ARG2 (v / value-interval
            :op1 (e / error
                  :mod (s2 / standard
                        :ARG1-of (a / add-02
                              :ARG2 (m2 / mean~e.4
                                    :poss~e.7 (e3 / experiment-01~e.10
                                          :quant "3"~e.8
                                          :ARG0-of (d2 / depend-01~e.9 :polarity~e.9 "-"~e.9))))))
            :op2 (e2 / error
                  :mod (s / standard)
                  :ARG1-of (s3 / subtract-01
                        :ARG2 m2))))

# ::tok Results are expressed as a percentage of injected cells incorporating BrdU respect to uninjected ones .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 0-1.1.1 0-1.1.1.r 2-1 3-1.2.r 5-1.2 7-1.2.1.1 7-1.2.2.1 8-1.2.1 8-1.2.2 9-1.2.1.2 9-1.2.2.1.1 10-1.2.1.2.1.1.1
# ::id pmid_1177_7939.250
# ::preferred 
(e / express-01~e.2
      :ARG1 (t / thing~e.0
            :ARG2-of~e.0 (r / result-01~e.0))
      :manner~e.3 (p / percentage~e.5
            :quant-of (c / cell~e.8
                  :ARG2-of (i / inject-01~e.7)
                  :ARG2-of (i2 / incorporate-02~e.9
                        :ARG1 (p2 / protein
                              :name (n / name :op1 "BrdU"~e.10))))
            :compared-to (c2 / cell~e.8
                  :ARG2-of (i3 / inject-01~e.7 :polarity "-"~e.9))))

# ::tok Serum treatment induces BrdU incorporation in >95 % of not injected cells .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1 2-1 3-1.2.1.1.1 4-1.2 7-1.2.2.2.1 8-1.2.2.2.r 9-1.2.2.1.1 9-1.2.2.1.1.r 10-1.2.2.1 11-1.2.2
# ::id pmid_1177_7939.251
# ::preferred 
(i / induce-01~e.2
      :ARG0 (t / treat-04~e.1
            :ARG2 (s / serum~e.0))
      :ARG1 (i2 / incorporate-02~e.4
            :ARG1 (p / protein
                  :name (n / name :op1 "BrdU"~e.3))
            :ARG2 (c / cell~e.11
                  :ARG2-of (i3 / inject-01~e.10 :polarity~e.9 "-"~e.9)
                  :quant~e.8 (m / more-than
                        :op1 (p2 / percentage-entity~e.7 :value "95")))))

# ::tok Figure 5 .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.1
# ::id pmid_1177_7939.252
# ::preferred 
(f / figure~e.0 :mod "5"~e.1)

# ::tok <bold> E3b1 is a limiting factor in Rac activation . </bold>
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.2.1.1 2-1.2.r 4-1.1 5-1 6-1.1.1.r 7-1.1.1.1.1.1 8-1.1.1
# ::id pmid_1177_7939.253
# ::preferred 
(f / factor~e.5
      :ARG0-of (l / limit-01~e.4
            :ARG1~e.6 (a / activate-01~e.8
                  :ARG1 (e / enzyme
                        :name (n2 / name :op1 "Rac"~e.7))))
      :domain~e.2 (p / protein
            :name (n / name :op1 "E3b1"~e.1)))

# ::tok ( Top , left ) Lysates of Cos @-@ 7 cells were immunoprecipitated ( IP ) with the antibody indicated on the top and immunoblotted with the antibody indicated on the right .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3.1.1 3-1.3.1.2 7-1.1.1.1.1.1 9-1.1.1.1.1.1 10-1.1.1.1 18-1.1.2 19-1.1.2.1 20-1.1.2.1.1.r 22-1.1.2.1.1 23-1 23-1.3.1 27-1.2.2 28-1.2.2.1 29-1.2.2.1.1.r 31-1.2.2.1.1
# ::id pmid_1177_7939.254
# ::preferred 
(a / and~e.23
      :op1 (i / immunoprecipitate-00
            :ARG1 (l / lysate
                  :source (c / cell-line~e.10
                        :name (n / name :op1 "Cos-7"~e.7,9)))
            :ARG2 (a2 / antibody~e.18
                  :ARG1-of (i2 / indicate-01~e.19
                        :location~e.20 (t / top~e.22))))
      :op2 (i3 / immunoblot-00
            :ARG1 l
            :ARG2 (a3 / antibody~e.27
                  :ARG1-of (i4 / indicate-01~e.28
                        :location~e.29 (r / right~e.31))))
      :ARG1-of (d / describe-01
            :location (a4 / and~e.23
                  :op1 t~e.1
                  :op2 (l2 / left~e.3))))

# ::tok Lysate , 50 μg of total cellular lysate .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 0-1.2.1 2-1.1.1.1 5-1.2.1.2 6-1.2.1.1 7-1 7-1.2.1
# ::id pmid_1177_7939.255
# ::preferred 
(l / lysate~e.0,7
      :ARG1-of (h / have-quant-91
            :ARG2 (m / mass-quantity
                  :quant "50"~e.2
                  :unit (m2 / microgram)))
      :ARG1-of (i / include-91
            :ARG2 (l2 / lysate~e.0,7
                  :mod (c / cell~e.6)
                  :ARG2-of (t / total-01~e.5))))

# ::tok ( Top , right ) The efficiency of Grb2 and E3b1 immunoprecipitations was >95 % , as determined by immunoblot analysis of the supernatants of the immunoprecipitations performed with either the specific antibody with ( Grb2 and E3b1 , respectively , as indicated ) or with an irrelevant ( ctr ) antibody .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.4.1.1 3-1.4.1.2 6-1 8-1.1.1.1.1.1 9-1.1.1 10-1.1.1.2.1.1 14-1.2.1 16-1.3.r 17-1.3 18-1.3.1.r 19-1.3.1.2 20-1.3.1 21-1.3.1.1.r 23-1.3.1.1 27-1.3.1.1.1.1 31-1.3.1.1.1.1.1.1.1 32-1.3.1.1.1.1.1.1 35-1.1.1.1.1.1 36-1.1.1 37-1.1.1.2.1.1 39-1.3.1.1.1.1.1.1.2.2 42-1.3.1.1.1.1.1.1.2.3 44-1.3.1.1.1.1.1 45-1.3.1.1.1.1.1.r 47-1.3.1.1.1.1.1.2.1 47-1.3.1.1.1.1.1.2.1.1 47-1.3.1.1.1.1.1.2.1.1.r 51-1.3.1.1.1.1.1.2
# ::id pmid_1177_7939.256
# ::preferred 
(e / efficient-01~e.6
      :ARG1 (i / immunoprecipitate-00
            :ARG1 (a / and~e.9,36
                  :op1 (p2 / protein
                        :name (n / name :op1 "Grb2"~e.8,35))
                  :op2 (p3 / protein
                        :name (n2 / name :op1 "E3b1"~e.10,37))))
      :degree (m / more-than
            :op1 (p / percentage-entity~e.14 :value "95"))
      :ARG1-of~e.16 (d / determine-01~e.17
            :ARG0~e.18 (a2 / analyze-01~e.20
                  :ARG1~e.21 (s / supernatant~e.23
                        :mod (i3 / immunoprecipitate-00
                              :ARG1-of (p4 / perform-01~e.27
                                    :ARG2~e.45 (o / or~e.44
                                          :op1 (a3 / antibody~e.32
                                                :mod (s2 / specific~e.31)
                                                :ARG1-of (m2 / mean-01
                                                      :ARG2 (a4 / and
                                                            :op1 p2
                                                            :op2 p3)
                                                      :mod (r / respective~e.39)
                                                      :ARG1-of (i4 / indicate-01~e.42)))
                                          :op2 (a5 / antibody~e.51
                                                :ARG1-of (r2 / relevant-01~e.47 :polarity~e.47 "-"~e.47)
                                                :ARG1-of (m3 / mean-01
                                                      :ARG2 (c / control-01)))))))
                  :mod (i2 / immunoblot-00~e.19)))
      :ARG1-of (d2 / describe-01
            :location (a6 / and
                  :op1 (t / top~e.1)
                  :op2 (r3 / right~e.3))))

# ::tok ( Middle ) Cos @-@ 7 cells were transfected ( Tfx ) with HA @-@ tagged PAK65 ( all lanes ) together with the plasmids indicated on the top ( ctr , empty vector ) and serum starved for 24 h .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3.1 3-1.1.1.1.1 5-1.1.1.1.1 6-1.1.1 8-1.1 12-1.1.2.r 12-1.1.3.r 13-1.1.2.2.1.1.1 15-1.1.2.2 16-1.1.2.1.1 18-1.1.2.3.1.1 19-1.1.2.3.1 22-1.1.2.r 25-1.1.3.1 26-1.1.3.1.1.r 28-1.1.3.1.1 32-1.1.3.2.1.2 33-1.1.3.2.1 35-1 36-1.2.2 37-1.2 38-1.2.3.r 39-1.2.3.1
# ::id pmid_1177_7939.257
# ::preferred 
(a3 / and~e.35
      :op1 (t / transfect-00~e.8
            :ARG1 (c / cell-line~e.6
                  :name (n / name :op1 "Cos-7"~e.3,5))
            :instrument~e.12,22 (p / protein
                  :name (n2 / name :op1 "PAK65"~e.16)
                  :ARG1-of (t2 / tag-01~e.15
                        :ARG2 (p2 / protein
                              :name (n3 / name :op1 "HA"~e.13)))
                  :ARG1-of (m / mean-01
                        :ARG2 (l / lane~e.19
                              :mod (a / all~e.18))))
            :accompanier~e.12 (p3 / plasmid
                  :ARG1-of (i / indicate-01~e.25
                        :location~e.26 (t3 / top~e.28))
                  :ARG1-of (m2 / mean-01
                        :ARG2 (v / vector~e.33
                              :ARG2-of (c2 / control-01)
                              :mod (e / empty~e.32)))))
      :op2 (s / starve-01~e.37
            :ARG1 c
            :ARG2 (s2 / serum~e.36)
            :duration~e.38 (t4 / temporal-quantity
                  :quant "24"~e.39
                  :unit (h / hour)))
      :ARG1-of (d / describe-01
            :location (m3 / middle~e.1)))

# ::tok Equal amounts of anti @-@ HA immunoprecipitated PAK65 were subjected to an in vitro kinase assay using myelin basic protein ( MBP ) as a substrate .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2.1 1-1.1.2 2-1.1.2.r 3-1.1 3-1.1.4 3-1.1.4.r 5-1.1.4.1.1.1 7-1.1.1.1 9-1 12-1.2.2 13-1.2.2 14-1.2.1 15-1.2 16-1.2.3 17-1.2.3.1.1.1 18-1.2.3.1.1.2 19-1.2.3.1.1.3 23-1.2.3.2.r 25-1.2.3.2
# ::id pmid_1177_7939.258
# ::preferred 
(s / subject-01~e.9
      :ARG1 (p / protein~e.3
            :name (n / name :op1 "PAK65"~e.7)
            :quant~e.2 (a / amount~e.1
                  :mod (e / equal~e.0))
            :ARG1-of (i / immunoprecipitate-00)
            :ARG0-of~e.3 (c / counter-01~e.3
                  :ARG1 (p2 / protein
                        :name (n2 / name :op1 "HA"~e.5))))
      :ARG2 (a2 / assay-00~e.15
            :ARG1 (k / kinase~e.14)
            :mod (i2 / in-vitro~e.12,13)
            :ARG0-of (u / use-01~e.16
                  :ARG1 (p3 / protein
                        :name (n3 / name
                              :op1 "myelin"~e.17
                              :op2 "basic"~e.18
                              :op3 "protein"~e.19))
                  :ARG2~e.23 (s2 / substrate~e.25))))

# ::tok The levels of immunoprecipitated PAK65 and the expression of Sos @-@ 1 , E3b1 , and HARacN17 in the various transfectants are also shown .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1 4-1.1.1.1.1.1 5-1.1 7-1.1.2 8-1.1.2.1.r 9-1.1.2.1.1.1.1 11-1.1.2.1.1.1.1 13-1.1.2.1.2.1.1 16-1.1.2.1.3.1.1 17-1.1.2.2.r 19-1.1.2.2.1 22-1.2 23-1
# ::id pmid_1177_7939.259
# ::preferred 
(s / show-01~e.23
      :ARG1 (a / and~e.5
            :op1 (l / level~e.1
                  :quant-of (p / protein
                        :name (n / name :op1 "PAK65"~e.4)
                        :ARG1-of (i / immunoprecipitate-00)))
            :op2 (e / express-03~e.7
                  :ARG2~e.8 (a2 / and
                        :op1 (p2 / protein
                              :name (n2 / name :op1 "Sos-1"~e.9,11))
                        :op2 (p3 / protein
                              :name (n3 / name :op1 "E3b1"~e.13))
                        :op3 (p4 / protein
                              :name (n4 / name :op1 "HARacN17"~e.16)))
                  :ARG3~e.17 (c / cell
                        :mod (v / various~e.19)
                        :ARG3-of (t / transfect-00))))
      :mod (a3 / also~e.22))

# ::tok Similar results were obtained using Cos @-@ 7 cells .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2 1-1.1 1-1.1.1 1-1.1.1.r 3-1 4-1.2 5-1.2.1.1.1 7-1.2.1.1.1 8-1.2.1
# ::id pmid_1177_7939.260
# ::preferred 
(o / obtain-01~e.3
      :ARG1 (t / thing~e.1
            :ARG1-of~e.1 (r / result-01~e.1)
            :ARG1-of (r2 / resemble-01~e.0))
      :manner (u / use-01~e.4
            :ARG1 (c / cell-line~e.8
                  :name (n / name :op1 "Cos-7"~e.5,7))))

# ::tok ( Bottom ) Wild @-@ type (+/+) and eps8 @<sup> −/− </sup> (−/−) mouse embryo fibroblasts were infected with retroviral vectors coding for E3b1 ( E3b1 ) or the mutant of E3b1 @-@ DY ( E3b1 @-@ DY ) , or with an empty vector as a control ( ctr ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3.1 3-1.1.1.1 5-1.1.1.1 7-1.1 8-1.1.2.3.1.1.1 10-1.1.2.1.1 10-1.1.2.3.1.2.1 13-1.1.1.2.1 14-1.1.1.2 15-1.1.1 15-1.1.2 17-1 20-1.2.1 21-1.2.1.2 22-1.2.1.2.1.r 23-1.2.1.2.1.1.1 25-1.2.1.2.1.1.1 27-1.2 29-1.1.2.1 29-1.1.2.3.1 29-1.1.2.3.1.2 29-1.1.2.3.1.2.r 29-1.2.2 29-1.2.2.2 29-1.2.2.2.r 31-1.2.1.2.1.1.1 33-1.2.2.1.1 35-1.2.2.1.1 37-1.2.2.1.1 40-1.2 41-1.2.r 43-1.2.3.1 44-1.2.3 45-1.2.3.2.r 47-1.2.3.2
# ::id pmid_1177_7939.261
# ::preferred 
(i / infect-01~e.17
      :ARG1 (a / and~e.7
            :op1 (f / fibroblast~e.15
                  :mod (w / wild-type~e.3,5)
                  :source (e / embryo~e.14
                        :mod (m2 / mouse~e.13)))
            :op2 (f2 / fibroblast~e.15
                  :ARG2-of (m / mutate-01~e.29 :mod "−/−"~e.10)
                  :source e
                  :ARG0-of (c3 / contain-01
                        :ARG1 (e3 / enzyme~e.29
                              :name (n3 / name :op1 "eps8"~e.8)
                              :ARG2-of~e.29 (m4 / mutate-01~e.29 :mod "−/−"~e.10)))))
      :ARG2~e.41 (o / or~e.27,40
            :op1 (v / vector~e.20
                  :mod (r / retrovirus)
                  :ARG0-of (c2 / code-01~e.21
                        :ARG1~e.22 (p / protein
                              :name (n / name :op1 "E3b1"~e.23,25,31))))
            :op2 (p2 / protein~e.29
                  :name (n2 / name :op1 "E3b1-DY"~e.33,35,37)
                  :ARG2-of~e.29 (m3 / mutate-01~e.29))
            :op3 (v2 / vector~e.44
                  :mod (e2 / empty~e.43)
                  :ARG2-of~e.45 (c / control-01~e.47)))
      :ARG1-of (d / describe-01
            :location (b / bottom~e.1)))

# ::tok >95 % of the cells expressed the infected cDNA , as determined by immunostaining with anti @-@ E3b1 ( not shown ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.2.1.1 2-1.2.1.r 4-1.2 5-1 7-1.1.2 10-1.3.r 11-1.3 15-1.3.1.1.1 17-1.3.1.1.1.1.1.1 19-1.4.1 19-1.4.1.r 20-1.4
# ::id pmid_1177_7939.262
# ::preferred 
(e / express-03~e.5
      :ARG2 (d / DNA
            :ARG1-of (c2 / complement-01)
            :ARG1-of (i / infect-01~e.7))
      :ARG3 (c / cell~e.4
            :quant~e.2 (m / more-than
                  :op1 (p / percentage-entity~e.1 :value "95")))
      :ARG1-of~e.10 (d2 / determine-01~e.11
            :ARG2 (i2 / immunostain-00
                  :ARG2 (a / antibody
                        :ARG0-of (c3 / counter-01~e.15
                              :ARG1 (p2 / protein
                                    :name (n / name :op1 "E3b1"~e.17))))))
      :ARG1-of (s / show-01~e.20 :polarity~e.19 "-"~e.19))

# ::tok Equal amounts of lysates were subjected to in vitro binding assays with the immobilized CRIB domain of PAK65 .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 1-1.1.1 5-1 6-1.2.r 7-1.2.2 8-1.2.2 9-1.2.1 10-1.2 11-1.2.1.1.r 13-1.2.1.1.2 14-1.2.1.1.1.1 15-1.2.1.1.1.2 17-1.2.1.1.3.1.1
# ::id pmid_1177_7939.263
# ::preferred 
(s / subject-01~e.5
      :ARG1 (l / lysate
            :quant (a / amount~e.1
                  :mod (e / equal~e.0)))
      :ARG2~e.6 (a2 / assay-00~e.10
            :manner (b / bind-01~e.9
                  :ARG2~e.11 (p3 / protein-segment
                        :name (n3 / name :op1 "CRIB"~e.14 :op2 "domain"~e.15)
                        :ARG1-of (i2 / immobilize-01~e.13)
                        :part-of (p2 / protein
                              :name (n2 / name :op1 "PAK65"~e.17))))
            :manner (i / in-vitro~e.7,8)))

# ::tok After washing , bound proteins were resolved by SDS @-@ PAGE and immunoblotted with anti @-@ Rac antibodies ( Rac @-@ GTP ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3 1-1.3.1 3-1.1.1.1 4-1.1.1 6-1.1 7-1.1.2.r 8-1.1.2.1.1 10-1.1.2.1.1 11-1 14-1.2.2.1 16-1.2.2.1.1.1.1 17-1.2.2 19-1.2.2.2.1.1 21-1.2.2.2.1.2.1.1
# ::id pmid_1177_7939.264
# ::preferred 
(a / and~e.11
      :op1 (r / resolve-00~e.6
            :ARG1 (p / protein~e.4
                  :ARG1-of (b / bind-01~e.3))
            :ARG2~e.7 (m / molecular-physical-entity
                  :name (n / name :op1 "SDS-PAGE"~e.8,10)))
      :op2 (i / immunoblot-00
            :ARG1 p
            :ARG2 (a2 / antibody~e.17
                  :ARG0-of (c / counter-01~e.14
                        :ARG1 (e / enzyme
                              :name (n2 / name :op1 "Rac"~e.16)))
                  :ARG1-of (m2 / mean-01
                        :ARG2 (m3 / macro-molecular-complex
                              :part e~e.19
                              :part (s / small-molecule
                                    :name (n3 / name :op1 "GTP"~e.21))))))
      :time (a3 / after~e.0
            :op1 (w / wash-01~e.1)))

# ::tok The levels of total Rac ( Rac ) and E3b1 proteins are also shown .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1 1-1.1.2 3-1.1.1.1.2 4-1.1.1.1.1.1 6-1.1.1.1.1.1 8-1.1 9-1.1.2.1.1.1 10-1.1.1.1 10-1.1.2.1 12-1.2 13-1
# ::id pmid_1177_7939.265
# ::preferred 
(s / show-01~e.13
      :ARG1 (a2 / and~e.8
            :op1 (l / level~e.1
                  :quant-of (p / protein~e.10
                        :name (n / name :op1 "Rac"~e.4,6)
                        :mod (t / total~e.3)))
            :op2 (l2 / level~e.1
                  :quant-of (p2 / protein~e.10
                        :name (n2 / name :op1 "E3b1"~e.9))))
      :mod (a / also~e.12))

# ::tok Figure 6 .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.1
# ::id pmid_1177_7939.266
# ::preferred 
(f / figure~e.0 :mod "6"~e.1)

# ::tok <bold> The E3b1DY mutant inhibits actin remodeling induced by activated Ras , but not by activated Rac . </bold>
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1.1.1 3-1.1 3-1.1.2 3-1.1.2.r 4-1 5-1.2.1 6-1.2 7-1.2.2 7-1.2.2.2.1 8-1.2.2.1.r 9-1.2.2.1.2 10-1.2.2.1.1.1 12-1.2.2.2 13-1.2.2.2.1.1 13-1.2.2.2.1.1.r 14-1.2.2.2.1.2.r 15-1.2.2.2.1.2.2 16-1.2.2.2.1.2.1.1
# ::id pmid_1177_7939.267
# ::preferred 
(i / inhibit-01~e.4
      :ARG0 (p / protein~e.3
            :name (n / name :op1 "E3b1DY"~e.2)
            :ARG2-of~e.3 (m / mutate-01~e.3))
      :ARG1 (r / remodel-01~e.6
            :ARG1 (a / actin~e.5)
            :ARG1-of (i2 / induce-01~e.7
                  :ARG0~e.8 (e / enzyme
                        :name (n2 / name :op1 "Ras"~e.10)
                        :ARG1-of (a2 / activate-01~e.9))
                  :ARG1-of (c2 / contrast-01~e.12
                        :ARG2 (i3 / induce-01~e.7
                              :polarity~e.13 "-"~e.13
                              :ARG0~e.14 (e2 / enzyme
                                    :name (n3 / name :op1 "Rac"~e.16)
                                    :ARG1-of a2~e.15))))))

# ::tok Mouse embryo fibroblasts were transfected , as indicated on the top , with expression vectors for either RasV12 or RacQL , together with ECFP @-@ tagged versions of either E3b1 or the E3b1DY mutant .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 1-1.1.1 2-1.1 4-1 6-1.3.r 7-1.3 8-1.3.1.r 10-1.3.1 12-1.2.2.r 13-1.2.1 14-1.2 17-1.2.1.1.1.1.1 18-1.2.1.1 19-1.2.1.1.2.1.1 22-1.2.2.r 23-1.2.2.3.1.1.1 25-1.2.2.3 29-1.2.2.1.1.1 30-1.2.2 32-1.2.2.2.1.1 33-1.2.2.2 33-1.2.2.2.2 33-1.2.2.2.2.r
# ::id pmid_1177_7939.268
# ::preferred 
(t / transfect-00~e.4
      :ARG1 (f / fibroblast~e.2
            :source (e / embryo~e.1
                  :mod (m / mouse~e.0)))
      :ARG2 (v / vector~e.14
            :ARG1-of (e2 / express-03~e.13
                  :ARG2 (o / or~e.18
                        :op1 (e3 / enzyme
                              :name (n / name :op1 "RasV12"~e.17))
                        :op2 (p / protein
                              :name (n2 / name :op1 "RacQL"~e.19))))
            :accompanier~e.12,22 (o2 / or~e.30
                  :op1 (p2 / protein
                        :name (n3 / name :op1 "E3b1"~e.29))
                  :op2 (p3 / protein~e.33
                        :name (n4 / name :op1 "E3b1DY"~e.32)
                        :ARG2-of~e.33 (m2 / mutate-01~e.33))
                  :ARG1-of (t3 / tag-01~e.25
                        :ARG2 (p4 / protein
                              :name (n5 / name :op1 "ECFP"~e.23)))))
      :ARG1-of~e.6 (i / indicate-01~e.7
            :location~e.8 (t2 / top~e.10)))

# ::tok After serum starvation , cells were fixed and stained with rhodamine @-@ conjugated phalloidine to detect F @-@ actin ( top , red ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.4 1-1.4.1.2 2-1.4.1 4-1.1.1 6-1.1 7-1 8-1.2 9-1.2.2.r 10-1.2.2.2.1.1 12-1.2.2.3 13-1.2.2.1.1.1 15-1.3 16-1.3.1.1.1 18-1.3.1.1.1 20-1.5.1 22-1.5.2
# ::id pmid_1177_7939.269
# ::preferred 
(a / and~e.7
      :op1 (f / fix-02~e.6
            :ARG1 (c / cell~e.4))
      :op2 (s / stain-00~e.8
            :ARG1 c
            :ARG2~e.9 (a3 / and
                  :op1 (m / molecular-physical-entity
                        :name (n / name :op1 "phalloidine"~e.13))
                  :op2 (m2 / molecular-physical-entity
                        :name (n3 / name :op1 "rhodamine"~e.10))
                  :ARG1-of (c2 / conjugate-00~e.12)))
      :purpose (d / detect-01~e.15
            :ARG1 (p / protein
                  :name (n2 / name :op1 "F-actin"~e.16,18)))
      :time (a2 / after~e.0
            :op1 (s2 / starve-01~e.2
                  :ARG1 c
                  :ARG2 (s3 / serum~e.1)))
      :ARG1-of (d2 / describe-01
            :location (t / top~e.20)
            :mod (r / red~e.22)))

# ::tok Expression of the transfected proteins was detected ( bottom , green ) with either anti @-@ Ras or anti @-@ Rac antibodies or by epifluorescence ( ECFP ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1.1.1.r 3-1.1.1.1 4-1.1.1 6-1 8-1.3.1 10-1.3.2 14-1.2.1.1 16-1.2.1.1.1.1.1 17-1.2 18-1.2.1.1 18-1.2.2.1 20-1.2.2.1.1.1.1 21-1.2.1 21-1.2.2 22-1.2 23-1.2.r 24-1.2.3
# ::id pmid_1177_7939.270
# ::preferred 
(d / detect-01~e.6
      :ARG1 (e / express-03~e.0
            :ARG2~e.1 (p / protein~e.4
                  :ARG1-of (t / transfect-00~e.3)))
      :ARG2~e.23 (o / or~e.17,22
            :op1 (a / antibody~e.21
                  :ARG0-of (c / counter-01~e.14,18
                        :ARG1 (e2 / enzyme
                              :name (n / name :op1 "Ras"~e.16))))
            :op2 (a2 / antibody~e.21
                  :ARG0-of (c2 / counter-01~e.18
                        :ARG1 (e4 / enzyme
                              :name (n2 / name :op1 "Rac"~e.20))))
            :op3 (e3 / epifluorescence~e.24))
      :ARG1-of (d2 / describe-01
            :location (b / bottom~e.8)
            :mod (g / green~e.10)))

# ::tok In the cotransfection experiments a molar ratio of 1 @:@ 3 of the activated GTPases to the ECFP @-@ E3b1 constructs was used , such as that all of the epifluorescent cells expressed also the corresponding GTPase ( not shown ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 3-1.1 5-1.2.1 5-1.2.2 6-1.2 7-1.2 8-1.2.3.1 10-1.2.3.1 11-1.2 11-1.2.1.1.r 13-1.2.1.1.2 15-1.2.2.1.r 17-1.2.2.1.1.1.1 19-1.2.2.1.2.1.1 22-1 27-1.3.1.2.1 31-1.3.1.2 32-1.3.1 33-1.3.1.3 35-1.3.1.1 35-1.3.1.1.2 35-1.3.1.1.2.r 36-1.2.1.1.1.1 36-1.3.1.1.1.1 38-1.4.1 38-1.4.1.r 39-1.4
# ::id pmid_1177_7939.271
# ::preferred 
(u / use-01~e.22
      :ARG0 (e3 / experiment-01~e.3
            :ARG1 (c / cotransfect-00))
      :ARG1 (r / ratio-of~e.6,7,11
            :op1 (m2 / molar~e.5
                  :quant-of~e.11 (e2 / enzyme
                        :name (n2 / name :op1 "GTPase"~e.36)
                        :ARG1-of (a / activate-01~e.13)))
            :op2 (m3 / molar~e.5
                  :quant-of~e.15 (m / macro-molecular-complex
                        :part (p / protein
                              :name (n3 / name :op1 "ECFP"~e.17))
                        :part (p2 / protein
                              :name (n4 / name :op1 "E3b1"~e.19))))
            :ARG1-of (e7 / equal-01 :ARG2 "1/3"~e.8,10))
      :ARG0-of (c2 / cause-01
            :ARG1 (e4 / express-03~e.32
                  :ARG2 (e6 / enzyme~e.35
                        :name (n5 / name :op1 "GTPase"~e.36)
                        :ARG1-of~e.35 (c4 / correspond-02~e.35))
                  :ARG3 (c3 / cell~e.31
                        :mod (a2 / all~e.27)
                        :mod (e5 / epifluorescence))
                  :mod (a3 / also~e.33)))
      :ARG1-of (s / show-01~e.39 :polarity~e.38 "-"~e.38))

# ::tok The percent of transfected cells ( mean ± SEM ) undergoing ruffling was as follow : RasV12 = 65 ± 3 % ; RasV12 + E3b1 WT = 62 ± 4 % ; RasV12 + E3b1DY = 16 ± 2 % ; RacQL = 93 ± 3 % ; RacQL + E3b1 WT = 90 ± 4 % ; RacQL + E3b1DY = 95 ± 5 % .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1 2-1.1.1.1.r 3-1.1.1.1.1 4-1.1.1.1 6-1.1.1.1.3 6-1.1.1.1.3.1 6-1.1.1.1.3.1.r 10-1.1.1.1.2 11-1.1.1.1.2.1 14-1.1 16-1.2.2.1.1 16-1.3.2.1.1.1 16-1.4.2.1.1.1 18-1.2.1.1 20-1.2.1.2.1.1 20-1.2.1.2.2.1 20-1.5.1.2.1.1 20-1.5.1.2.2.1 21-1.2.1.2.1 21-1.2.1.2.2 21-1.5.1.2.1 21-1.5.1.2.2 23-1.2.2.1.1 23-1.3.2.1.1.1 23-1.4.2.1.1.1 25-1.3.2.2.1.1 25-1.6.2.2.1.1 26-1.3.2.2.2 26-1.6.2.2.2 28-1.3.1.1 30-1.3.1.2.1.1 30-1.3.1.2.2.1 30-1.6.1.2.1.1 30-1.6.1.2.2.1 31-1.3.1.2.1 31-1.3.1.2.2 31-1.6.1.2.1 31-1.6.1.2.2 33-1.2.2.1.1 33-1.3.2.1.1.1 33-1.4.2.1.1.1 35-1.4.2.2.1.1 35-1.7.2.2.1.1 37-1.4.1.1 39-1.4.1.2.1.1 39-1.4.1.2.2.1 40-1.4.1.2.1 40-1.4.1.2.2 42-1.5.2.1.1 42-1.6.2.1.1.1 42-1.7.2.1.1.1 44-1.5.1.1 46-1.2.1.2.1.1 46-1.2.1.2.2.1 46-1.5.1.2.1.1 46-1.5.1.2.2.1 47-1.2.1.2.1 47-1.2.1.2.2 47-1.5.1.2.1 47-1.5.1.2.2 49-1.5.2.1.1 49-1.6.2.1.1.1 49-1.7.2.1.1.1 51-1.3.2.2.1.1 51-1.6.2.2.1.1 52-1.3.2.2.2 52-1.6.2.2.2 54-1.6.1.1 56-1.3.1.2.1.1 56-1.3.1.2.2.1 56-1.6.1.2.1.1 56-1.6.1.2.2.1 57-1.3.1.2.1 57-1.3.1.2.2 57-1.6.1.2.1 57-1.6.1.2.2 59-1.5.2.1.1 59-1.6.2.1.1.1 59-1.7.2.1.1.1 61-1.4.2.2.1.1 61-1.7.2.2.1.1 63-1.7.1.1 65-1.7.1.2.1.1 65-1.7.1.2.2.1 66-1.7.1.2.1 66-1.7.1.2.2
# ::id pmid_1177_7939.272
# ::preferred 
(m3 / multi-sentence
      :snt1 (f / follow-04~e.14
            :ARG1 (p4 / percentage-entity~e.1
                  :quant-of~e.2 (c / cell~e.4
                        :ARG1-of (t / transfect-00~e.3)
                        :ARG1-of (u / undergo-01~e.10
                              :ARG2 (r / ruffle-02~e.11))
                        :ARG1-of (m / mean-01~e.6
                              :ARG2~e.6 (m2 / mean~e.6
                                    :mod (s / slash
                                          :op1 (e / error
                                                :mod (s2 / standard))
                                          :op2 (e2 / error
                                                :polarity "-"
                                                :mod s2)))))))
      :snt2 (e3 / equal-01
            :ARG1 (s3 / sum-of
                  :op1 "65"~e.18
                  :op2 (s4 / slash
                        :op1 (p / percentage-entity~e.21,47 :value "3"~e.20,46)
                        :op2 (p2 / percentage-entity~e.21,47 :value "-3"~e.20,46)))
            :ARG2 (e4 / enzyme
                  :name (n / name :op1 "RasV12"~e.16,23,33)))
      :snt3 (e5 / equal-01
            :ARG1 (s6 / sum-of
                  :op1 "62"~e.28
                  :op2 (s7 / slash
                        :op1 (p5 / percentage-entity~e.31,57 :value "4"~e.30,56)
                        :op2 (p6 / percentage-entity~e.31,57 :value "-4"~e.30,56)))
            :ARG2 (s5 / sum-of
                  :op1 (e6 / enzyme
                        :name (n2 / name :op1 "RasV12"~e.16,23,33))
                  :op2 (p3 / protein
                        :name (n3 / name :op1 "E3b1"~e.25,51)
                        :mod (w / wild-type~e.26,52))))
      :snt4 (e7 / equal-01
            :ARG1 (s9 / sum-of
                  :op1 "16"~e.37
                  :op2 (s10 / slash
                        :op1 (p8 / percentage-entity~e.40 :value "2"~e.39)
                        :op2 (p9 / percentage-entity~e.40 :value "-2"~e.39)))
            :ARG2 (s8 / sum-of
                  :op1 (e8 / enzyme
                        :name (n4 / name :op1 "RasV12"~e.16,23,33))
                  :op2 (p7 / protein
                        :name (n5 / name :op1 "E3b1DY"~e.35,61))))
      :snt5 (e9 / equal-01
            :ARG1 (s11 / sum-of
                  :op1 "93"~e.44
                  :op2 (s12 / slash
                        :op1 (p11 / percentage-entity~e.21,47 :value "3"~e.20,46)
                        :op2 (p12 / percentage-entity~e.21,47 :value "-3"~e.20,46)))
            :ARG2 (p10 / protein
                  :name (n6 / name :op1 "RacQL"~e.42,49,59)))
      :snt6 (e10 / equal-01
            :ARG1 (s14 / sum-of
                  :op1 "90"~e.54
                  :op2 (s15 / slash
                        :op1 (p15 / percentage-entity~e.31,57 :value "4"~e.30,56)
                        :op2 (p16 / percentage-entity~e.31,57 :value "-4"~e.30,56)))
            :ARG2 (s13 / sum-of
                  :op1 (p13 / protein
                        :name (n7 / name :op1 "RacQL"~e.42,49,59))
                  :op2 (p14 / protein
                        :name (n8 / name :op1 "E3b1"~e.25,51)
                        :mod (w2 / wild-type~e.26,52))))
      :snt7 (e11 / equal-01
            :ARG1 (s17 / sum-of
                  :op1 "95"~e.63
                  :op2 (s18 / slash
                        :op1 (p19 / percentage-entity~e.66 :value "5"~e.65)
                        :op2 (p20 / percentage-entity~e.66 :value "-5"~e.65)))
            :ARG2 (s16 / sum-of
                  :op1 (p17 / protein
                        :name (n9 / name :op1 "RacQL"~e.42,49,59))
                  :op2 (p18 / protein
                        :name (n10 / name :op1 "E3b1DY"~e.35,61)))))

# ::tok Bar , 10 μm .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 2-1.1.1
# ::id pmid_1177_7939.273
# ::preferred 
(b / bar~e.0
      :mod (d / distance-quantity
            :quant "10"~e.2
            :unit (m / micron)))

# ::tok Figure 7 .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.1
# ::id pmid_1177_7939.274
# ::preferred 
(f / figure~e.0 :mod "7"~e.1)

# ::tok <bold> The bifunctional guanine nucleotide exchange activity of Sos @-@ 1 is regulated by its assembly into distinct molecular complexes . </bold>
# ::amr-annotator SDL-AMR-09
# ::alignments 3-1.2.2.1.1 4-1.2.2.1.2 5-1.2.2.1.3 8-1.1.1.1.1 10-1.1.1.1.1 12-1 15-1.1 16-1.1.2.r 17-1.1.2.1 18-1.1.2.2 19-1.1.2
# ::id pmid_1177_7939.275
# ::preferred 
(r / regulate-01~e.12
      :ARG0 (a / assemble-02~e.15
            :ARG0 (p2 / protein
                  :name (n2 / name :op1 "Sos-1"~e.8,10))
            :ARG1~e.16 (c / complex~e.19
                  :mod (d / distinct~e.17)
                  :mod (m / molecule~e.18)))
      :ARG1 (a2 / act-01
            :ARG0 p2
            :ARG1 (p / protein
                  :name (n / name
                        :op1 "guanine"~e.3
                        :op2 "nucleotide"~e.4
                        :op3 "exchange"~e.5
                        :op4 "factor")
                  :ARG0-of (f / function-01 :quant "2"))))

# ::tok ( A ) Cos @-@ 7 cells were transfected with expression vectors for Sos @-@ 1 ( SosTfx ) or for Sos @-@ 1 , E3b1 , and Eps8 ( TripleTfx ) or with the corresponding empty vectors ( mock ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3.1.1 3-1.1.1.1 5-1.1.1.1 6-1.1 8-1 10-1.2.1.1 10-1.2.2.1 11-1.2.1 11-1.2.2 13-1.2.1.1.1.1.1 13-1.2.2.1.1.1.1.1 15-1.2.1.1.1.1.1 15-1.2.2.1.1.1.1.1 17-1.2.1.1.1.2.1.1 19-1.2 21-1.2.1.1.1.1.1 21-1.2.2.1.1.1.1.1 23-1.2.1.1.1.1.1 23-1.2.2.1.1.1.1.1 25-1.2.2.1.1.2.1.1 28-1.2.2.1.1.3.1.1 30-1.2.2.1.1.4.1.1 32-1.2 33-1.2.r 35-1.2.3.2 36-1.2.3.1 37-1.2.3 39-1.2.3.3.1.1
# ::id pmid_1177_7939.276
# ::preferred 
(t / transfect-00~e.8
      :ARG1 (c / cell-line~e.6
            :name (n / name :op1 "Cos-7"~e.3,5))
      :ARG2~e.33 (o2 / or~e.19,32
            :op1 (v / vector~e.11
                  :ARG1-of (e / express-03~e.10
                        :ARG2 (p4 / protein
                              :name (n5 / name :op1 "Sos-1"~e.13,15,21,23)
                              :ARG1-of (d3 / describe-01
                                    :ARG2 (n6 / name :op1 "SosTfx"~e.17)))))
            :op2 (v3 / vector~e.11
                  :ARG1-of (e3 / express-03~e.10
                        :ARG2 (m2 / macro-molecular-complex
                              :part (p / protein
                                    :name (n2 / name :op1 "Sos-1"~e.13,15,21,23))
                              :part (p2 / protein
                                    :name (n3 / name :op1 "E3b1"~e.25))
                              :part (p3 / protein
                                    :name (n4 / name :op1 "Eps8"~e.28))
                              :ARG1-of (d4 / describe-01
                                    :ARG2 (n7 / name :op1 "TripleTfx"~e.30)))))
            :op3 (v2 / vector~e.37
                  :mod (e2 / empty~e.36)
                  :ARG1-of (c2 / correspond-02~e.35)
                  :ARG1-of (d2 / describe-01
                        :ARG2 (n8 / name
                              :op1 (m3 / mock~e.39)))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "A"~e.1)))

# ::tok Total cellular lysates ( 100 μg , left ) , or immunoprecipitates ( IP , right ) with the antibody indicated on the top ( ctr , irrelevant antibody ) , were immunoblotted ( WB ) with the indicated antibody .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.4 1-1.1.1.1 4-1.1.1.2.1 7-1.1.1.3.1.1 13-1.1.2.1.2.1 15-1.1.2.1.1.1 19-1.2 20-1.2.1 23-1.2.1.1.1 25-1.2.2.1 27-1.2.2.1.1.1 27-1.2.2.1.1.1.1 27-1.2.2.1.1.1.1.r 28-1.2.2.1.1 34-1.3.1.1 38-1.2.1 39-1.2
# ::id pmid_1177_7939.277
# ::preferred 
(i / immunoblot-00
      :ARG1 (a / and
            :op1 (l / lysate
                  :mod (c / cell~e.1)
                  :quant (m / mass-quantity
                        :quant "100"~e.4
                        :unit (m2 / microgram))
                  :ARG1-of (d / describe-01
                        :ARG0 (f / figure
                              :location (l2 / left~e.7)))
                  :mod (t2 / total~e.0))
            :op2 (p / protein
                  :ARG1-of (d2 / describe-01
                        :ARG0 (f2 / figure
                              :location (r / right~e.15))
                        :ARG2 (n / name :op1 "IP"~e.13))
                  :ARG1-of (i2 / immunoprecipitate-00)))
      :ARG2 (a2 / antibody~e.19,39
            :ARG1-of (i4 / indicate-01~e.20,38
                  :location (f4 / figure
                        :mod (t / top~e.23)))
            :ARG1-of (d4 / describe-01
                  :ARG2 (c2 / ctr~e.25
                        :mod (a3 / antibody~e.28
                              :mod (r2 / relevant~e.27 :polarity~e.27 "-"~e.27)))))
      :ARG1-of (d3 / describe-01
            :ARG2 (n2 / name :op1 "WB"~e.34)))

# ::tok 5 mg of total cellular lysates were used for the immunoprecipitations , except in the SosTfx 1 @/@ 10 lanes , in which 0.5 mg were used .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.3.1 3-1.1.1 4-1.1.2 7-1 12-1.3 18-1.3.1.2.1.1.1 19-1.3.1.2 23-1.3.1.1.1.1 26-1.3.1
# ::id pmid_1177_7939.278
# ::preferred 
(u / use-01~e.7
      :ARG1 (l / lysate
            :mod (t / total~e.3)
            :mod (c / cell~e.4)
            :quant (m / mass-quantity
                  :quant "5"~e.0
                  :unit (m2 / miligram)))
      :ARG2 (i / immunoprecipitate-00)
      :ARG2-of (e / except-01~e.12
            :ARG1 (u2 / use-01~e.26
                  :ARG1 (l3 / lysate
                        :quant (m3 / mass-quantity
                              :quant "0.5"~e.23
                              :unit (m4 / milligram)))
                  :location (l2 / lane~e.19
                        :ARG1-of (d / describe-01
                              :ARG2 (n / name :op1 "SosTfx 1/10"~e.18))))))

# ::tok ( B ) Ras @-@ GEF ( empty bars ) and Rac @-@ GEF ( closed bars ) activities in aliquots of the same immunoprecipitates ( IP ) shown in B.
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3.1.1 3-1.1.2.1.1 7-1.1.3.1.1 8-1.1.3.1 10-1 11-1.2.2.1.1 15-1.2.3.1.1 16-1.2.3.1 20-1.1.4 23-1.1.4.1.1.2 28-1.3
# ::id pmid_1177_7939.279
# ::preferred 
(a2 / and~e.10
      :op1 (a3 / activate-01
            :ARG0 (p / protein
                  :name (n3 / name
                        :op1 "guanine"
                        :op2 "nucleotide"
                        :op3 "exchange"
                        :op4 "factor"))
            :ARG1 (e / enzyme
                  :name (n / name :op1 "Ras"~e.3))
            :ARG1-of (d2 / describe-01
                  :ARG2 (b / bar~e.8
                        :mod (e3 / empty~e.7)))
            :location (a / aliquot~e.20
                  :ARG1-of (i / include-91
                        :ARG2 (p2 / protein
                              :ARG1-of (i2 / immunoprecipitate-00)
                              :mod (s / same-01~e.23)))))
      :op2 (a4 / activate-01
            :ARG0 p
            :ARG1 (e2 / enzyme
                  :name (n2 / name :op1 "Rac"~e.11))
            :ARG1-of (d3 / describe-01
                  :ARG2 (b2 / bar~e.16
                        :ARG1-of (c / close-01~e.15)))
            :location a)
      :ARG1-of (s2 / show-01~e.28
            :ARG0 (f / figure :mod "B"~e.1)))

# ::tok Data are expressed as described in Material and methods .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 2-1.1 4-1.2 5-1.2.1.r 6-1.2.1.1.1.1 7-1.2.1.1.1 8-1.2.1.1.1.2
# ::id pmid_1177_7939.280
# ::preferred 
(r / resemble-01
      :ARG1 (e / express-01~e.2
            :ARG1 (d2 / data~e.0))
      :ARG2 (d / describe-01~e.4
            :ARG0~e.5 (t2 / thing
                  :ARG1-of (t / title-01
                        :ARG2 (a / and~e.7
                              :op1 (m / material~e.6)
                              :op2 (m2 / method~e.8))))))

# ::tok ( C ) Immobilized , purified GST @-@ Rac ( Rac ) and GST @-@ Cdc42 ( Cdc42 ) were depleted of guanine nucleotide by extensive washing in 10 mM EDTA as described in Material and methods .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.4.1.1 3-1.1.1.2 5-1.1.1.3 6-1.1.1.4.1.1 8-1.1.1.5.1.1 10-1.1.1.5.1.1 13-1.1.1.4.1.1 15-1.1.2.5.1.1 17-1.1.2.5.1.1 20-1 21-1.2.r 22-1.2.1.1.1 23-1.2 24-1.3.r 25-1.3.4 26-1.3 27-1.3.2.r 28-1.3.2.2.1 30-1.3.2.1.1 32-1.1.1.1 32-1.1.2.1 32-1.3.3 32-1.4 33-1.3.3.1.r 34-1.3.3.1.1.1.1 35-1.3.3.1.1.1 36-1.3.3.1.1.1.2
# ::id pmid_1177_7939.281
# ::preferred 
(d2 / deplete-01~e.20
      :ARG1 (a / and
            :op1 (m4 / macro-molecular-complex
                  :ARG1-of (d3 / describe-01~e.32
                        :ARG2 (n7 / name :op1 "Rac"))
                  :ARG1-of (i / immobilize-00~e.3)
                  :ARG1-of (p / purify-01~e.5)
                  :part (p4 / protein
                        :name (n / name :op1 "GST"~e.6,13))
                  :part (e / enzyme
                        :name (n5 / name :op1 "Rac"~e.8,10)))
            :op2 (m5 / macro-molecular-complex
                  :ARG1-of (d4 / describe-01~e.32
                        :ARG2 (n8 / name :op1 "Cdc42"))
                  :ARG1-of i
                  :ARG1-of p
                  :part p4
                  :part (e3 / enzyme
                        :name (n2 / name :op1 "Cdc42"~e.15,17))))
      :ARG2~e.21 (n6 / nucleotide~e.23
            :mod (m2 / molecular-physical-entity
                  :name (n3 / name :op1 "guanine"~e.22)))
      :manner~e.24 (w / wash-00~e.26
            :ARG1 (a2 / and
                  :op1 m4
                  :op2 m5)
            :ARG2~e.27 (m3 / molecular-physical-entity
                  :name (n4 / name :op1 "EDTA"~e.30)
                  :mod (c / concentration-quantity
                        :quant "10"~e.28
                        :unit (m / millimolar)))
            :ARG1-of (d5 / describe-01~e.32
                  :ARG0~e.33 (t2 / thing
                        :ARG1-of (t / title-01
                              :ARG2 (a3 / and~e.35
                                    :op1 (m6 / material~e.34)
                                    :op2 (m7 / method~e.36)))))
            :degree (e2 / extensive~e.25))
      :ARG1-of (d / describe-01~e.32
            :ARG0 (f / figure :mod "C"~e.1)))

# ::tok Equal amounts of the nucleotide @-@ free GST @-@ GTPases or GST alone ( GST ) were incubated with total cellular lysates from eps8 @<sup> −/− </sup> fibroblasts (−/−) or eps8 @<sup> −/− </sup> stably expressing Eps8 myc (−/−[Eps8 myc]) in the presence or absence (−) of the 40 ng @/@ ml of the indicated peptides ( peptides ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.1.3.1 4-1.2.1.4.1 7-1.2.1.1.1.1 7-1.2.2.1.1 10-1.3 11-1.2.1.1.1.1 11-1.2.2.1.1 14-1.2.1.1.1.1 14-1.2.2.1.1 17-1 19-1.1.1 20-1.1.2 23-1.1.3.1.1.1.1.1 25-1.1.3.1.1.1.2.1 27-1.1.3.1.1 27-1.1.3.1.2 29-1.1.3.1 30-1.1.3.1.2.3 31-1.1.3.1.2.3 32-1.1.3.1.2.3 34-1.1.3.1.2.1.2 34-1.1.3.1.2.1.2.r 35-1.1.3.1.2.1 36-1.1.3.1.2.3 40-1.3.r 42-1.3.1 43-1.3 44-1.3.2 46-1.3.1.1.r 48-1.3.1.1.3.1 54-1.3.1.1.1 55-1.3.1.1 55-1.3.1.1.2.1 57-1.3.1.1 57-1.3.1.1.2.1
# ::id pmid_1177_7939.282
# ::preferred 
(i / incubate-01~e.17
      :ARG0 (l / lysate
            :mod (t / total~e.19)
            :mod (c / cell~e.20)
            :ARG1-of (o / obtain-01
                  :ARG2 (o2 / or~e.29
                        :op1 (f2 / fibroblast~e.27
                              :part (e6 / enzyme
                                    :name (n4 / name :op1 "eps8"~e.23)
                                    :ARG2-of (m4 / mutate-01 :mod "−/−"~e.25)))
                        :op2 (f3 / fibroblast~e.27
                              :ARG3-of (e5 / express-03~e.35
                                    :ARG2 (p3 / protein
                                          :name (n5 / name :op1 "Eps8myc"))
                                    :manner~e.34 (s / stable~e.34))
                              :ARG1-of (d3 / describe-01 :ARG2 "−/−[Eps8myc]")
                              :part e6~e.30,31,32,36))))
      :ARG1 (a / and
            :op1 (m / macro-molecular-complex
                  :part (e / enzyme
                        :name (n / name :op1 "GST"~e.7,11,14))
                  :part (e2 / enzyme
                        :name (n2 / name :op1 "GTPase"))
                  :mod (m2 / mass-quantity
                        :degree (e4 / equal~e.0))
                  :ARG0-of (l5 / lack-01
                        :ARG1 (n6 / nucleotide~e.4)))
            :op2 (e3 / enzyme
                  :name (n3 / name :op1 "GST"~e.7,11,14)
                  :mod m2))
      :ARG2~e.40 (o3 / or~e.10,43
            :op1 (p4 / present~e.42
                  :domain~e.46 (p / peptide~e.55,57
                        :ARG1-of (i2 / indicate-01~e.54)
                        :ARG1-of (d4 / describe-01
                              :ARG2 (p2 / peptides~e.55,57))
                        :mod (m3 / mass-quantity
                              :quant "40"~e.48
                              :unit (n7 / nanogram-per-milliliter))))
            :op2 (a3 / absent-01~e.44
                  :ARG1 p
                  :ARG1-of (d5 / describe-01 :ARG2 "−"))))

# ::tok The peptide used were PPPPPPVDATEDEE ( PXXDA ) , used as control ( see text and <xref ref-type="fig" rid="fig1"> Fig . 1 </xref> ) ; PPPPPVDYTEDEE ( PXXDY ) , which corresponds to the E3b1 binding site for the SH3 domain of Eps8 and prevents Eps8 @-@ E3b1 association ( refer to <xref ref-type="fig" rid="fig1"> Fig . 1 </xref> B ) ; VPVPPPVPPRRR ( PXXP ) , which corresponds to the Sos @-@ 1 binding site for the SH3 domain of E3b1 and readily competes the interaction between Sos @-@ 1 and E3b1 ( refer to <xref ref-type="fig" rid="fig2"> Fig . 2 </xref> C ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1 1-1.1.2 1-1.1.3 2-1 4-1.1.1.1.1 6-1.1.1.2.2.1 9-1 10-1.1.1.3.r 11-1.1.1.3 13-1.1.1.2.1.3 14-1.1.1.2.1.1 15-1.1 15-1.1.1.2.1 21-1.1.1.2.1.2.1 25-1.1.2.1.1 27-1.1.2.2.2.1 32-1.1.2.3.r 34-1.1.2.3.1.1.1.1 35-1.1.2.4 35-1.1.3.4 35-1.1.3.4.2.1 36-1.1.3.4.1 39-1.1.3.4.1.1.1 40-1.1.3.4.1.1.2 42-1.1.2.3.1.2.1.1 44-1.1.2.3 45-1.1.2.3.1.2.1.1 47-1.1.2.3.1.1.1.1 48-1.1.2.3.1 50-1.1.2.2.1.2 57-1.1.1.2.1.2.1 62-1.1.3.1.1 64-1.1.3.2.2.1 69-1.1.3.3.r 71-1.1.3.3.1.1.1 73-1.1.1.2.1.2.1 73-1.1.3.3.1.1.1 74-1.1.2.4 74-1.1.2.4.2.1 75-1.1.2.4.1 78-1.1.2.4.1.1.1 79-1.1.2.4.1.1.2 80-1.1.2.4.2 81-1.1.2.3.1.1.1.1 82-1.1 83-1.1.3.3.3 83-1.1.3.3.3.r 84-1.1.3.3 86-1.1.3.3.2 88-1.1.3.3.1.1.1 90-1.1.1.2.1.2.1 90-1.1.3.3.1.1.1 91-1.1 92-1.1.2.3.1.1.1.1 94-1.1.2.2.1.2
# ::id pmid_1177_7939.283
# ::preferred 
(u / use-01~e.2,9
      :ARG1 (a / and~e.15,82,91
            :op1 (p / peptide~e.1
                  :name (n / name :op1 "PPPPPPVDATEDEE"~e.4)
                  :ARG1-of (d / describe-01
                        :ARG0 (a2 / and~e.15
                              :op1 (t / text~e.14)
                              :op2 (f / figure :mod "1"~e.21,57,73,90)
                              :ARG1-of (s / see-01~e.13
                                    :mode "imperative"
                                    :ARG0 (y / you)))
                        :ARG2 (n7 / name :op1 "PXXDA"~e.6))
                  :ARG0-of~e.10 (c / control-01~e.11))
            :op2 (p2 / peptide~e.1
                  :name (n2 / name :op1 "PPPPPVDYTEDEE"~e.25)
                  :ARG1-of (d2 / describe-01
                        :ARG0 (f2 / figure
                              :mod "1B"
                              :ARG1-of (r2 / refer-03~e.50,94
                                    :mode "imperative"
                                    :ARG0 y))
                        :ARG2 (n10 / name :op1 "PXXDY"~e.27))
                  :ARG0-of~e.32 (p4 / prevent-01~e.44
                        :ARG1 (a3 / associate-01~e.48
                              :ARG1 (p6 / protein
                                    :name (n5 / name :op1 "E3b1"~e.34,47,81,92))
                              :ARG2 (e / enzyme
                                    :name (n4 / name :op1 "Eps8"~e.42,45))))
                  :ARG1-of (b2 / bind-01~e.35,74
                        :ARG2 (p9 / protein-segment~e.75
                              :name (n8 / name :op1 "SH3"~e.78 :op2 "domain"~e.79)
                              :part-of e)
                        :ARG1-of (i3 / instead-of-91~e.80
                              :ARG2 (b3 / bind-01~e.74
                                    :ARG1 p6
                                    :ARG2 e))))
            :op3 (p3 / peptide~e.1
                  :name (n3 / name :op1 "VPVPPPVPPRRR"~e.62)
                  :ARG1-of (d3 / describe-01
                        :ARG0 (f3 / figure :mod "2C")
                        :ARG2 (n11 / name :op1 "PXXP"~e.64))
                  :ARG0-of~e.69 (c3 / compete-01~e.84
                        :ARG1 (p7 / protein
                              :name (n6 / name :op1 "Sos-1"~e.71,73,88,90))
                        :ARG2 (i2 / interact-01~e.86
                              :ARG1 p6)
                        :manner~e.83 (r / ready~e.83))
                  :ARG1-of (b4 / bind-01~e.35
                        :ARG2 (p5 / protein-segment~e.36
                              :name (n9 / name :op1 "SH3"~e.39 :op2 "domain"~e.40)
                              :part-of p6)
                        :ARG1-of (i4 / instead-of-91
                              :ARG2 (b5 / bind-01~e.35
                                    :ARG1 p7
                                    :ARG2 p6))))))

# ::tok Bound proteins were resolved by SDS @-@ PAGE .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1 3-1 4-1.2.r 5-1.2.1.1 7-1.2.1.1
# ::id pmid_1177_7939.284
# ::preferred 
(r / resolve-00~e.3
      :ARG1 (p / protein~e.1
            :ARG1-of (b / bind-01~e.0))
      :ARG2~e.4 (e / event
            :name (n / name :op1 "SDS-PAGE"~e.5,7)))

# ::tok Detection was with anti–Sos @-@ 1 antibody ( Sos @-@ 1 ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 5-1.1.1.1.1 5-1.1.2.1.1.1 6-1.1 8-1.1.1.1.1 8-1.1.2.1.1.1 10-1.1.1.1.1 10-1.1.2.1.1.1
# ::id pmid_1177_7939.285
# ::preferred 
(d / detect-01~e.0
      :ARG0 (a / antibody~e.6
            :ARG1-of (d2 / describe-01
                  :ARG2 (n2 / name :op1 "Sos-1"~e.5,8,10))
            :ARG0-of (c / counter-01
                  :ARG1 (p / protein
                        :name (n / name :op1 "Sos-1"~e.5,8,10)))))

# ::tok The indicted lanes ( lysate ) were loaded with 50 μg of total cellular lysates .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1 4-1.1.2.1.1 4-1.2 7-1 8-1.2.3.r 9-1.2.3.1 11-1.2.1.r 12-1.2.1 13-1.2.2
# ::id pmid_1177_7939.286
# ::preferred 
(l / load-01~e.7
      :ARG1 (l2 / lane~e.2
            :ARG1-of (i / indicate-01)
            :ARG1-of (d / describe-01
                  :ARG2 (n / name
                        :op1 (l5 / lysate~e.4))))
      :ARG2 (l3 / lysate~e.4
            :mod~e.11 (t / total~e.12)
            :mod (c / cell~e.13)
            :mod~e.8 (m / mass-quantity
                  :quant "50"~e.9
                  :unit (m2 / microgram))))

# ::tok Figure 8 .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.1
# ::id pmid_1177_7939.287
# ::preferred 
(f / figure~e.0 :mod "8"~e.1)

# ::tok <bold> The differential regulation of the S/G and S/E/E8 complexes by RTKs correlates with the kinetics of activation of Ras and Rac . </bold>
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1.3 3-1.1 4-1.1.2.r 6-1.1.2.1.1.1 7-1.1.2 8-1.1.2.2.1.1 9-1.1.2.1 9-1.1.2.2 12-1 13-1.2.r 15-1.2 16-1.2.1.r 17-1.2.1 18-1.2.1.1.r 19-1.2.1.1.1.1.1 20-1.2.1.1 21-1.2.1.1.2.1.1
# ::id pmid_1177_7939.288
# ::preferred 
(c / correlate-01~e.12
      :ARG1 (r / regulate-01~e.3
            :ARG0 (e2 / enzyme
                  :name (n2 / name :op1 "RTK"))
            :ARG1~e.4 (a2 / and~e.7
                  :op1 (m / macro-molecular-complex~e.9
                        :name (n3 / name :op1 "S/G"~e.6))
                  :op2 (m2 / macro-molecular-complex~e.9
                        :name (n4 / name :op1 "S/E/E8"~e.8)))
            :ARG1-of (d / differ-02~e.2))
      :ARG2~e.13 (k / kinetics~e.15
            :mod~e.16 (a / activate-01~e.17
                  :ARG1~e.18 (a3 / and~e.20
                        :op1 (e / enzyme
                              :name (n / name :op1 "Ras"~e.19))
                        :op2 (e3 / enzyme
                              :name (n5 / name :op1 "Rac"~e.21))))))

# ::tok ( A ) Mouse embryo fibroblasts cells were treated with PDGF for 15 min (+) or mock treated (−).
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3 3-1.1.1.1.1 4-1.1.1.1 5-1.1.1 8-1.1 8-1.2 10-1.1.2.1.1 12-1.1.3.1 17-1.1
# ::id pmid_1177_7939.289
# ::preferred 
(a / and
      :op1 (t / treat-03~e.8,17
            :ARG1 (f / fibroblast~e.5
                  :part-of (e / embryo~e.4
                        :mod (m / mouse~e.3)))
            :ARG3 (p / protein
                  :name (n / name :op1 "PDGF"~e.10)
                  :ARG1-of (d / describe-01 :ARG2 "+"))
            :duration (t3 / temporal-quantity
                  :quant "15"~e.12
                  :unit (m2 / minute)))
      :op2 (t2 / treat-03~e.8
            :polarity "-"
            :ARG1 f
            :ARG1-of (d2 / describe-01 :ARG2 "−"))
      :li (a2 / A~e.1))

# ::tok Lysates were immunoprecipitated ( IP ) with anti @-@ Grb2 ( left ) or anti @-@ E3b1 ( right ) antibody and detected with anti–Sos @-@ 1 antibody ( top ) or anti @-@ Grb2 ( bottom , left ) , or anti @-@ E3b1 ( bottom , right ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 4-1.1.3.1.1 7-1.1.2.2.1 9-1.1.2.1.1.1.1.1 11-1.1.2.1.2 13-1.1.2 14-1.1.2.2.1 16-1.1.2.2.1.1.1.1 18-1.1.2.2.2 20-1.1.2.2 21-1 22-1.2 26-1.2.2.1.1.1.1.1 27-1.1.2.1 27-1.2.2.1 27-1.2.2.2 27-1.2.2.3 29-1.2.2.1.2 31-1.1.2 31-1.2.2 32-1.1.2.1.1 32-1.2.2.1.1 32-1.2.2.2.1 32-1.2.2.3.1 34-1.1.2.1.1.1.1.1 36-1.2.2.2.2 38-1.2.2.2.2.1 41-1.2.2 42-1.1.2.1.1 44-1.1.2.2.1.1.1.1 46-1.2.2.3.2 48-1.2.2.3.2.1
# ::id pmid_1177_7939.290
# ::preferred 
(a / and~e.21
      :op1 (i / immunoprecipitate-00
            :ARG1 (l / lysate)
            :ARG2 (o / or~e.13,31
                  :op1 (a2 / antibody~e.27
                        :ARG0-of (c / counter-01~e.32,42
                              :ARG1 (p3 / protein
                                    :name (n / name :op1 "Grb2"~e.9,34)))
                        :location (l2 / left~e.11))
                  :op2 (a9 / antibody~e.20
                        :ARG0-of (c2 / counter-01~e.7,14
                              :ARG1 (p4 / protein
                                    :name (n2 / name :op1 "E3b1"~e.16,44)))
                        :location (r2 / right~e.18)))
            :ARG1-of (d2 / describe-01
                  :ARG2 (n4 / name :op1 "IP"~e.4)))
      :op2 (d / detect-01~e.22
            :ARG1 l
            :ARG2 (o2 / or~e.31,41
                  :op1 (a7 / antibody~e.27
                        :ARG0-of (c3 / counter-01~e.32
                              :ARG1 (p / protein
                                    :name (n3 / name :op1 "Sos-1"~e.26)))
                        :location (t / top~e.29))
                  :op2 (a10 / antibody~e.27
                        :ARG0-of (c4 / counter-01~e.32
                              :ARG1 p3)
                        :location (b / bottom~e.36
                              :location (l3 / left~e.38)))
                  :op3 (a4 / antibody~e.27
                        :ARG0-of (c5 / counter-01~e.32
                              :ARG1 p4)
                        :location (b2 / bottom~e.46
                              :location (r / right~e.48))))))

# ::tok The indicated lanes ( lysate ) ( 50 μg ) were detected with anti–Sos @-@ 1 antibody to show the mobility shift after PDGF stimulation .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1.1 2-1.1.1 4-1.1.1.3.1.1 7-1.1.1.2.1 11-1.1 15-1.1.2.1.1.1.1 16-1.1.2 18-1.2 20-1.2.1.1 21-1.2.1 22-1.2.1.2 23-1.2.1.2.1.1.1.1 24-1.2.1.2.1
# ::id pmid_1177_7939.291
# ::preferred 
(h / have-purpose-91
      :ARG1 (d / detect-01~e.11
            :ARG1 (l / lane~e.2
                  :ARG1-of (i / indicate-01~e.1)
                  :quant (m2 / mass-quantity
                        :quant "50"~e.7
                        :unit (m3 / microgram))
                  :ARG1-of (d2 / describe-01
                        :ARG2 (n3 / name :op1 "lysate"~e.4)))
            :ARG2 (a2 / antibody~e.16
                  :ARG0-of (c / counter-01
                        :ARG1 (p2 / protein
                              :name (n2 / name :op1 "Sos-1"~e.15)))))
      :ARG2 (s / show-01~e.18
            :ARG1 (s2 / shift-01~e.21
                  :ARG1 (m / mobility~e.20)
                  :time (a / after~e.22
                        :op1 (s4 / stimulate-01~e.24
                              :ARG0 (p / protein
                                    :name (n / name :op1 "PDGF"~e.23)))))))

# ::tok Similar results were obtained upon EGF stimulation in Cos @-@ 7 cells ( not shown ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2 1-1.1 1-1.1.1 1-1.1.1.r 3-1 5-1.1.1.1.1.1.1 6-1.1.1.1 7-1.1.1.1.2.r 8-1.1.1.1.2.2.1 10-1.1.1.1.2.1 11-1.1.1.1.2 13-1.2.1 13-1.2.1.r 14-1.2
# ::id pmid_1177_7939.292
# ::preferred 
(o / obtain-01~e.3
      :ARG1 (t / thing~e.1
            :ARG2-of~e.1 (r2 / result-01~e.1
                  :ARG1 (s / stimulate-01~e.6
                        :ARG0 (p / protein
                              :name (n / name :op1 "EGF"~e.5))
                        :location~e.7 (c / cell-line~e.11
                              :mod "7"~e.10
                              :name (n2 / name :op1 "Cos"~e.8))))
            :ARG1-of (r / resemble-01~e.0))
      :ARG1-of (s2 / show-01~e.14 :polarity~e.13 "-"~e.13))

# ::tok ( B ) Fibroblasts were treated with PDGF for the indicated lengths of time .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.4 3-1.2 5-1 6-1.1.r 7-1.1.1.1 8-1.3.r 10-1.3.2 11-1.3 12-1.3.1.r 13-1.3.1
# ::id pmid_1177_7939.293
# ::preferred 
(t / treat-04~e.5
      :ARG0~e.6 (p / protein
            :name (n / name :op1 "PDGF"~e.7))
      :ARG1 (f / fibroblast~e.3)
      :duration~e.8 (l2 / length~e.11
            :mod~e.12 (t3 / time~e.13)
            :ARG1-of (i / indicate-01~e.10))
      :li (b / B~e.1))

# ::tok Lysates were immunoprecipitated ( IP ) with anti @-@ PDGFR ( PDGFR ) or an irrelevant antibody as a control ( ctr ) and detected with the indicated antibodies ( WB ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 4-1.1.3.1.1 7-1.2.1.1.1 9-1.2.1.1.1.1.1.1 11-1.2.1.1.1.1.1.1 13-1.2.1 15-1.2.1.2.1 15-1.2.1.2.1.1 15-1.2.1.2.1.1.r 16-1.2.1.1 16-1.2.1.2 19-1.2.1.2.2.1 21-1.2.1.2.2.1.1.1.1 24-1.2 25-1.2.1.r 27-1.2.1.3 28-1.2.1.2 30-1.2.1.4.1.1
# ::id pmid_1177_7939.294
# ::preferred 
(a / and
      :op1 (i / immunoprecipitate-00
            :ARG0 (o / or~e.13
                  :op1 (a2 / antibody~e.16
                        :ARG0-of (c2 / counter-01~e.7
                              :ARG1 (p / protein
                                    :name (n / name :op1 "PDGFR"~e.9,11)
                                    :ARG1-of (d3 / describe-01
                                          :ARG2 (n5 / name :op1 "PDGFR")))))
                  :op2 (a3 / antibody~e.16,28
                        :mod (r / relevant-01~e.15 :polarity~e.15 "-"~e.15)
                        :ARG0-of (a4 / act-01
                              :ARG1 (c / control-01~e.19
                                    :ARG1-of (d4 / describe-01
                                          :ARG2 (n4 / name
                                                :op1 (c3 / ctr~e.21))))))
                  :ARG1-of (i3 / indicate-01~e.27)
                  :ARG1-of (d5 / describe-01
                        :ARG2 (n3 / name :op1 "WB"~e.30)))
            :ARG1 (l / lysate)
            :ARG1-of (d2 / describe-01
                  :ARG2 (n2 / name :op1 "IP"~e.4)))
      :op2 (d / detect-01~e.24
            :ARG0~e.25 o
            :ARG1 l))

# ::tok ( C ) −/− [Eps8 myc] cells were treated with 20 ng @/@ ml of PDGF (+) or mock treated (−), and total cellular lysates were prepared .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3 3-1.1.1.2.1.2.1 6-1.1.1.2 8-1.1.1 9-1.1.1.1.r 10-1.1.1.1.3.1 15-1.1.1.1.2.1 17-1.1 18-1.1.2.3 19-1.1.2 21-1 22-1.2.1.1.1 23-1.2.1.1 26-1.2
# ::id pmid_1177_7939.295
# ::preferred 
(a / and~e.21
      :op1 (o / or~e.17
            :op1 (t / treat-04~e.8
                  :ARG1~e.9 (p / protein
                        :mod "+"
                        :name (n / name :op1 "PDGF"~e.15)
                        :quant (c4 / concentration-quantity
                              :quant "20"~e.10
                              :unit (n3 / nanogram-per-milliliter)))
                  :ARG2 (c / cell~e.6
                        :part (p3 / protein
                              :name (n2 / name :op1 "Eps8myc")
                              :ARG2-of (m3 / mutate-01 :mod "−/−"~e.3))))
            :op2 (t3 / treat-04~e.19
                  :mod "-"
                  :ARG1 c
                  :manner (m / mock-01~e.18)))
      :op2 (p2 / prepare-01~e.26
            :ARG1 (l / lysate
                  :mod (c2 / cellular~e.23
                        :mod (t2 / total~e.22))))
      :li (c3 / C~e.1))

# ::tok Immmunoprecipitations ( IP ) were performed with anti @-@ myc antibody or with an irrelevant ( ctr ) antibody , followed by immunoblot with the antibody indicated on the right ( WB ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1.1.1.1 5-1 6-1.2.r 7-1.2.1.1 7-1.2.2.3 9-1.2.1.1.1.1.1 10-1.2.1 10-1.2.2 11-1.2 14-1.2.2.2 14-1.2.2.2.1 14-1.2.2.2.1.r 16-1.2.2.1.1.1 18-1.2.2 20-1.3 21-1.3.1.r 22-1.3.1 23-1.3.1.1.r 25-1.3.1.1 26-1.3.1.1.1 27-1.3.1.1.1.1.r 29-1.3.1.1.1.1 31-1.3.1.1.1.2.1.1
# ::id pmid_1177_7939.296
# ::preferred 
(p / perform-01~e.5
      :ARG1 (i / immunoprecipitate-00
            :ARG1-of (d2 / describe-01
                  :ARG2 (n2 / name :op1 "IP"~e.2)))
      :ARG2~e.6 (o / or~e.11
            :op1 (a / antibody~e.10
                  :ARG0-of (c3 / counter-01~e.7
                        :ARG1 (g / gene
                              :name (n / name :op1 "myc"~e.9))))
            :op2 (a2 / antibody~e.10,18
                  :ARG1-of (d / describe-01
                        :ARG2 (n3 / name
                              :op1 (c / ctr~e.16)))
                  :ARG2-of (r2 / relevant-01~e.14 :polarity~e.14 "-"~e.14)
                  :ARG0-of (c2 / counter-01~e.7)))
      :ARG2-of (f / follow-01~e.20
            :ARG1~e.21 (i3 / immunoblot-00~e.22
                  :ARG2~e.23 (a3 / antibody~e.25
                        :ARG1-of (i4 / indicate-01~e.26
                              :location~e.27 (r / right~e.29)
                              :ARG1-of (d3 / describe-01
                                    :ARG2 (n4 / name :op1 "WB"~e.31)))))))

# ::tok The indicated lanes ( lysates ) were loaded with 100 μg of total cellular lysates .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1 2-1.1 7-1 9-1.2.1.1.1 12-1.2.1 13-1.2.2
# ::id pmid_1177_7939.297
# ::preferred 
(l / load-01~e.7
      :ARG1 (l2 / lane~e.2
            :ARG1-of (i / indicate-01~e.1)
            :ARG1-of (d / describe-01
                  :ARG2 (n / name
                        :op1 (l3 / lysate))))
      :ARG2 (l4 / lysate
            :ARG1-of (t / total-01~e.12
                  :ARG2 (m / mass-quantity
                        :quant "100"~e.9
                        :unit (m2 / microgram)))
            :mod (c / cell~e.13)))

# ::tok ( D ) Fibroblasts were treated with PDGF for the indicated lengths of time .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.4 3-1.1 5-1 6-1.2.r 7-1.2.1.1 8-1.3.r 10-1.3.1 11-1.3 12-1.3.2.r 13-1.3.2
# ::id pmid_1177_7939.298
# ::preferred 
(t / treat-04~e.5
      :ARG1 (f / fibroblast~e.3)
      :ARG2~e.6 (p / protein
            :name (n / name :op1 "PDGF"~e.7))
      :duration~e.8 (l2 / length~e.11
            :ARG1-of (i / indicate-01~e.10)
            :mod~e.12 (t2 / time~e.13))
      :li (d / D~e.1))

# ::tok The levels of Ras @-@ GTP and Rac @-@ GTP in total cellular lysates were determined by affinity precipitation using GST @-@ RBD and GST @-@ CRIB , as described in Materials and methods .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1 2-1.1.1.r 3-1.1.1.1.2.1.1 5-1.1.1.1.1.1.1 6-1.1.1 7-1.1.1.2.1.1.1 9-1.1.1.2.2 11-1.1.2.1 12-1.1.2.2 15-1 16-1.2.r 17-1.2.1 18-1.2 19-1.2.2 20-1.2.2.1.1.1.1 20-1.2.2.1.2.1.1 22-1.2.2.1.1.1.1 23-1.2.2.1 24-1.2.2.1.1.1.1 24-1.2.2.1.2.1.1 26-1.2.2.1.2.1.1 28-1.3.r 29-1.3 30-1.3.1.r 31-1.3.1.1 32-1.3.1 33-1.3.1.2
# ::id pmid_1177_7939.299
# ::preferred 
(d / determine-01~e.15
      :ARG1 (l / level~e.1
            :quant-of~e.2 (a / and~e.6
                  :op1 (m3 / macro-molecular-complex
                        :part (s2 / small-molecule
                              :name (n3 / name :op1 "GTP"~e.5))
                        :part (e / enzyme
                              :name (n / name :op1 "Ras"~e.3)))
                  :op2 (m4 / macro-molecular-complex
                        :part (e2 / enzyme
                              :name (n4 / name :op1 "Rac"~e.7))
                        :part s2~e.9))
            :location (l3 / lysate
                  :quant (t / total~e.11)
                  :source (c / cell~e.12)))
      :ARG2~e.16 (p / precipitate-01~e.18
            :mod (a2 / affinity~e.17)
            :manner (u / use-01~e.19
                  :ARG1 (a5 / and~e.23
                        :op1 (p2 / protein
                              :name (n2 / name :op1 "GST-RBD"~e.20,22,24))
                        :op2 (p3 / protein
                              :name (n5 / name :op1 "GST-CRIB"~e.20,24,26)))))
      :ARG1-of~e.28 (d2 / describe-01~e.29
            :location~e.30 (a4 / and~e.32
                  :op1 (m / material~e.31)
                  :op2 (m2 / method~e.33))))

# ::tok Elevated levels of Rac @-@ GTP could be observed ≤30 min of RTK stimulation ( not shown ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.2 1-1.1.1 2-1.1.1.1.r 3-1.1.1.1.2.1.1 5-1.1.1.1.1.1.1 6-1 7-1.1.r 8-1.1 12-1.1.2.1.1.1.1 13-1.1.2.1 15-1.2.1 15-1.2.1.r 16-1.2
# ::id pmid_1177_7939.300
# ::preferred 
(p / possible~e.6
      :domain~e.7 (o / observe-01~e.8
            :ARG1 (l / level~e.1
                  :degree-of~e.2 (m / macro-molecular-complex
                        :part (s / small-molecule
                              :name (n / name :op1 "GTP"~e.5))
                        :part (e / enzyme
                              :name (n2 / name :op1 "Rac"~e.3)))
                  :ARG1-of (e2 / elevate-01~e.0))
            :time (b2 / before
                  :op1 (s2 / stimulate-01~e.13
                        :ARG0 (e3 / enzyme
                              :name (n3 / name :op1 "RTK"~e.12)))
                  :duration (t / temporal-quantity
                        :quant "30"
                        :unit (m2 / minute))))
      :ARG1-of (s3 / show-01~e.16 :polarity~e.15 "-"~e.15))

# ::tok The expression levels of Ras ( total Ras ) and Rac ( total Rac ) , in the same lysates , were determined by immunoblotting with anti @-@ Ras and anti @-@ Rac antibodies , respectively .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1 2-1.1.1 3-1.1.1.1.r 4-1.1.1.1.1.1.1 6-1.1.1.1.1.2.1 7-1.1.1.1.1.1.1 9-1.1.1.1 10-1.1.1.1.2.1.1 12-1.1.1.1.2.2.1 13-1.1.1.1.2.1.1 16-1.1.2.r 18-1.1.2 22-1 26-1.2.1.1.1 28-1.2.1.1.1.1 29-1.2.1 30-1.2.1.1.1 30-1.2.1.2.1 32-1.1.1.1.2.1.1 33-1.2.1.1 33-1.2.1.2
# ::id pmid_1177_7939.301
# ::preferred 
(d / determine-01~e.22
      :ARG1 (e2 / express-03~e.1
            :ARG1 (l / level~e.2
                  :degree-of~e.3 (a / and~e.9
                        :op1 (e3 / enzyme
                              :name (n2 / name :op1 "Ras"~e.4,7)
                              :ARG1-of (d2 / describe-01
                                    :ARG2 (t / total-01~e.6
                                          :ARG1 e3)))
                        :op2 (e4 / enzyme
                              :name (n3 / name :op1 "Rac"~e.10,13,32)
                              :ARG1-of (d3 / describe-01
                                    :ARG2 (t2 / total-01~e.12
                                          :ARG1 e4)))))
            :location~e.16 (s / same-01~e.18
                  :ARG1 (l2 / lysate)))
      :manner (i / immunoblot-00
            :ARG2 (a2 / and~e.29
                  :op1 (a3 / antibody~e.33
                        :ARG0-of (c / counter-01~e.26,30
                              :ARG1 e3~e.28))
                  :op2 (a4 / antibody~e.33
                        :ARG0-of (c2 / counter-01~e.30
                              :ARG1 e4)))))

# ::tok The kinetic of the mobility shift of Sos @-@ 1 , after PDGF stimulation , was determined by immunoblotting with anti–Sos @-@ 1 antibodies .
# ::amr-annotator SDL-AMR-09
# ::alignments 4-1.1.1.1 5-1.1.1 6-1.1.1.1.1.r 7-1.1.1.1.1.1.1 9-1.1.1.1.1.1.1 11-1.3 12-1.3.1.1.1.1 13-1.3.1 16-1 22-1.2.1.1.1 23-1.2.1
# ::id pmid_1177_7939.302
# ::preferred 
(d / determine-01~e.16
      :ARG1 (k / kinetics
            :poss (s / shift-01~e.5
                  :mod (m / mobility~e.4
                        :poss~e.6 (p / protein
                              :name (n / name :op1 "Sos-1"~e.7,9)))))
      :ARG2 (i / immunoblot-00
            :ARG2 (a2 / antibody~e.23
                  :ARG0-of (c / counter-01
                        :ARG1 p~e.22)))
      :time (a / after~e.11
            :op1 (s2 / stimulate-01~e.13
                  :ARG0 (p2 / protein
                        :name (n2 / name :op1 "PDGF"~e.12)))))

# ::tok A Signaling Pathway Involving TGF-β2 and Snail in Hair Follicle Morphogenesis ( PMID : 15630473 )
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1 2-1.1 3-1 4-1.2.1.1.1 5-1.2 6-1.2.2.1.1 7-1.3.r 8-1.3.1.1 9-1.3.1 10-1.3 12-1.4.1.1 14-1.4.1.1.1
# ::id pmid_1563_0473.1
# ::preferred 
(i / involve-01~e.3
      :ARG0 (p / pathway~e.2
            :ARG0-of (s / signal-07~e.1))
      :ARG1 (a / and~e.5
            :op1 (p3 / protein
                  :name (n / name :op1 "TGF-β2"~e.4))
            :op2 (e / enzyme
                  :name (n2 / name :op1 "Snail"~e.6)))
      :ARG2~e.7 (m / morphogenesis~e.10
            :mod (f / follicle~e.9
                  :mod (h / hair~e.8)))
      :ARG1-of (d / describe-01
            :ARG0 (p2 / publication-91
                  :ARG8 (p4 / PMID~e.12 :mod "15630473"~e.14))))

# ::tok In a common theme of organogenesis , certain cells within a multipotent epithelial sheet exchange signals with their neighbors and develop into a bud structure .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.3.1 3-1.3 7-1.1.1.2 8-1.1.1 8-1.1.3 11-1.1.1.1.1 12-1.1.1.1.2 13-1.1.1.1 14-1.1 15-1.1.2 15-1.1.2.1 15-1.1.2.1.r 16-1.1.3.1.r 17-1.1.3.1.1 17-1.1.3.1.1.r 18-1.1.3.1 19-1 20-1.2 21-1.2.1.r 23-1.2.1.1 24-1.2.1
# ::id pmid_1563_0473.2
# ::preferred 
(a / and~e.19
      :op1 (e / exchange-01~e.14
            :ARG0 (c / cell~e.8
                  :location (s / sheet~e.13
                        :mod (m / multipotent~e.11)
                        :mod (e2 / epithelium~e.12))
                  :mod (c2 / certain~e.7))
            :ARG1 (t2 / thing~e.15
                  :ARG1-of~e.15 (s2 / signal-07~e.15))
            :ARG2 (c4 / cell~e.8
                  :ARG1-of~e.16 (n / neighbor-01~e.18
                        :ARG1~e.17 c~e.17)))
      :op2 (d / develop-02~e.20
            :ARG1~e.21 (s3 / structure~e.24
                  :mod (b / bud~e.23))
            :ARG2 c)
      :subevent-of (t / theme~e.3
            :mod (c3 / common~e.2)
            :purpose (g / genesis
                  :mod (o / organ))))

# ::tok Using hair bud morphogenesis as a paradigm , we employed mutant mouse models and cultured keratinocytes to dissect the contributions of multiple extracellular cues in orchestrating adhesion dynamics and proliferation to shape the cluster of cells involved .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3.r 0-1.4 1-1.4.1.1.1 2-1.4.1.1 3-1.4.1 4-1.4.2.r 6-1.4.2 8-1.1 9-1 10-1.2.1.2 11-1.2.1.1 12-1.2.1 13-1.2 14-1.2.2.2 17-1.3 19-1.3.2 20-1.3.2.1.r 21-1.3.2.1.2 22-1.3.2.1.1 23-1.3.2.1 24-1.3.2.2.r 25-1.3.2.2 27-1.3.2.2.1.1 28-1.3.2.2.1 29-1.3.2.2.1.2 31-1.3.2.2.2 33-1.3.2.2.2.2 34-1.3.2.2.2.2.1.r 35-1.3.2.2.2.2.1 36-1.3.2.2.2.2.2
# ::id pmid_1563_0473.3
# ::preferred 
(e / employ-02~e.9
      :ARG0 (w / we~e.8)
      :ARG1 (a / and~e.13
            :op1 (m / model~e.12
                  :topic (m2 / mouse~e.11)
                  :ARG1-of (m3 / mutate-01~e.10))
            :op2 (c / cell
                  :name (n / name :op1 "keratinocyte")
                  :ARG1-of (c2 / culture-01~e.14)))
      :purpose~e.0 (d / dissect-01~e.17
            :ARG0 w
            :ARG1 (c3 / contribute-01~e.19
                  :ARG0~e.20 (c6 / cue~e.23
                        :location (e3 / extracellular~e.22)
                        :quant (m4 / multiple~e.21))
                  :ARG2~e.24 (o / orchestrate-01~e.25
                        :ARG1 (a2 / and~e.28
                              :op1 (d2 / dynamic~e.27
                                    :mod (a3 / adhere-01))
                              :op2 (p / proliferate-01~e.29))
                        :purpose (s / shape-01~e.31
                              :ARG0 c6
                              :ARG1 (c4 / cluster~e.33
                                    :consist-of~e.34 (c5 / cell~e.35)
                                    :ARG1-of (i / involve-01~e.36))))))
      :manner (u / use-01~e.0
            :ARG1 (m5 / morphogenesis~e.3
                  :mod (b / bud~e.2
                        :mod (h / hair~e.1)))
            :ARG2~e.4 (p2 / paradigm~e.6)))

# ::tok We found that transforming growth factor β2 signaling is necessary to transiently induce the transcription factor Snail and activate the Ras @-@ mitogen @-@ activated protein kinase ( MAPK ) pathway in the bud .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1 2-1.2.r 3-1.2.1.1.1.1 4-1.2.1.1.1.2 5-1.2.1.1.1.3 6-1.2.1.1.1.4 7-1.2.1 9-1.2 10-1.2.2.r 11-1.2.2.1.2 11-1.2.2.1.2.r 12-1.2.2.1 14-1.2.2.1.1.2.1 15-1.2.2.1.1.2 16-1.2.2.1.1.1.1 17-1.2.2 18-1.2.2.2 20-1.2.2.2.1.1.1 22-1.2.2.2.1.1.1 24-1.2.2.2.1.1.1 25-1.2.2.2.1.1.2 26-1.2.2.2.1.1.3 30-1.2.2.2.1 31-1.2.2.2.2.r 33-1.2.2.2.2
# ::id pmid_1563_0473.4
# ::preferred 
(f / find-01~e.1
      :ARG0 (w / we~e.0)
      :ARG1~e.2 (n2 / need-01~e.9
            :ARG1 (s2 / signal-07~e.7
                  :ARG0 (p2 / protein
                        :name (n / name
                              :op1 "transforming"~e.3
                              :op2 "growth"~e.4
                              :op3 "factor"~e.5
                              :op4 "β2"~e.6)))
            :purpose~e.10 (a / and~e.17
                  :op1 (i / induce-01~e.12
                        :ARG1 (e / enzyme
                              :name (n4 / name :op1 "Snail"~e.16)
                              :mod (f2 / factor~e.15
                                    :ARG0-of (t2 / transcribe-01~e.14)))
                        :manner~e.11 (t / transient~e.11))
                  :op2 (a2 / activate-01~e.18
                        :ARG1 (p / pathway~e.30
                              :name (n3 / name
                                    :op1 "Ras-mitogen-activated"~e.20,22,24
                                    :op2 "protein"~e.25
                                    :op3 "kinase"~e.26))
                        :location~e.31 (b / bud~e.33)))))

# ::tok In the epidermis , <i> Snail </i> misexpression leads to hyperproliferation and a reduction in intercellular adhesion .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.3 5-1.1.1.1.1 8-1 11-1.2 13-1.2.2
# ::id pmid_1563_0473.5
# ::preferred 
(l / lead-03~e.8
      :ARG0 (e / express-03
            :ARG2 (e2 / enzyme
                  :name (n / name :op1 "Snail"~e.5))
            :ARG1-of (w / wrong-04))
      :ARG2 (a / and~e.11
            :op1 (p / proliferate-01
                  :degree (h / hyper))
            :op2 (r / reduce-01~e.13
                  :ARG1 (a2 / adhere-01
                        :ARG1 (c / cell)
                        :ARG2 (c2 / cell))))
      :location (e3 / epidermis~e.2))

# ::tok When <i> E @-@ cadherin </i> is transcriptionally down @-@ regulated , associated adhesion proteins with dual functions in signaling are released from cell @-@ cell contacts , a process which we demonstrate leads to Ras @-@ MAPK activation .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3.r 2-1.3.1.1.1 4-1.3.1.1.1 12-1.1.2 14-1.1 15-1.1.3.r 16-1.1.3.2 17-1.1.3 18-1.1.3.1.r 19-1.1.3.1 21-1 22-1.2.r 23-1.2.1 25-1.2.1 25-1.2.2 26-1.2 31-1.4.2.1 32-1.4.2 33-1.4 34-1.4.1.r 35-1.4.1.1.1.1 37-1.4.1.1.1.1 38-1.4.1
# ::id pmid_1563_0473.6
# ::preferred 
(r / release-01~e.21
      :ARG1 (p / proteins~e.14
            :ARG0-of (a / adhere-01)
            :ARG1-of (a2 / associate-01~e.12)
            :ARG0-of~e.15 (f / function-01~e.17
                  :ARG1~e.18 (s / signal-07~e.19)
                  :mod (d / dual~e.16)))
      :ARG2~e.22 (c / contact-01~e.26
            :ARG0 (c2 / cell~e.23,25)
            :ARG1 (c3 / cell~e.25))
      :time~e.0 (d2 / downregulate-01
            :ARG1 (p2 / protein
                  :name (n / name :op1 "E-cadherin"~e.2,4))
            :manner (t / transcribe-01))
      :ARG0-of (l / lead-03~e.33
            :ARG1~e.34 (a3 / activate-01~e.38
                  :ARG1 (p3 / pathway
                        :name (n2 / name :op1 "Ras-MAPK"~e.35,37)))
            :ARG1-of (d3 / demonstrate-01~e.32
                  :ARG0 (w / we~e.31))))

# ::tok These studies provide insights into how multipotent cells within a sheet are stimulated to undergo transcriptional changes that result in proliferation , junctional remodeling , and bud formation .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1 2-1 3-1.2 4-1.2.1.r 5-1.2.1.1.r 6-1.2.1.1.1.1 7-1.2.1.1.1 10-1.2.1.1.1.2 12-1.2.1.1 14-1.2.1.1.2 16-1.2.1.1.2.2 18-1.2.1.1.2.2.2 19-1.2.1.1.2.2.2.1.r 20-1.2.1.1.2.2.2.1.1 23-1.2.1.1.2.2.2.1.2 25-1.2.1.1.2.2.2.1 26-1.2.1.1.2.2.2.1.3.1 27-1.2.1.1.2.2.2.1.3
# ::id pmid_1563_0473.7
# ::preferred 
(p / provide-01~e.2
      :ARG0 (s / study~e.1
            :mod (t / this~e.0))
      :ARG1 (i / insight~e.3
            :topic~e.4 (t3 / thing
                  :manner-of~e.5 (s2 / stimulate-01~e.12
                        :ARG1 (c / cell~e.7
                              :mod (m2 / multipotent~e.6)
                              :location (s3 / sheet~e.10))
                        :purpose (u / undergo-01~e.14
                              :ARG1 c
                              :ARG2 (c2 / change-01~e.16
                                    :ARG1 (t2 / transcribe-01)
                                    :ARG1-of (r / result-01~e.18
                                          :ARG2~e.19 (a / and~e.25
                                                :op1 (p2 / proliferate-01~e.20
                                                      :ARG0 c)
                                                :op2 (r2 / remodel-01~e.23
                                                      :ARG1 c
                                                      :mod (j / junction))
                                                :op3 (f / form-01~e.27
                                                      :ARG1 (b / bud~e.26))))))))))

# ::tok This novel signaling pathway further weaves together the web of different morphogens and downstream transcriptional events that guide hair bud formation within the developing skin .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.3 1-1.1.2 2-1.1.1 3-1.1 4-1.3 5-1 8-1.2 9-1.2.1.r 10-1.2.1.1 10-1.2.1.1.2 10-1.2.1.1.2.r 12-1.2.1 13-1.2.1.2.2 15-1.2.1.2 17-1.2.1.3 18-1.2.1.3.1.1.1 19-1.2.1.3.1.1 20-1.2.1.3.1 23-1.2.1.3.1.2.1 24-1.2.1.3.1.2
# ::id pmid_1563_0473.8
# ::preferred 
(w / weave-01~e.5
      :ARG0 (p / pathway~e.3
            :ARG0-of (s / signal-07~e.2)
            :mod (n / novel~e.1)
            :mod (t / this~e.0))
      :ARG1 (w2 / web~e.8
            :consist-of~e.9 (a / and~e.12
                  :op1 (s2 / small-molecule~e.10
                        :name (n2 / name :op1 "morphogen")
                        :ARG1-of~e.10 (d / differ-02~e.10))
                  :op2 (e / event~e.15
                        :mod (t2 / transcribe-01)
                        :location (d2 / downstream~e.13))
                  :ARG0-of (g / guide-01~e.17
                        :ARG1 (f2 / form-01~e.20
                              :ARG1 (b / bud~e.19
                                    :mod (h / hair~e.18))
                              :location (s3 / skin~e.24
                                    :ARG1-of (d3 / develop-02~e.23))))))
      :degree (f / further~e.4))

# ::tok The study of hair follicle morphogenesis provides insights into how cells within a sheet can be triggered to proliferate , remodel , and form buds - a recurring theme in development
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1 2-1.1.1.r 3-1.1.1.1.1 4-1.1.1.1 5-1.1.1 6-1 7-1.2 8-1.2.1.r 9-1.2.1.1.r 10-1.2.1.1.1.1 13-1.2.1.1.1.1.2 14-1.2.1.1 15-1.2.1.1.1.r 16-1.2.1.1.1 17-1.2.1.1.1.1.1.r 18-1.2.1.1.1.1.1.1 20-1.2.1.1.1.1.1.2 22-1.2.1.1.1.1.1 23-1.2.1.1.1.1.1.3 24-1.2.1.1.1.1.1.3.2 27-1.2.1.1.1.1.1.4.1.1 28-1.2.1.1.1.1.1.4.1 29-1.2.1.1.1.1.1.4.1.2.r 30-1.2.1.1.1.1.1.4.1.2
# ::id pmid_1563_0473.9
# ::preferred 
(p / provide-01~e.6
      :ARG0 (s / study-01~e.1
            :ARG1~e.2 (m / morphogenesis~e.5
                  :mod (f / follicle~e.4
                        :mod (h / hair~e.3))))
      :ARG1 (i / insight~e.7
            :topic~e.8 (t / thing
                  :manner-of~e.9 (p2 / possible~e.14
                        :domain~e.15 (t4 / trigger-01~e.16
                              :ARG1 (c / cell~e.10
                                    :purpose~e.17 (a / and~e.22
                                          :op1 (p3 / proliferate-01~e.18
                                                :ARG0 t4)
                                          :op2 (r / remodel-01~e.20
                                                :ARG1 t4)
                                          :op3 (f2 / form-01~e.23
                                                :ARG0 t4
                                                :ARG1 (b / bud~e.24))
                                          :ARG1-of (m2 / mean-01
                                                :ARG2 (t3 / theme~e.28
                                                      :ARG0-of (r2 / recur-01~e.27)
                                                      :subevent-of~e.29 (d / develop-02~e.30))))
                                    :location (s2 / sheet~e.13)))))))

# ::tok Introduction
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1
# ::id pmid_1563_0473.10
# ::preferred 
(i / introduce-01~e.0)

# ::tok Mammalian development involves the morphogenesis of complex three @-@ dimensional structures from seemingly uniform sheets or masses of cells .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1 2-1 4-1.2 5-1.2.1.r 6-1.2.1.1 7-1.2.1.2.1 9-1.2.1.2 10-1.2.1 11-1.2.2.r 12-1.2.2.3.1 13-1.2.2.3 14-1.2.2.1 15-1.2.2 16-1.2.2.2 18-1.2.2.4
# ::id pmid_1563_0473.11
# ::preferred 
(i / involve-01~e.2
      :ARG0 (d / develop-02~e.1
            :ARG1 (m / mammal))
      :ARG1 (m2 / morphogenesis~e.4
            :mod~e.5 (s / structure~e.10
                  :mod (c / complex~e.6)
                  :mod (d2 / dimension~e.9 :quant "3"~e.7))
            :source~e.11 (o / or~e.15
                  :op1 (s2 / sheet~e.14)
                  :op2 (m3 / mass~e.16)
                  :mod (u / uniform~e.13
                        :ARG1-of (s3 / seem-01~e.12))
                  :consist-of (c2 / cell~e.18))))

# ::tok A simple bud @-@ like structure initiates the formation of many organs , including lungs , spinal cord , mammary glands , and hair follicles [ @<xref ref-type="bibr" rid="pbio-0030011-b01"> 1 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.2 2-1.1.1.1 4-1.1.1 5-1.1 6-1 8-1.2 9-1.2.1.r 10-1.2.1.1 11-1.2.1 13-1.2.1.2 14-1.2.1.2.1.1 17-1.2.1.2.1.2 20-1.2.1.2.1.3 22-1.2.1.2.1 23-1.2.1.2.1.4.1 24-1.2.1.2.1.4 29-1.3.1.1.1
# ::id pmid_1563_0473.12
# ::preferred 
(i / initiate-01~e.6
      :ARG0 (s / structure~e.5
            :ARG1-of (r / resemble-01~e.4
                  :ARG2 (b / bud~e.2))
            :mod (s2 / simple~e.1))
      :ARG1 (f / form-01~e.8
            :ARG1~e.9 (o / organ~e.11
                  :quant (m / many~e.10)
                  :ARG2-of (i2 / include-01~e.13
                        :ARG1 (a / and~e.22
                              :op1 (l / lung~e.14)
                              :op2 (c / cord~e.17
                                    :mod (s3 / spine))
                              :op3 (g / gland~e.20
                                    :source (b2 / breast))
                              :op4 (f2 / follicle~e.24
                                    :mod (h / hair~e.23))))))
      :ARG1-of (d / describe-01
            :ARG0 (p / publication-91
                  :ARG1-of (c2 / cite-01 :ARG2 "1"~e.29))))

# ::tok The multipotent , adhering epithelial cells are typically attached to an underlying basal lamina that polarizes the epithelial sheet and separates it from surrounding mesenchyme .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.2 3-1.1.3 4-1.1.1 5-1.1 7-1.3 8-1 12-1.2.2 13-1.2 15-1.2.3 17-1.2.3.1.1 18-1.2.3.1 20-1.2.4 22-1.2.4.2.r 23-1.2.4.2.1 24-1.2.4.2
# ::id pmid_1563_0473.13
# ::preferred 
(a / attach-01~e.8
      :ARG1 (c / cell~e.5
            :part-of (e / epithelium~e.4)
            :mod (m / multipotent~e.1)
            :ARG1-of (a2 / adhere-01~e.3))
      :ARG2 (l / lamina~e.13
            :ARG0-of (u / underlay-01
                  :ARG1 c)
            :mod (b / basal~e.12)
            :ARG0-of (p / polarize-01~e.15
                  :ARG1 (s / sheet~e.18
                        :mod e~e.17))
            :ARG0-of (s2 / separate-01~e.20
                  :ARG1 s
                  :ARG2~e.22 (m2 / mesenchyme~e.24
                        :ARG1-of (s3 / surround-01~e.23
                              :ARG2 s))))
      :mod (t / typical~e.7))

# ::tok Budding morphogenesis is guided by a reciprocal exchange of signals between epithelium and mesenchyme to specify the identity of the organ that will form and to govern its growth .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.1 1-1.2 3-1 4-1.1.r 6-1.1.4 7-1.1 8-1.1.2.r 9-1.1.2 9-1.1.2.1 9-1.1.2.1.r 11-1.1.1 13-1.1.3 14-1.3.r 15-1.3.1 17-1.3.1.1 18-1.3.1.1.1.r 20-1.3.1.1.1 23-1.3.1.1.1.1 24-1.3 26-1.3.2 27-1.3.2.1.1 27-1.3.2.1.1.r 28-1.3.2.1
# ::id pmid_1563_0473.14
# ::preferred 
(g / guide-01~e.3
      :ARG0~e.4 (e / exchange-01~e.7
            :ARG0 (e2 / epithelium~e.11)
            :ARG1~e.8 (t / thing~e.9
                  :ARG0-of~e.9 (s / signal-07~e.9))
            :ARG2 (m2 / mesenchyme~e.13)
            :mod (r / reciprocal~e.6))
      :ARG1 (m / morphogenesis~e.1
            :ARG1-of (b / bud-01~e.0))
      :purpose~e.14 (a / and~e.24
            :op1 (s2 / specify-01~e.15
                  :ARG1 (i / identity~e.17
                        :mod~e.18 (o / organ~e.20
                              :ARG1-of (f / form-01~e.23))))
            :op2 (g2 / govern-01~e.26
                  :ARG1 (g3 / grow-01~e.28
                        :ARG1~e.27 o~e.27))))

# ::tok At the helm of these molecular communication pathways are Wnts , bone morphogenic proteins ( BMPs ) , transforming growth factor βs ( TGF-βs ) , and fibroblast growth factors ( FGFs ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 2-1.2 4-1.2.1.1.1 5-1.2.1.1.2.1 6-1.2.1.1.2 7-1.2.1.1 8-1 11-1.1.2.1.1 12-1.1.2.1.2 13-1.1.2.1.3 18-1.1.3.1.1 19-1.1.3.1.2 19-1.1.4.1.2 20-1.1.3.1.3 20-1.1.4.1.3 26-1.1 27-1.1.4.1.1 28-1.1.3.1.2 28-1.1.4.1.2 29-1.1.3.1.3 29-1.1.4.1.3
# ::id pmid_1563_0473.15
# ::preferred 
(b / be-located-at-91~e.0,8
      :ARG1 (a / and~e.26
            :op1 (p / pathway
                  :name (n2 / name :op1 "Wnt"))
            :op2 (p2 / protein
                  :name (n / name
                        :op1 "bone"~e.11
                        :op2 "morphogenic"~e.12
                        :op3 "protein"~e.13))
            :op3 (s / small-molecule
                  :name (n3 / name
                        :op1 "transforming"~e.18
                        :op2 "growth"~e.19,28
                        :op3 "factor"~e.20,29
                        :op4 "β"))
            :op4 (s2 / small-molecule
                  :name (n4 / name
                        :op1 "fibroblast"~e.27
                        :op2 "growth"~e.19,28
                        :op3 "factor"~e.20,29)))
      :ARG2 (h / helm~e.2
            :location (r / relative-position
                  :op1 (p3 / pathway~e.7
                        :mod (t / this~e.4)
                        :path-of (c / communication~e.6
                              :mod (m / molecule~e.5))))))

# ::tok Through activation of cell surface transmembrane receptors , these external signaling molecules trigger distinct cascades of intracellular events that culminate in changes in gene expression , growth , and differentiation [ @<xref ref-type="bibr" rid="pbio-0030011-b02"> 2 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3 3-1.2.1.1 3-1.3.1.2.1 4-1.3.1.2 5-1.3.1.1 6-1.3.1 8-1.1.1 9-1.1.2 10-1.1.3 11-1.1 12-1 13-1.2.2 14-1.2 17-1.2.1 19-1.2.3 20-1.2.3.1.r 21-1.2.3.1 22-1.2.3.1.1.r 23-1.2.3.1.1.1.1 24-1.2.3.1.1.1 26-1.2.3.1.1.2 28-1.2.3.1.1 29-1.2.3.1.1.3 34-1.4.1.1.1
# ::id pmid_1563_0473.16
# ::preferred 
(t / trigger-01~e.12
      :ARG0 (m / molecule~e.11
            :mod (t2 / this~e.8)
            :mod (e / external~e.9)
            :ARG0-of (s / signal-07~e.10))
      :ARG1 (c / cascade~e.14
            :consist-of (e2 / event~e.17
                  :location (c2 / cell~e.3))
            :mod (d / distinct~e.13)
            :ARG1-of (c3 / culminate-01~e.19
                  :ARG2~e.20 (c4 / change-01~e.21
                        :ARG1~e.22 (a / and~e.28
                              :op1 (e3 / express-03~e.24
                                    :ARG1 (g / gene~e.23))
                              :op2 (g2 / grow-01~e.26
                                    :ARG1 c2)
                              :op3 (d2 / differentiate-01~e.29
                                    :ARG1 c2)))))
      :ARG2 (a2 / activate-01~e.1
            :ARG1 (r / receptor~e.6
                  :mod (t3 / transmembrane~e.5)
                  :location (s2 / surface~e.4
                        :poss (c5 / cell~e.3))))
      :ARG1-of (d3 / describe-01
            :ARG0 (p / publication-91
                  :ARG1-of (c6 / cite-01 :ARG2 "2"~e.34))))

# ::tok How this constellation of signals collaborates in tailoring each budding process so that it executes a distinct morphogenetic program has yet to be comprehensively defined .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1.r 0-1.1.2.r 1-1.1.1.1.1.2 2-1.1.1.1.1 3-1.1.1.1.1.1.r 4-1.1.1.1.1.1 4-1.1.1.1.1.1.1 4-1.1.1.1.1.1.1.r 5-1.1.1.1 6-1.1.1.1.2.r 7-1.1.1.1.2 8-1.1.1.1.2.1.2 9-1.1.1.1.2.1.1 10-1.1.1.1.2.1 11-1.1.1.1.3.r 12-1.1.1.1.3.r 13-1.1.1.1.3.1 14-1.1.1.1.3 16-1.1.1.1.3.2.2 18-1.1.1.1.3.2 20-1.2 23-1.1.2 24-1.1
# ::id pmid_1563_0473.17
# ::preferred 
(n / need-01
      :ARG1 (d / define-01~e.24
            :ARG1 (t / thing
                  :manner-of~e.0 (c2 / collaborate-01~e.5
                        :ARG0 (c3 / constellation~e.2
                              :consist-of~e.3 (t3 / thing~e.4
                                    :ARG1-of~e.4 (s / signal-07~e.4))
                              :mod (t4 / this~e.1))
                        :ARG2~e.6 (t2 / tailor-01~e.7
                              :ARG1 (p / process~e.10
                                    :ARG1-of (b / bud-01~e.9)
                                    :mod (e / each~e.8)))
                        :purpose~e.11,12 (e2 / execute-02~e.14
                              :ARG0 p~e.13
                              :ARG1 (p2 / program~e.18
                                    :topic (m / morphogenesis)
                                    :mod (d2 / distinct~e.16)))))
            :manner~e.0 (c / comprehensive~e.23))
      :mod (y / yet~e.20))

# ::tok However , the process appears to be patterned at the initial stages of bud formation , since the relative importance of these pathways and their downstream effectors differ as buds begin to develop and cell fates are specified .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 3-1.1.1 4-1.1 5-1.1.2 7-1.1.1.1 10-1.1.1.1.1.1 11-1.1.1.1.1 12-1.1.1.1.1.2.r 13-1.1.1.1.1.2.1 14-1.1.1.1.1.2 16-1.1.2 18-1.1.2.1.1.1.1 19-1.1.2.1.1.1 20-1.1.2.1.1.1.2.r 21-1.1.2.1.1.1.2.1 22-1.1.2.1.1.1.2 23-1.1.2.1.1 24-1.1.2.1.1.2.2 24-1.1.2.1.1.2.2.r 25-1.1.2.1.1.2.1 26-1.1.2.1.1.2 27-1.1.2.1 28-1.1.1.1.1.r 28-1.1.2.1.2.r 29-1.1.2.1.2.1.1 30-1.1.2.1.2.1 32-1.1.2.1.2.1.2 33-1.1.2.1.2 34-1.1.2.1.2.2.1.1 35-1.1.2.1.2.2.1 37-1.1.2.1.2.2
# ::id pmid_1563_0473.18
# ::preferred 
(c / contrast-01~e.0
      :ARG2 (a / appear-02~e.4
            :ARG1 (p / process~e.3
                  :ARG1-of (p2 / pattern-01~e.7
                        :time~e.28 (s / stage~e.11
                              :mod (i / initial~e.10)
                              :subevent-of~e.12 (f / form-01~e.14
                                    :ARG1 (b / bud~e.13)))))
            :ARG1-of (c2 / cause-01~e.5,16
                  :ARG0 (d / differ-02~e.27
                        :ARG1 (a2 / and~e.23
                              :op1 (i2 / importance~e.19
                                    :mod (r / relative~e.18)
                                    :poss~e.20 (p3 / pathway~e.22
                                          :mod (t / this~e.21)))
                              :op2 (e / effector~e.26
                                    :location (d2 / downstream~e.25)
                                    :poss~e.24 p3~e.24))
                        :condition~e.28 (a3 / and~e.33
                              :op1 (b2 / begin-01~e.30
                                    :ARG0 b~e.29
                                    :ARG1 (d3 / develop-02~e.32))
                              :op2 (s2 / specify-01~e.37
                                    :ARG1 (f2 / fate-01~e.35
                                          :ARG1 (c3 / cell~e.34))))))))

# ::tok The development of a bud requires a number of coordinated changes in the behavior of the targeted cells within an epithelial sheet .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1 2-1.1.1.r 4-1.1.1 5-1 7-1.2.2 8-1.2.2.r 9-1.2.3 10-1.2 11-1.2.1.r 13-1.2.1 14-1.2.1.1.r 16-1.2.1.1.1 17-1.2.1.1 20-1.2.1.1.2.1 21-1.2.1.1.2
# ::id pmid_1563_0473.19
# ::preferred 
(r / require-01~e.5
      :ARG0 (d / develop-02~e.1
            :ARG1~e.2 (b / bud~e.4))
      :ARG1 (c / change-01~e.10
            :ARG1~e.11 (b2 / behave-01~e.13
                  :ARG0~e.14 (c3 / cell~e.17
                        :ARG1-of (t / target-01~e.16)
                        :location (s / sheet~e.21
                              :mod (e / epithelium~e.20))))
            :quant~e.8 (n / number~e.7)
            :ARG1-of (c2 / coordinate-01~e.9)))

# ::tok The process must be accompanied by alterations in the proliferation , polarity , shape , and adhesiveness of selected cells , as well as by modifications in their underlying basal lamina .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.2 2-1 4-1.1 5-1.1.1.r 6-1.1.1.1 7-1.1.1.1.1.r 9-1.1.1.1.1.1 11-1.1.1.1.1.2 13-1.1.1.1.1.3 15-1.1.1.1.1 17-1.1.1.1.1.1.1.r 18-1.1.1.1.1.1.1.1 19-1.1.1.1.1.1.1 25-1.1.1.2 30-1.1.1.2.1
# ::id pmid_1563_0473.20
# ::preferred 
(o / obligate-01~e.2
      :ARG2 (a / accompany-01~e.4
            :ARG0~e.5 (a5 / and
                  :op1 (a2 / alter-01~e.6
                        :ARG1~e.7 (a3 / and~e.15
                              :op1 (p2 / proliferate-01~e.9
                                    :ARG0~e.17 (c / cell~e.19
                                          :ARG1-of (s2 / select-01~e.18)))
                              :op2 (p3 / polarity~e.11
                                    :poss c)
                              :op3 (s / shape~e.13
                                    :poss c)
                              :op4 (c2 / capable-01
                                    :ARG1 c
                                    :ARG2 (a4 / adhere-01))))
                  :op2 (m / modify-01~e.25
                        :ARG1 (l / lamina~e.30
                              :ARG0-of (u / underlay-01
                                    :ARG1 c)
                              :mod (b / base))))
            :ARG1 (p / process~e.1)))

# ::tok Thus , extracellular epithelial @-@ mesenchymal crosstalk must be intricately orchestrated to couple the determination of distinct cell fates with the contemporaneous remodeling of the physical and structural properties of the cell .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1.1.1.1 3-1.1.1.1.2.1 6-1.1.1.1 7-1 7-1.1 7-1.1.r 9-1.1.1.2 9-1.1.1.2.r 10-1.1.1 12-1.1.1.3 14-1.1.1.3.1 15-1.1.1.3.1.1.r 16-1.1.1.3.1.1.2 17-1.1.1.3.1.1.1 18-1.1.1.3.1.1 19-1.1.1.3.2.r 21-1.1.1.3.2.2 22-1.1.1.3.2 23-1.1.1.3.2.1.r 25-1.1.1.3.2.1.1.1 26-1.1.1.3.2.1 27-1.1.1.3.2.1.2.1 28-1.1.1.3.2.1.1 28-1.1.1.3.2.1.2 31-1.1.1.3.1.1.1
# ::id pmid_1563_0473.21
# ::preferred 
(i / infer-01~e.7
      :ARG1~e.7 (o / obligate-01~e.7
            :ARG2 (o2 / orchestrate-01~e.10
                  :ARG1 (c / crosstalk~e.6
                        :mod (e / extracellular~e.2)
                        :location (b / between
                              :op1 (e2 / epithelium~e.3)
                              :op2 (m / mesenchyme)))
                  :manner~e.9 (i2 / intricate~e.9)
                  :purpose (c2 / couple-01~e.12
                        :ARG1 (d / determine-01~e.14
                              :ARG1~e.15 (f / fate-01~e.18
                                    :ARG1 (c3 / cell~e.17,31)
                                    :mod (d2 / distinct~e.16)))
                        :ARG2~e.19 (r / remodel-01~e.22
                              :ARG1~e.23 (a / and~e.26
                                    :op1 (p / property~e.28
                                          :mod (p2 / physical~e.25)
                                          :poss c3)
                                    :op2 (p3 / property~e.28
                                          :mod (s / structure~e.27)
                                          :poss c3))
                              :mod (c4 / contemporaneous~e.21))))))

# ::tok Among the few dispensable organs , hair follicles offer an excellent model system to study epithelial bud formation .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2 2-1.1.2.1.1 3-1.1.2.1.2 4-1.1.2.1 6-1.1.1 7-1.1 8-1 10-1.2.2 11-1.2.1 12-1.2 14-1.3 15-1.3.1.2 16-1.3.1.1 17-1.3.1
# ::id pmid_1563_0473.22
# ::preferred 
(o / offer-01~e.8
      :ARG0 (f / follicle~e.7
            :mod (h / hair~e.6)
            :ARG1-of (i / include-91~e.0
                  :ARG2 (o2 / organ~e.4
                        :quant (f3 / few~e.2)
                        :mod (d / dispensable~e.3))))
      :ARG1 (s / system~e.12
            :mod (m / model~e.11)
            :mod (e / excellent~e.10))
      :purpose (s2 / study-01~e.14
            :ARG1 (f2 / form-01~e.17
                  :ARG1 (b / bud~e.16)
                  :location (e2 / epithelium~e.15))))

# ::tok Mammalian skin epithelium begins as a single sheet of multipotent ectodermal cells .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1 2-1.1 3-1 7-1.2 8-1.2.2.r 9-1.2.2.1 10-1.2.2.2 11-1.2.2
# ::id pmid_1563_0473.23
# ::preferred 
(b / begin-01~e.3
      :ARG1 (e / epithelium~e.2
            :part-of (s / skin~e.1
                  :part-of (m / mammal)))
      :ARG2 (s2 / sheet~e.7
            :quant "1"
            :consist-of~e.8 (c / cell~e.11
                  :mod (m2 / multipotent~e.9)
                  :part-of (e2 / ectoderm~e.10))))

# ::tok During development , specialized mesenchymal cells populate the skin in a spatially defined pattern to initiate the complex epithelial @-@ mesenchymal crosstalk that will specify the bud [ @<xref ref-type="bibr" rid="pbio-0030011-b03"> 3 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.6.r 1-1.6 3-1.2.2 5-1.2 6-1 8-1.1 9-1.3.r 11-1.3.1.1 12-1.3.1 13-1.3 15-1.4 17-1.4.2.1 18-1.4.2.2.1 21-1.4.2 24-1.4.2.3 26-1.4.2.3.1 31-1.5.1.1.1
# ::id pmid_1563_0473.24
# ::preferred 
(p / populate-01~e.6
      :ARG1 (s2 / skin~e.8)
      :ARG2 (c / cell~e.5
            :part-of (m / mesenchyme)
            :ARG0-of (s / specialize-01~e.3))
      :manner~e.9 (p2 / pattern~e.13
            :ARG1-of (d / define-01~e.12
                  :mod (s3 / space~e.11)))
      :purpose (i / initiate-01~e.15
            :ARG0 c
            :ARG1 (c2 / crosstalk~e.21
                  :mod (c3 / complex~e.17)
                  :location (b / between
                        :op1 (e / epithelium~e.18)
                        :op2 m)
                  :ARG0-of (s4 / specify-01~e.24
                        :ARG1 (b2 / bud-01~e.26))))
      :ARG1-of (d2 / describe-01
            :ARG0 (p3 / publication-91
                  :ARG1-of (c4 / cite-01 :ARG2 "3"~e.31)))
      :time~e.0 (d3 / develop-02~e.1))

# ::tok Once committed , a small cluster of epithelial cells , the placode , instructs a group of underlying mesenchymal cells to condense and form the nascent dermal papilla , which will be a permanent fixture of the hair follicle .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.4.1 4-1.1.2 5-1.1 6-1.1.1.r 7-1.1.1.1 8-1.1.1 11-1.1.3.1 13-1 15-1.2 19-1.2.1 20-1.3.r 21-1.3.1 22-1.3 23-1.3.2 26-1.3.2.2.1 27-1.3.2.2 33-1.3.2.2.3.2 37-1.3.2.2.3.1.1 38-1.3.2.2.3.1
# ::id pmid_1563_0473.25
# ::preferred 
(i / instruct-01~e.13
      :ARG0 (c / cluster-01~e.5
            :ARG1~e.6 (c2 / cell~e.8
                  :part-of (e / epithelium~e.7))
            :mod (s / small~e.4)
            :ARG1-of (m2 / mean-01
                  :ARG2 (p3 / placode~e.11)))
      :ARG1 (g / group~e.15
            :consist-of (c3 / cell~e.19
                  :part-of (m / mesenchyme)
                  :ARG0-of (u / underlay-01)))
      :ARG2~e.20 (a / and~e.22
            :op1 (c4 / condense-01~e.21
                  :ARG1 c3)
            :op2 (f / form-01~e.23
                  :ARG0 c3
                  :ARG1 (p / papilla~e.27
                        :part-of (d / dermis~e.26)
                        :ARG1-of (b / birth-01)
                        :ARG0-of (f2 / fix-03
                              :ARG1 (f3 / follicle~e.38
                                    :mod (h / hair~e.37))
                              :manner (p2 / permanent~e.33)))))
      :time (a2 / after
            :op1 (c5 / commit-01~e.1
                  :ARG1 c)))

# ::tok Subsequent exchanges between the placode and nascent dermal papilla result in further growth of the follicle into the underlying dermis , or down @-@ growth , and eventual differentiation into the six concentric layers of the mature follicle .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.3 0-1.1.3.r 1-1.1 4-1.1.1 5-1.2 7-1.1.2.2 8-1.1.2 9-1 10-1.2.r 11-1.2.1.1.2 12-1.2.1.1 13-1.2.1.1.1.r 15-1.2.1.1.1 19-1.2.1.1.3 21-1.2.1 22-1.2.1.2.2 24-1.2.1.2 26-1.2 27-1.2.2.3 28-1.2.2 29-1.2.2.2.r 31-1.2.2.2.1 32-1.2.2.2.2 33-1.2.2.2 34-1.2.2.2.3.r 36-1.2.2.2.3.1 37-1.2.2.2.3
# ::id pmid_1563_0473.26
# ::preferred 
(r / result-01~e.9
      :ARG1 (e / exchange-01~e.1
            :ARG0 (p / placode~e.4)
            :ARG2 (p2 / papilla~e.8
                  :ARG1-of (b / birth-01)
                  :part-of d~e.7)
            :time~e.0 (s / subsequent~e.0))
      :ARG2~e.10 (a / and~e.5,26
            :op1 (o / or~e.21
                  :op1 (g / grow-01~e.12
                        :ARG1~e.13 (f2 / follicle~e.15)
                        :ARG2 (f / further~e.11)
                        :direction (d / dermis~e.19
                              :ARG0-of (u5 / underlay-01)))
                  :op2 (g2 / grow-01~e.24
                        :ARG1 f2
                        :ARG2 (d2 / down~e.22)))
            :op2 (d3 / differentiate-01~e.28
                  :ARG1 f2
                  :direction~e.29 (l / layer~e.33
                        :quant "6"~e.31
                        :mod (c / concentric~e.32)
                        :part-of~e.34 (f3 / follicle~e.37
                              :ARG1-of (m / mature-01~e.36)))
                  :time (e2 / eventual~e.27))))

# ::tok Previously , we delineated how two respective epithelial and mesenchymal signals , Wnts and the BMP @-@ inhibitory factor noggin , function in concert to induce lymphoid enhancer factor @-@ 1/β-catenin ( LEF @-@ 1/β-catenin )-mediated gene transcription within the follicle placode [ @<xref ref-type="bibr" rid="pbio-0030011-b04"> 4 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3 2-1.1 3-1 4-1.2.1.2.r 4-1.2.1.r 5-1.2.1.3.1 6-1.2.1.3.1 7-1.2.1.3.1 8-1.2.1.3.1 9-1.2.1.3.1 10-1.2.1.3.1 11-1.2.1.3.1 12-1.2.1.3.1 13-1.2.1.3.1 14-1.2.1.3.1 15-1.2.1.3.1 18-1.2.1.3.2.2.1.1.3 19-1.2.1.1.3.1.2.1.1 21-1.2.1 22-1.2.1.2 23-1.2.1.2 25-1.2.1.3 26-1.2.1.3.2.2.1.1.1 27-1.2.1.3.2.2.1.1.2 28-1.2.1.3.2.2.1.1.3 36-1.2.1.3.2.1 37-1.2.1.3.2 40-1.2.1.3.2.3.1 41-1.2.1.3.2.3 46-1.4.1.1.1
# ::id pmid_1563_0473.27
# ::preferred 
(d / delineate-01~e.3
      :ARG0 (w / we~e.2)
      :ARG1 (t / thing
            :manner-of~e.4 (f / function-01~e.21
                  :ARG0 (t3 / thing
                        :quant "2"
                        :ARG1-of (s / signal-07)
                        :ARG1-of (m / mean-01
                              :ARG2 (a / and
                                    :op1 (p5 / pathway
                                          :name (n2 / name :op1 "Wnt")
                                          :source (e / epithelium))
                                    :op2 (p / protein
                                          :name (n3 / name :op1 "noggin"~e.19)
                                          :ARG0-of (i2 / inhibit-01
                                                :ARG1 (p6 / protein
                                                      :name (n4 / name :op1 "BMP")))
                                          :source (m3 / mesenchyme)))
                              :manner (r / respective)))
                  :manner~e.4 (i3 / in-concert~e.22,23)
                  :purpose (i / induce-01~e.25
                        :ARG0 t3~e.5,6,7,8,9,10,11,12,13,14,15
                        :ARG1 (t2 / transcribe-01~e.37
                              :ARG1 (g / gene~e.36)
                              :ARG1-of (m2 / mediate-01
                                    :ARG0 (p7 / pathway
                                          :name (n5 / name
                                                :op1 "lymphoid"~e.26
                                                :op2 "enhancer"~e.27
                                                :op3 "factor-1/β-catenin"~e.18,28)))
                              :location (p2 / placode~e.41
                                    :part-of (f2 / follicle~e.40))))))
      :time (p3 / previous~e.0)
      :ARG1-of (d2 / describe-01
            :ARG0 (p4 / publication-91
                  :ARG1-of (c2 / cite-01 :ARG2 "4"~e.46))))

# ::tok The downstream changes elicited through convergence of these two early signaling pathways include down @-@ regulation of the gene encoding E @-@ cadherin , the prototypical epithelial cadherin that forms the transmembrane core of intercellular adherens junctions ( AJs ) [ @<xref ref-type="bibr" rid="pbio-0030011-b05"> 5 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.2.1 2-1.2 3-1.2.2 5-1.2.2.1 6-1.2.2.1.1.r 7-1.2.2.1.1.2 8-1.2.2.1.1.1 9-1.2.2.1.1.3 10-1.2.2.1.1.4 11-1.2.2.1.1 12-1 18-1.1.1 19-1.1.1.1 20-1.1.1.1.1.1.1 22-1.1.1.1.1.2.1.1.1 26-1.1.1.1.1.2.1.2 27-1.1.1.1.1.2.1.1.1 29-1.1.1.1.1.2.1 29-1.1.1.1.1.2.1.4 29-1.1.1.1.1.2.1.4.r 31-1.1.1.1.1.2.1.4.1.1 32-1.1.1.1.1.2.1.4.1 33-1.1.1.1.1.2.1.4.1.2.r 34-1.1.1.1.1.2.1.4.1.2.2 35-1.1.1.1.1.2.1.4.1.2.1.1 36-1.1.1.1.1.2.1.4.1.2.1.2 44-1.3.1.1.1
# ::id pmid_1563_0473.28
# ::preferred 
(i / include-01~e.12
      :ARG1 (d / downregulate-01
            :ARG1 (g / gene~e.18
                  :ARG0-of (e3 / encode-01~e.19
                        :ARG1 (p2 / protein
                              :name (n / name :op1 "E-cadherin"~e.20)
                              :ARG1-of (m / mean-01
                                    :ARG2 (p4 / protein~e.29
                                          :name (n2 / name :op1 "cadherin"~e.22,27)
                                          :location (e4 / epithelium~e.26)
                                          :mod (p3 / prototype)
                                          :ARG0-of~e.29 (f / form-01~e.29
                                                :ARG1 (c3 / core~e.32
                                                      :mod (t2 / transmembrane~e.31)
                                                      :part-of~e.33 (m3 / macro-molecular-complex
                                                            :name (n4 / name :op1 "adherens"~e.35 :op2 "junction"~e.36)
                                                            :location (i2 / intercellular~e.34))))))))))
      :ARG2 (c / change-01~e.2
            :location (d2 / downstream~e.1)
            :ARG1-of (e / elicit-01~e.3
                  :ARG0 (c2 / converge-01~e.5
                        :ARG0~e.6 (p / pathway~e.11
                              :quant "2"~e.8
                              :mod (t / this~e.7)
                              :time (e2 / early~e.9)
                              :ARG0-of (s / signal-07~e.10)))))
      :ARG1-of (d3 / describe-01
            :ARG0 (p5 / publication-91
                  :ARG1-of (c4 / cite-01 :ARG2 "5"~e.44))))

# ::tok We subsequently showed that when E @-@ cadherin is transgenically elevated in mouse skin , hair follicle morphogenesis is blocked , suggesting that E @-@ cadherin down @-@ regulation is a critical event in governing the adhesion dynamics necessary for budding morphogenesis [ @<xref ref-type="bibr" rid="pbio-0030011-b04"> 4 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1.3 1-1.3.r 2-1 4-1.3.r 5-1.2.3.1 6-1.2.3.1 7-1.2.3.1 8-1.2.2.1.2.r 10-1.2.3 11-1.2.3.3.r 12-1.2.3.3.1 13-1.2.3.3 15-1.2.1.1.1 16-1.2.1.1 17-1.2.1 18-1.2.2.1.2.r 19-1.2 21-1.2.2 22-1.2.2.1.r 23-1.2.2.1.2.1.1.1 25-1.2.2.1.2.1.1.1 29-1.2.2.1.2.r 31-1.2.2.1.1 32-1.2.2.1 33-1.2.2.1.3.r 34-1.2.2.1.3 37-1.2.2.1.3.1 38-1.2.2.1.3.1.2 39-1.2.2.1.3.1.2.1.r 40-1.2.2.1.3.1.2.1.1 41-1.2.2.1.3.1.2.1 46-1.4.1.1.1
# ::id pmid_1563_0473.29
# ::preferred 
(s / show-01~e.2
      :ARG0 (w / we~e.0)
      :ARG1 (b / block-01~e.19
            :ARG1 (m / morphogenesis~e.17
                  :mod (f / follicle~e.16
                        :mod (h / hair~e.15)))
            :ARG0-of (s2 / suggest-01~e.21
                  :ARG1~e.22 (e / event~e.32
                        :mod (c / critical~e.31)
                        :domain~e.8,18,29 (d / downregulate-01
                              :ARG1 (p / protein
                                    :name (n2 / name :op1 "E-cadherin"~e.23,25)))
                        :purpose~e.33 (g / govern-01~e.34
                              :ARG1 (d2 / dynamic~e.37
                                    :ARG0-of (a / adhere-01)
                                    :ARG1-of (n3 / need-01~e.38
                                          :purpose~e.39 (m2 / morphogenesis~e.41
                                                :ARG1-of (b2 / bud-01~e.40)))))))
            :time (e2 / elevate-01~e.10
                  :ARG1 p~e.5,6,7
                  :manner (t / transgenic)
                  :location~e.11 (s4 / skin~e.13
                        :part-of (m3 / mouse~e.12))))
      :time~e.1,4 (s3 / subsequent~e.1)
      :ARG1-of (d3 / describe-01
            :ARG0 (p2 / publication-91
                  :ARG1-of (c2 / cite-01 :ARG2 "4"~e.46))))

# ::tok Like LEF @-@ 1 , E @-@ cadherin also binds to β-catenin .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2 0-1.2.2 0-1.2.2.r 1-1.2.2.1.1.1 3-1.2.2.1.1.1 5-1.1.1.1 7-1.1.1.1 8-1.3 9-1 11-1.2.1.1
# ::id pmid_1563_0473.30
# ::preferred 
(b / bind-01~e.9
      :ARG1 (p3 / protein
            :name (n / name :op1 "E-cadherin"~e.5,7))
      :ARG2 (p / protein~e.0
            :name (n2 / name :op1 "β-catenin"~e.11)
            :ARG1-of~e.0 (r / resemble-01~e.0
                  :ARG2 (p2 / protein
                        :name (n3 / name :op1 "LEF-1"~e.1,3))))
      :mod (a / also~e.8))

# ::tok At sites of cell @-@ cell contact , however , E @-@ cadherin-β-catenin complexes recruit α-catenin , which in turn coordinates the associated actin polymerization dynamics necessary to stabilize nascent AJs and integrate the cytoskeleton across an epithelial sheet [ @<xref ref-type="bibr" rid="pbio-0030011-b06"> 6 </xref> , <xref ref-type="bibr" rid="pbio-0030011-b07"> 7 </xref> , <xref ref-type="bibr" rid="pbio-0030011-b08"> 8 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.3 2-1.1.3.1.r 3-1.1.3.1.1.1 5-1.1.3.1.1.1 5-1.1.3.1.1.2 6-1.1.3.1 8-1 10-1.1.1.1.1.1 13-1.1.1 14-1.1 15-1.1.2.1.1 18-1.1.4.2 19-1.1.4.2 20-1.1.4 22-1.1.4.1 23-1.1.4.1.1.1.1 24-1.1.4.1.1 24-1.1.4.1.1.2 24-1.1.4.1.1.2.r 25-1.1.4.1.1.3 26-1.1.4.1.2 27-1.1.4.1.2.1.r 28-1.1.4.1.2.1.1 29-1.1.4.1.2.1.1.1.2 31-1.1.4.1.2.1 32-1.1.4.1.2.1.2 34-1.1.4.1.2.1.2.1 35-1.1.4.1.2.1.2.2 37-1.1.4.1.2.1.2.2.1.1 38-1.1.4.1.2.1.2.2.1 43-1.2.1.1.1.1 49-1.2.1.1.1.2 55-1.2.1.1.1.3
# ::id pmid_1563_0473.31
# ::preferred 
(h / have-concession-91~e.8
      :ARG2 (r / recruit-01~e.14
            :ARG0 (m2 / macro-molecular-complex~e.13
                  :part (p7 / protein
                        :name (n / name :op1 "E-cadherin"~e.10))
                  :part (p8 / protein
                        :name (n9 / name :op1 "β-catenin")))
            :ARG1 (p / protein
                  :name (n3 / name :op1 "α-catenin"~e.15))
            :location (s / site~e.1
                  :location-of~e.2 (c3 / contact-01~e.6
                        :ARG1 (a5 / and
                              :op1 (c5 / cell~e.3,5)
                              :op2 (c6 / cell~e.5))))
            :ARG0-of (c / coordinate-01~e.20
                  :ARG1 (a / associate-01~e.22
                        :ARG1 (p3 / protein~e.24
                              :name (n4 / name :op1 "actin"~e.23)
                              :ARG1-of~e.24 (p2 / polymerize-01~e.24)
                              :mod (d / dynamic~e.25))
                        :ARG1-of (n5 / need-01~e.26
                              :ARG0~e.27 (a2 / and~e.31
                                    :op1 (s2 / stabilize-01~e.28
                                          :ARG1 (p4 / protein
                                                :name (n6 / name :op1 "AJ")
                                                :mod (n7 / nascent~e.29)))
                                    :op2 (i2 / integrate-01~e.32
                                          :ARG1 (c4 / cytoskeleton~e.34)
                                          :ARG2 (a3 / across~e.35
                                                :op1 (s3 / sheet~e.38
                                                      :consist-of (e / epithelium~e.37)))))))
                  :mod (i / in-turn~e.18,19)))
      :ARG1-of (d2 / describe-01
            :ARG0 (p6 / publication
                  :ARG1-of (c2 / cite-01
                        :ARG2 (a4 / and
                              :op1 "6"~e.43
                              :op2 "7"~e.49
                              :op3 "8"~e.55)))))

# ::tok α-Catenin also binds to the class III Lin @-@ 1 , Isl @-@ 1 , Mec @-@ 3 ( LIM ) protein Ajuba ( a member of the zyxin family of proteins ) , which appears to function dually in both adhesion and in activation of the Ras @-@ mitogen @-@ activated protein kinase ( MAPK ) pathway [ @<xref ref-type="bibr" rid="pbio-0030011-b09"> 9 </xref> , <xref ref-type="bibr" rid="pbio-0030011-b10"> 10 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 1-1.4 2-1 3-1.3.r 5-1.3.5 6-1.3.3.1.1 6-1.3.5.1.1 7-1.3.1.1.1 9-1.3.1.1.1 9-1.3.2.1.1 11-1.3.2.1.1 13-1.3.1.1.1 13-1.3.2.1.1 15-1.3.3.1.1 17-1.3.3.1.1 17-1.3.5.1.1 19-1.3.4.1.1 21-1.1 22-1.2.1.1 25-1.2.2.1 26-1.2.2.1.1.r 28-1.2.2.1.1 29-1.2.2.1.1.1 30-1.2.2.1.1.1.1.r 31-1.2.2.1.1.1.1 35-1.2.3.2 37-1.2 37-1.2.3 37-1.2.3.r 42-1.2.3.1 43-1.2.3.1.r 44-1.2.3.1.2 44-1.2.3.1.2.1.2 45-1.2.3.1.2.1.2.1.r 47-1.2.3.1.2.1.2.1.1.1.1 49-1.2.3.1.2.1.2.1.2.1.1 51-1.2.3.1.2 52-1.2.3.1.2.1.1.1 53-1.2.3.1.2.1.1.2 55-1.2.3.1.2.1.3.1.1.1 57-1.2.3.1.2.1 57-1.2.3.1.2.1.3.1 62-1.5.1.1.1.1 68-1.5.1.1.1.2
# ::id pmid_1563_0473.32
# ::preferred 
(b / bind-01~e.2
      :ARG0 (p2 / protein~e.21
            :name (n2 / name :op1 "α-Catenin"~e.0))
      :ARG1 (p5 / protein~e.37
            :name (n5 / name :op1 "Ajuba"~e.22)
            :ARG1-of (m3 / mean-01
                  :ARG2 (m / member~e.25
                        :part-of~e.26 (z / zyxin~e.28
                              :mod (f / family~e.29
                                    :mod~e.30 (p7 / protein~e.31)))))
            :ARG0-of~e.37 (f2 / function-01~e.37
                  :ARG1~e.43 (a4 / and~e.42
                        :op1 (a5 / adhere-01)
                        :op2 (a6 / activate-01~e.44,51
                              :ARG1 (p9 / pathway~e.57
                                    :name (n11 / name :op1 "protein"~e.52 :op2 "kinase"~e.53)
                                    :ARG1-of (a7 / activate-01~e.44
                                          :ARG0~e.45 (a8 / and
                                                :op1 (e / enzyme
                                                      :name (n7 / name :op1 "Ras"~e.47))
                                                :op2 (p8 / protein
                                                      :name (n8 / name :op1 "mitogen"~e.49))))
                                    :ARG1-of (m4 / mean-01
                                          :ARG2 (p / pathway~e.57
                                                :name (n / name :op1 "MAPK"~e.55))))))
                  :ARG1-of (a2 / appear-02~e.35)
                  :manner (d / dual)))
      :ARG2~e.3 (a / and
            :op1 (p3 / protein
                  :name (n3 / name :op1 "Lin-1"~e.7,9,13))
            :op2 (p4 / protein
                  :name (n4 / name :op1 "Isl-1"~e.9,11,13))
            :op3 (p6 / protein
                  :name (n6 / name :op1 "Mec-3"~e.6,15,17))
            :ARG1-of (m2 / mean-01
                  :ARG2 (n10 / name :op1 "LIM"~e.19))
            :part-of (c2 / class~e.5
                  :ord (o / ordinal-entity :value "3"~e.6,17)))
      :mod (a3 / also~e.1)
      :ARG1-of (d2 / describe-01
            :ARG0 (p10 / publication
                  :ARG1-of (c / cite-01
                        :ARG2 (a9 / and :op1 "9"~e.62 :op2 "10"~e.68)))))

# ::tok Through these links , AJs appear able to couple adhesion with cytoskeletal dynamics as well as with nuclear and cytoplasmic signaling .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1 2-1.1 5-1.2.1.4 6-1.2 8-1.2.1 12-1.2.1.3.1 16-1.2.1.3.r 17-1.2.1.3.2.1.1 18-1.2.1.3.2.1 19-1.2.1.3.2.1.2 20-1.2.1.3.2
# ::id pmid_1563_0473.33
# ::preferred 
(h / have-condition-91
      :ARG1 (l / link-01~e.2
            :mod (t / this~e.1))
      :ARG2 (p2 / possible~e.6
            :domain (c / couple-01~e.8
                  :ARG0 (p3 / protein
                        :name (n / name :op1 "AJ"))
                  :ARG1 (a / adhere-01)
                  :ARG2~e.16 (a2 / and
                        :op1 (d / dynamic~e.12
                              :mod (c3 / cytoskeleton))
                        :op2 (s / signal-07~e.20
                              :ARG0 (a3 / and~e.18
                                    :op1 (n3 / nucleus~e.17)
                                    :op2 (c2 / cytoplasm~e.19))))
                  :ARG1-of (a4 / appear-02~e.5))))

# ::tok This provides a framework for conceptualizing why E @-@ cadherin levels appear to impact upon a plethora of developmental processes ( reviewed in [ @<xref ref-type="bibr" rid="pbio-0030011-b11"> 11 </xref>@ ]).
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1 3-1.2 4-1.3.r 5-1.3 6-1.3.1 6-1.3.1.1 6-1.3.1.1.r 7-1.3.1.1.1.1.1.1.1 9-1.3.1.1.1.1.1.1.1 10-1.3.1.1.1.1 11-1.3.1.1.1 13-1.3.1.1.1.1.2 16-1.3.1.1.1.1.2.1.2 17-1.3.1.1.1.1.2.1.2.r 18-1.3.1.1.1.1.2.1.1 19-1.3.1.1.1.1.2.1 21-1.4 27-1.4.1.1.1
# ::id pmid_1563_0473.34
# ::preferred 
(p / provide-01~e.1
      :ARG0 (t / this~e.0)
      :ARG1 (f / framework~e.3)
      :ARG2~e.4 (c / conceptualize-00~e.5
            :ARG1 (t2 / thing~e.6
                  :ARG0-of~e.6 (c3 / cause-01~e.6
                        :ARG1 (a / appear-02~e.11
                              :ARG1 (l / level~e.10
                                    :quant-of (p5 / protein
                                          :name (n / name :op1 "E-cadherin"~e.7,9))
                                    :ARG0-of (i / impact-01~e.13
                                          :ARG1 (p2 / process~e.19
                                                :mod (g2 / growth~e.18)
                                                :quant~e.17 (p3 / plethora~e.16))))))))
      :ARG1-of (r / review-01~e.21
            :ARG0 (p4 / publication
                  :ARG1-of (c2 / cite-01 :ARG2 "11"~e.27))))

# ::tok As we probed more deeply into the underlying mechanisms governing <i> E @-@ cadherin </i> promoter activity , we were intrigued by the close proximity of the LEF @-@ 1/β-catenin binding site to a site known to bind the Snail @/@ Slug family of zinc finger transcriptional repressor proteins [ @<xref ref-type="bibr" rid="pbio-0030011-b12"> 12 </xref> , <xref ref-type="bibr" rid="pbio-0030011-b13"> 13 </xref> , <xref ref-type="bibr" rid="pbio-0030011-b14"> 14 </xref> , <xref ref-type="bibr" rid="pbio-0030011-b15"> 15 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1 2-1.1 3-1.1.3.1 4-1.1.3 4-1.1.3.r 5-1.1.2.r 7-1.1.2.1 8-1.1.2 9-1.1.2.2 11-1.1.2.2.1.1.1.1 13-1.1.2.2.1.1.1.1 18-1.2.2 20-1.2 21-1.2.1.r 23-1.2.1 25-1.2.1.1.r 27-1.2.1.1.1.1.1.1 30-1.2.1.1.1 31-1.2.1.1 31-1.2.1.2 34-1.2.1.1 35-1.2.1.2.1.2 37-1.2.1.2.1 39-1.2.1.2.1.1.2.1.1.1.1 41-1.2.1.2.1.1.2.2.1.1.1 42-1.2.1.2.1.1.2.1 42-1.2.1.2.1.1.2.2 44-1.2.1.2.1.1.1.1.1.1.1 45-1.2.1.2.1.1.1.1.1.1.2 47-1.2.1.2.1.1 47-1.2.1.2.1.1.1 47-1.2.1.2.1.1.1.r 48-1.2.1.2.1.1 53-1.3.1.1.1.1 59-1.3.1.1.1.2 65-1.3.1.1.1.3 71-1.3.1.1.1.4
# ::id pmid_1563_0473.35
# ::preferred 
(c3 / cause-01
      :ARG0 (p2 / probe-01~e.2
            :ARG0 w2~e.1
            :ARG1~e.5 (m / mechanism~e.8
                  :ARG0-of (u / underlie-01~e.7)
                  :ARG0-of (g / govern-01~e.9
                        :ARG1 (a / act-01
                              :ARG0 (p / protein
                                    :name (n / name :op1 "E-cadherin"~e.11,13))
                              :ARG1 (p3 / promote-01))))
            :manner~e.4 (d / deep~e.4
                  :degree (m2 / more~e.3)))
      :ARG1 (i2 / intrigue-01~e.20
            :ARG0~e.21 (c / close-10~e.23
                  :ARG1~e.25 (s / site~e.31,34
                        :location-of (b / bind-01~e.30
                              :ARG1 (p4 / protein
                                    :name (n2 / name :op1 "LEF-1"~e.27))
                              :ARG2 (p5 / protein
                                    :name (n3 / name :op1 "β-catenin"))))
                  :ARG2 (s2 / site~e.31
                        :location-of (b2 / bind-01~e.37
                              :ARG1 (p6 / protein~e.47,48
                                    :ARG0-of~e.47 (r2 / repress-01~e.47
                                          :ARG1 (t / transcribe-01
                                                :ARG1 (p8 / protein
                                                      :name (n6 / name :op1 "zinc"~e.44 :op2 "finger"~e.45))))
                                    :part-of (s3 / slash
                                          :op1 (f / family~e.42
                                                :mod (g2 / gene
                                                      :name (n4 / name :op1 "Snail"~e.39)))
                                          :op2 (f2 / family~e.42
                                                :mod (g3 / gene
                                                      :name (n5 / name :op1 "Slug"~e.41)))))
                              :ARG1-of (k / know-01~e.35))))
            :ARG1 (w2 / we~e.18))
      :ARG1-of (d2 / describe-01
            :ARG0 (p7 / publication
                  :ARG1-of (c2 / cite-01
                        :ARG2 (a5 / and
                              :op1 "12"~e.53
                              :op2 "13"~e.59
                              :op3 "14"~e.65
                              :op4 "15"~e.71)))))

# ::tok Both activity of Snail and down @-@ regulation of E @-@ cadherin play pivotal roles in epithelial to mesenchymal transitions ( EMTs ) , typified by the transformation of polarized , adhering epithelial cells into motile mesenchymal cells [ @<xref ref-type="bibr" rid="pbio-0030011-b16"> 16 </xref> , <xref ref-type="bibr" rid="pbio-0030011-b17"> 17 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 3-1.1.1.1.1.1 4-1.1 9-1.1.2.1.1.1 11-1.1.2.1.1.1 12-1 13-1.2.1 14-1.2 15-1.2.2.r 16-1.2.2.1 19-1.2.2 24-1.2.2.4 25-1.2.2.4.1.r 27-1.2.2.4.1 29-1.2.2.4.1.1.2 31-1.2.2.4.1.1.3 32-1.2.2.4.1.1.1 33-1.2.2.4.1.1 33-1.2.2.4.1.2 34-1.2.2.4.1.2.r 35-1.2.2.4.1.2.1 37-1.2.2.4.1.2 42-1.3.1.1.1.1 48-1.3.1.1.1.2
# ::id pmid_1563_0473.36
# ::preferred 
(p / play-02~e.12
      :ARG0 (a / and~e.4
            :op1 (a2 / act-01
                  :ARG0 (g / gene
                        :name (n / name :op1 "Snail"~e.3)))
            :op2 (d / downregulate-01
                  :ARG1 (p5 / protein
                        :name (n2 / name :op1 "E-cadherin"~e.9,11))))
      :ARG1 (r / role~e.14
            :mod (p2 / pivotal~e.13)
            :topic~e.15 (t / transition-01~e.19
                  :ARG1 (e / epithelium~e.16)
                  :ARG2 (m / mesenchyme)
                  :ARG1-of (m2 / mean-01
                        :ARG2 (n3 / name :op1 "EMT"))
                  :ARG1-of (t2 / typify-01~e.24
                        :ARG0~e.25 (t3 / transform-01~e.27
                              :ARG1 (c / cell~e.33
                                    :mod (e2 / epithelium~e.32)
                                    :ARG1-of (p3 / polarize-01~e.29)
                                    :ARG1-of (a4 / adhere-01~e.31))
                              :ARG2~e.34 (c4 / cell~e.33,37
                                    :mod (m3 / motile~e.35)
                                    :part-of m)))))
      :ARG1-of (d2 / describe-01
            :ARG0 (p4 / publication
                  :ARG1-of (c5 / cite-01
                        :ARG2 (a5 / and :op1 "16"~e.42 :op2 "17"~e.48)))))

# ::tok Bud formation differs from an EMT in that E @-@ cadherin activity needs to be down @-@ regulated but not prevented , so that adhesive junctions are remodeled rather than quantitatively impaired .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1 2-1 3-1.2.r 5-1.2 8-1.3.1.1.1.1.1 10-1.3.1.1.1.1.1 11-1.3.1.1 12-1.3 18-1.3.1.2 19-1.3.1.2.1.1 19-1.3.1.2.1.1.r 20-1.3.1.2.1 22-1.3.1.3 23-1.3.1.3 24-1.3.1.3.1.1.1.1 25-1.3.1.3.1.1.1.2 27-1.3.1.3.1 30-1.3.1.3.1.2.1.2 30-1.3.1.3.1.2.1.2.r 31-1.3.1.3.1.2.1
# ::id pmid_1563_0473.37
# ::preferred 
(d / differ-02~e.2
      :ARG1 (f / form-01~e.1
            :ARG1 (b / bud~e.0))
      :ARG2~e.3 (e / EMT~e.5)
      :ARG3 (n2 / need-01~e.12
            :ARG1 (d2 / downregulate-01
                  :ARG1 (a2 / act-02~e.11
                        :ARG0 (p / protein
                              :name (n / name :op1 "E-cadherin"~e.8,10)))
                  :ARG1-of (c / contrast-01~e.18
                        :ARG2 (p2 / prevent-01~e.20
                              :polarity~e.19 "-"~e.19
                              :ARG1 a2))
                  :ARG1-of (h / have-purpose-91~e.22,23
                        :ARG2 (r / remodel-01~e.27
                              :ARG1 (p3 / protein
                                    :name (n3 / name :op1 "adhesive"~e.24 :op2 "junctions"~e.25))
                              :ARG1-of (i / instead-of-91
                                    :ARG2 (i2 / impair-01~e.31
                                          :ARG1 p3
                                          :manner~e.30 (q / quantitative~e.30))))))))

# ::tok Supportive of an underlying ability to fine @-@ tune cadherin expression at the transcriptional level , Snail seems to have an additive effect with LEF @-@ 1/β-catenin in negatively modulating <i> E @-@ cadherin </i> promoter activity [ @<xref ref-type="bibr" rid="pbio-0030011-b04"> 4 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 3-1.1.1.2 4-1.1.1 5-1.1.1.1.r 6-1.1.1.1 8-1.1.1.1 9-1.1.1.1.1.1.1.1 10-1.1.1.1.1 14-1.1.1.1.1.2 16-1.2.1.1.1.1.1 17-1.2 22-1.2.1 24-1.2.1.1.2.1.1.1 28-1.2.1.2.2.1 28-1.2.1.2.2.1.r 29-1.2.1.2.2 31-1.2.1.2.1.1.1 33-1.1.1.1.1.1.1.1 41-1.1.2.1.1.1
# ::id pmid_1563_0473.38
# ::preferred 
(c2 / cause-01
      :ARG0 (s / support-01
            :ARG1 (c3 / capable-01~e.4
                  :ARG2~e.5 (f / fine-tune-01~e.6,8
                        :ARG1 (e / express-03~e.10
                              :ARG1 (g / gene
                                    :name (n / name :op1 "cadherin"~e.9,33))
                              :ARG3 (l / level~e.14
                                    :mod (t / transcribe-01))))
                  :ARG0-of (u / underlie-01~e.3))
            :ARG1-of (d / describe-01
                  :ARG0 (p5 / publication-91
                        :ARG0-of (c / cite-01 :ARG2 "4"~e.41))))
      :ARG1 (s2 / seem-01~e.17
            :ARG1 (a2 / affect-01~e.22
                  :ARG0 (a3 / and
                        :op1 (p6 / protein
                              :name (n2 / name :op1 "Snail"~e.16))
                        :op2 (a4 / and
                              :op1 (p / protein
                                    :name (n3 / name :op1 "LEF-1"~e.24))
                              :op2 (p2 / protein
                                    :name (n4 / name :op1 "β-catenin"))))
                  :ARG1 (a5 / act-01
                        :ARG0 (p4 / protein
                              :name (n5 / name :op1 "E-cadherin"~e.31)
                              :ARG1-of (p3 / promote-01))
                        :ARG1-of (m / modulate-01~e.29
                              :manner~e.28 (n6 / negative~e.28))))))

# ::tok In the present study , we discovered that Snail is expressed briefly at an early stage of hair bud formation , when E @-@ cadherin down @-@ regulation and activation of proliferation take place .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.3.1 3-1.3 5-1.1 6-1 7-1.2.r 8-1.2.1.1.1 10-1.2 11-1.2.2 12-1.2.3.r 14-1.2.3 15-1.2.3.1 16-1.2.3.1.1.r 17-1.2.3.1.1.1.1 18-1.2.3.1.1.1 19-1.2.3.1.1 21-1.4.r 22-1.4.1.1.1.1 24-1.4.1.1.1.1 28-1.4 29-1.4.2 30-1.4.2.1.r 31-1.4.2.1
# ::id pmid_1563_0473.39
# ::preferred 
(d / discover-01~e.6
      :ARG0 (w / we~e.5)
      :ARG1~e.7 (e / express-03~e.10
            :ARG1 (g / gene
                  :name (n / name :op1 "Snail"~e.8))
            :duration (b / brief~e.11)
            :time~e.12 (e2 / early~e.14
                  :op1 (s / stage~e.15
                        :duration-of~e.16 (f / form-01~e.19
                              :ARG1 (b2 / bud~e.18
                                    :mod (h2 / hair~e.17))))))
      :location (s2 / study~e.3
            :time (p / present~e.2))
      :time~e.21 (a / and~e.28
            :op1 (d2 / downregulate-01
                  :ARG1 (p2 / protein
                        :name (n2 / name :op1 "E-cadherin"~e.22,24)))
            :op2 (a2 / activate-01~e.29
                  :ARG1~e.30 (p3 / proliferate-01~e.31))))

# ::tok Thereafter , Snail disappears and remains absent during subsequent follicle down @-@ growth and maturation .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3 2-1.1.1.1.1 3-1.1 4-1 5-1.2 6-1.2.2 7-1.2.3.3.r 7-1.2.3.r 8-1.2.3.3 8-1.2.3.3.r 9-1.2.3.1.1 10-1.2.3.1.2 12-1.2.3.1 13-1.2.3
# ::id pmid_1563_0473.40
# ::preferred 
(a / and~e.4
      :op1 (d / disappear-01~e.3
            :ARG1 (g / gene
                  :name (n / name :op1 "Snail"~e.2)))
      :op2 (r / remain-01~e.5
            :ARG1 g
            :ARG3 (a2 / absent-01~e.6
                  :ARG1 g)
            :time~e.7 (a3 / and~e.13
                  :op1 (g2 / grow-01~e.12
                        :ARG1 (f / follicle~e.9)
                        :direction (d2 / down~e.10))
                  :op2 (m / mature-01
                        :ARG1 f)
                  :time~e.7,8 (s / subsequent~e.8)))
      :time (t / thereafter~e.0))

# ::tok This exquisite pattern appears to be functionally relevant since altering it in vivo correspondingly affects features associated with hair bud formation , including down @-@ regulation of E @-@ cadherin , increased proliferation , and repressed terminal differentiation .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.1.1.1 1-1.2.1.1.2 2-1.2.1.1 3-1.2 6-1.2.1.2 7-1.2.1 8-1 9-1.1 10-1.1.1 11-1.1.2 12-1.1.2 14-1.1.4 15-1.1.4.1 16-1.1.4.1.1 17-1.1.4.1.1.1.r 18-1.1.4.1.1.1.1.1 19-1.1.4.1.1.1.1 20-1.1.4.1.1.1 22-1.1.4.1.2 26-1.1.4.1.2.1.r 27-1.1.4.1.2.1.1.1.1.1 29-1.1.4.1.2.1.1.1.1.1 31-1.1.4.1.2.1.2.1 32-1.1.4.1.2.1.2 34-1.1.4.1.2.1 35-1.1.4.1.2.1.3.2 36-1.1.4.1.2.1.3.1 37-1.1.4.1.2.1.3
# ::id pmid_1563_0473.41
# ::preferred 
(c2 / cause-01~e.8
      :ARG0 (a2 / alter-01~e.9
            :ARG1 p~e.10
            :manner (i / in-vivo~e.11,12)
            :ARG1-of (c / correspond-02)
            :ARG0-of (a3 / affect-01~e.14
                  :ARG1 (f2 / feature~e.15
                        :ARG1-of (a4 / associate-01~e.16
                              :ARG2~e.17 (f3 / form-01~e.20
                                    :ARG1 (b / bud~e.19
                                          :mod (h / hair~e.18))))
                        :ARG1-of (i2 / include-01~e.22
                              :ARG2~e.26 (a5 / and~e.34
                                    :op1 (d / downregulate-01
                                          :ARG1 (p2 / protein
                                                :name (n / name :op1 "E-cadherin"~e.27,29)))
                                    :op2 (p3 / proliferate-01~e.32
                                          :ARG1-of (i3 / increase-01~e.31))
                                    :op3 (d2 / differentiate-01~e.37
                                          :ARG1 (t2 / terminus~e.36)
                                          :ARG1-of (r2 / repress-01~e.35)))))))
      :ARG1 (a / appear-02~e.3
            :ARG1 (r / relevant-01~e.7
                  :ARG1 (p / pattern~e.2
                        :mod (t / this~e.0)
                        :mod (e / exquisite~e.1))
                  :ARG2 (f / function-01~e.6))))

# ::tok Although the temporal spike of Snail in the hair bud is reflected at the mRNA level and seems to follow Wnt signaling and BMP inhibition , LEF @-@ 1/β-catenin activation does not appear to induce <i> Snail </i> gene expression in embryonic skin keratinocytes .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3 2-1.1.2.2 3-1.1.2 4-1.1.2.1.r 5-1.1.2.1.1.1 6-1.1.2.3.r 8-1.1.2.3.1 9-1.1.2.3 11-1.1 12-1.1.1.r 14-1.1.1.1.1.1 15-1.1.1 16-1 17-1.2 19-1.2.1 20-1.2.1.2.1.1.1.1 21-1.2.1.2.1 22-1.2.1.2 23-1.2.1.2.2.1.1.1 24-1.2.1.2.2 26-1.3.1.2.1.1.1.1.1 29-1.3.1.2.1 31-1.3.1.1 31-1.3.1.1.r 32-1.3.1 34-1.3.1.2 36-1.3.1.2.2.1 37-1.3.1.2.2.1 38-1.3.1.2.2.1 39-1.3.1.2.2 42-1.3.1.2.3.3 43-1.3.1.2.3.1.1
# ::id pmid_1563_0473.42
# ::preferred 
(a / and~e.16
      :op1 (r / reflect-01~e.11
            :ARG1~e.12 (l / level~e.15
                  :mod (r2 / rna
                        :name (n7 / name :op1 "mRNA"~e.14)))
            :ARG2 (s / spike-04~e.3
                  :ARG1~e.4 (g / gene
                        :name (n / name :op1 "Snail"~e.5))
                  :mod (t / time~e.2)
                  :location~e.6 (b / bud~e.9
                        :mod (h / hair~e.8))))
      :op2 (s2 / seem-01~e.17
            :ARG1 (f / follow-01~e.19
                  :ARG1 s
                  :ARG2 (a2 / and~e.22
                        :op1 (s3 / signal-07~e.21
                              :ARG0 (p / pathway
                                    :name (n2 / name :op1 "Wnt"~e.20)))
                        :op2 (i / inhibit-01~e.24
                              :ARG1 (p2 / protein
                                    :name (n3 / name :op1 "BMP"~e.23))))))
      :ARG2-of (h2 / have-concession-91~e.0
            :ARG1 (a5 / appear-02~e.32
                  :polarity~e.31 "-"~e.31
                  :ARG1 (i2 / induce-01~e.34
                        :ARG0 (a3 / activate-01~e.29
                              :ARG1 (a4 / and
                                    :op1 (p3 / protein
                                          :name (n4 / name :op1 "LEF-1"~e.26))
                                    :op2 (p4 / protein
                                          :name (n5 / name :op1 "β-catenin"))))
                        :ARG1 (e / express-03~e.39
                              :ARG1 g~e.36,37,38)
                        :location (c / cell
                              :name (n6 / name :op1 "keratinocytes"~e.43)
                              :mod (e2 / embryo)
                              :part-of (s4 / skin~e.42))))))

# ::tok In contrast , we provide in vitro , transgenic ( Tg ) , and gene targeting evidence to show that TGF-β2 and small phenotype– and mothers against decapentaplegic–related protein 2 ( SMAD2 ) signaling are upstream inducers of <i> Snail </i> gene expression in skin epithelium .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3 1-1.4 3-1.1 4-1 5-1.3 6-1.3 8-1.2.1.1.1 10-1.2.1.1.1.1.1.1 13-1.2 14-1.2.2.1.1 15-1.2.1.1 15-1.2.2.1 16-1.2.1 16-1.2.2 18-1.5 19-1.5.2.r 20-1.5.2.1.1.1 22-1.5.2.2.2.1.1 24-1.5.2 25-1.5.2.3.1.1 26-1.5.2.3.1.2 28-1.5.2.2.1.1 29-1.5.2.2.1.2 33-1.5.2.4 35-1.5.2.4.1.2 39-1.5.2.4.1.1.1.1.1 41-1.5.2.4.1.1.1 42-1.5.2.4.1.1 43-1.3 44-1.5.2.4.1.3.1 45-1.5.2.4.1.3
# ::id pmid_1563_0473.43
# ::preferred 
(p / provide-01~e.4
      :ARG0 (w / we~e.3)
      :ARG1 (a / and~e.13
            :op1 (e / evidence~e.16
                  :ARG1-of (t / target-01~e.15
                        :mod (t2 / transgenic~e.8
                              :ARG1-of (m / mean-01
                                    :ARG2 (n5 / name :op1 "Tg"~e.10)))))
            :op2 (e2 / evidence~e.16
                  :ARG1-of (t3 / target-01~e.15
                        :ARG0 (g / gene~e.14))))
      :manner (i / in-vitro~e.0,5,6,43)
      :ARG2-of (c / contrast-01~e.1)
      :purpose (s / show-01~e.18
            :ARG0 a
            :ARG1~e.19 (a2 / and~e.24
                  :op1 (p2 / protein
                        :name (n / name :op1 "TGF-β2"~e.20))
                  :op2 (p5 / protein
                        :name (n3 / name :op1 "protein"~e.28 :op2 "2"~e.29)
                        :ARG1-of (r / relate-01
                              :ARG2 (p4 / phenotype
                                    :mod (s2 / small~e.22))))
                  :op3 (p6 / protein
                        :name (n2 / name
                              :op1 "mothers"~e.25
                              :op2 "against"~e.26
                              :op3 "decapentaplegic"
                              :op4 "protein"
                              :op5 "2"))
                  :ARG0-of (s3 / signal-07~e.33
                        :ARG0-of (i2 / induce-01
                              :ARG1 (e3 / express-03~e.42
                                    :ARG1 (g2 / gene~e.41
                                          :name (n4 / name :op1 "Snail"~e.39)))
                              :direction (u / upstream~e.35)
                              :location (e4 / epithelium~e.45
                                    :mod (s4 / skin~e.44)))))))

# ::tok In the absence of TGF-β2 signaling and <i> Snail </i> gene expression , hair placodes can form , but further follicle down @-@ growth is blocked .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1 3-1.1.r 4-1.1.1.1.1.1 5-1.1.1 6-1.1 8-1.1.2.1.1.1 10-1.1.2.1 11-1.1.2 13-1.2.1.1.1.1 15-1.2.1 16-1.2.1.1 18-1.2.1.2 19-1.2.1.2.1.1.3 20-1.2.1.2.1.1.1 21-1.2.1.2.1.1.2 23-1.2.1.2.1.1 25-1.2.1.2.1
# ::id pmid_1563_0473.44
# ::preferred 
(a / absent-01~e.2
      :ARG1~e.3 (a2 / and~e.6
            :op1 (s / signal-07~e.5
                  :ARG0 (p / protein
                        :name (n / name :op1 "TGF-β2"~e.4)))
            :op2 (e / express-03~e.11
                  :ARG1 (g / gene~e.10
                        :name (n2 / name :op1 "Snail"~e.8))))
      :ARG2-of (h / have-condition-91
            :ARG1 (p2 / possible~e.15
                  :domain (f / form-01~e.16
                        :ARG1 (p3 / placode
                              :mod (h2 / hair~e.13)))
                  :ARG1-of (c / contrast-01~e.18
                        :ARG2 (b / block-01~e.25
                              :ARG1 (g2 / grow-01~e.23
                                    :ARG1 (f2 / follicle~e.20)
                                    :direction (d / down~e.21)
                                    :degree (f3 / further~e.19)))))))

# ::tok Our studies point to the view that Snail likely functions downstream of cell fate specification , at a stage where the bud begins to exhibit enhanced proliferation and migration .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 0-1.1.1.r 1-1.1 2-1 5-1.2 6-1.2.1.r 7-1.2.1.1.1.1.1 8-1.2.1 9-1.2.1.1 10-1.2.1.1.2.2 12-1.2.1.1.2.1.1.1 13-1.2.1.1.2.1.1 14-1.2.1.1.2.1 16-1.3.r 18-1.3 19-1.2.1.1.2.r 21-1.3.1.1 22-1.3.1 24-1.3.1.2 25-1.3.1.2.2.3 26-1.3.1.2.2.1 27-1.3.1.2.2 28-1.3.1.2.2.2
# ::id pmid_1563_0473.45
# ::preferred 
(p / point-01~e.2
      :ARG0 (s / study-01~e.1
            :ARG0~e.0 (w / we~e.0))
      :ARG1 (v / view-01~e.5
            :ARG1~e.6 (l / likely~e.8
                  :domain (f / function-01~e.9
                        :ARG0 (g / gene
                              :name (n / name :op1 "Snail"~e.7))
                        :location~e.19 (r / relative-position
                              :op1 (s2 / specify-01~e.14
                                    :ARG1 (f2 / fate~e.13
                                          :mod (c / cell~e.12)))
                              :direction (d2 / downstream~e.10)))))
      :time~e.16 (s3 / stage~e.18
            :time-of (b / begin-01~e.22
                  :ARG0 (b2 / bud~e.21)
                  :ARG1 (e / exhibit-01~e.24
                        :ARG0 b2
                        :ARG1 (a / and~e.27
                              :op1 (p2 / proliferate-01~e.26)
                              :op2 (m / migrate-01~e.28)
                              :ARG1-of (e2 / enhance-01~e.25))))))

# ::tok Results
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 0-1.1 0-1.1.r
# ::id pmid_1563_0473.46
# ::preferred 
(t / thing~e.0
      :ARG2-of~e.0 (r2 / result-01~e.0))

# ::tok <i> Snail </i> mRNA and Protein Are Expressed Transiently at the Hair Bud Stage of Follicle Morphogenesis
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.2.1.1 4-1.1 5-1.1.2 7-1 8-1.2 8-1.2.r 9-1.3.r 11-1.3.2.1 12-1.3.2 13-1.3 14-1.3.1.r 15-1.3.1.1 16-1.3.1
# ::id pmid_1563_0473.47
# ::preferred 
(e / express-03~e.7
      :ARG2 (a / and~e.4
            :op1 (r / rna
                  :name (n / name
                        :op1 "Snail"
                        :op2 "messenger"
                        :op3 "RNA"))
            :op2 (p / protein~e.5
                  :name (n2 / name :op1 "Snail"~e.1)))
      :manner~e.8 (t / transient~e.8)
      :time~e.9 (s / stage~e.13
            :subevent-of~e.14 (m / morphogenesis~e.16
                  :mod (f / follicle~e.15))
            :mod (b / bud~e.12
                  :mod (h / hair~e.11))))

# ::tok Although Snail family members are most frequently associated with EMTs , they also participate in many malignant processes involving a down @-@ regulation but not a quantitative abrogation of intercellular junctions [ @<xref ref-type="bibr" rid="pbio-0030011-b18"> 18 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3.r 1-1.1.1.1.1.1 2-1.1.1.1.2 3-1.1 5-1.3.3.1 6-1.3.3 7-1.3 11-1.3.1 12-1.5 13-1 14-1.2.r 15-1.2.2 16-1.2.1 17-1.2 18-1.2.3 18-1.2.3.1.2.1 23-1.2.3.1.2 24-1.2.3.1.2.1.1 24-1.2.3.1.2.1.1.r 26-1.2.3.1.2.1.2.2 27-1.2.3.1.2.1.2 28-1.2.3.1.2.1.2.1.r 29-1.2.3.1.2.1.2.1.1 30-1.2.3.1.2.1.2.1 35-1.4.1.1.1
# ::id pmid_1563_0473.48
# ::preferred 
(p / participate-01~e.13
      :ARG0 (m3 / member~e.3
            :ARG1-of (i / include-91
                  :ARG2 (p2 / protein
                        :name (n / name :op1 "Snail"~e.1)
                        :mod (f / family~e.2))))
      :ARG1~e.14 (p3 / process~e.17
            :mod (m / malignant~e.16)
            :quant (m2 / many~e.15)
            :ARG2-of (i2 / involve-01~e.18
                  :ARG1 (d / downregulate-01
                        :ARG1 (j / junction~e.30
                              :mod (i3 / intercellular~e.29))
                        :ARG1-of (c2 / contrast-01~e.23
                              :ARG2 (i4 / involve-01~e.18
                                    :polarity~e.24 "-"~e.24
                                    :ARG1 (a2 / abrogate-01~e.27
                                          :ARG1~e.28 j
                                          :mod (q / quantity~e.26)))))))
      :concession~e.0 (a / associate-01~e.7
            :ARG1 m3~e.11
            :ARG2 (e / EMT)
            :frequency (f2 / frequent~e.6
                  :degree (m4 / most~e.5)))
      :ARG1-of (d2 / describe-01
            :ARG0 (p4 / publication
                  :ARG1-of (c / cite-01 :ARG2 "18"~e.35)))
      :mod (a3 / also~e.12))

# ::tok The range of developmental processes in which Snail family members have been implicated thus includes the type of epithelial remodeling that is observed in hair follicle bud formation .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.2.3 2-1.1.2.3.r 3-1.1.2.1 4-1.1.2 7-1.1.2.2.1.1.1.1.1 8-1.1.2.2.1.1.1.2 9-1.1.2.2.1 12-1.1.2.2 14-1.1 14-1.1.2.2.1.1 16-1.1.1.3 17-1.1.1.3.r 18-1.1.1.1 19-1.1.1 22-1.1.1.2 23-1.1.1.2.1.r 24-1.1.1.2.1.1.1.1 25-1.1.1.2.1.1.1 26-1.1.1.2.1.1 27-1.1.1.2.1
# ::id pmid_1563_0473.49
# ::preferred 
(i4 / infer-01
      :ARG1 (i / include-01~e.14
            :ARG1 (r / remodel-01~e.19
                  :ARG1 (e / epithelium~e.18)
                  :ARG1-of (o / observe-01~e.22
                        :time~e.23 (f2 / form-01~e.27
                              :ARG1 (b / bud~e.26
                                    :part-of (f3 / follicle~e.25
                                          :mod (h / hair~e.24)))))
                  :mod~e.17 (t / type~e.16))
            :ARG2 (p / process~e.4
                  :mod (g / growth~e.3)
                  :ARG2-of (i2 / implicate-01~e.12
                        :ARG1 (m / member~e.9
                              :ARG1-of (i3 / include-91~e.14
                                    :ARG2 (p2 / protein
                                          :name (n / name :op1 "Snail"~e.7)
                                          :mod (f / family~e.8)))))
                  :quant~e.2 (r2 / range~e.1))))

# ::tok Given our prior observation that exogenously added Snail can participate with LEF @-@ 1/β-catenin in down @-@ regulating <i> E @-@ cadherin </i> expression in keratinocytes [ @<xref ref-type="bibr" rid="pbio-0030011-b04"> 4 </xref>@ ], coupled with the established requirement for LEF @-@ 1/β-catenin in hair follicle morphogenesis [ @<xref ref-type="bibr" rid="pbio-0030011-b04"> 4 </xref> , <xref ref-type="bibr" rid="pbio-0030011-b19"> 19 </xref>@ ], we turned to addressing whether Snail @/@ Slug family members might also participate in the process .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3.1.1.1 1-1.3.1.1.1.r 2-1.3.1.1.3 3-1.3.1.1 6-1.3.1.1.2.1.1.2 7-1.2.2.1.1.1.1.1 7-1.3.1.1.2.1.1.1.1 8-1.3.1.1.2 9-1.3.1.1.2.1 10-1.3.1.1.2.1.1.3.r 11-1.3.1.1.2.1.1.3.1.1.1 19-1.3.1.1.2.1.2.1.1.1.1 21-1.3.1.1.2.1.2.1.1.1.1 23-1.3.1.1.2.1.2.1 30-1.3.1.1.4.1.1.1 34-1.3.1.2.2 36-1.3.1.2.4 37-1.3.1.2 39-1.3.1.2.2 42-1.3.1.2.1.r 43-1.3.1.2.1.1.1 44-1.3.1.2.1.1 45-1.3.1.2.1 50-1.3.1.2.3.1.1.1.1 56-1.3.1.2.3.1.1.1.2 59-1.1 61-1.3 62-1 63-1.2.1 63-1.2.1.r 64-1.3.1.1.2.1.1.1.1 66-1.2.2.1.1.2.1.1 67-1.2.2.1.1.1.2 68-1.2.2 69-1.3.1.1.2 70-1.2.4 71-1.2 72-1.2.3.r 74-1.2.3
# ::id pmid_1563_0473.50
# ::preferred 
(a / address-02~e.62
      :ARG0 (w / we~e.59)
      :ARG1 (p2 / participate-01~e.71
            :mode~e.63 "interrogative"~e.63
            :ARG0 (m / member~e.68
                  :ARG1-of (i / include-91
                        :ARG2 (a2 / and
                              :op1 (p3 / protein
                                    :name (n / name :op1 "Snail"~e.7)
                                    :mod (f / family~e.67))
                              :op2 (p4 / protein
                                    :name (n2 / name :op1 "Slug"~e.66)
                                    :mod f))))
            :ARG1~e.72 (p5 / process~e.74)
            :mod (a6 / also~e.70))
      :ARG1-of (c / cause-01~e.61
            :ARG0 (a4 / and
                  :op1 (o / observe-01~e.3
                        :ARG0~e.1 (w2 / we~e.1)
                        :ARG1 (p / possible~e.8,69
                              :domain (p7 / participate-01~e.9
                                    :ARG0 (p8 / protein
                                          :name (n3 / name :op1 "Snail"~e.7,64)
                                          :ARG1-of (a3 / add-02~e.6
                                                :manner (e / exogenous))
                                          :accompanier~e.10 (m2 / macro-molecular-complex
                                                :part (p12 / protein
                                                      :name (n6 / name :op1 "LEF-1"~e.11))
                                                :part (p13 / protein
                                                      :name (n7 / name :op1 "β-catenin"))))
                                    :ARG1 (d / downregulate-01
                                          :ARG1 (e2 / express-03~e.23
                                                :ARG2 (p9 / protein
                                                      :name (n5 / name :op1 "E-cadherin"~e.19,21))
                                                :ARG3 (k / keratinocyte)))))
                        :time (p6 / prior~e.2)
                        :ARG1-of (d2 / describe-01
                              :ARG0 (p10 / publication
                                    :ARG1-of (c2 / cite-01 :ARG2 "4"~e.30))))
                  :op2 (r / require-01~e.37
                        :ARG0~e.42 (m3 / morphogenesis~e.45
                              :mod (f2 / follicle~e.44
                                    :mod (h / hair~e.43)))
                        :ARG1 m2~e.34,39
                        :ARG1-of (d3 / describe-01
                              :ARG0 (p11 / publication
                                    :ARG1-of (c3 / cite-01
                                          :ARG2 (a5 / and :op1 "4"~e.50 :op2 "19"~e.56))))
                        :ARG1-of (e3 / establish-01~e.36)))))

# ::tok PCR analyses identified transient <i> Snail </i> mRNA expression during a period of skin embryogenesis when waves of hair follicles are forming ( unpublished data ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1 1-1.1.1 1-1.1.1.r 2-1 3-1.2.2 5-1.2.1.1.1 7-1.2.1.1.2 8-1.2 9-1.2.3.2.r 9-1.2.3.r 11-1.2.3 13-1.2.3.1.1 14-1.2.3.1 15-1.2.3.1.r 16-1.2.3.2.1 17-1.2.3.2.1.1.r 18-1.2.3.2.1.1.1 19-1.2.3.2.1.1 21-1.2.3.2 23-1.3.1.1.1 24-1.3.1
# ::id pmid_1563_0473.51
# ::preferred 
(i / identify-01~e.2
      :ARG0 (a2 / analyze-01~e.1
            :instrument~e.1 (a / analysis~e.1
                  :name (n / name
                        :op1 "polymerase"
                        :op2 "chain"
                        :op3 "reaction")))
      :ARG1 (e / express-03~e.8
            :ARG1 (r / rna
                  :name (n2 / name :op1 "Snail"~e.5 :op2 "mRNA"~e.7))
            :manner (t / transient~e.3)
            :time~e.9 (p2 / period~e.11
                  :time-of~e.15 (e2 / embryogenesis~e.14
                        :mod (s / skin~e.13))
                  :time-of~e.9 (f2 / form-01~e.21
                        :ARG1 (w / wave~e.16
                              :mod~e.17 (f / follicle~e.19
                                    :mod (h / hair~e.18))))))
      :ARG1-of (d / describe-01
            :ARG0 (d2 / data~e.24
                  :ARG1-of (p / publish-01 :polarity "-"~e.23))))

# ::tok To pinpoint specifically where <i> Snail </i> mRNA is expressed in the developing skin , we conducted in situ hybridization using a cRNA probe unique to the <i> Snail </i> 3′ untranslated region ( UTR ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.2 2-1.2.2 5-1.2.1.1.1.1.1 7-1.2.1.1.1.1.2 9-1.2.1.1 10-1.4 12-1.2.1.2.1 13-1.2.1.2 15-1.1 17-1.4 18-1.4 19-1 20-1.2.r 20-1.3 23-1.3.2 24-1.3.2.2 28-1.3.2.2.1.3.1.1 31-1.3.2.2.1.2.1 32-1.3.2.2.1.2.2
# ::id pmid_1563_0473.52
# ::preferred 
(h / hybridize-01~e.19
      :ARG0 (w / we~e.15)
      :purpose~e.20 (p / pinpoint-01~e.1
            :ARG1 (l / location
                  :ARG3-of (e / express-03~e.9
                        :ARG1 (r / rna
                              :name (n / name :op1 "Snail"~e.5 :op2 "mRNA"~e.7)))
                  :part-of (s2 / skin~e.13
                        :ARG1-of (d / develop-02~e.12)))
            :manner (s / specific~e.2))
      :ARG2-of (u / use-01~e.20
            :ARG0 w
            :ARG1 (p2 / probe~e.23
                  :mod (r2 / rna
                        :name (n2 / name :op1 "complementary" :op2 "RNA"))
                  :mod (u2 / unique~e.24
                        :topic (r4 / region
                              :mod "3'"
                              :name (n3 / name :op1 "untranslated"~e.31 :op2 "region"~e.32)
                              :part-of (p3 / protein
                                    :name (n4 / name :op1 "Snail"~e.28))))))
      :manner (i / in-situ~e.10,17,18))

# ::tok Embryonic day 17.5 ( E17.5 ) was chosen , since the multiple waves of follicle morphogenesis occurring at this time enabled us to evaluate Snail expression at different stages of the process .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.2.2 2-1.2.1 7-1 9-1.3 11-1.3.1.1.1 12-1.3.1.1 13-1.3.1.1.2.r 14-1.3.1.1.2.1 15-1.3.1.1.2 19-1.2 19-1.3.1.1.3.r 20-1.3.1 21-1.3.1.2.1 23-1.3.1.2 24-1.3.1.2.2.1.1.1 25-1.3.1.2.2 26-1.3.1.2.2.2.r 27-1.3.1.2.2.2.2 28-1.3.1.2.2.2
# ::id pmid_1563_0473.53
# ::preferred 
(c / choose-01~e.7
      :ARG0 (w2 / we~e.21)
      :ARG1 (t / temporal-quantity~e.19
            :quant "17.5"~e.2
            :unit (d2 / day~e.1)
            :age-of (e / embryo))
      :ARG1-of (c2 / cause-01~e.9
            :ARG0 (e2 / enable-01~e.20
                  :ARG0 (w / wave~e.12
                        :quant (m / multiple~e.11)
                        :subevent-of~e.13 (m2 / morphogenesis~e.15
                              :mod (f / follicle~e.14))
                        :time~e.19 t)
                  :ARG1 (e3 / evaluate-101~e.23
                        :ARG0 w2
                        :ARG2 (e4 / express-03~e.25
                              :ARG1 (g / gene
                                    :name (n / name :op1 "Snail"~e.24))
                              :time~e.26 (s / stage~e.28
                                    :subevent-of m2
                                    :ARG1-of (d3 / differ-02~e.27))))
                  :ARG2 w2)))

# ::tok As shown in <xref ref-type="fig" rid="pbio-0030011-g001"> Figure 1 </xref>@ A , specific hybridization was detected within the epithelium of nascent hair buds .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3 6-1.3.1 11-1.1.1 12-1.1 14-1 17-1.2 18-1.2.1.r 19-1.2.1.2 20-1.2.1.1 21-1.2.1
# ::id pmid_1563_0473.54
# ::preferred 
(d / detect-01~e.14
      :ARG1 (h / hybridize-01~e.12
            :mod (s / specific~e.11))
      :location (e / epithelium~e.17
            :part-of~e.18 (b / bud~e.21
                  :mod (h2 / hair~e.20)
                  :mod (n / nascent~e.19)))
      :ARG1-of (s2 / show-01~e.1
            :ARG0 (f / figure~e.6 :mod "1A")))

# ::tok By contrast , as follicles progressed further through their development ( e.g . , germ and peg stages ) , they exhibited no signs of hybridization ( <xref ref-type="fig" rid="pbio-0030011-g001"> Figure 1 </xref>@ A ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1 3-1.1.4.r 4-1.1.4.1 6-1.1.4.3 9-1.1.4 14-1.1.4.2.1.1 15-1.1.4.2 16-1.1.4.2.2.1 17-1.1.4.2.1 17-1.1.4.2.2 20-1.1.2 21-1.1 22-1.1.1 22-1.1.1.r 23-1.1.3 24-1.1.3.1.r 25-1.1.3.1 30-1.2.1
# ::id pmid_1563_0473.55
# ::preferred 
(c / contrast-01~e.1
      :ARG2 (e / exhibit-01~e.21
            :polarity~e.22 "-"~e.22
            :ARG0 f~e.20
            :ARG1 (s3 / sign~e.23
                  :ARG1-of~e.24 (h / hybridize-01~e.25))
            :time~e.3 (d / develop-02~e.9
                  :ARG1 (f / follicle~e.4)
                  :example (a / and~e.15
                        :op1 (s / stage~e.17
                              :mod (g / germ~e.14))
                        :op2 (s2 / stage~e.17
                              :mod (p / peg~e.16)))
                  :degree (f3 / further~e.6)))
      :ARG1-of (d2 / describe-01
            :ARG2 (f2 / figure~e.30 :mod "1A")))

# ::tok The transient nature of <i> Snail </i> mRNA expression during follicle development was most apparent in hybridized skin sections containing follicles from two different waves of morphogenesis ( as shown in <xref ref-type="fig" rid="pbio-0030011-g001"> Figure 1 </xref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.2.2 5-1.2.1.1.1 7-1.2.1.1.2 8-1.2 9-1.2.3.r 10-1.2.3.1 11-1.2.3 12-1.2.r 13-1.1 14-1 15-1.3.r 16-1.3.1.1 17-1.3.1 18-1.3 19-1.3.2 20-1.3.2.1 21-1.3.2.1.1.r 22-1.3.2.1.1.1 23-1.3.2.1.1.3 24-1.3.2.1.1 25-1.3.2.1.1.2.r 26-1.3.2.1.1.2 28-1.2.3.r 28-1.4.r 29-1.4 34-1.4.1 35-1.4.1.1
# ::id pmid_1563_0473.56
# ::preferred 
(a / apparent~e.14
      :degree (m / most~e.13)
      :domain~e.12 (e / express-03~e.8
            :ARG1 (r / rna
                  :name (n / name :op1 "Snail"~e.5 :op2 "mRNA"~e.7))
            :manner (t / transient~e.1)
            :time~e.9,28 (d / develop-02~e.11
                  :ARG1 (f / follicle~e.10)))
      :location~e.15 (s / section~e.18
            :part-of (s2 / skin~e.17
                  :ARG1-of (h / hybridize-01~e.16))
            :ARG0-of (c / contain-01~e.19
                  :ARG1 (f2 / follicle~e.20
                        :source~e.21 (w / wave~e.24
                              :quant "2"~e.22
                              :subevent-of~e.25 (m2 / morphogenesis~e.26)
                              :ARG1-of (d2 / differ-02~e.23)))))
      :ARG1-of~e.28 (s3 / show-01~e.29
            :ARG0 (f3 / figure~e.34 :mod "1"~e.35)))

# ::tok Hybridizing hair buds from a later wave appeared juxtaposed with nonhybridizing follicles from an earlier wave .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 0-1.1.2.1 1-1.1.1.2 2-1.1.1 3-1.1.1.3.r 5-1.1.1.3.1 5-1.1.1.3.1.1 5-1.1.1.3.1.1.r 6-1.1.1.3 7-1 8-1.1 11-1.1.2 12-1.1.2.2.r 14-1.1.2.2.1 14-1.1.2.2.1.1 14-1.1.2.2.1.1.r 15-1.1.2.2
# ::id pmid_1563_0473.57
# ::preferred 
(a / appear-01~e.7
      :ARG1 (j / juxtapose-01~e.8
            :ARG1 (b / bud~e.2
                  :ARG1-of (h / hybridize-01~e.0)
                  :mod (h2 / hair~e.1)
                  :source~e.3 (w / wave~e.6
                        :mod (l / late~e.5
                              :degree~e.5 (m / more~e.5))))
            :ARG2 (f / follicle~e.11
                  :ARG1-of (h3 / hybridize-01~e.0 :polarity "-")
                  :source~e.12 (w2 / wave~e.15
                        :mod (e / early~e.14
                              :degree~e.14 (m2 / more~e.14))))))

# ::tok To determine whether this transient nature of <i> Snail </i> mRNA expression is reflected at the protein level , we generated an antibody against the N @-@ terminal sequence that resides upstream of the more conserved zinc finger domains .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3 2-1.3.2.1 2-1.3.2.1.r 3-1.3.2.3.1 4-1.3.2.3.2 5-1.3.2.3 8-1.3.2.3.2.1.1.1.1 10-1.3.2.3.2.1.1.1.2 11-1.3.2.3.2.1 13-1.3.2 14-1.3.2.2.r 16-1.3.2.2.1 17-1.3.2.2 19-1.1 20-1 22-1.2 23-1.2.1 25-1.2.1.1.1.1.1 27-1.2.1.1.1.1.2 28-1.2.1.1 30-1.2.1.1.1 30-1.2.1.1.1.2 30-1.2.1.1.1.2.r 31-1.2.1.1.1.2.1.2 34-1.2.1.1.1.2.1.1.2.1 35-1.2.1.1.1.2.1.1.2 36-1.2.1.1.1.2.1.1.1.1 37-1.2.1.1.1.2.1.1.1.2 38-1.2.1.1.1.2.1.1.1.3
# ::id pmid_1563_0473.58
# ::preferred 
(g / generate-01~e.20
      :ARG0 (w / we~e.19)
      :ARG1 (a / antibody~e.22
            :ARG0-of (o / oppose-01~e.23
                  :ARG1 (s / sequence~e.28
                        :mod (p2 / protein-segment~e.30
                              :name (n2 / name :op1 "N"~e.25 :op2 "terminus"~e.27)
                              :ARG0-of~e.30 (r3 / reside-01~e.30
                                    :ARG1 (r4 / relative-position
                                          :op1 (p3 / protein-segment
                                                :name (n3 / name
                                                      :op1 "zinc"~e.36
                                                      :op2 "finger"~e.37
                                                      :op3 "domain"~e.38)
                                                :ARG1-of (c / conserve-01~e.35
                                                      :degree (m / more~e.34)))
                                          :direction (u / upstream~e.31)))))))
      :purpose (d / determine-01~e.1
            :ARG0 w
            :ARG1 (r / reflect-01~e.13
                  :mode~e.2 "interrogative"~e.2
                  :ARG1~e.14 (l / level~e.17
                        :mod (p / protein~e.16))
                  :ARG2 (n4 / nature~e.5
                        :mod (t2 / this~e.3)
                        :mod (t / transient~e.4
                              :manner-of (e / express-03~e.11
                                    :ARG1 (r2 / rna
                                          :name (n / name :op1 "Snail"~e.8 :op2 "mRNA"~e.10))))))))

# ::tok As judged by Western blot analysis , the antibody did not detect endogenous proteins from cultured keratinocytes , but it did yield a band of the expected size from keratinocytes transiently expressing a hemagglutinin ( HA )-tagged Snail protein ( <xref ref-type="fig" rid="pbio-0030011-g001"> Figure 1 </xref>@ B ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3 2-1.3.1.r 3-1.3.1.1.1 4-1.3.1.1.2 5-1.3.1 8-1.1.2 10-1.1.1 10-1.1.1.r 11-1.1 12-1.1.3.1 13-1.1.3 14-1.2.3.r 15-1.1.4.1 18-1 21-1.2 23-1.2.2 24-1.2.2.1.r 26-1.2.2.1.1 27-1.2.2.1 28-1.2.3.r 30-1.2.3.1.2 31-1.2.3.1 33-1.2.3.1.1.2.1.1.1 37-1.2.3.1.1.1.1 38-1.2.3.1.1 43-1.3.2.1
# ::id pmid_1563_0473.59
# ::preferred 
(c / contrast-01~e.18
      :ARG1 (d / detect-01~e.11
            :polarity~e.10 "-"~e.10
            :ARG0 (a2 / antibody~e.8)
            :ARG1 (p / protein~e.13
                  :mod (e / endogenous~e.12))
            :ARG2 (k / keratinocyte
                  :ARG1-of (c2 / culture-01~e.15)))
      :ARG2 (y / yield-01~e.21
            :ARG0 a2
            :ARG1 (b / band~e.23
                  :mod~e.24 (s2 / size~e.27
                        :ARG1-of (e3 / expect-01~e.26)))
            :source~e.14,28 (k2 / keratinocyte
                  :ARG3-of (e2 / express-03~e.31
                        :ARG2 (p2 / protein~e.38
                              :name (n3 / name :op1 "Snail"~e.37)
                              :ARG1-of (t2 / tag-01
                                    :ARG2 (s / small-molecule
                                          :name (n4 / name :op1 "hemagglutinin"~e.33))))
                        :mod (t / transient~e.30))))
      :ARG2-of (j / judge-01~e.1
            :ARG3~e.2 (a3 / analyze-01~e.5
                  :name (n2 / name :op1 "Western"~e.3 :op2 "blot"~e.4))
            :ARG1-of (d3 / describe-01
                  :ARG2 (f / figure~e.43 :mod "1B"))))

# ::tok The antibody also recognized a band corresponding to the size of endogenous Snail ( approximately 28 kDa ) in lysates from embryonic mouse skin , the temporal appearance of which corresponded to the waves of hair follicle morphogenesis from E15.5 to newborn when over 90 % of the hair on the mouse is formed ( <xref ref-type="fig" rid="pbio-0030011-g001"> Figure 1 </xref>@ B ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1 2-1.4 3-1 5-1.2 6-1.2.1 7-1.2.1.1.r 9-1.2.1.1 10-1.2.1.1.1.r 11-1.2.1.1.1.2 12-1.2.1.1.1.1.1 14-1.2.1.1.2.1.2 15-1.2.1.1.2.1.2.1 20-1.3.1.r 22-1.3.1.2 23-1.3.1 26-1.2.2.1.1.2.1 26-1.2.2.2 27-1.2.2 30-1.2.2.1 31-1.2.2.1.1.r 33-1.2.2.1.1 34-1.2.2.1.1.1.r 35-1.2.2.1.1.1.1.1 36-1.2.2.1.1.1.1 37-1.2.2.1.1.1 38-1.3.1.r 40-1.2.2.1.1.2.2.r 40-1.2.2.1.1.2.r 41-1.2.2.1.1.2.2 42-1.2.2.1.1.2.3.r 43-1.2.2.1.1.2.3.1.1.1 44-1.2.2.1.1.2.3.1.1.1.1 45-1.2.2.1.1.2.3.1.1 48-1.2.2.1.1.2.3.1 49-1.2.2.1.1.2.3.1.2.r 51-1.2.2.1.1.2.3.1.2 53-1.2.2.1.1.2.3
# ::id pmid_1563_0473.60
# ::preferred 
(r / recognize-02~e.3
      :ARG0 (a3 / antibody~e.1)
      :ARG1 (b / band~e.5
            :ARG1-of (c / correspond-02~e.6
                  :ARG2~e.7 (s / size~e.9
                        :poss~e.10 (p2 / protein
                              :name (n / name :op1 "Snail"~e.12)
                              :mod (e / endogenous~e.11))
                        :ARG1-of (e2 / equal-01
                              :ARG2 (m / mass-quantity
                                    :unit (k / kilodalton)
                                    :quant (a4 / approximately~e.14 :op1 "28"~e.15)))))
            :ARG1-of (a5 / appear-01~e.27
                  :ARG1-of (c2 / correspond-02~e.30
                        :ARG2~e.31 (w / wave~e.33
                              :subevent-of~e.34 (m3 / morphogenesis~e.37
                                    :mod (f / follicle~e.36
                                          :mod (h / hair~e.35)))
                              :time~e.40 (d / date-interval
                                    :op1 (t2 / temporal-quantity~e.26
                                          :quant "15.5"
                                          :unit (d2 / day)
                                          :age-of (e4 / embryo))
                                    :op2~e.40 (n2 / newborn~e.41)
                                    :time-of~e.42 (f2 / form-01~e.53
                                          :ARG1 (h2 / hair~e.48
                                                :mod (p / percentage-entity~e.45
                                                      :value (o2 / over~e.43 :op1 "90"~e.44))
                                                :part-of~e.49 (m4 / mouse~e.51))))))
                  :mod (t / time~e.26)))
      :location (l / lysate
            :source~e.20,38 (s2 / skin~e.23
                  :mod (e3 / embryo)
                  :mod (m2 / mouse~e.22)))
      :mod (a / also~e.2))

# ::tok Consistent with the Western blot data , immunohistochemical analysis did not detect Snail in single @-@ layered E13.5 epidermis ( <xref ref-type="fig" rid="pbio-0030011-g001"> Figure 1 </xref>@ C ) nor in the placode , which is the earliest morphological sign of the commitment of multipotent cells of the embryonic ectoderm to a hair cell fate ( <xref ref-type="fig" rid="pbio-0030011-g001"> Figure 1 </xref>@ D ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.4 1-1.4.1.r 3-1.4.1.1.1.1.1 4-1.4.1.1.1.1.2 5-1.4.1 8-1.2 8-1.4.1.1.1 10-1.1 10-1.1.r 11-1 12-1.3.1.1 16-1.5.1.1 18-1.5.1 23-1.5.1.2.1 24-1.5.1.1.1 28-1.1.r 29-1.5.r 31-1.5.2 36-1.5.2.2.2 36-1.5.2.2.2.1 36-1.5.2.2.2.1.r 38-1.5.2.2 39-1.5.2.2.1.r 41-1.5.2.2.1 42-1.5.2.2.1.1.r 43-1.5.2.2.1.1.1 44-1.5.2.2.1.1 48-1.5.2.2.1.1.2 49-1.5.2.2.1.2.r 51-1.5.2.2.1.2.1.1 52-1.5.2.2.1.2.1 53-1.5.2.2.1.2 58-1.5.1.2.1 58-1.5.2.1.1 59-1.5.1.1.1
# ::id pmid_1563_0473.61
# ::preferred 
(d / detect-01~e.11
      :polarity~e.10,28 "-"~e.10
      :ARG0 (a2 / analyze-01~e.8
            :mod (i / immunohistochemistry))
      :ARG1 (p / protein
            :name (n3 / name :op1 "Snail"~e.12))
      :ARG1-of (c / consistent-01~e.0
            :ARG2~e.1 (d2 / data~e.5
                  :ARG2-of (r / result-01
                        :ARG1 (a / analysis~e.8
                              :name (n2 / name :op1 "Western"~e.3 :op2 "blot"~e.4)))))
      :location~e.29 (a3 / and
            :op1 (e / epidermis~e.18
                  :mod (l / layer~e.16 :quant "1"~e.24,59)
                  :ARG1-of (d4 / describe-01
                        :ARG0 (f / figure~e.23,58 :mod "1C"))
                  :part-of (e2 / embryo
                        :age (t / temporal-quantity
                              :quant "13.5"
                              :unit (d3 / day))))
            :op2 (p2 / placode~e.31
                  :ARG1-of (d5 / describe-01
                        :ARG0 (f2 / figure~e.58 :mod "1D"))
                  :ARG0-of (s3 / signal-07~e.38
                        :ARG1~e.39 (c2 / commit-01~e.41
                              :ARG1~e.42 (c3 / cell~e.44
                                    :mod (m3 / multipotent~e.43)
                                    :part-of (e4 / ectoderm~e.48
                                          :mod (e5 / embryo)))
                              :ARG2~e.49 (f3 / fate~e.53
                                    :mod (c4 / cell~e.52
                                          :mod (h / hair~e.51))))
                        :mod (e3 / early~e.36
                              :degree~e.36 (m / most~e.36))
                        :mod (m2 / morphology)))))

# ::tok Consistent with the in situ hybridization results , anti @-@ Snail antibody labeled only hair buds and not follicles at more mature stages of development ( <xref ref-type="fig" rid="pbio-0030011-g001"> Figure 1 </xref>@ E ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.3 1-1.1.3.1.r 3-1.1.3.1.1.1.1 4-1.1.3.1.1.1.1 5-1.1.3.1.1.1 6-1.1.3.1 6-1.1.3.1.1 6-1.1.3.1.1.r 8-1.1.1.1 10-1.1.1.1.1.1.1 11-1.1.1 12-1.1 12-1.2 13-1.1.2.2 14-1.1.2.1 15-1.1.2 16-1 17-1.2.1 17-1.2.1.r 18-1.2.3 19-1.2.4.r 20-1.2.4.2.1 21-1.2.4.2 22-1.2.4 23-1.2.4.1.r 24-1.2.4.1 29-1.3.1
# ::id pmid_1563_0473.62
# ::preferred 
(a2 / and~e.16
      :op1 (l / label-01~e.12
            :ARG0 (a / antibody~e.11
                  :ARG0-of (c2 / counter-01~e.8
                        :ARG1 (p / protein
                              :name (n / name :op1 "Snail"~e.10))))
            :ARG1 (b / bud~e.15
                  :mod (h2 / hair~e.14)
                  :mod (o / only~e.13))
            :ARG1-of (c / consistent-01~e.0
                  :ARG2~e.1 (t / thing~e.6
                        :ARG2-of~e.6 (r / result-01~e.6
                              :ARG1 (h / hybridize-01~e.5
                                    :manner (i / in-situ~e.3,4))))))
      :op2 (l2 / label-01~e.12
            :polarity~e.17 "-"~e.17
            :ARG0 a
            :ARG1 (f / follicle~e.18)
            :time~e.19 (s / stage~e.22
                  :subevent-of~e.23 (d / develop-02~e.24)
                  :mod (m / mature~e.21
                        :degree (m2 / more~e.20))))
      :ARG1-of (d2 / describe-01
            :ARG2 (f2 / figure~e.29 :mod "1E")))

# ::tok Taken together , the anti @-@ Snail antibody appeared to be specific for its target protein .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.1 1-1.2.1.1 4-1.1.1.1 6-1.1.1.1.1.1.1 7-1.1.1 8-1 9-1.2 10-1.1.1.r 11-1.1 12-1.1.2.r 13-1.1.2.1.1 13-1.1.2.1.1.r 14-1.1.2.1 15-1.1.2
# ::id pmid_1563_0473.63
# ::preferred 
(a2 / appear-01~e.8
      :ARG1 (s / specific~e.11
            :domain~e.10 (a / antibody~e.7
                  :ARG0-of (c / counter-01~e.4
                        :ARG1 (p / protein
                              :name (n / name :op1 "Snail"~e.6))))
            :topic~e.12 (p2 / protein~e.15
                  :ARG1-of (t / target-01~e.14
                        :ARG0~e.13 a~e.13)))
      :ARG1-of (c2 / cause-01~e.9
            :ARG0 (t2 / take-01~e.0
                  :mod (t3 / together~e.1))))

# ::tok It did not detect other Snail family members known to be expressed in keratinocytes and @/@ or skin ( unpublished data ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2 2-1.1 2-1.1.r 2-1.4.1.1.1 2-1.4.1.1.1.r 3-1 4-1.3.2 5-1.3.1.1.1.1 6-1.3.1.1.2 7-1.3 8-1.3.1.1.3.2 11-1.3.1.1.3 14-1.3.1.1.3.1 16-1.3.1.1.3.1 17-1.3.1.1.3.1.2 19-1.1 19-1.4.1.1.1 20-1.4.1
# ::id pmid_1563_0473.64
# ::preferred 
(d / detect-01~e.3
      :polarity~e.2 "-"~e.2,19
      :ARG0 (i / it~e.0)
      :ARG1 (m / member~e.7
            :ARG1-of (i2 / include-91
                  :ARG2 (p / protein
                        :name (n / name :op1 "Snail"~e.5)
                        :mod (f / family~e.6)
                        :ARG2-of (e / express-03~e.11
                              :ARG3 (a / and-or~e.14,16
                                    :op1 (k2 / keratinocyte)
                                    :op2 (s / skin~e.17))
                              :ARG1-of (k / know-01~e.8))))
            :mod (o / other~e.4))
      :ARG1-of (d2 / describe-01
            :ARG0 (d3 / data~e.20
                  :ARG1-of (p2 / publish-01 :polarity~e.2 "-"~e.2,19))))

# ::tok Furthermore , the immunohistochemical data paralleled our <i> Snail </i> in situ hybridization data revealing transient <i> Snail </i> expression at the hair bud stage ( <xref ref-type="fig" rid="pbio-0030011-g001"> Figure 1 </xref>@ A ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 4-1.1.1 4-1.1.2 5-1.1 6-1.1.2.1.1 6-1.1.2.1.1.r 8-1.1.2.1.2.1.1 10-1.1.2.1.3 11-1.1.2.1.3 12-1.1.2.1 13-1.1.2 14-1.1.2.2 15-1.1.2.2.1.2 17-1.1.2.2.1.1 19-1.1.2.2.1 20-1.1.2.2.1.3.r 22-1.1.2.2.1.3.1.1 23-1.1.2.2.1.3.1 24-1.1.2.2.1.3 29-1.1.2.2.1.4.1
# ::id pmid_1563_0473.65
# ::preferred 
(a / and
      :op2 (p / parallel-01~e.5
            :ARG0 (d / data~e.4
                  :mod (i / immunohistochemistry))
            :ARG1 (d2 / data~e.4,13
                  :topic (h / hybridize-01~e.12
                        :ARG0~e.6 (w / we~e.6)
                        :ARG1 (p2 / protein
                              :name (n / name :op1 "Snail"~e.8))
                        :manner (i2 / in-situ~e.10,11))
                  :ARG0-of (r / reveal-01~e.14
                        :ARG1 (e / express-03~e.19
                              :ARG2 p2~e.17
                              :mod (t / transient~e.15)
                              :time~e.20 (s / stage~e.24
                                    :mod (b / bud~e.23
                                          :mod (h2 / hair~e.22)))
                              :ARG1-of (d3 / describe-01
                                    :ARG0 (f / figure~e.29 :mod "1A")))))))

# ::tok As judged by immunohistochemistry , Snail protein was localized to the nuclei of the hair bud cells ( <xref ref-type="fig" rid="pbio-0030011-g001"> Figure 1 </xref>@ E ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1 2-1.1.r 3-1.1 5-1.2.1.1.1 6-1.2.1 7-1.2 11-1.2.2 12-1.2.2.1.r 14-1.2.2.1.1.1 15-1.2.2.1.1 16-1.2.2.1 21-1.3.1
# ::id pmid_1563_0473.66
# ::preferred 
(j / judge-01~e.1
      :ARG0~e.2 (i / immunohistochemistry~e.3)
      :ARG1 (b2 / be-located-at-91~e.7
            :ARG1 (p2 / protein~e.6
                  :name (n2 / name :op1 "Snail"~e.5))
            :ARG2 (n / nucleus~e.11
                  :poss~e.12 (c2 / cell~e.16
                        :part-of (b / bud~e.15
                              :part-of (h2 / hair~e.14)))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure~e.21 :mod "1E")))

# ::tok This feature was consistent with Snail 's known function as a transcriptional repressor [ @<xref ref-type="bibr" rid="pbio-0030011-b12"> 12 </xref> , <xref ref-type="bibr" rid="pbio-0030011-b13"> 13 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1 3-1 4-1.2.r 5-1.2.1.1.1 6-1.2.1.r 7-1.2.3 8-1.2 12-1.2.2 17-1.3.1.1.1.1 23-1.3.1.1.1.2
# ::id pmid_1563_0473.67
# ::preferred 
(c / consistent-01~e.3
      :ARG1 (f / feature~e.1
            :mod (t / this~e.0))
      :ARG2~e.4 (f2 / function-01~e.8
            :ARG0~e.6 (p2 / protein
                  :name (n / name :op1 "Snail"~e.5))
            :ARG1 (r2 / repress-01~e.12
                  :ARG1 (t2 / transcribe-01))
            :ARG1-of (k / know-01~e.7))
      :ARG1-of (d / describe-01
            :ARG0 (p3 / publication
                  :ARG1-of (c2 / cite-01
                        :ARG2 (a / and :op1 "12"~e.17 :op2 "13"~e.23)))))

# ::tok Additionally , anti @-@ Snail labeling was detected in only three of the four major waves of follicle morphogenesis .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1.1.1 4-1.1.1.1.1.1.1 5-1.1.1 7-1.1 8-1.1.2.r 9-1.1.2.5 10-1.1.2.1 13-1.1.2.2.1.1 14-1.1.2.3 15-1.1.2 15-1.1.2.2.1 16-1.1.2.4.r 17-1.1.2.4.1 18-1.1.2.4
# ::id pmid_1563_0473.68
# ::preferred 
(a / and
      :op2 (d / detect-01~e.7
            :ARG1 (l / label-01~e.5
                  :ARG0-of (o / oppose-01~e.2
                        :ARG1 (p / protein
                              :name (n / name :op1 "Snail"~e.4))))
            :location~e.8 (w / wave~e.15
                  :quant "3"~e.10
                  :ARG1-of (i / include-91
                        :ARG2 (w2 / wave~e.15 :quant "4"~e.13))
                  :mod (m / major~e.14)
                  :mod~e.16 (m2 / morphogenesis~e.18
                        :mod (f / follicle~e.17))
                  :mod (o2 / only~e.9))))

# ::tok Snail was not found in the buds of guard hairs that are the earliest of all hairs to form ( at E13.5 ) , and which constitute less than 5 % of the mouse coat ( unpublished data ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.1.1 2-1.1 2-1.1.r 3-1 4-1.3.r 6-1.3 7-1.3.1.r 8-1.3.1.1 9-1.3.1 13-1.3.1.2.1 14-1.3.1.2.1.2.r 15-1.3.1.2.1.2.1 16-1.3.1.2.1.2 18-1.3.1.2 24-1.3.1.2.2 26-1.3.1.2.2.1 27-1.3.1.3.2 28-1.3.1.3.2 29-1.3.1.3.2.1.1 30-1.3.1.3.2.1 33-1.3.1.3.1.1 34-1.3.1.3.1 36-1.3.1.3.3.1.1.1 37-1.3.1.3.3.1
# ::id pmid_1563_0473.69
# ::preferred 
(f4 / find-01~e.3
      :polarity~e.2 "-"~e.2
      :ARG1 (p2 / protein
            :name (n / name :op1 "Snail"~e.0))
      :location~e.4 (b / bud~e.6
            :poss~e.7 (h / hair~e.9
                  :mod (g / guard~e.8)
                  :ARG1-of (f2 / form-01~e.18
                        :time (e / early~e.13
                              :mod (m / most)
                              :compared-to~e.14 (h2 / hair~e.16
                                    :mod (a / all~e.15)))
                        :op1-of (a2 / and~e.24
                              :op2 (c / constitute-01~e.26
                                    :ARG0 h))
                        :time (a3 / age-01
                              :ARG1 (e2 / embryo)
                              :ARG2 (t / temporal-quantity
                                    :quant "13.5"
                                    :unit (d / day))))
                  :ARG1-of (i / include-91
                        :ARG2 (c2 / coat~e.34
                              :poss (m2 / mouse~e.33))
                        :ARG3 (l2 / less-than~e.27,28
                              :op1 (p3 / percentage-entity~e.30 :value "5"~e.29))
                        :ARG1-of (d2 / describe-01
                              :ARG0 (d3 / data~e.37
                                    :ARG1-of (p4 / publish-01 :polarity "-"~e.36)))))))

# ::tok As judged by immunofluorescence with antibodies against the proliferating nuclear antigen Ki67 , the timing of Snail expression coincided with the stage at which the developing follicle enhanced its proliferation and down @-@ growth ( <xref ref-type="fig" rid="pbio-0030011-g001"> Figure 1 </xref>@ F ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.1.2.1.r 1-1 5-1.1.1 6-1.1.1.1 8-1.1.1.1.1 8-1.1.1.1.1.3 8-1.1.1.1.1.3.r 9-1.1.1.1.1.2 10-1.1.1.1.1.4 11-1.1.1.1.1.1.1 14-1.2.1.1 14-1.2.1.2.1.r 15-1.2.1.1.1.r 16-1.2.1.1.1.1.1.1 17-1.2.1.1.1 18-1.2 21-1.2.1.2 25-1.2.1.2.1.1.1 26-1.2.1.2.1.1 27-1.2.1.2.1 29-1.2.1.2.1.2.1 30-1.2.1.2.1.2 31-1.2.1.2.1.2.2.2 33-1.2.1.2.1.2.2 38-1.3.1
# ::id pmid_1563_0473.70
# ::preferred 
(j / judge-01~e.1
      :ARG0 (i / immunofluoresce-00
            :ARG1 (a / antibody~e.5
                  :ARG0-of (o / oppose-01~e.6
                        :ARG1 (p5 / protein~e.8
                              :name (n4 / name :op1 "Ki67"~e.11)
                              :mod (n5 / nucleus~e.9)
                              :ARG0-of~e.8 (p / proliferate-01~e.8)
                              :mod (a2 / antigen~e.10)))))
      :ARG1 (c / coincide-01~e.18
            :ARG1 (a4 / and
                  :op1 (t / time-02~e.14
                        :ARG1~e.15 (e / express-03~e.17
                              :ARG2 (p2 / protein
                                    :name (n / name :op1 "Snail"~e.16))))
                  :op2 (s / stage~e.21
                        :time-of~e.0,14 (e2 / enhance-01~e.27
                              :ARG0 (f / follicle~e.26
                                    :ARG1-of (d / develop-02~e.25))
                              :ARG1 (a5 / and~e.30
                                    :op1 (p3 / proliferate-01~e.29
                                          :ARG0 f)
                                    :op2 (g / grow-01~e.33
                                          :ARG1 f
                                          :direction (d2 / down~e.31)))))))
      :ARG1-of (d3 / describe-01
            :ARG0 (f2 / figure~e.38 :mod "1F")))

# ::tok Immunohistochemistry with antibodies against the active ( phosphorylated ) form of MAPK ( pMAPK ) marked a subset of the proliferating ( Ki67 @-@ positive ) cells , and pMAPK @-@ positive cells were enriched in the hair bud ( <xref ref-type="fig" rid="pbio-0030011-g001"> Figure 1 </xref>@ G ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1.1.1.r 2-1.1.1.1 3-1.1.1.2 7-1.1.1.2.1.3 11-1.1.1.2.1.1.1 15-1.1 17-1.1.2 18-1.1.2.1.r 20-1.1.2.1.1 22-1.1.2.1.2.1.1 26-1.1.2.1 28-1 32-1.2.1 34-1.2 35-1.2.1.1.r 37-1.2.1.1.1 38-1.2.1.1 43-1.3.1
# ::id pmid_1563_0473.71
# ::preferred 
(a3 / and~e.28
      :op1 (m / mark-02~e.15
            :ARG0 (i / immunohistochemistry~e.0
                  :mod~e.1 (a / antibody~e.2)
                  :ARG0-of (o2 / oppose-01~e.3
                        :ARG1 (e2 / enzyme
                              :name (n2 / name :op1 "MAPK"~e.11)
                              :ARG1-of (a2 / activate-01)
                              :ARG1-of (p2 / phosphorylate-01~e.7))))
            :ARG2 (s / subset~e.17
                  :quant-of~e.18 (c2 / cell~e.26
                        :ARG0-of (p4 / proliferate-01~e.20)
                        :part (p5 / protein
                              :name (n3 / name :op1 "Ki67"~e.22)))))
      :op2 (e / enrich-01~e.34
            :ARG1 (c3 / cell~e.32
                  :location~e.35 (b / bud~e.38
                        :mod (h2 / hair~e.37))
                  :part e2))
      :ARG1-of (d / describe-01
            :ARG0 (f2 / figure~e.43 :mod "1G")))

# ::tok The timing of Snail induction and Ki67 and pMAPK enrichment in the hair bud appeared to follow closely the induction of LEF @-@ 1/β-catenin activity , known to initiate in the hair placode stage [ @<xref ref-type="bibr" rid="pbio-0030011-b20"> 20 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1 2-1.1.1.1.r 3-1.1.1.1.1.1.1.1 4-1.1.1.1.1 5-1.1.1.1 6-1.1.1.1.2.1.1.1.1 7-1.1.1.1.2.1 9-1.1.1.1.2 10-1.1.1.1.2.2.r 12-1.1.1.1.2.2.1 13-1.1.1.1.2.2 14-1 16-1.1 17-1.1.3 17-1.1.3.r 19-1.1.2 20-1.1.2.1.r 21-1.1.2.1.1.1.1.1 24-1.1.2.1 26-1.1.2.1.2.2 28-1.1.2.1.2 29-1.1.2.1.2.1.r 31-1.1.2.1.2.1.2 32-1.1.2.1.2.1.1 33-1.1.2.1.2.1 38-1.2.1.1.1
# ::id pmid_1563_0473.72
# ::preferred 
(a / appear-02~e.14
      :ARG1 (f / follow-01~e.16
            :ARG1 (t / time-02~e.1
                  :ARG1~e.2 (a5 / and~e.5
                        :op1 (i / induce-01~e.4
                              :ARG1 (p / protein
                                    :name (n / name :op1 "Snail"~e.3)))
                        :op2 (e / enrich-01~e.9
                              :ARG1 (a3 / and~e.7
                                    :op1 (p2 / protein
                                          :name (n2 / name :op1 "Ki67"~e.6))
                                    :op2 (e2 / enzyme
                                          :name (n3 / name :op1 "MAPK")
                                          :ARG3-of (p7 / phosphorylate-01)))
                              :location~e.10 (b / bud~e.13
                                    :poss (h / hair~e.12)))))
            :ARG2 (i2 / induce-01~e.19
                  :ARG1~e.20 (a4 / act-02~e.24
                        :ARG0 (m / macro-molecular-complex
                              :part (p4 / protein
                                    :name (n4 / name :op1 "LEF-1"~e.21))
                              :part (p3 / protein
                                    :name (n5 / name :op1 "β-catenin")))
                        :ARG1-of (i3 / initiate-01~e.28
                              :time~e.29 (s / stage~e.33
                                    :mod (p5 / placode~e.32)
                                    :mod (h2 / hair~e.31))
                              :ARG1-of (k / know-01~e.26))))
            :manner~e.17 (c2 / close~e.17))
      :ARG1-of (d / describe-01
            :ARG0 (p6 / publication
                  :ARG1-of (c / cite-01 :ARG2 "20"~e.38))))

# ::tok However , like placodes , hair buds exhibited down @-@ regulation in E @-@ cadherin expression ( <xref ref-type="fig" rid="pbio-0030011-g001"> Figure 1 </xref>@ H ; see also [ @<xref ref-type="bibr" rid="pbio-0030011-b04"> 4 </xref>@ ]).
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 2-1.1.1.2 5-1.1.1.1 6-1.1.1 7-1.1 12-1.1.2.1.1.1.1 14-1.1.2.1.1.1.1 15-1.1.2.1 20-1.2.1.1 25-1.2.1.2 25-1.2.1.2.2 25-1.2.1.2.2.r 31-1.2.1.2.1.1
# ::id pmid_1563_0473.73
# ::preferred 
(c / contrast-01~e.0
      :ARG2 (e / exhibit-01~e.7
            :ARG0 (b / bud~e.6
                  :poss (h / hair~e.5)
                  :ARG1-of (r2 / resemble-01~e.2
                        :ARG2 (p3 / placode)))
            :ARG1 (d / downregulate-01
                  :ARG1 (e2 / express-03~e.15
                        :ARG2 (p / protein
                              :name (n / name :op1 "E-cadherin"~e.12,14)))))
      :ARG1-of (d2 / describe-01
            :ARG0 (a / and
                  :op1 (f / figure~e.20 :mod "1H")
                  :op2 (p2 / publication~e.25
                        :ARG1-of (c2 / cite-01 :ARG2 "4"~e.31)
                        :ARG1-of~e.25 (s / see-01~e.25
                              :mode "imperative"
                              :ARG0 (y / you))))))

# ::tok Sustained Expression of Snail Results in Epidermal Hyperproliferation and Differentiation Defects in Tg Mouse Skin
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2 1-1.1 2-1.1.1.r 3-1.1.1.1.1 4-1 8-1.2 9-1.2.2.2 10-1.2.2 13-1.2.2.1.1 14-1.2.2.1
# ::id pmid_1563_0473.74
# ::preferred 
(r / result-01~e.4
      :ARG1 (e / express-03~e.1
            :ARG2~e.2 (p / protein
                  :name (n / name :op1 "Snail"~e.3))
            :ARG1-of (s / sustain-01~e.0))
      :ARG2 (a / and~e.8
            :op1 (p2 / proliferate-01
                  :ARG0 (e2 / epidermis)
                  :degree (h / hyper))
            :op2 (d / defect~e.10
                  :location (s2 / skin~e.14
                        :part-of (m / mouse~e.13
                              :mod (t / transgenic)))
                  :mod (d2 / differentiate-01~e.9))))

# ::tok The striking spike of Snail expression coincident with hair bud formation and enhanced proliferation prompted us to examine the consequences of ectopically expressing Snail elsewhere in mouse skin epidermis .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1.2 2-1.1.1 3-1.1.1.1.r 4-1.1.1.1.1.1.1 5-1.1.1.1 8-1.1.2.1.1 9-1.1.2.1 10-1.1.2 11-1.1 12-1.1.3.1 13-1.1.3 14-1 15-1.2 17-1.3 19-1.3.2 22-1.3.2.1 23-1.3.2.1.1 24-1.3.2.1.2.2 26-1.3.2.1.2.1.1 27-1.3.2.1.2.1 28-1.3.2.1.2
# ::id pmid_1563_0473.75
# ::preferred 
(p / prompt-02~e.14
      :ARG0 (a2 / and~e.11
            :op1 (s3 / spike-04~e.2
                  :ARG1~e.3 (e / express-03~e.5
                        :ARG2 (p2 / protein
                              :name (n3 / name :op1 "Snail"~e.4)))
                  :ARG1-of (s / strike-04~e.1))
            :op2 (f / form-01~e.10
                  :ARG1 (b / bud~e.9
                        :poss (h / hair~e.8)))
            :op3 (p3 / proliferate-01~e.13
                  :ARG1-of (e2 / enhance-01~e.12))
            :ARG1-of (c2 / coincide-01))
      :ARG1 (w / we~e.15)
      :ARG2 (e3 / examine-01~e.17
            :ARG0 w
            :ARG1 (c3 / consequence~e.19
                  :poss (e4 / express-03~e.22
                        :ARG2 p2~e.23
                        :ARG3 (e6 / epidermis~e.28
                              :part-of (s2 / skin~e.27
                                    :part-of (m / mouse~e.26))
                              :mod (e7 / elsewhere~e.24))
                        :manner (e5 / ectopic)))))

# ::tok To distinguish Tg from endogenous Snail , we used the HA @-@ epitope , shown previously not to alter Snail 's transcriptional activity [ @<xref ref-type="bibr" rid="pbio-0030011-b12"> 12 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3 3-1.3.3.r 4-1.3.3.2 5-1.3.2.1.1 5-1.3.3.1.1 7-1.1 8-1 8-1.3.r 10-1.2.1.1 12-1.2.1.1 14-1.2.2.3 15-1.2.2.3.1 16-1.2.2.1 16-1.2.2.1.r 18-1.2 18-1.2.2 18-1.2.2.r 19-1.2.2.2.1.1.1 19-1.3.2.1.1 19-1.3.3.1.1 27-1.4.1.1.1
# ::id pmid_1563_0473.76
# ::preferred 
(u / use-01~e.8
      :ARG0 (w / we~e.7)
      :ARG1 (d / dna-sequence~e.18
            :name (n / name :op1 "HA-epitope"~e.10,12)
            :ARG0-of~e.18 (a / alter-01~e.18
                  :polarity~e.16 "-"~e.16
                  :ARG1 (a2 / act-01
                        :ARG0 (p2 / protein
                              :name (n2 / name :op1 "Snail"~e.19))
                        :ARG1 (t / transcribe-01))
                  :ARG1-of (s / show-01~e.14
                        :time (p / previous~e.15))))
      :purpose~e.8 (d2 / distinguish-01~e.1
            :ARG0 w
            :ARG1 (p5 / protein
                  :name (n4 / name :op1 "Snail"~e.5,19)
                  :mod (t2 / transgenic))
            :ARG2~e.3 (p3 / protein
                  :name (n3 / name :op1 "Snail"~e.5,19)
                  :mod (e / endogenous~e.4)))
      :ARG1-of (d3 / describe-01
            :ARG0 (p4 / publication
                  :ARG1-of (c / cite-01 :ARG2 "12"~e.27))))

# ::tok Of 20 <i> K14 @-@ Snail[HA] </i> Tg animals generated , three expressed the transgene and all exhibited analogous phenotypes .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1 3-1.1.3.1.1 8-1.1 8-1.1.4.1 9-1 11-1.1.4.1.1 12-1.1.4.1.2 14-1.1.2 17-1.1.5 19-1.1.5.1
# ::id pmid_1563_0473.77
# ::preferred 
(g / generate-01~e.9
      :ARG1 (a / animal~e.8
            :quant "20"~e.1
            :mod (t / transgene~e.14)
            :part (p / protein
                  :name (n / name :op1 "K14-Snail"~e.3)
                  :part (p2 / protein
                        :name (n2 / name :op1 "HA")))
            :ARG2-of (i / include-91
                  :ARG1 (a2 / animal~e.8
                        :quant "3"~e.11
                        :ARG1-of (e / express-03~e.12
                              :ARG2 t)))
            :ARG0-of (e2 / exhibit-01~e.17
                  :ARG1 (p3 / phenotype~e.19
                        :mod (a3 / analogue)))))

# ::tok Mice that integrated the transgene at the single @-@ cell stage died at or shortly after birth .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 2-1.1.1 4-1.1.1.1 5-1.1.1.2.r 7-1.1.1.2.1.1 9-1.1.1.2.1 10-1.1.1.2 11-1 12-1.2.r 13-1.2 14-1.2.2.2 15-1.2.2 16-1.2.1
# ::id pmid_1563_0473.78
# ::preferred 
(d / die-01~e.11
      :ARG1 (m / mouse~e.0
            :ARG0-of (i / integrate-01~e.2
                  :ARG1 (t / transgene~e.4)
                  :time~e.5 (s / stage~e.10
                        :mod (c / cell~e.9
                              :mod (s2 / single~e.7)))))
      :time~e.12 (o / or~e.13
            :op1 (b / birth~e.16)
            :op2 (a / after~e.15
                  :op1 b
                  :quant (s3 / short~e.14))))

# ::tok The three surviving full @-@ Tg founder mice harbored transgene integrations that gave stable transmission of mosaic <i> Snail </i> gene expression through the germline .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1 2-1.1.3 3-1.1.5.1 6-1.1.2 6-1.1.4 7-1.1 8-1 9-1.1.5 9-1.2.1 10-1.2 12-1.2.2 13-1.2.2.1.3 14-1.2.2.1 15-1.2.2.1.1.r 16-1.2.2.1.1.2 18-1.2.2.1.1.1.1.1 20-1.2.2.1.1.1 21-1.2.2.1.1 24-1.2.2.1.2.1.1
# ::id pmid_1563_0473.79
# ::preferred 
(h / harbor-01~e.8
      :ARG0 (m / mouse~e.7
            :quant "3"~e.1
            :ARG0-of (f / found-01~e.6)
            :ARG0-of (s / survive-01~e.2)
            :mod (f3 / founder~e.6)
            :mod (t / transgene~e.9
                  :degree (f2 / full~e.3)))
      :ARG1 (i / integrate-01~e.10
            :ARG1 (t3 / transgene~e.9)
            :ARG0-of (g / give-01~e.12
                  :ARG1 (t2 / transmit-01~e.14
                        :ARG1~e.15 (e / express-03~e.21
                              :ARG1 (g3 / gene~e.20
                                    :name (n / name :op1 "Snail"~e.18))
                              :mod (m2 / mosaic~e.16))
                        :instrument (c / cell-line
                              :name (n2 / name :op1 "germline"~e.24))
                        :mod (s2 / stable~e.13)))))

# ::tok Progressively poor health necessitated our sacrificing most offspring from these lines within a year of birth .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 1-1.1.1 2-1.1 3-1 4-1.2.1 4-1.2.1.r 5-1.2 6-1.2.2.1 7-1.2.2 8-1.2.2.2.r 9-1.2.2.2.1 10-1.2.2.2 12-1.2.3.2.1.1 13-1.2.3.2.1.2 15-1.2.3.1
# ::id pmid_1563_0473.80
# ::preferred 
(n / necessitate-01~e.3
      :ARG0 (h / health~e.2
            :mod (p / poor~e.1
                  :mod (p2 / progressive~e.0)))
      :ARG1 (s / sacrifice-01~e.5
            :ARG0~e.4 (w / we~e.4)
            :ARG1 (o / offspring~e.7
                  :mod (m / most~e.6)
                  :source~e.8 (l / line~e.10
                        :mod (t2 / this~e.9)))
            :time (a / after
                  :op1 (b / birth-01~e.15)
                  :quant (u / up-to
                        :op1 (t3 / temporal-quantity
                              :quant "1"~e.12
                              :unit (y2 / year~e.13))))))

# ::tok As <i> Snail </i> Tg animals grew , they became distinguished by their small size , short tails , and flaky skin ( <xref ref-type="fig" rid="pbio-0030011-g002"> Figure 2 </xref>@ A ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3.r 2-1.2.1.1.1 4-1.2.2.1.1 5-1.2 6-1.3 8-1.3.1 10-1 11-1.1.r 12-1.1.1.2 12-1.1.1.2.r 13-1.1.1.1 14-1.1.1 16-1.1.2.1 17-1.1.2 19-1.1 21-1.1.3 26-1.4.1
# ::id pmid_1563_0473.81
# ::preferred 
(d / distinguish-01~e.10
      :ARG0~e.11 (a2 / and~e.19
            :op1 (s / size~e.14
                  :mod (s4 / small~e.13)
                  :poss~e.12 a~e.12)
            :op2 (t2 / tail~e.17
                  :mod (s2 / short~e.16)
                  :poss (a / animal~e.5
                        :mod (t / transgene
                              :name (n / name :op1 "Snail"~e.2))
                        :part (g2 / gene
                              :name (n2 / name :op1 "Tg"~e.4))))
            :op3 (s3 / skin~e.21
                  :mod (f / flake)
                  :poss a))
      :ARG1 a
      :time~e.0 (g / grow-01~e.6
            :ARG1 a~e.8)
      :ARG1-of (d2 / describe-01
            :ARG0 (f2 / figure~e.26 :mod "2A")))

# ::tok Histological analyses of 3 @-@ d old ( P3 ) mice revealed mosaic patches marked by epidermal thickening ( <xref ref-type="fig" rid="pbio-0030011-g002"> Figure 2 </xref>@ B ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2 1-1.1 2-1.1.1.r 3-1.1.1.1.1.1 6-1.1.1.1 10-1.1.1 11-1 12-1.2.1 13-1.2 14-1.2.2 17-1.2.2.1 22-1.3.1
# ::id pmid_1563_0473.82
# ::preferred 
(r / reveal-01~e.11
      :ARG0 (a / analyze-01~e.1
            :ARG1~e.2 (m / mouse~e.10
                  :ARG1-of (a2 / age-01~e.6
                        :ARG2 (t / temporal-quantity
                              :quant "3"~e.3
                              :unit (d / day))))
            :mod (h / histology~e.0))
      :ARG1 (p / patch~e.13
            :mod (m2 / mosaic~e.12)
            :ARG1-of (m3 / mark-02~e.14
                  :ARG3 (t2 / thicken-01~e.17
                        :ARG1 (e / epidermis))))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure~e.22 :mod "2B")))

# ::tok The mosaic morphology was reflected at the level of Tg Snail protein , with only the hyperthickened regions expressing nuclear HA @-@ tagged Snail ( <xref ref-type="fig" rid="pbio-0030011-g002"> Figure 2 </xref>@ C ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.2.1 2-1.1.2 4-1 7-1.1 8-1.1.1.r 9-1.1.1.2.1.1 10-1.1.1.1.1 11-1.1.1 11-1.1.1.3.1.2.1 11-1.1.1.3.1.2.1.2.1 17-1.1.1.3.1 18-1.1.1.3.1.2 19-1.1.1.3.1.2.1.2.1.2 20-1.1.1.3.1.2.1.2.1.1.1 22-1.1.1.3.1.2.1.2 23-1.1.1.1.1 23-1.1.1.3.1.2.1.1.1 28-1.2.1
# ::id pmid_1563_0473.83
# ::preferred 
(r / reflect-01~e.4
      :ARG2 (l / level~e.7
            :poss~e.8 (p / protein~e.11
                  :name (n / name :op1 "Snail"~e.10,23)
                  :part (g / gene
                        :name (n2 / name :op1 "Tg"~e.9))
                  :ARG0-of (h / have-03
                        :ARG1 (r2 / region~e.17
                              :mod (t / thicken-01
                                    :degree (h2 / hyper))
                              :ARG1-of (e / express-03~e.18
                                    :ARG2 (p2 / protein~e.11
                                          :name (n3 / name :op1 "Snail"~e.23)
                                          :ARG1-of (t2 / tag-01~e.22
                                                :ARG2 (p3 / protein~e.11
                                                      :name (n4 / name :op1 "HA"~e.20)
                                                      :mod (n5 / nucleus~e.19))))))))
            :part (m / morphology~e.2
                  :mod (m2 / mosaic~e.1)))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure~e.28 :mod "2C")))

# ::tok These hyperthickened areas were marked by excessive proliferation , as revealed by antibodies against the proliferating nuclear antigen Ki67 ( <xref ref-type="fig" rid="pbio-0030011-g002"> Figure 2 </xref>@ D and <xref ref-type="fig" rid="pbio-0030011-g002"> 2 </xref>@ E ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2 2-1.1 4-1 5-1.2.r 6-1.2.1 7-1.2 9-1.3.r 10-1.3 11-1.3.1.r 12-1.3.1 13-1.3.1.1 15-1.3.1.1.1 15-1.3.1.1.1.2 15-1.3.1.1.1.2.r 16-1.3.1.1.1.3 17-1.3.1.1.1.4 18-1.3.1.1.1.1.1 23-1.4.1.1 23-1.4.1.2 27-1.4.1
# ::id pmid_1563_0473.84
# ::preferred 
(m / mark-02~e.4
      :ARG1 (a / area~e.2
            :ARG1-of (t / thicken-01
                  :degree (h / hyper))
            :mod (t2 / this~e.0))
      :ARG3~e.5 (p / proliferate-01~e.7
            :mod (e / excessive~e.6))
      :ARG1-of~e.9 (r / reveal-01~e.10
            :ARG0~e.11 (a2 / antibody~e.12
                  :ARG0-of (o / oppose-01~e.13
                        :ARG1 (p2 / protein~e.15
                              :name (n / name :op1 "Ki67"~e.18)
                              :ARG0-of~e.15 (p3 / proliferate-01~e.15)
                              :mod (n2 / nucleus~e.16)
                              :mod (a3 / antigen~e.17)))))
      :ARG1-of (d / describe-01
            :ARG0 (a4 / and~e.27
                  :op1 (f / figure~e.23 :mod "2D")
                  :op2 (f2 / figure~e.23 :mod "2E"))))

# ::tok Activated , pMAPK @-@ positive cells were also prevalent in these areas ( <xref ref-type="fig" rid="pbio-0030011-g002"> Figure 2 </xref>@ F and <xref ref-type="fig" rid="pbio-0030011-g002"> 2 </xref>@ G ) , as were cells expressing keratin 6 , a keratin induced in the suprabasal layers of hyperproliferative skin ( <xref ref-type="fig" rid="pbio-0030011-g002"> Figure 2 </xref>@ H and <xref ref-type="fig" rid="pbio-0030011-g002"> 2 </xref>@ I ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1.2 5-1.1.2 7-1.2.2 8-1 10-1.2.1 11-1.2 16-1.1.2.2.1.1 16-1.1.2.2.1.2 16-1.3.1.1 16-1.3.1.2 20-1.1 20-1.1.2.2.1 20-1.3.1 31-1.1.1 31-1.1.2 32-1.1.2.1 33-1.1.2.1.1.1.1 34-1.1.2.1.1.1.1 37-1.1.2.1.1.1.1 38-1.1.2.1.1.2 39-1.1.2.1.1.2.1.r 41-1.1.2.1.1.2.1.1 42-1.1.2.1.1.2.1 45-1.1.2.1.1.2.1.2 50-1.1.2.2.1.1 50-1.1.2.2.1.2 50-1.3.1.1 50-1.3.1.2 54-1.1.2.2.1 54-1.3.1
# ::id pmid_1563_0473.85
# ::preferred 
(p5 / prevail-02~e.8
      :ARG1 (a4 / and~e.20
            :op1 (c / cell~e.31
                  :part (e2 / enzyme
                        :name (n / name :op1 "MAPK")
                        :ARG1-of (a / activate-01~e.0)
                        :ARG1-of (p / phosphorylate-01)))
            :op2 (c2 / cell~e.5,31
                  :ARG3-of (e / express-03~e.32
                        :ARG2 (p3 / protein
                              :name (n2 / name :op1 "keratin-6"~e.33,34,37)
                              :ARG1-of (i / induce-01~e.38
                                    :location~e.39 (l / layer~e.42
                                          :mod (s3 / suprabasal~e.41)
                                          :part-of (s2 / skin~e.45
                                                :ARG0-of (p4 / proliferate-01
                                                      :degree (h / hyper)))))))
                  :ARG1-of (d2 / describe-01
                        :ARG0 (a5 / and~e.20,54
                              :op1 (f3 / figure~e.16,50 :mod "2H")
                              :op2 (f4 / figure~e.16,50 :mod "2I")))))
      :location (a2 / area~e.11
            :mod (t / this~e.10)
            :mod (a8 / also~e.7))
      :ARG1-of (d / describe-01
            :ARG0 (a3 / and~e.20,54
                  :op1 (f / figure~e.16,50 :mod "2F")
                  :op2 (f2 / figure~e.16,50 :mod "2G"))))

# ::tok Expression of the <i> Snail </i> transgene did not block terminal differentiation in the hyperproliferative epidermis , but it distorted it markedly ( <xref ref-type="fig" rid="pbio-0030011-g003"> Figure 3 </xref>@ A– @<xref ref-type="fig" rid="pbio-0030011-g003"> 3 </xref>@ H ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2 4-1.1.2.1.1.1 6-1.1.2.1 8-1.1.1 8-1.1.1.r 9-1.1 10-1.1.3.2 11-1.1.3 15-1.1.3.1 17-1 19-1.2 21-1.2.3 21-1.2.3.r 26-1.3.1
# ::id pmid_1563_0473.86
# ::preferred 
(c / contrast-01~e.17
      :ARG1 (b / block-01~e.9
            :polarity~e.8 "-"~e.8
            :ARG0 (e / express-03~e.0
                  :ARG1 (t2 / transgene~e.6
                        :name (n2 / name :op1 "Snail"~e.4)))
            :ARG1 (d / differentiate-01~e.11
                  :ARG1 (e2 / epidermis~e.15
                        :ARG0-of (p2 / proliferate-01
                              :degree (h / hyper)))
                  :mod (t / terminus~e.10)))
      :ARG2 (d2 / distort-01~e.19
            :ARG0 e
            :ARG1 d
            :manner~e.21 (m / marked~e.21))
      :ARG1-of (d3 / describe-01
            :ARG0 (f / figure~e.26
                  :mod (v / value-interval :op1 "3A" :op2 "3H"))))

# ::tok Typical of most hyperproliferating conditions , Snail expression led to a large expansion in layers with spinous and granular morphology .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3 2-1.4.2 4-1.4.r 6-1.1.1.1.1 7-1.1 8-1 9-1.2.r 11-1.2.2 12-1.2 13-1.2.1.r 14-1.2.1 19-1.2.1.1
# ::id pmid_1563_0473.87
# ::preferred 
(l / lead-03~e.8
      :ARG0 (e / express-03~e.7
            :ARG2 (p / protein
                  :name (n / name :op1 "Snail"~e.6)))
      :ARG2~e.9 (e2 / expand-01~e.12
            :location~e.13 (l2 / layer~e.14
                  :mod (m / morphology~e.19
                        :mod (s / spine)
                        :mod (g / granule)))
            :degree (l3 / large~e.11))
      :mod (t / typical~e.0)
      :condition~e.4 (p2 / proliferate-01
            :degree (h / hyper)
            :mod (m2 / most~e.2)))

# ::tok Additionally , however , was a marked and variable expansion of keratin 5 ( K5 ) , normally restricted to the innermost basal layer ( see <xref ref-type="fig" rid="pbio-0030011-g003"> Figure 3 </xref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1 6-1.1.1.3 9-1.1.1 10-1.1.1.1.r 11-1.1.1.1.1.1 12-1.1.1.1.1.1 17-1.1.1.2.2 18-1.1.1.2 22-1.1.1.2.1.1 23-1.1.1.2.1 25-1.2.1.2 29-1.2.1 30-1.2.1.1
# ::id pmid_1563_0473.88
# ::preferred 
(a2 / and
      :op2 (c / contrast-01~e.2
            :ARG2 (e / expand-01~e.9
                  :ARG1~e.10 (p / protein
                        :name (n / name :op1 "keratin-5"~e.11,12))
                  :ARG1-of (r / restrict-01~e.18
                        :ARG2 (l / layer~e.23
                              :mod (b / basal~e.22)
                              :mod (i / inner
                                    :degree (m2 / most)))
                        :mod (n3 / normal~e.17))
                  :ARG1-of (m / mark-01~e.6)
                  :ARG1-of (v / vary-01)))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure~e.29
                  :mod "3"~e.30
                  :ARG1-of (s / see-01~e.25
                        :mode "imperative"
                        :ARG0 (y / you)))))

# ::tok Although the failure of <i> Snail </i>@ -@ null mice to develop past gastrulation [ @<xref ref-type="bibr" rid="pbio-0030011-b21"> 21 </xref>@ ] precluded our ability to study the loss of Snail function in skin development , a good correlation emerged between the expression of Snail protein and the extension of K5 , Ki67 , and pMAPK suprabasally ( compare data in <xref ref-type="fig" rid="pbio-0030011-g002"> Figures 2 </xref> and <xref ref-type="fig" rid="pbio-0030011-g003"> 3 </xref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 2-1.1.2.1 5-1.1.2.1.2.1 6-1.1.2.1.2.1 7-1.1.2.1.2.1 8-1.1.2.1.2.1 9-1.1.2.1.2.1 11-1.1.2.1.2 18-1.1.2.1.3.1.1.1 21-1.1.2 22-1.1.2.2.1.1 22-1.1.2.2.1.1.r 25-1.1.2.2.1 27-1.1.2.2.1.2 29-1.1.2.1.1.1.1.1 30-1.1.2.2.1.2.1 31-1.1.2.2.1.2.2.r 32-1.1.2.2.1.2.2.1 33-1.1.2.2.1.2.2 36-1.1.1.1.3 37-1.1.1.1 38-1.1.1 41-1.1.1.1.1 43-1.1.1.1.1.1.1.1 44-1.1.1.1.1.1 44-1.1.1.1.2.1.1 44-1.1.1.1.2.1.2 44-1.1.2.1.1.1 45-1.1.1.1.2.1 47-1.1.1.1.2 49-1.1.1.1.2.1.1.2.1 51-1.1.1.1.2.1.2.1.1 53-1.1.1.1.2.1 57-1.2 58-1.2.1 63-1.2.1.1.1.1 63-1.2.1.1.1.2 64-1.2.1.1.1.1.1 66-1.2.1.1.1 70-1.2.1.1.1.2.1
# ::id pmid_1563_0473.89
# ::preferred 
(m / multi-sentence
      :snt1 (h / have-concession-91~e.0
            :ARG1 (e / emerge-02~e.38
                  :ARG0 (c / correlate-01~e.37
                        :ARG1 (e2 / express-03~e.41
                              :ARG2 (p / protein~e.44
                                    :name (n / name :op1 "Snail"~e.43)))
                        :ARG2 (e3 / extend-01~e.47
                              :ARG1 (a / and~e.45,53
                                    :op1 (p7 / protein~e.44
                                          :mod "7"
                                          :name (n2 / name :op1 "K5"~e.49))
                                    :op2 (p2 / protein~e.44
                                          :name (n3 / name :op1 "Ki67"~e.51))
                                    :op3 (p3 / pathway
                                          :name (n4 / name :op1 "MAPK")
                                          :ARG1-of (p8 / phosphorylate-01)))
                              :manner (s / suprabasal))
                        :mod (g / good~e.36)))
            :ARG2 (p4 / preclude-01~e.21
                  :ARG0 (f / fail-01~e.2
                        :ARG1 (m2 / mouse
                              :mod (p9 / protein~e.44
                                    :name (n5 / name :op1 "Snail"~e.29)
                                    :ARG2-of (m3 / mutate-01 :mod "−/−")))
                        :ARG2 (d / develop-02~e.11
                              :ARG1 m2~e.5,6,7,8,9
                              :time (a2 / after
                                    :op1 (g2 / gastrulate-00)))
                        :ARG1-of (d5 / describe-01
                              :ARG0 (p5 / publication
                                    :ARG1-of (c2 / cite-01 :ARG2 "21"~e.18))))
                  :ARG1 (p6 / possible
                        :domain (s2 / study-01~e.25
                              :ARG0~e.22 (w / we~e.22)
                              :ARG1 (l / lose-01~e.27
                                    :ARG1 (f2 / function~e.30
                                          :mod p)
                                    :location~e.31 (d2 / develop-01~e.33
                                          :ARG2 (s3 / skin~e.32)))))))
      :snt2 (c3 / compare-01~e.57
            :ARG1 (d3 / data~e.58
                  :ARG1-of (d4 / describe-01
                        :ARG0 (a3 / and~e.66
                              :op1 (f3 / figure~e.63 :mod "2"~e.64)
                              :op2 (f4 / figure~e.63 :mod "3"~e.70))))))

# ::tok The changes in hyperproliferation and differentiation were not initially accompanied by gross signs of epithelial invaginations .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.2 4-1.2.1 5-1.2.1.2 7-1.1 7-1.1.r 8-1.4 9-1 10-1.3.r 11-1.3.2 12-1.3 13-1.3.1.r 14-1.3.1 15-1.3.1.1
# ::id pmid_1563_0473.90
# ::preferred 
(a / accompany-01~e.9
      :polarity~e.7 "-"~e.7
      :ARG0 (c / change-01~e.1
            :ARG1 (a2 / and~e.4
                  :op1 (h / hyperproliferate-00)
                  :op2 (d / differentiate-01~e.5)))
      :ARG1~e.10 (s / signal-07~e.12
            :ARG1~e.13 (e / epithelium~e.14
                  :ARG1-of (i3 / invaginate-00~e.15))
            :mod (g / gross~e.11))
      :time (i / initial~e.8))

# ::tok With age , however , epidermal folds and undulations developed in areas where Snail was expressed , and proliferative markers persisted in these regions ( <xref ref-type="fig" rid="pbio-0030011-g003"> Figure 3 </xref>@ I and <xref ref-type="fig" rid="pbio-0030011-g003"> 3 </xref>@ J ; anti @-@ cyclin D staining ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1.1 3-1 6-1.1.1.2.1.1.1 7-1.1.1.2.1.1 9-1.1.1.2.1 10-1.1.1.2.1.2.r 11-1.1.1.2.1.2 12-1.1.1.2.1.2.1.r 13-1.1.1.2.1.2.1.1.1.1 15-1.1.1.2.1.2.1 17-1.1.1.2 19-1.1.1.2.2.1 20-1.1.1.2.2 28-1.2.1.1 28-1.2.1.2 32-1.2.1 40-1.2.2.1 40-1.2.2.1.1 40-1.2.2.1.1.r 42-1.2.2.1.1.1.1.1 43-1.2.2.1.1.1.1.2 44-1.2.2
# ::id pmid_1563_0473.91
# ::preferred 
(h / have-concession-91~e.3
      :ARG1 (a2 / and
            :op1 (c / cause-01
                  :ARG0 (a / age-01~e.1)
                  :ARG1 (a5 / and~e.17
                        :op1 (d / develop-02~e.9
                              :ARG1 (a3 / and~e.7
                                    :op1 (f / fold-00~e.6
                                          :ARG1 (e / epidermis))
                                    :op2 (u / undulate-01
                                          :ARG1 e))
                              :location~e.10 (a4 / area~e.11
                                    :location-of~e.12 (e2 / express-03~e.15
                                          :ARG2 (p / protein
                                                :name (n / name :op1 "Snail"~e.13)))))
                        :op2 (p2 / persist-01~e.20
                              :ARG0 (m / marker~e.19
                                    :ARG0-of (p3 / proliferate-01))
                              :location a4))))
      :ARG1-of (d2 / describe-01
            :ARG0 (a6 / and~e.32
                  :op1 (f2 / figure~e.28 :mod "3I")
                  :op2 (f3 / figure~e.28 :mod "3J"))
            :ARG2 (s / stain-01~e.44
                  :ARG2 (m2 / molecular-physical-entity~e.40
                        :ARG0-of~e.40 (c3 / counter-01~e.40
                              :ARG1 (p4 / protein
                                    :name (n4 / name :op1 "cyclin"~e.42 :op2 "D"~e.43)))))))

# ::tok The undulations were accompanied by partial dissolution of the underlying basement membrane ( <xref ref-type="fig" rid="pbio-0030011-g003"> Figure 3 </xref>@ K and <xref ref-type="fig" rid="pbio-0030011-g003"> 3 </xref>@ L ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 3-1 5-1.1.2 9-1.1.1.2 10-1.1.1.1 11-1.1.1
# ::id pmid_1563_0473.92
# ::preferred 
(a / accompany-01~e.3
      :ARG0 (d / dissolute-00
            :ARG1 (m / membrane~e.11
                  :mod (b / basement~e.10)
                  :ARG1-of (u / underlie-01~e.9))
            :degree (p / partial~e.5))
      :ARG1 (u2 / undulate-01))

# ::tok Aberrant staining was also observed with antibodies against components of the hemidesmosomes , which provide strong adhesion of basal epidermal cells to the underlying basal lamina ( <xref ref-type="fig" rid="pbio-0030011-g003"> Figure 3 </xref>@ M and <xref ref-type="fig" rid="pbio-0030011-g003"> 3 </xref>@ N ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2 1-1.1 3-1.2 4-1 5-1.1.1.r 6-1.1.1 7-1.1.1.1 8-1.1.1.1.1 14-1.1.1.1.1.1.1 15-1.1.1.1.1.1.1.1.3 18-1.1.1.1.1.1.1.1.1.1.1 18-1.1.1.1.1.1.1.1.2.1 20-1.1.1.1.1.1.1.1.1 23-1.1.1.1.1.1.1.1.2.2 24-1.1.1.1.1.1.1.1.2.1 25-1.1.1.1.1.1.1.1.2 30-1.3.1.1 30-1.3.1.2 34-1.3.1
# ::id pmid_1563_0473.93
# ::preferred 
(o / observe-01~e.4
      :ARG1 (s / stain-01~e.1
            :ARG2~e.5 (a2 / antibody~e.6
                  :ARG0-of (c / counter-01~e.7
                        :ARG1 (c2 / component~e.8
                              :part-of (h / hemidesmosome
                                    :ARG0-of (p / provide-01~e.14
                                          :ARG1 (a4 / adhere-01
                                                :ARG1 (c3 / cell~e.20
                                                      :mod (e / epidermis
                                                            :mod (b / basal~e.18)))
                                                :ARG2 (l2 / lamina~e.25
                                                      :mod (b2 / basal~e.18,24)
                                                      :ARG1-of (u / underlie-01~e.23))
                                                :manner (s2 / strong~e.15)))))))
            :manner (a / aberrant~e.0))
      :mod (a3 / also~e.3)
      :ARG1-of (d / describe-01
            :ARG0 (a5 / and~e.34
                  :op1 (f / figure~e.30 :mod "3M")
                  :op2 (f2 / figure~e.30 :mod "3N"))))

# ::tok Interestingly , similar types of alterations occur in the basement membrane in the hair bud of embryonic and newborn mice when Snail is normally expressed .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.3.1 3-1.3 4-1.3.r 5-1 7-1.1.r 9-1.1.1 10-1.1 11-1.1.2.r 13-1.1.2.1.1 14-1.1.2.1 14-1.1.2.2 16-1.1.2.1.2.1 17-1.1.2 18-1.1.2.2.2.1 19-1.1.2.1.2 19-1.1.2.2.2 20-1.2.r 21-1.2.1.1.1 23-1.2.2 23-1.2.2.r 24-1.2
# ::id pmid_1563_0473.94
# ::preferred 
(a / alter-01~e.5
      :location~e.7 (m / membrane~e.10
            :mod (b / basement~e.9)
            :part-of~e.11 (a2 / and~e.17
                  :op1 (b3 / bud~e.14
                        :mod (h / hair~e.13)
                        :poss (m2 / mouse~e.19
                              :mod (e / embryonic~e.16)))
                  :op2 (b2 / bud~e.14
                        :mod h
                        :poss (m3 / mouse~e.19
                              :mod (n / newborn~e.18)))))
      :time~e.20 (e2 / express-03~e.24
            :ARG2 (p / protein
                  :name (n2 / name :op1 "Snail"~e.21))
            :manner~e.23 (n3 / normal~e.23))
      :mod~e.4 (t / type~e.3
            :ARG1-of (r / resemble-01~e.2))
      :ARG2-of (i2 / interest-01))

# ::tok The fact that the basement membrane separating the epidermis from the dermis is altered only in the adult Tg animals suggests the involvement of intermediary factors not as readily available in the epidermis as they are in the follicle .
# ::amr-annotator SDL-AMR-09
# ::alignments 4-1.1.1.1 5-1.1.1 6-1.1.1.2 8-1.1.1.2.1 9-1.1.1.2.2.r 11-1.1.1.2.2 13-1.1 14-1.1.3 15-1.1.2.r 17-1.1.2.1 19-1.1.2 20-1 22-1.2 23-1.2.1.r 24-1.2.1.1 25-1.2.1 26-1.2.1.2.1 26-1.2.1.2.1.r 28-1.2.1.2.2 28-1.2.1.2.2.r 29-1.2.1.2 30-1.2.1.2.3.r 32-1.2.1.2.3 36-1.2.1.2.4.r 38-1.2.1.2.4
# ::id pmid_1563_0473.95
# ::preferred 
(s / suggest-01~e.20
      :ARG0 (a / alter-01~e.13
            :ARG1 (m / membrane~e.5
                  :mod (b / basement~e.4)
                  :ARG0-of (s2 / separate-01~e.6
                        :ARG1 (e / epidermis~e.8)
                        :ARG2~e.9 (d / dermis~e.11)))
            :location~e.15 (a2 / animal~e.19
                  :mod (a3 / adult~e.17)
                  :mod (t / transgenic))
            :mod (o / only~e.14))
      :ARG1 (i / involve-01~e.22
            :ARG1~e.23 (f2 / factor~e.25
                  :mod (i2 / intermediary~e.24)
                  :mod (a4 / available~e.29
                        :polarity~e.26 "-"~e.26
                        :manner~e.28 (r / ready~e.28)
                        :location~e.30 (e2 / epidermis~e.32)
                        :compared-to~e.36 (f3 / follicle~e.38)))))

# ::tok Possible Links between Epidermal Hyperproliferation and Down @-@ regulation of AJ Proteins in <i> Snail </i> Tg Mice
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.1 10-1.1.2.1.1.1 11-1.1.2.1 11-1.1.3.1 14-1.1.3.1.1.1 17-1.1.3
# ::id pmid_1563_0473.96
# ::preferred 
(p / possible~e.0
      :domain (l / link-01~e.1
            :ARG1 (h / hyperproliferate-00
                  :ARG0 (e / epidermis))
            :ARG2 (d / downregulate-01
                  :ARG1 (p3 / protein~e.11
                        :name (n / name :op1 "AJ"~e.10)))
            :location (m / mouse~e.17
                  :mod (p2 / protein~e.11
                        :name (n3 / name :op1 "Snail"~e.14))
                  :mod (t / transgenic))))

# ::tok Given that the <i> E @-@ cadherin </i> promoter is a direct target for Snail @-@ mediated repression in vitro [ @<xref ref-type="bibr" rid="pbio-0030011-b04"> 4 </xref> , <xref ref-type="bibr" rid="pbio-0030011-b12"> 12 </xref> , <xref ref-type="bibr" rid="pbio-0030011-b13"> 13 </xref>@ ], and that E @-@ cadherin was down @-@ regulated in Snail @-@ expressing hair buds , we examined the status of E @-@ cadherin and other AJ proteins within regions of hyperproliferative epidermis where Tg Snail was present ( <xref ref-type="fig" rid="pbio-0030011-g004"> Figure 4 </xref>@ A ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 4-1.1.1.2.1.1.1.1 6-1.1.1.2.1.1.1.1 11-1.1.1.3 12-1.1.1 13-1.1.1.1.r 14-1.1.1.1.1.1.1.1 16-1.1.1.1.1 17-1.1.1.1 18-1.1.1.1.2 19-1.1.1.1.2 24-1.1.1.4.1.1.1.1 30-1.1.1.4.1.1.1.2 36-1.1.1.4.1.1.1.3 39-1.1.1.4.1.1.1 41-1.1.1.2.1.1.1.1 43-1.1.1.2.1.1.1.1 48-1.1.1.1.2 49-1.2.2.3.2.1.1 51-1.1.2.2.2 52-1.1.2.2.1 53-1.1.2.2 55-1.2.1 56-1.2 58-1.2.2.1 58-1.2.2.2 60-1.1.1.2.1.1.1.1 62-1.1.1.2.1.1.1.1 63-1.2.2 64-1.2.2.2.1.2 65-1.2.2.2.1.1.1 66-1.1.1.1.1.1 66-1.1.1.2.1.1 66-1.2.2.2.1 66-1.2.2.3.2 68-1.2.2.3 71-1.2.2.3.1 72-1.2.2.3.2.r 72-1.2.2.3.r 74-1.2.2.3.2.1.1 81-1.2.3.1 82-1.1.1.4.1.1.1.1
# ::id pmid_1563_0473.97
# ::preferred 
(c2 / cause-01
      :ARG0 (a / and
            :op1 (t / target-01~e.12
                  :ARG0~e.13 (r / repress-01~e.17
                        :ARG1-of (m / mediate-01~e.16
                              :ARG0 (p2 / protein~e.66
                                    :name (n2 / name :op1 "Snail"~e.14)))
                        :manner (i / in-vitro~e.18,19,48))
                  :ARG1 (m2 / molecular-physical-entity
                        :ARG0-of (p4 / promote-01
                              :ARG1 (p / protein~e.66
                                    :name (n / name :op1 "E-cadherin"~e.4,6,41,43,60,62))))
                  :mod (d3 / direct~e.11)
                  :ARG1-of (d4 / describe-01
                        :ARG0 (p5 / publication
                              :ARG1-of (c / cite-01
                                    :ARG2 (a3 / and~e.39
                                          :op1 "4"~e.24,82
                                          :op2 "12"~e.30
                                          :op3 "13"~e.36)))))
            :op2 (d / downregulate-01
                  :ARG1 p
                  :location (b / bud~e.53
                        :mod (h / hair~e.52)
                        :ARG3-of (e / express-03~e.51
                              :ARG2 p2))))
      :ARG1 (e2 / examine-01~e.56
            :ARG0 (w / we~e.55)
            :ARG1 (a2 / and~e.63
                  :op1 (s / status~e.58
                        :poss p)
                  :op2 (s2 / status~e.58
                        :poss (p3 / protein~e.66
                              :name (n3 / name :op1 "AJ"~e.65)
                              :mod (o / other~e.64)))
                  :location~e.72 (r2 / region~e.68
                        :poss (e3 / epidermis~e.71
                              :ARG1-of (h2 / hyperprofilerate-00))
                        :location-of~e.72 (p6 / protein~e.66
                              :name (n4 / name :op1 "Snail"~e.49,74)
                              :mod (t2 / transgenic))))
            :ARG1-of (d2 / describe-01
                  :ARG0 (f / figure~e.81 :mod "4A"))))

# ::tok In these regions , immunofluorescence staining of E @-@ cadherin and α-catenin were markedly diminished .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3.1 2-1.3 4-1.1.2 5-1.1 6-1.1.1.r 7-1.1.1.1.1.1 9-1.1.1.1.1.1 10-1.1.1 11-1.1.1.2.1.1 13-1.2 14-1
# ::id pmid_1563_0473.98
# ::preferred 
(d / diminish-01~e.14
      :ARG1 (s / stain-01~e.5
            :ARG1~e.6 (a2 / and~e.10
                  :op1 (p / protein
                        :name (n / name :op1 "E-cadherin"~e.7,9))
                  :op2 (p2 / protein
                        :name (n2 / name :op1 "α-catenin"~e.11)))
            :ARG2 (i / immunofluorescence~e.4))
      :degree (m / marked~e.13)
      :location (r / region~e.2
            :mod (t / this~e.1)))

# ::tok In contrast , the intensity of antibody staining for two other AJ proteins , β-catenin and Ajuba , was still strong .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1 4-1.1 5-1.1.1.r 6-1.1.1.2 7-1.1.1 8-1.1.1.1.r 9-1.1.1.1.1 10-1.1.1.1.4 11-1.1.1.1.2.1 12-1.1.1.1 12-1.1.1.1.3.1 12-1.1.1.1.3.2 14-1.1.1.1.3.1.1.1 15-1.1.1.1.3 16-1.1.1.1.3.2.1.1 19-1.1.2.1 20-1.1.2
# ::id pmid_1563_0473.99
# ::preferred 
(c / contrast-01~e.1
      :ARG2 (i / intensity~e.4
            :degree-of~e.5 (s / stain-01~e.7
                  :ARG1~e.8 (p / protein~e.12
                        :quant "2"~e.9
                        :name (n / name :op1 "AJ"~e.11)
                        :example (a2 / and~e.15
                              :op1 (p2 / protein~e.12
                                    :name (n2 / name :op1 "β-catenin"~e.14))
                              :op2 (p3 / protein~e.12
                                    :name (n3 / name :op1 "Ajuba"~e.16)))
                        :mod (o / other~e.10))
                  :ARG2 (a / antibody~e.6))
            :mod (s2 / strong~e.20
                  :mod (s3 / still~e.19))))

# ::tok Interestingly , however , despite appreciable immunofluorescence , localization of β-catenin and Ajuba appeared to be largely cytoplasmic rather than at cell @-@ cell borders ( <xref ref-type="fig" rid="pbio-0030011-g004"> Figure 4 </xref>@ A insets ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1 4-1 5-1.2.1.1 6-1.2 9-1.1.1.2 10-1.1.1.1.1.1.1.1 11-1.1.1.1.1 12-1.1.1.1.1.2.1.1 13-1.1 15-1.1.1.1 16-1.1.2 17-1.1.1 20-1.1.1.1 21-1.1.1.2.1.1 23-1.1.1.2.1.1 23-1.1.1.2.1.2 24-1.1.1.2.1 29-1.3.1
# ::id pmid_1563_0473.100
# ::preferred 
(h / have-concession-91~e.2,4
      :ARG1 (a / appear-02~e.13
            :ARG1 (c / cytoplasmic~e.17
                  :ARG2-of (b2 / be-located-at-91~e.15,20
                        :ARG1 (a2 / and~e.11
                              :op1 (p / protein
                                    :name (n / name :op1 "β-catenin"~e.10))
                              :op2 (p2 / protein
                                    :name (n2 / name :op1 "Ajuba"~e.12))))
                  :ARG1-of (i / instead-of-91~e.9
                        :ARG2 (b / border-01~e.24
                              :ARG1 (c2 / cell~e.21,23)
                              :ARG2 (c3 / cell~e.23))))
            :degree (l2 / large~e.16))
      :ARG2 (i2 / immunofluorescence~e.6
            :ARG1-of (a3 / appreciate-01
                  :mod (p3 / possible~e.5)))
      :ARG1-of (d / describe-01
            :ARG2 (f / figure~e.29
                  :mod "4A"
                  :mod (i4 / inset)))
      :ARG2-of (i3 / interest-01))

# ::tok Architectural differences in the epidermis made Western blot analyses somewhat difficult to gauge .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1 2-1.1.2.r 4-1.1.2 5-1 6-1.2.1.1.1.1.1 7-1.2.1.1.1 8-1.2.1.1 9-1.2.1.2.1 10-1.2 10-1.2.1.2 12-1.2.1
# ::id pmid_1563_0473.101
# ::preferred 
(m / make-02~e.5
      :ARG0 (d3 / differ-02~e.1
            :mod (a2 / architecture~e.0)
            :location~e.2 (e / epidermis~e.4))
      :ARG1 (d / difficult~e.10
            :domain (g / gauge-01~e.12
                  :ARG1 (a / analyze-01~e.8
                        :ARG1 (b / blot-01~e.7
                              :mod (n / name
                                    :op1 (w / western~e.6))))
                  :mod (d2 / difficult~e.10
                        :degree (s / somewhat~e.9)))))

# ::tok However , in regions such as ear skin , where the highest levels of Snail protein were expressed , the effects were accentuated .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 3-1.1.2 4-1.1.2.1.r 5-1.1.2.1.r 6-1.1.2.1.1 7-1.1.2.1 9-1.1.2.2.r 9-1.1.2.r 11-1.1.2.2.1 11-1.1.2.2.1.1 11-1.1.2.2.1.1.r 12-1.1.2.2 13-1.1.2.2.2.r 14-1.1.2.2.2.1.1 15-1.1.2.2.2 17-1.1.2.2.2.2 20-1.1.1 22-1.1
# ::id pmid_1563_0473.102
# ::preferred 
(h / have-concession-91~e.0
      :ARG1 (a / accentuate-01~e.22
            :ARG1 (a2 / affect-01~e.20)
            :location~e.9 (r / region~e.3
                  :example~e.4,5 (s / skin~e.7
                        :mod (e / ear~e.6))
                  :location-of~e.9 (l / level~e.12
                        :mod (h2 / high~e.11
                              :degree~e.11 (m2 / most~e.11))
                        :quant-of~e.13 (p / protein~e.15
                              :name (n / name :op1 "Snail"~e.14)
                              :ARG2-of (e2 / express-03~e.17))))))

# ::tok In both back skin and ear skin , overall levels of E @-@ cadherin and α-catenin were reduced , under conditions where β-catenin and Ajuba levels remained unchanged relative to controls ( <xref ref-type="fig" rid="pbio-0030011-g004"> Figure 4 </xref>@ B ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.2.1.1 3-1.2.1 3-1.2.2 4-1.2 5-1.2.2.1 6-1.2.2 8-1.1.3 9-1.1.1 10-1.1.1.1.r 11-1.1.1.1.1.1 13-1.1.1.1.1.1 14-1.1 15-1.1.2.1.1.1 17-1 20-1.3.r 21-1.2.r 22-1.3.1.2.1.1.1.1 23-1.3.1.2 24-1.3.1.2.2.1.1.1 25-1.1.2 25-1.3.1.2.1 25-1.3.1.2.2 26-1.3 27-1.3.1.1 30-1.3.2.1 35-1.4.1
# ::id pmid_1563_0473.103
# ::preferred 
(r / reduce-01~e.17
      :ARG1 (a4 / and~e.14
            :op1 (l / level~e.9
                  :quant-of~e.10 (p / protein
                        :name (n / name :op1 "E-cadherin"~e.11,13)))
            :op2 (l3 / level~e.25
                  :quant-of (p2 / protein
                        :name (n2 / name :op1 "α-catenin"~e.15)))
            :degree (o / overall~e.8))
      :location~e.21 (a2 / and~e.4
            :op1 (s / skin~e.3
                  :mod (b / back~e.2))
            :op2 (s2 / skin~e.3,6
                  :mod (e / ear~e.5)))
      :condition~e.20 (r2 / remain-01~e.26
            :ARG1 (c / change-01
                  :polarity "-"~e.27
                  :ARG1 (a / and~e.23
                        :op1 (l2 / level~e.25
                              :quant-of (p3 / protein
                                    :name (n3 / name :op1 "β-catenin"~e.22)))
                        :op2 (l4 / level~e.25
                              :quant-of (p4 / protein
                                    :name (n4 / name :op1 "Ajuba"~e.24)))))
            :ARG1-of (r3 / relate-01
                  :ARG2 (c2 / control-01~e.30)))
      :ARG1-of (d / describe-01
            :ARG2 (f / figure~e.35 :mod "4B")))

# ::tok Taken together , these data were consistent with our results obtained from immunofluorescence microscopy .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2 1-1.2.1 3-1.1.2 4-1.1 6-1.1.1 7-1.1.1.1.r 8-1.1.1.1.2 8-1.1.1.1.2.r 9-1.1.1.1 9-1.1.1.1.1 9-1.1.1.1.1.r 10-1.1.1.1.1.1 11-1.1.1.1.1.1.2.r 12-1.1.1.1.1.1.2.1 13-1.1.1.1.1.1.2
# ::id pmid_1563_0473.104
# ::preferred 
(h / have-condition-91
      :ARG1 (d / data~e.4
            :ARG1-of (c / consistent-01~e.6
                  :ARG2~e.7 (t3 / thing~e.9
                        :ARG2-of~e.9 (r / result-01~e.9
                              :ARG1-of (o / obtain-01~e.10
                                    :ARG0 (w / we~e.8)
                                    :ARG2~e.11 (m / microscopy~e.13
                                          :mod (i / immunofluorescence~e.12))))
                        :poss~e.8 w))
            :mod (t4 / this~e.3))
      :ARG2 (t / take-01~e.0
            :mod (t5 / together~e.1)))

# ::tok A priori , the decrease in α-catenin levels could be due to either direct transcriptional repression by Snail or perturbations in AJ formation caused by the decrease in <i> E @-@ cadherin </i> gene expression .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2 1-1.2 4-1.1 5-1.1.1.r 6-1.1.1.1.1.1 7-1.1.1 8-1 9-1.1.r 10-1.1.2 11-1.1.2 13-1.1.2.1.1.2.1 15-1.1.2.1.1 16-1.1.2.1.1.1.r 17-1.1.2.1.1.1.1.1 18-1.1.2.1 19-1.1.2.1.2 20-1.1.2.1.2.1.r 21-1.1.2.1.2.1.1.1.1 22-1.1.2.1.2.1 23-1.1.2.1.2.2 24-1.1.2.1.2.2.1.r 26-1.1.2.1.2.2.1 29-1.1.2.1.2.2.1.1.1.1.1 31-1.1.2.1.2.2.1.1.1.1.1 33-1.1.2.1.2.2.1.1.1 34-1.1.2.1.2.2.1.1
# ::id pmid_1563_0473.105
# ::preferred 
(p / possible~e.8
      :domain~e.9 (d / decrease-01~e.4
            :ARG1~e.5 (l / level~e.7
                  :quant-of (p2 / protein
                        :name (n / name :op1 "α-catenin"~e.6)))
            :ARG1-of (c / cause-01~e.10,11
                  :ARG0 (o / or~e.18
                        :op1 (r / repress-01~e.15
                              :ARG0~e.16 (p3 / protein
                                    :name (n2 / name :op1 "Snail"~e.17))
                              :ARG1 (t / transcribe-01
                                    :manner (d2 / direct~e.13)))
                        :op2 (p4 / perturb-01~e.19
                              :ARG1~e.20 (f / form-01~e.22
                                    :ARG1 (p5 / protein
                                          :name (n3 / name :op1 "AJ"~e.21)))
                              :ARG1-of (c2 / cause-01~e.23
                                    :ARG0~e.24 (d3 / decrease-01~e.26
                                          :ARG1 (e / express-03~e.34
                                                :ARG2 (g2 / gene~e.33
                                                      :name (n4 / name :op1 "E-cadherin"~e.29,31)))))))))
      :time (a / a-priori~e.0,1))

# ::tok To distinguish between these possibilities , we tested whether α-catenin levels could be restored by exogenous expression of <i> E @-@ cadherin </i> in Snail @-@ expressing keratinocytes .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3.1 3-1.3.1.2.1 4-1.3.1.2 6-1.1 7-1 8-1.2.1.1 8-1.2.1.1.r 9-1.2.1.3.1.1.1 10-1.2.1.3 11-1.2 12-1.2.1.r 13-1.2.1 14-1.2.1.4.r 15-1.2.1.4.2 16-1.2.1.4 16-1.2.1.4.3.2 19-1.2.1.4.1.1.1 21-1.2.1.4.1.1.1 24-1.2.1.4.3.2.1.1.1 26-1.2.1.4 26-1.2.1.4.3.2
# ::id pmid_1563_0473.106
# ::preferred 
(t / test-01~e.7
      :ARG0 (w / we~e.6)
      :ARG1 (p / possible~e.11
            :domain~e.12 (r / restore-01~e.13
                  :mode~e.8 "interrogative"~e.8
                  :ARG0 w
                  :ARG1 (l / level~e.10
                        :quant-of (p2 / protein
                              :name (n / name :op1 "α-catenin"~e.9)))
                  :manner~e.14 (e / express-03~e.16,26
                        :ARG2 (p3 / protein
                              :name (n2 / name :op1 "E-cadherin"~e.19,21))
                        :mod (e2 / exogenous~e.15)
                        :location (c / cell
                              :name (n3 / name :op1 "keratinocyte")
                              :ARG3-of (e3 / express-03~e.16,26
                                    :ARG2 (p4 / protein
                                          :name (n4 / name :op1 "Snail"~e.24)))))))
      :ARG1-of (h / have-purpose-91
            :ARG2 (d / distinguish-01~e.1
                  :ARG0 w
                  :ARG1 (p5 / possible~e.4
                        :mod (t2 / this~e.3)))))

# ::tok As shown in <xref ref-type="fig" rid="pbio-0030011-g004"> Figure 4 </xref>@ C , transiently transfected keratinocytes expressing HA @-@ tagged Snail displayed a loss of E @-@ cadherin and α-catenin at cell @-@ cell borders .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3 6-1.3.1 11-1.1.2.1 11-1.1.2.1.r 12-1.1.2 14-1.1.3 15-1.1.3.1.2.1.1.1 17-1.1.3.1.2 18-1.1.3.1.1.1 19-1 21-1.2 22-1.2.1.r 23-1.2.1.1.1.1 25-1.2.1.1.1.1 26-1.2.1 27-1.2.1.2.1.1 28-1.2.2.r 29-1.2.2.1 31-1.2.2.1 31-1.2.2.2 32-1.2.2
# ::id pmid_1563_0473.107
# ::preferred 
(d / display-01~e.19
      :ARG0 (c / cell
            :name (n / name :op1 "keratinocyte")
            :ARG1-of (t / transfect-00~e.12
                  :manner~e.11 (t2 / transient~e.11))
            :ARG3-of (e / express-03~e.14
                  :ARG2 (p / protein
                        :name (n2 / name :op1 "Snail"~e.18)
                        :ARG1-of (t3 / tag-01~e.17
                              :ARG0 (p4 / protein
                                    :name (n6 / name :op1 "HA"~e.15))))))
      :ARG1 (l / lose-02~e.21
            :ARG1~e.22 (a / and~e.26
                  :op1 (p2 / protein
                        :name (n4 / name :op1 "E-cadherin"~e.23,25))
                  :op2 (p3 / protein
                        :name (n5 / name :op1 "α-catenin"~e.27)))
            :location~e.28 (b / border-01~e.32
                  :ARG1 (c2 / cell~e.29,31)
                  :ARG2 (c3 / cell~e.31)))
      :ARG1-of (s / show-01~e.1
            :ARG0 (f / figure~e.6 :mod "4C")))

# ::tok Coexpression of exogenous HA @-@ tagged E @-@ cadherin not only enabled cell @-@ cell border localization of E @-@ cadherin protein , but also rescued the cell @-@ cell border staining of α-catenin ( <xref ref-type="fig" rid="pbio-0030011-g004"> Figure 4 </xref>@ C ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1.1.3 3-1.1.1.2.1.1.1 5-1.1.1.2 6-1.1.1.1.1 6-1.2.1.1.1.1 8-1.1.1.1.1 8-1.2.1.1.1.1 11-1 12-1.2.1.2.1 14-1.2.1.2.1 14-1.2.1.2.2 15-1.2.1.2 18-1.2.1.1.1.1 20-1.2.1.1.1.1 21-1.1.1 21-1.1.1.2.1 21-1.2.1.1 21-1.2.2.1.1 25-1.2.2 27-1.2.1.2.1 29-1.2.1.2.1 29-1.2.1.2.2 30-1.2.1.2 31-1.2.2.1 33-1.2.2.1.1.1.1 38-1.3.1
# ::id pmid_1563_0473.108
# ::preferred 
(e / enable-01~e.11
      :ARG0 (c / coexpress-00
            :ARG2 (p / protein~e.21
                  :name (n / name :op1 "E-cadherin"~e.6,8)
                  :ARG1-of (t / tag-01~e.5
                        :ARG0 (p4 / protein~e.21
                              :name (n5 / name :op1 "HA"~e.3)))
                  :mod (e3 / exogenous~e.2)))
      :ARG1 (a / and
            :op1 (b2 / be-located-at-91
                  :ARG1 (p2 / protein~e.21
                        :name (n3 / name :op1 "E-cadherin"~e.6,8,18,20))
                  :mod (b / border-01~e.15,30
                        :ARG1 (c2 / cell~e.12,14,27,29)
                        :ARG2 (c3 / cell~e.14,29)))
            :op2 (r / rescue-01~e.25
                  :ARG1 (s / stain-01~e.31
                        :ARG1 (p3 / protein~e.21
                              :name (n4 / name :op1 "α-catenin"~e.33))
                        :mod (a2 / and))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure~e.38 :mod "4C")))

# ::tok The ability to restore α-catenin expression and localization under these conditions argues against the notion that Snail transcriptionally represses <i> α-catenin . </i>
# ::amr-annotator SDL-AMR-09
# ::alignments 3-1.1.1 4-1.1.1.1.1.1 5-1.1.1.1.1 6-1.1.1.1 7-1.1.1.1.2 9-1.1.1.2 10-1.1.1.2.r 11-1 12-1.2 14-1.2.1 16-1.2.1.1.1.1.1 18-1.2.1.1 20-1.2.1.1.2.1.1
# ::id pmid_1563_0473.109
# ::preferred 
(a3 / argue-01~e.11
      :ARG1 (p / possible
            :domain (r / restore-01~e.3
                  :ARG1 (a / and~e.6
                        :op1 (e / express-03~e.5
                              :ARG2 p4~e.4)
                        :op2 (l / localize-01~e.7
                              :ARG1 (p4 / protein
                                    :name (n4 / name :op1 "α-catenin"~e.20))))
                  :condition~e.10 (t / this~e.9)))
      :ARG0-of (c / counter-01~e.12
            :ARG1 (n2 / notion~e.14
                  :topic (r2 / repress-01~e.18
                        :ARG0 (p3 / protein
                              :name (n3 / name :op1 "Snail"~e.16))
                        :ARG1 p4
                        :manner (t2 / transcribe-01)))))

# ::tok Rather , the findings are consistent with a previous report that E @-@ cadherin is required for the translation of <i> α-catenin </i> mRNA [ @<xref ref-type="bibr" rid="pbio-0030011-b22"> 22 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3 3-1.1 3-1.1.1 3-1.1.1.r 5-1 6-1.2.r 8-1.2.2 9-1.2 10-1.2.1.r 11-1.2.1.2.1.1 13-1.2.1.2.1.1 15-1.2.1 16-1.2.1.1.r 18-1.2.1.1 21-1.2.1.1.1.2.1.1.1 23-1.2.1.1.1.1.1 28-1.4.1.1.1
# ::id pmid_1563_0473.110
# ::preferred 
(c / consistent-01~e.5
      :ARG1 (t / thing~e.3
            :ARG1-of~e.3 (f / find-01~e.3))
      :ARG2~e.6 (r2 / report-01~e.9
            :ARG1~e.10 (r3 / require-01~e.15
                  :ARG0~e.16 (t2 / translate-01~e.18
                        :ARG1 (m / ma
                              :name (n2 / name :op1 "mRNA"~e.23)
                              :ARG0-of (e / encode-01
                                    :ARG1 (p3 / protein
                                          :name (n3 / name :op1 "α-catenin"~e.21)))))
                  :ARG1 (p2 / protein
                        :name (n / name :op1 "E-cadherin"~e.11,13)))
            :time (p / previous~e.8))
      :mod (r / rather~e.0)
      :ARG1-of (d / describe-01
            :ARG0 (p4 / publication
                  :ARG1-of (c2 / cite-01 :ARG2 "22"~e.28))))

# ::tok Despite the reductions in AJ markers , Tg skin still displayed sealed membranes and intercellular junctions that were largely intact , as judged by ultrastructural analyses ( unpublished data ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.4.r 2-1.4 3-1.4.1.r 4-1.4.1.1.1.1 5-1.4.1 8-1.1 9-1.3 10-1 11-1.2.1.1 12-1.2.1 13-1.2 14-1.2.2.1 15-1.2.2 18-1.2.3.1 19-1.2.3 21-1.2.3.2.r 22-1.2.3.2 23-1.2.3.2.1.r 24-1.2.3.2.1.1 25-1.2.3.2.1 27-1.5.1.1.1 28-1.5.1
# ::id pmid_1563_0473.111
# ::preferred 
(d / display-01~e.10
      :ARG0 (s / skin~e.8
            :mod (t / transgenic))
      :ARG1 (a / and~e.13
            :op1 (m / membrane~e.12
                  :ARG1-of (s3 / seal-01~e.11))
            :op2 (j / junction~e.15
                  :mod (i2 / intercellular~e.14))
            :mod (i / intact~e.19
                  :degree (l / large~e.18)
                  :ARG1-of~e.21 (j2 / judge-01~e.22
                        :ARG3~e.23 (a2 / analyze-01~e.25
                              :mod (u / ultrastructural~e.24)))))
      :mod (s2 / still~e.9)
      :concession~e.0 (r / reduce-01~e.2
            :ARG1~e.3 (m2 / marker~e.5
                  :mod (p2 / protein
                        :name (n2 / name :op1 "AJ"~e.4))))
      :ARG1-of (d2 / describe-01
            :ARG0 (d3 / data~e.28
                  :ARG1-of (p / publish-01 :polarity "-"~e.27))))

# ::tok In this respect , the skin epithelium resembled that of the hair bud , where the down @-@ regulation in junction proteins is permissive for cell @-@ cell remodeling without abrogating intercellular adhesion .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3.r 1-1.3.1 2-1.3 5-1.1.1 6-1.1 6-1.2 7-1 9-1.2.1.r 11-1.2.1.1 12-1.2.1 14-1.2.2.1.1.1.r 19-1.3.r 20-1.2.2.1.2.1 21-1.2.2.1.2.1 25-1.2.2.1.2.2.1 25-1.2.2.1.2.2.2 27-1.2.2.1.2.2.1 27-1.2.2.1.2.2.2 28-1.2.2.1.2 29-1.2.2.1.3.1 29-1.2.2.1.3.1.r 30-1.2.2.1.3 31-1.2.2.1.3.2.1
# ::id pmid_1563_0473.112
# ::preferred 
(r / resemble-01~e.7
      :ARG1 (e / epithelium~e.6
            :part-of (s / skin~e.5))
      :ARG2 (e2 / epithelium~e.6
            :poss~e.9 (b / bud~e.12
                  :mod (h / hair~e.11))
            :ARG2-of (b2 / be-located-at-91
                  :ARG1 (p / permit-01
                        :ARG0 (d / downregulate-01
                              :location~e.14 (p2 / protein
                                    :mod (j / junction)))
                        :ARG1 (r3 / remodel-01~e.28
                              :ARG0 d~e.20,21
                              :ARG1 (a / and
                                    :op1 (c / cell~e.25,27)
                                    :op2 (c2 / cell~e.25,27)))
                        :ARG0-of (a2 / abrogate-01~e.30
                              :polarity~e.29 "-"~e.29
                              :ARG1 (a3 / adhere-01
                                    :mod (i / intercellular~e.31))))))
      :prep-in~e.0,19 (r4 / respect~e.2
            :mod (t / this~e.1)))

# ::tok The similarities between <i> Snail </i> Tg epidermis and hair buds extended to the hyperproliferative state , leading us to wonder whether the down @-@ regulation of AJ proteins might contribute to this condition .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1 1-1.1.1 1-1.1.1.r 4-1.1.1.1.1.1.1.1 7-1.1.1.1.1 8-1.1.1.1 9-1.1.1.1.2.1 10-1.1.1.1.2 11-1 15-1.2 17-1.3 18-1.3.1 20-1.3.2 21-1.3.2.2.1 21-1.3.2.2.1.r 27-1.3.2.2.2.1.1.1.1 28-1.1.1.1.1.1 28-1.3.2.2.2.1.1 29-1.3.2.2 30-1.3.2.2.2 31-1.3.2.2.2.2.r 32-1.3.2.2.2.2.1 33-1.3.2.2.2.2
# ::id pmid_1563_0473.113
# ::preferred 
(e3 / extend-01~e.11
      :ARG0 (t2 / thing~e.1
            :ARG1-of~e.1 (r2 / resemble-01~e.1
                  :ARG2 (a / and~e.8
                        :op1 (e2 / epidermis~e.7
                              :mod (p4 / protein~e.28
                                    :name (n2 / name :op1 "Snail"~e.4)
                                    :mod (t3 / transgenic)))
                        :op2 (b / bud~e.10
                              :mod (h / hair~e.9)))))
      :ARG4 (s / state~e.15
            :mod (h2 / hyperproliferate-00))
      :ARG0-of (l / lead-03~e.17
            :ARG1 (w / we~e.18)
            :ARG2 (w2 / wonder-01~e.20
                  :ARG0 w
                  :ARG1 (p / possible~e.29
                        :mode~e.21 "interrogative"~e.21
                        :domain (c2 / contribute-01~e.30
                              :ARG0 (d / downregulate-01
                                    :ARG1 (p3 / protein~e.28
                                          :name (n / name :op1 "AJ"~e.27)))
                              :ARG2~e.31 (c3 / condition~e.33
                                    :mod (t / this~e.32)))))))

# ::tok Given the increase in pMAPK staining in <i> Snail </i> Tg epidermis ( see <xref ref-type="fig" rid="pbio-0030011-g002"> Figure 2 </xref>@ G ) , we used pMAPK levels as our assay to test whether the loss of E @-@ cadherin contributed to the Snail @-@ mediated increase in proliferation .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1 3-1.1.1.r 4-1.1.1.2.1.1 5-1.1.1 8-1.1.1.1.1.1.1 11-1.1.1.1 13-1.1.2 17-1.1.2.1 23-1.2.1 24-1.2 25-1.2.2.1 26-1.2.2 27-1.2.3.r 28-1.2.3.1 28-1.2.3.1.r 29-1.2.3 31-1.2.3.2 32-1.2.3.2.3.1 32-1.2.3.2.3.1.r 34-1.2.3.2.3.2 35-1.2.3.2.3.2.1.r 36-1.2.3.2.3.2.1.1.1 38-1.2.3.2.3.2.1.1.1 39-1.2.3.2.3 40-1 42-1.2.3.2.3.3.2.1 44-1.2.3.2.3.3.2 45-1.2.3.2.3.3 46-1.2.3.2.3.3.1.r 47-1.2.3.2.3.3.1
# ::id pmid_1563_0473.114
# ::preferred 
(c / cause-01~e.40
      :ARG0 (i / increase-01~e.2
            :ARG1~e.3 (s / stain-01~e.5
                  :ARG1 (e / epidermis~e.11
                        :mod (p / protein
                              :name (n / name :op1 "Snail"~e.8)
                              :mod (t2 / transgenic)))
                  :ARG2 (p2 / pathway
                        :name (n2 / name :op1 "pMAPK"~e.4)))
            :ARG1-of (s2 / see-01~e.13
                  :ARG2 (f / figure~e.17 :mod "2G")))
      :ARG1 (u / use-01~e.24
            :ARG0 (w / we~e.23)
            :ARG1 (l / level~e.26
                  :quant-of p2~e.25)
            :ARG2~e.27 (a / assay-00~e.29
                  :ARG0~e.28 w~e.28
                  :purpose (t / test-01~e.31
                        :ARG0 w
                        :ARG1 l
                        :ARG2 (c2 / contribute-01~e.39
                              :mode~e.32 "interrogative"~e.32
                              :ARG0 (l2 / lose-02~e.34
                                    :ARG1~e.35 (p4 / protein
                                          :name (n3 / name :op1 "E-cadherin"~e.36,38)))
                              :ARG2 (i2 / increase-01~e.45
                                    :ARG1~e.46 (p5 / proliferate-01~e.47)
                                    :ARG1-of (m / mediate-01~e.44
                                          :ARG0 p~e.42)))))))

# ::tok Consistent with our in vivo observations , transfected keratinocytes expressing Snail exhibited a substantial increase in pMAPK levels relative to control cells ( <xref ref-type="fig" rid="pbio-0030011-g004"> Figure 4 </xref>@ D ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.4 1-1.4.1.r 2-1.4.1.1.1 2-1.4.1.1.1.r 3-1.4.1.1.2 4-1.4.1.1.2 5-1.4.1 5-1.4.1.1 5-1.4.1.1.r 7-1.1.1 9-1.1.2 10-1.1.2.1.1.1 11-1 13-1.2.2 14-1.2 15-1.2.1.r 15-1.4.1.1.2 16-1.2.1.1.1.1 17-1.2.1 18-1.2.1.2 19-1.2.1.2.1.r 20-1.2.1.2.1.1 21-1.2.1.2.1 26-1.3.1
# ::id pmid_1563_0473.115
# ::preferred 
(e / exhibit-01~e.11
      :ARG0 (k / keratinocyte
            :ARG1-of (t / transfect-00~e.7)
            :ARG3-of (e2 / express-03~e.9
                  :ARG2 (p / protein
                        :name (n / name :op1 "Snail"~e.10))))
      :ARG1 (i / increase-01~e.14
            :ARG1~e.15 (l / level~e.17
                  :quant-of (p2 / pathway
                        :name (n2 / name :op1 "pMAPK"~e.16))
                  :ARG1-of (r / relative-05~e.18
                        :ARG3~e.19 (c / cell~e.21
                              :ARG0-of (c2 / control-01~e.20))))
            :mod (s / substantial~e.13))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure~e.26 :mod "4D"))
      :ARG1-of (c3 / consistent-01~e.0
            :ARG2~e.1 (t2 / thing~e.5
                  :ARG1-of~e.5 (o / observe-01~e.5
                        :ARG0~e.2 (w / we~e.2)
                        :manner (i2 / in-vivo~e.3,4,15)))))

# ::tok Coexpression of E @-@ cadherin with Snail appeared to abrogate this effect .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1.1.1.1.1 4-1.1.1.1.1.1 6-1.1.1.2.1.1 7-1 9-1.1 10-1.1.2.1 11-1.1.2
# ::id pmid_1563_0473.116
# ::preferred 
(a / appear-02~e.7
      :ARG1 (a2 / abrogate-01~e.9
            :ARG0 (c / coexpress-00
                  :ARG0 (p / protein
                        :name (n / name :op1 "E-cadherin"~e.2,4))
                  :ARG1 (p2 / protein
                        :name (n2 / name :op1 "Snail"~e.6)))
            :ARG1 (e / effect~e.11
                  :mod (t / this~e.10))))

# ::tok Together , these findings raised the possibility that an AJ @-@ associated protein that is normally sequestered at the plasma membrane may participate in a proliferation signaling pathway when AJs are deconstructed .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3 2-1.1.2 3-1.1 3-1.1.1 3-1.1.1.r 4-1 6-1.2 9-1.2.1.1.1.1.1.1.1 11-1.2.1.1.1.1 12-1.2.1.1.1 15-1.2.1.1.1.2.1 15-1.2.1.1.1.2.1.r 16-1.2.1.1.1.2 17-1.2.1.1.1.2.2.r 19-1.2.1.1.1.2.2.1 20-1.2.1.1.1.2.2 21-1.2.1 22-1.2.1.1 23-1.2.1.1.2.r 25-1.2.1.1.2 26-1.2.1.1.2.1.1 27-1.2.1.1.2.1 28-1.2.1.1.3.r 30-1.2.1.1.r
# ::id pmid_1563_0473.117
# ::preferred 
(r / raise-01~e.4
      :ARG0 (t / thing~e.3
            :ARG1-of~e.3 (f / find-01~e.3)
            :mod (t2 / this~e.2))
      :ARG1 (p6 / possible~e.6
            :domain (p2 / possible~e.21
                  :domain~e.30 (p3 / participate-01~e.22
                        :ARG0 (p7 / protein~e.12
                              :ARG1-of (a / associate-01~e.11
                                    :ARG2 (p8 / protein
                                          :name (n2 / name :op1 "AJ"~e.9)))
                              :ARG1-of (s2 / sequester-01~e.16
                                    :manner~e.15 (n3 / normal~e.15)
                                    :location~e.17 (m / membrane~e.20
                                          :part-of (p9 / plasma~e.19))))
                        :ARG1~e.23 (p4 / proliferate-01~e.25
                              :ARG0 (p5 / pathway~e.27
                                    :ARG0-of (s / signal-07~e.26)))
                        :time~e.28 (c / construct-01
                              :polarity "-"
                              :ARG1 p8))))
      :mod (t3 / together~e.0))

# ::tok Numerous studies have correlated a down @-@ regulation of E @-@ cadherin with a translocation of β-catenin to the nucleus and a transactivation of genes that are regulated by the LEF @-@ 1/T cell factor ( TCF ) family of DNA binding proteins [ @<xref ref-type="bibr" rid="pbio-0030011-b23"> 23 </xref> , <xref ref-type="bibr" rid="pbio-0030011-b24"> 24 </xref> , <xref ref-type="bibr" rid="pbio-0030011-b25"> 25 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1 3-1 7-1.3.2.1.1 9-1.2.1.1.1 11-1.2.1.1.1 12-1.3.r 14-1.3.1 15-1.3.1.1.r 16-1.3.1.1.1.1 17-1.3.1.2.r 19-1.3.1.2 20-1.3 22-1.3.2 24-1.3.2.1 27-1.3.2.1.1 28-1.3.2.1.1.1.r 30-1.3.2.1.1.1.1.1.1.1 33-1.3.2.1.1.1.1.1 34-1.3.2.1.1.1.1 36-1.3.2.1.1.1.1.2.1.1 38-1.3.2.1.1.1 39-1.3.2.1.1.1.2.r 40-1.3.2.1.1.1.2.1.1 41-1.3.2.1.1.1.2.1 42-1.3.2.1.1.1.2 47-1.4.1.1.1.1 53-1.4.1.1.1.2 59-1.4.1.1.1.3
# ::id pmid_1563_0473.118
# ::preferred 
(c / correlate-01~e.3
      :ARG0 (s / study-01~e.1
            :quant (n / numerous~e.0))
      :ARG1 (d3 / downregulate-01
            :ARG1 (p / protein
                  :name (n2 / name :op1 "E-cadherin"~e.9,11)))
      :ARG2~e.12 (a / and~e.20
            :op1 (t / translocate-00~e.14
                  :ARG0~e.15 (p2 / protein
                        :name (n3 / name :op1 "β-catenin"~e.16))
                  :ARG1~e.17 (n4 / nucleus~e.19))
            :op2 (t2 / transactivate-00~e.22
                  :ARG1 (g / gene~e.24
                        :ARG1-of (r2 / regulate-01~e.7,27
                              :ARG0~e.28 (f / family~e.38
                                    :mod (f2 / factor~e.34
                                          :mod (c2 / cell~e.33
                                                :name (n5 / name :op1 "LEF-1/T"~e.30))
                                          :ARG1-of (m / mean-01
                                                :ARG2 (n6 / name :op1 "TCF"~e.36)))
                                    :poss~e.39 (p3 / protein~e.42
                                          :ARG1-of (b / bind-01~e.41
                                                :ARG2 (d4 / DNA~e.40))))))))
      :ARG1-of (d2 / describe-01
            :ARG0 (p4 / publication
                  :ARG1-of (c3 / cite-01
                        :ARG2 (a3 / and
                              :op1 "23"~e.47
                              :op2 "24"~e.53
                              :op3 "25"~e.59)))))

# ::tok The presence of nuclear cyclin D in hyperproliferative <i> Snail </i> Tg epidermis was particularly intriguing since prior studies have reported <i> cyclin D </i> gene as a direct target of TCF/β-catenin transcription [ @<xref ref-type="bibr" rid="pbio-0030011-b26"> 26 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 3-1.1.1.2 4-1.1.1 5-1.1.1.1.1 9-1.1.2.1.1.1 12-1.1.2 13-1.1 14-1.2 14-1.2.r 15-1 16-1.3 17-1.3.1.1.1 18-1.3.1.1 20-1.3.1 22-1.1.1 23-1.1.1.1.1 25-1.3.1.2.2 26-1.3.1.1.1.r 28-1.3.1.2.3 29-1.3.1.2 32-1.3.1.2.1 37-1.4.1.1.1
# ::id pmid_1563_0473.119
# ::preferred 
(i / intrigue-01~e.15
      :ARG0 (b / be-located-at-91~e.13
            :ARG1 (c / cyclin~e.4,22
                  :name (n / name :op1 "D"~e.5,23)
                  :mod (n2 / nucleus~e.3))
            :ARG2 (e / epidermis~e.12
                  :mod (p2 / protein
                        :name (n3 / name :op1 "Snail"~e.9)
                        :mod (t3 / transgenic))
                  :ARG1-of (h / hyperploriferate-00)))
      :manner~e.14 (p3 / particular~e.14)
      :ARG1-of (c5 / cause-01~e.16
            :ARG0 (r / report-01~e.20
                  :ARG0 (s / study-01~e.18
                        :time~e.26 (p4 / prior~e.17))
                  :ARG1 (t / target-01~e.29
                        :ARG0 (t2 / transcribe-01~e.32
                              :ARG1 (s2 / slash
                                    :op1 (f / factor
                                          :mod (c4 / cell :mod "1/T"))
                                    :op2 (p5 / protein
                                          :name (n5 / name :op1 "β-catenin"))))
                        :ARG1 (g / gene~e.25
                              :name (n4 / name :op1 "cyclin D"))
                        :mod (d / direct~e.28))))
      :ARG1-of (d2 / describe-01
            :ARG0 (p6 / publication
                  :ARG1-of (c3 / cite-01 :ARG2 "26"~e.37))))

# ::tok This said , we did not detect nuclear β-catenin in our Tg epidermis , and mating the Snail Tg mice against the TOPGal reporter mouse [ @<xref ref-type="bibr" rid="pbio-0030011-b20"> 20 </xref>@ ] gave no signs of ectopic LEF @-@ 1/Tcf/β-catenin activity ( unpublished data ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1 3-1.2.1.2 5-1.2.1.1 5-1.2.1.1.r 6-1.2.1 7-1.2.1.3.3 8-1.2.1.3.1.1 10-1.2.1.3.2.2 10-1.2.1.3.2.2.r 11-1.2.1.3.2.1.1.1 12-1.2.1.3.2 14-1.2 15-1.2.2.2 17-1.2.2.2.2.1.1.1 18-1.2.1.3.2.1.1.1 19-1.2.2.2.2 19-1.2.2.2.3 22-1.2.2.2.3.1.1.1 23-1.2.2.2.3.1 24-1.2.2.2.3 29-1.2.2.2.3.2.1.1.1 32-1.2.2 33-1.2.2.1 33-1.2.2.1.r 34-1.2.2.3 35-1.2.2.3.1.r 36-1.2.2.3.1.1.4 37-1.2.2.3.1.1.1.1.1 40-1.2.2.3.1 42-1.2.2.1 42-1.2.3.1.1.1 43-1.2.3.1
# ::id pmid_1563_0473.120
# ::preferred 
(c2 / cause-01
      :ARG0 (s2 / say-01~e.1
            :ARG1 (t2 / this~e.0))
      :ARG1 (a3 / and~e.14
            :op1 (d / detect-01~e.6
                  :polarity~e.5 "-"~e.5
                  :ARG0 (w / we~e.3)
                  :ARG1 (p2 / protein
                        :name (n / name :op1 "β-catenin"~e.8)
                        :location (e / epidermis~e.12
                              :mod (p3 / protein
                                    :name (n2 / name :op1 "Tg"~e.11,18))
                              :poss~e.10 w~e.10)
                        :mod (n7 / nucleus~e.7)))
            :op2 (g / give-01~e.32
                  :polarity~e.33 "-"~e.33,42
                  :ARG0 (m / mate-02~e.15
                        :ARG0 w
                        :ARG1 (m2 / mouse~e.19
                              :mod (p4 / protein
                                    :name (n3 / name :op1 "Snail"~e.17)
                                    :mod (t / transgenic)))
                        :ARG2 (m3 / mouse~e.19,24
                              :mod (r2 / reporter~e.23
                                    :name (n8 / name :op1 "TopGal"~e.22))
                              :ARG1-of (d2 / describe-01
                                    :ARG0 (p / publication
                                          :ARG0-of (c / cite-01 :ARG2 "20"~e.29)))))
                  :ARG1 (s / sign~e.34
                        :topic~e.35 (a2 / act-02~e.40
                              :ARG0 (m4 / macro-molecular-complex
                                    :part (g2 / gene
                                          :name (n4 / name :op1 "LEF-1"~e.37))
                                    :part (p5 / protein
                                          :name (n5 / name :op1 "Tcf"))
                                    :part (c3 / catenin
                                          :name (n6 / name :op1 "β"))
                                    :mod (e2 / ectopic~e.36)))))
            :ARG1-of (d4 / describe-01
                  :ARG0 (d5 / data~e.43
                        :ARG1-of (p6 / publish-01 :polarity "-"~e.42)))))

# ::tok We next turned to the presence of cytoplasmic Ajuba for a possible mechanistic link to the proliferative increase in our <i> Snail </i> Tg epidermis .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1.4 2-1 3-1.2.r 5-1.2 6-1.2.1.r 7-1.2.1.2 8-1.2.1.1.1 9-1.3.r 11-1.3.3 12-1.3.4 13-1.3 17-1.3.2 19-1.1 21-1.3.2.1.1.1.1 24-1.3.2.1
# ::id pmid_1563_0473.121
# ::preferred 
(t / turn-14~e.2
      :ARG0 (w / we~e.0,19)
      :ARG1~e.3 (p / present-102~e.5
            :ARG1~e.6 (p4 / protein
                  :name (n / name :op1 "Ajuba"~e.8)
                  :mod (c / cytoplasm~e.7)))
      :purpose~e.9 (l / link-01~e.13
            :ARG1 p4
            :ARG1 (i / increase-01~e.17
                  :ARG1 (e / epidermis~e.24
                        :mod (p5 / protein
                              :name (n2 / name :op1 "Snail"~e.21)
                              :mod (t2 / transgenic)))
                  :ARG0-of (p3 / proliferate-01))
            :mod (p2 / possible~e.11)
            :mod (m / mechanistic~e.12))
      :time (n3 / next~e.1))

# ::tok In addition to its documented ability to bind α-catenin [ @<xref ref-type="bibr" rid="pbio-0030011-b10"> 10 </xref>@ ], Ajuba can also associate with growth factor receptor @-@ bound protein @-@ 2 ( Grb @-@ 2 )/son of sevenless ( Sos ) , the nucleotide exchange factor for Ras , which is upstream from activation of MAPK [ @<xref ref-type="bibr" rid="pbio-0030011-b09"> 9 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1 3-1.1.1 3-1.1.1.r 4-1.1.3 5-1.1 7-1.1.2 8-1.1.2.2.1.1 13-1.1.4.1.1.1 16-1.2.1.1.1.1 17-1.2 19-1.2.1 21-1.2.1.2.1.2.1.1.1.1 22-1.2.1.2.1.2.1.1.1.2 23-1.2.1.2.1.2.1 25-1.2.1.2.1 25-1.2.1.2.1.2 25-1.2.1.2.1.2.r 26-1.2.1.2.1.1.1 28-1.2.1.2.1.1.1 28-1.2.1.2.1.3.1.1.1 30-1.2.1.2.1.3.1.1.1 32-1.2.1.2.1.1.1 32-1.2.1.2.1.3.1.1.1 34-1.2.1.2.2.1.2 35-1.2.1.2.2.1.3 37-1.2.1.2.2.2.1.1.1 41-1.2.1.3.1.1 42-1.2.1.3.1 43-1.2.1.3 44-1.2.1.3.2.r 45-1.2.1.3.2.1.1 49-1.2.1.3.3.2 51-1.2.1.3.3.1 52-1.2.1.3.3.1.1.r 53-1.2.1.3.3.1.1.1.1 58-1.2.2.1.1.1
# ::id pmid_1563_0473.122
# ::preferred 
(a / and~e.0,1
      :op1 (c3 / capable-01~e.5
            :ARG1~e.3 p3~e.3
            :ARG2 (b2 / bind-01~e.7
                  :ARG1 (p3 / protein
                        :name (n4 / name :op1 "Ajuba"~e.16))
                  :ARG2 (p8 / protein
                        :name (n / name :op1 "α-catenin"~e.8)))
            :ARG1-of (d2 / document-01~e.4)
            :ARG1-of (d3 / describe-01
                  :ARG0 (p9 / publication
                        :ARG0-of (c4 / cite-01 :ARG2 "10"~e.13))))
      :op2 (p2 / possible~e.17
            :domain (a2 / associate-01~e.19
                  :ARG0 p3
                  :ARG1 (s / slash
                        :op1 (p12 / protein~e.25
                              :name (n10 / name :op1 "protein-2"~e.26,28,32)
                              :ARG1-of~e.25 (b / bind-01~e.25
                                    :ARG2 (r2 / receptor~e.23
                                          :mod (s4 / small-molecule
                                                :name (n11 / name :op1 "growth"~e.21 :op2 "factor"~e.22))))
                              :ARG1-of (m / mean-01
                                    :ARG2 (p5 / protein
                                          :name (n5 / name :op1 "Grb-2"~e.28,30,32))))
                        :op2 (p4 / protein
                              :name (n9 / name
                                    :op1 "son"
                                    :op2 "of"~e.34
                                    :op3 "sevenless"~e.35)
                              :ARG1-of (m2 / mean-01
                                    :ARG2 (p11 / protein
                                          :name (n2 / name :op1 "Sos"~e.37)))))
                  :ARG2 (f / factor~e.43
                        :mod (e / exchange-01~e.42
                              :ARG1 (n7 / nucleotide~e.41))
                        :purpose~e.44 (e2 / enzyme
                              :name (n8 / name :op1 "Ras"~e.45))
                        :location (r / relative-position
                              :op1 (a4 / activate-01~e.51
                                    :ARG1~e.52 (p / pathway
                                          :name (n3 / name :op1 "MAPK"~e.53)))
                              :direction (u / upstream~e.49))))
            :ARG1-of (d / describe-01
                  :ARG0 (p7 / publication
                        :ARG0-of (c2 / cite-01 :ARG2 "9"~e.58)))))

# ::tok Given the increase in pMAPK staining in Tg skin , we examined the possibility that Ajuba might have changed its binding partner in Snail @-@ expressing epidermis .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1 3-1.1.1.r 4-1.1.1.1.1.1 5-1.1.1 7-1.1.1.1.2.1.1.1.1 8-1.1.1.1.2.1 10-1.2.1 11-1.2 13-1.2.2 13-1.2.2.1 13-1.2.2.1.r 15-1.2.2.1.1.1.1.1 16-1.2.2.1 18-1.2.2.1.1 19-1.2.2.1.1.2.1.1 19-1.2.2.1.1.2.1.1.r 20-1.2.2.1.1.2.1 21-1.2.2.1.1.2 23-1.2.2.1.1.2.2.1.1.1.1.1 25-1.2.2.1.1.2.2.1.1 26-1.2.2.1.1.2.2.1
# ::id pmid_1563_0473.123
# ::preferred 
(c2 / cause-01
      :ARG0 (i / increase-01~e.2
            :ARG1~e.3 (s2 / stain-01~e.5
                  :ARG1 (p / pathway
                        :name (n3 / name :op1 "pMAPK"~e.4)
                        :ARG1-of (b3 / be-located-at-91
                              :ARG2 (s / skin~e.8
                                    :mod (p6 / protein
                                          :name (n4 / name :op1 "Tg"~e.7)))))))
      :ARG1 (e4 / examine-01~e.11
            :ARG0 (w / we~e.10)
            :ARG1 (p2 / possible~e.13
                  :domain~e.13 (p3 / possible~e.13,16
                        :domain (c / change-01~e.18
                              :ARG0 (p7 / protein
                                    :name (n / name :op1 "Ajuba"~e.15))
                              :ARG1 (p4 / partner~e.21
                                    :ARG2-of (b / bind-01~e.20
                                          :ARG1~e.19 p4~e.19)
                                    :ARG1-of (b2 / be-located-at-91
                                          :ARG2 (e2 / epidermis~e.26
                                                :ARG1-of (e3 / express-03~e.25
                                                      :ARG2 (p5 / protein
                                                            :name (n2 / name :op1 "Snail"~e.23)))))))))))

# ::tok Interestingly , Ajuba was readily detected in anti @-@ Grb @-@ 2 immunoprecipitates of protein lysates from skins of <i> Snail </i> Tg mice but not from the corresponding wild @-@ type ( WT ) animals ( <xref ref-type="fig" rid="pbio-0030011-g004"> Figure 4 </xref>@ E ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3 0-1.3.r 2-1.1.1.1.1 4-1.1.3 4-1.1.3.r 5-1.1 5-1.2 7-1.1.2.1.1 14-1.1.2.1.2 14-1.2.2 16-1.1.2.2.r 17-1.1.2.2 20-1.1.2.2.1.1.1.1 23-1.1.2.2.1 24-1 25-1.2.1 25-1.2.1.r 26-1.2.3.1.r 28-1.2.3.1.2 29-1.2.3.1.1 31-1.2.3.1.1 33-1.2.3.1.1 33-1.2.3.1.1.1.1.1 35-1.2.3.1 40-1.4.1
# ::id pmid_1563_0473.124
# ::preferred 
(c / contrast-01~e.24
      :ARG1 (d / detect-01~e.5
            :ARG1 (p5 / protein
                  :name (n / name :op1 "Ajuba"~e.2))
            :location (i / immunoprecipitate-00
                  :ARG1 (l / lysate
                        :ARG0-of (o / oppose-01~e.7
                              :ARG1 (p2 / protein
                                    :name (n3 / name :op1 "Grb2")))
                        :part-of (p / protein~e.14))
                  :source~e.16 (s / skin~e.17
                        :poss (m / mice~e.23
                              :mod (p3 / protein
                                    :name (n4 / name :op1 "Snail"~e.20)))
                        :mod (t / transgenic)))
            :manner~e.4 (r / ready~e.4))
      :ARG2 (d3 / detect-01~e.5
            :polarity~e.25 "-"~e.25
            :ARG1 (p4 / protein~e.14)
            :location (i3 / immunoprecipitate-00
                  :source~e.26 (a / animal~e.35
                        :mod (w / wild-type~e.29,31,33
                              :ARG1-of (m3 / mean-01
                                    :ARG2 (n2 / name :op1 "WT"~e.33)))
                        :ARG1-of (c2 / correspond-01~e.28))))
      :manner~e.0 (i2 / interesting~e.0)
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure~e.40 :mod "4E")))

# ::tok When these experiments were repeated with <i> α-catenin </i>@ -@ null epidermis , a similar Grb @-@ 2 @-@ Ajuba association was detected , and again , this interaction was not detected in the protein extracts from control littermate skin ( <xref ref-type="fig" rid="pbio-0030011-g004"> Figure 4 </xref>@ E ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3.r 1-1.3.1.2 2-1.3.1 2-1.3.1.1 2-1.3.1.1.r 4-1.3 7-1.3.1.1.1.2.1.1 10-1.3.1.1.1.3 11-1.3.1.1.1 14-1.1.1.2 15-1.1.1.1.1.1.1 17-1.1.1.1.1.1.1 19-1.1.1.1.2.1.1 20-1.1.1 22-1.1 24-1 25-1.2.4 27-1.2.2.3 28-1.2.2 30-1.2.1 30-1.2.1.r 30-1.3.1.1.1.1 31-1.2 32-1.2.3.r 34-1.2.3.1 35-1.2.3 36-1.2.3.2.r 37-1.2.3.2.2 38-1.2.3.2.1 39-1.2.3.2 44-1.4.1
# ::id pmid_1563_0473.125
# ::preferred 
(a / and~e.24
      :op1 (d / detect-01~e.22
            :ARG1 (a3 / associate-01~e.20
                  :ARG1 (m / macro-molecular-complex
                        :part (p2 / protein
                              :name (n3 / name :op1 "Grb-2"~e.15,17))
                        :part (p3 / protein
                              :name (n2 / name :op1 "Ajuba"~e.19)))
                  :ARG1-of (r2 / resemble-01~e.14)))
      :op2 (d2 / detect-01~e.31
            :polarity~e.30 "-"~e.30
            :ARG1 (i / interact-01~e.28
                  :ARG0 (e2 / epidermis~e.11
                        :polarity "-"~e.30
                        :mod (p / protein
                              :name (n / name :op1 "α-catenin"~e.7))
                        :mod (n4 / null~e.10))
                  :ARG1 p3
                  :mod (t3 / this~e.27))
            :location~e.32 (e3 / extract-01~e.35
                  :ARG1 (p4 / protein~e.34)
                  :ARG2~e.36 (s / skin~e.39
                        :mod (l / littermate~e.38)
                        :ARG0-of (c / control-01~e.37)))
            :mod (a2 / again~e.25))
      :time~e.0 (r / repeat-01~e.4
            :ARG1 (t / thing~e.2
                  :ARG1-of~e.2 (e / experiment-01~e.2
                        :ARG2 e2)
                  :mod (t2 / this~e.1)))
      :ARG1-of (d3 / describe-01
            :ARG0 (f / figure~e.44 :mod "4E")))

# ::tok Together , these data demonstrate that the reduction in α-catenin levels , either by Snail @-@ mediated down @-@ regulation of <i> E @-@ cadherin </i> or by <i> α-catenin </i> conditional targeting , allows Ajuba to interact with Grb @-@ 2/Sos .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3 2-1.1.1 3-1.1 4-1 5-1.2.r 7-1.2.1 8-1.2.1.2.r 9-1.2.1.2.1.1.1 10-1.2.1.2 13-1.2.1.1.r 14-1.2.1.1.1.1.2.1.1.1 16-1.2.1.1.1.1.2 22-1.2.1.1.1.1.1.1 24-1.2.1.1.1.1.1.1 26-1.2.1.1 29-1.2.1.1.2.1 31-1.2.1.1.2.2 32-1.2.1.1.2 34-1.2 35-1.2.2.1.1 37-1.2.3 38-1.2.3.2.r 39-1.2.3.2.1.1.1
# ::id pmid_1563_0473.126
# ::preferred 
(d / demonstrate-01~e.4
      :ARG0 (d2 / data~e.3
            :mod (t / this~e.2))
      :ARG1~e.5 (a / allow-02~e.34
            :ARG0 (r / reduce-01~e.7
                  :ARG0~e.13 (o / or~e.26
                        :op1 (d3 / downregulate-01
                              :ARG1 (p6 / protein
                                    :name (n6 / name :op1 "E-cadherin"~e.22,24)
                                    :ARG1-of (m2 / mediate-01~e.16
                                          :ARG0 (p5 / protein
                                                :name (n5 / name :op1 "Snail"~e.14)))))
                        :op2 (t2 / target-01~e.32
                              :ARG1 p4~e.29
                              :mod (c2 / conditional~e.31)))
                  :ARG1~e.8 (l / level~e.10
                        :degree-of (p4 / protein
                              :name (n4 / name :op1 "α-catenin"~e.9))))
            :ARG1 (p / protein
                  :name (n / name :op1 "Ajuba"~e.35))
            :ARG2 (i / interact-01~e.37
                  :ARG0 p
                  :ARG1~e.38 (m / macro-molecular-complex
                        :part (p2 / protein
                              :name (n2 / name :op1 "Grb-2"~e.39))
                        :part (p3 / protein
                              :name (n3 / name :op1 "Sos")))))
      :mod (t3 / together~e.0))

# ::tok If the competition between Grb @-@ 2/Sos and α-catenin for Ajuba is functionally relevant to the hyperproliferative state of a keratinocyte , then overexpression of Ajuba would be expected to bypass the competition and promote activation of the Ras @-@ MAPK pathway in WT keratinocytes .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.r 2-1.2.1 4-1.2.1.1.1.1.1 8-1.2.1.2.1.1 9-1.2.1.3.r 10-1.2.1.3.1.1 12-1.2.3 12-1.2.3.r 13-1.2 17-1.2.2 20-1.1.2.2.2 20-1.2.2.2 25-1.2.1.3.1.1 28-1 29-1.1.r 30-1.1.1 32-1.1.1.2 33-1.1 34-1.1.2 35-1.1.2.2 36-1.1.2.2.1.r 38-1.1.2.2.1.1.1 40-1.1.2.2.1.1.1 41-1.1.2.2.1 42-1.1.2.2.2.1.r 43-1.1.2.2.2.1
# ::id pmid_1563_0473.127
# ::preferred 
(e / expect-01~e.28
      :ARG1~e.29 (a / and~e.33
            :op1 (b / bypass-01~e.30
                  :ARG0 (o2 / overexpress-00
                        :ARG1 (p2 / protein
                              :name (n / name :op1 "Ajuba"~e.10,25)))
                  :ARG1 c~e.32)
            :op2 (p / promote-01~e.34
                  :ARG0 o2
                  :ARG1 (a2 / activate-01~e.35
                        :ARG1~e.36 (p8 / pathway~e.41
                              :name (n5 / name :op1 "Ras-MAPK"~e.38,40))
                        :location (k2 / keratinocyte~e.20
                              :mod~e.42 (w / wild-type~e.43)))))
      :condition~e.0 (r / relevant-01~e.13
            :ARG1 (c / compete-01~e.2
                  :ARG0 (m / macro-molecular-complex
                        :part (p4 / protein
                              :name (n2 / name :op1 "Grb-2"~e.4))
                        :part (p5 / protein
                              :name (n3 / name :op1 "Sos")))
                  :ARG1 (p3 / protein
                        :name (n4 / name :op1 "α-catenin"~e.8))
                  :ARG2~e.9 p2)
            :ARG2 (s / state~e.17
                  :ARG1-of (h / hyperproliferate-00)
                  :mod (k / keratinocyte~e.20))
            :manner~e.12 (f / functional~e.12)))

# ::tok Indeed , when serum @-@ starved keratinocytes were transiently transfected with an Ajuba expression vector , the levels of pMAPK were not only elevated but also comparable to those transfected with the <i> K14 @-@ HASnail </i> transgene ( <xref ref-type="fig" rid="pbio-0030011-g004"> Figure 4 </xref>@ F ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.4 2-1.5.r 3-1.5.1.1.1 5-1.5.1.1 8-1.5.2 8-1.5.2.r 9-1.5 10-1.5.1.2.r 12-1.5.1.2.1.1.1.1 13-1.5.1.2.1 14-1.5.1.2 17-1.1.1 17-1.2.1.2 20-1.2.1.r 22-1.1.2 23-1.1 29-1.2.1.2.1.2 30-1.5.1.2.r 33-1.2.1.2.1.2.1.1.1 35-1.2.1.2.1.2.1.1.1 37-1.2.1.2.1.2.1 42-1.3.1
# ::id pmid_1563_0473.128
# ::preferred 
(a / and
      :op1 (e / elevate-01~e.23
            :ARG1 (l / level~e.17
                  :quant-of (e3 / enzyme
                        :name (n / name :op1 "MAPK")
                        :ARG3-of (p / phosphorylate-01)))
            :mod (o / only~e.22))
      :op2 (p3 / possible
            :domain~e.20 (c2 / compare-01
                  :ARG1 l
                  :ARG2 (l2 / level~e.17
                        :quant-of (e4 / enzyme
                              :name (n4 / name :op1 "MAPK")
                              :ARG1-of (t4 / transfect-00~e.29
                                    :ARG2 (t5 / transgene~e.37
                                          :name (n3 / name :op1 "K14-HASnail"~e.33,35)))
                              :ARG3-of (p4 / phosphorylate-01)))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure~e.42 :mod "4F"))
      :mod (i / indeed~e.0)
      :time~e.2 (t / transfect-00~e.9
            :ARG0 (k / keratinocyte
                  :ARG1-of (s / starve-01~e.5
                        :ARG2 (s2 / serum~e.3))
                  :instrument~e.10,30 (v / vector~e.14
                        :ARG1-of (e2 / express-03~e.13
                              :ARG2 (p2 / protein
                                    :name (n2 / name :op1 "Ajuba"~e.12)))))
            :manner~e.8 (t2 / transient~e.8)))

# ::tok This activation was abolished when cells were treated with a small peptide inhibitor that specifically interrupts the Grb @-@ 2/Sos interaction ( <xref ref-type="fig" rid="pbio-0030011-g004"> Figure 4 </xref>@ F ; see lanes marked “ inh ”) [ @<xref ref-type="bibr" rid="pbio-0030011-b27"> 27 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1 3-1 4-1.4.r 5-1.4.1 7-1.4 8-1.4.2.r 10-1.4.2.2 11-1.4.2.1.1 12-1.4.2 12-1.4.2.1 12-1.4.2.1.r 14-1.4.2.3.2 15-1.4.2.3 17-1.4.2.3.1.1.1.1 20-1.4.2.3.1 25-1.2.1.1 30-1.2.1.2 31-1.2.1.2.1 32-1.2.1.2.1.1 34-1.2.1.2.1.1.1 40-1.3.1.1.1
# ::id pmid_1563_0473.129
# ::preferred 
(a / abolish-01~e.3
      :ARG1 (a2 / activate-01~e.1
            :mod (t3 / this~e.0))
      :ARG1-of (d / describe-01
            :ARG0 (a3 / and
                  :op1 (f / figure~e.25 :mod "4F")
                  :op2 (s3 / see-01~e.30
                        :ARG1 (l / lane~e.31
                              :ARG1-of (m / mark-01~e.32
                                    :ARG0 (i4 / inh~e.34))))))
      :ARG1-of (d2 / describe-01
            :ARG0 (p4 / publication
                  :ARG0-of (c3 / cite-01 :ARG2 "27"~e.40)))
      :time~e.4 (t2 / treat-04~e.7
            :ARG1 (c2 / cell~e.5)
            :ARG2~e.8 (m2 / molecular-physical-entity~e.12
                  :ARG0-of~e.12 (i / inhibit-01~e.12
                        :ARG1 (p / peptide~e.11))
                  :mod (s / small~e.10)
                  :ARG0-of (i2 / interrupt-01~e.15
                        :ARG1 (i3 / interact-01~e.20
                              :ARG0 (p2 / protein
                                    :name (n / name :op1 "Grb-2"~e.17))
                              :ARG1 (p3 / protein
                                    :name (n2 / name :op1 "Sos")))
                        :manner (s2 / specific~e.14)))))

# ::tok Ajuba 's pre @-@ LIM domain is the segment that associates with Grb @-@ 2 's Src @-@ homology 3 domain [ @<xref ref-type="bibr" rid="pbio-0030011-b09"> 9 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3.1.1.1 1-1.3.1.r 1-1.3.r 2-1.3.2.1.1 4-1.3.2.1.1 5-1.3 6-1.3.r 8-1 10-1.1 11-1.1.1.r 12-1.1.1.2.1.1 14-1.1.1.2.1.1 15-1.1.1.2.r 16-1.1.1.1.1 18-1.1.1.1.1 19-1.1.1.1.2 20-1.1.1.1.3 20-1.3 25-1.2.1.1.1
# ::id pmid_1563_0473.130
# ::preferred 
(s / segment~e.8
      :ARG1-of (a / associate-01~e.10
            :ARG2~e.11 (p5 / protein-segment
                  :name (n / name
                        :op1 "Src-homology"~e.16,18
                        :op2 "3"~e.19
                        :op3 "domain"~e.20)
                  :part-of~e.15 (p2 / protein
                        :name (n2 / name :op1 "Grb-2"~e.12,14))))
      :ARG1-of (d2 / describe-01
            :ARG0 (p / publication
                  :ARG1-of (c / cite-01 :ARG2 "9"~e.25)))
      :domain~e.1,6 (d3 / domain~e.5,20
            :part-of~e.1 (p3 / protein
                  :name (n3 / name :op1 "Ajuba"~e.0))
            :mod (p4 / protein-segment
                  :name (n4 / name :op1 "pre-LIM"~e.2,4))))

# ::tok When this domain was overexpressed in serum @-@ starved keratinocytes , a comparable elevation in pMAPK was observed ( <xref ref-type="fig" rid="pbio-0030011-g004"> Figure 4 </xref>@ F ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.r 1-1.2.1.1 2-1.2.1 6-1.2.2.2.1 8-1.2.2.2 13-1.1 17-1 22-1.3.1
# ::id pmid_1563_0473.131
# ::preferred 
(o / observe-01~e.17
      :ARG1 (e / elevate-01~e.13
            :ARG1 (p / pathway
                  :name (n / name :op1 "MAPK")
                  :ARG1-of (p2 / phosphorylate-01))
            :ARG1-of (c / compare-01
                  :mod (p3 / possible)))
      :time~e.0 (o2 / overexpress-00
            :ARG1 (d / domain~e.2
                  :mod (t / this~e.1))
            :location (c2 / cell
                  :name (n2 / name :op1 "keratinocyte")
                  :ARG1-of (s / starve-01~e.8
                        :ARG2 (s2 / serum~e.6))))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure~e.22 :mod "4F")))

# ::tok As expected , the small peptide inhibitor that interrupts the Grb @-@ 2/Sos association blocked the effects .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3 4-1.1.1.1.1 5-1.1.1.1 6-1.1 6-1.1.1 6-1.1.1.r 8-1.1.2 10-1.1.2.1.1.1.1 13-1.1.2.1 14-1 16-1.2
# ::id pmid_1563_0473.132
# ::preferred 
(b / block-01~e.14
      :ARG0 (m / molecular-physical-entity~e.6
            :ARG0-of~e.6 (i / inhibit-01~e.6
                  :ARG1 (p / peptide~e.5
                        :mod (s / small~e.4)))
            :ARG0-of (i2 / interrupt-01~e.8
                  :ARG1 (a / associate-01~e.13
                        :ARG1 (p2 / protein
                              :name (n2 / name :op1 "Grb-2"~e.10))
                        :ARG2 (p3 / protein
                              :name (n3 / name :op1 "Sos")))))
      :ARG1 (e / effect~e.16)
      :ARG1-of (e2 / expect-01~e.1))

# ::tok These data suggested that by elevating cytosolic Ajuba levels , Ajuba 's pre @-@ LIM domain may associate with Grb @-@ 2/Sos in a manner that stimulates its nucleotide exchange activity and leads to activation of the Ras @-@ MAPK pathway .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1 2-1 4-1.2.r 5-1.2.1.4 6-1.2.1.4.1.1 7-1.2.1.4.1.1 8-1.2.1.4.1 10-1.2.1.1.2.1.1 11-1.2.1.1.2.r 12-1.2.1.1.1.1 14-1.2.1.1.1.1 15-1.2.1.1.1.2 16-1.2 17-1.2.1 18-1.2.1.2.r 19-1.2.1.2.1.1.1 24-1.2.1.3.r 24-1.2.1.4.r 26-1.2.1.3.1 28-1.2.1.3.1.2.2.1 29-1.2.1.3.1.2.2 31-1.2.1.3 32-1.2.1.3.2 33-1.2.1.3.2.2.r 34-1.2.1.3.2.2 35-1.2.1.3.2.2.1.r 37-1.2.1.3.2.2.1.1.1 39-1.2.1.3.2.2.1.1.1 40-1.2.1.3.2.2.1
# ::id pmid_1563_0473.133
# ::preferred 
(s / suggest-01~e.2
      :ARG0 (d / data~e.1
            :mod (t / this~e.0))
      :ARG1~e.4 (p / possible~e.16
            :domain (a / associate-01~e.17
                  :ARG1 (p2 / protein-segment
                        :name (n / name :op1 "pre-LIM"~e.12,14 :op2 "domain"~e.15)
                        :part-of~e.11 (p3 / protein
                              :name (n2 / name :op1 "Ajuba"~e.10)
                              :location (c / cytosol)))
                  :ARG2~e.18 (m / macro-molecular-complex
                        :part (p4 / protein
                              :name (n3 / name :op1 "Grb-2"~e.19))
                        :part (p5 / protein
                              :name (n4 / name :op1 "Sos")))
                  :manner~e.24 (a2 / and~e.31
                        :op1 (s2 / stimulate-01~e.26
                              :ARG0 a
                              :ARG1 (a3 / act-01
                                    :ARG0 p2
                                    :ARG1 (e / exchange-01~e.29
                                          :ARG1 (n5 / nucleotide~e.28))))
                        :op2 (l / lead-03~e.32
                              :ARG0 a
                              :ARG2~e.33 (a4 / activate-01~e.34
                                    :ARG1~e.35 (p6 / pathway~e.40
                                          :name (n6 / name :op1 "Ras-MAPK"~e.37,39)))))
                  :manner-of~e.24 (e2 / elevate-01~e.5
                        :ARG1 (l2 / level~e.8
                              :degree-of p3~e.6,7)))))

# ::tok Although this pathway provides one mechanism by which Snail expression and proliferation may be coupled in skin epithelium , proliferative circuitries involving AJs are known to be complex and often interwoven .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.r 1-1.2.1.1 2-1.2.1 3-1.2 4-1.2.2.1.4.1 5-1.2.2.1.4 8-1.2.2.1.1.1.1.1 9-1.2.2.1.1 11-1.1.1.1.1 11-1.2.2.1.2 12-1.2.2 13-1.2.2.1.r 14-1.2.2.1 15-1.2.2.1.3.r 16-1.2.2.1.3.1 17-1.2.2.1.3 20-1.1.1.1 21-1.1.1.1.2 23-1.1.1.1.r 24-1 26-1.1.1.1.r 27-1.1.1 28-1.1 29-1.1.2.2
# ::id pmid_1563_0473.134
# ::preferred 
(k / know-01~e.24
      :ARG1 (a / and~e.28
            :op1 (c / complex~e.27
                  :domain~e.23,26 (c2 / circuitry~e.20
                        :ARG0-of (p / proliferate-01~e.11)
                        :ARG2-of (i / involve-01~e.21
                              :ARG1 (p2 / protein
                                    :name (n / name :op1 "AJ")))))
            :op2 (i2 / interweave-01
                  :ARG1 c2
                  :frequency (o / often~e.29)))
      :concession~e.0 (p3 / provide-01~e.3
            :ARG0 (p4 / pathway~e.2
                  :mod (t / this~e.1))
            :ARG1 (p5 / possible~e.12
                  :domain~e.13 (c3 / couple-01~e.14
                        :ARG1 (e / express-03~e.9
                              :ARG2 (p6 / protein
                                    :name (n2 / name :op1 "Snail"~e.8)))
                        :ARG2 (p7 / proliferate-01~e.11
                              :ARG0 p6)
                        :location~e.15 (e2 / epithelium~e.17
                              :part-of (s / skin~e.16))
                        :instrument (m / mechanism~e.5 :quant "1"~e.4)))))

# ::tok Future studies will be needed to systematically dissect these putative intricacies at a molecular level .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1 4-1 6-1.2.2 7-1.2 8-1.2.1.1 9-1.2.1.2 10-1.2.1 11-1.2.3.r 13-1.2.3.1 14-1.2.3
# ::id pmid_1563_0473.135
# ::preferred 
(n / need-01~e.4
      :ARG1 (s / study-01~e.1
            :time (f / future~e.0))
      :purpose (d / dissect-01~e.7
            :ARG1 (i / intricacy~e.10
                  :mod (t / this~e.8)
                  :ARG2-of (t2 / think-01~e.9))
            :manner (s2 / systematic~e.6)
            :location~e.11 (l / level~e.14
                  :mod (m / molecule~e.13))))

# ::tok Probing the Regulation of <i> Snail </i> Gene Expression Reveals an Essential Link to TGF-β2 Signaling in the Developing Hair Bud
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 2-1.1.1 5-1.1.1.1.1.1.1 7-1.1.1.1.1 8-1.1.1.1 9-1 11-1.2.2 12-1.2 13-1.2.1.r 14-1.2.1.1.1.1 15-1.2.1 16-1.2.1.2.r 18-1.2.1.2.1 19-1.2.1.2.2 20-1.2.1.2
# ::id pmid_1563_0473.136
# ::preferred 
(r / reveal-01~e.9
      :ARG0 (p / probe-01~e.0
            :ARG1 (r2 / regulate-01~e.2
                  :ARG1 (e / express-03~e.8
                        :ARG1 (g / gene~e.7
                              :name (n / name :op1 "Snail"~e.5)))))
      :ARG1 (l / link-01~e.12
            :ARG1~e.13 (s / signal-07~e.15
                  :ARG0 (p2 / protein
                        :name (n2 / name :op1 "TGF-β2"~e.14))
                  :location~e.16 (b / bud~e.20
                        :ARG1-of (d / develop-02~e.18)
                        :mod (h / hair~e.19)))
            :mod (e2 / essential~e.11)))

# ::tok The temporal spike of <i> Snail </i> mRNA expression in the hair bud prompted us to consider what factor( s ) may be regulating the <i> Snail </i> gene .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.2 1-1.1.2.r 2-1.1 5-1.1.1.2.1.1 7-1.1.1.1.1.1 8-1.1.1 9-1.1.1.3.r 11-1.1.1.3.1 12-1.1.1.3 13-1 14-1.2.1 16-1.2 21-1.2.2.2.2 23-1.2.2.2 26-1.2.2.2.1 27-1.2.2.2.1 28-1.2.2.2.1
# ::id pmid_1563_0473.137
# ::preferred 
(p / prompt-01~e.13
      :ARG0 (s / spike~e.2
            :poss (e / express-03~e.8
                  :ARG1 (r / rna
                        :name (n / name :op1 "mRNA"~e.7))
                  :part-of (g / gene
                        :name (n2 / name :op1 "Snail"~e.5))
                  :location~e.9 (b / bud~e.12
                        :mod (h / hair~e.11)))
            :time~e.1 (t / temporal~e.1))
      :ARG1 (c / consider-02~e.16
            :ARG0 (w / we~e.14)
            :ARG1 (f / factor
                  :mode "interrogative"
                  :ARG0-of (r2 / regulate-01~e.23
                        :ARG1 g~e.26,27,28
                        :mod (p2 / possible~e.21)))))

# ::tok A variety of extracellular signals have an impact on the cell type @-@ specific expression of different Snail family members , and many of them , including Wnts , BMPs , FGFs , and TGF-βs , also affect hair bud development [ @<xref ref-type="bibr" rid="pbio-0030011-b02"> 2 </xref> , <xref ref-type="bibr" rid="pbio-0030011-b16"> 16 </xref> , <xref ref-type="bibr" rid="pbio-0030011-b28"> 28 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1.2 3-1.1.1.1 4-1.1.1 4-1.2.1 5-1.1 7-1.1 8-1.1.2.r 10-1.1.2.2.1.1 11-1.1.2.2.1 13-1.1.2.2 14-1.1.2 15-1.1.2.1.r 16-1.1.2.1 16-1.1.2.1.2 16-1.1.2.1.2.r 17-1.1.2.1.1.1 18-1.1.2.1.3.1.1 19-1.1.2.1.3.1 21-1.2.1.3.1 22-1.2.1.1 26-1.1.2.1.3 26-1.2.1.2 26-1.2.1.3 36-1.2.3 37-1.2 38-1.2.2.1.1 39-1.2.2.1 40-1.2.2 45-1.3.1.1.1.1 51-1.3.1.1.1.2 57-1.3.1.1.1.3
# ::id pmid_1563_0473.138
# ::preferred 
(a / and
      :op1 (i / impact-01~e.5,7
            :ARG0 (s / signal-07~e.4
                  :location (e / extracellular~e.3)
                  :mod (v / variety~e.1))
            :ARG1~e.8 (e2 / express-03~e.14
                  :ARG2~e.15 (p / protein~e.16
                        :name (n / name :op1 "Snail"~e.17)
                        :ARG1-of~e.16 (d / differ-02~e.16)
                        :ARG2-of (i2 / include-91~e.26
                              :ARG1 (m / member~e.19
                                    :mod (f / family~e.18))))
                  :mod (s2 / specific~e.13
                        :prep-to (t / type~e.11
                              :mod (c / cell~e.10)))))
      :op2 (a2 / affect-01~e.37
            :ARG0 (s3 / signal-07~e.4
                  :quant (m2 / many~e.22)
                  :ARG1-of (i3 / include-91~e.26
                        :ARG2 s)
                  :ARG2-of (i4 / include-91~e.26
                        :ARG1 (a3 / and~e.21
                              :op1 (p2 / protein
                                    :name (n2 / name :op1 "Wnt"))
                              :op2 (p3 / protein
                                    :name (n3 / name :op1 "BMP"))
                              :op3 (p4 / protein
                                    :name (n4 / name :op1 "FGF"))
                              :op4 (p5 / protein
                                    :name (n5 / name :op1 "TGF-β")))))
            :ARG1 (d2 / develop-02~e.40
                  :ARG1 (b / bud~e.39
                        :mod (h / hair~e.38)))
            :mod (a4 / also~e.36))
      :ARG1-of (d3 / describe-01
            :ARG0 (p6 / publication
                  :ARG1-of (c2 / cite-01
                        :ARG2 (a5 / and
                              :op1 "2"~e.45
                              :op2 "16"~e.51
                              :op3 "28"~e.57)))))

# ::tok Since Snail is not expressed in cultured skin keratinocytes that secrete active BMPs and FGFs ( see <xref ref-type="fig" rid="pbio-0030011-g001"> Figure 1 </xref>@ B ) , we focused our attention on Wnt and TGF-β signaling as more likely candidates for Snail induction in this cell type .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.1.2.1.1 3-1.1.1 3-1.1.1.r 4-1.1 6-1.1.3.2 7-1.1.3.1 10-1.1.3.3 13-1.1.3.3.1 16-1.1.4 20-1.1.4.1 26-1.2.1 27-1.2 28-1.2.2.1 28-1.2.2.1.r 29-1.2.2 30-1.2.3.r 31-1.2.3.1.1.1.1 32-1.2.3.1 33-1.2.3.1.2.1.1 34-1.2.3 36-1.2.3.2.1.2 37-1.2.3.2.1 38-1.2.3.2.1.1 39-1.2.3.2.1.1.1.r 40-1.2.3.2.1.1.1.1 41-1.2.3.2.1.1.1 42-1.2.3.2.1.1.1.2.r 43-1.2.3.2.1.1.1.2.2 44-1.2.3.2.1.1.1.2.1 45-1.2.3.2.1.1.1.2
# ::id pmid_1563_0473.139
# ::preferred 
(c / cause-01~e.0
      :ARG0 (e / express-03~e.4
            :polarity~e.3 "-"~e.3
            :ARG2 (p / protein
                  :name (n / name :op1 "Snail"~e.1))
            :ARG3 (k / keratinocyte
                  :mod (s / skin~e.7)
                  :ARG1-of (c2 / culture-01~e.6)
                  :ARG0-of (s2 / secrete-01~e.10
                        :ARG1 (a / and~e.13
                              :op1 (p2 / protein
                                    :name (n2 / name :op1 "BMP"))
                              :op2 (p3 / protein
                                    :name (n3 / name :op1 "FGF"))
                              :ARG1-of (a2 / activate-01))))
            :ARG1-of (s3 / see-01~e.16
                  :ARG2 (f / figure~e.20 :mod "1B")))
      :ARG1 (f2 / focus-01~e.27
            :ARG0 (w / we~e.26)
            :ARG1 (a3 / attention~e.29
                  :poss~e.28 w~e.28)
            :ARG2~e.30 (s4 / signal-07~e.34
                  :ARG0 (a4 / and~e.32
                        :op1 (p4 / protein
                              :name (n4 / name :op1 "Wnt"~e.31))
                        :op2 (p5 / protein
                              :name (n5 / name :op1 "TGF-β"~e.33)))
                  :ARG0-of (a5 / act-01
                        :ARG1 (l / likely~e.37
                              :domain (c3 / candidate~e.38
                                    :purpose~e.39 (i / induce-01~e.41
                                          :ARG1 p~e.40
                                          :location~e.42 (t / type~e.45
                                                :mod (c4 / cell~e.44)
                                                :mod (t2 / this~e.43))))
                              :degree (m / more~e.36))))))

# ::tok Previously , we showed that effective transmission of a Wnt @-@ 3a signal in cultured keratinocytes can be achieved through their exposure to the BMP inhibitor noggin , which induces LEF @-@ 1 expression [ @<xref ref-type="bibr" rid="pbio-0030011-b04"> 4 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3 2-1.1 3-1 4-1.2.r 5-1.2.1.1.2 6-1.2.1.1 7-1.2.1.1.1.r 9-1.2.1.1.1.1.1.1 11-1.2.1.1.1.1.1.1 12-1.2.1.1.1 13-1.2.1.1.1.2.r 14-1.2.1.1.1.2.2 16-1.2 17-1.2.1.r 18-1.2.1 20-1.2.1.2.1 20-1.2.1.2.1.r 21-1.2.1.2 22-1.2.1.2.2.r 24-1.2.1.2.2.2.1.1.1 25-1.2.1.2.2 25-1.2.1.2.2.2 25-1.2.1.2.2.2.r 26-1.2.1.2.2.1.1 29-1.2.1.2.2.2.1 29-1.2.1.2.2.2.1.2 29-1.2.1.2.2.2.1.2.r 30-1.2.1.2.2.2.1.2.1.1.1.1 32-1.2.1.2.2.2.1.2.1.1.1.1 33-1.2.1.2.2.2.1.2.1 38-1.4.1.1.1
# ::id pmid_1563_0473.140
# ::preferred 
(s / show-01~e.3
      :ARG0 (w / we~e.2)
      :ARG1~e.4 (p / possible~e.16
            :domain~e.17 (a / achieve-01~e.18
                  :ARG1 (t / transmit-01~e.6
                        :ARG1~e.7 (s2 / signal-07~e.12
                              :ARG0 (p2 / protein
                                    :name (n / name :op1 "Wnt-3a"~e.9,11))
                              :location~e.13 (c / cell
                                    :name (n2 / name :op1 "keratinocyte")
                                    :ARG1-of (c2 / culture-01~e.14)))
                        :mod (e / effective~e.5))
                  :manner (e2 / expose-01~e.21
                        :ARG1~e.20 c~e.20
                        :ARG2~e.22 (p3 / protein~e.25
                              :name (n3 / name :op1 "noggin"~e.26)
                              :ARG0-of~e.25 (i / inhibit-01~e.25
                                    :ARG1 (p4 / protein~e.29
                                          :name (n4 / name :op1 "BMP"~e.24)
                                          :ARG0-of~e.29 (i2 / induce-01~e.29
                                                :ARG1 (e3 / express-03~e.33
                                                      :ARG2 (p5 / protein
                                                            :name (n5 / name :op1 "LEF-1"~e.30,32))))))))))
      :time (p6 / previous~e.0)
      :ARG1-of (d / describe-01
            :ARG0 (p7 / publication
                  :ARG1-of (c3 / cite-01 :ARG2 "4"~e.38))))

# ::tok In vitro , these conditions down @-@ regulated the <i> E @-@ cadherin </i> promoter and induced a LEF @-@ 1/β-catenin @-@ sensitive reporter gene , <i> TOPFLASH </i> [ @<xref ref-type="bibr" rid="pbio-0030011-b04"> 4 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3 1-1.3 3-1.1.1.1 4-1.1.1 10-1.1.2.1.1.1.1 12-1.1.2.1.1.1.1 15-1 16-1.2 18-1.2.2.3.1.1.1.1 22-1.2.2.3 23-1.2.2.2 24-1.2.2 27-1.2.2.1.1 33-1.4.1.1.1
# ::id pmid_1563_0473.141
# ::preferred 
(a / and~e.15
      :op1 (d / downregulate-01
            :ARG0 (c / condition~e.4
                  :mod (t / this~e.3))
            :ARG1 (m / molecular-physical-entity
                  :ARG0-of (p / promote-01
                        :ARG1 (p2 / protein
                              :name (n / name :op1 "E-cadherin"~e.10,12)))))
      :op2 (i / induce-01~e.16
            :ARG0 c
            :ARG1 (g / gene~e.24
                  :name (n2 / name :op1 "TOPFLASH"~e.27)
                  :ARG0-of (r / report-01~e.23)
                  :ARG0-of (s / sensitive-03~e.22
                        :ARG1 (m2 / macro-molecular-complex
                              :part (p3 / protein
                                    :name (n3 / name :op1 "LEF-1"~e.18))
                              :part (p4 / protein
                                    :name (n4 / name :op1 "β-catenin"))))))
      :manner (i2 / in-vitro~e.0,1)
      :ARG1-of (d2 / describe-01
            :ARG0 (p5 / publication
                  :ARG1-of (c2 / cite-01 :ARG2 "4"~e.33))))

# ::tok In contrast , Snail expression was not induced by these conditions ( <xref ref-type="fig" rid="pbio-0030011-g005"> Figure 5 </xref>@ A ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1 3-1.1.3.1.1.1 4-1.1.3 6-1.1.1 6-1.1.1.r 7-1.1 8-1.1.2.r 9-1.1.2.1 10-1.1.2 15-1.1.4.1
# ::id pmid_1563_0473.142
# ::preferred 
(c / contrast-01~e.1
      :ARG2 (i / induce-01~e.7
            :polarity~e.6 "-"~e.6
            :ARG0~e.8 (c2 / condition~e.10
                  :mod (t / this~e.9))
            :ARG1 (e / express-03~e.4
                  :ARG2 (p / protein
                        :name (n / name :op1 "Snail"~e.3)))
            :ARG1-of (d / describe-01
                  :ARG0 (f / figure~e.15 :mod "5A"))))

# ::tok Thus , despite essential roles for Wnts and noggin in hair follicle specification [ @<xref ref-type="bibr" rid="pbio-0030011-b04"> 4 </xref> , <xref ref-type="bibr" rid="pbio-0030011-b29"> 29 </xref> , <xref ref-type="bibr" rid="pbio-0030011-b30"> 30 </xref>@ ], our studies did not support an essential role for these signals in governing <i> Snail </i> expression in keratinocytes .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 2-1.1.4.r 3-1.1.4.1 4-1.1.4 7-1.1.4.2 7-1.1.4.4.1.1.1 8-1.1.4.2.2.1.1 9-1.1.4.3.r 10-1.1.4.3.1.1 11-1.1.4.3.1 12-1.1.4.3 17-1.1.4.4.1.1.1.1 23-1.1.4.4.1.1.1.2 29-1.1.4.4.1.1.1.3 32-1.1.2.1 32-1.1.2.1.r 33-1.1.2 34-1.1.2 35-1.1.1 35-1.1.1.r 36-1.1 38-1.1.3.1 39-1.1.3 40-1.1.3.2.r 41-1.1.3.2.1 42-1.1.3.2 43-1.1.3.3.r 44-1.1.3.3 46-1.1.3.3.1.1.1.1 48-1.1.3.3.1
# ::id pmid_1563_0473.143
# ::preferred 
(c / cause-01~e.0
      :ARG1 (s / support-01~e.36
            :polarity~e.35 "-"~e.35
            :ARG0 (s2 / study-01~e.33,34
                  :ARG0~e.32 (w / we~e.32))
            :ARG1 (r / role~e.39
                  :mod (e / essential~e.38)
                  :beneficiary~e.40 (s3 / signal-07~e.42
                        :mod (t / this~e.41))
                  :topic~e.43 (g / govern-01~e.44
                        :ARG1 (e2 / express-03~e.48
                              :ARG2 (g2 / gene
                                    :name (n2 / name :op1 "Snail"~e.46))
                              :location (c2 / cell
                                    :name (n / name :op1 "keratinocyte")))))
            :concession~e.2 (r2 / role~e.4
                  :mod (e3 / essential~e.3)
                  :beneficiary (a / and~e.7
                        :op1 (p / protein
                              :name (n3 / name :op1 "Wnt"))
                        :op2 (p2 / protein
                              :name (n4 / name :op1 "noggin"~e.8)))
                  :topic~e.9 (s4 / specify-01~e.12
                        :ARG1 (f / follicle~e.11
                              :mod (h / hair~e.10)))
                  :ARG1-of (d / describe-01
                        :ARG0 (p3 / publication
                              :ARG1-of (c3 / cite-01
                                    :ARG2 (a2 / and~e.7
                                          :op1 "4"~e.17
                                          :op2 "29"~e.23
                                          :op3 "30"~e.29)))))))

# ::tok TGF-β1 has been shown to induce Snail family members in hepatocytes and heart [ @<xref ref-type="bibr" rid="pbio-0030011-b15"> 15 </xref> , <xref ref-type="bibr" rid="pbio-0030011-b31"> 31 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1.1 3-1 5-1.1 6-1.1.2.1.1 7-1.1.2.2.1.1 8-1.1.2.2.1 11-1.1.3 12-1.1.3.2 17-1.2.1.1.1.1 23-1.2.1.1.1.2
# ::id pmid_1563_0473.144
# ::preferred 
(s / show-01~e.3
      :ARG1 (i / induce-01~e.5
            :ARG0 (p / protein
                  :name (n / name :op1 "TGF-β1"~e.0))
            :ARG1 (p2 / protein
                  :name (n2 / name :op1 "Snail"~e.6)
                  :ARG2-of (i2 / include-91
                        :ARG1 (m / member~e.8
                              :mod (f / family~e.7))))
            :location (a / and~e.11
                  :op1 (c / cell
                        :name (n3 / name :op1 "hepatocyte"))
                  :op2 (h / heart~e.12)))
      :ARG1-of (d / describe-01
            :ARG0 (p3 / publication
                  :ARG1-of (c2 / cite-01
                        :ARG2 (a2 / and :op1 "15"~e.17 :op2 "31"~e.23)))))

# ::tok In keratinocytes , however , TGF-β1 inhibits keratinocyte growth and seems to be involved in triggering the destructive phase of the cycling hair follicle [ @<xref ref-type="bibr" rid="pbio-0030011-b32"> 32 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 3-1 5-1.1.1.1.1.1 6-1.1.1 7-1.1.1.2.1.1.1 8-1.1.1.2 9-1.1 10-1.1.2 13-1.1.2.1 14-1.1.2.1.2.r 15-1.1.2.1.2 17-1.1.2.1.2.2.1 18-1.1.2.1.2.2 19-1.1.2.1.2.2.2.r 21-1.1.2.1.2.2.2.2 22-1.1.2.1.2.2.2.1 23-1.1.2.1.2.2.2 28-1.2.1.1.1
# ::id pmid_1563_0473.145
# ::preferred 
(h / have-concession-91~e.3
      :ARG2 (a / and~e.9
            :op1 (i / inhibit-01~e.6
                  :ARG0 (p / protein
                        :name (n / name :op1 "TGF-β1"~e.5))
                  :ARG1 (g / grow-01~e.8
                        :ARG1 (c / cell
                              :name (n2 / name :op1 "keratinocyte"~e.7))))
            :op2 (s / seem-01~e.10
                  :ARG1 (i2 / involve-01~e.13
                        :ARG1 p
                        :ARG2~e.14 (t / trigger-01~e.15
                              :ARG0 p
                              :ARG1 (p2 / phase~e.18
                                    :ARG0-of (d / destroy-01~e.17)
                                    :part-of~e.19 (f / follicle~e.23
                                          :mod (h2 / hair~e.22)
                                          :mod (c2 / cycle~e.21))))))
            :location c)
      :ARG1-of (d2 / describe-01
            :ARG0 (p3 / publication
                  :ARG1-of (c3 / cite-01 :ARG2 "32"~e.28))))

# ::tok Of the loss @-@ of @-@ function mutations generated in each of the <i> TGF-β </i> genes , only the <i> TGF-β2 </i> null state blocked follicle development at the hair bud stage [ @<xref ref-type="bibr" rid="pbio-0030011-b32"> 32 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1.4.1.1 6-1.1.4.1.1.1 7-1.1.4.1 8-1.1.4.1.2 10-1.1.4.1.2.1.2 14-1.1.4.1.2.1.1.1 16-1.1.2 16-1.1.4.1.2.1 18-1.1.3 21-1.1.2.1.1 23-1.1.1 24-1.1 25-1 26-1.2 27-1.2.1 28-1.3.r 30-1.3.1.1 31-1.3.1 32-1.3 37-1.4.1.1.1
# ::id pmid_1563_0473.146
# ::preferred 
(b / block-01~e.25
      :ARG0 (s / state~e.24
            :mod (n / null~e.23)
            :poss (g / gene~e.16
                  :name (n2 / name :op1 "TGF-β2"~e.21))
            :mod (o / only~e.18)
            :ARG1-of (i / include-91
                  :ARG2 (m / mutate-01~e.7
                        :ARG2 (l / lose-02~e.2
                              :ARG1 (f2 / function-01~e.6))
                        :ARG1-of (g2 / generate-01~e.8
                              :ARG3 (g3 / gene~e.16
                                    :name (n3 / name :op1 "TGF-β"~e.14)
                                    :mod (e / each~e.10))))))
      :ARG1 (f / follicle~e.26
            :ARG1-of (d / develop-02~e.27))
      :time~e.28 (s2 / stage~e.32
            :mod (b2 / bud~e.31
                  :mod (h / hair~e.30)))
      :ARG1-of (d2 / describe-01
            :ARG0 (p / publication
                  :ARG1-of (c / cite-01 :ARG2 "32"~e.37))))

# ::tok Thus , we turned towards addressing whether TGF-β2 might be involved in regulating <i> Snail </i> expression in keratinocytes isolated from the basal layer of the epidermis .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 2-1.1.1 3-1.1 5-1.1.2 6-1.1.2.2.1 6-1.1.2.2.1.r 7-1.1.2.2.2.1.1.1 8-1.1.2.2 9-1.1.2.2.2.r 10-1.1.2.2.2 11-1.1.2.2.2.2.r 12-1.1.2.2.2.2 14-1.1.2.2.2.2.2.1.1.1 16-1.1.2.2.2.2.2 19-1.1.2.2.2.2.3.2 20-1.1.2.2.2.2.3.2.1.r 22-1.1.2.2.2.2.3.2.1.1 23-1.1.2.2.2.2.3.2.1 24-1.1.2.2.2.2.3.2.1.2.r 26-1.1.2.2.2.2.3.2.1.2
# ::id pmid_1563_0473.147
# ::preferred 
(c / cause-01~e.0
      :ARG1 (t / turn-01~e.3
            :ARG0 (w / we~e.2)
            :location (a / address-02~e.5
                  :ARG0 w
                  :ARG1 (p / possible~e.8
                        :mode~e.6 "interrogative"~e.6
                        :domain~e.9 (i / involve-01~e.10
                              :ARG1 (p2 / protein
                                    :name (n / name :op1 "TGF-β2"~e.7))
                              :ARG2~e.11 (r / regulate-01~e.12
                                    :ARG0 p2
                                    :ARG1 (e / express-03~e.16
                                          :ARG2 (g / gene
                                                :name (n2 / name :op1 "Snail"~e.14)))
                                    :location (c2 / cell
                                          :name (n3 / name :op1 "keratinocyte")
                                          :ARG1-of (i2 / isolate-01~e.19
                                                :ARG2~e.20 (l / layer~e.23
                                                      :mod (b / basal~e.22)
                                                      :part-of~e.24 (e2 / epidermis~e.26))))))))))

# ::tok Though there is no cell culture system available to specifically study placodal cells , these keratinocytes are their progenitors and are the closest approximation available to study the behavior of epithelial cells of the placode .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3.r 2-1.3.2.r 3-1.3.1 3-1.3.1.r 4-1.3.2.1.1 5-1.3.2.1 6-1.3.2 7-1.3 9-1.3.3.2 10-1.3.3 12-1.1.2 14-1.1.1.2 18-1.1.3 19-1 20-1.2.1.r 22-1.2.1.2 22-1.2.1.2.1 22-1.2.1.2.1.r 23-1.2.1 24-1.2 26-1.2.1.3 28-1.2.1.3.1 29-1.2.1.3.1.1.r 30-1.2.1.3.1.1.1 31-1.2.1.3.1.1 32-1.1.2.1.r 34-1.1.2.1
# ::id pmid_1563_0473.148
# ::preferred 
(a / and~e.19
      :op1 (h / have-rel-role-91
            :ARG0 (c / cell
                  :name (n / name :op1 "keratinocyte")
                  :mod (t / this~e.14))
            :ARG1 (c2 / cell~e.12
                  :location~e.32 (p2 / placode~e.34))
            :ARG2 (p / progenitor~e.18))
      :op2 (a2 / available~e.24
            :domain~e.20 (a3 / approximate-01~e.23
                  :ARG0 c
                  :mod (c3 / close~e.22
                        :degree~e.22 (m / most~e.22))
                  :purpose (s / study-01~e.26
                        :ARG1 (b / behave-01~e.28
                              :ARG0~e.29 (c4 / cell~e.31
                                    :location (e / epithelium~e.30)
                                    :part-of p2)))))
      :concession~e.0 (a4 / available~e.7
            :polarity~e.3 "-"~e.3
            :domain~e.2 (s2 / system~e.6
                  :mod (c5 / culture-01~e.5
                        :ARG1 (c6 / cell~e.4)))
            :purpose (s3 / study-01~e.10
                  :ARG1 c2
                  :manner (s4 / specific~e.9))))

# ::tok Interestingly , treatment of cultured keratinocytes with as little as 5 ng @/@ ml of TGF-β2 caused a rapid and transient induction of Snail ( <xref ref-type="fig" rid="pbio-0030011-g005"> Figure 5 </xref>@ B ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3 0-1.3.r 2-1.1 3-1.1.1.r 4-1.1.1.2 7-1.1.2.r 8-1.1.2.2.2 10-1.1.2.2.1 15-1.1.2.1.1 16-1 18-1.2.3 20-1.2.4 21-1.2 22-1.2.2.r 23-1.2.2.1.1 28-1.4.1 29-1.1.2.2.1
# ::id pmid_1563_0473.149
# ::preferred 
(c / cause-01~e.16
      :ARG0 (t / treat-04~e.2
            :ARG1~e.3 (c2 / cell
                  :name (n / name :op1 "keratinocyte")
                  :ARG1-of (c3 / culture-01~e.4))
            :ARG2~e.7 (p / protein
                  :name (n2 / name :op1 "TGF-β2"~e.15)
                  :quant (c4 / concentration-quantity
                        :quant "5"~e.10,29
                        :mod (l / little~e.8)
                        :unit (n4 / nanogram-per-milliliter))))
      :ARG1 (i / induce-01~e.21
            :ARG0 t
            :ARG1~e.22 (p2 / protein
                  :name (n3 / name :op1 "Snail"~e.23))
            :mod (r / rapid~e.18)
            :duration (t2 / transient~e.20))
      :manner~e.0 (i2 / interesting~e.0)
      :ARG1-of (d / describe-01
            :ARG0 (f / figure~e.28 :mod "5B")))

# ::tok Following this treatment , Snail protein was detected within 30 min , peaked at 2 h , and then declined thereafter .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.1.1.2.1.1 2-1.1.1.2.1 4-1.1.1.1.1.1 5-1.1.1.1 7-1.1.1 9-1.1.1.2.2.1.1 12-1.1.2 14-1.1.2.2.1.1 17-1.1 19-1.1.3
# ::id pmid_1563_0473.150
# ::preferred 
(f / follow-01~e.0
      :ARG1 (a / and~e.17
            :op1 (d / detect-01~e.7
                  :ARG1 (p / protein~e.5
                        :name (n / name :op1 "Snail"~e.4))
                  :time (a2 / after
                        :op1 (t / treat-04~e.2
                              :mod (t2 / this~e.1))
                        :quant (u / up-to
                              :op1 (t3 / temporal-quantity
                                    :quant "30"~e.9
                                    :unit (m / minute)))))
            :op2 (p2 / peak-01~e.12
                  :ARG1 p
                  :time (a4 / after
                        :op1 (t4 / temporal-quantity
                              :quant "2"~e.14
                              :unit (h / hour))))
            :op3 (d2 / decline-01~e.19
                  :ARG1 p
                  :time (a3 / after
                        :op1 p2))))

# ::tok The induction of Snail appeared to be specific for the active form of the growth factor , as pretreatment of TGF-β2 for 10 min at 100 °C obliterated the response [ @<xref ref-type="fig" rid="pbio-0030011-g005"> Figure 5 </xref>@ B , lanes marked (–)].
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.2.1 2-1.2.1.1.r 3-1.2.1.1.1.1 4-1.2 7-1.2.1.2 11-1.2.1.2.1 12-1.2.1.2.1.2.r 14-1.2.1.2.1.2.1.1 15-1.2.1.2.1.2.1.2 20-1.1.1.1.1.1 22-1.1.1.3.1 25-1.1.1.2.1 27-1.1 29-1.1.2 34-1.3.1 39-1.3.2.1 40-1.3.2
# ::id pmid_1563_0473.151
# ::preferred 
(c / cause-01
      :ARG0 (o / obliterate-01~e.27
            :ARG0 (p / pretreat-00
                  :ARG1 (p2 / protein
                        :name (n / name :op1 "TGF-β2"~e.20))
                  :ARG2 (t / temperature-quantity
                        :quant "100"~e.25
                        :scale (c2 / celsius))
                  :duration (t2 / temporal-quantity
                        :quant "10"~e.22
                        :unit (m / minute)))
            :ARG1 (r / respond-01~e.29))
      :ARG1 (a / appear-02~e.4
            :ARG1 (i / induce-01~e.1
                  :ARG1~e.2 (p3 / protein
                        :name (n2 / name :op1 "Snail"~e.3))
                  :mod (s / specific~e.7
                        :topic (f / form~e.11
                              :ARG1-of (a2 / activate-01)
                              :domain~e.12 (s2 / small-molecule
                                    :name (n3 / name :op1 "growth"~e.14 :op2 "factor"~e.15))))))
      :ARG1-of (d / describe-01
            :ARG0 (f2 / figure~e.34 :mod "5B")
            :ARG2-of (m2 / mark-02~e.40
                  :ARG1 (l / lane~e.39))))

# ::tok By contrast , although TGF-β receptor activation remained elevated during the duration of the experiment ( as measured by the sustained phosphorylation of the downstream effector SMAD2 ) <i> Snail </i> expression could not be maintained ( <xref ref-type="fig" rid="pbio-0030011-g005"> Figure 5 </xref>@ B ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1 3-1.1.2.2.r 4-1.1.2.2.1.1.1.1 5-1.1.2.2.1.1 6-1.1.2.2.1 7-1.1.2.2 8-1.1.2.2.1.2.2 9-1.1.2.2.3.r 11-1.1.2.2.3 12-1.1.2.2.3.1.r 14-1.1.2.2.3.1 16-1.1.2.2.3.r 17-1.1.2.2.1.2 18-1.1.2.2.1.2.1.r 20-1.1.2.2.1.2.1.2 21-1.1.2.2.1.2.1 22-1.1.2.2.1.2.1.1.r 24-1.1.2.2.1.2.1.1.2 25-1.1.2.2.1.2.1.1 26-1.1.2.2.1.2.1.1.1.1.1 29-1.1.2.1.1.1.1 31-1.1.2.1 32-1.1 33-1.1.1 33-1.1.1.r 34-1.1.2.r 35-1.1.2 40-1.2.1
# ::id pmid_1563_0473.152
# ::preferred 
(c / contrast-01~e.1
      :ARG2 (p / possible~e.32
            :polarity~e.33 "-"~e.33
            :domain~e.34 (m / maintain-01~e.35
                  :ARG1 (e / express-03~e.31
                        :ARG2 (g / gene
                              :name (n / name :op1 "Snail"~e.29)))
                  :concession~e.3 (r / remain-01~e.7
                        :ARG1 (a / activate-01~e.6
                              :ARG1 (r2 / receptor~e.5
                                    :name (n2 / name :op1 "TGF-β"~e.4))
                              :ARG1-of (m2 / measure-01~e.17
                                    :ARG0~e.18 (p2 / phosphorylate-01~e.21
                                          :ARG1~e.22 (e2 / effector~e.25
                                                :mod (p3 / protein
                                                      :name (n3 / name :op1 "SMAD2"~e.26))
                                                :mod (d / downstream~e.24))
                                          :ARG1-of (s / sustain-01~e.20))
                                    :ARG3 (e3 / elevate-01~e.8)))
                        :ARG3 e3
                        :time~e.9,16 (d2 / duration~e.11
                              :duration-of~e.12 (e4 / experiment-01~e.14)))))
      :ARG1-of (d3 / describe-01
            :ARG0 (f / figure~e.40 :mod "5B")))

# ::tok Thus , although <i> Snail </i> expression correlated with phosphorylated SMAD2 ( pSMAD2 ) induction , its decline seemed to rely on secondary downstream events .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 2-1.1.2.r 6-1.1.1.1.1 7-1.1.2 8-1.1.2.2.r 9-1.1.2.2.1.2 10-1.1.1.1.1.1.1.1 10-1.1.2.2.1.1.1 12-1.1.2.2.1.3.1.1.1 14-1.1.2.2 16-1.1.2.1 16-1.1.2.1.r 17-1.1.1.1 18-1.1 20-1.1.1 21-1.1.1.2.r 22-1.1.1.2.2 23-1.1.1.2.1 24-1.1.1.2
# ::id pmid_1563_0473.153
# ::preferred 
(c / cause-01~e.0
      :ARG1 (s / seem-01~e.18
            :ARG1 (r / rely-01~e.20
                  :ARG0 (d / decline-01~e.17
                        :ARG1 (e / express-03~e.6
                              :ARG1 (g / gene
                                    :name (n / name :op1 "SMAD2"~e.10))))
                  :ARG1~e.21 (e2 / event~e.24
                        :direction (d2 / downstream~e.23)
                        :mod (s2 / secondary~e.22)))
            :concession~e.2 (c2 / correlate-01~e.7
                  :ARG1~e.16 e~e.16
                  :ARG2~e.8 (i / induce-01~e.14
                        :ARG1 (p / protein
                              :name (n2 / name :op1 "SMAD2"~e.10)
                              :ARG1-of (p2 / phosphorylate-01~e.9)
                              :ARG1-of (d3 / describe-01
                                    :ARG0 (p3 / protein
                                          :name (n3 / name :op1 "pSMAD2"~e.12))))))))

# ::tok The rapid kinetics of Snail expression were reflected at the mRNA level , suggesting that <i> Snail </i> promoter activity in keratinocytes might be sensitive to TGF-β2 signaling ( <xref ref-type="fig" rid="pbio-0030011-g005"> Figure 5 </xref>@ C ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.2.1 2-1.2 3-1.2.2.r 4-1.2.2.1.1.1 5-1.2.2 7-1 8-1.1.r 10-1.1.1.1.1 11-1.1 13-1.3 16-1.3.1.1.1.1 18-1.3.1.1.1.2 22-1.3.1 23-1.3.1.1.r 24-1.3.1.1 25-1.3.1.1.2.r 26-1.3.1.1.2.1.1.1 27-1.3.1.1.2 32-1.4.1
# ::id pmid_1563_0473.154
# ::preferred 
(r / reflect-01~e.7
      :ARG1~e.8 (l / level~e.11
            :mod (r3 / rna
                  :name (n2 / name :op1 "mRNA"~e.10)))
      :ARG2 (k / kinetics~e.2
            :mod (r2 / rapid~e.1)
            :poss~e.3 (e / express-03~e.5
                  :ARG1 (g / gene
                        :name (n / name :op1 "Snail"~e.4))))
      :ARG0-of (s / suggest-01~e.13
            :ARG1 (p / possible~e.22
                  :domain~e.23 (s2 / sensitive-03~e.24
                        :ARG0 (a / act-01
                              :ARG0 g~e.16
                              :ARG1 (p2 / promoter~e.18)
                              :location (k2 / keratinocyte))
                        :ARG1~e.25 (s3 / signal-07~e.27
                              :ARG0 (p3 / protein
                                    :name (n3 / name :op1 "TGF-β2"~e.26))))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure~e.32 :mod "5C")))

# ::tok To test this possibility , we engineered a transgene driving the β-galactosidase reporter under the control of approximately 2.2 kb of promoter sequence located 5′ from the transcription initiation site of the mouse <i> Snail </i> gene .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3 2-1.3.2 3-1.3.2.1 5-1.1 6-1 8-1.2 9-1.4 11-1.4.2.1.1 12-1.4.2.2 15-1.4.3 16-1.4.3.1.r 17-1.4.3.1.1 18-1.4.3.1.1.1.1 21-1.4.3.1.3 22-1.4.3.1 23-1.4.3.1.2.1.1.r 23-1.4.3.1.2.r 27-1.4.3.1.2.1.1.1 28-1.4.3.1.2.1.1 29-1.4.3.1.2.1 30-1.4.3.1.2.1.2.r 32-1.4.3.1.2.1.2.2 34-1.4.3.1.2.1.2.1.1 36-1.4.3.1.2.1.2
# ::id pmid_1563_0473.155
# ::preferred 
(e / engineer-01~e.6
      :ARG0 (w / we~e.5)
      :ARG1 (t3 / transgene~e.8)
      :purpose (t / test-01~e.1
            :ARG0 w
            :ARG1 (t2 / this~e.2
                  :mod (p / possible~e.3)))
      :manner (d / drive-02~e.9
            :ARG0 w
            :ARG1 (e2 / enzyme
                  :name (n / name :op1 "β-galactosidase"~e.11)
                  :mod (r / reporter~e.12))
            :ARG2 (c / control-01~e.15
                  :ARG0~e.16 (s / sequence~e.22
                        :quant (a / approximately~e.17
                              :op1 (d2 / distance-quantity
                                    :quant "2.2"~e.18
                                    :unit (k / kilo-base-pair)))
                        :location~e.23 (r2 / relative-position
                              :op1 (p3 / protein-segment~e.29
                                    :location-of~e.23 (i / initiate-01~e.28
                                          :ARG1 (t4 / transcribe-01~e.27))
                                    :part-of~e.30 (g / gene~e.36
                                          :name (n2 / name :op1 "Snail"~e.34)
                                          :mod (m2 / mouse~e.32)))
                              :direction (e3 / end :mod "5'"))
                        :mod (p2 / promoter~e.21))
                  :ARG1 e2)))

# ::tok At 2 d after transient transfection , keratinocytes were treated with TGF-β2 ( t = 0 ) and then assayed for transgene activity over the same time course in which we had observed Snail protein induction .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.3.2.1 3-1.1.3 4-1.1.3.1.1 5-1.1.3.1 9-1.1 11-1.1.2.1.1 15-1.1.4.1 17-1 18-1.2.2 19-1.2 21-1.2.1.2 25-1.2.3.1 26-1.1.3.2 26-1.1.4.2 26-1.2.3 27-1.2.3.1.1 30-1.2.3.1.1.1.1 32-1.2.3.1.1.1 33-1.2.3.1.1.1.2.1.1.1 34-1.1.2 34-1.2.3.1.1.1.2.1 35-1.2.3.1.1.1.2
# ::id pmid_1563_0473.156
# ::preferred 
(a / and~e.17
      :op1 (t2 / treat-04~e.9
            :ARG1 (k / keratinocyte)
            :ARG2 (p / protein~e.34
                  :name (n / name :op1 "TGF-β2"~e.11))
            :time (a3 / after~e.3
                  :op1 (t3 / transfect-00~e.5
                        :mod (t4 / transient~e.4))
                  :quant (t5 / temporal-quantity~e.26
                        :quant "2"~e.1
                        :unit (d / day)))
            :mod (e / equal-01
                  :ARG2 "0"~e.15
                  :ARG1 (t8 / time~e.26)))
      :op2 (a2 / assay-00~e.19
            :ARG1 (a4 / act-01
                  :ARG0 k
                  :ARG1 (t7 / transgene~e.21))
            :time (t6 / then~e.18)
            :duration (t / time~e.26
                  :ARG1-of (s / same-01~e.25
                        :ARG2 (c / course~e.27
                              :time-of (o2 / observe-01~e.32
                                    :ARG0 (w / we~e.30)
                                    :ARG1 (i / induce-01~e.35
                                          :ARG1 (p2 / protein~e.34
                                                :name (n2 / name :op1 "Snail"~e.33)))))))))

# ::tok The results of this experiment are presented in <xref ref-type="fig" rid="pbio-0030011-g005"> Figure 5 </xref>@ D .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.2 1-1.2.1 1-1.2.1.r 2-1.2.1.1.r 3-1.2.1.1.1 4-1.2.1.1 6-1 11-1.1 12-1.1.1
# ::id pmid_1563_0473.157
# ::preferred 
(p / present-01~e.6
      :ARG0 (f / figure~e.11 :mod "5"~e.12)
      :ARG1 (t / thing~e.1
            :ARG2-of~e.1 (r / result-01~e.1
                  :ARG1~e.2 (e / experiment-01~e.4
                        :mod (t2 / this~e.3)))))

# ::tok Within 0.5 h of TGF-β2 treatment , <i> Snail </i> promoter activity had increased 3 @-@ fold , and by 2 h , it peaked to approximately 10 @-@ fold over control levels ( <xref ref-type="fig" rid="pbio-0030011-g005"> Figure 5 </xref>@ D ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.3.2.1.1 4-1.1.3.1.1.1.1 5-1.1.3.1 8-1.1.1.1.1.1 10-1.1.1.2 13-1.1 14-1.1.2.1 18-1 20-1.2.2.2.1.1 24-1.2 25-1.2.1.r 25-1.2.2.2 26-1.2.1 27-1.2.1.1.1 31-1.1.2.2.1 32-1.1.2.2 37-1.3.1
# ::id pmid_1563_0473.158
# ::preferred 
(a / and~e.18
      :op1 (i / increase-01~e.13
            :ARG1 (a2 / act-01
                  :ARG0 (g / gene
                        :name (n / name :op1 "Snail"~e.8))
                  :ARG1 (p / promoter~e.10))
            :ARG4 (p4 / product-of
                  :op1 "3"~e.14
                  :op2 (l / level~e.32
                        :mod (c / control~e.31)))
            :time (a3 / after
                  :op1 (t / treat-04~e.5
                        :ARG2 (p2 / protein
                              :name (n2 / name :op1 "TGF-β2"~e.4)))
                  :quant (u / up-to
                        :op1 (t2 / temporal-quantity
                              :quant "0.5"~e.1
                              :unit (h / hour)))))
      :op2 (p3 / peak-01~e.24
            :ARG1~e.25 (a4 / approximately~e.26
                  :op1 (p5 / product-of
                        :op1 "10"~e.27
                        :op2 l))
            :time (a5 / after
                  :op1 t
                  :quant (u2 / up-to~e.25
                        :op1 (t3 / temporal-quantity
                              :quant "2"~e.20
                              :unit h))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure~e.37 :mod "5D")))

# ::tok Thereafter , <i> Snail </i> promoter activity rapidly returned to the basal levels seen in unstimulated keratinocytes .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.4 3-1.1.1.1.1 5-1.1.2 7-1.3 7-1.3.r 8-1 9-1.2.r 11-1.2.2 12-1.2 13-1.2.1
# ::id pmid_1563_0473.159
# ::preferred 
(r / return-01~e.8
      :ARG1 (a / act-01
            :ARG0 (g / gene
                  :name (n / name :op1 "Snail"~e.3))
            :ARG1 (p / promoter~e.5))
      :ARG4~e.9 (l / level~e.12
            :ARG1-of (s / see-01~e.13
                  :location (k / keratinocyte
                        :ARG1-of (s2 / stimulate-01 :polarity "-")))
            :mod (b / basal~e.11))
      :manner~e.7 (r2 / rapid~e.7)
      :time (t / thereafter~e.0))

# ::tok The kinetics of <i> Snail </i> promoter activity closely paralleled those observed for Snail protein induction .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1 1-1.2 4-1.1.1.1.1.1 6-1.1.1.2 8-1.3 8-1.3.r 9-1 11-1.2.1 12-1.2.1.1.r 13-1.2.1.1.1.1.1 14-1.2.1.1.1 15-1.2.1.1
# ::id pmid_1563_0473.160
# ::preferred 
(p / parallel-01~e.9
      :ARG0 (k / kinetics~e.1
            :mod (a / act-01
                  :ARG0 (g / gene
                        :name (n / name :op1 "Snail"~e.4))
                  :ARG1 (p2 / promoter~e.6)))
      :ARG1 (k2 / kinetics~e.1
            :ARG1-of (o / observe-01~e.11
                  :topic~e.12 (i / induce-01~e.15
                        :ARG1 (p3 / protein~e.14
                              :name (n2 / name :op1 "Snail"~e.13)))))
      :manner~e.8 (c / close~e.8))

# ::tok Moreover , the stimulatory effects appeared to be specific to TGF-β2 , since they were abrogated either by heat inactivation of the TGF-β2 protein or by mutation of a putative SMAD binding element located about 1.8 kb 5′ from the <i> Snail </i> transcription start site ( <xref ref-type="fig" rid="pbio-0030011-g005"> Figure 5 </xref>@ D ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 4-1.1.1.1 5-1.1 6-1.1.2 7-1.1.1.1.r 8-1.1.1 10-1.1.1.2.1.1 12-1.1.2 13-1.1.2.1.1 15-1.1.2.1 17-1.1.2.1.2.r 18-1.1.2.1.2.1.3 19-1.1.2.1.2.1 19-1.1.2.1.2.1.1 19-1.1.2.1.2.1.1.r 20-1.1.2.1.2.1.2.r 22-1.1.2.1.2.1.2 23-1.1.1.2 23-1.1.2.1.2.2.1.1.1 24-1.1.2.1.2 26-1.1.2.1.2.2 27-1.1.2.1.2.2.1.r 29-1.1.2.1.2.2.1.1.2 30-1.1.2.1.2.2.1.1.1.1.1 31-1.1.2.1.2.2.1.1 32-1.1.2.1.2.2.1 33-1.1.2.1.2.2.1.2 33-1.1.2.1.2.2.1.2.1.r 34-1.1.1.2.r 35-1.1.2.1.2.2.1.2.1.2.1 41-1.1.2.1.2.2.1.2.1.1.1.1.1.1.1 43-1.1.2.1.2.2.1.2.1.1.1.1 44-1.1.2.1.2.2.1.2.1.1.1 45-1.1.2.1.2.2.1.2.1.1 50-1.2.1 51-1.1.2.1.2.2.1.2.1.3.1
# ::id pmid_1563_0473.161
# ::preferred 
(a / and
      :op1 (a2 / appear-02~e.5
            :ARG1 (s / specific~e.8
                  :domain~e.7 (e / effect-03~e.4
                        :ARG1 (s2 / stimulate-01))
                  :topic~e.34 (p / protein~e.23
                        :name (n / name :op1 "TGF-β2"~e.10)))
            :ARG1-of (c / cause-01~e.6,12
                  :ARG0 (a3 / abrogate-01~e.15
                        :ARG1 e~e.13
                        :ARG2~e.17 (o / or~e.24
                              :op1 (a4 / activate-01~e.19
                                    :polarity~e.19 "-"~e.19
                                    :ARG1~e.20 p~e.22
                                    :mod (h / heat~e.18))
                              :op2 (m / mutate-01~e.26
                                    :ARG1~e.27 (e2 / element~e.32
                                          :ARG1-of (b / bind-01~e.31
                                                :ARG2 (p2 / protein~e.23
                                                      :name (n2 / name :op1 "SMAD"~e.30))
                                                :ARG1-of (t / think-01~e.29))
                                          :ARG1-of (l / locate-01~e.33
                                                :location~e.33 (r / relative-position
                                                      :op1 (p3 / protein-segment~e.45
                                                            :location-of (s3 / start-01~e.44
                                                                  :ARG1 (t2 / transcribe-01~e.43
                                                                        :ARG1 (g / gene
                                                                              :name (n3 / name :op1 "Snail"~e.41)))))
                                                      :quant (d / distance-quantity
                                                            :quant "1.8"~e.35
                                                            :unit (k / kilo-base-pair))
                                                      :direction (e3 / end :mod "5'"~e.51)))))))))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure~e.50 :mod "5D")))

# ::tok Taken together , these results suggested that in keratinocytes , TGF-β2 signaling results in a pSMAD2 @-@ dependent transient activation of the <i> Snail </i> gene , and that maintenance of Snail protein relies , in part , upon sustained promoter activity .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.3 1-1.1.3.1 3-1.1.1 4-1.1 4-1.1.2 4-1.1.2.r 4-1.2.1 5-1 10-1.2.1.1.1.1.1 11-1.2.1.1 12-1.2.1 17-1.2.1.2.3 18-1.2.1.2.2 19-1.2.1.2 23-1.2.1.2.1.1.1 25-1.2.1.2.1 27-1.2 28-1.2.r 29-1.2.2.1 31-1.2.2.1.1.1.1 32-1.2.1.1.1 32-1.2.1.2.3.1 32-1.2.2.1.1 33-1.2.2 35-1.2.2.3.r 36-1.2.2.3 39-1.2.2.2.2 40-1.2.2.2.1
# ::id pmid_1563_0473.162
# ::preferred 
(s / suggest-01~e.5
      :ARG0 (t / thing~e.4
            :mod (t2 / this~e.3)
            :ARG2-of~e.4 (r / result-01~e.4)
            :ARG1-of (t3 / take-04~e.0
                  :ARG2 (t4 / together~e.1)))
      :ARG1~e.28 (a / and~e.27
            :op1 (r2 / result-01~e.4,12
                  :ARG1 (s2 / signal-07~e.11
                        :ARG0 (p / protein~e.32
                              :name (n / name :op1 "TGF-β2"~e.10)))
                  :ARG2 (a2 / activate-01~e.19
                        :ARG1 (g / gene~e.25
                              :name (n2 / name :op1 "Snail"~e.23))
                        :mod (t5 / transient~e.18)
                        :ARG0-of (d / depend-01~e.17
                              :ARG1 (p2 / protein~e.32
                                    :name (n3 / name :op1 "SMAD2")
                                    :ARG1-of (p3 / phosphorylate-01)))))
            :op2 (r3 / rely-01~e.33
                  :ARG0 (m / maintain-01~e.29
                        :ARG1 (p4 / protein~e.32
                              :name (n4 / name :op1 "Snail"~e.31)))
                  :ARG1 (a3 / act-01
                        :ARG1 (p5 / promoter~e.40)
                        :ARG1-of (s3 / sustain-01~e.39))
                  :degree~e.35 (p6 / part~e.36))))

# ::tok The brevity of <i> Snail </i> gene and protein induction in TGF-β2 treated cultured keratinocytes resembled the temporal appearance of <i> Snail </i> mRNA and protein at the initiation of hair follicle morphogenesis in embryonic mouse skin .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1 4-1.1.1.1.1.1 6-1.1.1.1 7-1.1 8-1.1.2.1 9-1.1.2 11-1.1.2.2.2.1.1.1 12-1.1.2.2.2 13-1.1.2.2.1 15-1 17-1.2.2 18-1.2 21-1.2.1.1.2 23-1.2.1.1.1.1 24-1.2.1 25-1.2.1.2 26-1.2.3.r 28-1.2.3 29-1.2.3.1.r 30-1.2.3.1.1.1 31-1.2.3.1.1 32-1.2.3.1 35-1.2.3.2.1.1 36-1.2.3.2
# ::id pmid_1563_0473.163
# ::preferred 
(r / resemble-01~e.15
      :ARG1 (a / and~e.7
            :op1 (b / brevity~e.1
                  :poss (g / gene~e.6
                        :name (n / name :op1 "Snail"~e.4)))
            :op2 (i / induce-01~e.9
                  :ARG1 (p / protein~e.8)
                  :location (k / keratinocyte
                        :ARG1-of (c / culture-01~e.13)
                        :ARG1-of (t / treat-04~e.12
                              :ARG2 (p2 / protein
                                    :name (n2 / name :op1 "TGF-β2"~e.11))))))
      :ARG2 (a2 / appear-01~e.18
            :ARG1 (a3 / and~e.24
                  :op1 (r3 / rna
                        :name (n4 / name :op1 "mRNA"~e.23)
                        :part-of g~e.21)
                  :op2 (p3 / protein~e.25))
            :mod (t2 / time~e.17)
            :time~e.26 (i2 / initiate-01~e.28
                  :ARG1~e.29 (m2 / morphogenesis~e.32
                        :mod (f / follicle~e.31
                              :mod (h / hair~e.30)))
                  :location (s / skin~e.36
                        :part-of (e / embryo
                              :mod (m3 / mouse~e.35))))))

# ::tok To test whether TGF-β2 might be required for <i> Snail </i> induction in hair bud formation in vivo , we first analyzed whether TGF-β2 was expressed in or around the hair bud .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.4 2-1.4.2.1 2-1.4.2.1.r 3-1.2.2.1.1 4-1.4.2 5-1.4.2.2.r 6-1.4.2.2 9-1.4.2.2.1.1.1.1 11-1.4.2.2.1 12-1.4.2.2.1.2.2 13-1.2.3.1.1 14-1.2.3.1 15-1.4.2.2.1.2 16-1.4.2.2.1.2.2 17-1.4.2.2.1.2.2 19-1.1 20-1.3 21-1 22-1.2.1 22-1.2.1.r 23-1.2.2.1.1 25-1.2 26-1.4.2.2.1.2.2 27-1.2.3 28-1.2.3.2 30-1.2.3.1.1 31-1.2.3.1
# ::id pmid_1563_0473.164
# ::preferred 
(a / analyze-01~e.21
      :ARG0 (w / we~e.19)
      :ARG1 (e / express-03~e.25
            :mode~e.22 "interrogative"~e.22
            :ARG2 (p / protein
                  :name (n / name :op1 "TGF-β2"~e.3,23))
            :ARG3 (o / or~e.27
                  :op1 (b / bud~e.14,31
                        :mod (h / hair~e.13,30))
                  :op2 (a2 / around~e.28
                        :op1 h)))
      :mod (f / first~e.20)
      :purpose (t / test-01~e.1
            :ARG0 w
            :ARG1 (p2 / possible~e.4
                  :mode~e.2 "interrogative"~e.2
                  :domain~e.5 (r / require-01~e.6
                        :ARG0 (i / induce-01~e.11
                              :ARG1 (g / gene
                                    :name (n2 / name :op1 "Snail"~e.9))
                              :subevent-of (f2 / form-01~e.15
                                    :ARG1 b
                                    :manner (i2 / in-vivo~e.12,16,17,26)))
                        :ARG1 p))))

# ::tok Consistent with previous observations [ @<xref ref-type="bibr" rid="pbio-0030011-b33"> 33 </xref>@ ], an anti @-@ TGF-β2 antibody labeled developing hair buds ( <xref ref-type="fig" rid="pbio-0030011-g006"> Figure 6 </xref>@ A ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3 1-1.3.1.r 2-1.3.1.1.1 3-1.3.1 3-1.3.1.1 3-1.3.1.1.r 8-1.3.1.2.1.1.1 12-1.1.1.1 15-1.1 16-1 17-1.2.2 18-1.2.1 19-1.2 24-1.4.1
# ::id pmid_1563_0473.165
# ::preferred 
(l / label-01~e.16
      :ARG0 (a / antibody~e.15
            :name (n / name :op1 "anti-TGF-β2"~e.12))
      :ARG1 (b / bud~e.19
            :mod (h / hair~e.18)
            :ARG1-of (d / develop-01~e.17))
      :ARG1-of (c / consistent-01~e.0
            :ARG2~e.1 (t / thing~e.3
                  :ARG1-of~e.3 (o / observe-01~e.3
                        :time (p / previous~e.2))
                  :ARG1-of (d3 / describe-01
                        :ARG0 (p2 / publication
                              :ARG1-of (c2 / cite-01 :ARG2 "33"~e.8)))))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure~e.24 :mod "6A")))

# ::tok This labeling appeared to be specific as judged by the lack of staining in follicle buds from mice homozygous for a <i> TGF-β2 </i> null mutation ( <xref ref-type="fig" rid="pbio-0030011-g006"> Figure 6 </xref>@ A ; [ @<xref ref-type="bibr" rid="pbio-0030011-b34"> 34 </xref>@ ]).
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 1-1.1.1 2-1 4-1.1.1.r 5-1.1 6-1.2.r 7-1.2 11-1.2.1.r 12-1.2.1 13-1.2.1.2.r 14-1.2.1.2.1 15-1.2.1.2 16-1.2.1.2.1.1.r 17-1.2.1.2.1.1 18-1.2.1.2.1.2 22-1.2.1.2.1.2.1.1.1.1 24-1.2.1.2.1.2.1.1.2 25-1.2.1.2.1.2.1 30-1.3.1.1 39-1.3.1.2.1.1
# ::id pmid_1563_0473.166
# ::preferred 
(a / appear-02~e.2
      :ARG1 (s / specific~e.5
            :domain~e.4 (l / label-01~e.1
                  :mod (t / this~e.0)))
      :ARG2-of~e.6 (j / judge-01~e.7
            :ARG3~e.11 (s2 / stain-00~e.12
                  :polarity "-"
                  :location~e.13 (b2 / bud~e.15
                        :mod (f / follicle~e.14
                              :mod~e.16 (m2 / mouse~e.17)
                              :mod (h / homozygous~e.18
                                    :topic (m / mutate-01~e.25
                                          :ARG2 (p / protein
                                                :name (n2 / name :op1 "TGF-β2"~e.22)
                                                :mod (n / null~e.24))))))))
      :ARG1-of (d / describe-01
            :ARG0 (a2 / and
                  :op1 (f2 / figure~e.30 :mod "6A")
                  :op2 (p2 / publication
                        :ARG1-of (c / cite-01 :ARG2 "34"~e.39)))))

# ::tok Moreover , the downstream effector of TGF-β2 signaling , pSMAD2 , was also expressed in WT , but not <i> TGF-β2 </i>@ -@ null , hair buds ( <xref ref-type="fig" rid="pbio-0030011-g006"> Figure 6 </xref>@ B ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 3-1.1.1.1 4-1.1.1 5-1.1.1.2.r 6-1.1.1.2.1.1.1 7-1.1.1.2 12-1.1.3 13-1.1 13-1.1.4.1 15-1.1.2.2 17-1.1.4 18-1.1.4.1.1 18-1.1.4.1.1.r 20-1.1.1.2.1.1.1 20-1.1.4.1.3.1.1.1 25-1.1.2.1 25-1.1.4.1.3.2 26-1.1.2 26-1.1.4.1.3 31-1.2.1
# ::id pmid_1563_0473.167
# ::preferred 
(a / and
      :op2 (e / express-03~e.13
            :ARG2 (e2 / effector~e.4
                  :location (d / downstream~e.3)
                  :mod~e.5 (s / signal-07~e.7
                        :ARG0 (p / protein
                              :name (n / name :op1 "TGF-β2"~e.6,20)))
                  :ARG1-of (m / mean-01
                        :ARG2 (p2 / protein
                              :name (n2 / name :op1 "SMAD2")
                              :ARG1-of (p3 / phosphorylate-01))))
            :ARG3 (b / bud~e.26
                  :mod (h / hair~e.25)
                  :mod (w / wild-type~e.15))
            :mod (a2 / also~e.12)
            :ARG1-of (c / contrast-01~e.17
                  :ARG2 (e3 / express-03~e.13
                        :polarity~e.18 "-"~e.18
                        :ARG2 p2
                        :ARG3 (b2 / bud~e.26
                              :mod (p5 / protein
                                    :name (n4 / name :op1 "TGF-β2"~e.20)
                                    :ARG2-of (m2 / mutate-01 :mod "−/−"))
                              :mod (h2 / hair~e.25)))))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure~e.31 :mod "6B")))

# ::tok Together , these data underscore the importance of the TGF-β2 isoform despite expression of both TGF-β1 and TGF-β2 in developing hair buds at this stage .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2 2-1.1.1 3-1.1 4-1 6-1.2 7-1.2.1.r 9-1.2.1.1.1.1 10-1.2.1 11-1.2.2.r 12-1.2.2 15-1.2.2.1.1.1.1 16-1.2.2.1 17-1.2.2.1.2 18-1.2.2.2.r 19-1.2.2.2.2 20-1.2.2.2.1 21-1.2.2.2 22-1.2.2.3.r 23-1.2.2.3.1 24-1.2.2.3
# ::id pmid_1563_0473.168
# ::preferred 
(u / underscore-01~e.4
      :ARG0 (d / data~e.3
            :mod (t / this~e.2)
            :mod (t2 / together~e.0))
      :ARG1 (i / importance~e.6
            :poss~e.7 (i2 / isoform~e.10
                  :mod (p / protein
                        :name (n / name :op1 "TGF-β2"~e.9)))
            :concession~e.11 (e / express-03~e.12
                  :ARG2 (a / and~e.16
                        :op1 (p2 / protein
                              :name (n2 / name :op1 "TGF-β1"~e.15))
                        :op2 p~e.17)
                  :ARG3~e.18 (b / bud~e.21
                        :mod (h / hair~e.20)
                        :ARG2-of (d2 / develop-01~e.19))
                  :time~e.22 (s / stage~e.24
                        :mod (t3 / this~e.23)))))

# ::tok To further explore the possible relation between Snail and TGF-β2 , we examined the status of Snail expression in <i> TGF-β2 </i>@ -@ null hair buds .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3.3 2-1.3 4-1.3.2.1 5-1.3.2 6-1.3.2.2 7-1.2.1.1.1.1 9-1.2.1.2.2.1.1 11-1.1 12-1 14-1.2 16-1.2.1.1.1.1 17-1.2.1 20-1.2.1.2.2.1.1 23-1.2.1.2.2.2 24-1.2.1.2.1 25-1.2.1.2
# ::id pmid_1563_0473.169
# ::preferred 
(e / examine-01~e.12
      :ARG0 (w / we~e.11)
      :ARG1 (s / status~e.14
            :mod (e2 / express-03~e.17
                  :ARG2 (p / protein
                        :name (n / name :op1 "Snail"~e.7,16))
                  :ARG3 (b / bud~e.25
                        :mod (h / hair~e.24)
                        :mod (p2 / protein
                              :name (n3 / name :op1 "TGF-β2"~e.9,20)
                              :mod (n2 / null~e.23)))))
      :purpose (e3 / explore-01~e.2
            :ARG0 w
            :ARG1 (r / relation~e.5
                  :mod (p3 / possible~e.4)
                  :mod (b2 / between~e.6
                        :op1 p
                        :op2 p2))
            :degree (f / further~e.1)))

# ::tok As judged by immunohistochemistry , Snail protein was absent from E17.5 skin of <i> TGF-β2 @- </i>@ null embryos but not from that of control littermates ( <xref ref-type="fig" rid="pbio-0030011-g006"> Figure 6 </xref>@ C ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.4 2-1.4.1.r 3-1.4.1 5-1.1.1.1 6-1.1 6-1.2.1.1.1 8-1 8-1.3.1 11-1.2 11-1.3.1.3 14-1.2.1.1.1.1.1 17-1.2.1.1 18-1.2.1 19-1.3 20-1.3.1.1 20-1.3.1.1.r 24-1.3.1.3.1.1 30-1.5.1
# ::id pmid_1563_0473.170
# ::preferred 
(a / absent-01~e.8
      :ARG1 (p / protein~e.6
            :name (n / name :op1 "Snail"~e.5))
      :ARG2 (s / skin~e.11
            :part-of (e2 / embryo~e.18
                  :mod (n2 / null~e.17
                        :mod (p2 / protein~e.6
                              :name (n3 / name :op1 "TGF-β2"~e.14)))
                  :age (t / temporal-quantity
                        :quant "17.5"
                        :unit (d2 / day))))
      :ARG1-of (c / contrast-01~e.19
            :ARG2 (a2 / absent-01~e.8
                  :polarity~e.20 "-"~e.20
                  :ARG1 p
                  :ARG2 (s2 / skin~e.11
                        :part-of (l / littermate
                              :mod (c2 / control~e.24)))))
      :ARG2-of (j / judge-01~e.1
            :ARG0~e.2 (i / immunohistochemistry~e.3))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure~e.30 :mod "6C")))

# ::tok This effect appeared to be exerted at the transcriptional level , since <i> Snail </i> mRNAs were also not found in <i> TGF-β2 </i> null hair buds under conditions in which the signal was readily detected in the hair buds of littermate skin ( <xref ref-type="fig" rid="pbio-0030011-g006"> Figure 6 </xref>@ D ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 1-1.1.1 2-1 3-1.2 5-1.1 9-1.1.2 11-1.2 13-1.2.1.2.2.1.1 15-1.2.1.2.1.1 17-1.2.1.3 18-1.2.1.1 18-1.2.1.1.r 19-1.2.1 22-1.2.1.4.2.1.1 24-1.2.1.4.2.2 25-1.2.1.4.1 26-1.2.1.4 28-1.2.1.5.r 32-1.2.1.5.1 34-1.2.1.5.2 34-1.2.1.5.2.r 35-1.2.1.5 36-1.2.1.5.3.r 38-1.2.1.5.3.1 39-1.2.1.5.3 40-1.2.1.5.3.2.r 41-1.2.1.5.3.2.1 42-1.2.1.5.3.2 47-1.3.1
# ::id pmid_1563_0473.171
# ::preferred 
(a / appear-02~e.2
      :ARG1 (e2 / exert-01~e.5
            :ARG1 (e / effect-03~e.1
                  :mod (t / this~e.0))
            :location (l / level~e.9
                  :mod (t2 / transcribe-01)))
      :ARG1-of (c / cause-01~e.3,11
            :ARG0 (f / find-01~e.19
                  :polarity~e.18 "-"~e.18
                  :ARG1 (r3 / rna
                        :name (n5 / name :op1 "mRNA"~e.15)
                        :mod (p / protein
                              :name (n / name :op1 "Snail"~e.13)))
                  :mod (a2 / also~e.17)
                  :location (b / bud~e.26
                        :mod (h / hair~e.25)
                        :mod (p2 / protein
                              :name (n3 / name :op1 "TGF-β2"~e.22)
                              :mod (n2 / null~e.24)))
                  :condition~e.28 (d / detect-01~e.35
                        :ARG1 (s / signal~e.32)
                        :manner~e.34 (r / ready~e.34)
                        :location~e.36 (b2 / bud~e.39
                              :mod h~e.38
                              :part-of~e.40 (s2 / skin~e.42
                                    :part-of (l2 / littermate~e.41))))))
      :ARG1-of (d2 / describe-01
            :ARG0 (f2 / figure~e.47 :mod "6D")))

# ::tok Conversely , in 2 @-@ wk @-@ old <i> K14 @-@ Smad2 </i> Tg mice , which display elevated TGF-β signaling in skin [ @<xref ref-type="bibr" rid="pbio-0030011-b35"> 35 </xref>@ ], Snail protein was readily detected by Western blot analyses , where it was not found in postnatal skin ( <xref ref-type="fig" rid="pbio-0030011-g006"> Figure 6 </xref>@ E ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 3-1.1.6.1.1 7-1.1.6.1.r 9-1.1.6.3.1.1.1 11-1.1.6.3.2.1.1 14-1.1.6 17-1.1.6.4 18-1.1.6.4.1.2 19-1.1.6.4.1.1.1.1 20-1.1.6.4.1 21-1.1.6.4.2.r 22-1.1.6.4.2 27-1.1.6.4.3.1.1.1 30-1.1.1.1.1 31-1.1.1 31-1.1.6.3.1 31-1.1.6.3.2 31-1.1.6.4.1.1 33-1.1.3 33-1.1.3.r 34-1.1 35-1.1.2.r 36-1.1.2.1.1 37-1.1.2.1.2 38-1.1.2 40-1.1.4.r 40-1.1.6.r 41-1.1.4.2 43-1.1.4.1 43-1.1.4.1.r 44-1.1.4 45-1.1.4.3.r 46-1.1.4.3.1 47-1.1.4.3 52-1.1.5.1
# ::id pmid_1563_0473.172
# ::preferred 
(c / contrast-01
      :ARG2 (d / detect-01~e.34
            :ARG1 (p / protein~e.31
                  :name (n / name :op1 "Snail"~e.30))
            :ARG2~e.35 (a / analyze-01~e.38
                  :name (n5 / name :op1 "Western"~e.36 :op2 "blot"~e.37))
            :manner~e.33 (r / ready~e.33)
            :location~e.40 (f / find-01~e.44
                  :polarity~e.43 "-"~e.43
                  :ARG1 p~e.41
                  :location~e.45 (s / skin~e.47
                        :mod (p2 / postnatal~e.46)))
            :ARG1-of (d2 / describe-01
                  :ARG0 (f2 / figure~e.52 :mod "6A"))
            :location~e.40 (m / mouse~e.14
                  :age~e.7 (t / temporal-quantity
                        :quant "2"~e.3
                        :unit (w2 / week))
                  :mod (t2 / transgenic)
                  :mod (m2 / macro-molecular-complex
                        :part (p3 / protein~e.31
                              :name (n2 / name :op1 "K14"~e.9))
                        :part (p4 / protein~e.31
                              :name (n3 / name :op1 "Smad2"~e.11)))
                  :ARG0-of (d3 / display-01~e.17
                        :ARG1 (s2 / signal-07~e.20
                              :ARG0 (p5 / protein~e.31
                                    :name (n4 / name :op1 "TGF-β"~e.19))
                              :ARG1-of (e / elevate-01~e.18))
                        :ARG2~e.21 (s3 / skin~e.22)
                        :ARG1-of (d4 / describe-01
                              :ARG0 (p6 / publication
                                    :ARG1-of (c2 / cite-01 :ARG2 "35"~e.27)))))))

# ::tok Taken together , these results provide compelling evidence that TGF-β2 is functionally important for inducing <i> Snail </i> gene expression in a pSMAD @-@ dependent manner in developing hair buds .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.3 1-1.1.3.1 3-1.1.1 4-1.1 4-1.1.2 4-1.1.2.r 5-1 6-1.2.2 7-1.2 8-1.2.1.r 9-1.2.1.1.1.1 10-1.2.1.1.r 11-1.2.1.2 12-1.2.1 13-1.2.1.3.r 14-1.2.1.3 16-1.2.1.3.1.1.1.1 18-1.2.1.3.1.1 19-1.2.1.3.1 24-1.2.1.3.2 26-1.2.1.3.1.2.r 27-1.2.1.3.1.2.2 28-1.2.1.3.1.2.1 29-1.2.1.3.1.2
# ::id pmid_1563_0473.173
# ::preferred 
(p / provide-01~e.5
      :ARG0 (t / thing~e.4
            :mod (t2 / this~e.3)
            :ARG2-of~e.4 (r / result-01~e.4)
            :ARG1-of (t3 / take-04~e.0
                  :ARG2 (t4 / together~e.1)))
      :ARG1 (e / evidence-01~e.7
            :ARG1~e.8 (i / important~e.12
                  :domain~e.10 (p2 / protein
                        :name (n / name :op1 "TGF-β2"~e.9))
                  :mod (f / function-01~e.11)
                  :purpose~e.13 (i2 / induce-01~e.14
                        :ARG1 (e2 / express-03~e.19
                              :ARG1 (g / gene~e.18
                                    :name (n2 / name :op1 "Snail"~e.16))
                              :ARG3~e.26 (b / bud~e.29
                                    :mod (h / hair~e.28)
                                    :ARG2-of (d / develop-01~e.27)))
                        :ARG0-of (d2 / depend-01~e.24
                              :ARG1 (p3 / protein
                                    :name (n3 / name :op1 "SMAD")
                                    :ARG1-of (p4 / phosphorylate-01)))))
            :ARG0-of (c / compel-01~e.6)))

# ::tok Whether pMARK activity also contributes to Snail induction was not addressed in the present study [ @<xref ref-type="bibr" rid="pbio-0030011-b15"> 15 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.1 0-1.2.1.r 3-1.2.4 4-1.2 5-1.2.3.r 6-1.2.3.1.1.1 7-1.2.3 9-1.1 9-1.1.r 10-1 11-1.3.r 13-1.3.1 14-1.3 19-1.4.1.1.1
# ::id pmid_1563_0473.174
# ::preferred 
(a / address-02~e.10
      :polarity~e.9 "-"~e.9
      :ARG1 (c / contribute-01~e.4
            :mode~e.0 "interrogative"~e.0
            :ARG0 (a3 / act-01
                  :ARG0 (m / molecular-physical-entity
                        :name (n / name :op1 "MARK")
                        :ARG1-of (p2 / phosphorylate-01)))
            :ARG2~e.5 (i / induce-01~e.7
                  :ARG1 (p3 / protein
                        :name (n2 / name :op1 "Snail"~e.6)))
            :mod (a2 / also~e.3))
      :medium~e.11 (s / study~e.14
            :mod (p / present~e.13))
      :ARG1-of (d / describe-01
            :ARG0 (p4 / publication
                  :ARG1-of (c2 / cite-01 :ARG2 "15"~e.19))))

# ::tok Although some hair buds still formed in <i> TGF-β2 </i> null skin , their number was reduced by approximately 50 % [ @<xref ref-type="bibr" rid="pbio-0030011-b32"> 32 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.2.1.2 2-1.2.1.1 3-1.2.1 4-1.2.2 5-1.2 8-1.2.3.1.1.1 11-1.2.3 13-1.1.1.1 13-1.1.1.1.r 14-1.1.1 16-1.1 17-1.1.2.r 18-1.1.2 19-1.1.2.1.1 20-1.1.2.1 25-1.3.1.1.1
# ::id pmid_1563_0473.175
# ::preferred 
(h / have-concession-91~e.0
      :ARG1 (r / reduce-01~e.16
            :ARG1 (n3 / number~e.14
                  :quant-of~e.13 b~e.13)
            :ARG2~e.17 (a / approximately~e.18
                  :op1 (p2 / percentage-entity~e.20 :value "50"~e.19)))
      :ARG2 (f / form-01~e.5
            :ARG1 (b / bud~e.3
                  :mod (h2 / hair~e.2)
                  :mod (s2 / some~e.1))
            :mod (s / still~e.4)
            :location (s3 / skin~e.11
                  :mod (p / protein
                        :name (n2 / name :op1 "TGF-β2"~e.8)
                        :ARG2-of (m / mutate-01 :mod "−/−"))))
      :ARG1-of (d / describe-01
            :ARG0 (p3 / publication
                  :ARG1-of (c / cite-01 :ARG2 "32"~e.25))))

# ::tok Thus , although the pathway mediated by TGF-β2 signaling impacts the earliest step of epithelial invagination , it does not appear to be essential for bud morphogenesis .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1 4-1.1.2.1 5-1.1.2.1.1 6-1.1.2.1.1.1.r 7-1.1.2.1.1.1.1.1.1 8-1.1.2.1.1.1 9-1.1.2 11-1.1.2.2.1 11-1.1.2.2.1.1 11-1.1.2.2.1.1.r 12-1.1.2.2 13-1.1.2.2.2.r 14-1.1.2.2.2.1 15-1.1.2.2.2 19-1.1.1.1 19-1.1.1.1.r 20-1.1.1 21-1.1.1.2.r 22-1.1.1.2.1.r 23-1.1.1.2 24-1.1.1.2.2.r 25-1.1.1.2.2.1 26-1.1.1.2.2
# ::id pmid_1563_0473.176
# ::preferred 
(i / infer-01
      :ARG1 (h / have-concession-91~e.2
            :ARG1 (a / appear-02~e.20
                  :polarity~e.19 "-"~e.19
                  :ARG1~e.21 (e3 / essential~e.23
                        :domain~e.22 (p / pathway~e.4
                              :ARG1-of (m / mediate-01~e.5
                                    :ARG0~e.6 (s / signal-07~e.8
                                          :ARG0 (p2 / protein
                                                :name (n / name :op1 "TGF-β2"~e.7)))))
                        :purpose~e.24 (m3 / morphogenesis~e.26
                              :mod (b / bud~e.25))))
            :ARG2 (i2 / impact-01~e.9
                  :ARG0 p
                  :ARG1 (s2 / step~e.12
                        :mod (e / early~e.11
                              :degree~e.11 (m2 / most~e.11))
                        :subevent-of~e.13 (i3 / invaginate-00~e.15
                              :ARG1 (e2 / epithelium~e.14))))))

# ::tok Consistent with this notion , basement membrane remodeling still took place in the <i> TGF-β2 </i>@ -@ null buds , as judged by immunofluorescence with antibodies against β4 integrin , an integral component of keratinocyte @-@ mediated adhesion to its underlying basement membrane ( <xref ref-type="fig" rid="pbio-0030011-g006"> Figure 6 </xref>@ F ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.1.4.1.1.r 1-1.2.r 2-1.2.1 3-1.2 5-1.1.1.1 6-1.1.1 7-1.1 8-1.1.3 14-1.1.2.1.1.1 17-1.1.2.1.2 18-1.1.2 21-1.1.4 23-1.1.4.1 24-1.1.4.1.1.r 25-1.1.4.1.1 26-1.1.4.1.1.1 27-1.1.4.1.1.1.1.1.1 28-1.1.4.1.1.1.1.1.2 31-1.1.4.1.1.1.1.2.1.1 32-1.1.4.1.1.1.1.2.1 34-1.1.4.1.1.1.1.2.1.2.2.1 36-1.1.4.1.1.1.1.2.1.2.2 40-1.1.4.1.1.1.1.2.1.2.1.2 41-1.1.4.1.1.1.1.2.1.2.1.1 42-1.1.4.1.1.1.1.2.1.2.1 47-1.1.5.1
# ::id pmid_1563_0473.177
# ::preferred 
(c / consistent-01~e.0
      :ARG1 (r / remodel-01~e.7
            :ARG1 (m / membrane~e.6
                  :mod (b / basement~e.5))
            :location (b2 / bud~e.18
                  :mod (p / protein
                        :name (n2 / name :op1 "TGF-β2"~e.14)
                        :mod (n / null~e.17)))
            :mod (s / still~e.8)
            :ARG1-of (j / judge-01~e.21
                  :ARG3 (i / immunofluorescence~e.23
                        :instrument~e.1,24 (a / antibody~e.25
                              :ARG0-of (o / oppose-01~e.26
                                    :ARG1 (g / gene
                                          :name (n4 / name :op1 "β4"~e.27 :op2 "integrin"~e.28)
                                          :ARG1-of (m2 / mean-01
                                                :ARG2 (c2 / component~e.32
                                                      :mod (i2 / integral~e.31)
                                                      :mod (a2 / adhere-01
                                                            :ARG2 (m4 / membrane~e.42
                                                                  :mod (b3 / basement~e.41)
                                                                  :ARG1-of (u / underlie-01~e.40))
                                                            :ARG1-of (m3 / mediate-01~e.36
                                                                  :ARG0 (k / keratinocyte~e.34))))))))))
            :ARG1-of (d / describe-01
                  :ARG0 (f / figure~e.47 :mod "6F")))
      :ARG2~e.1 (n3 / notion~e.3
            :mod (t / this~e.2)))

# ::tok In contrast , TGF-β2 signaling appeared to be an important factor for the early proliferation that occurs in the developing hair buds , as judged by anti @-@ Ki67 and anti @-@ pMAPK immunofluorescence ( <xref ref-type="fig" rid="pbio-0030011-g006"> Figure 6 </xref>@ F and <xref ref-type="fig" rid="pbio-0030011-g006"> 6 </xref>@ G ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1 3-1.1.1.3.1.1.1 4-1.1.1.3 5-1.1 7-1.1.1.3.r 9-1.1.1.1 10-1.1.1 11-1.1.1.2.r 13-1.1.1.2.1 14-1.1.1.2 17-1.1.1.2.2.r 19-1.1.1.2.2.2 20-1.1.1.2.2.1 21-1.1.1.2.2 23-1.1.1.4.r 24-1.1.1.4 25-1.1.1.4.1.r 26-1.1.1.4.1.1 28-1.1.1.4.1.1.1.1.1 30-1.1.1.4.1.1 30-1.1.1.4.1.2 33-1.1.1.4.1 38-1.2.1.1 38-1.2.1.2 42-1.2.1
# ::id pmid_1563_0473.178
# ::preferred 
(c / contrast-01~e.1
      :ARG2 (a / appear-02~e.5
            :ARG1 (f / factor~e.10
                  :mod (i / important~e.9)
                  :mod~e.11 (p / proliferate-01~e.14
                        :mod (e / early~e.13)
                        :location~e.17 (b / bud~e.21
                              :mod (h / hair~e.20)
                              :ARG2-of (d / develop-01~e.19)))
                  :domain~e.7 (s / signal-07~e.4
                        :ARG0 (p2 / protein
                              :name (n / name :op1 "TGF-β2"~e.3)))
                  :ARG1-of~e.23 (j / judge-01~e.24
                        :ARG3~e.25 (i2 / immunofluorescence~e.33
                              :ARG0-of (c2 / counter-01~e.26,30
                                    :ARG1 (p3 / protein
                                          :name (n2 / name :op1 "Ki67"~e.28)))
                              :ARG0-of (c3 / counter-01~e.30
                                    :ARG1 (e2 / enzyme
                                          :name (n3 / name :op1 "MAPK")
                                          :ARG1-of (p4 / phosphorylate-01)))))))
      :ARG1-of (d2 / describe-01
            :ARG0 (a5 / and~e.42
                  :op1 (f2 / figure~e.38 :mod "6F")
                  :op2 (f3 / figure~e.38 :mod "6G"))))

# ::tok If TGF-β2 stimulates <i> Snail </i> expression in developing buds , loss of this morphogen would be expected to affect the expression of genes that are typically repressed by Snail .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.r 1-1.2.1.1.1 2-1.2 4-1.2.2.1.1.1 6-1.2.2 7-1.2.2.2.r 8-1.2.2.2.1 9-1.2.2.2 11-1.1.1 14-1.1.1.1 17-1 19-1.1 21-1.1.2 22-1.1.2.1.r 23-1.1.2.1 26-1.1.2.1.1.2 27-1.1.2.1.1 28-1.1.2.1.1.1.r 29-1.1.2.1.1.1
# ::id pmid_1563_0473.179
# ::preferred 
(e / expect-01~e.17
      :ARG1 (a / affect-01~e.19
            :ARG0 (l / lose-02~e.11
                  :ARG1 m2~e.14)
            :ARG1 (e3 / express-03~e.21
                  :ARG1~e.22 (g / gene~e.23
                        :ARG1-of (r / repress-01~e.27
                              :ARG0~e.28 g2~e.29
                              :mod (t / typical~e.26)))))
      :condition~e.0 (s / stimulate-01~e.2
            :ARG0 (m2 / morphogen
                  :name (n / name :op1 "TGF-β2"~e.1))
            :ARG1 (e2 / express-03~e.6
                  :ARG1 (g2 / gene
                        :name (n2 / name :op1 "Snail"~e.4))
                  :ARG3~e.7 (b / bud~e.9
                        :ARG2-of (d / develop-01~e.8)))))

# ::tok Since a major target for Snail @-@ mediated repression is the <i> E @-@ cadherin </i> gene [ @<xref ref-type="bibr" rid="pbio-0030011-b12"> 12 </xref> , <xref ref-type="bibr" rid="pbio-0030011-b13"> 13 </xref>@ ], we investigated the status of E @-@ cadherin in <i> TGF-β2 </i>@ -@ null buds .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3 2-1.3.1.3 3-1.3.1 4-1.3.1.1.r 5-1.3.1.1.1.1.1.1 7-1.3.1.1.1 8-1.3.1.1 12-1.3.1.2 13-1.3.1.2 14-1.3.1.2 15-1.3.1.2 16-1.3.1.2 21-1.3.1.4.1.1.1.1 27-1.3.1.4.1.1.1.2 30-1.1 31-1 33-1.2 34-1.2.1.r 35-1.2.1.1.1 37-1.2.1.1.1 40-1.2.2.1.1.1 44-1.2.2
# ::id pmid_1563_0473.180
# ::preferred 
(i / investigate-01~e.31
      :ARG0 (w / we~e.30)
      :ARG1 (s / status~e.33
            :mod~e.34 (g / gene
                  :name (n / name :op1 "E-cadherin"~e.35,37))
            :location (b / bud~e.44
                  :mod (p2 / protein
                        :name (n3 / name :op1 "TGF-β2"~e.40)
                        :ARG2-of (m3 / mutate-01 :mod "−/−"))))
      :ARG1-of (c / cause-01~e.0
            :ARG0 (t / target-01~e.3
                  :ARG0~e.4 (r / repress-01~e.8
                        :ARG1-of (m2 / mediate-01~e.7
                              :ARG0 (p / protein
                                    :name (n4 / name :op1 "Snail"~e.5))))
                  :ARG1 g~e.12,13,14,15,16
                  :mod (m / major~e.2)
                  :ARG1-of (d / describe-01
                        :ARG0 (p3 / publication
                              :ARG1-of (c2 / cite-01
                                    :ARG2 (a / and :op1 "12"~e.21 :op2 "13"~e.27)))))))

# ::tok As shown in <xref ref-type="fig" rid="pbio-0030011-g006"> Figure 6 </xref>@ H , hair buds in TGF-β2 null skin displayed elevated immunofluorescence staining relative to their WT counterparts .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3 6-1.3.1 11-1.1.1 12-1.1 13-1.1.2.r 14-1.1.2.1.1.1 15-1.1.2.1.2 16-1.1.2 17-1 18-1.2.3 19-1.2.2 20-1.2 22-1.2.3.1.r 23-1.2.3.1.1 23-1.2.3.1.1.r 24-1.2.3.1.2 25-1.2.3.1
# ::id pmid_1563_0473.181
# ::preferred 
(d / display-01~e.17
      :ARG0 (b / bud~e.12
            :mod (h / hair~e.11)
            :location~e.13 (s / skin~e.16
                  :mod (p / protein
                        :name (n2 / name :op1 "TGF-β2"~e.14)
                        :mod (n / null~e.15))))
      :ARG1 (s2 / stain-00~e.20
            :ARG1 b
            :mod (i / immunofluorescence~e.19)
            :ARG1-of (e / elevate-01~e.18
                  :compared-to~e.22 (c / counterpart~e.25
                        :poss~e.23 b~e.23
                        :mod (w / wild-type~e.24))))
      :ARG1-of (s3 / show-01~e.1
            :ARG0 (f / figure~e.6 :mod "6H")))

# ::tok Previously we demonstrated that the concerted action of the extracellular signals Wnt and noggin are required for the generation of a LEF @-@ 1/β-catenin transcription complex to repress <i> E @-@ cadherin </i> transcription at the onset of hair fate specification .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3 1-1.1 2-1 3-1.2.r 5-1.2.2.2 6-1.2.2 7-1.2.2.1.r 9-1.2.2.1.1.2 10-1.2.2.1.1 10-1.2.2.1.2 11-1.2.2.1.1.1.1 12-1.2.2.1 13-1.2.2.1.2.1.1 15-1.2 16-1.2.1.r 18-1.2.1.1 19-1.2.1.1.1.r 21-1.2.1.1.1.2.1.1 24-1.2.1.1.1.1 25-1.2.1.1.1 27-1.2.1 29-1.2.1.2.1.1.1 31-1.2.1.2.1.1.1 33-1.2.1.2 34-1.2.1.2.2.r 36-1.2.1.2.2 37-1.2.1.2.2.1.r 38-1.2.1.2.2.1.1.1 39-1.2.1.2.2.1.1 40-1.2.1.2.2.1
# ::id pmid_1563_0473.182
# ::preferred 
(d / demonstrate-01~e.2
      :ARG0 (w / we~e.1)
      :ARG1~e.3 (r / require-01~e.15
            :ARG0~e.16 (r2 / repress-01~e.27
                  :ARG0 (g / generate-01~e.18
                        :ARG1~e.19 (m / macro-molecular-complex~e.25
                              :ARG0-of (t / transcribe-01~e.24)
                              :part (p3 / protein
                                    :name (n3 / name :op1 "LEF-1"~e.21))
                              :part (p4 / protein
                                    :name (n4 / name :op1 "β-catenin"))))
                  :ARG1 (t2 / transcribe-01~e.33
                        :ARG1 (g2 / gene
                              :name (n5 / name :op1 "E-cadherin"~e.29,31))
                        :time~e.34 (o / onset~e.36
                              :poss~e.37 (s / specify-01~e.40
                                    :ARG1 (f / fate~e.39
                                          :poss (h / hair~e.38))))))
            :ARG1 (a / act-01~e.6
                  :ARG0~e.7 (a2 / and~e.12
                        :op1 (s2 / signal~e.10
                              :name (n6 / name :op1 "Wnt"~e.11)
                              :mod (e / extracellular~e.9))
                        :op2 (s3 / signal~e.10
                              :name (n / name :op1 "noggin"~e.13)
                              :mod e))
                  :mod (c / concerted~e.5)))
      :time (p5 / previous~e.0))

# ::tok As shown in <xref ref-type="fig" rid="pbio-0030011-g006"> Figure 6 </xref>@ I and <xref ref-type="fig" rid="pbio-0030011-g006"> 6 </xref>@ J , both WT and TGF-β2 null buds exhibited nuclear LEF @-@ 1 and β-catenin localization , signs that the Wnt @-@ noggin signaling pathway was intact .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3 6-1.3.1.1 6-1.3.1.2 9-1.2.1.1.1.1 10-1.3.1 19-1.1.1.1 20-1.1 21-1.1.2.1.1.1 22-1.1.2.1.2 23-1.1.1 23-1.1.2 24-1 25-1.2.2 26-1.2.1.1.1.1 28-1.2.1.1.1.1 29-1.2.1 30-1.2.1.2.1.1 33-1.4 34-1.4.1.r 36-1.4.1.1.1.1 38-1.4.1.1.1.1 39-1.4.1.1.2 40-1.4.1.1 41-1.4.1.1.r 42-1.4.1
# ::id pmid_1563_0473.183
# ::preferred 
(e / exhibit-01~e.24
      :ARG0 (a / and~e.20
            :op1 (b / bud~e.23
                  :mod (w / wild-type~e.19))
            :op2 (b2 / bud~e.23
                  :mod (p / protein
                        :name (n2 / name :op1 "TGF-β2"~e.21)
                        :mod (n / null~e.22))))
      :ARG1 (b3 / be-located-at-91
            :ARG1 (a3 / and~e.29
                  :op1 (p2 / protein
                        :name (n3 / name :op1 "LEF-1"~e.9,26,28))
                  :op2 (p4 / protein
                        :name (n6 / name :op1 "β-catenin"~e.30)))
            :ARG2 (n4 / nucleus~e.25))
      :ARG1-of (s / show-01~e.1
            :ARG0 (a2 / and~e.10
                  :op1 (f / figure~e.6 :mod "6I")
                  :op2 (f2 / figure~e.6 :mod "6J")))
      :ARG0-of (s2 / signal-07~e.33
            :ARG1~e.34 (i / intact~e.42
                  :domain~e.41 (p3 / pathway~e.40
                        :name (n5 / name :op1 "Wnt-noggin"~e.36,38)
                        :ARG0-of (s3 / signal-07~e.39)))))

# ::tok These data suggest that during hair follicle morphogenesis , TGF-β2 functions subsequently to Wnt @/@ noggin @-@ mediated determination of hair fate .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1 2-1 3-1.2.r 4-1.2.2.r 5-1.2.2.1.1 6-1.2.2.1 7-1.2.2 9-1.2.1.1.1 10-1.2 11-1.2.2.r 11-1.2.3 11-1.2.3.r 12-1.2.3.1.r 13-1.2.3.1.2.1.1.1 15-1.2.3.1.2.1.1.1 17-1.2.3.1.2 18-1.2.3.1 19-1.2.3.1.1.r 20-1.2.3.1.1.1 21-1.2.3.1.1
# ::id pmid_1563_0473.184
# ::preferred 
(s / suggest-01~e.2
      :ARG0 (d / data~e.1
            :mod (t / this~e.0))
      :ARG1~e.3 (f / function-01~e.10
            :ARG0 (p2 / protein
                  :name (n2 / name :op1 "TGF-β2"~e.9))
            :time~e.4,11 (m / morphogenesis~e.7
                  :mod (f2 / follicle~e.6
                        :mod (h / hair~e.5)))
            :time~e.11 (s2 / subsequent~e.11
                  :op1~e.12 (d2 / determine-01~e.18
                        :ARG1~e.19 (f3 / fate~e.21
                              :poss (h2 / hair~e.20))
                        :ARG1-of (m2 / mediate-01~e.17
                              :ARG0 (p / pathway
                                    :name (n / name :op1 "Wnt/noggin"~e.13,15)))))))

# ::tok Moreover , through activation of <i> Snail </i> gene expression , TGF-β2 appears to work in tandem with these other morphogens to down @-@ regulate E @-@ cadherin levels , which contributes to the activation of proliferative circuitries .
# ::amr-annotator SDL-AMR-09
# ::alignments 3-1.1.2.1 6-1.1.2.1.1.1.1.1 8-1.1.1.2.2.1 8-1.1.2.1.1.1 9-1.1.2.1.1 11-1.1.1.1.1.1 12-1.1 13-1.1.2 14-1.1.1 15-1.1.1.4.r 16-1.1.1.4 18-1.1.1.3.2 19-1.1.1.3.1 25-1.1.1.2.2.1.1.1 27-1.1.1.2.2.1.1.1 28-1.1.1.2.2 31-1.1.1.2.3 32-1.1.1.2.3.1.r 34-1.1.1.2.3.1 37-1.1.1.2.3.1.1
# ::id pmid_1563_0473.185
# ::preferred 
(a / and
      :op2 (a2 / appear-02~e.12
            :ARG2 (w / work-01~e.14
                  :ARG0 (p / protein
                        :name (n / name :op1 "TGF-β2"~e.11))
                  :ARG1 (d / downregulate-01
                        :ARG0 (a4 / and
                              :op1 p
                              :op2 (m / morphogen
                                    :mod (o / other~e.19)
                                    :mod (t2 / this~e.18)))
                        :ARG1 (l / level~e.28
                              :quant-of (g2 / gene~e.8
                                    :name (n3 / name :op1 "E-cadherin"~e.25,27)))
                        :ARG0-of (c2 / contribute-01~e.31
                              :ARG2~e.32 (a5 / activate-01~e.34
                                    :ARG1 (c3 / circuitry~e.37
                                          :ARG0-of (p3 / proliferate-01)))))
                  :ARG3 m
                  :mod~e.15 (t / tandem~e.16))
            :ARG1-of (c / cause-01~e.13
                  :ARG0 (a3 / activate-01~e.3
                        :ARG1 (e / express-03~e.9
                              :ARG1 (g / gene~e.8
                                    :name (n2 / name :op1 "Snail"~e.6)))))))

# ::tok Discussion
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1
# ::id pmid_1563_0473.186
# ::preferred 
(d / discuss-01~e.0)

# ::tok During budding morphogenesis , intersecting signaling networks from the epithelium and mesenchyme govern transcriptional , adhesive , polarity , and motility programs in these select groups of cells .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.4.r 1-1.4.1 2-1.4 4-1.1.3 5-1.1.2 6-1.1 6-1.1.1 6-1.1.1.r 7-1.1.4.r 9-1.1.4.1 10-1.1.4 11-1.1.4.2 12-1 19-1.2 20-1.2.4.1 21-1.2.1 21-1.2.2 21-1.2.3 21-1.2.4 22-1.3.r 23-1.3.2 24-1.3.3 25-1.3 26-1.3.1.r 27-1.3.1
# ::id pmid_1563_0473.187
# ::preferred 
(g / govern-01~e.12
      :ARG0 (t / thing~e.6
            :ARG1-of~e.6 (n / network-01~e.6)
            :ARG0-of (s / signal-07~e.5)
            :ARG0-of (i / intersect-01~e.4)
            :source~e.7 (a / and~e.10
                  :op1 (e / epithelium~e.9)
                  :op2 (m / mesenchyme~e.11)))
      :ARG1 (a4 / and~e.19
            :op1 (p3 / program~e.21
                  :topic (t3 / transcribe-01))
            :op2 (p4 / program~e.21
                  :topic (a3 / adhere-01))
            :op3 (p5 / program~e.21
                  :topic (p2 / polarize-01))
            :op4 (p6 / program~e.21
                  :topic (m2 / motility~e.20)))
      :location~e.22 (g2 / group~e.25
            :consist-of~e.26 (c / cell~e.27)
            :mod (t4 / this~e.23)
            :mod (s2 / select~e.24))
      :time~e.0 (m3 / morphogenesis~e.2
            :ARG1-of (b / bud-01~e.1)))

# ::tok The dynamic nuclear and cytosolic changes that take place during this time form the cornerstone for organ morphogenesis .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.2 2-1.1.1.1 3-1.1.1 4-1.1.1.2 5-1.1 9-1.1.3.r 10-1.1.3 11-1.1.3.r 12-1 14-1.2 15-1.3.r 16-1.3.1 17-1.3
# ::id pmid_1563_0473.188
# ::preferred 
(f / form-01~e.12
      :ARG0 (c4 / change-01~e.5
            :ARG0 (a2 / and~e.3
                  :op1 (n / nucleus~e.2)
                  :op2 (c2 / cytosol~e.4))
            :mod (d / dynamic~e.1)
            :time~e.9,11 (t / this~e.10))
      :ARG1 (c3 / cornerstone~e.14)
      :purpose~e.15 (m / morphogenesis~e.17
            :mod (o / organ~e.16)))

# ::tok Two major challenges in understanding the mechanisms underlying a particular budding process are to order the temporal sequence of external cues involved and then to dissect how the cells of the developing bud translate these signals into the downstream events of cellular remodeling , proliferation , and differentiation .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3.1 1-1.3.3 2-1.3 3-1.3.2.r 4-1.3.2 6-1.3.2.1 7-1.3.2.1.1 9-1.3.2.1.1.1.2 10-1.3.2.1.1.1.1 11-1.3.2.1.1.1 13-1.3.2 14-1.1 16-1.1.1.1 17-1.1.1 18-1.1.1.2.r 19-1.1.1.2.1 20-1.1.1.2 21-1.1.1.2.2 22-1 23-1.2.2 25-1.2 26-1.2.1.1.r 28-1.2.1.1.1 29-1.2.1.1.1.1.r 31-1.2.1.1.1.1.1 32-1.2.1.1.1.1 33-1.2.1.1 34-1.2.1.1.2.2 35-1.2.1.1.2 35-1.2.1.1.2.1 35-1.2.1.1.2.1.r 36-1.2.1.1.3.r 38-1.2.1.1.3.4 39-1.2.1.1.3.1 39-1.2.1.1.3.2 39-1.2.1.1.3.3 40-1.2.1.1.3.1.1.r 41-1.2.1.1.3.1.1.1 42-1.2.1.1.3.1.1 44-1.2.1.1.3.3.1 46-1.2.1.1.3 47-1.2.1.1.3.2.1
# ::id pmid_1563_0473.189
# ::preferred 
(a / and~e.22
      :op1 (o / order-00~e.14
            :ARG1 (s / sequence~e.17
                  :mod (t / time~e.16)
                  :consist-of~e.18 (c / cue~e.20
                        :source (e / external~e.19)
                        :ARG1-of (i / involve-01~e.21))))
      :op2 (d / dissect-01~e.25
            :ARG1 (t3 / thing
                  :manner-of~e.26 (t4 / translate-01~e.33
                        :ARG0 (c2 / cell~e.28
                              :part-of~e.29 (b / bud~e.32
                                    :ARG1-of (d2 / develop-02~e.31)))
                        :ARG1 (t5 / thing~e.35
                              :ARG0-of~e.35 (s2 / signal-07~e.35)
                              :mod (t6 / this~e.34))
                        :ARG2~e.36 (a2 / and~e.46
                              :op1 (e3 / event~e.39
                                    :mod~e.40 (r / remodel-01~e.42
                                          :ARG1 c2~e.41))
                              :op2 (e4 / event~e.39
                                    :mod (d4 / differentiate-01~e.47
                                          :ARG1 c2))
                              :op3 (e5 / event~e.39
                                    :mod (p / proliferate-01~e.44
                                          :ARG0 c2))
                              :location (d3 / downstream~e.38))))
            :time (t2 / then~e.23))
      :domain (c3 / challenge-01~e.2
            :quant "2"~e.0
            :ARG2~e.3 (u / understand-01~e.4,13
                  :ARG1 (m2 / mechanism~e.6
                        :ARG0-of (u2 / underlie-01~e.7
                              :ARG1 (p2 / process~e.11
                                    :ARG1-of (b2 / bud-01~e.10)
                                    :mod (p3 / particular~e.9)))))
            :mod (m / major~e.1)))

# ::tok Our studies here provide some insights into how these events are orchestrated during hair bud formation in developing skin .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 0-1.1.1.r 1-1.1 2-1.1.2 3-1 4-1.2.1 5-1.2 6-1.2.2.r 7-1.2.2.1.r 8-1.2.2.1.1.1 9-1.2.2.1.1 11-1.2.2.1 12-1.2.2.1.2.r 13-1.2.2.1.2.1.1 14-1.2.2.1.2.1 15-1.2.2.1.2 16-1.2.2.1.2.2.r 17-1.2.2.1.2.2.1 18-1.2.2.1.2.2
# ::id pmid_1563_0473.190
# ::preferred 
(p / provide-01~e.3
      :ARG0 (s / study-01~e.1
            :ARG0~e.0 (w / we~e.0)
            :mod (h / here~e.2))
      :ARG1 (i / insight~e.5
            :quant (s2 / some~e.4)
            :topic~e.6 (t / thing
                  :manner-of~e.7 (o / orchestrate-01~e.11
                        :ARG1 (e / event~e.9
                              :mod (t2 / this~e.8))
                        :time~e.12 (f / form-01~e.15
                              :ARG1 (b / bud~e.14
                                    :mod (h2 / hair~e.13))
                              :location~e.16 (s3 / skin~e.18
                                    :ARG1-of (d / develop-02~e.17)))))))

# ::tok Signaling during Early Hair Follicle Morphogenesis
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.1.r 2-1.1 3-1.1.1.1.1 4-1.1.1.1 5-1.1.1
# ::id pmid_1563_0473.191
# ::preferred 
(s / signal-07~e.0
      :time~e.1 (e / early~e.2
            :op1 (m / morphogenesis~e.5
                  :mod (f / follicle~e.4
                        :mod (h / hair~e.3)))))

# ::tok Recent studies on hair bud morphogenesis suggest that Wnt signals likely from the epithelium and BMP inhibitory signals from the underlying mesenchyme converge to produce an active transcription factor complex involving β-catenin and LEF @-@ 1 , which in turn plays a key role in specifying the hair follicle fate [ @<xref ref-type="bibr" rid="pbio-0030011-b04"> 4 </xref> , <xref ref-type="bibr" rid="pbio-0030011-b29"> 29 </xref> , <xref ref-type="bibr" rid="pbio-0030011-b30"> 30 </xref> , <xref ref-type="bibr" rid="pbio-0030011-b36"> 36 </xref> , <xref ref-type="bibr" rid="pbio-0030011-b37"> 37 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2 1-1.1 2-1.1.1.r 3-1.1.1.1.1 4-1.1.1.1 5-1.1.1 6-1 7-1.2.r 8-1.2.1.1.1.1 9-1.2.1 10-1.2.1.2 11-1.2.1.2.1.r 11-1.2.1.2.r 13-1.2.1.2.1 14-1.2.3.1 15-1.2.2.1.1.1.1 17-1.2.2 18-1.2.2.2.r 20-1.2.2.2.1 21-1.2.2.2 22-1.2 24-1.2.3 27-1.2.3.2.1.1 28-1.2.3.2.1 29-1.2.3.2 30-1.2.3.2.2 31-1.2.3.2.2.1.1.1.1 32-1.2.3.2.2.1 33-1.2.3.2.2.1.2.1.1 35-1.2.3.2.2.1.2.1.1 38-1.2.3.2.4.3 39-1.2.3.2.4.3 40-1.2.3.2.4 42-1.2.3.2.4.1.1 43-1.2.3.2.4.1 44-1.2.3.2.4.2.r 44-1.2.3.2.4.3 45-1.2.3.2.4.2 47-1.2.3.2.4.2.1.1.1 48-1.2.3.2.4.2.1.1 49-1.2.3.2.4.2.1 54-1.3.1.1.1.1 60-1.3.1.1.1.2 66-1.3.1.1.1.3 72-1.3.1.1.1.4 78-1.3.1.1.1.5
# ::id pmid_1563_0473.192
# ::preferred 
(s / suggest-01~e.6
      :ARG0 (s2 / study-01~e.1
            :ARG1~e.2 (m / morphogenesis~e.5
                  :mod (b / bud~e.4
                        :mod (h / hair~e.3)))
            :time (r / recent~e.0))
      :ARG1~e.7 (c / converge-01~e.22
            :ARG0 (s6 / signal-07~e.9
                  :ARG0 (p / pathway
                        :name (n / name :op1 "Wnt"~e.8))
                  :source~e.11 (l / likely~e.10
                        :domain~e.11 (e / epithelium~e.13)))
            :ARG1 (s3 / signal-07~e.17
                  :ARG0-of (i / inhibit-01
                        :ARG1 (p2 / protein
                              :name (n2 / name :op1 "BMP"~e.15)))
                  :source~e.18 (m2 / mesenchyme~e.21
                        :ARG0-of (u / underlie-01~e.20)))
            :purpose (p3 / produce-01~e.24
                  :ARG0 (a / and~e.14)
                  :ARG1 (m3 / macro-molecular-complex~e.29
                        :part (f / factor~e.28
                              :ARG0-of (t3 / transcribe-01~e.27))
                        :ARG0-of (i2 / involve-01~e.30
                              :ARG1 (a3 / and~e.32
                                    :op1 (p4 / protein
                                          :name (n4 / name :op1 "β-catenin"~e.31))
                                    :op2 (p5 / protein
                                          :name (n5 / name :op1 "LEF-1"~e.33,35))))
                        :ARG1-of (a2 / activate-01)
                        :ARG0-of (p6 / play-02~e.40
                              :ARG1 (r2 / role~e.43
                                    :mod (k / key~e.42))
                              :purpose~e.44 (s5 / specify-01~e.45
                                    :ARG1 (f2 / fate-01~e.49
                                          :ARG1 (f3 / follicle~e.48
                                                :mod (h2 / hair~e.47))))
                              :mod (i3 / in-turn~e.38,39,44)))))
      :ARG1-of (d / describe-01
            :ARG0 (p7 / publication
                  :ARG1-of (c2 / cite-01
                        :ARG2 (a4 / and
                              :op1 "4"~e.54
                              :op2 "29"~e.60
                              :op3 "30"~e.66
                              :op4 "36"~e.72
                              :op5 "37"~e.78)))))

# ::tok Sonic hedgehog ( Shh ) and TGF-β2 signaling also play essential roles in follicle morphogenesis , but in contrast to <i> β-catenin </i> null skin , in which follicle invaginations are absent [ @<xref ref-type="bibr" rid="pbio-0030011-b30"> 30 </xref>@ ], some hair buds still form in the absence of LEF @-@ 1 , Shh , or TGF-β2 [ @<xref ref-type="bibr" rid="pbio-0030011-b32"> 32 </xref> , <xref ref-type="bibr" rid="pbio-0030011-b38"> 38 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1.1.1 1-1.1.1.1.1.2 3-1.1.1.1.2.1.1 5-1.1 6-1.1.2.1.1.1 7-1.1.1 7-1.1.2 8-1.3 9-1 10-1.2.1 11-1.2 12-1.4.r 13-1.4.1 14-1.4 16-1.5 18-1.5.1.4 21-1.5.1.4.1.2.1.1.1 24-1.5.1.4.1 28-1.5.1.4.1.1.2.1 29-1.5.1.4.1.1.2 30-1.5.1.4.1.1 36-1.5.1.4.1.3.1.1.1 39-1.5.1.1.2 40-1.5.1.1.1 41-1.5.1.1 42-1.5.1.2 43-1.5.1 48-1.5.1.3.2.1.1.1 50-1.5.1.3.2.1.1.1 52-1.5.1.3.2.2 55-1.1.2.1.1.1 60-1.5.1.3.3.1.1.1.1 66-1.5.1.3.3.1.1.1.2
# ::id pmid_1563_0473.193
# ::preferred 
(p / play-02~e.9
      :ARG0 (a / and~e.5
            :op1 (s2 / signal-07~e.7
                  :ARG0 (p2 / protein
                        :name (n / name :op1 "Sonic"~e.0 :op2 "hedgehog"~e.1)
                        :ARG1-of (d3 / describe-01
                              :ARG2 (n5 / name :op1 "Shh"~e.3))))
            :op2 (s3 / signal-07~e.7
                  :ARG0 (p7 / protein
                        :name (n2 / name :op1 "TGF-β2"~e.6,55))))
      :ARG1 (r / role~e.11
            :mod (e / essential~e.10))
      :mod (a2 / also~e.8)
      :purpose~e.12 (m / morphogenesis~e.14
            :mod (f / follicle~e.13))
      :ARG1-of (h / have-concession-91~e.16
            :ARG2 (f2 / form-01~e.43
                  :ARG1 (b / bud~e.41
                        :mod (h2 / hair~e.40)
                        :quant (s4 / some~e.39))
                  :mod (s5 / still~e.42)
                  :condition (b2 / be-located-at-91
                        :polarity "-"
                        :ARG1 (a3 / and
                              :op1 (p3 / protein
                                    :name (n3 / name :op1 "LEF-1"~e.48,50))
                              :op2 p2~e.52
                              :op3 p7)
                        :ARG1-of (d2 / describe-01
                              :ARG0 (p6 / publication
                                    :ARG1-of (c3 / cite-01
                                          :ARG2 (a4 / and :op1 "32"~e.60 :op2 "38"~e.66)))))
                  :ARG1-of (c / contrast-01~e.18
                        :ARG2 (s7 / skin~e.24
                              :ARG2-of (b3 / be-located-at-91~e.30
                                    :polarity "-"
                                    :ARG1 (i / invaginate-00~e.29
                                          :ARG1 (f3 / follicle~e.28)))
                              :ARG0-of (c4 / contain-01
                                    :ARG1 (p4 / protein
                                          :name (n4 / name :op1 "β-catenin"~e.21)
                                          :ARG2-of (m2 / mutate-01 :mod "−/−")))
                              :ARG1-of (d / describe-01
                                    :ARG0 (p5 / publication
                                          :ARG1-of (c2 / cite-01 :ARG2 "30"~e.36))))))))

# ::tok These likely reflect the first wave of follicle ( i.e . , guard hair ) morphogenesis , which accounts for a small number ( fewer than 5 %) of hairs and is under distinct regulatory control .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1 2-1.1 4-1.1.2.1 4-1.1.2.1.1 4-1.1.2.1.1.r 5-1.1.2 6-1.1.2.2.r 7-1.1.2.2.1 12-1.1.2.5.1.1 13-1.1.2.5.1 15-1.1.2.2 18-1.1.2.3 19-1.1.2.3.1.r 21-1.1.2.3.1.1.1 22-1.1.2.3.1.1 25-1.1.2.3.1.1.2.1 26-1.1.2.3.1.1.2.1.1.1 29-1.1.2.3.1 33-1.1.2.4.1 34-1.1.2.4.2 35-1.1.2.4
# ::id pmid_1563_0473.194
# ::preferred 
(l / likely~e.1
      :domain (r / reflect-01~e.2
            :ARG1 (t / this~e.0)
            :ARG2 (w / wave~e.5
                  :ord (o / ordinal-entity~e.4 :value~e.4 "1"~e.4)
                  :mod~e.6 (m / morphogenesis~e.15
                        :mod (f / follicle~e.7))
                  :ARG0-of (a / account-01~e.18
                        :ARG1~e.19 (h3 / hair~e.29
                              :quant (n / number~e.22
                                    :mod (s / small~e.21)
                                    :ARG0-of (m3 / mean-01
                                          :ARG1 (l2 / less-than~e.25
                                                :op1 (p / percentage-entity :value "5"~e.26))))))
                  :ARG1-of (c / control-01~e.35
                        :mod (d / distinct~e.33)
                        :ARG0-of (r2 / regulate-01~e.34))
                  :ARG0-of (m2 / mean-01
                        :ARG1 (h2 / hair~e.13
                              :mod (g / guard~e.12))))))

# ::tok Guard hairs form in the absence of LEF @-@ 1 and TGF-β2 , and we have found that they also fail to express Snail at the budding stage of development ( unpublished data ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 1-1.1.1 2-1.1 7-1.1.2.2.1.1.1 9-1.1.2.2.1.1.1 11-1.1.2.2.2.1.1 13-1 13-1.1.2.2 14-1.2.1 16-1.2 17-1.2.2.r 18-1.2.2.1 19-1.2.2.3 20-1.2.2 22-1.2.2.2 23-1.2.2.2.2.1.1 24-1.1.2 24-1.2.2.4.r 26-1.2.2.4.2 27-1.2.2.4 28-1.2.2.4.1.r 29-1.2.2.4.1 31-1.1.2.1 31-1.3.1.1.1 32-1.3.1
# ::id pmid_1563_0473.195
# ::preferred 
(a / and~e.13
      :op1 (f / form-01~e.2
            :ARG1 (h / hair~e.1
                  :mod (g / guard~e.0))
            :condition (b / be-located-at-91~e.24
                  :polarity "-"~e.31
                  :ARG1 (a2 / and~e.13
                        :op1 (p / protein
                              :name (n / name :op1 "LEF-1"~e.7,9))
                        :op2 (p3 / protein
                              :name (n2 / name :op1 "TGF-β2"~e.11)))))
      :op2 (f2 / find-01~e.16
            :ARG0 (w / we~e.14)
            :ARG1~e.17 (f3 / fail-01~e.20
                  :ARG1 h~e.18
                  :ARG2 (e / express-03~e.22
                        :ARG1 h
                        :ARG2 (p4 / protein
                              :name (n3 / name :op1 "Snail"~e.23)))
                  :mod (a3 / also~e.19)
                  :time~e.24 (s2 / stage~e.27
                        :subevent-of~e.28 (d / develop-02~e.29)
                        :mod (b2 / bud-01~e.26))))
      :ARG1-of (d2 / describe-01
            :ARG0 (d3 / data~e.32
                  :ARG1-of (p2 / publish-01 :polarity "-"~e.31))))

# ::tok How E @-@ cadherin is regulated in guard hairs remains to be determined .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1.r 1-1.1.1.1.1.1.1 3-1.1.1.1.1.1.1 5-1.1.1.1 6-1.1.1.1.2.r 7-1.1.1.1.2.1 8-1.1.1.1.2 9-1 12-1.1
# ::id pmid_1563_0473.196
# ::preferred 
(r / remain-01~e.9
      :ARG1 (d / determine-01~e.12
            :ARG1 (t / thing
                  :manner-of~e.0 (r2 / regulate-01~e.5
                        :ARG1 (p / protein
                              :name (n / name :op1 "E-cadherin"~e.1,3))
                        :location~e.6 (h / hair~e.8
                              :mod (g / guard~e.7))))))

# ::tok Several candidates include other Snail family members such as Slug or twist , or alternatively , transcription factors involving β-catenin and a different member of the LEF @-@ 1/TCF/ @<i> Sry </i>@ -@ type HMG box ( commonly known as SOX ) family [ @<xref ref-type="bibr" rid="pbio-0030011-b39"> 39 </xref> , <xref ref-type="bibr" rid="pbio-0030011-b40"> 40 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.1 1-1.2 2-1 3-1.1.1.2 4-1.1.1.1.1.1.1 5-1.1.1.1 6-1.1.1 7-1.1.1.3.r 8-1.1.1.3.r 9-1.1.1.3.1.1.1 10-1.1.1.3 11-1.1.1.3.2.1.1 13-1.1 14-1.1.3 14-1.1.3.r 16-1.1.2.1 17-1.1.2 18-1.1.2.2 19-1.1.2.2.1.1.1.1 20-1.1.2.2.1 22-1.1.2.2.1.2.1 23-1.1.2.2.1.2 24-1.1.2.2.1.2.2.r 26-1.1.2.2.1.2.2.1.1.1.1 30-1.1.2.2.1.2.2.1.3.1.1 33-1.1.2.2.1.2.2.1.3.1.1 34-1.1.2.2.1.2.2.1.3.1.2 35-1.1.2.2.1.2.2.1.3.1.3 37-1.1.2.2.1.2.2.1.3.2.2 37-1.1.2.2.1.2.2.1.3.2.2.r 38-1.1.2.2.1.2.2.1.3 38-1.1.2.2.1.2.2.1.3.1.r 38-1.1.2.2.1.2.2.1.3.2 38-1.1.2.2.1.2.2.1.3.2.r 39-1.1.2.2.1.2.2.1.3.1.r 39-1.1.2.2.1.2.2.1.3.2.1.r 40-1.1.2.2.1.2.2.1.3.2.1 42-1.1.2.2.1.2.2 47-1.3.1.1.1.1 53-1.3.1.1.1.2
# ::id pmid_1563_0473.197
# ::preferred 
(i / include-01~e.2
      :ARG1 (o3 / or~e.13
            :op1 (m / member~e.6
                  :part-of (f / family~e.5
                        :mod (p4 / protein
                              :name (n / name :op1 "Snail"~e.4)))
                  :mod (o / other~e.3)
                  :example~e.7,8 (o2 / or~e.10
                        :op1 (p8 / protein
                              :name (n2 / name :op1 "Slug"~e.9))
                        :op2 (p9 / protein
                              :name (n3 / name :op1 "twist"~e.11))))
            :op2 (f2 / factor~e.17
                  :ARG0-of (t / transcribe-01~e.16)
                  :ARG2-of (i2 / involve-01~e.18
                        :ARG1 (a2 / and~e.20
                              :op1 (p / protein
                                    :name (n4 / name :op1 "β-catenin"~e.19))
                              :op2 (m2 / member~e.23
                                    :ARG1-of (d / differ-02~e.22)
                                    :part-of~e.24 (f3 / family~e.42
                                          :consist-of (a3 / and
                                                :op1 (p2 / protein
                                                      :name (n6 / name :op1 "LEF-1"~e.26))
                                                :op2 (m3 / molecular-physical-entity
                                                      :name (n7 / name :op1 "TCF"))
                                                :op3 (m4 / molecular-physical-entity~e.38
                                                      :name~e.38,39 (n8 / name
                                                            :op1 "Sry-type"~e.30,33
                                                            :op2 "HMG"~e.34
                                                            :op3 "box"~e.35)
                                                      :ARG1-of~e.38 (k / know-02~e.38
                                                            :ARG2~e.39 (s2 / SOX~e.40)
                                                            :manner~e.37 (c2 / common~e.37)))))))))
            :manner~e.14 (a / alternative~e.14))
      :ARG2 (c / candidate~e.1
            :quant (s / several~e.0))
      :ARG1-of (d2 / describe-01
            :ARG0 (p3 / publication
                  :ARG1-of (c3 / cite-01
                        :ARG2 (a4 / and :op1 "39"~e.47 :op2 "40"~e.53)))))

# ::tok Further investigation will be required to determine whether the signaling pathway we have elucidated here is a theme with multiple variations .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1 4-1 6-1.2 7-1.2.1.1 7-1.2.1.1.r 9-1.2.1.2.1 10-1.2.1.2 11-1.2.1.2.2.1 13-1.2.1.2.2 14-1.2.1.2.2.2 15-1.2.1.2.r 17-1.2.1 18-1.2.1.3.r 19-1.2.1.3.1 20-1.2.1.3
# ::id pmid_1563_0473.198
# ::preferred 
(r / require-01~e.4
      :ARG1 (i / investigate-01~e.1
            :degree (f / further~e.0))
      :purpose (d / determine-01~e.6
            :ARG1 (t / theme~e.17
                  :mode~e.7 "interrogative"~e.7
                  :domain~e.15 (p / pathway~e.10
                        :ARG0-of (s / signal-07~e.9)
                        :ARG1-of (e / elucidate-01~e.13
                              :ARG0 (w / we~e.11)
                              :location (h / here~e.14)))
                  :ARG0-of~e.18 (v / vary-01~e.20
                        :mod (m / multiple~e.19)))))

# ::tok TGF-βs are known to promote withdrawal of keratinocytes from the cell cycle [ @<xref ref-type="bibr" rid="pbio-0030011-b41"> 41 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1 4-1.1 5-1.1.2 8-1.1.2.2.r 10-1.1.2.2.1 11-1.1.2.2 16-1.2.1.1.1
# ::id pmid_1563_0473.199
# ::preferred 
(k / know-01~e.2
      :ARG1 (p / promote-02~e.4
            :ARG0 (p3 / protein
                  :name (n / name :op1 "TGF-β"))
            :ARG1 (w / withdraw-01~e.5
                  :ARG1 (c / cell
                        :name (n2 / name :op1 "keratinocyte"))
                  :ARG2~e.8 (c2 / cycle~e.11
                        :poss (c3 / cell~e.10))))
      :ARG1-of (d / describe-01
            :ARG0 (p2 / publication
                  :ARG1-of (c4 / cite-01 :ARG2 "41"~e.16))))

# ::tok Hence , when TGF-β2 protein was detected at the transition between the growing and destructive phases of the adult hair cycle , research initially and naturally focused on a role for this family member in cessation of growth and @/@ or triggering apoptosis ([ @<xref ref-type="bibr" rid="pbio-0030011-b42"> 42 </xref>@ ] and references therein ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 2-1.1.3.r 2-1.1.5.r 3-1.1.5.1.1.1 4-1.1.5.1 6-1.1.5 7-1.1.5.2.r 9-1.1.5.2 12-1.1.5.2.2.1 14-1.1.5.2.1.1 15-1.1.5.2.1 15-1.1.5.2.2 16-1.1.5.2.1.2.r 18-1.1.5.2.1.2.1.1 19-1.1.5.2.1.2.1 20-1.1.5.2.1.2 22-1.1.1 23-1.1.3 25-1.1.4 25-1.1.4.r 26-1.1 27-1.1.2.r 29-1.1.2 32-1.1.2.1.1 33-1.1.2.1 34-1.1.2.2.r 35-1.1.2.2.1 36-1.1.2.2.1.1.r 37-1.1.2.2.1.1 38-1.1.2.2 40-1.1.2.2 41-1.1.2.2.2 42-1.1.2.2.2.1 47-1.2.1.1.1.1 50-1.2.1.1.1 51-1.2.1.1.1.2
# ::id pmid_1563_0473.200
# ::preferred 
(i2 / infer-01~e.0
      :ARG1 (f / focus-01~e.26
            :ARG1 (r / research-01~e.22)
            :ARG2~e.27 (r2 / role~e.29
                  :poss (m / member~e.33
                        :part-of (f2 / family~e.32)
                        :mod (p / protein~e.4
                              :name (n2 / name :op1 "TGF-β2"~e.3)))
                  :purpose~e.34 (a4 / and-or~e.38,40
                        :op1 (c / cease-01~e.35
                              :ARG1~e.36 (g / grow-01~e.37))
                        :op2 (t2 / trigger-01~e.41
                              :ARG1 (a / apoptosis~e.42))))
            :time~e.2 (i / initial~e.23)
            :manner~e.25 (n / natural~e.25)
            :time~e.2 (d / detect-01~e.6
                  :ARG1 p
                  :time~e.7 (t3 / transition-01~e.9
                        :ARG2 (p3 / phase~e.15
                              :mod (d2 / destroy-01~e.14)
                              :subevent-of~e.16 (c2 / cycle~e.20
                                    :mod (h / hair~e.19
                                          :mod (a2 / adult~e.18))))
                        :ARG3 (p2 / phase~e.15
                              :mod (g2 / grow-01~e.12)
                              :subevent-of c2))))
      :ARG1-of (d3 / describe-01
            :ARG0 (p4 / publication
                  :ARG1-of (c3 / cite-01
                        :ARG2 (a3 / and~e.50
                              :op1 "42"~e.47
                              :op2 (r3 / reference~e.51
                                    :location (h2 / herein)))))))

# ::tok However , in contrast to <i> TGF-β1 </i>@ -@ null skin , which exhibits an extended growing phase of postnatal hair follicles , <i> TGF-β2 </i>@ -@ null skin displays an embryonic block in follicle bud progression [ @<xref ref-type="bibr" rid="pbio-0030011-b32"> 32 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 0-1.1.3 3-1.1.3 6-1.1.3.1.2.1.1.1 10-1.1.3.1 13-1.1.3.1.1 15-1.1.3.1.1.1.2 16-1.1.3.1.1.1.1 17-1.1.3.1.1.1 18-1.1.3.1.1.1.1.1.r 19-1.1.3.1.1.1.1.1.2 20-1.1.3.1.1.1.1.1.1 21-1.1.3.1.1.1.1.1 24-1.1.1.1.1.1.1 28-1.1.1 29-1.1 32-1.1.2 33-1.1.2.2.r 34-1.1.2.2.1.1 35-1.1.2.2.1 36-1.1.2.2 41-1.2.1.1.1
# ::id pmid_1563_0473.201
# ::preferred 
(h2 / have-concession-91~e.0
      :ARG2 (d / display-01~e.29
            :ARG0 (s / skin~e.28
                  :ARG0-of (c / contain-01
                        :ARG1 (p6 / protein
                              :name (n / name :op1 "TGF-β2"~e.24)
                              :ARG2-of (m / mutate-01 :mod "−/−"))))
            :ARG1 (b / block~e.32
                  :mod (e / embryo)
                  :time~e.33 (p2 / progress-01~e.36
                        :ARG1 (b2 / bud~e.35
                              :mod (f / follicle~e.34))))
            :ARG1-of (c2 / contrast-01~e.0,3
                  :ARG2 (s2 / skin~e.10
                        :ARG0-of (e2 / exhibit-01~e.13
                              :ARG1 (p4 / phase~e.17
                                    :mod (g / grow-01~e.16
                                          :ARG1~e.18 (f2 / follicle~e.21
                                                :mod (h / hair~e.20)
                                                :mod (p5 / postnatal~e.19)))
                                    :ARG1-of (e3 / extend-01~e.15)))
                        :ARG0-of (c3 / contain-01
                              :ARG1 (p3 / protein
                                    :name (n2 / name :op1 "TGF-β1"~e.6)
                                    :ARG2-of m)))))
      :ARG1-of (d2 / describe-01
            :ARG0 (p / publication
                  :ARG1-of (c4 / cite-01 :ARG2 "32"~e.41))))

# ::tok Although this phenotype is consistent with TGF-β2 's embryonic expression patterns [ @<xref ref-type="bibr" rid="pbio-0030011-b33"> 33 </xref>@ ], about 50 % of <i> TGF-β2 </i> null buds appear unable to progress to the down @-@ growth phase , a feature that cannot be explained readily on the basis of previously established effects of TGF-βs .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.r 1-1.2.1.1 2-1.2.1 4-1.2 5-1.2.2.r 6-1.2.2.1.1 7-1.2.2.1.1.r 9-1.2.2.1 10-1.2.2 15-1.2.3.1.1.1 18-1.1.2 19-1.1.2.1.1 20-1.1.2.1 23-1.1.1.1.1.1.1 26-1.1.1 27-1 28-1.1.3.1 28-1.1.3.3.1.1 28-1.1.3.3.1.1.1 30-1.1.3.2 36-1.1.3.2.1 39-1.1.3.3.1 41-1.1.3.3.1.1 41-1.1.3.3.1.1.1 41-1.1.3.3.1.1.1.r 43-1.1.3.3.1.2 44-1.1.3.3.1.2.2 44-1.1.3.3.1.2.2.r 48-1.1.3.3.1.2.1.r 49-1.1.3.3.1.2.1.2.1 50-1.1.3.3.1.2.1.2 51-1.1.3.3.1.2.1
# ::id pmid_1563_0473.202
# ::preferred 
(a / appear-02~e.27
      :ARG1 (i / include-91
            :ARG2 (b / bud~e.26
                  :ARG0-of (c4 / contain-01
                        :ARG1 (p3 / protein
                              :name (n / name :op1 "TGF-β2"~e.23)
                              :ARG2-of (m / mutate-01 :mod "−/−"))))
            :ARG3 (a4 / about~e.18
                  :op1 (p4 / percentage-entity~e.20 :value "50"~e.19))
            :ARG1-of (c / capable-01
                  :polarity "-"~e.28
                  :ARG2 (p5 / progress-01~e.30
                        :ARG4 (p6 / phase~e.36
                              :mod (d / downgrow-00)))
                  :ARG0-of (m2 / mean-01
                        :ARG1 (f / feature~e.39
                              :mod (p2 / possible~e.28,41 :polarity~e.41 "-"~e.28,41)
                              :ARG1-of (e / explain-01~e.43
                                    :ARG0~e.48 (a3 / affect-01~e.51
                                          :ARG0 (p10 / protein
                                                :name (n2 / name :op1 "TGF-β"))
                                          :ARG1-of (e2 / establish-01~e.50
                                                :time (p7 / previous~e.49)))
                                    :manner~e.44 (r / ready~e.44))))))
      :concession~e.0 (c2 / consistent-01~e.4
            :ARG1 (p / phenotype~e.2
                  :mod (t / this~e.1))
            :ARG2~e.5 (p9 / pattern~e.10
                  :path-of (e3 / express-03~e.9
                        :ARG2~e.7 p3~e.6
                        :ARG3 (e4 / embryo)))
            :ARG1-of (d2 / describe-01
                  :ARG0 (p8 / publication
                        :ARG1-of (c3 / cite-01 :ARG2 "33"~e.15)))))

# ::tok Our finding that TGF-β2 is upstream from Ki67 expression and MAPK activation lends further support to the notion that hair follicle keratinocytes at this early stage of development react to TGF-β2 signaling in a fashion opposite to that typically expected for TGF-β factors .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 0-1.1.1.r 1-1.1 2-1.1.2.r 3-1.1.2.1.1 4-1.1.2.2 5-1.1.2.2.1.2 7-1.1.2.2.1.1.1.1.1.1 8-1.1.2.2.1.1.1 9-1.1.2.2.1.1 10-1.1.2.2.1.1.2.1.1.1 11-1.1.2.2.1.1.2 12-1 13-1.2.2 14-1.2 15-1.3.r 17-1.3 19-1.3.1.1.1.2.1 20-1.3.1.1.1.2 22-1.1.2.2 23-1.3.1.1.4.1.2 24-1.3.1.1.4 25-1.3.1.1.4.1 26-1.3.1.1.4.1.1.r 27-1.3.1.1.4.1.1 28-1.3.1.1 29-1.3.1.1.2.r 30-1.3.1.1.2.1 31-1.3.1.1.2 32-1.3.1.1.3.r 34-1.3.1.1.3 34-1.3.1.1.3.1.1 35-1.3.1.1.3.1 38-1.3.1.1.3.1.1.1.1 38-1.3.1.1.3.1.1.1.1.r 39-1.3.1.1.3.1.1.1 40-1.3.1.1.3.1.1.1.2.r 41-1.3.1.1.3.1.1.1.2.1.1 42-1.3.1.1.3.1.1.1.2.1.2
# ::id pmid_1563_0473.203
# ::preferred 
(l / lend-01~e.12
      :ARG0 (f5 / find-01~e.1
            :ARG0~e.0 (w / we~e.0)
            :ARG1~e.2 (p2 / protein
                  :name (n2 / name :op1 "TGF-β2"~e.3)
                  :ARG1-of (b / be-located-at-91~e.4,22
                        :ARG2 (r / relative-position
                              :op1 (a / and~e.9
                                    :op1 (e / express-03~e.8
                                          :ARG2 (p3 / protein
                                                :name (n3 / name :op1 "Ki67"~e.7)))
                                    :op2 (a2 / activate-01~e.11
                                          :ARG1 (p / pathway
                                                :name (n / name :op1 "MAPK"~e.10))))
                              :direction (u / upstream~e.5)))))
      :ARG1 (s / support-01~e.14
            :ARG0 f5
            :degree (f2 / further~e.13))
      :ARG2~e.15 (n4 / notion~e.17
            :ARG0-of (m2 / mean-01
                  :ARG1 (r2 / react-01~e.28
                        :ARG0 (c / cell
                              :name (n5 / name :op1 "keratinocyte")
                              :part-of (f3 / follicle~e.20
                                    :mod (h / hair~e.19)))
                        :ARG1~e.29 (s3 / signal-07~e.31
                              :ARG0 p2~e.30)
                        :ARG2~e.32 (f4 / fashion~e.34
                              :ARG1-of (o / opposite-01~e.35
                                    :ARG2 (f / fashion~e.34
                                          :ARG1-of (e2 / expect-01~e.39
                                                :manner~e.38 (t3 / typical~e.38)
                                                :topic~e.40 (s4 / small-molecule
                                                      :name (n6 / name :op1 "TGF-β"~e.41 :op2 "factor"~e.42))))))
                        :time (e3 / early~e.24
                              :op1 (s2 / stage~e.25
                                    :subevent-of~e.26 (d / develop-02~e.27)
                                    :mod (t4 / this~e.23)))))))

# ::tok This said , based upon pSMAD2 immunohistochemistry , the immediate steps of downstream signaling appeared to be intact .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.1.1 1-1.2.1 3-1.3 6-1.3.1 9-1.1.1.1 10-1.1.1 11-1.1.1.2.r 12-1.1.1.2.1 13-1.1.1.2 14-1 16-1.1.1.r 17-1.1
# ::id pmid_1563_0473.204
# ::preferred 
(a / appear-02~e.14
      :ARG1 (i2 / intact~e.17
            :domain~e.16 (s / step~e.10
                  :mod (i / immediate~e.9)
                  :subevent-of~e.11 (s2 / signal-07~e.13
                        :location (d / downstream~e.12))))
      :time (a2 / after
            :op1 (s3 / say-01~e.1
                  :ARG1 (t / this~e.0)))
      :ARG1-of (b / base-02~e.3
            :ARG2 (i3 / immunohistochemistry~e.6
                  :instrument (p2 / protein
                        :name (n2 / name :op1 "SMAD2")
                        :ARG1-of (p / phosphorylate-01)))))

# ::tok Thus , we surmise that the proliferative outcome is likely to be rooted in differences in the repertoire of activated SMAD target genes .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2.1.1.1 2-1.1.1 3-1.1 7-1.1.2.1.1 8-1.1.2.1.r 9-1.1.2 11-1.1.2.1.r 12-1.1.2.1 13-1.1.2.1.2.r 14-1.1.2.1.2 15-1.1.2.1.2.1.r 17-1.1.2.1.2.1 18-1.1.2.1.2.1.1.r 19-1.1.2.1.2.1.1.1 20-1.1.2.1.2.1.1.2.1.1.1 21-1.1.2.1.2.1.1.2 22-1.1.2.1.2.1.1
# ::id pmid_1563_0473.205
# ::preferred 
(i / infer-01
      :ARG1 (s / surmise-01~e.3
            :ARG0 (w / we~e.2)
            :ARG1 (l / likely~e.9
                  :domain~e.8,11 (r / root-02~e.12
                        :ARG1 (o / outcome~e.7
                              :ARG1-of (c / cause-01~e.0
                                    :ARG0 (p / proliferate-01)))
                        :ARG2~e.13 (d / differ-02~e.14
                              :ARG1~e.15 (r2 / repertoire~e.17
                                    :consist-of~e.18 (g / gene~e.22
                                          :ARG1-of (a / activate-01~e.19)
                                          :ARG1-of (t / target-01~e.21
                                                :ARG0 (p2 / protein
                                                      :name (n / name :op1 "SMAD"~e.20))))))))))

# ::tok In this regard , the positive effects of TGF-β2 on proliferation within the hair bud may be more analogous to what has been seen in progression of squamous cell carcinoma to metastatic carcinoma [ @<xref ref-type="bibr" rid="pbio-0030011-b43"> 43 </xref>@ ] rather than that typically observed for keratinocytes [ @<xref ref-type="bibr" rid="pbio-0030011-b44"> 44 </xref> , <xref ref-type="bibr" rid="pbio-0030011-b45"> 45 </xref> , <xref ref-type="bibr" rid="pbio-0030011-b46"> 46 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.2 5-1.1.3 6-1.1 7-1.1.1.r 8-1.1.1.1.1 9-1.1.2.r 10-1.1.2 13-1.1.4.1 14-1.1.4 15-1.5 16-1.1.r 17-1.3 18-1 19-1.4.r 20-1.4 23-1.4.1 24-1.4.1.1.r 25-1.4.1.1 26-1.4.1.1.1.r 27-1.4.1.1.1.1 28-1.4.1.1.1.1 29-1.4.1.1.1 30-1.4.1.1.2.r 31-1.4.1.1.2.1 32-1.4.1.1.2 37-1.4.2.1.1.1 42-1.4.3.1 43-1.4.3.1.1.1 43-1.4.3.1.1.1.r 44-1.4.3.1.1 51-1.4.3.2.1.1.1.1 57-1.4.3.2.1.1.1.2 63-1.4.3.2.1.1.1.3
# ::id pmid_1563_0473.206
# ::preferred 
(a4 / analogous~e.18
      :domain~e.16 (a / affect-01~e.6
            :ARG0~e.7 (p3 / protein
                  :name (n / name :op1 "TGF-β2"~e.8))
            :ARG1~e.9 (p4 / proliferate-01~e.10)
            :mod (p2 / positive~e.5)
            :location (b / bud~e.14
                  :mod (h / hair~e.13)))
      :purpose (t4 / this~e.1)
      :degree (m / more~e.17)
      :prep-to~e.19 (t / thing~e.20
            :ARG1-of (s / see-01~e.23
                  :ARG2~e.24 (p5 / progress-01~e.25
                        :ARG1~e.26 (c / carcinoma~e.29
                              :mod (s2 / squamous-cell~e.27,28))
                        :ARG4~e.30 (c2 / carcinoma~e.32
                              :mod (m2 / metastatic~e.31))))
            :ARG1-of (d2 / describe-01
                  :ARG0 (p7 / publication
                        :ARG1-of (c5 / cite-01 :ARG2 "43"~e.37)))
            :ARG1-of (i / instead-of-91
                  :ARG2 (t2 / that~e.42
                        :ARG1-of (o / observe-01~e.44
                              :manner~e.43 (t3 / typical~e.43)
                              :location (c3 / cell
                                    :name (n2 / name :op1 "keratinocyte"))))
                  :ARG1-of (d / describe-01
                        :ARG0 (p6 / publication
                              :ARG1-of (c4 / cite-01
                                    :ARG2 (a3 / and
                                          :op1 "44"~e.51
                                          :op2 "45"~e.57
                                          :op3 "46"~e.63))))))
      :mod (p / possible~e.15))

# ::tok The prior identification of the <i> Snail </i> gene as a potential target of TGF-β signaling [ @<xref ref-type="bibr" rid="pbio-0030011-b15"> 15 </xref>@ ] was intriguing , given the temporal wave of <i> Snail </i> gene expression that occurs in the developing hair bud .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.3 2-1.1 6-1.1.1.1.1 8-1.1.1 9-1.1.2.r 9-1.1.3.r 11-1.1.2.2 12-1.1.2 13-1.1.2.1.r 14-1.1.2.1.1.1.1 15-1.1.2.1 20-1.1.4.1.1.1 24-1 28-1.2.1.1 28-1.2.1.2.r 29-1.2.1 32-1.2.1.2.1 33-1.2.1.2.1 34-1.2.1.2.1 35-1.2.1.2 38-1.2.1.2.2.r 40-1.2.1.2.2.2 41-1.2.1.2.2.1 42-1.2.1.2.2
# ::id pmid_1563_0473.207
# ::preferred 
(i / intrigue-01~e.24
      :ARG0 (i2 / identify-01~e.2
            :ARG1 (g / gene~e.8
                  :name (n / name :op1 "Snail"~e.6))
            :ARG2~e.9 (t / target-01~e.12
                  :ARG1-of~e.13 (s / signal-07~e.15
                        :ARG0 (s2 / small-molecule
                              :name (n2 / name :op1 "TGF-β"~e.14)))
                  :mod (p3 / potential~e.11))
            :time~e.9 (p / prior~e.1)
            :ARG1-of (d / describe-01
                  :ARG0 (p2 / publication
                        :ARG1-of (c / cite-01 :ARG2 "15"~e.20))))
      :ARG1-of (c2 / cause-01
            :ARG0 (w / wave~e.29
                  :mod (t2 / time~e.28)
                  :time-of~e.28 (e / express-03~e.35
                        :ARG1 g~e.32,33,34
                        :location~e.38 (b / bud~e.42
                              :mod (h / hair~e.41)
                              :ARG1-of (d2 / develop-02~e.40))))))

# ::tok The additional correlation between epithelial hyperproliferation and <i> Snail </i> transgene expression further fostered our interest in a possible link between TGF-β2 and Snail .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1 3-1.2.2.1 4-1.1.1.1 8-1.1.2.1.1.1 11-1.1.2 12-1.3 13-1 14-1.2.1 14-1.2.1.r 15-1.2 18-1.2.2.2 19-1.2.2 20-1.2.2.1 20-1.2.2.1.r 21-1.2.2.1.1.1.1 22-1.2.2.1 23-1.1.2.1.1.1 23-1.2.2.1.2.1.1
# ::id pmid_1563_0473.208
# ::preferred 
(f / foster-01~e.13
      :ARG0 (c / correlate-01~e.2
            :ARG1 (h2 / hyperproliferate-00
                  :ARG0 (e / epithelium~e.4))
            :ARG2 (e2 / express-03~e.11
                  :ARG1 (g / gene
                        :name (n / name :op1 "Snail"~e.8,23)
                        :ARG2-of (m / mutate-01)))
            :ARG1-of (a / add-02))
      :ARG1 (i / interest-01~e.15
            :ARG0~e.14 (w / we~e.14)
            :ARG2 (l / link-01~e.19
                  :ARG1~e.20 (b / between~e.3,20,22
                        :op1 (p4 / protein
                              :name (n2 / name :op1 "TGF-β2"~e.21))
                        :op2 (p3 / protein
                              :name (n3 / name :op1 "Snail"~e.23)))
                  :mod (p2 / possible~e.18)))
      :degree (f2 / further~e.12))

# ::tok Our functional studies demonstrate that without TGF-β2 , <i> Snail </i> expression is abolished in the mutant hair buds , and conversely , in <i> K14 @-@ Smad2 </i> skin , <i> Snail </i> is ectopically activated .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 0-1.1.1.r 1-1.1.2 2-1.1 3-1 5-1.3.1 5-1.3.1.r 6-1.3.2.1.1 9-1.2.1.1.1.1.1 11-1.2.1.1 13-1.2.1 14-1.2.1.2.r 16-1.2.1.2.1 17-1.2.1.2.2 18-1.2.1.2 20-1.2 25-1.2.2.3.1.1.1.1 27-1.2.2.3.1.1.1.1 29-1.2.2.3 32-1.2.2.1 36-1.2.2
# ::id pmid_1563_0473.209
# ::preferred 
(d / demonstrate-01~e.3
      :ARG0 (s / study-01~e.2
            :ARG0~e.0 (w / we~e.0)
            :mod (f / function-01~e.1))
      :ARG1 (a / and~e.20
            :op1 (a2 / abolish-01~e.13
                  :ARG1 (e / express-03~e.11
                        :ARG1 (g / gene
                              :name (n / name :op1 "Snail"~e.9)))
                  :location~e.14 (b / bud~e.18
                        :ARG1-of (m / mutate-01~e.16)
                        :mod (h / hair~e.17)))
            :op2 (a3 / activate-01~e.36
                  :ARG1 g~e.32
                  :manner (e2 / ectopical)
                  :location (s2 / skin~e.29
                        :ARG0-of (c2 / contain-01
                              :ARG1 (g2 / gene
                                    :name (n3 / name :op1 "K14-Smad2"~e.25,27))))
                  :ARG2-of (c / contrast-01
                        :ARG1 a2)))
      :condition (b2 / be-located-at-91
            :polarity~e.5 "-"~e.5
            :ARG1 (p / protein
                  :name (n2 / name :op1 "TGF-β2"~e.6))))

# ::tok Moreover , our in vitro studies indicate that even sustained TGF-β2 exposure may cause only a transient induction of Snail , offering a possible explanation as to why Snail is so briefly expressed during hair follicle morphogenesis .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1.1.1 2-1.1.1.1.r 3-1.1.1.2 4-1.1.1.2 5-1.1.1 6-1.1 7-1.1.2.r 8-1.1.2.1.1.3 9-1.1.2.1.1.2 10-1.1.2.1.1.1.1.1 11-1.1.2.1.1 12-1.1.2 13-1.1.2.1 14-1.1.2.1.2.3 16-1.1.2.1.2.2 17-1.1.2.1.2 18-1.1.2.1.2.1.r 19-1.1.2.1.2.1.1.1 21-1.1.3 23-1.1.3.1.2 24-1.1.3.1 25-1.1.3.1.1.1.1.3.r 26-1.1.3.1.1 26-1.1.3.1.1.1 26-1.1.3.1.1.1.r 27-1.1.3.1.1 27-1.1.3.1.1.1 27-1.1.3.1.1.1.r 28-1.1.2.1.2.1.1.1 29-1.1.2.1.r 30-1.1.3.1.1 30-1.1.3.1.1.1 30-1.1.3.1.1.1.1.2.1 30-1.1.3.1.1.1.r 31-1.1.3.1.1.1.1.2 31-1.1.3.1.1.1.1.2.r 32-1.1.3.1.1.1.1 33-1.1.3.1.1.1.1.3.r 34-1.1.3.1.1.1.1.3.1.1 35-1.1.3.1.1.1.1.3.1 36-1.1.3.1.1.1.1.3
# ::id pmid_1563_0473.210
# ::preferred 
(a / and
      :op2 (i / indicate-01~e.6
            :ARG0 (s / study-01~e.5
                  :ARG0~e.2 (w / we~e.2)
                  :manner (i2 / in-vitro~e.3,4))
            :ARG1~e.7 (p / possible~e.12
                  :domain~e.29 (c / cause-01~e.13
                        :ARG0 (e / expose-01~e.11
                              :ARG1 (p4 / protein
                                    :name (n / name :op1 "TGF-β2"~e.10))
                              :ARG1-of (s3 / sustain-01~e.9)
                              :mod (e2 / even~e.8))
                        :ARG1 (i3 / induce-01~e.17
                              :ARG1~e.18 (p2 / protein
                                    :name (n2 / name :op1 "Snail"~e.19,28))
                              :manner (t / transient~e.16)
                              :mod (o / only~e.14))))
            :ARG0-of (o2 / offer-01~e.21
                  :ARG1 (e3 / explain-01~e.24
                        :ARG1 (t2 / thing~e.26,27,30
                              :ARG0-of~e.26,27,30 (c2 / cause-01~e.26,27,30
                                    :ARG1 (e4 / express-03~e.32
                                          :ARG2 p2
                                          :manner~e.31 (b / brief~e.31
                                                :degree (s4 / so~e.30))
                                          :time~e.25,33 (m / morphogenesis~e.36
                                                :mod (f / follicle~e.35
                                                      :mod (h / hair~e.34))))))
                        :mod (p3 / possible~e.23)))))

# ::tok An additional point worth mentioning is that prolonged expression of Tg <i> Snail </i> in postnatal skin resulted in morphological and biochemical signs of epithelial to mesenchymal transitions ( unpublished data ) , underscoring why transient Snail expression may be so important during normal hair follicle morphogenesis [ @<xref ref-type="bibr" rid="pbio-0030011-b18"> 18 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1.1 3-1 4-1.1 5-1.1.r 7-1.2.1.1.3 8-1.2.1.1 12-1.2.1.1.1.1.1 14-1.2.1.1.2.r 15-1.2.1.1.2.1 16-1.2.1.1.2 17-1.2.1 18-1.2.1.2.r 19-1.2.1.2.1.2 20-1.2.1.2 21-1.2.1.2.2.2 22-1.2.1.2.1 22-1.2.1.2.2 23-1.2.1.2.1.1.r 24-1.2.1.2.1.1.1 27-1.2.1.2.1.1 29-1.2.1.3.1.1.1 30-1.2.1.3.1 33-1.2.1.4 34-1.2.1.4.1 34-1.2.1.4.1.1 34-1.2.1.4.1.1.r 35-1.2.1.4.1.1.1.1.2.2 36-1.2.1.4.1.1.1.1.2.1 37-1.2.1.4.1.1.1.1.2 38-1.2.1.4.1.1.1 39-1.2.1.4.1.1.1.1.2.r 39-1.2.1.4.1.1.1.1.r 40-1.2.1.4.1.1.1.1.1 41-1.2.1.4.1.1.1.1 42-1.2.1.4.1.1.1.1.3.r 43-1.2.1.4.1.1.1.1.3.1 44-1.2.1.4.1.1.1.1.3.2.1 45-1.2.1.4.1.1.1.1.3.2 46-1.2.1.4.1.1.1.1.3 51-1.2.1.4.2.1.1.1
# ::id pmid_1563_0473.211
# ::preferred 
(w / worth~e.3
      :domain~e.5 (m / mention-01~e.4
            :ARG1 (p / point~e.2
                  :ARG1-of (a / add-02)))
      :ARG0-of (m2 / mean-01
            :ARG1 (r / result-01~e.17
                  :ARG1 (e / express-03~e.8
                        :ARG1 (g / gene
                              :name (n / name :op1 "Snail"~e.12)
                              :mod (t4 / transgenic))
                        :ARG3~e.14 (s / skin~e.16
                              :mod (p3 / postnatal~e.15))
                        :ARG1-of (p2 / prolong-01~e.7))
                  :ARG2~e.18 (a2 / and~e.20
                        :op1 (s4 / signal-07~e.22
                              :ARG1~e.23 (t / transit-01~e.27
                                    :source (e2 / epithelium~e.24)
                                    :direction (m5 / mesenchyme))
                              :mod (m3 / morphological~e.19))
                        :op2 (s5 / signal-07~e.22
                              :ARG1 t
                              :mod (b / biochemical~e.21)))
                  :ARG1-of (d / describe-01
                        :ARG0 (d2 / data~e.30
                              :ARG1-of (p4 / publish-01 :polarity "-"~e.29)))
                  :ARG0-of (u / underscore-01~e.33
                        :ARG1 (t3 / thing~e.34
                              :ARG0-of~e.34 (c2 / cause-01~e.34
                                    :ARG1 (p5 / possible~e.38
                                          :domain~e.39 (i / important~e.41
                                                :degree (s3 / so~e.40)
                                                :domain~e.39 (e3 / express-03~e.37
                                                      :ARG1 g~e.36
                                                      :mod (t2 / transient~e.35))
                                                :time~e.42 (m6 / morphogenesis~e.46
                                                      :mod (n2 / normal~e.43)
                                                      :mod (f / follicle~e.45
                                                            :mod (h / hair~e.44)))))))
                        :ARG1-of (d3 / describe-01
                              :ARG0 (p6 / publication
                                    :ARG1-of (c / cite-01 :ARG2 "18"~e.51)))))))

# ::tok At first glance , the sparsity in hair coat of K14 @- @<i> Snail </i> Tg mice seemed indicative of a defect in follicle formation ( see <xref ref-type="fig" rid="pbio-0030011-g002"> Figure 2 </xref>@ A ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.2.1 1-1.2.1.1 1-1.2.1.1.r 2-1.2 5-1.1.1 6-1.1.1.1.r 7-1.1.1.1.1 8-1.1.1.1 9-1.1.1.1.2.r 10-1.1.1.1.2.1.1.1.1 13-1.1.1.1.2.1.2.1.1 16-1.1.1.1.2 17-1 21-1.1.2 22-1.1.2.1.r 23-1.1.2.1.1 24-1.1.2.1 26-1.3 30-1.3.1
# ::id pmid_1563_0473.212
# ::preferred 
(s / seem-01~e.17
      :ARG1 (i / indicate-01
            :ARG0 (s2 / sparse~e.5
                  :domain~e.6 (c / coat~e.8
                        :mod (h / hair~e.7)
                        :part-of~e.9 (m / mouse~e.16
                              :mod (m2 / macro-molecular-complex
                                    :part (p / protein
                                          :name (n / name :op1 "K14"~e.10))
                                    :part (p2 / protein
                                          :name (n2 / name :op1 "Snail"~e.13)))
                              :mod (t / transgenic))))
            :ARG1 (d / defect-01~e.21
                  :ARG1~e.22 (f / form-01~e.24
                        :ARG1 (f2 / follicle~e.23))))
      :time (g / glance-01~e.2
            :mod (o / ordinal-entity~e.1 :value~e.1 "1"~e.1))
      :ARG1-of (s3 / see-01~e.26
            :ARG2 (f3 / figure~e.30 :mod "2A")))

# ::tok Closer inspection , however , revealed that not all hairs penetrated the hyperthickened Tg epidermis .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 0-1.1.1.1.1 0-1.1.1.1.1.r 1-1.1.1 3-1 5-1.1 6-1.1.2.r 7-1.1.2.1 7-1.1.2.1.r 8-1.1.2.2.1 9-1.1.2.2 10-1.1.2 14-1.1.2.3
# ::id pmid_1563_0473.213
# ::preferred 
(h3 / have-concession-91~e.3
      :ARG1 (r / reveal-01~e.5
            :ARG0 (i / inspect-01~e.1
                  :ARG1-of (c / close-10~e.0
                        :degree~e.0 (m / more~e.0)))
            :ARG1~e.6 (p / penetrate-01~e.10
                  :polarity~e.7 "-"~e.7
                  :ARG0 (h / hair~e.9
                        :mod (a / all~e.8))
                  :ARG1 (e / epidermis~e.14
                        :mod (t / transgenic)
                        :ARG1-of (t2 / thicken-01
                              :degree (h2 / hyper))))))

# ::tok Several factors may contribute to the seemingly normal follicle development in these mice .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 1-1.1.1 2-1 3-1.1 4-1.1.2.r 6-1.1.2.1.1.1 7-1.1.2.1.1 8-1.1.2.1 9-1.1.2 10-1.1.2.2.r 11-1.1.2.2.1 12-1.1.2.2
# ::id pmid_1563_0473.214
# ::preferred 
(p / possible~e.2
      :domain (c / contribute-01~e.3
            :ARG0 (f / factor~e.1
                  :quant (s / several~e.0))
            :ARG2~e.4 (d2 / develop-02~e.9
                  :ARG1 (f2 / follicle~e.8
                        :mod (n / normal~e.7
                              :ARG1-of (s2 / seem-01~e.6)))
                  :location~e.10 (m / mouse~e.12
                        :mod (t / this~e.11)))))

# ::tok One obvious factor is the K14 promoter , which is elevated in the basal layer of the epidermis and the outer root sheath ( ORS ) of the hair follicle , but is markedly down @-@ regulated in developing embryonic hair buds as well as in the postnatal hair progenitor cells .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1.3 2-1.1 3-1.1.2.r 5-1.1.2.1.1.1.1 9-1.1.2.r 10-1.1.4 11-1.1.4.1.r 13-1.1.4.1.1.1 14-1.1.4.1.1 15-1.1.4.1.1.2.r 17-1.1.4.1.1.2 18-1.1.4.1 20-1.1.4.1.2.2 21-1.1.4.1.2.1 22-1.1.4.1.2 24-1.1.4.1.2.3.1.1 26-1.1.4.1.2.4.r 28-1.1.4.1.2.4.1 29-1.1.4.1.2.4 31-1 33-1.2.2 33-1.2.2.r 38-1.2.3.1.2 40-1.2.3.1.1 41-1.2.3.1 42-1.2.3.2.3.r 44-1.2.3.2.3.r 47-1.2.3.2.3 48-1.2.3.2.2 49-1.2.3.2.1 50-1.2.3.2
# ::id pmid_1563_0473.215
# ::preferred 
(c / contrast-01~e.31
      :ARG1 (f / factor~e.2
            :quant "1"~e.0
            :domain~e.3,9 (m3 / molecular-physical-entity
                  :ARG0-of (p / promote-01
                        :ARG1 (p2 / protein
                              :name (n / name :op1 "K14"~e.5))))
            :ARG1-of (o / obvious-01~e.1)
            :ARG1-of (e / elevate-01~e.10
                  :location~e.11 (a / and~e.18
                        :op1 (l / layer~e.14
                              :mod (b / basal~e.13)
                              :part-of~e.15 (e2 / epidermis~e.17))
                        :op2 (s / sheath~e.22
                              :part-of (r / root~e.21)
                              :mod (o2 / outer~e.20)
                              :ARG1-of (m / mean-01
                                    :ARG2 (n2 / name :op1 "ORS"~e.24))
                              :part-of~e.26 (f2 / follicle~e.29
                                    :mod (h / hair~e.28))))))
      :ARG2 (d / downregulate-01
            :ARG1 f
            :manner~e.33 (m2 / marked~e.33)
            :location (a2 / and
                  :op1 (b2 / bud~e.41
                        :mod (h2 / hair~e.40)
                        :ARG1-of (d2 / develop-02~e.38)
                        :mod (e3 / embryo))
                  :op2 (c2 / cell~e.50
                        :mod (p3 / progenitor~e.49)
                        :part-of (h3 / hair~e.48)
                        :time~e.42,44 (p4 / postnatal~e.47)))))

# ::tok The K14 promoter is also less active in the ORS than epidermis and hence this might also account for the lack of apparent response of the ORS to ectopic Snail .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.2.1.1 3-1.2.1.r 4-1.2.1.3 5-1.1.2 9-1.1.3 10-1.1.2.1.r 11-1.1.2.1 13-1 15-1.2 16-1.2.1.3 17-1.2.1 18-1.2.1.2.r 20-1.2.1.2 21-1.2.1.2.1.r 22-1.2.1.2.1.3 23-1.2.1.2.1 24-1.2.1.2.1.1.r 26-1.2.1.2.1.1 27-1 27-1.2.1.2.1.2.r 28-1.2.1.2.1.2.2 29-1.2.1.2.1.2.1.1
# ::id pmid_1563_0473.216
# ::preferred 
(c / cause-01~e.13,27
      :ARG0 (a / activate-01
            :ARG1 (m / molecular-physical-entity
                  :ARG0-of (p / promote-01
                        :ARG1 (p2 / protein
                              :name (n / name :op1 "K14"))))
            :degree (l / less~e.5
                  :compared-to~e.10 (e / epidermis~e.11))
            :location (o / ORS~e.9))
      :ARG1 (p4 / possible~e.15
            :domain~e.3 (a2 / account-01~e.17
                  :ARG0 a~e.1
                  :ARG1~e.18 (l2 / lack-01~e.20
                        :ARG1~e.21 (r / respond-01~e.23
                              :ARG0~e.24 o~e.26
                              :ARG1~e.27 (p5 / protein
                                    :name (n3 / name :op1 "Snail"~e.29)
                                    :mod (e2 / ectopic~e.28))
                              :mod (a4 / apparent~e.22)))
                  :mod (a3 / also~e.4,16))))

# ::tok Additional contributing factors could be the multiplicity of Snail family members and their differential expression , the saturation , and @/@ or diversity of regulatory mechanisms that govern AJ formation , migration , and proliferation in the follicle ORS .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.3 2-1.1 3-1 4-1.1.1.r 4-1.1.r 8-1.1.1.1.1.1.1.1.1.1 9-1.1.1.1.1.1.1 10-1.1.1.1.1.1 11-1.1.1.1.1 12-1.1.1.2.1 12-1.1.1.2.1.r 13-1.1.1.2.2 14-1.1.1.2 17-1.1.1.3.1 19-1.1.1.3 21-1.1.1.3 22-1.1.1.3.2 23-1.1.1.3.2.1.r 24-1.1.1.3.2.1.1 25-1.1.1.3.2.1 27-1.1.1.3.2.1.2 28-1.1.1.3.2.1.2.1.1.1.1.1 29-1.1.1.3.2.1.2.1.1 31-1.1.1.3.2.1.2.1.2 33-1.1.1.3.2.1.2.1 34-1.1.1.3.2.1.2.1.3 35-1.1.1.3.2.1.2.1.3.2.r 37-1.1.1.3.2.1.2.1.3.2 38-1.1.1.3.2.1.2.1.3.2.1.1
# ::id pmid_1563_0473.217
# ::preferred 
(p / possible~e.3
      :domain~e.4 (f / factor~e.2
            :domain~e.4 (a / and
                  :op1 (m / multiply-01
                        :ARG1 (a3 / and~e.11
                              :op1 (m2 / member~e.10
                                    :part-of (f2 / family~e.9
                                          :mod (p2 / protein
                                                :name (n / name :op1 "Snail"~e.8))))))
                  :op2 (e / express-03~e.14
                        :ARG1~e.12 m2~e.12
                        :ARG1-of (d2 / differ-02~e.13))
                  :op3 (a5 / and-or~e.19,21
                        :op1 (s / saturate-00~e.17
                              :ARG1 (m3 / mechanism~e.25
                                    :ARG0-of (r / regulate-01~e.24)
                                    :ARG0-of (g / govern-01~e.27
                                          :ARG1 (a4 / and~e.33
                                                :op1 (f3 / form-01~e.29
                                                      :ARG1 (p4 / protein
                                                            :name (n2 / name :op1 "AJ"~e.28)))
                                                :op2 (m4 / migrate-01~e.31
                                                      :ARG0 p4)
                                                :op3 (p3 / proliferate-01~e.34
                                                      :ARG0 p4
                                                      :location~e.35 (f4 / follicle~e.37
                                                            :name (n3 / name :op1 "ORS"~e.38)))))))
                        :op2 (d / diversity~e.22
                              :domain~e.23 m3)))
            :ARG1-of (a2 / add-02)
            :ARG0-of (c / contribute-01~e.1)))

# ::tok Distinguishing between these possibilities must await the generation of mice harboring skin @-@ specific loss @-@ of @-@ function <i> Snail </i> mutations .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 2-1.1.1.1.2 3-1.1.1.1.1 4-1 5-1.1 7-1.1.2 8-1.1.2.1.r 9-1.1.2.1 10-1.1.2.1.1 11-1.1.2.1.1.1.3.1 13-1.1.2.1.1.1.3 14-1.1.2.1.1.1.2 18-1.1.2.1.1.1.2.1 20-1.1.2.1.1.1.1.1.1 22-1.1.2.1.1.1
# ::id pmid_1563_0473.218
# ::preferred 
(o2 / obligate-01~e.4
      :ARG2 (a / await-01~e.5
            :ARG1 (d / distinguish-01~e.0
                  :ARG1 (t / thing
                        :mod (p / possible~e.3)
                        :mod (t2 / this~e.2)))
            :ARG2 (g / generation~e.7
                  :mod~e.8 (m / mouse~e.9
                        :ARG0-of (h / harbor-01~e.10
                              :ARG1 (m3 / mutate-01~e.22
                                    :ARG1 (p2 / protein
                                          :name (n / name :op1 "Snail"~e.20))
                                    :ARG0-of (l / lose-02~e.14
                                          :ARG1 (f / function~e.18))
                                    :mod (s2 / specific~e.13
                                          :topic (s / skin~e.11))))))))

# ::tok Links between Signaling , Transcriptional Cascades , Epithelial Remodeling , and Proliferation in the Hair Bud
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.1.r 2-1.1.1 5-1.1.2 7-1.1.3.1 8-1.1.3 10-1.1 11-1.1.4 14-1.1.5.1 15-1.1.5
# ::id pmid_1563_0473.219
# ::preferred 
(l / link-01~e.0
      :ARG1~e.1 (a / and~e.10
            :op1 (s / signal-07~e.2)
            :op2 (c / cascade~e.5
                  :ARG1-of (t / transcribe-01))
            :op3 (r / remodel-01~e.8
                  :ARG1 (e / epithelium~e.7))
            :op4 (p / proliferate-01~e.11)
            :location (b / bud~e.15
                  :mod (h / hair~e.14))))

# ::tok Previously , we discovered that early during hair follicle morphogenesis , <i> E @-@ cadherin </i> gene expression is down @-@ regulated concomitantly with the invagination of developing bud cells into the skin [ @<xref ref-type="bibr" rid="pbio-0030011-b04"> 4 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3 2-1.1 3-1 5-1.2.3 6-1.2.3.r 7-1.2.3.1.1.1 8-1.2.3.1.1 9-1.2.3.1 12-1.2.1.1.1.1 14-1.2.1.1.1.1 16-1.2.1.1 17-1.2.1 22-1.2.4 22-1.2.4.r 25-1.2.2 26-1.2.2.1.r 27-1.2.2.1.2 28-1.2.2.1.1 29-1.2.2.1 30-1.2.2.2.r 32-1.2.2.2 37-1.4.1.1.1
# ::id pmid_1563_0473.220
# ::preferred 
(d / discover-01~e.3
      :ARG0 (w / we~e.2)
      :ARG1 (d2 / downregulate-01
            :ARG1 (e / express-03~e.17
                  :ARG2 (g / gene~e.16
                        :name (n / name :op1 "E-cadherin"~e.12,14)))
            :time (i / invaginate-00~e.25
                  :ARG1~e.26 (c / cell~e.29
                        :part-of (b / bud~e.28)
                        :ARG1-of (d3 / develop-02~e.27))
                  :location~e.30 (s / skin~e.32))
            :time~e.6 (e2 / early~e.5
                  :op1 (m / morphogenesis~e.9
                        :mod (f / follicle~e.8
                              :mod (h / hair~e.7))))
            :manner~e.22 (c3 / concomitant~e.22))
      :time (p / previous~e.0)
      :ARG1-of (d4 / describe-01
            :ARG0 (p2 / publication
                  :ARG1-of (c2 / cite-01 :ARG2 "4"~e.37))))

# ::tok Because the timing of this event correlated with the activation of a LEF @-@ 1/β-catenin transcription factor complex [ @<xref ref-type="bibr" rid="pbio-0030011-b20"> 20 </xref>@ ], we were intrigued by the presence of a putative LEF @-@ 1/TCF binding site in the <i> E @-@ cadherin </i> promoter .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 2-1.1.1 3-1.1.1.1.r 4-1.1.1.1.1 5-1.1.1.1 6-1.1 7-1.1.2.r 9-1.1.2 12-1.1.2.1.1 15-1.1.2.1.3.1 16-1.1.2.1.3 17-1.1.2.1 17-1.2.1.2.1 22-1.1.2.2.1.1.1 25-1.2.2 26-1.2.1.1 27-1.2 31-1.2.1.r 33-1.2.1.3 34-1.2.1.2.1.1.1.1 37-1.2.1.2 38-1.2.1 42-1.2.1.1.1.1.1.1.1 44-1.2.1.1.1.1.1.1.1
# ::id pmid_1563_0473.221
# ::preferred 
(c / cause-01~e.0
      :ARG0 (c2 / correlate-01~e.6
            :ARG1 (t2 / time-02~e.2
                  :ARG1~e.3 (e / event~e.5
                        :mod (t3 / this~e.4)))
            :ARG2~e.7 (a / activate-01~e.9
                  :ARG1 (m2 / macro-molecular-complex~e.17
                        :part g~e.12
                        :part (p5 / protein
                              :name (n4 / name :op1 "β-catenin"))
                        :mod (f / factor~e.16
                              :ARG0-of (t4 / transcribe-01~e.15)))
                  :ARG1-of (d / describe-01
                        :ARG0 (p6 / publication
                              :ARG1-of (c3 / cite-01 :ARG2 "20"~e.22)))))
      :ARG1 (i / intrigue-01~e.27
            :ARG0~e.31 (p3 / protein-segment~e.38
                  :ARG1-of (b / be-located-at-91~e.26
                        :ARG2 (m4 / molecular-physical-entity
                              :ARG0-of (p / promote-01
                                    :ARG1 (p2 / protein
                                          :name (n / name :op1 "E-cadherin"~e.42,44)))))
                  :ARG1-of (b2 / bind-01~e.37
                        :ARG2 (m / macro-molecular-complex~e.17
                              :part (g / gene
                                    :name (n2 / name :op1 "LEF-1"~e.34))
                              :part (m3 / molecular-physical-entity
                                    :name (n3 / name :op1 "TCF"))))
                  :ARG2-of (t5 / think-01~e.33))
            :ARG1 (w / we~e.25)))

# ::tok This prompted an investigation that subsequently led to our discovery that LEF @-@ 1/β-catenin can contribute to repression of <i> E @-@ cadherin </i> gene expression in skin keratinocytes [ @<xref ref-type="bibr" rid="pbio-0030011-b04"> 4 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1 3-1.2 5-1.2.1.2 5-1.2.1.2.r 6-1.2.1 7-1.2.1.1.r 8-1.2.1.1.1 8-1.2.1.1.1.r 9-1.2.1.1 10-1.2.1.1.2.r 11-1.2.1.1.2.1.1.1.1.1 14-1.2.1.1.2 15-1.2.1.1.2.1 16-1.2.1.1.2.1.2.r 17-1.2.1.1.2.1.2 20-1.2.1.1.2.1.2.2.1.1.1 22-1.2.1.1.2.1.2.2.1.1.1 24-1.2.1.1.2.1.1.1 24-1.2.1.1.2.1.2.2.1 25-1.2.1.1.2.1.2.2 27-1.2.1.1.2.1.2.2.2.1 33-1.3.1.1.1
# ::id pmid_1563_0473.222
# ::preferred 
(p / prompt-01~e.1
      :ARG0 (t / this~e.0)
      :ARG1 (i / investigate-01~e.3
            :ARG0-of (l / lead-03~e.6
                  :ARG2~e.7 (d / discover-01~e.9
                        :ARG0~e.8 (w / we~e.8)
                        :ARG1~e.10 (p5 / possible~e.14
                              :domain (c / contribute-01~e.15
                                    :ARG0 (m / macro-molecular-complex
                                          :part (g / gene~e.24
                                                :name (n / name :op1 "LEF-1"~e.11))
                                          :part (p2 / protein
                                                :name (n2 / name :op1 "β-catenin")))
                                    :ARG2~e.16 (r / repress-01~e.17
                                          :ARG0 m
                                          :ARG1 (e / express-03~e.25
                                                :ARG1 (g2 / gene~e.24
                                                      :name (n3 / name :op1 "E-cadherin"~e.20,22))
                                                :ARG3 (k / keratinocyte
                                                      :part-of (s2 / skin~e.27)))))))
                  :time~e.5 (s / subsequent~e.5)))
      :ARG1-of (d2 / describe-01
            :ARG0 (p4 / publication
                  :ARG1-of (c2 / cite-01 :ARG2 "4"~e.33))))

# ::tok In the course of these studies , we also noted that Snail can also contribute to this process in keratinocytes in vitro , and our present studies revealed that Snail is expressed at the right place and time to be physiologically relevant in the process .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2.1.5 4-1.1.3.1 5-1.1.3 7-1.1.1 8-1.1.4 9-1.1 11-1.1.2.1.1.1.1 12-1.1.2 13-1.1.2.1.3 14-1.1.2.1 15-1.1.2.1.2.r 16-1.1.2.1.2.1 17-1.1.2.1.2 18-1.1.2.1.5 20-1.1.2.1.5 21-1.1.2.1.5 24-1.2.1.1 24-1.2.1.1.r 25-1.2.1.2 26-1.2.1 27-1.2 28-1.2.2.r 29-1.2.2.1 30-1.1.2.1.r 31-1.2.2 34-1.2.2.2.1 34-1.2.2.4 35-1.2.2.2 37-1.2.2.4.r 41-1.2.2.3 42-1.1.2.1.5 44-1.1.2.1.2
# ::id pmid_1563_0473.223
# ::preferred 
(a / and
      :op1 (n / note-01~e.9
            :ARG0 (w / we~e.7)
            :ARG1 (p / possible~e.12
                  :domain~e.30 (c / contribute-01~e.14
                        :ARG0 (p2 / protein
                              :name (n2 / name :op1 "Snail"~e.11))
                        :ARG2~e.15 (p3 / process~e.17,44
                              :mod t~e.16)
                        :mod (a2 / also~e.13)
                        :location (k / keratinocyte)
                        :manner (i / in-vitro~e.0,18,20,21,42)))
            :time (s / study-01~e.5
                  :mod (t / this~e.4))
            :mod (a3 / also~e.8))
      :op2 (r / reveal-01~e.27
            :ARG0 (s2 / study-01~e.26
                  :ARG0~e.24 w~e.24
                  :time (p4 / present~e.25))
            :ARG1~e.28 (e / express-03~e.31
                  :ARG2 p2~e.29
                  :ARG3 (p5 / place~e.35
                        :ARG1-of (r2 / right-06~e.34))
                  :purpose (r3 / relevant-01~e.41
                        :ARG1 p2
                        :ARG2 p3
                        :manner (p6 / physiological))
                  :time~e.37 (r4 / right-03~e.34))))

# ::tok In <i> noggin </i>@ -@ null embryonic skin , LEF @-@ 1 expression and subsequent activation of the LEF @-@ 1/β-catenin reporter gene is abrogated in the developing placodes .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.3.2.1.1 5-1.3.2.2 7-1.3 9-1.1.1.1.1.1 11-1.1.1.1.1.1 12-1.1.1 13-1.1 14-1.1.2.2 14-1.1.2.2.r 15-1.1.2 16-1.1.2.1.r 18-1.1.2.1.1.1.1 21-1.1.2.1.1 22-1.1.2.1 24-1 27-1.2.1
# ::id pmid_1563_0473.224
# ::preferred 
(a4 / abrogate-01~e.24
      :ARG1 (a2 / and~e.13
            :op1 (e / express-03~e.12
                  :ARG2 (g / gene
                        :name (n3 / name :op1 "LEF-1"~e.9,11)))
            :op2 (a3 / activate-01~e.15
                  :ARG1~e.16 (g2 / gene~e.22
                        :ARG0-of (r / report-01~e.21
                              :ARG1 (m / macro-molecular-complex
                                    :part g~e.18
                                    :part (p / protein
                                          :name (n4 / name :op1 "β-catenin")))))
                  :time~e.14 (s2 / subsequent~e.14)))
      :location (p2 / placode
            :ARG1-of (d / develop-02~e.27))
      :location (s / skin~e.7
            :mod (e2 / embryo)
            :mod (p3 / protein
                  :name (n / name :op1 "noggin"~e.2)
                  :mod (n2 / null~e.5))))

# ::tok The corresponding failure of <i> E @-@ cadherin </i> down @-@ regulation underscores the importance of Wnt @/@ noggin signaling in regulating this event in follicle morphogenesis [ @<xref ref-type="bibr" rid="pbio-0030011-b04"> 4 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.2 2-1.1 5-1.1.1.1.1.1 7-1.1.1.1.1.1 11-1.2.2 12-1 14-1.2 15-1.2.1.r 16-1.2.1.1.2.1.1 18-1.2.1.1.1.1.1 19-1.2.1 21-1.2.2 22-1.2.2.1.1 23-1.2.2.1 24-1.2.2.2.r 25-1.2.2.2.1 26-1.2.2.2 31-1.3.1.1.1
# ::id pmid_1563_0473.225
# ::preferred 
(u2 / underscore-01~e.12
      :ARG0 (f / fail-01~e.2
            :ARG1 (d / downregulate-01
                  :ARG1 (p / protein
                        :name (n / name :op1 "E-cadherin"~e.5,7)))
            :ARG1-of (c2 / correspond-02~e.1))
      :ARG1 (i / important~e.14
            :domain~e.15 (s / signal-07~e.19
                  :ARG0 (s2 / slash
                        :op1 (p4 / protein
                              :name (n5 / name :op1 "noggin"~e.18))
                        :op2 (p2 / pathway
                              :name (n2 / name :op1 "Wnt"~e.16))))
            :purpose (r / regulate-01~e.11,21
                  :ARG1 (e / event~e.23
                        :mod (t / this~e.22))
                  :location~e.24 (m / morphogenesis~e.26
                        :mod (f2 / follicle~e.25))))
      :ARG1-of (d2 / describe-01
            :ARG0 (p3 / publication
                  :ARG1-of (c3 / cite-01 :ARG2 "4"~e.31))))

# ::tok Conditional gene targeting studies will be necessary to establish whether Snail family members also contribute to the down @-@ regulation in <i> E @-@ cadherin </i> gene expression that occurs during follicle formation .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.2 1-1.1.1.1 2-1.1.1 3-1.1 6-1 8-1.2 9-1.2.1.1 9-1.2.1.1.r 10-1.2.1.2.1.1.1 11-1.2.1.2.1 12-1.2.1.2 13-1.2.1.4 14-1.2.1 22-1.2.1.3.1.1.1.1 24-1.2.1.3.1.1.1.1 26-1.2.1.3.1.1 27-1.2.1.3.1 30-1.2.1.3.1.2.r 31-1.2.1.3.1.2.1 32-1.2.1.3.1.2
# ::id pmid_1563_0473.226
# ::preferred 
(n / need-01~e.6
      :ARG1 (s / study-01~e.3
            :ARG1 (t / target-01~e.2
                  :ARG1 (g / gene~e.1)
                  :mod (c / conditional~e.0)))
      :purpose (e / establish-01~e.8
            :ARG1 (c2 / contribute-01~e.14
                  :mode~e.9 "interrogative"~e.9
                  :ARG0 (m / member~e.12
                        :part-of (f / family~e.11
                              :name (n2 / name :op1 "Snail"~e.10)))
                  :ARG2 (d / downregulate-01
                        :ARG1 (e2 / express-03~e.27
                              :ARG2 (g2 / gene~e.26
                                    :name (n3 / name :op1 "E-cadherin"~e.22,24))
                              :time~e.30 (f2 / form-01~e.32
                                    :ARG1 (f3 / follicle~e.31))))
                  :mod (a / also~e.13))))

# ::tok However , it is intriguing that <i> K14 @-@ Snail </i> Tg epidermis displayed a marked down @-@ regulation in E @-@ cadherin expression , thereby demonstrating its potential to do so in skin .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 4-1.1.1.3 7-1.1.1.1.1.1.1.1 9-1.1.1.1.1.2.1.1 12-1.1.1.1 13-1.1.1 15-1.1.1.2.2 20-1.1.1.2.1.1.1.1 22-1.1.1.2.1.1.1.1 23-1.1.1.2.1 26-1.1.2 28-1.1.2.2 29-1.1 31-1.1 32-1.1.2.2.2.r 33-1.1.2.2.2
# ::id pmid_1563_0473.227
# ::preferred 
(h / have-concession-91~e.0
      :ARG1 (c2 / cause-01~e.29,31
            :ARG0 (d2 / display-01~e.13
                  :ARG0 (e / epidermis~e.12
                        :mod (m / macro-molecular-complex
                              :part (p / protein
                                    :name (n / name :op1 "K14"~e.7))
                              :part (p2 / protein
                                    :name (n2 / name :op1 "Snail"~e.9)))
                        :mod (t / transgenic))
                  :ARG1 (d3 / downregulate-01
                        :ARG1 (e2 / express-03~e.23
                              :ARG2 (p3 / protein
                                    :name (n3 / name :op1 "E-cadherin"~e.20,22)))
                        :ARG1-of (m2 / mark-01~e.15))
                  :ARG0-of (i / intrigue-01~e.4))
            :ARG1 (d / demonstrate-01~e.26
                  :ARG0 e
                  :ARG1 (p4 / potential~e.28
                        :topic d3
                        :location~e.32 (s / skin~e.33)))))

# ::tok Our prior findings showed that by elevating E @-@ cadherin levels or by conditionally ablating <i> α-catenin , </i> hair follicle morphogenesis can be impaired [ @<xref ref-type="bibr" rid="pbio-0030011-b04"> 4 </xref> , <xref ref-type="bibr" rid="pbio-0030011-b07"> 7 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 0-1.1.1.1.r 1-1.3 2-1.1 2-1.1.1 2-1.1.1.r 3-1 3-1.2.1.1.3 5-1.2.r 6-1.2.1.1.1 7-1.2.1.1.1.1.1.1.1 9-1.2.1.1.1.1.1.1.1 10-1.2.1.1.1.1 11-1.2.1.1 13-1.2.1.1.2.2 13-1.2.1.1.2.2.r 14-1.2.1.1.2 16-1.2.1.1.2.1.1.1 19-1.2.1.2.1.1 20-1.2.1.2.1 21-1.2.1.2 22-1.2 23-1.2.1.r 24-1.2.1 29-1.4.1.1.1.1 35-1.4.1.2.1.1
# ::id pmid_1563_0473.228
# ::preferred 
(s2 / show-01~e.3
      :ARG0 (t / thing~e.2
            :ARG1-of~e.2 (f2 / find-01~e.2
                  :ARG0~e.0 (w / we~e.0)))
      :ARG1~e.5 (p7 / possible~e.22
            :domain~e.23 (i / impair-01~e.24
                  :ARG0 (o / or~e.11
                        :op1 (e / elevate-01~e.6
                              :ARG1 (l / level~e.10
                                    :quant-of (p3 / protein
                                          :name (n / name :op1 "E-cadherin"~e.7,9))))
                        :op2 (a / ablate-00~e.14
                              :ARG1 (p4 / protein
                                    :name (n2 / name :op1 "α-catenin"~e.16))
                              :manner~e.13 (c / conditional~e.13))
                        :ARG1-of (s / show-01~e.3))
                  :ARG1 (m / morphogenesis~e.21
                        :mod (f / follicle~e.20
                              :mod (h / hair~e.19)))))
      :time (p2 / prior~e.1)
      :ARG1-of (d / describe-01
            :ARG0 (a2 / and
                  :op1 (p5 / publication
                        :ARG1-of (c2 / cite-01 :ARG2 "4"~e.29))
                  :op2 (p6 / publication
                        :ARG1-of (c3 / cite-01 :ARG2 "7"~e.35)))))

# ::tok The marked epidermal hyperproliferation seen in the <i> K14 @-@ Snail </i> Tg skin , coupled with the converse suppression of proliferation and Snail in <i> TGF-β2 </i>@ -@ null hair buds led us to wonder whether the down @-@ regulation of E @-@ cadherin during follicle morphogenesis might have a direct impact on elevating the proliferative state of these cells .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.2 4-1.1.3 8-1.1.3.1.2.1.1.1 10-1.1.3.1.2.2.1.1 13-1.1.3.1 15-1.1.4 16-1.1.4.1.r 18-1.1.4.1.1.2 19-1.1.4.1.1 21-1.1.4.1.1.1 21-1.3.2.1.3.2 22-1.1.4.1 23-1.1.4.1.2 26-1.1.4.1.3.1.2.1.1 29-1.1.4.1.3.1.2.2 30-1.1.4.1.3.1.1 31-1.1.4.1.3.1 32-1 33-1.2 35-1.3 36-1.3.2.1.1 36-1.3.2.1.1.r 42-1.3.2.1.2.1.1.1 44-1.3.2.1.2.1.1.1 45-1.3.2.1.2.2.r 46-1.3.2.1.2.2.1 47-1.3.2.1.2.2 48-1.3.2 49-1.3.2.1 51-1.3.2.1.4 52-1.3.2.1 53-1.3.2.1.3.r 54-1.3.2.1.3 58-1.3.2.1.3.2.1.r 59-1.3.2.1.3.2.1.1 60-1.3.2.1.3.2.1
# ::id pmid_1563_0473.229
# ::preferred 
(l / lead-03~e.32
      :ARG0 (h / hyperproliferate-00
            :ARG1 (e / epidermis)
            :ARG1-of (m / mark-01~e.1)
            :ARG1-of (s / see-01~e.4
                  :location (s2 / skin~e.13
                        :mod (t / transgenic)
                        :mod (m2 / macro-molecular-complex
                              :part (p / protein
                                    :name (n / name :op1 "K14"~e.8))
                              :part (p2 / protein
                                    :name (n2 / name :op1 "Snail"~e.10)))))
            :ARG1-of (c / couple-01~e.15
                  :ARG2~e.16 (a / and~e.22
                        :op1 (s3 / suppress-01~e.19
                              :ARG1 (p3 / proliferate-01~e.21)
                              :mod (c2 / converse~e.18))
                        :op2 p2~e.23
                        :ARG1-of (b / be-located-at-91
                              :ARG2 (b2 / bud~e.31
                                    :mod (h2 / hair~e.30)
                                    :mod (p7 / protein
                                          :name (n4 / name :op1 "TGF-β2"~e.26)
                                          :mod (n5 / null~e.29)))))))
      :ARG1 (w / we~e.33)
      :ARG2 (w2 / wonder-01~e.35
            :ARG0 w
            :ARG1 (p6 / possible~e.48
                  :domain (i / impact-01~e.49,52
                        :mode~e.36 "interrogative"~e.36
                        :ARG0 (d2 / downregulate-01
                              :ARG1 (p4 / protein
                                    :name (n3 / name :op1 "E-cadherin"~e.42,44))
                              :time~e.45 (m3 / morphogenesis~e.47
                                    :mod (f / follicle~e.46)))
                        :ARG1~e.53 (e2 / elevate-01~e.54
                              :ARG0 d2
                              :ARG1 (p5 / proliferate-01~e.21
                                    :ARG0~e.58 (c3 / cell~e.60
                                          :mod (t2 / this~e.59))))
                        :mod (d / direct~e.51)))))

# ::tok Our Tg studies suggested that , at least in part through its regulation of <i> E @-@ cadherin </i> , Snail is able to influence the subcellular localization of a variety of AJ @-@ associated proteins .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 0-1.1.1.r 2-1.1 3-1 6-1.2.1.4.1 7-1.2.1.4.1 9-1.2.1.4 11-1.2.1.3.1.1 11-1.2.1.3.1.1.r 12-1.2.1.3.1 15-1.2.1.3.1.2.1.1 17-1.2.1.3.1.2.1.1 20-1.2.1.1.1.1 21-1.2.1.r 22-1.2 23-1.2.1.3 24-1.2.1 26-1.2.1.2.2 27-1.2.1.2 28-1.2.1.2.1.r 30-1.2.1.2.1.2 32-1.2.1.2.1.1.1.1.1 34-1.2.1.2.1.1 35-1.2.1.2.1
# ::id pmid_1563_0473.230
# ::preferred 
(s / suggest-01~e.3
      :ARG0 (s2 / study-01~e.2
            :ARG0~e.0 (w / we~e.0)
            :ARG1 (t / transgenic))
      :ARG1 (p2 / possible~e.22
            :domain~e.21 (i / influence-01~e.24
                  :ARG0 (p3 / protein
                        :name (n / name :op1 "Snail"~e.20))
                  :ARG1 (l / localize-01~e.27
                        :ARG1~e.28 (p / protein~e.35
                              :ARG1-of (a / associate-01~e.34
                                    :ARG2 (p6 / protein
                                          :name (n3 / name :op1 "AJ"~e.32)))
                              :mod (v2 / variety~e.30))
                        :mod (s3 / subcellular~e.26))
                  :ARG1-of (c / cause-01~e.23
                        :ARG0 (r / regulate-01~e.12
                              :ARG0~e.11 p3~e.11
                              :ARG1 (p5 / protein
                                    :name (n2 / name :op1 "E-cadherin"~e.15,17))))
                  :degree (p4 / part~e.9
                        :mod (a2 / at-least~e.6,7)))))

# ::tok One of these appears to be Ajuba , which was previously shown to have the dual capacity to bind Grb @-@ 2 as well as α-catenin [ @<xref ref-type="bibr" rid="pbio-0030011-b09"> 9 </xref> , <xref ref-type="bibr" rid="pbio-0030011-b10"> 10 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 2-1.1.3.1 3-1 6-1.1.2.1 10-1.1.4.2 11-1.1.4.3 15-1.1.4.4 16-1.1 16-1.1.4 16-1.1.4.r 18-1.1.4.1 19-1.1.4.1.2.1.1.1 21-1.1.4.1.2.1.1.1 22-1.1.4.2.r 24-1.1.4.1.2.r 24-1.1.4.2.r 25-1.1.4.1.2.2.1.1 30-1.2.1.1.1.1.1 36-1.2.1.1.1.1.2
# ::id pmid_1563_0473.231
# ::preferred 
(a / appear-02~e.3
      :ARG1 (p / protein~e.16
            :quant "1"~e.0
            :name (n / name :op1 "Ajuba"~e.6)
            :ARG1-of (i / include-91
                  :ARG2 (t2 / this~e.2))
            :ARG1-of~e.16 (c / capable-01~e.16
                  :ARG2 (b / bind-01~e.18
                        :ARG1 p
                        :ARG2~e.24 (a2 / and
                              :op1 (p3 / protein
                                    :name (n2 / name :op1 "Grb-2"~e.19,21))
                              :op2 (p4 / protein
                                    :name (n3 / name :op1 "α-catenin"~e.25))))
                  :time~e.22,24 (p2 / previous~e.10)
                  :ARG1-of (s / show-01~e.11)
                  :mod (d / dual~e.15)))
      :ARG1-of (d2 / describe-01
            :ARG0 (a3 / and
                  :op1 (p5 / publication
                        :ARG1-of (c2 / cite-01
                              :ARG2 (a4 / and :op1 "9"~e.30 :op2 "10"~e.36))))))

# ::tok Our studies revealed that in skin keratinocytes that either harbor a conditional null mutation in <i> α-catenin </i> or that overexpress Snail , Ajuba develops an interaction with Grb @-@ 2 that is otherwise not observed in WT keratinocytes .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 0-1.1.1.r 1-1.1 2-1 4-1.2.r 5-1.2.3.1.2 9-1.2.3.1.1 11-1.2.3.1.1.1.3 12-1.2.3.1.1.1.2 13-1.2.3.1.1.1 16-1.2.3.1.1.1.1.1.1 18-1.2.3 20-1.2.3.2.1 21-1.2.3.2.1.1.1.1 23-1.2.1.1.1 24-1.2 26-1.2.2 27-1.2.2.2.r 28-1.2.2.2.1.1 30-1.2.2.2.1.1 33-1.2.2.3.2 34-1.2.2.3.1 34-1.2.2.3.1.r 35-1.2.2.3 37-1.2.2.3.3.1
# ::id pmid_1563_0473.232
# ::preferred 
(r / reveal-01~e.2
      :ARG0 (s / study-01~e.1
            :ARG0~e.0 (w2 / we~e.0))
      :ARG1~e.4 (d / develop-02~e.24
            :ARG0 (p / protein
                  :name (n / name :op1 "Ajuba"~e.23))
            :ARG1 (i / interact-01~e.26
                  :ARG0 p
                  :ARG1~e.27 (p2 / protein
                        :name (n2 / name :op1 "Grb-2"~e.28,30))
                  :ARG1-of (o / observe-01~e.35
                        :polarity~e.34 "-"~e.34
                        :mod (o2 / otherwise~e.33)
                        :location (k2 / keratinocyte
                              :mod (w / wild-type~e.37))))
            :location (o3 / or~e.18
                  :op1 (k / keratinocyte
                        :ARG0-of (h / harbor-01~e.9
                              :ARG1 (m / mutate-01~e.13
                                    :ARG1 (p3 / protein
                                          :name (n4 / name :op1 "α-catenin"~e.16))
                                    :mod (n3 / null~e.12)
                                    :mod (c / conditional~e.11)))
                        :mod (s2 / skin~e.5))
                  :op2 (k3 / keratinocyte
                        :ARG1-of (o4 / overexpress-00~e.20
                              :ARG2 (p4 / protein
                                    :name (n5 / name :op1 "Snail"~e.21)))))))

# ::tok The corresponding abilities of either <i> Snail </i>@ -@ transfected or <i> Ajuba </i>@ -@ transfected keratinocytes to exhibit elevated activation of the Ras @-@ MAPK pathway suggest that the Grb @-@ 2 association of Ajuba under conditions of reduced levels of AJ proteins may be directly relevant to the parallel in hyperproliferation .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.3 2-1.1 6-1.1.1.1.1.1.1.1 9-1.1.1.1.1 10-1.1.1 12-1.1.1.2.1.1.1.1 15-1.1.1.1.1 15-1.1.1.2.1 18-1.1.2 19-1.1.2.2.2 20-1.1.2.2 21-1.1.2.2.1.r 23-1.1.2.2.1.1.1 25-1.1.2.2.1.1.1 26-1.1.2.2.1 27-1 28-1.2.r 30-1.2.1.1.2.1.1 32-1.2.1.1.2.1.1 33-1.2.1.1 34-1.2.1.1.1.r 35-1.2.1.1.1 37-1.2.2.r 39-1.2.2.2 40-1.2.2 42-1.2.2.1.1.1 43-1.1.1.1.1.1 43-1.1.1.2.1.1 43-1.2.1.1.2 43-1.2.2.1 44-1.2 45-1.2.1.2.1 45-1.2.1.r 46-1.2.1.3 46-1.2.1.3.r 47-1.2.1 48-1.2.1.2.r 50-1.2.1.2
# ::id pmid_1563_0473.233
# ::preferred 
(s / suggest-01~e.27
      :ARG0 (c / capable-01~e.2
            :ARG1 (o / or~e.10
                  :op1 (k / keratinocyte
                        :ARG1-of (t / transfect-00~e.9,15
                              :ARG2 (p6 / protein~e.43
                                    :name (n4 / name :op1 "Snail"~e.6))))
                  :op2 (k2 / keratinocyte
                        :ARG1-of (t2 / transfect-00~e.15
                              :ARG2 (p7 / protein~e.43
                                    :name (n5 / name :op1 "Ajuba"~e.12)))))
            :ARG2 (e / exhibit-01~e.18
                  :ARG0 (a3 / and
                        :op1 k
                        :op2 k2)
                  :ARG1 (a2 / activate-01~e.20
                        :ARG1~e.21 (p8 / pathway~e.26
                              :name (n6 / name :op1 "Ras-MAPK"~e.23,25))
                        :ARG1-of (e2 / elevate-01~e.19)))
            :ARG1-of (c2 / correspond-02~e.1))
      :ARG1~e.28 (p / possible~e.44
            :domain~e.45 (r / relevant-01~e.47
                  :ARG1 (a / associate-01~e.33
                        :ARG1~e.34 p7~e.35
                        :ARG2 (p3 / protein~e.43
                              :name (n2 / name :op1 "Grb-2"~e.30,32)))
                  :ARG2~e.48 (p5 / parallel~e.50
                        :ARG1-of (b / be-located-at-91~e.45
                              :ARG2 (h / hyperproliferate-00)))
                  :manner~e.46 (d / direct~e.46))
            :condition~e.37 (l / level~e.40
                  :quant-of (p4 / protein~e.43
                        :name (n3 / name :op1 "AJ"~e.42))
                  :ARG1-of (r2 / reduce-01~e.39))))

# ::tok In stable epithelial ( i.e . , Madin @-@ Darby canine kidney , or MDCK ) cell lines , Snail has been shown to block cell cycle progression and promote motility and shape changes for invasion [ @<xref ref-type="bibr" rid="pbio-0030011-b47"> 47 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.2.2 2-1.2.1 7-1.2.3.1.1.1 9-1.2.3.1.1.1 10-1.2.3.1.1.2 11-1.2.3.1.1.3 16-1.2 17-1.2 19-1.1.1.1.1.1 22-1 24-1.1.1 25-1.1.1.2.1.1 26-1.1.1.2.1 27-1.1.1.2 28-1.1 29-1.1.2 30-1.1.2.2 31-1.1 32-1.1.3 33-1.1.3.1 34-1.1.3.2.r 35-1.1.3.2 40-1.3.1.1.1
# ::id pmid_1563_0473.234
# ::preferred 
(s / show-01~e.22
      :ARG1 (a2 / and~e.28,31
            :op1 (b / block-01~e.24
                  :ARG0 (p2 / protein
                        :name (n / name :op1 "Snail"~e.19))
                  :ARG1 (p3 / progress-01~e.27
                        :ARG1 (c2 / cycle~e.26
                              :mod (c / cell~e.25))))
            :op2 (p / promote-01~e.29
                  :ARG0 p2
                  :ARG1 (m2 / motility~e.30))
            :op3 (s3 / shape-01~e.32
                  :ARG1 (c3 / change~e.33)
                  :purpose~e.34 (i / invade-01~e.35)))
      :location (c6 / cell-line~e.16,17
            :mod (e / epithelium~e.2)
            :ARG1-of (s2 / stable-02~e.1
                  :ARG0 p2)
            :ARG1-of (m / mean-01
                  :ARG2 (c4 / cell-line
                        :name (n2 / name
                              :op1 "Madin-Darby"~e.7,9
                              :op2 "canine"~e.10
                              :op3 "kidney"~e.11))))
      :ARG1-of (d / describe-01
            :ARG0 (p4 / publication
                  :ARG1-of (c5 / cite-01 :ARG2 "47"~e.40))))

# ::tok While our in vivo studies are consistent with a role for Snail in motility and epithelial remodeling , they differ with respect to Snail 's apparent proliferative effects .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.2.1.1 1-1.2.1.1.r 2-1.2.1.2 3-1.2.1.2 4-1.2.1 6-1.2 7-1.2.2.r 9-1.2.2 11-1.1.2.1.1.1 12-1.2.1.2 12-1.2.2.1.r 13-1.2.2.1.1 14-1.2.2.1 15-1.2.2.1.2.1 16-1.2.2.1.2 18-1.2.2.2 19-1.1 23-1.1.2.1.1.1 24-1.1.2.1.r 27-1.1.2
# ::id pmid_1563_0473.235
# ::preferred 
(h / have-concession-91
      :ARG1 (d2 / differ-01~e.19
            :ARG0 (s / study-01~e.4
                  :ARG0~e.1 (w / we~e.1)
                  :manner (i / in-vivo~e.2,3,12))
            :ARG2 (a3 / affect-01~e.27
                  :ARG0~e.24 (p2 / protein
                        :name (n / name :op1 "Snail"~e.11,23))
                  :ARG0-of (p / proliferate-01)
                  :ARG1-of (a / appear-01)))
      :ARG2 (c / consistent-01~e.6
            :ARG1 s
            :ARG2~e.7 (r / role~e.9
                  :topic~e.12 (a2 / and~e.14
                        :op1 (m / motility~e.13)
                        :op2 (r2 / remodel-01~e.16
                              :ARG1 (e2 / epithelium~e.15)))
                  :purpose p2~e.18)))

# ::tok A priori , this could be simply due to variations in the response of different cell types to Snail expression .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2 1-1.2 3-1.1.1.2 4-1.1 5-1.1.1.r 6-1.1.1.3 7-1.1.1 8-1.1.1 9-1.1.1.1 10-1.1.1.1.1.r 12-1.1.1.1.1 13-1.1.1.1.1.1.r 14-1.1.1.1.1.1.2 15-1.1.1.1.1.1 16-1.1.1.1.1.1.1 17-1.1.1.1.1.2.r 18-1.1.1.1.1.2.1.1.1 19-1.1.1.1.1.2
# ::id pmid_1563_0473.236
# ::preferred 
(i / infer-01
      :ARG1 (p / possible~e.4
            :domain~e.5 (c / cause-01~e.7,8
                  :ARG0 (v / vary-01~e.9
                        :ARG1~e.10 (r / respond-01~e.12
                              :ARG0~e.13 (c2 / cell~e.15
                                    :mod (t / type~e.16)
                                    :ARG1-of (d / differ-02~e.14))
                              :ARG1~e.17 (e / express-03~e.19
                                    :ARG1 (g / gene
                                          :name (n / name :op1 "Snail"~e.18)))))
                  :ARG1 (t2 / this~e.3)
                  :manner (s / simple~e.6)))
      :mod (a / a-priori~e.0,1))

# ::tok Alternatively , these differences may be relevant to the benefit of using mouse models to reveal functions not always recapitulated in stable cell line models .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 0-1.1.r 2-1.2.1.2 3-1.2.1 3-1.2.1.1 3-1.2.1.1.r 4-1 5-1.2.r 6-1.2 9-1.2.2 10-1.2.2.1.r 11-1.2.2.1 12-1.2.2.1.1.1 13-1.2.2.1.1 15-1.2.2.1.2 16-1.2.2.1.2.1 17-1.2.2.1.2.1.1.1.1 17-1.2.2.1.2.1.1.1.1.r 18-1.2.2.1.2.1.1.1 19-1.2.2.1.2.1.1 20-1.2.2.1.2.1.1.2.r 21-1.2.2.1.2.1.1.2.2 22-1.2.2.1.2.1.1.2.1 23-1.2.2.1.2.1.1.2.1 24-1.2.2.1.2.1.1.2
# ::id pmid_1563_0473.237
# ::preferred 
(p / possible~e.4
      :manner~e.0 (a / alternative~e.0)
      :domain~e.5 (r / relevant-01~e.6
            :ARG1 (t / thing~e.3
                  :ARG1-of~e.3 (d / differ-02~e.3)
                  :mod (t2 / this~e.2))
            :ARG2 (b / benefit-01~e.9
                  :ARG0~e.10 (u / use-01~e.11
                        :ARG1 (m / model~e.13
                              :mod (m2 / mouse~e.12))
                        :ARG2 (r2 / reveal-01~e.15
                              :ARG1 (f / function-01~e.16
                                    :ARG1-of (r3 / recapitulate-01~e.19
                                          :time (a2 / always~e.18 :polarity~e.17 "-"~e.17)
                                          :location~e.20 (m3 / model~e.24
                                                :mod (c / cell-line~e.22,23)
                                                :mod (s / stable~e.21)))))))))

# ::tok Future studies should highlight the underlying reasons for these opposing results .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 1-1.1.1 2-1 3-1.1 5-1.1.2 5-1.1.2.2 5-1.1.2.2.r 8-1.1.2.1.1.2 9-1.1.2.1.1.3 10-1.1.2.1.1 10-1.1.2.1.1.1 10-1.1.2.1.1.1.r
# ::id pmid_1563_0473.238
# ::preferred 
(r / recommend-01~e.2
      :ARG1 (h / highlight-01~e.3
            :ARG0 (s / study-01~e.1
                  :time (f / future~e.0))
            :ARG1 (t / thing~e.5
                  :ARG0-of (c / cause-01
                        :ARG1 (t2 / thing~e.10
                              :ARG2-of~e.10 (r2 / result-01~e.10)
                              :mod (t3 / this~e.8)
                              :ARG0-of (o / oppose-01~e.9)))
                  :ARG0-of~e.5 (u / underlie-01~e.5))))

# ::tok Irrespective of these differences , our in vivo studies do not stand alone , as there are many situations in which a down @-@ regulation in AJ proteins correlate with enhanced proliferation .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.4 2-1.4.1.2 3-1.4.1 3-1.4.1.1 3-1.4.1.1.r 5-1.2.1 5-1.2.1.r 6-1.2.2 7-1.2.2 8-1.2 9-1.2 10-1.1 10-1.1.r 11-1 12-1.3 16-1.4.1.r 17-1.5.1.1 18-1.5.1 19-1.2.2 25-1.2.2 25-1.5.1.2.r 26-1.5.1.2.1.1.1.1 27-1.5.1.2.1.1 28-1.5.1.2 29-1.5.1.2.2.r 30-1.5.1.2.2.1 31-1.5.1.2.2
# ::id pmid_1563_0473.239
# ::preferred 
(s / stand-01~e.11
      :polarity~e.10 "-"~e.10
      :ARG1 (s2 / study-01~e.8,9
            :ARG0~e.5 (w / we~e.5)
            :manner (i / in-vivo~e.6,7,19,25))
      :manner (a / alone~e.12)
      :concession (i2 / irrespective~e.0
            :domain~e.16 (t / thing~e.3
                  :ARG1-of~e.3 (d / differ-02~e.3)
                  :mod (t2 / this~e.2)))
      :ARG1-of (c / cause-01
            :ARG0 (s3 / situation~e.18
                  :quant (m / many~e.17)
                  :mod~e.25 (c2 / correlate-01~e.28
                        :ARG1 (d2 / downregulate-01
                              :ARG1 (p / protein~e.27
                                    :name (n / name :op1 "AJ"~e.26)))
                        :ARG2~e.29 (p2 / proliferate-01~e.31
                              :ARG1-of (e / enhance-01~e.30))))))

# ::tok In fact , a myriad of diverse mechanisms have been implicated in activating epithelial proliferation upon down @-@ regulation of AJ proteins [ @<xref ref-type="bibr" rid="pbio-0030011-b07"> 7 </xref> , <xref ref-type="bibr" rid="pbio-0030011-b23"> 23 </xref> , <xref ref-type="bibr" rid="pbio-0030011-b24"> 24 </xref> , <xref ref-type="bibr" rid="pbio-0030011-b48"> 48 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3 1-1.3 4-1.1.2 5-1.1.2.r 6-1.1.1 7-1.1 10-1 11-1.2.r 11-1.3 12-1.2 13-1.2.1.1 14-1.2.1 20-1.2.2.1.1.1 21-1.2.2.1 26-1.4.1.1.1.1 32-1.4.1.1.1.2 38-1.4.1.1.1.3 44-1.4.1.1.1.4
# ::id pmid_1563_0473.240
# ::preferred 
(i / implicate-01~e.10
      :ARG1 (m / mechanism~e.7
            :mod (d / diverse~e.6)
            :quant~e.5 (m2 / myriad~e.4))
      :ARG2~e.11 (a / activate-01~e.12
            :ARG1 (p / proliferate-01~e.14
                  :ARG0 (e / epithelium~e.13))
            :time (d2 / downregulate-01
                  :ARG1 (p2 / protein~e.21
                        :name (n / name :op1 "AJ"~e.20))))
      :mod (i2 / in-fact~e.0,1,11)
      :ARG1-of (d3 / describe-01
            :ARG0 (p3 / publication
                  :ARG1-of (c / cite-01
                        :ARG2 (a2 / and
                              :op1 "7"~e.26
                              :op2 "23"~e.32
                              :op3 "24"~e.38
                              :op4 "48"~e.44)))))

# ::tok Sifting through these converging pathways is likely to be a difficult and painstaking process .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.3 2-1.1.3.1.2 3-1.1.3.1.1 4-1.1.3.1 5-1.1.3.r 5-1.1.r 6-1 8-1.1.3.r 8-1.1.r 10-1.1.1 12-1.1.2 13-1.1
# ::id pmid_1563_0473.241
# ::preferred 
(l / likely~e.6
      :domain~e.5,8 (p / process~e.13
            :mod (d / difficult~e.10)
            :mod (p2 / painstaking~e.12)
            :domain~e.5,8 (s / sift-01~e.0
                  :ARG1 (p3 / pathway~e.4
                        :ARG0-of (c / converge-01~e.3)
                        :mod (t / this~e.2)))))

# ::tok This said , by identifying the status of different players involved in specific cell types and at specific stages in development , our mechanistic understanding of how intercellular remodeling is linked to proliferation in epithelial morphogenesis should begin to surface in the future .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.1.1 1-1.2.1 4-1.1.2 6-1.1.2.1 7-1.1.2.1.1.r 8-1.1.2.1.1 8-1.1.2.1.1.1 8-1.1.2.1.1.1.r 9-1.1.2.1.1.3 10-1.1.2.1.1.2 11-1.1.2.1.1.2.1.r 12-1.1.2.1.1.2.1.2 13-1.1.2.1.1.2.1 14-1.1.2.1.1.2.1.1 17-1.1.2.1.1.2.1.2 18-1.1.2.1.1.2.2 19-1.1.2.1.1.2.2.2.r 20-1.1.2.1.1.2.2.2 22-1.1.1.1.1 22-1.1.1.1.1.r 23-1.1.1.1.3 24-1.1.1.1 26-1.1.1.1.2.2 26-1.1.1.1.2.2.r 27-1.1.1.1.2.1.1.1 28-1.1.1.1.2.1.1 30-1.1.1.1.2 31-1.1.1.1.2.1.r 32-1.1.1.1.2.1.2 33-1.1.1.1.2.1.2.1.r 34-1.1.1.1.2.1.2.1.1 35-1.1.1.1.2.1.2.1 36-1 37-1.1 38-1.1.1.1 39-1.1.1 40-1.1.1.2.r 42-1.1.1.2
# ::id pmid_1563_0473.242
# ::preferred 
(r / recommend-01~e.36
      :ARG1 (b / begin-01~e.37
            :ARG1 (s / surface-01~e.39
                  :ARG1 (u / understand-01~e.24,38
                        :ARG0~e.22 (w / we~e.22)
                        :ARG1 (l / link-01~e.30
                              :ARG1~e.31 (a / and
                                    :op1 (r2 / remodel-01~e.28
                                          :mod (i / intercellular~e.27))
                                    :op2 (p / proliferate-01~e.32
                                          :ARG0~e.33 (m / morphogenesis~e.35
                                                :mod (e / epithelium~e.34))))
                              :manner~e.26 (a2 / amr-unknown~e.26))
                        :mod (m2 / mechanism~e.23))
                  :time~e.40 (f / future~e.42))
            :manner (i2 / identify-01~e.4
                  :ARG1 (s2 / status~e.6
                        :poss~e.7 (t / thing~e.8
                              :ARG1-of~e.8 (d / differ-02~e.8)
                              :ARG1-of (i3 / involve-01~e.10
                                    :ARG2~e.11 (c / cell~e.13
                                          :mod (t2 / type~e.14)
                                          :mod (s3 / specific~e.12,17))
                                    :time (s4 / stage~e.18
                                          :mod s3
                                          :subevent-of~e.19 (d2 / develop-02~e.20)))
                              :ARG0-of (p3 / play-01~e.9)))))
      :time (a3 / after
            :op1 (s5 / say-01~e.1
                  :ARG1 (t3 / this~e.0))))

# ::tok Elucidating the molecular mechanisms through which these networks converge is also a prerequisite for understanding how these processes go awry during tumorigenesis .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2 2-1.2.1.1 3-1.2.1 5-1.1.1.4 6-1.2.1.2.1.1 7-1.2.1.2.1 8-1.2.1.2 10-1.3 14-1.1 15-1.1.1.4 15-1.1.1.4.r 16-1.1.1.1.1 17-1.1.1.1 18-1.1.1 19-1.1.1.2 20-1.1.1.3.r
# ::id pmid_1563_0473.243
# ::preferred 
(r / require-01
      :ARG0 (u / understand-01~e.14
            :ARG1 (g / go-08~e.18
                  :ARG1 (p / process~e.17
                        :mod (t / this~e.16))
                  :ARG2 (a / awry~e.19)
                  :time~e.20 (c / create-01
                        :ARG1 (t2 / tumor))
                  :manner~e.15 (a2 / amr-unknown~e.5,15)))
      :ARG1 (e / elucidate-01~e.0
            :ARG1 (m / mechanism~e.3
                  :mod (m2 / molecule~e.2)
                  :manner-of (c2 / converge-01~e.8
                        :ARG0 (n / network~e.7
                              :mod (t3 / this~e.6)))))
      :mod (a3 / also~e.10))

# ::tok Materials and Methods
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1 2-1.2
# ::id pmid_1563_0473.244
# ::preferred 
(a / and~e.1
      :op1 (m / material~e.0)
      :op2 (m2 / method~e.2))

# ::tok Reagents
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1
# ::id pmid_1563_0473.245
# ::preferred 
(r / reagent~e.0)

# ::tok Primary antibodies used were against : E @-@ cadherin ( M . Takeichi , Kyoto University , Japan ) ; α-catenin , β-catenin , pMAPK , tubulin ( Sigma , St. Louis , Missouri , United States ) , Ajuba ( G . Longmore , Washington University , St. Louis , Missouri , United States ) ; β4 integrin @/@ CD104 ( BD Pharmingen , San Diego , California , United States ) , laminin 5 ( R . Burgeson , Harvard University , Cambridge , Massachusetts , United States ) , K5 , K1 , loricrin ( Fuchs Lab ) , involucrin , fillagrin ( Covance , Berkeley , California , United States ) , MAPK , pSMAD2 ( Cell Signaling , Beverly , Massachusetts , United States ) ; Grb @-@ 2 ( Santa Cruz Biotech , Santa Cruz , California , United States ) ; P @-@ cadherin ( Zymed Laboratories , South San Francisco , California , United States ) ; HA ( Roche Biochemicals ) , vimentin ( Chemicon , Temecula , California , United States ) , Ki67 ( Novo Castra , Newcastle Upon Tyne , United Kingdom ) , keratin 6 ( P . Coulombe , John Hopkins University , Baltimore , Maryland , United States ) , cyclin D ( Oncogene , San Diego , California , United States ) , and TGF-β2 ( L . Gold , New York University , New York , New York , United States ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 1-1.1.1 1-1.1.10 1-1.1.11 1-1.1.12 1-1.1.13 1-1.1.14 1-1.1.15 1-1.1.16 1-1.1.2 1-1.1.3 1-1.1.4 1-1.1.5 1-1.1.6 1-1.1.7 1-1.1.8 1-1.1.9 2-1 4-1.1.1.2 4-1.1.10.2 4-1.1.11.2 4-1.1.12.2 4-1.1.13.2 4-1.1.14.2 4-1.1.15.2 4-1.1.16.2 4-1.1.2.2 4-1.1.3.2 4-1.1.4.2 4-1.1.5.2 4-1.1.6.2 4-1.1.7.2 4-1.1.8.2 4-1.1.9.2 6-1.1.1.2.1.1.1 8-1.1.1.2.1.1.1 12-1.1.1.2.1.2.1.2 14-1.1.1.2.1.2.2.2.1 15-1.1.1.2.1.2.2.2.2 17-1.1.1.2.1.2.2.3.2.1 20-1.1.2.2.1.1.1.1 22-1.1.2.2.1.2.1.1 26-1.1.2.2.1.4.1.1 28-1.1.2.2.1.5.1.1 30-1.1.2.2.1.5.2.2.1 31-1.1.2.2.1.5.2.2.2 33-1.1.2.2.1.5.2.3.2.1 35-1.1.2.2.1.5.2.3.3.2.1 36-1.1.2.2.1.5.2.3.3.2.2 39-1.1.3.2.1.1.1 43-1.1.3.2.1.2.1.2 45-1.1.3.2.1.2.2.2.1 46-1.1.3.2.1.2.2.2.2 48-1.1.2.2.1.5.2.2.1 49-1.1.2.2.1.5.2.2.2 51-1.1.2.2.1.5.2.3.2.1 53-1.1.2.2.1.5.2.3.3.2.1 54-1.1.2.2.1.5.2.3.3.2.2 57-1.1.4.2.1.1.1 58-1.1.4.2.1.1.1 60-1.1.4.2.1.1.1 62-1.1.4.2.1.2.1.1 63-1.1.4.2.1.2.1.2 65-1.1.4.2.1.2.2.2.1 66-1.1.4.2.1.2.2.2.2 68-1.1.4.2.1.2.2.3.2.1 70-1.1.2.2.1.5.2.3.3.2.1 71-1.1.2.2.1.5.2.3.3.2.2 74-1.1.5.2.1.1.1 75-1.1.5.2.1.1.1 79-1.1.5.2.1.2.1.2 81-1.1.5.2.1.2.2.2.1 82-1.1.5.2.1.2.2.2.2 84-1.1.5.2.1.2.2.3.2.1 86-1.1.5.2.1.2.2.3.3.2.1 88-1.1.2.2.1.5.2.3.3.2.1 89-1.1.2.2.1.5.2.3.3.2.2 92-1.1.6.2.1.1.1.1 94-1.1.6.2.1.2.1.1 96-1.1.6.2.1.3.1.1 98-1.1.6.2.1.4.1.1 99-1.1.6.2.1.4.1.2 102-1.1.7.2.1.1.1.1 104-1.1.7.2.1.2.1.1 106-1.1.7.2.1.3.2.1 108-1.1.7.2.1.3.3.2.1 110-1.1.7.2.1.3.3.3 112-1.1.2.2.1.5.2.3.3.2.1 113-1.1.2.2.1.5.2.3.3.2.2 116-1.1.2.2.1.3.1.1 120-1.1.8.2.1.3.1.1 121-1.1.8.2.1.3.1.2 123-1.1.8.2.1.3.2.2.1 125-1.1.8.2.1.3.2.3 127-1.1.5.2.1.2.2.3.3.3 128-1.1.4.2.1.2.2.3 128-1.1.5.2.1.2.2.3.3 131-1.1.9.2.1.1.1 133-1.1.9.2.1.1.1 135-1.1.9.2.1.2.1.1 135-1.1.9.2.1.2.2.2.1 136-1.1.9.2.1.2.1.2 136-1.1.9.2.1.2.2.2.2 137-1.1.9.2.1.2.1.3 139-1.1.9.2.1.2.2.2.1 140-1.1.9.2.1.2.2.2.2 142-1.1.4.2.1.2.2.3.2.1 145-1.1.4.2.1.2.2.3 145-1.1.5.2.1.2.2.3.3 148-1.1.10.2.1.1.1 150-1.1.10.2.1.1.1 152-1.1.10.2.1.2.1.1 153-1.1.10.2.1.2.1.2 155-1.1.10.2.1.2.2.2.1 156-1.1.10.2.1.2.2.2.2 157-1.1.10.2.1.2.2.2.3 159-1.1.10.2.1.2.2.3 162-1.1.4.2.1.2.2.3 162-1.1.5.2.1.2.2.3.3 165-1.1.11.2.1.1.1 167-1.1.11.2.1.2.1.1 168-1.1.11.2.1.2.1.2 171-1.1.12.2.1.1.1 173-1.1.12.2.1.2.1.1 175-1.1.12.2.1.2.2.2.1 177-1.1.12.2.1.2.2.3 180-1.1.4.2.1.2.2.3 180-1.1.5.2.1.2.2.3.3 183-1.1.13.2.1.1.1 185-1.1.13.2.1.2.1.1 186-1.1.13.2.1.2.1.2 188-1.1.13.2.1.2.2.2.1 189-1.1.13.2.1.2.2.2.2 190-1.1.13.2.1.2.2.2.3 192-1.1.13.2.1.2.2.3.2.1 193-1.1.13.2.1.2.2.3.2.2 196-1.1.14.2.1.1.1 197-1.1.14.2.1.1.1 199-1.1.10.2.1.1.1 201-1.1.14.2.1.2.1.2 203-1.1.14.2.1.2.2.2.1 204-1.1.14.2.1.2.2.2.2 205-1.1.14.2.1.2.2.2.3 207-1.1.14.2.1.2.2.3.2.1 209-1.1.14.2.1.2.2.3.3.2.1 212-1.1.14.2.1.2.2.3.3 212-1.1.4.2.1.2.2.3 212-1.1.5.2.1.2.2.3.3 215-1.1.15.2.1.1.1 216-1.1.15.2.1.1.1 218-1.1.15.2.1.2.1.1 220-1.1.15.2.1.2.2 221-1.1.15.2.1.2.2 222-1.1.15.2.1.2.2 223-1.1.15.2.1.2.2 226-1.1.14.2.1.2.2.3.3 226-1.1.4.2.1.2.2.3 226-1.1.5.2.1.2.2.3.3 229-1.1 229-1.1.2.2.1 229-1.1.6.2.1 229-1.1.7.2.1 229-1.1.8.2.1 230-1.1.16.2.1.1.1 234-1.1.16.2.1.2.1.2 236-1.1.16.2.1.2.2.2.1 236-1.1.16.2.1.2.2.3.2.1 237-1.1.16.2.1.2.2.2.2 237-1.1.16.2.1.2.2.3.2.2 238-1.1.16.2.1.2.2.2.3 240-1.1.16.2.1.2.2.3.2.1 241-1.1.16.2.1.2.2.3.2.2 243-1.1.16.2.1.2.2.3.2.1 244-1.1.16.2.1.2.2.3.2.2 247-1.1.16.2.1.2.2.3.3
# ::id pmid_1563_0473.246
# ::preferred 
(u / use-01~e.2
      :ARG1 (a / and~e.229
            :op1 (a2 / antibody~e.1
                  :mod (p / primary~e.0)
                  :ARG0-of (o / oppose-01~e.4
                        :ARG1 (p2 / protein
                              :name (n / name :op1 "E-cadherin"~e.6,8)
                              :source (p3 / person
                                    :name (n2 / name :op1 "M." :op2 "Takeichi"~e.12)
                                    :location (u2 / university
                                          :wiki "Kyoto_University"
                                          :name (n3 / name :op1 "Kyoto"~e.14 :op2 "University"~e.15)
                                          :location (c / country
                                                :wiki "Japan"
                                                :name (n4 / name :op1 "Japan"~e.17)))))))
            :op2 (a7 / antibody~e.1
                  :mod p
                  :ARG0-of (o2 / oppose-01~e.4
                        :ARG1 (a3 / and~e.229
                              :op1 (p4 / protein
                                    :name (n5 / name :op1 "α-catenin"~e.20))
                              :op2 (p5 / protein
                                    :name (n6 / name :op1 "β-catenin"~e.22))
                              :op3 (e / enzyme
                                    :name (n7 / name :op1 "MAPK"~e.116)
                                    :ARG1-of (p6 / phosphorylate-01))
                              :op4 (p7 / protein
                                    :name (n8 / name :op1 "tubulin"~e.26))
                              :source (c2 / company
                                    :name (n9 / name :op1 "Sigma"~e.28)
                                    :location (c3 / city
                                          :wiki "St._Louis"
                                          :name (n10 / name :op1 "St."~e.30,48 :op2 "Louis"~e.31,49)
                                          :location (s / state
                                                :wiki "Missouri"
                                                :name (n11 / name :op1 "Missouri"~e.33,51)
                                                :location (c4 / country
                                                      :wiki "United_States"
                                                      :name (n12 / name :op1 "United"~e.35,53,70,88,112 :op2 "States"~e.36,54,71,89,113))))))))
            :op3 (a8 / antibody~e.1
                  :mod p
                  :ARG0-of (o3 / oppose-01~e.4
                        :ARG1 (p8 / protein
                              :name (n13 / name :op1 "Ajuba"~e.39)
                              :source (p9 / person
                                    :name (n14 / name :op1 "G." :op2 "Longmore"~e.43)
                                    :location (u3 / university
                                          :wiki "Washington_University"
                                          :name (n15 / name :op1 "Washington"~e.45 :op2 "University"~e.46)
                                          :location c3)))))
            :op4 (a9 / antibody~e.1
                  :mod p
                  :ARG0-of (o4 / oppose-01~e.4
                        :ARG1 (p10 / protein
                              :name (n16 / name :op1 "β4-integrin/CD104"~e.57,58,60)
                              :source (c5 / company
                                    :name (n17 / name :op1 "BD"~e.62 :op2 "Pharmingen"~e.63)
                                    :location (c6 / city
                                          :wiki "San_Diego"
                                          :name (n18 / name :op1 "San"~e.65 :op2 "Diego"~e.66)
                                          :location (s2 / state~e.128,145,162,180,212,226
                                                :wiki "California"
                                                :name (n19 / name :op1 "California"~e.68,142)
                                                :location c4))))))
            :op5 (a10 / antibody~e.1
                  :mod p
                  :ARG0-of (o5 / oppose-01~e.4
                        :ARG1 (p11 / protein
                              :name (n20 / name :op1 "laminin-5"~e.74,75)
                              :source (p12 / person
                                    :name (n21 / name :op1 "R." :op2 "Burgeson"~e.79)
                                    :location (u4 / university
                                          :wiki "Harvard_University"
                                          :name (n22 / name :op1 "Harvard"~e.81 :op2 "University"~e.82)
                                          :location (c7 / city
                                                :wiki "Cambridge"
                                                :name (n23 / name :op1 "Cambridge"~e.84)
                                                :location (s3 / state~e.128,145,162,180,212,226
                                                      :wiki "Massachusetts"
                                                      :name (n24 / name :op1 "Massachusetts"~e.86)
                                                      :location c4~e.127)))))))
            :op6 (a11 / antibody~e.1
                  :mod p
                  :ARG0-of (o6 / oppose-01~e.4
                        :ARG1 (a4 / and~e.229
                              :op1 (p13 / protein
                                    :name (n25 / name :op1 "K5"~e.92))
                              :op2 (p14 / protein
                                    :name (n26 / name :op1 "K1"~e.94))
                              :op3 (p15 / protein
                                    :name (n27 / name :op1 "loricrin"~e.96))
                              :location (r / research-institute
                                    :name (n28 / name :op1 "Fuchs"~e.98 :op2 "Lab"~e.99)))))
            :op7 (a12 / antibody~e.1
                  :mod p
                  :ARG0-of (o7 / oppose-01~e.4
                        :ARG1 (a5 / and~e.229
                              :op1 (p16 / protein
                                    :name (n29 / name :op1 "involucrin"~e.102))
                              :op2 (p17 / protein
                                    :name (n30 / name :op1 "fillagrin"~e.104))
                              :source (c8 / company
                                    :wiki "Covance"
                                    :name (n31 / name :op1 "Covance"~e.106)
                                    :location (c9 / city
                                          :wiki "Berkeley"
                                          :name (n32 / name :op1 "Berkeley"~e.108)
                                          :location s2~e.110)))))
            :op8 (a13 / antibody~e.1
                  :mod p
                  :ARG0-of (o8 / oppose-01~e.4
                        :ARG1 (a6 / and~e.229
                              :op1 e
                              :op2 (p18 / protein
                                    :name (n33 / name :op1 "SMAD2")
                                    :ARG1-of p6)
                              :source (c10 / company
                                    :name (n34 / name :op1 "Cell"~e.120 :op2 "Signaling"~e.121)
                                    :location (c11 / city
                                          :wiki "Beverly"
                                          :name (n35 / name :op1 "Beverly"~e.123)
                                          :location s3~e.125)))))
            :op9 (a14 / antibody~e.1
                  :mod p
                  :ARG0-of (o9 / oppose-01~e.4
                        :ARG1 (p19 / protein
                              :name (n36 / name :op1 "Grb-2"~e.131,133)
                              :source (c12 / company
                                    :name (n37 / name
                                          :op1 "Santa"~e.135
                                          :op2 "Cruz"~e.136
                                          :op3 "Biotech"~e.137)
                                    :location (c13 / city
                                          :wiki "Santa_Cruz"
                                          :name (n38 / name :op1 "Santa"~e.135,139 :op2 "Cruz"~e.136,140)
                                          :location s2)))))
            :op10 (a15 / antibody~e.1
                  :mod p
                  :ARG0-of (o10 / oppose-01~e.4
                        :ARG1 (p20 / protein
                              :name (n39 / name :op1 "P-cadherin"~e.148,150,199)
                              :source (c14 / company
                                    :name (n40 / name :op1 "Zymed"~e.152 :op2 "Laboratories"~e.153)
                                    :location (c15 / city
                                          :wiki "South_San_Francisco"
                                          :name (n41 / name
                                                :op1 "South"~e.155
                                                :op2 "San"~e.156
                                                :op3 "Francisco"~e.157)
                                          :location s2~e.159)))))
            :op11 (a16 / antibody~e.1
                  :mod p
                  :ARG0-of (o11 / oppose-01~e.4
                        :ARG1 (p21 / protein
                              :name (n42 / name :op1 "HA"~e.165)
                              :source (c16 / company
                                    :name (n43 / name :op1 "Roche"~e.167 :op2 "Biochemicals"~e.168)))))
            :op12 (a17 / antibody~e.1
                  :mod p
                  :ARG0-of (o12 / oppose-01~e.4
                        :ARG1 (p22 / protein
                              :name (n44 / name :op1 "vimentin"~e.171)
                              :source (c17 / company
                                    :name (n45 / name :op1 "Chemicon"~e.173)
                                    :location (c18 / city
                                          :wiki "Temecula"
                                          :name (n46 / name :op1 "Temecula"~e.175)
                                          :location s2~e.177)))))
            :op13 (a18 / antibody~e.1
                  :mod p
                  :ARG0-of (o13 / oppose-01~e.4
                        :ARG1 (p23 / protein
                              :name (n47 / name :op1 "Ki67"~e.183)
                              :source (c19 / company
                                    :name (n48 / name :op1 "Novo"~e.185 :op2 "Castra"~e.186)
                                    :location (c20 / city
                                          :wiki "Newcastle_Upon_Tyne"
                                          :name (n49 / name
                                                :op1 "Newcastle"~e.188
                                                :op2 "Upon"~e.189
                                                :op3 "Tyne"~e.190)
                                          :location (c21 / country
                                                :wiki "United_Kingdom"
                                                :name (n50 / name :op1 "United"~e.192 :op2 "Kingdom"~e.193)))))))
            :op14 (a19 / antibody~e.1
                  :mod p
                  :ARG0-of (o14 / oppose-01~e.4
                        :ARG1 (p24 / protein
                              :name (n51 / name :op1 "keratin-6"~e.196,197)
                              :source (p25 / person
                                    :name (n52 / name :op1 "P." :op2 "Coulombe"~e.201)
                                    :location (u5 / university
                                          :wiki "John_Hopkins_University"
                                          :name (n53 / name
                                                :op1 "John"~e.203
                                                :op2 "Hopkins"~e.204
                                                :op3 "University"~e.205)
                                          :location (c22 / city
                                                :wiki "Baltimore"
                                                :name (n54 / name :op1 "Baltimore"~e.207)
                                                :location (s4 / state~e.212,226
                                                      :wiki "Maryland"
                                                      :name (n55 / name :op1 "Maryland"~e.209)
                                                      :location c4)))))))
            :op15 (a20 / antibody~e.1
                  :mod p
                  :ARG0-of (o15 / oppose-01~e.4
                        :ARG1 (p26 / protein
                              :name (n56 / name :op1 "cyclin-D"~e.215,216)
                              :source (c23 / company
                                    :name (n57 / name :op1 "Oncogene"~e.218)
                                    :location c6~e.220,221,222,223))))
            :op16 (a21 / antibody~e.1
                  :mod p
                  :ARG0-of (o16 / oppose-01~e.4
                        :ARG1 (p27 / protein
                              :name (n58 / name :op1 "TGF-β2"~e.230)
                              :source (p28 / person
                                    :name (n59 / name :op1 "L." :op2 "Gold"~e.234)
                                    :location (u6 / university
                                          :wiki "New_York_University"
                                          :name (n60 / name
                                                :op1 "New"~e.236
                                                :op2 "York"~e.237
                                                :op3 "University"~e.238)
                                          :location (c24 / city
                                                :wiki "New_York"
                                                :name (n61 / name :op1 "New"~e.236,240,243 :op2 "York"~e.237,241,244)
                                                :location (s5 / state~e.247
                                                      :name n61
                                                      :location c4)))))))))

# ::tok FITC-, Texas Red-, or HRP @-@ conjugated secondary antibodies were from Jackson ImmunoResearch ( West Grove , Pennsylvania , United States ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.2.1.2.1.1 3-1.2.1 4-1.2.1.3.1.1 6-1.2 7-1.1 8-1 10-1.3.r 11-1.3.1.1 12-1.3.1.2 14-1.3.2.1.1 15-1.3.2.1.2 17-1.3.2.2.1.1 19-1.3.2.2.2.1.1 20-1.3.2.2.2.1.2
# ::id pmid_1563_0473.247
# ::preferred 
(a / antibody~e.8
      :mod (s / secondary~e.7)
      :ARG1-of (c / conjugate-00~e.6
            :ARG2 (o / or~e.3
                  :op1 (m / molecular-physical-entity
                        :name (n / name :op1 "FITC"))
                  :op2 (m2 / molecular-physical-entity
                        :name (n2 / name :op1 "Texas"~e.1 :op2 "Red"))
                  :op3 (e / enzyme
                        :name (n3 / name :op1 "HRP"~e.4))))
      :source~e.10 (c2 / company
            :name (n4 / name :op1 "Jackson"~e.11 :op2 "ImmunoResearch"~e.12)
            :location (c3 / city
                  :name (n5 / name :op1 "West"~e.14 :op2 "Grove"~e.15)
                  :location (s2 / state
                        :name (n6 / name :op1 "Pennsylvania"~e.17)
                        :location (c4 / country
                              :name (n7 / name :op1 "United"~e.19 :op2 "States"~e.20))))))

# ::tok Biotinylated secondary antibodies were from Vector Labs ( Burlingame , California , United States ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1 2-1 4-1.3.r 5-1.3.1.1 6-1.3.1.2 8-1.3.2.2.1 10-1.3.2.3.2.1 12-1.3.2.3.3.2.1 13-1.3.2.3.3.2.2
# ::id pmid_1563_0473.248
# ::preferred 
(a / antibody~e.2
      :mod (s / secondary~e.1)
      :ARG1-of (b / biotinylate-00)
      :source~e.4 (c / company
            :name (n / name :op1 "Vector"~e.5 :op2 "Labs"~e.6)
            :location (c2 / city
                  :wiki "Burlingame"
                  :name (n2 / name :op1 "Burlingame"~e.8)
                  :location (s2 / state
                        :wiki "California"
                        :name (n3 / name :op1 "California"~e.10)
                        :location (c3 / country
                              :wiki "United_States"
                              :name (n4 / name :op1 "United"~e.12 :op2 "States"~e.13))))))

# ::tok Dilutions were according to the manufacturer 's recommendation .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 5-1.2.1 5-1.2.1.1 5-1.2.1.1.r 6-1.2.1.r 7-1.2
# ::id pmid_1563_0473.249
# ::preferred 
(c / conform-01
      :ARG1 (d / dilute-01~e.0)
      :ARG2 (r / recommend-01~e.7
            :ARG0~e.6 (c2 / company~e.5
                  :ARG0-of~e.5 (m / manufacture-01~e.5))
            :ARG4 d))

# ::tok The Snail antibody was generated in Guinea pigs by inoculating them with the N @-@ terminal sequence of murine <i> Snail </i> fused to GST ( Covance , Princeton , New Jersey , United States ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1.1.1 2-1.1 4-1 5-1.2.r 6-1.2.1.1 7-1.2.1.2 8-1.3.r 9-1.3 10-1.3.1 11-1.3.2.r 13-1.3.2.1.1 15-1.3.2.1.2 20-1.3.2.2.1.1 22-1.3.2.3 23-1.3.2.3.1.r 24-1.3.2.3.1.1.1 26-1.3.2.3.1.2.2.1 28-1.3.2.3.1.2.3.2.1 30-1.3.2.3.1.2.3.3.2.1 31-1.3.2.3.1.2.3.3.2.2 33-1.3.2.3.1.2.3.3.3.2.1 34-1.3.2.3.1.2.3.3.3.2.2
# ::id pmid_1563_0473.250
# ::preferred 
(g / generate-01~e.4
      :ARG1 (a / antibody~e.2
            :mod (p / protein
                  :name (n / name :op1 "Snail"~e.1)))
      :location~e.5 (a2 / animal
            :name (n2 / name :op1 "Guinea"~e.6 :op2 "pig"~e.7))
      :manner~e.8 (i / inoculate-00~e.9
            :ARG1 a2~e.10
            :ARG2~e.11 (p2 / protein-segment
                  :name (n3 / name :op1 "N"~e.13 :op2 "terminus"~e.15)
                  :part-of (g2 / gene
                        :name (n4 / name :op1 "Snail"~e.20)
                        :part-of (o / organism
                              :name (n5 / name :op1 "Murinae")))
                  :ARG1-of (f / fuse-01~e.22
                        :ARG3~e.23 (e / enzyme
                              :name (n6 / name :op1 "GST"~e.24)
                              :source (c / company
                                    :wiki "Covance"
                                    :name (n7 / name :op1 "Covance"~e.26)
                                    :location (c2 / city
                                          :wiki "Princeton"
                                          :name (n8 / name :op1 "Princeton"~e.28)
                                          :location (s / state
                                                :wiki "New_Jersey"
                                                :name (n9 / name :op1 "New"~e.30 :op2 "Jersey"~e.31)
                                                :location (c3 / country
                                                      :wiki "United_States"
                                                      :name (n10 / name :op1 "United"~e.33 :op2 "States"~e.34))))))))))

# ::tok Recombinant human TGF-β2 was purchased from R&D ( Minneapolis , Minnesota , United States ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.2 2-1.1.1.1 4-1 5-1.2.r 6-1.2.1.1 8-1.2.2.2.1 10-1.2.2.3.2.1 12-1.2.2.3.3.2.1 13-1.2.2.3.3.2.2
# ::id pmid_1563_0473.251
# ::preferred 
(p / purchase-01~e.4
      :ARG1 (p2 / protein
            :name (n / name :op1 "TGF-β2"~e.2)
            :mod (h / human~e.1)
            :ARG3-of (r / recombine-01))
      :ARG2~e.5 (c / company
            :name (n2 / name :op1 "R&D"~e.6)
            :location (c2 / city
                  :wiki "Minneapolis"
                  :name (n3 / name :op1 "Minneapolis"~e.8)
                  :location (s / state
                        :wiki "Minnesota"
                        :name (n4 / name :op1 "Minnesota"~e.10)
                        :location (c3 / country
                              :wiki "United_States"
                              :name (n5 / name :op1 "United"~e.12 :op2 "States"~e.13))))))

# ::tok Heat inactivated TGF-β2 was generated by heating the recombinant protein at 100 °C for 10 min .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2.2 0-1.2 1-1.1.2.1 2-1.1.1.1 4-1 6-1.2 9-1.2.1 10-1.2.2.r 11-1.2.2.1 13-1.2.3.r 14-1.2.3.1
# ::id pmid_1563_0473.252
# ::preferred 
(g / generate-01~e.4
      :ARG1 (p / protein
            :name (n / name :op1 "TGF-β2"~e.2)
            :ARG1-of (a / activate-01
                  :polarity "-"~e.1
                  :ARG0 (h / heat-01~e.0)))
      :manner (h2 / heat-01~e.0,6
            :ARG1 (p2 / protein~e.9
                  :ARG3-of (r / recombine-01))
            :destination~e.10 (t / temperature-quantity
                  :quant "100"~e.11
                  :scale (c / celsius))
            :duration~e.13 (t2 / temporal-quantity
                  :quant "10"~e.14
                  :unit (m / minute))))

# ::tok Mice
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1
# ::id pmid_1563_0473.253
# ::preferred 
(m / mouse~e.0)

# ::tok The <i> K14 @-@ Snail </i> Tg mouse was generated by digesting the pcDNA3 @-@ mm <i> Snail </i>@ -@ HA plasmid ( G . de Herreros , Universitat Pompeu , Fabra , Barcelona , Spain ) with BamHI and NotI and subcloned into the K14 vector [ @<xref ref-type="bibr" rid="pbio-0030011-b49"> 49 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1.1.2.1.1.1 4-1.1.1.2.2.1.1 7-1.1.1 9-1.1 10-1.1.2.r 11-1.1.2 13-1.1.2.1.2.1.1.1 15-1.1.2.1.2.1.1.1 17-1.1.2.1.2.2 20-1.1.2.1.2.3.1.1 21-1.1.2.1.1.1 25-1.1.2.1.3.1.2 26-1.1.2.1.3.1.3 28-1.1.2.1.3.2.2.1 29-1.1.2.1.3.2.2.2 31-1.1.2.1.3.2.2.3 33-1.1.2.1.3.2.3.2.1 35-1.1.2.1.3.2.3.3.2.1 37-1.1.2.2.r 38-1.1.2.2.1.1.1 39-1.1.2.2 40-1.1.2.2.2.1.1 41-1.1.2.2 45-1.2.2.1 46-1.2.2 51-1.3.1.1.1
# ::id pmid_1563_0473.254
# ::preferred 
(a / and
      :op1 (g / generate-01~e.9
            :ARG1 (m / mouse~e.7
                  :mod (t / transgenic)
                  :mod (m2 / macro-molecular-complex
                        :part (p / protein
                              :name (n / name :op1 "K14"~e.2))
                        :part (p2 / protein
                              :name (n2 / name :op1 "Snail"~e.4))))
            :manner~e.10 (d / digest-01~e.11
                  :ARG1 (s / small-molecule
                        :name (n3 / name :op1 "plasmid"~e.21)
                        :mod (m3 / macro-molecular-complex
                              :part (m4 / molecular-physical-entity
                                    :name (n4 / name :op1 "pcDNA3-mm"~e.13,15))
                              :part p2~e.17
                              :part (p3 / protein
                                    :name (n5 / name :op1 "HA"~e.20)))
                        :source (p4 / person
                              :name (n6 / name
                                    :op1 "G."
                                    :op2 "de"~e.25
                                    :op3 "Herreros"~e.26)
                              :location (u / university
                                    :wiki "Universitat_Pompeu_Fabra"
                                    :name (n7 / name
                                          :op1 "Universitat"~e.28
                                          :op2 "Pompeu"~e.29
                                          :op3 "Fabra"~e.31)
                                    :location (c / city
                                          :wiki "Barcelona"
                                          :name (n8 / name :op1 "Barcelona"~e.33)
                                          :location (c2 / country
                                                :wiki "Spain"
                                                :name (n9 / name :op1 "Spain"~e.35))))))
                  :instrument~e.37 (a2 / and~e.39,41
                        :op1 (e / enzyme
                              :name (n10 / name :op1 "BamHI"~e.38))
                        :op2 (e2 / enzyme
                              :name (n11 / name :op1 "NotI"~e.40)))))
      :op2 (s2 / subclone-00
            :ARG1 m
            :ARG3 (v / vector~e.46
                  :mod p~e.45))
      :ARG1-of (d2 / describe-01
            :ARG0 (p5 / publication
                  :ARG1-of (c3 / cite-01 :ARG2 "49"~e.51))))

# ::tok The linearized construct was injected into the nucleus of embryos from CD1 mice .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1 2-1.1 4-1 5-1.2.r 7-1.2 8-1.2.1.r 9-1.2.1 10-1.2.1.1.r 11-1.2.1.1.1.1 12-1.2.1.1.1.2
# ::id pmid_1563_0473.255
# ::preferred 
(i / inject-01~e.4
      :ARG1 (c / construct~e.2
            :ARG1-of (l / linearize-00~e.1))
      :ARG2~e.5 (n / nucleus~e.7
            :part-of~e.8 (e / embryo~e.9
                  :source~e.10 (o / organism
                        :name (n2 / name :op1 "CD1"~e.11 :op2 "mouse"~e.12)))))

# ::tok The <i> K14 @-@ Smad 2 </i> Tg mouse was reported in Ito et al. , 2001 .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.2.2.1.1.1 8-1.2 10-1 12-1.1.1.1.1.1 13-1.1.1 14-1.1.1.2.1 16-1.1.2.1
# ::id pmid_1563_0473.256
# ::preferred 
(r / report-01~e.10
      :ARG0 (p / publication-91
            :ARG0 (a / and~e.13
                  :op1 (p2 / person
                        :name (n / name :op1 "Ito"~e.12))
                  :op2 (p3 / person
                        :mod (o / other~e.14)))
            :time (d / date-entity :year "2001"~e.16))
      :ARG1 (m / mouse~e.8
            :mod (t / transgenic)
            :mod (m2 / macro-molecular-complex
                  :part (p4 / protein
                        :name (n2 / name :op1 "K14"~e.2))
                  :part (p5 / protein
                        :name (n3 / name :op1 "SMAD2")))))

# ::tok The <i> TGF-β2 </i> knockout ( KO ) mouse was described in [ @<xref ref-type="bibr" rid="pbio-0030011-b34"> 34 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.2.1.1.1.1 4-1.2.1 8-1.2 10-1 16-1.1.1.1
# ::id pmid_1563_0473.257
# ::preferred 
(d / describe-01~e.10
      :ARG0 (p / publication-91
            :ARG1-of (c / cite-01 :ARG2 "34"~e.16))
      :ARG1 (m / mouse~e.8
            :location-of (k / knockout-00~e.4
                  :ARG1 (g / gene
                        :name (n / name :op1 "TGF-β2"~e.2)))))

# ::tok The <i> shh </i> KO mouse [ @<xref ref-type="bibr" rid="pbio-0030011-b38"> 38 </xref>@ ] and TOPGal mouse [ @<xref ref-type="bibr" rid="pbio-0030011-b20"> 20 </xref>@ ] have previously been reported .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1.1.1.1.1.1 5-1.1.1 10-1.1.1.2.1.1.1 13-1.1 14-1.1.2.1.1.1.1 15-1.1.2 20-1.1.2.2.1.1.1 24-1.2 26-1
# ::id pmid_1563_0473.258
# ::preferred 
(r / report-01~e.26
      :ARG1 (a / and~e.13
            :op1 (m / mouse~e.5
                  :location-of (k / knockout-00
                        :ARG1 (g / gene
                              :name (n / name :op1 "shh"~e.2)))
                  :ARG1-of (d / describe-01
                        :ARG0 (p / publication
                              :ARG1-of (c / cite-01 :ARG2 "38"~e.10))))
            :op2 (m2 / mouse~e.15
                  :ARG3-of (e / express-03
                        :ARG2 (m3 / molecular-physical-entity
                              :name (n2 / name :op1 "TOPGal"~e.14)))
                  :ARG1-of (d2 / describe-01
                        :ARG0 (p2 / publication
                              :ARG1-of (c2 / cite-01 :ARG2 "20"~e.20)))))
      :time (p3 / previous~e.24))

# ::tok Western blot and immunoprecipitation
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 1-1.1.1.2 2-1
# ::id pmid_1563_0473.259
# ::preferred 
(a / and~e.2
      :op1 (t / technique
            :name (n / name :op1 "western"~e.0 :op2 "blot"~e.1))
      :op2 (i / immunoprecipitate-00))

# ::tok Protein extracts from primary keratinocytes were generated either by lysing cells in lysis buffer ( 1 % NP @-@ 40 , 1 % sodium deoxycholate , 20 mM Tris @-@ Cl [pH 7.4], 140 mM NaCl containing 1 mM sodium vanadate , 2 mM phenylmethylsulfonyl fluoride , and protease inhibitors ) or directly in Laemmli bβuffer and boiled .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 1-1.1.1 3-1.1.1.2.1 6-1.1 10-1.1.2.1.1 12-1.1.2.1.2.1 13-1.1.2.1.2 13-1.1.2.2.1.1.2 15-1.1.2.1.2.2.1.2.1 16-1.1.2.1.2.2.1.2 17-1.1.2.1.2.2.1.1.1 19-1.1.2.1.2.2.1.1.1 21-1.1.2.1.2.2.1.2.1 22-1.1.2.1.2.2.1.2 23-1.1.2.1.2.2.2.1.1 24-1.1.2.1.2.2.2.1.2 26-1.1.2.1.2.2.3.2.1 28-1.1.2.1.2.2.3.1.1 30-1.1.2.1.2.2.3.1.1 33-1.1.2.1.2.2.4.2.1 35-1.1.2.1.2.2.4.1.1 36-1.1.2.1.2.2.4.3 37-1.1.2.1.2.2.4.3.1.1.2.1 39-1.1.2.1.2.2.4.3.1.1.1.1 40-1.1.2.1.2.2.4.3.1.1.1.2 42-1.1.2.1.2.2.4.3.1.2.2.1 44-1.1.2.1.2.2.4.3.1.2.1.1 45-1.1.2.1.2.2.4.3.1.2.1.2 47-1.1.2.1.2.2.4.3.1 48-1.1.2.1.2.2.4.3.1.3.1.1.1.1 49-1.1.2.1.2.2.4.3.1.3 49-1.1.2.1.2.2.4.3.1.3.1 49-1.1.2.1.2.2.4.3.1.3.1.r 51-1.1.2 52-1.1.2.2.2 52-1.1.2.2.2.r 54-1.1.2.2.1.1.1 56-1 57-1.2
# ::id pmid_1563_0473.260
# ::preferred 
(a / and~e.56
      :op1 (g / generate-01~e.6
            :ARG1 (e / extract-01~e.1
                  :ARG1 (p / protein~e.0)
                  :ARG2 (k / keratinocyte
                        :mod (p2 / primary~e.3)))
            :ARG2 (o / or~e.51
                  :op1 (l / lyse-00
                        :ARG1 (c / cell~e.10)
                        :location (b / buffer~e.13
                              :mod (l2 / lysis~e.12)
                              :consist-of (a2 / and
                                    :op1 (m / molecular-physical-entity
                                          :name (n / name :op1 "NP-40"~e.17,19)
                                          :quant (p3 / percentage-entity~e.16,22 :value "1"~e.15,21))
                                    :op2 (m2 / molecular-physical-entity
                                          :name (n2 / name :op1 "sodium"~e.23 :op2 "deoxycholate"~e.24)
                                          :quant p3)
                                    :op3 (m3 / molecular-physical-entity
                                          :name (n3 / name :op1 "Tris-Cl"~e.28,30)
                                          :quant (c2 / concentration-quantity
                                                :quant "20"~e.26
                                                :unit (m4 / millimolar))
                                          :mod (a3 / acidity-quantity
                                                :quant "7.4"
                                                :scale (p4 / ph)))
                                    :op4 (m5 / molecular-physical-entity
                                          :name (n4 / name :op1 "NaCl"~e.35)
                                          :quant (c3 / concentration-quantity
                                                :quant "140"~e.33
                                                :unit m4)
                                          :ARG0-of (c4 / contain-01~e.36
                                                :ARG1 (a4 / and~e.47
                                                      :op1 (m6 / molecular-physical-entity
                                                            :name (n5 / name :op1 "sodium"~e.39 :op2 "vanadate"~e.40)
                                                            :quant (c5 / concentration-quantity
                                                                  :quant "1"~e.37
                                                                  :unit m4))
                                                      :op2 (m7 / molecular-physical-entity
                                                            :name (n6 / name :op1 "phenylmethylsulfonyl"~e.44 :op2 "fluoride"~e.45)
                                                            :quant (c6 / concentration-quantity
                                                                  :quant "2"~e.42
                                                                  :unit m4))
                                                      :op3 (m8 / molecular-physical-entity~e.49
                                                            :ARG0-of~e.49 (i / inhibit-01~e.49
                                                                  :ARG1 (e2 / enzyme
                                                                        :name (n7 / name :op1 "protease"~e.48))))))))))
                  :op2 (l3 / lyse-00
                        :location (m9 / molecular-physical-entity
                              :name (n8 / name :op1 "Laemmli"~e.54 :op2 "buffer"~e.13))
                        :manner~e.52 (d / direct~e.52))))
      :op2 (b2 / boil-01~e.57
            :ARG1 e))

# ::tok For skin tissue : Frozen tissue was pulverized in a liquid nitrogen @-@ cooled Gevebesmascher and the powder scraped into a chilled microcentrifuge tube .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3.1 2-1.3 4-1.1.1.1 5-1.1.1 7-1.1 8-1.1.2.r 10-1.1.2.3 11-1.1.2.2.1 13-1.1.2.2 14-1.1.2.1.1 15-1 17-1.2.1 18-1.2 19-1.2.2.r 21-1.2.2.2 22-1.2.2.1 23-1.2.2
# ::id pmid_1563_0473.261
# ::preferred 
(a / and~e.15
      :op1 (p / pulverize-01~e.7
            :ARG1 (t / tissue~e.5
                  :ARG1-of (f / freeze-01~e.4))
            :location~e.8 (m / molecular-physical-entity
                  :name (n / name :op1 "Gevebesmascher"~e.14)
                  :ARG1-of (c / cool-01~e.13
                        :instrument (n2 / nitrogen~e.11))
                  :mod (l / liquid~e.10)))
      :op2 (s / scrape-02~e.18
            :ARG1 (p2 / powder~e.17)
            :destination~e.19 (t2 / tube~e.23
                  :mod (m2 / microcentrifuge~e.22)
                  :ARG1-of (c2 / chill-01~e.21)))
      :topic (t3 / tissue~e.2
            :part-of (s2 / skin~e.1)))

# ::tok RIPA buffer ( 1 % Triton X @-@ 100 in PBS with 10 mM EDTA , 150 mN NaCl , 1 % sodium deoxycholate , and 0.1 % SDS ) and protease inhibitors or Laemmli buffer was added .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1.1 1-1.1.1.1.2 3-1.1.1.2.1.1.2.1 4-1.1.1.2.1.1.2 5-1.1.1.2.1.1.1.1 6-1.1.1.2.1.1.1.2 8-1.1.1.2.1.1.1.2 10-1.1.1.2.1.2.1.1 11-1.1.1.2.1.3.r 12-1.1.1.2.1.3.2.1 14-1.1.1.2.1.3.1.1 16-1.1.1.2.2.2.1 18-1.1.1.2.2.1.1 20-1.1.1.2.3.2 21-1.1.1.2.3.2 22-1.1.1.2.3.1.1 23-1.1.1.2.3.1.2 25-1.1.1.2 26-1.1.1.2.4.2.1 27-1.1.1.2.4.2 28-1.1.1.2.4.1.1 30-1.1 30-1.1.1.2 31-1.1.2.1.1.1.1.1 32-1.1.2.1 32-1.1.2.1.1 32-1.1.2.1.1.r 33-1.1.2 34-1.1.2.2.1.1 35-1.1.2.2.1.2 37-1
# ::id pmid_1563_0473.262
# ::preferred 
(a / add-02~e.37
      :ARG1 (a2 / and~e.30
            :op1 (m / molecular-physical-entity
                  :name (n / name :op1 "RIPA"~e.0 :op2 "buffer"~e.1)
                  :consist-of (a3 / and~e.25,30
                        :op1 (i / include-01
                              :ARG1 (m2 / molecular-physical-entity
                                    :name (n2 / name :op1 "Triton"~e.5 :op2 "X-100"~e.6,8)
                                    :quant (p / percentage-entity~e.4 :value "1"~e.3))
                              :ARG2 (m3 / molecular-physical-entity
                                    :name (n3 / name :op1 "PBS"~e.10))
                              :accompanier~e.11 (m4 / molecular-physical-entity
                                    :name (n4 / name :op1 "EDTA"~e.14)
                                    :quant (c / concentration-quantity
                                          :quant "10"~e.12
                                          :unit (m5 / millimolar))))
                        :op2 (m6 / molecular-physical-entity
                              :name (n5 / name :op1 "NaCl"~e.18)
                              :quant (c2 / concentration-quantity
                                    :quant "150"~e.16
                                    :unit m5))
                        :op3 (m7 / molecular-physical-entity
                              :name (n6 / name :op1 "sodium"~e.22 :op2 "deoxycholate"~e.23)
                              :quant p~e.20,21)
                        :op4 (m8 / molecular-physical-entity
                              :name (n7 / name :op1 "SDS"~e.28)
                              :quant (p2 / percentage-entity~e.27 :value "0.1"~e.26))))
            :op2 (o / or~e.33
                  :op1 (m9 / molecular-physical-entity~e.32
                        :ARG0-of~e.32 (i2 / inhibit-01~e.32
                              :ARG1 (e / enzyme
                                    :name (n8 / name :op1 "protease"~e.31))))
                  :op2 (m10 / molecular-physical-entity
                        :name (n9 / name :op1 "Laemmli"~e.34 :op2 "buffer"~e.35)))))

# ::tok The cell suspension was sonicated three times for 15 s and centrifuged at 14,000 rpm at 4 °C .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.2.1 2-1.1.2 5-1.1.1 6-1.1.1.r 6-1.1.3 8-1.1.3.1 10-1 11-1.2 12-1.2.3.r 13-1.2.3.1 15-1.2.2.r 16-1.2.2.1
# ::id pmid_1563_0473.263
# ::preferred 
(a / and~e.10
      :op1 (s / sonicate-00
            :frequency~e.6 "3"~e.5
            :ARG1 (s2 / suspend-02~e.2
                  :ARG1 (c / cell~e.1))
            :duration (t / temporal-quantity~e.6
                  :quant "15"~e.8
                  :unit (s3 / second)))
      :op2 (c2 / centrifuge-00~e.11
            :ARG1 s2
            :ARG2~e.15 (t2 / temperature-quantity
                  :quant "4"~e.16
                  :scale (c3 / celsius))
            :frequency~e.12 (s4 / speed-quantity
                  :quant "14000"~e.13
                  :unit (r / rotation-per-minute))))

# ::tok The supernatant was separated from the pellet and used in the experiments .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1 3-1.1 4-1.1.2.r 6-1.1.2 7-1 8-1.2 9-1.2.2.r 11-1.2.2
# ::id pmid_1563_0473.264
# ::preferred 
(a / and~e.7
      :op1 (s / separate-01~e.3
            :ARG1 (s2 / supernatant~e.1)
            :ARG2~e.4 (p / pellet~e.6))
      :op2 (u / use-01~e.8
            :ARG1 s2
            :ARG2~e.9 (e / experiment-01~e.11)))

# ::tok Extracts subjected to immunoprecipitation were precleared with Protein G Sepharose ( Amersham , Piscataway , New York , United States ) and incubated with antibody with rocking overnight at 4 °C .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1.1.1 7-1.1.2.1.1 8-1.1.2.1.2 9-1.1.2.1.3 11-1.1.2.2.1.1 13-1.1.2.2.2.1.1 15-1.1.2.2.2.2.2.1 16-1.1.2.2.2.2.2.2 18-1.1.2.2.2.2.3.2.1 19-1.1.2.2.2.2.3.2.2 21-1 22-1.2 23-1.2.2.r 24-1.2.2.1 26-1.2.2.2 27-1.2.3 28-1.2.4.r 29-1.2.4.1
# ::id pmid_1563_0473.265
# ::preferred 
(a / and~e.21
      :op1 (p / preclear-00
            :ARG1 (e / extract-01~e.0
                  :ARG1-of (s2 / subject-01~e.1
                        :ARG2 (i / immunoprecipitate-00)))
            :ARG2 (p3 / product
                  :name (n6 / name
                        :op1 "Protein"~e.7
                        :op2 "G"~e.8
                        :op3 "Sepharose"~e.9)
                  :source (c3 / company
                        :name (n5 / name :op1 "Amersham"~e.11)
                        :location (c5 / city
                              :name (n4 / name :op1 "Piscataway"~e.13)
                              :location (s / state
                                    :wiki "New_York"
                                    :name (n2 / name :op1 "New"~e.15 :op2 "York"~e.16)
                                    :location (c2 / country
                                          :wiki "United_States"
                                          :name (n3 / name :op1 "United"~e.18 :op2 "States"~e.19)))))))
      :op2 (i2 / incubate-01~e.22
            :ARG1 e
            :ARG2~e.23 (a2 / and
                  :op1 (a3 / antibody~e.24)
                  :op2 (r / rock-01~e.26
                        :ARG1 e))
            :time (o / overnight~e.27)
            :mod~e.28 (t / temperature-quantity
                  :quant "4"~e.29
                  :scale (c4 / celsius))))

# ::tok Protein G Sepharose was added and samples were incubated for 1 h at 4 °C with rocking .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1.1 1-1.1.1.1.2 2-1.1.1.1.3 4-1.1 5-1 6-1.2.1 8-1.2 9-1.2.3.r 10-1.2.3.1 12-1.2.4.r 13-1.2.4.1 15-1.2.2.r 16-1.2.2
# ::id pmid_1563_0473.266
# ::preferred 
(a / and~e.5
      :op1 (a2 / add-02~e.4
            :ARG1 (p2 / product
                  :name (n2 / name
                        :op1 "Protein"~e.0
                        :op2 "G"~e.1
                        :op3 "Sepharose"~e.2)))
      :op2 (i / incubate-01~e.8
            :ARG1 (s / sample-01~e.6)
            :ARG2~e.15 (r / rock-01~e.16)
            :duration~e.9 (t / temporal-quantity
                  :quant "1"~e.10
                  :unit (h / hour))
            :mod~e.12 (t2 / temperature-quantity
                  :quant "4"~e.13
                  :scale (c / celsius))))

# ::tok Samples were washed three times for 5 min each in lysis buffer , and the Protein G Sepharose @-@ antibody @-@ antigen pellet was resuspended in Laemmli buffer and boiled for 10 min .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2 2-1.1 3-1.1.1 4-1.1.1.r 4-1.1.4 4-1.2.2.2 6-1.1.4.1 8-1.1.2.1 9-1.1.3.r 10-1.1.3.1 11-1.1.3 13-1 15-1.2.1.1.3.1.1 16-1.2.1.1.3.1.2 17-1.2.1.1.3.1.3 19-1.2.1.1.2 21-1.2.1.1.1 22-1.2.1.1 26-1.2.1.2.1.1 27-1.2.1.2 28-1.2 29-1.2.2 31-1.2.2.2.1
# ::id pmid_1563_0473.267
# ::preferred 
(a / and~e.13
      :op1 (w / wash-01~e.2
            :frequency~e.4 "3"~e.3
            :ARG1 (s / sample-01~e.0
                  :mod (e / each~e.8))
            :ARG2~e.9 (b / buffer~e.11
                  :mod (l / lysis~e.10))
            :duration (t / temporal-quantity~e.4
                  :quant "5"~e.6
                  :unit (m / minute)))
      :op2 (a4 / and~e.28
            :op1 (s2 / suspend-02
                  :ARG1 (p / pellet~e.22
                        :mod (a2 / antigen~e.21)
                        :mod (a3 / antibody~e.19)
                        :mod (p3 / product
                              :name (n4 / name
                                    :op1 "Protein"~e.15
                                    :op2 "G"~e.16
                                    :op3 "Sepharose"~e.17)))
                  :location (b2 / buffer~e.27
                        :name (n2 / name :op1 "Laemmli"~e.26))
                  :mod (a5 / again))
            :op2 (b3 / boil-01~e.29
                  :ARG1 p
                  :duration (t2 / temporal-quantity~e.4
                        :quant "10"~e.31
                        :unit (m2 / minute)))))

# ::tok Samples were run on SDS @-@ PAGE and transferred to nitrocellulose membrane ( Schleicher and Schuell Bioscience , Keene , New Hampshire , United States ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 2-1.1 3-1.1.2.r 4-1.1.2.1.1 6-1.1.2.1.1 7-1 8-1.2 9-1.2.2.r 10-1.2.2.1 11-1.2.2 13-1.2.2.2.1.1 14-1.2.2.2.1.2 15-1.2.2.2.1.3 16-1.2.2.2.1.4 18-1.2.2.2.2.1.1 20-1.2.2.2.2.2.2.1 21-1.2.2.2.2.2.2.2 23-1.2.2.2.2.2.3.2.1 24-1.2.2.2.2.2.3.2.2
# ::id pmid_1563_0473.268
# ::preferred 
(a / and~e.7
      :op1 (r / run-01~e.2
            :ARG1 (s2 / sample-01~e.0)
            :manner~e.3 (e / event
                  :name (n7 / name :op1 "SDS-PAGE"~e.4,6)))
      :op2 (t / transfer-01~e.8
            :ARG1 s2
            :ARG2~e.9 (m / membrane~e.11
                  :mod (n4 / nitrocellulose~e.10)
                  :source (c2 / company
                        :name (n5 / name
                              :op1 "Schleicher"~e.13
                              :op2 "and"~e.14
                              :op3 "Schuell"~e.15
                              :op4 "Bioscience"~e.16)
                        :location (c4 / city
                              :name (n6 / name :op1 "Keene"~e.18)
                              :location (s / state
                                    :wiki "New_Hampshire"
                                    :name (n / name :op1 "New"~e.20 :op2 "Hampshire"~e.21)
                                    :location (c / country
                                          :wiki "United_States"
                                          :name (n2 / name :op1 "United"~e.23 :op2 "States"~e.24))))))))

# ::tok Western blot signals were developed using the enhanced chemiluminescence kit from Amersham
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1.1 1-1.1.1.1.2 2-1.1 4-1 5-1.2 7-1.2.1.1 8-1.2.1.2 9-1.2.1 10-1.2.1.3.r 11-1.2.1.3.1.1
# ::id pmid_1563_0473.269
# ::preferred 
(d / develop-02~e.4
      :ARG1 (s / signal-07~e.2
            :ARG0 (t / thing
                  :name (n3 / name :op1 "Western"~e.0 :op2 "blot"~e.1)))
      :ARG2-of (u / use-01~e.5
            :ARG1 (k / kit~e.9
                  :ARG1-of (e / enhance-01~e.7)
                  :mod (c / chemiluminescence~e.8)
                  :source~e.10 (c2 / company
                        :name (n2 / name :op1 "Amersham"~e.11)))))

# ::tok Cell culture
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1
# ::id pmid_1563_0473.270
# ::preferred 
(c / culture~e.1
      :mod (c2 / cell~e.0))

# ::tok Primary keratinocytes were culture in low @-@ calcium medium as previously described [ @<xref ref-type="bibr" rid="pbio-0030011-b04"> 4 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 3-1 4-1.2.r 5-1.2.1 7-1.2.1.1 8-1.2 9-1.3.2.r 10-1.3.2 11-1.3 16-1.3.1.1.1
# ::id pmid_1563_0473.271
# ::preferred 
(c / culture-01~e.3
      :ARG1 (k / keratinocyte
            :mod (p / primary~e.0))
      :location~e.4 (m / medium~e.8
            :ARG1-of (l / low-04~e.5
                  :ARG2 (c2 / calcium~e.7)))
      :ARG1-of (d2 / describe-01~e.11
            :ARG0 (p3 / publication
                  :ARG1-of (c3 / cite-01 :ARG2 "4"~e.16))
            :time~e.9 (p2 / previous~e.10)))

# ::tok Transient transfections were carried out with FuGENE6 reagent ( Roche , Indianapolis , Indiana , United States ) according to the manufacturer 's protocol .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 3-1 4-1 5-1.3.r 6-1.3.1.1 7-1.3 9-1.3.2.1.1 11-1.3.2.2.2.1 13-1.3.2.2.3.2.1 15-1.3.2.2.3.3.2.1 16-1.3.2.2.3.3.2.2 18-1.2 19-1.2 21-1.2.1.1 22-1.2.1.1.r 23-1.2.1
# ::id pmid_1563_0473.272
# ::preferred 
(c4 / carry-03~e.3,4
      :ARG1 (t / transfect-00
            :mod (t2 / transient~e.0))
      :ARG1-of (s2 / say-01~e.18,19
            :ARG0 (p / protocol~e.23
                  :poss~e.22 c5~e.21))
      :instrument~e.5 (r / reagent~e.7
            :name (n5 / name :op1 "FuGENE6"~e.6)
            :source (c5 / company
                  :name (n4 / name :op1 "Roche"~e.9)
                  :location (c / city
                        :wiki "Indianapolis"
                        :name (n / name :op1 "Indianapolis"~e.11)
                        :location (s / state
                              :wiki "Indiana"
                              :name (n2 / name :op1 "Indiana"~e.13)
                              :location (c2 / country
                                    :wiki "United_States"
                                    :name (n3 / name :op1 "United"~e.15 :op2 "States"~e.16))))
                  :ARG0-of (m / manufacture-01))))

# ::tok Measurement of β-galactosidase or luciferase levels in promoter activity studies were carried out with the Galacto @-@ Lite assay kit ( TROPIX , Bedford , Massachusetts , United States ) and the Dual luciferase ( Promega , Madison , Wisconsin , United States ) , respectively .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1.1.1.r 2-1.1.1.1.1.1.1 3-1.1.1 4-1.1.1.2.1 5-1.1.1.1 5-1.1.1.2 9-1.1.2 11-1 12-1 13-1.3.r 15-1.3.1.1.1 17-1.3.1.1.1 18-1.3.1.2.1 19-1.3.1.2 21-1.3.1.3.1.1 23-1.3.1.3.2.1.1 25-1.3.1.3.2.2.2.1 27-1.3.1.3.2.2.3.2.1 28-1.3.1.3.2.2.3.2.2 30-1.3 32-1.3.2.1.1 33-1.3.2.1.2 35-1.3.2.2.1.1 37-1.3.2.2.2.1.1 39-1.3.2.2.2.2.2.1 41-1.3.2.2.2.2.3 42-1.3.1.3.2.2 42-1.3.2.2.2.2 45-1.2
# ::id pmid_1563_0473.273
# ::preferred 
(c6 / carry-03~e.11,12
      :ARG1 (m / measure-01~e.0
            :ARG1~e.1 (o / or~e.3
                  :op1 (l3 / level~e.5
                        :quant-of (e / enzyme
                              :name (n4 / name :op1 "β-galactosidase"~e.2)))
                  :op2 (l / level~e.5
                        :quant-of (l2 / luciferase~e.4)))
            :subevent-of (s3 / study-01~e.9
                  :ARG1 (a4 / act-01
                        :part (m2 / molecular-physical-entity
                              :ARG0-of (p / promote-01)))))
      :mod (r / respective~e.45)
      :instrument~e.13 (a3 / and~e.30
            :op1 (p3 / product
                  :name (n7 / name :op1 "Galacto-Lite"~e.15,17)
                  :mod (k2 / kit~e.19
                        :mod (a / assay-00~e.18))
                  :source (c3 / company
                        :name (n5 / name :op1 "TROPIX"~e.21)
                        :location (c4 / city
                              :name (n6 / name :op1 "Bedford"~e.23)
                              :location (s / state~e.42
                                    :wiki "Massachusetts"
                                    :name (n / name :op1 "Massachusetts"~e.25)
                                    :location (c / country
                                          :wiki "United_States"
                                          :name (n2 / name :op1 "United"~e.27 :op2 "States"~e.28))))))
            :op2 (p2 / product
                  :name (n8 / name :op1 "Dual"~e.32 :op2 "luciferase"~e.33)
                  :source (c2 / company
                        :name (n9 / name :op1 "Promega"~e.35)
                        :location (c5 / city
                              :name (n10 / name :op1 "Madison"~e.37)
                              :location (s2 / state~e.42
                                    :wiki "Wisconsin"
                                    :name (n3 / name :op1 "Wisconsin"~e.39)
                                    :location c~e.41))))))

# ::tok Runella luciferase was cotransfected into cells to correct for transfection efficiency .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 1-1.1 5-1.2 7-1.3 8-1.3.1.r 9-1.3.1.1 10-1.3.1
# ::id pmid_1563_0473.274
# ::preferred 
(c / cotransfect-00
      :ARG1 (l / luciferase~e.1
            :name (n / name :op1 "Runella"~e.0))
      :ARG2 (c2 / cell~e.5)
      :ARG0-of (c3 / correct-01~e.7
            :ARG1~e.8 (e / efficient-01~e.10
                  :ARG1 (t / transfect-00~e.9))))

# ::tok Experiments were done in triplicate and repeated at least three times .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 3-1.1.r 4-1.1 6-1.2 7-1.2.2 8-1.2.2 9-1.2.1 10-1.2.1.r
# ::id pmid_1563_0473.275
# ::preferred 
(e2 / experiment-01~e.0
      :quant~e.3 (t / triplicate~e.4)
      :ARG1-of (r / repeat-01~e.6
            :frequency~e.10 "3"~e.9
            :mod (a / at-least~e.7,8)))

# ::tok Measurements were done on a luminometer ( MGM Instruments , Hamden , Connecticut , United States ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 3-1.1.r 5-1.1 7-1.1.1.1.1 8-1.1.1.1.2 10-1.1.1.2.1.1 12-1.1.1.2.2.2.1 14-1.1.1.2.2.3.2.1 15-1.1.1.2.2.3.2.2
# ::id pmid_1563_0473.276
# ::preferred 
(m2 / measure-01~e.0
      :instrument~e.3 (l / luminometer~e.5
            :source (c2 / company
                  :name (n3 / name :op1 "MGM"~e.7 :op2 "Instruments"~e.8)
                  :location (c3 / city
                        :name (n4 / name :op1 "Hamden"~e.10)
                        :location (s / state
                              :wiki "Connecticut"
                              :name (n / name :op1 "Connecticut"~e.12)
                              :location (c / country
                                    :wiki "United_States"
                                    :name (n2 / name :op1 "United"~e.14 :op2 "States"~e.15)))))))

# ::tok For experiments measuring phosphorylation of MAPK , keratinocytes were serum starved for 3 h prior to harvesting of cells by incubation in medium lacking serum .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.2.1 2-1.2 3-1.2.2 4-1.2.2.1.r 5-1.2.2.1.1.1 9-1.1.2 10-1.1 11-1.1.3.r 12-1.1.3.1 14-1.1.4 15-1.1.4.1.r 16-1.1.4.1 17-1.1.4.1.1.r 18-1.1.4.1.1 19-1.1.5.r 20-1.1.5 21-1.1.5.2.r 22-1.1.5.2 23-1.1.5.2.1 24-1.1.5.2.1.1
# ::id pmid_1563_0473.277
# ::preferred 
(h / have-purpose-91
      :ARG1 (s / starve-01~e.10
            :ARG1 (k / keratinocyte)
            :ARG2 (s2 / serum~e.9)
            :duration~e.11 (t / temporal-quantity
                  :quant "3"~e.12
                  :unit (h2 / hour))
            :time (p3 / prior~e.14
                  :op1~e.15 (h3 / harvest-01~e.16
                        :ARG1~e.17 (c / cell~e.18)))
            :manner~e.19 (i / incubate-01~e.20
                  :ARG1 k
                  :location~e.21 (m / medium~e.22
                        :ARG0-of (l / lack-01~e.23
                              :ARG1 s2~e.24))))
      :ARG2 (m2 / measure-01~e.2
            :ARG0 (e / experiment-01~e.1)
            :ARG1 (p / phosphorylate-01~e.3
                  :ARG1~e.4 (e2 / enzyme
                        :name (n / name :op1 "MAPK"~e.5)))))

# ::tok Treatment of cells with Wnt @- and noggin @-@ conditioned medium was previously described [ @<xref ref-type="bibr" rid="pbio-0030011-b04"> 4 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.1.r 2-1.1 3-1.2.r 4-1.2.1.1.1.1.1 6-1.2.1.1 7-1.2.1.1.2.1.1 9-1.2.1 10-1.2 12-1.3.2 13-1.3 18-1.3.1.1.1
# ::id pmid_1563_0473.278
# ::preferred 
(t / treat-04~e.0
      :ARG1~e.1 (c / cell~e.2)
      :ARG2~e.3 (m / medium~e.10
            :ARG1-of (c2 / condition-01~e.9
                  :ARG2 (a / and~e.6
                        :op1 (p / protein
                              :name (n / name :op1 "Wnt"~e.4))
                        :op2 (p2 / protein
                              :name (n2 / name :op1 "noggin"~e.7)))))
      :ARG1-of (d2 / describe-01~e.13
            :ARG0 (p4 / publication
                  :ARG1-of (c3 / cite-01 :ARG2 "4"~e.18))
            :time (p3 / previous~e.12)))

# ::tok Constructs
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1
# ::id pmid_1563_0473.279
# ::preferred 
(c / construct-01~e.0)

# ::tok The 2.2 @-@ kb murine <i> Snail </i> promoter was generated by PCR using a forward primer with an XbaI linker sequence , 5′-TCTAGAATTGTTTGCTGCTGTATGGTCTTC @-@ 3′, along with a reverse primer with a BglII linker sequence , 5′-AGATCTGTTGGCCAGAGCGACCTAG @-@ GTAG @-@ 3′, and mouse genomic DNA as a template .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.2.1.1.2.1 6-1.2.1.1.1.1 10-1 11-1.1.r 12-1.1.1.1 13-1.3 15-1.3.1.1.1 16-1.3.1.1 17-1.3.1.1.3.r 19-1.3.1.1.3.1.1 21-1.3.1.1.2.1 27-1.3.1.r 29-1.3.1.2.1 30-1.3.1.2 31-1.3.1.2.3.r 33-1.3.1.2.3.1.1 35-1.3.1.2.2.1 39-1.3.1.2.2.1.1.1 42-1.3.1 43-1.3.1.3.1.2 44-1.3.1.3.1.1 45-1.3.1.3.1 48-1.3.1.3
# ::id pmid_1563_0473.280
# ::preferred 
(g / generate-01~e.10
      :ARG0~e.11 (p / product
            :name (n / name :op1 "PCR"~e.12))
      :ARG1 (m2 / molecular-physical-entity
            :ARG0-of (p2 / promote-01
                  :ARG1 (g2 / gene
                        :name (n2 / name :op1 "Snail"~e.6)
                        :quant (d / distance-quanity
                              :quant "2.2"~e.1
                              :unit (k / kilo-base-pair))
                        :mod (o / organism
                              :name (n7 / name :op1 "Murinae")))))
      :ARG2-of (u / use-01~e.13
            :ARG1~e.27 (a / and~e.42
                  :op1 (p3 / primer~e.16
                        :ARG1-of (f / forward-01~e.15)
                        :ARG1-of (m / mean-01
                              :ARG2 (d2 / dna-sequence~e.21
                                    :name (n4 / name :op1 "5′-TCTAGAATTGTTTGCTGCTGTATGGTCTTC-3′")))
                        :part~e.17 (p5 / protein-segment
                              :name (n8 / name :op1 "XbaI"~e.19)
                              :ARG0-of (l / link-01)))
                  :op2 (p4 / primer~e.30
                        :ARG1-of (r / reverse-01~e.29)
                        :ARG1-of (m3 / mean-01
                              :ARG2 (d3 / dna-sequence~e.35
                                    :name (n6 / name :op1 "5′-AGATCTGTTGGCCAGAGCGACCTAG-GTAG-3′"~e.39)))
                        :part~e.31 (p6 / protein-segment
                              :name (n3 / name :op1 "BglII"~e.33)
                              :ARG0-of (l2 / link-01)))
                  :op3 (t / template~e.48
                        :mod (d4 / dna~e.45
                              :mod (g3 / genomic~e.44)
                              :mod (m4 / mouse~e.43))))))

# ::tok The PCR product was purified with the Gel Extraction Kit ( Qiagen , Valencia , California , United States ) and ligated into pCRII @-@ TOPO TA vector ( Invitrogen , Carlsbad , California , United States ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1.1.1 2-1.1.1 2-1.1.2 2-1.2.2 4-1.1 5-1.1.2.r 7-1.1.2.1.1 8-1.1.2.1.2 9-1.1.2.1.3 11-1.1.2.2.1.1 13-1.1.2.2.2.1.1 15-1.1.2.2.2.2.2.1 17-1.1.2.2.2.2.3.2.1 18-1.1.2.2.2.2.3.2.2 20-1 21-1.2 23-1.2.2.1.1 25-1.2.2.1.1 26-1.2.2.1.2 27-1.2.2.2 29-1.2.2.3.1.1 31-1.2.2.3.2.1.1 33-1.2.2.3.2.2 34-1.2.2.3.2.2 35-1.2.2.3.2.2 36-1.2.2.3.2.2
# ::id pmid_1563_0473.281
# ::preferred 
(a / and~e.20
      :op1 (p / purify-01~e.4
            :ARG1 (p2 / product~e.2
                  :name (n3 / name :op1 "PCR"~e.1))
            :instrument~e.5 (p3 / product~e.2
                  :name (n4 / name
                        :op1 "Gel"~e.7
                        :op2 "Extraction"~e.8
                        :op3 "Kit"~e.9)
                  :source (c2 / company
                        :name (n5 / name :op1 "Qiagen"~e.11)
                        :location (c3 / city
                              :name (n6 / name :op1 "Valencia"~e.13)
                              :location (s / state
                                    :wiki "California"
                                    :name (n / name :op1 "California"~e.15)
                                    :location (c / country
                                          :wiki "United_States"
                                          :name (n2 / name :op1 "United"~e.17 :op2 "States"~e.18)))))))
      :op2 (l / ligate-01~e.21
            :ARG1 p2
            :ARG2 (p4 / product~e.2
                  :name (n7 / name :op1 "pCRII-TOPO"~e.23,25 :op2 "TA"~e.26)
                  :mod (v / vector~e.27)
                  :source (c4 / company
                        :name (n8 / name :op1 "Invitrogen"~e.29)
                        :location (c5 / city
                              :name (n9 / name :op1 "Carlsbad"~e.31)
                              :location s~e.33,34,35,36)))))

# ::tok The promoter was verified by sequencing and digested with XbaI and BglII and subcloned into the pβ-gal BASIC vector ( BD Biosciences Clontech , Palo Alto , California , United States ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 3-1.1 4-1.1.2.r 5-1.1.2 6-1 7-1.2 8-1.2.2.r 9-1.2.2.1.1.1 11-1.2.2.2.1.1 12-1 14-1.3.2.r 16-1.3.2.1.1 17-1.3.2.1.2 18-1.3.2.2 20-1.3.2.3.1.1 21-1.3.2.3.1.2 22-1.3.2.3.1.3 24-1.3.2.3.2.1.1 25-1.3.2.3.2.1.2 27-1.3.2.3.2.2.2.1 29-1.3.2.3.2.2.3.2.1 30-1.3.2.3.2.2.3.2.2
# ::id pmid_1563_0473.282
# ::preferred 
(a / and~e.6,12
      :op1 (v / verify-01~e.3
            :ARG1 (m / molecular-physical-entity
                  :ARG0-of (p / promote-01))
            :manner~e.4 (s2 / sequence-00~e.5))
      :op2 (d / digest-01~e.7
            :ARG1 p
            :instrument~e.8 (a2 / and
                  :op1 (p2 / protein-segment
                        :name (n3 / name :op1 "XbaI"~e.9))
                  :op2 (p3 / protein-segment
                        :name (n4 / name :op1 "BglII"~e.11))))
      :op3 (s3 / subclone-00
            :ARG1 p
            :destination~e.14 (p4 / product
                  :name (n5 / name :op1 "pβ-gal"~e.16 :op2 "BASIC"~e.17)
                  :mod (v2 / vector~e.18)
                  :source (c2 / company
                        :name (n6 / name
                              :op1 "BD"~e.20
                              :op2 "Biosciences"~e.21
                              :op3 "Clontech"~e.22)
                        :location (c3 / city
                              :name (n7 / name :op1 "Palo"~e.24 :op2 "Alto"~e.25)
                              :location (s / state
                                    :wiki "California"
                                    :name (n / name :op1 "California"~e.27)
                                    :location (c / country
                                          :wiki "United_States"
                                          :name (n2 / name :op1 "United"~e.29 :op2 "States"~e.30))))))))

# ::tok The point mutations in the SMAD binding element was generated with the Quik @-@ Change Kit ( Stratagene , La Jolla , California , United States ) using the forward primer 5′-GGGCGGGCTTAGGTGTTTTCATTTACTCTTGAGGAAAAGCTTGGC @-@ 3′ and the reverse primer 5′-GCTTTT @-@ CCTCAAGAGTAAATGAAAACACCTAAGCCCGCCCTGCCC @-@ 3′.
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1 2-1.1 3-1.1.2.r 5-1.1.2.1.1.1.1 6-1.1.2.1 7-1.1.2 9-1 10-1.2.r 12-1.2.1.1 14-1.2.1.1 15-1.2.1.2 17-1.2.2.1.1 19-1.2.2.2.1.1 20-1.2.2.2.1.2 22-1.2.2.2.2.2.1 24-1.2.2.2.2.3.2.1 25-1.2.2.2.2.3.2.2 27-1.3 29-1.3.1.1.1 30-1.3.1.1 33-1.3.1.1.2.1.1 34-1.3.1 36-1.3.1.2.1 37-1.3.1.2 40-1.3.1.2.2.1.1
# ::id pmid_1563_0473.283
# ::preferred 
(g / generate-01~e.9
      :ARG1 (m / mutate-01~e.2
            :mod (p / point~e.1)
            :location~e.3 (e / element~e.7
                  :ARG0-of (b / bind-01~e.6
                        :ARG1 (p2 / protein
                              :name (n3 / name :op1 "SMAD"~e.5)))))
      :instrument~e.10 (p3 / product
            :name (n4 / name :op1 "Quik-Change"~e.12,14 :op2 "Kit"~e.15)
            :source (c2 / company
                  :name (n5 / name :op1 "Stratagene"~e.17)
                  :location (c3 / city
                        :name (n6 / name :op1 "La"~e.19 :op2 "Jolla"~e.20)
                        :location (s / state
                              :wiki "California"
                              :name (n / name :op1 "California"~e.22)
                              :location (c / country
                                    :wiki "United_States"
                                    :name (n2 / name :op1 "United"~e.24 :op2 "States"~e.25))))))
      :ARG2-of (u / use-01~e.27
            :ARG1 (a / and~e.34
                  :op1 (p4 / primer~e.30
                        :ARG1-of (f / forward-01~e.29)
                        :mod (d / dna-sequence
                              :name (n7 / name :op1 "5′-GGGCGGGCTTAGGTGTTTTCATTTACTCTTGAGGAAAAGCTTGGC-3′"~e.33)))
                  :op2 (p5 / primer~e.37
                        :ARG1-of (r / reverse-01~e.36)
                        :mod (d2 / dna-sequence
                              :name (n8 / name :op1 "5′-GCTTTT-CCTCAAGAGTAAATGAAAACACCTAAGCCCGCCCTGCCC-3′"~e.40))))))

# ::tok The probes for the <i> Snail </i> in situ hybridization were generated against the 3′ UTR by PCR using the forward primer 5′-ACCTTCTCCCGCATGTCCTTGCTCC @-@ 3′ and the reverse primer 5′-CTGCTGAGGCATGGTTACAGCTGG @-@ 3′, and genomic DNA as a template .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.2 5-1.2.1.1.1.1 7-1.2.1.2 8-1.2.1.2 9-1.2.1 11-1 12-1.3.r 14-1.4.1.1.2.1.1 14-1.4.1.2.2.1.1 15-1.3 16-1.1.r 17-1.1.1.1 18-1.4 20-1.4.1.1.1 21-1.4.1.1 24-1.4.1.1.2.1.1 24-1.4.1.2.2.1.1 25-1.4.1 27-1.4.1.2.1 28-1.4.1.2 32-1.4.1 33-1.4.1.3.1.1 34-1.4.1.3.1 37-1.4.1.3
# ::id pmid_1563_0473.284
# ::preferred 
(g4 / generate-01~e.11
      :ARG0~e.16 (p2 / product
            :name (n2 / name :op1 "PCR"~e.17))
      :ARG1 (p / probe-01~e.1
            :ARG2 (h / hybridize-01~e.9
                  :ARG1 (g2 / gene
                        :name (n / name :op1 "Snail"~e.5))
                  :manner (i2 / in-situ~e.7,8)))
      :prep-against~e.12 (u3 / UTR~e.15 :value "3")
      :ARG2-of (u / use-01~e.18
            :ARG1 (a / and~e.25,32
                  :op1 (p3 / primer~e.21
                        :ARG1-of (f / forward-01~e.20)
                        :mod (d / dna-sequence
                              :name (n4 / name :op1 "5′-ACCTTCTCCCGCATGTCCTTGCTCC-3′"~e.14,24)))
                  :op2 (p4 / primer~e.28
                        :ARG1-of (r / reverse-01~e.27)
                        :mod (d2 / dna-sequence
                              :name (n5 / name :op1 "5′-CTGCTGAGGCATGGTTACAGCTGG-3′"~e.14,24)))
                  :op3 (t / template~e.37
                        :mod (d3 / dna~e.34
                              :mod (g3 / genomic~e.33))))))

# ::tok The PCR product was gel purified and ligated into pCRII @-@ TOPO TA vector .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1.1.1 2-1.1.1 2-1.2.2 4-1.1.2 5-1.1 6-1 7-1.2 9-1.2.2.1.1 11-1.2.2.1.1 12-1.2.2.1.2 13-1.2.2.2
# ::id pmid_1563_0473.285
# ::preferred 
(a / and~e.6
      :op1 (p / purify-01~e.5
            :ARG1 (p2 / product~e.2
                  :name (n / name :op1 "PCR"~e.1))
            :mod (g / gel~e.4))
      :op2 (l / ligate-01~e.7
            :ARG1 p2
            :ARG3 (p3 / product~e.2
                  :name (n2 / name :op1 "pCRII-TOPO"~e.9,11 :op2 "TA"~e.12)
                  :mod (v / vector~e.13))))

# ::tok The pre @-@ LIM domain of Ajuba was generated essentially as described [ @<xref ref-type="bibr" rid="pbio-0030011-b09"> 9 </xref>@ ], but was fused to GFP by subcloning from the pEGFP @-@ N1 20 vector ( BD Biosciences Clontech )
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1.1.1 3-1.1.1.1.1 6-1.1.1.2.1.1 8-1.1 9-1.1.2.2 11-1.1.2 16-1.1.2.1.1.1 19-1 21-1.2 22-1.2.3.r 23-1.2.3.1.1 26-1.2.1.1.2.r 28-1.2.1.1.1.1 30-1.2.1.1.1.1 31-1.2.1.1.1.2 32-1.2.1.1.3 34-1.2.1.1.2.1.1 35-1.2.1.1.2.1.2 36-1.2.1.1.2.1.3
# ::id pmid_1563_0473.286
# ::preferred 
(c3 / contrast-01~e.19
      :ARG1 (g / generate-01~e.8
            :ARG1 (p5 / protein-segment
                  :name (n6 / name :op1 "pre-LIM"~e.1,3)
                  :part-of (p / protein
                        :name (n / name :op1 "Ajuba"~e.6)))
            :ARG1-of (d3 / describe-01~e.11
                  :ARG0 (p2 / publication
                        :ARG1-of (c / cite-01 :ARG2 "9"~e.16))
                  :mod (e / essential~e.9)))
      :ARG2 (f / fuse-01~e.21
            :ARG0 (s / subclone-00
                  :instrument (p4 / product
                        :name (n3 / name :op1 "pEGFP-N1"~e.28,30 :op2 "20"~e.31)
                        :source~e.26 (c2 / company
                              :name (n4 / name
                                    :op1 "BD"~e.34
                                    :op2 "Biosciences"~e.35
                                    :op3 "Clontech"~e.36))
                        :mod (v / vector~e.32)))
            :ARG1 p5
            :ARG2~e.22 (p3 / protein
                  :name (n2 / name :op1 "GFP"~e.23))))

# ::tok In situ hybridization
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1.1 2-1
# ::id pmid_1563_0473.287
# ::preferred 
(h / hybridize-01~e.2
      :manner (i / in-situ~e.0,1))

# ::tok The pCRII @-@ TOPO TA vector containing a region of the 3′ UTR of <i> Snail </i> was used as a template to generate digoxigenin @-@ labeled sense and antisense riboprobes ( Roche ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1.1 3-1.1.1.1 4-1.1.1.2 5-1.1.2 6-1.1.3 8-1.1.3.1 9-1.1.3.1.1.r 11-1.1.3.1.1.2.1 12-1.1.3.1.1.2 15-1.1.3.1.1.1.1 18-1 18-1.3.r 19-1.2.r 21-1.2 23-1.3 24-1.3.1.1.2.1 26-1.3.1.1.2 27-1.3.1.1.1 28-1.3.1 29-1.3.1.2.2 32-1.3.1.3.1.1
# ::id pmid_1563_0473.288
# ::preferred 
(u / use-01~e.18
      :ARG1 (p / product
            :name (n / name :op1 "pCRII-TOPO"~e.1,3 :op2 "TA"~e.4)
            :mod (v / vector~e.5)
            :ARG0-of (c / contain-01~e.6
                  :ARG1 (r / region~e.8
                        :part-of~e.9 (g / gene
                              :name (n2 / name :op1 "Snail"~e.15)
                              :mod (u2 / UTR~e.12 :mod "3′"~e.11)))))
      :ARG2~e.19 (t / template~e.21)
      :purpose~e.18 (g2 / generate-01~e.23
            :ARG1 (a / and~e.28
                  :op1 (r2 / riboprobe
                        :mod (s / sense~e.27)
                        :ARG1-of (l / label-01~e.26
                              :ARG2 (d / digoxigenin~e.24)))
                  :op2 (r3 / riboprobe
                        :ARG1-of l
                        :mod (a3 / antisense~e.29))
                  :source (c2 / company
                        :name (n3 / name :op1 "Roche"~e.32)))))

# ::tok The respective probes were obtained by XhoI and BamH1 digestions .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1 2-1.1 4-1 5-1.2.r 6-1.2.1.1.1.1 7-1.2.1 8-1.2.1.2.1.1 9-1.2
# ::id pmid_1563_0473.289
# ::preferred 
(o / obtain-01~e.4
      :ARG1 (p / probe-01~e.2
            :mod (r / respective~e.1))
      :ARG2~e.5 (d / digest-01~e.9
            :ARG1 (a / and~e.7
                  :op1 (p2 / product
                        :name (n / name :op1 "XhoI"~e.6))
                  :op2 (p3 / product
                        :name (n2 / name :op1 "BamH1"~e.8)))))

# ::tok In situ hybridizations were performed on 10-μm thick sections of E17.5 mouse embryos .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1.1 2-1.1 4-1 7-1.2.3 8-1.2 11-1.2.2.1 12-1.2.2
# ::id pmid_1563_0473.290
# ::preferred 
(p / perform-01~e.4
      :ARG1 (h / hybridize-01~e.2
            :manner (i / in-situ~e.0,1))
      :location (s / section-01~e.8
            :ARG2 (a / area-quantity
                  :quant "10"
                  :unit (m4 / micrometer))
            :ARG3 (e / embryo~e.12
                  :mod (m3 / mouse~e.11)
                  :mod (e2 / embryonic
                        :age (t2 / temporal-quantity
                              :quant "17.5"
                              :unit (d / day))))
            :mod (t / thick~e.7)))

# ::tok The sections were fixed with 4 % PFA for 10 min at room temperature , prehybridized at room temperature for 4.5 h , hybridized with the probe ( 2 μg/ml ) at 55 °C for 12–14 h , blocked with 10 % NGS , and treated with anti @-@ dig Fab @-@ AP antibody ( Roche #1093274 ) at a 1 @:@ 2,500 dilution for 3 h .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1 3-1.1 4-1.1.2.r 5-1.1.2.2.1 6-1.1.2.2 7-1.1.2.1.1 8-1.1.3.r 9-1.1.3.1 12-1.1.4.1 13-1.1.4 17-1.1.4.1 18-1.1.4 18-1.3.3 20-1.2.3.1 23-1.3 24-1.1.2.r 24-1.3.2.r 26-1.3.2 28-1.3.2.1.1 32-1.3.3.1 38-1.4 39-1.1.2.r 40-1.1.3.1 40-1.4.2.2.1 41-1.4.2.2 42-1.4.2.1.1 44-1 45-1.5 46-1.1.2.r 46-1.5.2.r 47-1.5.2.2.1 49-1.5.2.2.1 50-1.5.2.2.2 52-1.5.2.2.2 53-1.5.2 55-1.5.2.3.1.1 58-1.5.3.r 60-1.5.3.1.1 62-1.5.3.1.2 63-1.5.3 64-1.5.4.r 65-1.5.4.1
# ::id pmid_1563_0473.291
# ::preferred 
(a / and~e.44
      :op1 (f / fix-02~e.3
            :ARG1 (s2 / section-01~e.1)
            :instrument~e.4,24,39,46 (p3 / product
                  :name (n / name :op1 "PFA"~e.7)
                  :quant (p / percentage-entity~e.6 :value "4"~e.5))
            :duration~e.8 (t / temporal-quantity
                  :quant "10"~e.9,40
                  :unit (m / minute))
            :mod (t2 / temperature~e.13,18
                  :mod (r / room~e.12,17)))
      :op2 (p4 / prehybridize-00
            :ARG1 s2
            :mod t2
            :duration (t3 / temporal-quantity
                  :quant "4.5"~e.20
                  :unit (h / hour)))
      :op3 (h2 / hybridize-01~e.23
            :ARG1 s2
            :ARG2~e.24 (p5 / probe-01~e.26
                  :quant (c / concentration-quantity
                        :quant "2"~e.28
                        :unit (m2 / microgram-per-milliliter)))
            :manner (t4 / temperature-quantity~e.18
                  :quant "55"~e.32
                  :scale (c2 / celsius))
            :duration (v / value-interval
                  :op1 (t6 / temporal-quantity
                        :quant "12"
                        :unit (h3 / hour))
                  :op2 (t7 / temporal-quantity
                        :quant "14"
                        :unit (h4 / hour))))
      :op4 (b / block-01~e.38
            :ARG1 s2
            :ARG3 (p6 / product
                  :name (n2 / name :op1 "NGS"~e.42)
                  :quant (p2 / percentage-entity~e.41 :value "10"~e.40)))
      :op5 (t8 / treat-04~e.45
            :ARG1 s2
            :ARG2~e.46 (a2 / antibody~e.53
                  :mod "1093274"
                  :name (n3 / name :op1 "anti-dig"~e.47,49 :op2 "Fab-AP"~e.50,52)
                  :source (c3 / company
                        :name (n4 / name :op1 "Roche"~e.55)))
            :manner~e.58 (d / dilute-01~e.63
                  :quant (s / score-entity :op1 "1"~e.60 :op2 "2500"~e.62))
            :duration~e.64 (t9 / temporal-quantity
                  :quant "3"~e.65
                  :unit (h5 / hour))))

# ::tok The sections were incubated with NBT and BCIP until adequate signal was detected .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1 3-1 4-1.2.r 5-1.2.1.1.1 6-1.2 7-1.2.2.1.1 8-1.3 9-1.3.1.1.1 10-1.3.1.1 12-1.3.1
# ::id pmid_1563_0473.292
# ::preferred 
(i / incubate-01~e.3
      :ARG1 (s / section-01~e.1)
      :ARG2~e.4 (a / and~e.6
            :op1 (p / product
                  :name (n / name :op1 "NBT"~e.5))
            :op2 (p2 / product
                  :name (n2 / name :op1 "BCIP"~e.7)))
      :time (u / until~e.8
            :op1 (d / detect-01~e.12
                  :ARG1 (s2 / signal-07~e.10
                        :mod (a2 / adequate~e.9)))))

# ::tok Immunofluorescence and immunohistochemistry
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1 2-1.2
# ::id pmid_1563_0473.293
# ::preferred 
(a / and~e.1
      :op1 (i / immunofluoresce-00)
      :op2 (i2 / immunohistochemistry~e.2))

# ::tok Tissue samples for immunofluorescence were frozen in OCT and sectioned 10 μm thick on a cryostat .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1.1.1 5-1.1 8-1 9-1.2 10-1.2.2.1.1 12-1.2.2 13-1.2.3.r 15-1.2.3
# ::id pmid_1563_0473.294
# ::preferred 
(a / and~e.8
      :op1 (f / freeze-01~e.5
            :ARG1 (t / tissue~e.0
                  :ARG1-of (s2 / sample-01~e.1
                        :purpose (i / immunofluoresce-00)))
            :instrument (t3 / thing
                  :name (n / name
                        :op1 "Optimal"
                        :op2 "Cutting"
                        :op3 "Temperature")))
      :op2 (s / section-01~e.9
            :ARG1 t
            :ARG2 (t2 / thick~e.12
                  :mod (d / distance-quantity
                        :quant "10"~e.10
                        :unit (m2 / micron)))
            :location~e.13 (c / cryostat~e.15)))

# ::tok Sections were fixed in 4 % paraformaldehyde for 10 min at room temperature , blocked , and stained with antibodies .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 0-1.1.1.1 0-1.1.1.1.r 2-1.1 3-1.1.2.r 4-1.1.2.2.1 5-1.1.2.2 6-1.1.2.1.1 7-1.1.3.r 8-1.1.3.1 10-1.1.4.r 11-1.1.4.1 12-1.1.4 14-1.2 16-1 17-1.3 18-1.3.2.r 19-1.3.2
# ::id pmid_1563_0473.295
# ::preferred 
(a / and~e.16
      :op1 (f / fix-00~e.2
            :ARG1 (t / thing~e.0
                  :ARG2-of~e.0 (s2 / section-01~e.0))
            :ARG2~e.3 (m / molecular-physical-entity
                  :name (n / name :op1 "paraformaldehyde"~e.6)
                  :mod (p / percentage-entity~e.5 :value "4"~e.4))
            :duration~e.7 (t2 / temporal-quantity
                  :quant "10"~e.8
                  :unit (m2 / minute))
            :mod~e.10 (t3 / temperature~e.12
                  :poss (r / room~e.11)))
      :op2 (b / block-01~e.14
            :ARG1 t)
      :op2 (s / stain-00~e.17
            :ARG1 t
            :ARG2~e.18 (a2 / antibody~e.19)))

# ::tok Tissue samples for immunohistochemistry were fixed in 4 % paraformaldehyde , dehydrated , and embedded in paraffin .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1.1.1 2-1.1.1.1.1.r 3-1.1.1.1.1 5-1.1 6-1.1.2.r 7-1.1.2.2.1 8-1.1.2.2 9-1.1.2.1.1 11-1.2 13-1 14-1.3 15-1.3.2.r 16-1.3.2
# ::id pmid_1563_0473.296
# ::preferred 
(a / and~e.13
      :op1 (f / fix-00~e.5
            :ARG1 (t / tissue~e.0
                  :ARG1-of (s / sample-01~e.1
                        :purpose~e.2 (i / immunohistochemistry~e.3)))
            :ARG2~e.6 (m / molecular-physical-entity
                  :name (n / name :op1 "paraformaldehyde"~e.9)
                  :mod (p / percentage-entity~e.8 :value "4"~e.7)))
      :op2 (d / dehydrate-01~e.11
            :ARG1 t)
      :op3 (e / embed-01~e.14
            :ARG1 t
            :ARG2~e.15 (p2 / paraffin~e.16)))

# ::tok Samples were sectioned on a microtome ( 10 μm thick ) and rehydrated prior to staining with antibody .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 0-1.1.1.1 0-1.1.1.1.r 2-1.1 5-1.1.2 7-1.1.1.2.1.1 9-1.1.1.2 11-1 13-1.3 14-1.3.1.r 15-1.3.1 16-1.1.2.r 16-1.3.1.2.r 17-1.3.1.2
# ::id pmid_1563_0473.297
# ::preferred 
(a / and~e.11
      :op1 (s / section-01~e.2
            :ARG1 (t2 / thing~e.0
                  :ARG1-of~e.0 (s2 / sample-01~e.0)
                  :mod (t / thick~e.9
                        :mod (d / distance-quantity
                              :quant "10"~e.7
                              :unit (m2 / micron))))
            :instrument~e.16 (m / microtome~e.5))
      :op2 (h / hydrate-01
            :ARG1 t2
            :mod (a3 / again))
      :time (p / prior~e.13
            :op1~e.14 (s3 / stain-00~e.15
                  :ARG1 t2
                  :ARG2~e.16 (a2 / antibody~e.17))))

# ::tok Samples stained with Snail , pMAPK , pSmad2 , and cyclin D were antigen unmasked with 10 mM sodium citrate ( pH 6 ) in an Antigen Retriever 2100 ( Pickcell Laboratories , Leiden , Netherlands ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 0-1.1.1 0-1.1.1.r 1-1.1.2 2-1.1.2.1.r 2-1.3.r 3-1.1.2.1.1.1.1 9-1.1.2.1 10-1.1.2.1.4.1.1 11-1.1.2.1.4.1.2 13-1.2 14-1 15-1.3.r 16-1.3.2.1 18-1.3.1.1 19-1.3.1.2 21-1.3.3.2 22-1.3.3.1 24-1.4.r 26-1.4.1.1 27-1.4.1.2 28-1.4.1.3 30-1.4.2.1.1.1 31-1.4.2.1.1.2 33-1.4.2.1.2.1.1 35-1.4.2.1.2.2.1.1
# ::id pmid_1563_0473.298
# ::preferred 
(u / unmask-01~e.14
      :ARG1 (t / thing~e.0
            :ARG1-of~e.0 (s / sample-01~e.0)
            :ARG1-of (s2 / stain-00~e.1
                  :ARG2~e.2 (a / and~e.9
                        :op1 (p / protein
                              :name (n / name :op1 "Snail"~e.3))
                        :op2 (e / enzyme
                              :name (n2 / name :op1 "MAPK")
                              :ARG1-of (p2 / phosphorylate-01))
                        :op3 (p3 / protein
                              :name (n3 / name :op1 "Smad2")
                              :ARG1-of p2)
                        :op4 (p4 / protein
                              :name (n4 / name :op1 "cyclin"~e.10 :op2 "D"~e.11)))))
      :topic (a2 / antigen~e.13)
      :instrument~e.2,15 (s3 / small-molecule
            :name (n5 / name :op1 "sodium"~e.18 :op2 "citrate"~e.19)
            :mod (c / concentration-quantity
                  :quant "10"~e.16
                  :unit (m2 / micromolar))
            :mod (a3 / acidity-quantity
                  :quant "6"~e.22
                  :scale (p6 / ph~e.21)))
      :location~e.24 (p5 / product
            :name (n6 / name
                  :op1 "Antigen"~e.26
                  :op2 "Retriever"~e.27
                  :op3 "2100"~e.28)
            :ARG1-of (m3 / manufacture-01
                  :ARG0 (c2 / company
                        :name (n7 / name :op1 "Pickcell"~e.30 :op2 "Laboratories"~e.31)
                        :location (c3 / city
                              :name (n8 / name :op1 "Leiden"~e.33)
                              :location (c4 / country
                                    :name (n9 / name :op1 "Netherlands"~e.35)))))))

# ::tok The DAB substrate kit ( Vector Labs ) was used according to manufacturer 's instructions to develop the signal .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1.1 2-1.1.3 3-1.1 5-1.1.2.1.1.1 6-1.1.2.1.1.2 9-1 9-1.3.r 12-1.1.2 12-1.1.2.1.r 14-1.2 16-1.3 18-1.3.1
# ::id pmid_1563_0473.299
# ::preferred 
(u / use-01~e.9
      :ARG1 (k2 / kit~e.3
            :name (n2 / name :op1 "DAB"~e.1)
            :ARG1-of (m2 / manufacture-01~e.12
                  :ARG0~e.12 (c2 / company
                        :name (n / name :op1 "Vector"~e.5 :op2 "Labs"~e.6)))
            :mod (s / substrate~e.2))
      :ARG2-of (i / instruct-01~e.14
            :ARG0 c2)
      :purpose~e.9 (d / develop-02~e.16
            :ARG1 (s2 / signal-07~e.18)))

# ::tok RT @-@ PCR
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 2-1
# ::id pmid_1563_0473.300
# ::preferred 
(r / RT-PCR~e.0,2)

# ::tok RNA was extracted from keratinocytes or skin tissue with Trizol ( Invitrogen ) according to the manufacturer 's protocol .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 2-1 5-1.2 6-1.2.2.1 7-1.2.2 8-1.3.r 9-1.3.1.1 11-1.3.2.1.1 13-1.4 14-1.4 16-1.4.1.1 16-1.4.1.1.1 16-1.4.1.1.1.r 17-1.4.1.1.r 18-1.4.1
# ::id pmid_1563_0473.301
# ::preferred 
(e / extract-01~e.2
      :ARG1 (r / RNA~e.0)
      :ARG2 (o / or~e.5
            :op1 (k / keratinocyte)
            :op2 (t / tissue~e.7
                  :part-of (s / skin~e.6)))
      :instrument~e.8 (s2 / small-molecule
            :name (n2 / name :op1 "Trizol"~e.9)
            :mod (b / brand
                  :name (n3 / name :op1 "Invitrogen"~e.11)))
      :ARG1-of (s4 / say-01~e.13,14
            :ARG0 (p / protocol~e.18
                  :poss~e.17 (c / company~e.16
                        :ARG0-of~e.16 (m2 / manufacture-01~e.16)))))

# ::tok cDNA was generated using oligo @-@ dT primers and the Superscript II kit ( Invitrogen ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1 3-1.2 4-1.2.1.1.1.1 6-1.2.1.1.1.1 7-1.2.1.1.1.2 8-1.2.1 10-1.2.1.2.1.1.1 11-1.2.1.2.1.1.2 12-1.2.1.2 14-1.2.1.3.1.1
# ::id pmid_1563_0473.302
# ::preferred 
(g / generate-01~e.2
      :ARG1 (d / DNA
            :ARG1-of (c / complement-01))
      :ARG2 (u / use-01~e.3
            :ARG1 (a / and~e.8
                  :op1 (m / molecular-physical-entity
                        :name (n3 / name :op1 "oligo-dT"~e.4,6 :op2 "primer"~e.7))
                  :op2 (k / kit~e.12
                        :mod (e / enzyme
                              :name (n / name :op1 "Superscript"~e.10 :op2 "II"~e.11)))
                  :mod (b / brand
                        :name (n2 / name :op1 "Invitrogen"~e.14)))))

# ::tok The primers used for PCR were <i> Snail </i> forward : 5′-CAGCTGGCCAGGCTCTCGGT @-@ 3′; <i> Snail </i> reverse : 5′-GCGAGGGCCTCCGGAGCA @-@ 3′; GAPDH forward 5′-CGTAGACAAAATGGTGAAGGTCGG @-@ 3′; and GAPDH reverse : 5′-AAGCAGTTGGTGGTGCAGGATG @-@ 3′.
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1 1-1.1.2 1-1.1.3 1-1.1.4 2-1 3-1.2.r 4-1.2 7-1.1.1.3.1.1 9-1.1.1.2 15-1.1.2.3 17-1.1.2.2 22-1.1.3.2.1.1 23-1.1.1.2 27-1.1 28-1.1.3.2.1.1 29-1.1.2.2
# ::id pmid_1563_0473.303
# ::preferred 
(u / use-01~e.2
      :ARG1 (a / and~e.27
            :op1 (p / primer~e.1
                  :name (n4 / name :op1 "5′-CAGCTGGCCAGGCTCTCGGT-3′")
                  :mod (f / forward~e.9,23)
                  :mod (g / gene
                        :name (n2 / name :op1 "Snail"~e.7)))
            :op2 (p2 / primer~e.1
                  :name (n5 / name :op1 "5′-GCGAGGGCCTCCGGAGCA-3")
                  :mod (r / reverse~e.17,29)
                  :mod g~e.15)
            :op3 (p3 / primer~e.1
                  :name (n6 / name :op1 "5′-CGTAGACAAAATGGTGAAGGTCGG-3′")
                  :mod (g2 / gene
                        :name (n3 / name :op1 "GAPDH"~e.22,28))
                  :mod f)
            :op4 (p4 / primer~e.1
                  :name (n7 / name :op1 "5′-AAGCAGTTGGTGGTGCAGGATG-3′")
                  :mod r
                  :mod g2))
      :ARG2~e.3 (p5 / PCR~e.4))

# ::tok Figure 1
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.1
# ::id pmid_1563_0473.304
# ::preferred 
(f / figure~e.0 :mod "1"~e.1)

# ::tok Embryos were either frozen in OCT embedding compound ( A , F, and H ) or embedded in paraffin ( C , D, E , and G ) , and then sectioned ( 8 μm ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 3-1.1.1 4-1.1.1.3.r 5-1.1.1.3.1.1 6-1.1.1.3.2 7-1.1.1.3 9-1.1.1.2.1.1.1 12-1.1.1.2.1 13-1.1.1.2.1.3.1 15-1.1 16-1.1.2 17-1.1.2.2.r 18-1.1.2.2 20-1.1.2.3.1.1.1 23-1.1.2.3.1.3.1 25-1.1.2.3.1 26-1.1.2.3.1.4.1 29-1 29-1.1.2.3.1 30-1.2.3 31-1.2 33-1.2.2.1
# ::id pmid_1563_0473.305
# ::preferred 
(a / and~e.29
      :op1 (o / or~e.15
            :op1 (f / freeze-01~e.3
                  :ARG1 (e2 / embryo~e.0)
                  :ARG1-of (d / describe-01
                        :ARG0 (a2 / and~e.12
                              :op1 (f2 / figure
                                    :mod (a4 / A~e.9))
                              :op2 (f3 / figure
                                    :mod (f9 / F))
                              :op3 (f4 / figure
                                    :mod (h / H~e.13))))
                  :instrument~e.4 (c3 / compound~e.7
                        :name (n / name :op1 "OCT"~e.5)
                        :ARG2-of (e4 / embed-01~e.6)))
            :op2 (e / embed-01~e.16
                  :ARG1 e2
                  :ARG2~e.17 (p / paraffin~e.18)
                  :ARG1-of (d2 / describe-01
                        :ARG0 (a3 / and~e.25,29
                              :op1 (f5 / figure
                                    :mod (c2 / C~e.20))
                              :op2 (f6 / figure
                                    :mod (d4 / D))
                              :op3 (f7 / figure
                                    :mod (e5 / E~e.23))
                              :op4 (f8 / figure
                                    :mod (g / G~e.26))))))
      :op2 (s / section-01~e.31
            :ARG1 e2
            :ARG2 (d3 / distance-quantity
                  :quant "8"~e.33
                  :unit (m / micron))
            :time (t / then~e.30)))

# ::tok ( A ) In situ hybridizations with <i> Snail </i> sense or antisense cRNA probes .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3.1.1 3-1.2 4-1.2 5-1 8-1.1.1.2.1.1 10-1.1.1.3 11-1.1 12-1.1.2.3 13-1.1.1.1.1.1 14-1.1.1 14-1.1.2
# ::id pmid_1563_0473.306
# ::preferred 
(h / hybridize-01~e.5
      :ARG2 (o / or~e.11
            :op1 (p / probe-01~e.14
                  :ARG1 (r / rna
                        :name (n / name :op1 "cRNA"~e.13))
                  :ARG2 (p2 / protein
                        :name (n2 / name :op1 "Snail"~e.8))
                  :mod (s / sense~e.10))
            :op2 (p3 / probe-01~e.14
                  :ARG1 r
                  :ARG2 p2
                  :mod (a / antisense~e.12)))
      :manner (i / in-situ~e.3,4)
      :ARG1-of (d / describe-01
            :ARG0 (f / figure
                  :mod (a2 / A~e.1))))

# ::tok Black dotted lines demarcate the basement membrane that separates the epidermis ( epi ) from dermis ( der ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1.2 2-1.1 3-1 5-1.2.1 6-1.2 8-1.2.2 10-1.2.2.1 12-1.2.2.1.1.1 14-1.2.2.2.r 15-1.2.2.2 17-1.2.2.2.1.1
# ::id pmid_1563_0473.307
# ::preferred 
(d / demarcate-01~e.3
      :ARG0 (l / line~e.2
            :mod (b / black~e.0)
            :ARG1-of (d2 / dot-01~e.1))
      :ARG1 (m / membrane~e.6
            :mod (b2 / basement~e.5)
            :ARG0-of (s / separate-01~e.8
                  :ARG1 (e / epidermis~e.10
                        :ARG1-of (m2 / mean-01
                              :ARG2 (e2 / epi~e.12)))
                  :ARG2~e.14 (d3 / dermis~e.15
                        :ARG1-of (m3 / mean-01
                              :ARG2 (d4 / der~e.17))))))

# ::tok Arrows point to <i> Snail </i> RNA expression , restricted to the hair bud stage of follicle morphogenesis .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1 4-1.2.1.2.1.1 6-1.2.1.1.1 7-1.2 9-1.2.2 10-1.2.2.1.r 12-1.2.2.1.1.1 13-1.2.2.1.1 14-1.2.2.1 15-1.2.2.1.2.r 16-1.2.2.1.2.1 17-1.2.2.1.2
# ::id pmid_1563_0473.308
# ::preferred 
(p / point-01~e.1
      :ARG0 (a / arrow~e.0)
      :ARG1 (e / express-03~e.7
            :ARG2 (r / rna
                  :name (n / name :op1 "RNA"~e.6)
                  :mod (p2 / protein
                        :name (n2 / name :op1 "Snail"~e.4)))
            :ARG1-of (r2 / restrict-01~e.9
                  :ARG2~e.10 (s / stage~e.14
                        :mod (b / bud~e.13
                              :mod (h / hair~e.12))
                        :subevent-of~e.15 (m / morphogenesis~e.17
                              :mod (f / follicle~e.16))))))

# ::tok It was not seen in later hair germ or peg stages .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2 2-1.1 2-1.1.r 3-1 4-1.3.r 5-1.3.1.2 5-1.3.1.2.1 5-1.3.1.2.1.r 6-1.3.1.1 7-1.3.1 8-1.3 9-1.3.2.1 10-1.3.2
# ::id pmid_1563_0473.309
# ::preferred 
(s / see-01~e.3
      :polarity~e.2 "-"~e.2
      :ARG1 (i / it~e.0)
      :topic~e.4 (o / or~e.8
            :op1 (g / germ~e.7
                  :mod (h / hair~e.6)
                  :time (l / late~e.5
                        :degree~e.5 (m / more~e.5)))
            :op2 (s2 / stage~e.10
                  :mod (p / peg~e.9)
                  :time l)))

# ::tok ( B ) Expression of Snail protein coincides with hair development .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.2.1.1 3-1.1.1 4-1.1.1.1.r 5-1.1.1.1.1.1 6-1.1.1.1 7-1 8-1.1.r 9-1.1.2.1 10-1.1.2
# ::id pmid_1563_0473.310
# ::preferred 
(c / coincide-01~e.7
      :ARG1~e.8 (a / and
            :op1 (e / express-03~e.3
                  :ARG2~e.4 (p / protein~e.6
                        :name (n / name :op1 "Snail"~e.5)))
            :op2 (d / develop-01~e.10
                  :ARG2 (h / hair~e.9)))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure
                  :mod (b / B~e.1))))

# ::tok Protein extracts were prepared from keratinocytes transfected with empty expression vector ( K14 ) , containing the K14 promoter or with the vector driving HA @-@ tagged <i> Snail </i> ( K14 @- @<i> Snail </i> ) ; or from whole skin from E13.5 to P5 animals , including newborn ( nb ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1 3-1 6-1.2.1.1 7-1.2.1.1.1.r 8-1.2.1.1.1.1.2 9-1.2.1.1.1.1.1 10-1.2.1.1.1.1 12-1.2.1.1.1.1.3.1.1.1 15-1.2.1.1.1.1.4 17-1.2.1.1.1.1.3.1.1.1 19-1.2.1.1.1 22-1.2.1.1.1.2 23-1.2.1.1.1.2.1 24-1.2.1.1.1.2.1.1.2.1.1.1 26-1.2.1.1.1.2.1.1.2 28-1.2.1.1.1.2.1.1.1.1 28-1.2.1.1.1.2.2.1.2.1.1 31-1.2.1.1.1.1.3.1.1.1 34-1.2.1.1.1.2.1.1.1.1 34-1.2.1.1.1.2.2.1.2.1.1 38-1.2 39-1.2.r 40-1.2.2.1 41-1.2.2 46-1.2.2.2 48-1.2.2.2.1 49-1.2.2.2.1.1
# ::id pmid_1563_0473.311
# ::preferred 
(p / prepare-01~e.3
      :ARG1 (e / extract-01~e.1
            :ARG1 (p2 / protein~e.0))
      :ARG2~e.39 (o / or~e.38
            :op1 (k / keratinocyte
                  :ARG1-of (t / transfect-00~e.6
                        :ARG2~e.7 (o3 / or~e.19
                              :op1 (v / vector~e.10
                                    :mod (e2 / express-03~e.9)
                                    :mod (e3 / empty~e.8)
                                    :ARG1-of (m / mean-01
                                          :ARG2 (p3 / protein
                                                :name (n / name :op1 "K14"~e.12,17,31)))
                                    :ARG0-of (c / contain-01~e.15
                                          :ARG1 (m4 / molecular-physical-entity
                                                :ARG0-of (p8 / promote-01
                                                      :ARG1 p3))))
                              :op2 (v2 / vector~e.22
                                    :ARG0-of (d / drive-02~e.23
                                          :ARG1 (p5 / protein
                                                :name (n2 / name :op1 "Snail"~e.28,34)
                                                :ARG1-of (t2 / tag-01~e.26
                                                      :ARG2 (p6 / protein
                                                            :name (n3 / name :op1 "HA"~e.24)))))
                                    :ARG1-of (m2 / mean-01
                                          :ARG2 (m3 / macro-molecular-complex
                                                :part p3
                                                :part (p7 / protein
                                                      :name (n4 / name :op1 "Snail"~e.28,34))))))))
            :op2 (s / skin~e.41
                  :mod (w / whole~e.40)
                  :part-of (a / animal~e.46
                        :ARG2-of (i / include-91~e.48
                              :ARG1 (n7 / newborn~e.49))
                        :time (d2 / date-interval
                              :op1 (d3 / day
                                    :mod "13.5"
                                    :mod (e4 / embryo))
                              :op2 (d4 / day
                                    :mod "5"
                                    :time (a2 / after
                                          :op1 (b / birth))))))))

# ::tok Equal amounts of proteins were then resolved by SDS @-@ PAGE through 12 % gels and subjected to Western blotting using either an affinity @-@ purified Snail polyclonal antiserum , which we generated , or anti @-@ tubulin ( loading control ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1.1 1-1.1.1.1 2-1.1.1.1.r 3-1.1.1 5-1.1.2 6-1.1 7-1.1.3.r 8-1.1.3 10-1.1.3 12-1.1.3.1.1.1 13-1.1.3.1.1 14-1.1.3.1 15-1 16-1.2 18-1.2.2.1.1 19-1.2.2.1.2 20-1.2.2.2 23-1.2.2.2.1.1.3.1 25-1.2.2.2.1.1.3 26-1.2.2.2.1.1.1.1.1.1 27-1.2.2.2.1.1.2 31-1.2.2.2.1.1.4.1 32-1.2.2.2.1.1.4 34-1.2.2.2.1 35-1.2.2.2.1.1.1 35-1.2.2.2.1.2 35-1.2.2.2.1.2.1 35-1.2.2.2.1.2.1.r 37-1.2.2.2.1.2.1.1.1.1 39-1.2.2.2.1.2.2.1 40-1.2.2.2.1.2.2
# ::id pmid_1563_0473.312
# ::preferred 
(a / and~e.15
      :op1 (r / resolve-00~e.6
            :ARG1 (p / protein~e.3
                  :quant~e.2 (a2 / amount~e.1
                        :ARG1-of (e / equal-01~e.0)))
            :time (t / then~e.5)
            :manner~e.7 (s3 / SDS-PAGE~e.8,10
                  :instrument (g / gel~e.14
                        :mod (p2 / percentage-entity~e.13 :value "12"~e.12))))
      :op2 (s / subject-01~e.16
            :ARG1 p
            :ARG2 (a3 / analyze-01
                  :name (n2 / name :op1 "Western"~e.18 :op2 "blot"~e.19)
                  :ARG0-of (u / use-01~e.20
                        :ARG1 (o / or~e.34
                              :op1 (s2 / serum
                                    :ARG0-of (c / counter-01~e.35
                                          :ARG1 (p3 / protein
                                                :name (n3 / name :op1 "Snail"~e.26)))
                                    :mod (p4 / polyclonal~e.27)
                                    :ARG1-of (p5 / purify-01~e.25
                                          :ARG2 (a4 / affinity~e.23))
                                    :ARG1-of (g2 / generate-01~e.32
                                          :ARG0 (w / we~e.31)))
                              :op2 (m / molecular-physical-entity~e.35
                                    :ARG0-of~e.35 (c2 / counter-01~e.35
                                          :ARG1 (p6 / protein
                                                :name (n4 / name :op1 "tubulin"~e.37)))
                                    :ARG0-of (c3 / control-01~e.40
                                          :ARG1 (l / load-01~e.39))))))))

# ::tok ( C–E ) Immunohistochemistry shows expression of Snail protein in the nuclei of cells within the hair and skin .
# ::amr-annotator SDL-AMR-09
# ::alignments 3-1.1 4-1 5-1.2 6-1.2.1.r 7-1.2.1.1.1 8-1.2.1 9-1.2.2.r 11-1.2.2 12-1.2.2.1.r 13-1.2.2.1 16-1.2.2.1.1.1 17-1.2.2.1.1 18-1.2.2.1.1.2
# ::id pmid_1563_0473.313
# ::preferred 
(s / show-01~e.4
      :ARG0 (i / immunohistochemistry~e.3)
      :ARG1 (e / express-03~e.5
            :ARG2~e.6 (p / protein~e.8
                  :name (n / name :op1 "Snail"~e.7))
            :ARG3~e.9 (n2 / nucleus~e.11
                  :part-of~e.12 (c / cell~e.13
                        :part-of (a / and~e.17
                              :op1 (h / hair~e.16)
                              :op2 (s2 / skin~e.18)))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure
                  :mod (v / value-interval
                        :op1 (c2 / C)
                        :op2 (e2 / E)))))

# ::tok ( C ) E13.5 skin with a single layered epidermis ( epi ) shows no Snail expression .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3.1.1 4-1.1 8-1.1.1.1 9-1.1.1 13-1 14-1.2.1 14-1.2.1.r 15-1.2.2.1.1 16-1.2
# ::id pmid_1563_0473.314
# ::preferred 
(s / show-01~e.13
      :ARG0 (s2 / skin~e.4
            :part (e2 / epidermis~e.9
                  :mod (l / layer~e.8 :quant "1"))
            :time (d2 / day
                  :mod "13.5"
                  :mod (e3 / embryo)))
      :ARG1 (e / express-03~e.16
            :polarity~e.14 "-"~e.14
            :ARG2 (p / protein
                  :name (n / name :op1 "Snail"~e.15)))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure
                  :mod (c / C~e.1))))

# ::tok ( D ) The first morphological sign that cells have adopted a hair follicle fate is a cluster of cells called a placode in E16.5 skin .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.5.1.1 4-1.3 4-1.3.1 4-1.3.1.r 5-1.4 6-1 7-1.2.r 8-1.2.1 10-1.2 12-1.2.2.1.1 13-1.2.2.1 14-1.2.2 17-1.1 18-1.1.1.r 19-1.1.1 20-1.1.2 22-1.1.2.1 25-1.1.3
# ::id pmid_1563_0473.315
# ::preferred 
(s / signal-07~e.6
      :ARG0 (c / cluster-01~e.17
            :ARG1~e.18 (c2 / cell~e.19)
            :ARG1-of (c3 / call-01~e.20
                  :ARG2 (p / placode~e.22))
            :location (s2 / skin~e.25
                  :time (d3 / day
                        :mod "16.5"
                        :mod (e / embryo))))
      :ARG1~e.7 (a / adopt-01~e.10
            :ARG0 c2~e.8
            :ARG1 (f / fate~e.14
                  :poss (f2 / follicle~e.13
                        :mod (h / hair~e.12))))
      :ord (o / ordinal-entity~e.4 :value~e.4 "1"~e.4)
      :mod (m / morphological~e.5)
      :ARG1-of (d / describe-01
            :ARG0 (f3 / figure
                  :mod (d2 / D~e.1))))

# ::tok Snail is not expressed at this stage of development .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.1.1 2-1.1 2-1.1.r 3-1 4-1.3.r 5-1.3.1 6-1.3 7-1.3.2.r 8-1.3.2
# ::id pmid_1563_0473.316
# ::preferred 
(e / express-03~e.3
      :polarity~e.2 "-"~e.2
      :ARG2 (p / protein
            :name (n / name :op1 "Snail"~e.0))
      :time~e.4 (s / stage~e.6
            :mod (t / this~e.5)
            :subevent-of~e.7 (d / develop-01~e.8)))

# ::tok ( E ) Snail is expressed in the hair bud of E17.5 skin but not in later stages of development such as the germ or peg .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.4.1.1 3-1.1.1.1 5-1 5-1.3.1 6-1.2.r 8-1.2.1 9-1.2 12-1.2.2 13-1.3 14-1.3.1.1 14-1.3.1.1.r 15-1.3.1.3.r 16-1.3.1.3.1 16-1.3.1.3.1.1 16-1.3.1.3.1.1.r 17-1.3.1.3 18-1.3.1.3.2.r 19-1.3.1.3.2 20-1.3.1.3.3.r 21-1.3.1.3.3.r 23-1.3.1.3.3.1 24-1.3.1.3.3 25-1.3.1.3.3.2
# ::id pmid_1563_0473.317
# ::preferred 
(e / express-03~e.5
      :ARG2 (p / protein
            :name (n / name :op1 "Snail"~e.3))
      :ARG3~e.6 (b / bud~e.9
            :mod (h / hair~e.8)
            :part-of (s / skin~e.12
                  :time (d3 / day
                        :mod "17.5"
                        :mod (e4 / embryo))))
      :ARG1-of (c / contrast-01~e.13
            :ARG2 (e2 / express-03~e.5
                  :polarity~e.14 "-"~e.14
                  :ARG2 p
                  :ARG3~e.15 (s2 / stage~e.17
                        :time (l / late~e.16
                              :degree~e.16 (m / more~e.16))
                        :subevent-of~e.18 (d / develop-01~e.19)
                        :example~e.20,21 (o2 / or~e.24
                              :op1 (g / germ~e.23)
                              :op2 (p2 / peg~e.25)))))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure
                  :mod (e3 / E~e.1))))

# ::tok ( F ) Immunofluorescence with anti @-@ Ki67 ( green ) identifies the proliferating cells of the skin , restricted to the basal layer of the epidermis and developing hair follicles .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3.1.1 5-1.1.1 5-1.1.1.1 5-1.1.1.1.r 7-1.1.1.1.1.1.1 9-1.3.2 11-1 13-1.2.2 14-1.2 15-1.2.1.r 17-1.2.1 19-1.2.3 20-1.2.3.1.r 22-1.2.3.1.1 23-1.2.3.1 24-1.2.3.1.2.r 26-1.2.3.1.2.1 27-1.2.3.1.2 28-1.2.3.1.2.2.2 29-1.2.3.1.2.2.1 30-1.2.3.1.2.2
# ::id pmid_1563_0473.318
# ::preferred 
(i / identify-01~e.11
      :ARG0 (i2 / immunofluoresce-00
            :ARG2 (m / molecular-physical-entity~e.5
                  :ARG0-of~e.5 (c / counter-01~e.5
                        :ARG1 (p / protein
                              :name (n / name :op1 "Ki67"~e.7)))))
      :ARG1 (c2 / cell~e.14
            :part-of~e.15 (s / skin~e.17)
            :ARG0-of (p2 / proliferate-01~e.13)
            :ARG1-of (r / restrict-01~e.19
                  :ARG2~e.20 (l / layer~e.23
                        :mod (b / basal~e.22)
                        :part-of~e.24 (a2 / and~e.27
                              :op1 (e / epidermis~e.26)
                              :op2 (f / follicle~e.30
                                    :mod (h / hair~e.29)
                                    :ARG2-of (d / develop-01~e.28))))))
      :ARG1-of (d2 / describe-01
            :ARG0 (f2 / figure
                  :mod (f3 / F~e.1))
            :mod (g / green~e.9)))

# ::tok Anti-β4 int labeling reveals the presence of the hemidesmosomal integrin β4 , restricted to the base of cells adhering to the underlying basement membrane .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1 3-1 9-1.1.1.1.1.2 9-1.2.1.1.2 10-1.1.1.1.1.1 10-1.2.1.1.1 12-1.2.1.3 13-1.2.1.3.1.r 15-1.2.1.3.1 16-1.2.1.3.1.1.r 17-1.2.1.3.1.1 18-1.2.1.3.1.1.1 19-1.2.1.3.1.1.1.1.r 21-1.2.1.3.1.1.1.1.2 22-1.2.1.3.1.1.1.1.1 23-1.2.1.3.1.1.1.1
# ::id pmid_1563_0473.319
# ::preferred 
(r / reveal-01~e.3
      :ARG0 (l / label-01~e.2
            :ARG0-of (c / counter-01
                  :ARG1 (m / molecular-physical-entity
                        :name (n / name :op1 "β4"~e.10 :op2 "integrin"~e.9))))
      :ARG1 (b / be-located-at-91
            :ARG1 (p / protein
                  :name (n2 / name :op1 "β4"~e.10 :op2 "integrin"~e.9)
                  :mod (h / hemidesmosome)
                  :ARG1-of (r2 / restrict-01~e.12
                        :ARG2~e.13 (b2 / base~e.15
                              :part-of~e.16 (c2 / cell~e.17
                                    :ARG1-of (a / adhere-01~e.18
                                          :ARG2~e.19 (m3 / membrane~e.23
                                                :mod (b3 / basement~e.22)
                                                :ARG0-of (u / underlie-01~e.21)))))))))

# ::tok The white dotted line marks the outermost surface of the skin .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1 2-1.1.2 3-1.1 4-1 7-1.2 8-1.2.1.r 10-1.2.1
# ::id pmid_1563_0473.320
# ::preferred 
(m / mark-01~e.4
      :ARG0 (l / line~e.3
            :mod (w / white~e.1)
            :ARG1-of (d / dot-01~e.2))
      :ARG1 (s / surface~e.7
            :part-of~e.8 (s2 / skin~e.10
                  :mod (o / outer
                        :degree (m2 / most)))))

# ::tok ( G ) Immunohistochemistry with pMAPK marks a subset of proliferating cells within the epidermis and hair bud .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3.1.1 3-1.1 4-1.1.1.r 6-1 8-1.2 10-1.2.1.1.1 11-1.2.1.1 14-1.2.1.1.2.1 15-1.2.1.1.2 16-1.2.1.1.2.2.1 17-1.2.1.1.2.2
# ::id pmid_1563_0473.321
# ::preferred 
(m / mark-01~e.6
      :ARG0 (i / immunohistochemistry~e.3
            :instrument~e.4 (e / enzyme
                  :name (n / name :op1 "MAPK")
                  :ARG1-of (p / phosphorylate-01)))
      :ARG1 (s / subset~e.8
            :ARG1-of (i2 / include-91
                  :ARG2 (c / cell~e.11
                        :ARG0-of (p2 / proliferate-01~e.10)
                        :location (a / and~e.15
                              :op1 (e2 / epidermis~e.14)
                              :op2 (b / bud~e.17
                                    :mod (h / hair~e.16))))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure
                  :mod (g / G~e.1))))

# ::tok Anti @-@ pMAPK labeling was consistently robust within the hair bud .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.1 3-1.2 4-1.2.r 5-1.1 5-1.1.r 6-1 9-1.2.2.1 10-1.2.2
# ::id pmid_1563_0473.322
# ::preferred 
(r / robust~e.6
      :manner~e.5 (c / consistent~e.5)
      :domain~e.4 (l / label-01~e.3
            :ARG0-of (c2 / counter-01~e.0
                  :ARG1 (e / enzyme
                        :name (n / name :op1 "MAPK")
                        :ARG1-of (p / phosphorylate-01)))
            :location (b / bud~e.10
                  :mod (h / hair~e.9))))

# ::tok ( H ) Immunofluorescence with anti @-@ laminin 5 ( lam5 ) , which demarcates the basement membrane , and anti @-@ E @-@ cadherin ( E @-@ cad ) , a component of AJs .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.2.1.1 5-1.1.1 5-1.1.1.1 5-1.1.1.1.r 5-1.1.2 5-1.1.2.1 5-1.1.2.1.r 7-1.1.1.1.1.1.1 8-1.1.1.1.1.1.2 14-1.1.1.1.1 14-1.1.1.1.1.2 14-1.1.1.1.1.2.r 16-1.1.1.1.1.2.1.1 17-1.1.1.1.1.2.1 19-1.1 20-1.1.1 20-1.1.1.1 20-1.1.1.1.r 20-1.1.2 20-1.1.2.1 20-1.1.2.1.r 22-1.1.2.1.1.1.1 24-1.1.2.1.1.1.1 26-1.1.2.1.1.1.1
# ::id pmid_1563_0473.323
# ::preferred 
(i / immunofluoresce-00
      :ARG2 (a / and~e.19
            :op1 (m / molecular-physical-entity~e.5,20
                  :ARG0-of~e.5,20 (c / counter-01~e.5,20
                        :ARG1 (p / protein~e.14
                              :name (n / name :op1 "laminin"~e.7 :op2 "5"~e.8)
                              :ARG0-of~e.14 (d / demarcate-01~e.14
                                    :ARG1 (m2 / membrane~e.17
                                          :mod (b / basement~e.16))))))
            :op1 (m3 / molecular-physical-entity~e.5,20
                  :ARG0-of~e.5,20 (c2 / counter-01~e.5,20
                        :ARG1 (p2 / protein
                              :name (n2 / name :op1 "E-cadherin"~e.22,24,26)
                              :part-of (m4 / macro-molecular-complex
                                    :name (n3 / name :op1 "adherens" :op2 "junctions"))))))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure
                  :mod (h / H~e.1))))

# ::tok At the leading edge of the growing bud , cell @-@ cell borders show markedly diminished anti @-@ E @-@ cadherin labeling ( arrowheads ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.3.1 3-1.3 4-1.3.2.r 6-1.3.2.1 7-1.3.2 9-1.1.1 11-1.1.1 11-1.1.2 12-1.1 13-1 14-1.2.1.1 14-1.2.1.1.r 15-1.2.1 16-1.2.2 18-1.2.2.1.1.1 20-1.2.2.1.1.1 21-1.2 23-1.4.1
# ::id pmid_1563_0473.324
# ::preferred 
(s / show-01~e.13
      :ARG0 (b / border-01~e.12
            :ARG1 (c / cell~e.9,11)
            :ARG2 (c2 / cell~e.11))
      :ARG1 (l2 / label-01~e.21
            :ARG1-of (d / diminish-01~e.15
                  :manner~e.14 (m / marked~e.14))
            :ARG0-of (c3 / counter-01~e.16
                  :ARG1 (p / protein
                        :name (n / name :op1 "E-cadherin"~e.18,20))))
      :location (e / edge~e.3
            :ARG0-of (l / lead-01~e.2)
            :part-of~e.4 (b2 / bud~e.7
                  :ARG1-of (g / grow-01~e.6)))
      :ARG1-of (d2 / describe-01
            :ARG0 (a2 / arrowhead~e.23)))

# ::tok Figure 2
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.1
# ::id pmid_1563_0473.325
# ::preferred 
(f / figure~e.0 :mod "2"~e.1)

# ::tok Three different surviving Tg founder mice harbored a <i> K14 @-@ Snail </i> transgene that was integrated into a locus that resulted in inheritable , mosaic expression of the transgene in skin epidermis .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1.4 2-1.1.5 4-1.1.3 5-1.1 6-1 9-1.2.1.1.1.1 11-1.2.1.2.1.1 13-1.2 16-1.2.2 17-1.2.2.1.r 19-1.2.2.1 21-1.2.2.1.1 25-1.2.2.1.1.1.4 26-1.2.2.1.1.1 27-1.2.2.1.1.1.1.r 29-1.2.2.1.1.1.1 30-1.2.2.1.1.1.2.r 31-1.2.2.1.1.1.2.1 32-1.2.2.1.1.1.2
# ::id pmid_1563_0473.326
# ::preferred 
(h / harbor-01~e.6
      :ARG0 (m / mouse~e.5
            :quant "3"~e.0
            :mod (t / transgenic)
            :mod (f / founder~e.4)
            :ARG1-of (d / differ-02~e.1)
            :ARG0-of (s / survive-01~e.2))
      :ARG1 (t2 / transgene~e.13
            :mod (m2 / macro-molecular-complex
                  :part (p / protein
                        :name (n / name :op1 "K14"~e.9))
                  :part (p2 / protein
                        :name (n2 / name :op1 "Snail"~e.11)))
            :ARG1-of (i / integrate-01~e.16
                  :ARG2~e.17 (l / locus~e.19
                        :ARG1-of (r / result-01~e.21
                              :ARG2 (e / express-03~e.26
                                    :ARG1~e.27 (t3 / transgene~e.29)
                                    :ARG3~e.30 (e2 / epidermis~e.32
                                          :part-of (s2 / skin~e.31))
                                    :ARG1-of (i2 / inherit-01
                                          :mod (p3 / possible))
                                    :mod (m3 / mosaic~e.25)))))))

# ::tok All displayed similar abnormalities , as did their offspring .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1 2-1.2.1 3-1.2 7-1.1.2.1 7-1.1.2.1.r 8-1.1.2
# ::id pmid_1563_0473.327
# ::preferred 
(d / display-01~e.1
      :ARG0 (a3 / and
            :op1 (a / all~e.0)
            :op2 (o / offspring~e.8
                  :poss~e.7 a~e.7))
      :ARG1 (a2 / abnormality~e.3
            :ARG1-of (r / resemble-01~e.2)))

# ::tok ( A ) P16 WT and <i> K14 @-@ Snail </i> Tg mice .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3.1.1 4-1.1.1 5-1 7-1.2.2.1.1.1 9-1.2.2.2.1.1 12-1.1 12-1.2
# ::id pmid_1563_0473.328
# ::preferred 
(a / and~e.5
      :op1 (m3 / mouse~e.12
            :mod (w / wild-type~e.4)
            :time (d2 / day
                  :mod "16"
                  :time (a3 / after
                        :op1 (b / birth))))
      :op2 (m / mouse~e.12
            :mod (t / transgenic)
            :mod (m2 / macro-molecular-complex
                  :part (p / protein
                        :name (n2 / name :op1 "K14"~e.7))
                  :part (p2 / protein
                        :name (n3 / name :op1 "Snail"~e.9))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure
                  :mod (a2 / A~e.1))))

# ::tok Insets denote magnified tail segments , which displayed a mosaic , flaky appearance in Tg mice .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1 2-1.2.2 3-1.2.1 4-1.2 7-1.2.3 9-1.2.3.1.2 12-1.2.3.1 15-1.2.3.1.4
# ::id pmid_1563_0473.329
# ::preferred 
(d / denote-01~e.1
      :ARG0 (i / inset)
      :ARG1 (s / segment~e.4
            :part-of (t / tail~e.3)
            :ARG1-of (m / magnify-01~e.2)
            :ARG0-of (d2 / display-01~e.7
                  :ARG1 (a / appear-02~e.12
                        :ARG1 s
                        :mod (m2 / mosaic~e.9)
                        :mod (f / flake)
                        :location (m3 / mouse~e.15
                              :mod (t2 / transgenic))))))

# ::tok Size differences appeared with age , and are likely due to K14 @-@ promoter activity in the tongue and oral epithelium , resulting in progressive defects and reduced food intake .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 1-1.1.1 2-1.1 3-1.1.2.r 4-1.1.2 6-1 7-1.2.1.r 8-1.2 9-1.2.1 10-1.2.1 11-1.2.1.1.1.1.1 13-1.2.1.1.2 17-1.2.1.1.3.1 18-1.2.1.1.3 19-1.2.1.1.3.2.1 20-1.2.1.1.3.2 22-1.2.1.1.4 25-1.2.1.1.4.1.1 26-1.2.1.1.4.1 27-1.2.1.1.4.1.2.2 28-1.2.1.1.4.1.2.1 29-1.2.1.1.4.1.2
# ::id pmid_1563_0473.330
# ::preferred 
(a / and~e.6
      :op1 (a2 / appear-01~e.2
            :ARG1 (d / differ-02~e.1
                  :ARG3 (s / size~e.0))
            :time~e.3 (a3 / age~e.4))
      :op2 (l / likely~e.8
            :domain~e.7 (c / cause-01~e.9,10
                  :ARG0 (a4 / act-01
                        :ARG0 (p / protein
                              :name (n / name :op1 "K14"~e.11))
                        :ARG1 (p2 / promoter~e.13)
                        :location (a5 / and~e.18
                              :op1 (t / tongue~e.17)
                              :op2 (e / epithelium~e.20
                                    :part-of (m / mouth~e.19)))
                        :ARG1-of (r / result-01~e.22
                              :ARG2 (a6 / and~e.26
                                    :op1 (d2 / defect~e.25
                                          :ARG1-of (p3 / progress-01))
                                    :op2 (i / intake~e.29
                                          :mod (f / food~e.28)
                                          :ARG1-of (r2 / reduce-01~e.27)))))
                  :ARG1 d)))

# ::tok Hence , skin sections from young ( P3 ) mice were analyzed ( B–I ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 2-1.1.1.1.1 3-1.1.1 3-1.1.1.1 3-1.1.1.1.r 4-1.1.1.1.1.1.r 5-1.1.1.1.1.1.1 9-1.1.1.1.1.1 11-1.1
# ::id pmid_1563_0473.331
# ::preferred 
(c / cause-01~e.0
      :ARG1 (a / analyze-01~e.11
            :ARG1 (t / thing~e.3
                  :ARG2-of~e.3 (s / section-01~e.3
                        :ARG1 (s2 / skin~e.2
                              :source~e.4 (m / mouse~e.9
                                    :mod (y / young~e.5)
                                    :ARG1-of (m2 / mean-01
                                          :ARG2 (d2 / day
                                                :mod "3"
                                                :time (a2 / after
                                                      :op1 (b2 / birth))))))))
            :ARG1-of (d / describe-01
                  :ARG0 (f / figure
                        :mod (v / value-interval :op1 "B" :op2 "I")))))

# ::tok ( B ) Hematoxylin @- and eosin @-@ stained Tg skin section .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.2.1.1 3-1.1.1.1.1.1 5-1.1.1 6-1.1.1.2.1.1 8-1.1 10-1.3.1 11-1 11-1.3 11-1.3.r
# ::id pmid_1563_0473.332
# ::preferred 
(t / thing~e.11
      :ARG1-of (s3 / stain-00~e.8
            :ARG2 (a / and~e.5
                  :op1 (m / molecular-physical-entity
                        :name (n / name :op1 "hematoxylin"~e.3))
                  :op2 (m2 / molecular-physical-entity
                        :name (n2 / name :op1 "eosin"~e.6))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure
                  :mod (b / B~e.1)))
      :ARG2-of~e.11 (s / section-01~e.11
            :ARG1 (s2 / skin~e.10)))

# ::tok Double arrows demarcate the border of mosaic histology , with seemingly normal epidermis ( epi ) and a mature hair follicle ( hf ) at left and hyperthickened epidermis at right .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1 2-1 4-1.2 5-1.2.1.r 6-1.2.1.1 7-1.2.1 9-1.2.1.2.r 10-1.2.1.2.1.1 11-1.2.1.2.1 12-1.2.1.2 18-1.2.1.3.2 19-1.2.1.3.1 20-1.2.1.3 24-1.2.1.3.3.r 25-1.2.1.3.3 28-1.2.1.4 29-1.2.1.4.2.r 30-1.2.1.4.2
# ::id pmid_1563_0473.333
# ::preferred 
(d / demarcate-01~e.2
      :ARG0 (a / arrow~e.1
            :mod (d2 / double~e.0))
      :ARG1 (b / border-01~e.4
            :ARG1~e.5 (h / histology~e.7
                  :mod (m / mosaic~e.6)
                  :part~e.9 (e / epidermis~e.12
                        :mod (n / normal~e.11
                              :ARG1-of (s / seem-01~e.10)))
                  :part (f / follicle~e.20
                        :mod (h2 / hair~e.19)
                        :mod (m2 / mature~e.18)
                        :location~e.24 (l / left~e.25))
                  :part (e2 / epidermis~e.28
                        :ARG1-of (t / thicken-01
                              :degree (h3 / hyper))
                        :location~e.29 (r / right~e.30)))))

# ::tok ( C ) Immunofluorescence of Tg skin section labeled with antibodies as color @-@ coded on frame .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.2.1.1 6-1.1.3.1 7-1.1 7-1.1.3 7-1.1.3.r 8-1.1.1 9-1.1.1.1.r 10-1.1.1.1 11-1.1.1.2.r 12-1.1.1.2.1 14-1.1.1.2 15-1.1.1.2.2.r 16-1.1.1.2.2
# ::id pmid_1563_0473.334
# ::preferred 
(i / immunofluoresce-00
      :ARG1 (t2 / thing~e.7
            :ARG1-of (l / label-01~e.8
                  :ARG2~e.9 (a / antibody~e.10)
                  :ARG1-of~e.11 (c / code-01~e.14
                        :ARG0 (c2 / color~e.12)
                        :location~e.15 (f / frame~e.16)))
            :ARG1-of (d / describe-01
                  :ARG0 (f2 / figure
                        :mod (c3 / C~e.1)))
            :ARG2-of~e.7 (s / section-01~e.7
                  :ARG1 (s2 / skin~e.6
                        :mod (t / transgenic)))))

# ::tok Double arrows demarcate the border of mosaic anti @-@ Snail ( green ) , revealing Snail expression coincident with regions of hyperthickened epidermis ( at left ) and absent in regions of normal epidermis ( at right ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1 2-1 4-1.2 5-1.2.1.r 6-1.2.1.3 7-1.2.1 7-1.2.1.1 7-1.2.1.1.r 9-1.2.1.1.1.1.1 11-1.2.1.2 14-1.3 15-1.3.1.1.1.1.1 16-1.3.1.1.1.1 19-1.3.1.1.1.2 22-1.3.1.1.1.2.1 24-1.3.1.1.1.2.2.r 25-1.3.1.1.1.2.2 27-1.3.1 27-1.3.1.1.1 28-1.3.1.2 29-1.3.1.2.2.r 30-1.3.1.2.2 31-1.3.1.2.2.1.r 32-1.3.1.2.2.1.1 33-1.3.1.2.2.1 35-1.3.1.2.3.r 36-1.3.1.2.3
# ::id pmid_1563_0473.335
# ::preferred 
(d / demarcate-01~e.2
      :ARG0 (a / arrow~e.1
            :mod (d2 / double~e.0))
      :ARG1 (b / border-01~e.4
            :ARG1~e.5 (m / molecular-physical-entity~e.7
                  :ARG0-of~e.7 (c / counter-01~e.7
                        :ARG1 (p / protein
                              :name (n / name :op1 "Snail"~e.9)))
                  :mod (g / green~e.11)
                  :mod (m2 / mosaic~e.6)))
      :ARG0-of (r / reveal-01~e.14
            :ARG1 (a2 / and~e.27
                  :op1 (c2 / coincide-01
                        :ARG1 (a3 / and~e.27
                              :op1 (e / express-03~e.16
                                    :ARG2 p~e.15)
                              :op2 (r2 / region~e.19
                                    :part-of (e2 / epidermis~e.22
                                          :ARG1-of (t / thicken-01
                                                :degree (h / hyper)))
                                    :location~e.24 (l / left~e.25))))
                  :op2 (a4 / absent-01~e.28
                        :ARG1 e
                        :ARG2~e.29 (r3 / region~e.30
                              :part-of~e.31 (e3 / epidermis~e.33
                                    :mod (n2 / normal~e.32)))
                        :location~e.35 (r4 / right~e.36)))))

# ::tok ( D–I ) Sections of P3 WT or Tg skin ( affected region ) subjected to either immunofluorescence ( D , E, H , and I ) or immunohistochemistry ( F and G ) with antibodies as indicated on the panel .
# ::amr-annotator SDL-AMR-09
# ::alignments 3-1.1 3-1.1.1 3-1.1.1.r 6-1.1.1.1.1.2 7-1.1.1.1 9-1.1.1.1.1 9-1.1.1.1.2 11-1.1.1.1.3.1.1 12-1.1.1.1.3.1 14-1 19-1.3.1.1.1 22-1.2.1.2.1.3.1 24-1.2.1.2.1 25-1.3.1.1.2 27-1.2 28-1.2.2 30-1.2.2.2.1.1.1 31-1.2.2.2.1 32-1.2.2.2.1.2.1 34-1.2.2.1.r 35-1.2.2.1 36-1.1.1.1.1.1.2.r 36-1.1.1.1.1.1.r 36-1.2.2.1.1.r 37-1.2.2.1.1 38-1.2.2.1.1.1.r 40-1.2.2.1.1.1
# ::id pmid_1563_0473.336
# ::preferred 
(s / subject-01~e.14
      :ARG1 (t2 / thing~e.3
            :ARG2-of~e.3 (s2 / section-01~e.3
                  :ARG1 (o / or~e.7
                        :op1 (s3 / skin~e.9
                              :time~e.36 (d5 / day
                                    :mod "3"
                                    :time~e.36 (a5 / after
                                          :op1 (b / birth)))
                              :mod (w / wild-type~e.6))
                        :op2 (s4 / skin~e.9
                              :mod (t / transgenic))
                        :ARG1-of (m / mean-01
                              :ARG2 (r / region~e.12
                                    :ARG1-of (a / affect-01~e.11))))))
      :ARG2 (o3 / or~e.27
            :op1 (i / immunofluoresce-00
                  :ARG1 s2
                  :ARG1-of (d / describe-01
                        :ARG0 (a3 / and~e.24
                              :op1 (f3 / figure
                                    :mod (d3 / D~e.19))
                              :op2 (f4 / figure
                                    :mod (e / E))
                              :op3 (f5 / figure
                                    :mod (h / H~e.22))
                              :op4 (f6 / figure
                                    :mod (i5 / I~e.25)))))
            :op2 (i3 / immunohistochemistry~e.28
                  :instrument~e.34 (a2 / antibody~e.35
                        :ARG1-of~e.36 (i4 / indicate-01~e.37
                              :location~e.38 (p / panel~e.40)))
                  :ARG1-of (d4 / describe-01
                        :ARG0 (a4 / and~e.31
                              :op1 (f / figure
                                    :mod (f8 / F~e.30))
                              :op2 (f7 / figure
                                    :mod (g / G~e.32))))))
      :ARG1-of (d2 / describe-01
            :ARG0 (f2 / figure
                  :mod (v / value-interval
                        :op1 d3
                        :op2 i5))))

# ::tok Anti @-@ keratin 5 indicates K5 , normally restricted to the basal layer of the epidermis ; anti @-@ keratin 6 detects keratin 6 , expressed in postnatal epidermis under conditions such as wounding , in which hyperproliferation occurs .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 0-1.2.1.1 2-1.1.1.1.1.1.1 2-1.2.1.1.1.1.1 3-1.1.2 4-1.1 7-1.1.2 8-1.1.2 9-1.1.2 10-1.1.2 11-1.1.2 12-1.1.2 13-1.1.2 14-1.1.2 15-1.1.2 17-1.1.1.1 17-1.2.1.1 19-1.2.2 20-1.2.2 21-1.2 22-1.2.2 23-1.2.2 24-1.2.2 25-1.2.2 26-1.2.2 27-1.2.2 28-1.2.2 29-1.2.2 30-1.2.2 31-1.2.2 32-1.2.2 33-1.2.2
# ::id pmid_1563_0473.337
# ::preferred 
(m / multi-sentence
      :snt1 (i / indicate-01~e.4
            :ARG0 (a / antibody
                  :ARG0-of (c / counter-01~e.0,17
                        :ARG1 (p / protein
                              :name (n / name :op1 "keratin"~e.2 :op2 "5")
                              :ARG1-of (r / restrict-01
                                    :ARG2 (l / layer
                                          :part-of (e / epidermis)
                                          :mod (b / basal))
                                    :mod (n2 / normal)))))
            :ARG1 p~e.3,7,8,9,10,11,12,13,14,15)
      :snt2 (d / detect-01~e.21
            :ARG0 (a2 / antibody
                  :ARG0-of (c2 / counter-01~e.0,17
                        :ARG1 (p2 / protein
                              :name (n3 / name :op1 "keratin"~e.2 :op2 "6")
                              :ARG2-of (e2 / express-03
                                    :ARG3 (e3 / epidermis
                                          :mod (p3 / postnatal))
                                    :ARG1-of (c3 / condition-01
                                          :example (w / wound-01
                                                :time-of (h / hyperproliferate-00)))))))
            :ARG1 p2~e.19,20,22,23,24,25,26,27,28,29,30,31,32,33))

# ::tok All other antibodies are as in the legend to <xref ref-type="fig" rid="pbio-0030011-g002"> Figure 2 </xref>@ .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1.2 2-1.1 2-1.2 5-1.2.1.r 7-1.2.1 12-1.2.1.1 13-1.2.1.1.1
# ::id pmid_1563_0473.338
# ::preferred 
(r / resemble-01
      :ARG1 (a / antibody~e.2
            :mod (a2 / all~e.0)
            :mod (o / other~e.1))
      :ARG2 (a3 / antibody~e.2
            :location~e.5 (l / legend~e.7
                  :mod (f / figure~e.12 :mod "2"~e.13))))

# ::tok Comparison of D and E provide representative examples that illustrate that pMAPK is found in only a subset of all proliferating ( Ki67 @-@ positive ) cells .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 2-1.1.1.1 4-1.1.2.1 5-1 6-1.2.1 7-1.2 9-1.2.2 11-1.2.2.1.1.1.1 12-1.2.2.1 15-1.2.2.1.2.1 17-1.2.2.1.2 19-1.2.2.1.2.2.1.3 20-1.2.2.1.2.2.1.1 22-1.2.2.1.2.2.1.2.1.1.1 24-1.2.2.1.2.2.1.2 26-1.2.2.1.2.2.1
# ::id pmid_1563_0473.339
# ::preferred 
(p2 / provide-01~e.5
      :ARG0 (c / compare-01~e.0
            :ARG1 (f / figure :mod "D"~e.2)
            :ARG2 (f2 / figure :mod "E"~e.4))
      :ARG1 (e / example~e.7
            :ARG0-of (r2 / represent-01~e.6)
            :ARG0-of (i / illustrate-01~e.9
                  :ARG1 (b / be-located-at-91~e.12
                        :ARG1 (p3 / pathway
                              :name (n / name :op1 "pMAPK"~e.11))
                        :ARG2 (s / subset~e.17
                              :mod (o / only~e.15)
                              :ARG1-of (i2 / include-91
                                    :ARG2 (c2 / cell~e.26
                                          :ARG0-of (p4 / proliferate-01~e.20)
                                          :mod (p5 / positive~e.24
                                                :mod (p6 / protein
                                                      :name (n2 / name :op1 "Ki67"~e.22)))
                                          :mod (a / all~e.19))))))))

# ::tok Note also the presence of Ki67 @- ( E ) and pMAPK @-@ positive ( G ) cells in some suprabasal areas ; Ki67 @-@ positive cells colabeled with anti @-@ Snail ( E ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1.1.4 5-1.2.1.1.1.1.1 8-1.1.3.1.1.2.1.1 10-1.1.3.1 11-1.1.3.1.2.1.1.1.1 13-1.1.3.1.1.1 15-1.1.3.1.2.2.1.1 17-1.1.3.1.1 19-1.1.3.2.1 20-1.1.3.2.2 21-1.1.3.2 23-1.1.3.1.1.1.1.1.1 23-1.2.1.1.1.1.1 25-1.1.3.1.1.1 25-1.1.3.1.2.1 25-1.2.1.1 26-1.1.3.1.1 26-1.1.3.1.2 26-1.2.1 29-1.2.2.1 31-1.2.2.1.1.1.1 33-1.1.3.1.1.2.1.1
# ::id pmid_1563_0473.340
# ::preferred 
(m / multi-sentence
      :snt1 (n / note-02~e.0
            :mode "imperative"
            :ARG0 (y / you)
            :ARG1 (b / be-located-at-91
                  :ARG1 (a / and~e.10
                        :op1 (c / cell~e.17,26
                              :mod (p / positive~e.13,25
                                    :mod (p2 / protein
                                          :name (n2 / name :op1 "Ki67"~e.23)))
                              :ARG1-of (d / describe-01
                                    :ARG0 (f / figure :mod "E"~e.8,33)))
                        :op2 (c2 / cell~e.26
                              :mod (p3 / positive~e.25
                                    :mod (p4 / pathway
                                          :name (n3 / name :op1 "pMAPK"~e.11)))
                              :ARG1-of (d2 / describe-01
                                    :ARG0 (f2 / figure :mod "G"~e.15))))
                  :ARG2 (a2 / area~e.21
                        :quant (s / some~e.19)
                        :mod (s2 / suprabasal~e.20)))
            :mod (a4 / also~e.1))
      :snt2 (c3 / colabel-00
            :ARG1 (c5 / cell~e.26
                  :mod (p6 / positive~e.25
                        :mod (p7 / protein
                              :name (n5 / name :op1 "Ki67"~e.5,23))))
            :ARG2 (a3 / antibody
                  :ARG0-of (c4 / counter-01~e.29
                        :ARG1 (p5 / protein
                              :name (n4 / name :op1 "Snail"~e.31))))
            :ARG1-of (d3 / describe-01
                  :ARG0 f)))

# ::tok Figure 3
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.1
# ::id pmid_1563_0473.341
# ::preferred 
(f / figure~e.0 :mod "3"~e.1)

# ::tok ( A–H ) Immunofluorescence of skin sections from P3 WT and Tg mice .
# ::amr-annotator SDL-AMR-09
# ::alignments 3-1 4-1.1.r 5-1.1.1 6-1.1 7-1.1.1.1.r 9-1.1.1.1.1.1 10-1.1.1.1 12-1.1.1.1.1 12-1.1.1.1.2
# ::id pmid_1563_0473.342
# ::preferred 
(i / immunofluorescence~e.3
      :mod~e.4 (s2 / section-01~e.6
            :ARG1 (s / skin~e.5
                  :source~e.7 (a / and~e.10
                        :op1 (m / mouse~e.12
                              :mod (w / wild-type~e.9))
                        :op2 (m2 / mouse~e.12
                              :mod (t2 / transgenic)
                              :age (t / temporal-quantity
                                    :quant "3"
                                    :unit (d / day))))
                  :ARG1-of (a2 / age-01
                        :ARG2 t)))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure
                  :mod (v / value-interval :op1 "A" :op2 "H"))))

# ::tok Shown are affected areas of Tg skin ; in areas where Snail protein was not expressed , stainings were normal .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 2-1.1.1.2 3-1.1.1 6-1.1.1.1 9-1.1.1 9-1.2.2 10-1.2.2.r 11-1.2.2.1.2.1.1 12-1.2.2.1.2 14-1.2.2.1.1 14-1.2.2.1.1.r 15-1.2.2.1 17-1.2.1 18-1.2.1.r 19-1.2
# ::id pmid_1563_0473.343
# ::preferred 
(m / multi-sentence
      :snt1 (s / show-01~e.0
            :ARG1 (a / area~e.3,9
                  :mod (s2 / skin~e.6
                        :mod (t / transgenic))
                  :ARG1-of (a2 / affect-01~e.2)))
      :snt2 (n / normal~e.19
            :domain~e.18 (s3 / stain-01~e.17)
            :location~e.10 (a3 / area~e.9
                  :ARG3-of (e / express-03~e.15
                        :polarity~e.14 "-"~e.14
                        :ARG2 (p / protein~e.12
                              :name (n2 / name :op1 "Snail"~e.11))))))

# ::tok Sections were labeled with antibodies as indicated and color @-@ coded on each frame .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 0-1.1.1 0-1.1.1.r 2-1 3-1.2.r 4-1.2 5-1.2.1.r 6-1.2.1 8-1.2.2.1 10-1.2.2 11-1.2.1.1.r 12-1.2.1.1.1 13-1.2.1.1
# ::id pmid_1563_0473.344
# ::preferred 
(l / label-01~e.2
      :ARG1 (t / thing~e.0
            :ARG1-of~e.0 (s / section-01~e.0))
      :ARG2~e.3 (a / antibody~e.4
            :ARG1-of~e.5 (i / indicate-01~e.6
                  :location~e.11 (f / frame~e.13
                        :mod (e / each~e.12)))
            :ARG1-of (c / code-01~e.10
                  :mod (c2 / color~e.8)
                  :location f)))

# ::tok Antibodies are against markers of normal epidermal differentiation , and include K5 ( a basally expressed keratin ) , K1 ( a suprabasal keratin , expressed in spinous layer cells ) , involucrin ( Inv ; a suprabasally expressed cornified envelope protein found in upper spinous and granular layer cells ) , loricrin ( Lor ; a cornified envelope protein expressed in the granular layer ) , and filaggrin ( Fil ; a protein that bundles keratin filaments in the granular layer and stratum corneum ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 2-1.1 3-1.1.1 4-1.1.1.1.r 5-1.1.1.1.2 7-1.1.1.1 9-1.2.1 10-1.2 15-1.2.1.1.2.1.1 15-1.2.1.2.2.1.1 16-1.2.1.1.1.1 16-1.2.1.1.2.1 16-1.2.1.2.1.1 16-1.2.1.2.2.1 22-1.2.1.2.2.1.1.2 22-1.2.1.3.2.1.2.2 23-1.2.1.1.1.1 23-1.2.1.2.1.1 23-1.2.1.2.2.1 25-1.2.1.2.2.1.1 27-1.2.1.2.2.1.1.1.1.1 28-1.2.1.2.2.1.1.1.1 28-1.2.1.3.2.1.2.1.2.1 29-1.2.1.2.2.1.1.1 29-1.2.1.3.2.1.2.1.2 32-1.2.1.3.1.1 38-1.2.1.3.2.1.2 40-1.2.1.3.2.1.1 41-1.2.1.3.2.1 43-1.2.1.3.2.1.2.1.2.1.2.r 44-1.2.1.3.2.1.2.1.2.1.2 45-1.2.1.3.2.1.2.1.2.1.1 46-1.2.1.3.2.1.2.1 47-1.2.1.3.2.1.2.1.1.1.1 48-1.2.1.3.2.1.2.1.1.1 49-1.2.1.3.2.1.2.1.1 49-1.2.1.4.2.1.2.1 52-1.2.1.4.1.1 58-1.2.1.3.2.1.1 58-1.2.1.4.2.1.1 59-1.2.1.3.2.1 59-1.2.1.4.2.1 60-1.2.1.3.2.1.2 60-1.2.1.4.2.1.2 63-1.2.1.3.2.1.2.1.1.1.1 64-1.2.1.3.2.1.2.1.1.1 67-1.2.1 68-1.2.1.5.1.1 73-1.2.1.5.2.1 75-1.2.1.5.2.1.1 76-1.2.1.5.2.1.1.1.1.1.1 77-1.2.1.5.2.1.1.1 78-1.2.1.5.2.1.1.2.r 80-1.2.1.5.2.1.1.2.1 81-1.2.1.5.2.1.1.2.1 82-1.2.1.5.2.1.1.2 83-1.2.1.5.2.1.1.2.2.1.1 84-1.2.1.5.2.1.1.2.2.1.2
# ::id pmid_1563_0473.345
# ::preferred 
(a / antibody~e.0
      :ARG0-of (c / counter-01~e.2
            :ARG1 (m / marker~e.3
                  :ARG0-of~e.4 (d / differentiate-101~e.7
                        :ARG1 (e / epidermis)
                        :mod (n / normal~e.5))))
      :ARG2-of (i / include-01~e.10
            :ARG1 (a2 / and~e.9,67
                  :op1 (p / protein
                        :name (n2 / name :op1 "keratin"~e.16,23 :op2 "5")
                        :ARG1-of (m2 / mean-01
                              :ARG2 (k / keratin~e.16
                                    :ARG2-of (e2 / express-03~e.15
                                          :manner (b / basal)))))
                  :op2 (p2 / protein
                        :name (n3 / name :op1 "keratin"~e.16,23 :op2 "1")
                        :ARG1-of (m3 / mean-01
                              :ARG2 (k2 / keratin~e.16,23
                                    :ARG2-of (e3 / express-03~e.15,25
                                          :ARG3 (c2 / cell~e.29
                                                :part-of (l / layer~e.28
                                                      :mod (s / spinous~e.27)))
                                          :manner (s2 / suprabasal~e.22)))))
                  :op3 (p3 / protein
                        :name (n4 / name :op1 "involucrin"~e.32)
                        :ARG1-of (m4 / mean-01
                              :ARG2 (p7 / protein~e.41,59
                                    :mod (e6 / envelope~e.40,58
                                          :ARG1-of (c6 / cornify-00))
                                    :ARG2-of (e4 / express-03~e.38,60
                                          :ARG3 (a3 / and~e.46
                                                :op1 (c3 / cell~e.49
                                                      :part-of (l2 / layer~e.48,64
                                                            :mod (g / granular~e.47,63)))
                                                :op2 (c4 / cell~e.29
                                                      :part-of (l3 / layer~e.28
                                                            :mod (s4 / spinous~e.45)
                                                            :mod~e.43 (u / upper~e.44))))
                                          :manner (s3 / suprabasal~e.22)))))
                  :op4 (p4 / protein
                        :name (n5 / name :op1 "loricrin"~e.52)
                        :ARG1-of (m5 / mean-01
                              :ARG2 (p8 / protein~e.59
                                    :mod (e7 / envelope~e.58
                                          :ARG1-of (c7 / cornify-00))
                                    :ARG2-of (e5 / express-03~e.60
                                          :ARG3 (c5 / cell~e.49
                                                :part-of l2)))))
                  :op5 (p5 / protein
                        :name (n6 / name :op1 "filaggrin"~e.68)
                        :ARG1-of (m6 / mean-01
                              :ARG2 (p9 / protein~e.73
                                    :ARG0-of (b2 / bundle-01~e.75
                                          :ARG2 (f / filament~e.77
                                                :mod (p6 / protein
                                                      :name (n7 / name :op1 "keratin"~e.76)))
                                          :location~e.78 (a4 / and~e.82
                                                :op1 l2~e.80,81
                                                :op2 (l4 / location
                                                      :name (n8 / name :op1 "stratum"~e.83 :op2 "corneum"~e.84))))))))))

# ::tok Note abnormal extension of anti @-@ K5 suprabasally , often present in anti @-@ K1 positive suprabasal Tg cells .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.3.3 1-1.3.3.1 1-1.3.3.1.r 2-1.3 4-1.3.1.1 9-1.3.4.2 12-1.3.4.1.3.1.1 15-1.3.4.1.3 16-1.3.2 16-1.3.4.1.2 18-1.3.4.1
# ::id pmid_1563_0473.346
# ::preferred 
(n / note-02~e.0
      :mode "imperative"
      :ARG0 (y / you)
      :ARG1 (e / extend-01~e.2
            :ARG1 (a / antibody
                  :ARG0-of (c / counter-01~e.4
                        :ARG1 (p / protein
                              :name (n3 / name :op1 "keratin" :op2 "5"))))
            :ARG4 (s / suprabasal~e.16)
            :mod (n2 / normal~e.1 :polarity~e.1 "-"~e.1)
            :ARG1-of (b / be-located-at-91
                  :ARG2 (c2 / cell~e.18
                        :mod (t / transgenic)
                        :mod (s2 / suprabasal~e.16)
                        :mod (p2 / positive~e.15
                              :mod (a2 / antibody
                                    :ARG0-of (c3 / counter-01~e.12
                                          :ARG1 (p3 / protein
                                                :name (n4 / name :op1 "keratin" :op2 "1"))))))
                  :frequency (o / often~e.9))))

# ::tok ( I–N ) Immunohistochemistry ( I and J ) or immunofluorescence ( K–N ) of sections of P30 Wt ( I , K, and M ) and Tg ( J , L, and N ) ( affected areas ) skins using the antibodies indicated .
# ::amr-annotator SDL-AMR-09
# ::alignments 3-1.1 5-1.1.1.1.1.1 5-1.3.1.1.1 6-1.1.1.1 7-1.1.1.1.2.1 10-1.2 14-1.1.2.r 15-1.1.2 20-1.1.2.1.1.2.1.1.1 23-1.1.2.1 23-1.1.2.1.1.2.1 24-1.1.2.1.1.2.1.3.1 26-1.1.2.1 26-1.1.2.1.1.2.1 26-1.1.2.1.2.2.1 29-1.1.2.1.2.2.1.1.1 32-1.1.2.1 32-1.1.2.1.1.2.1 32-1.1.2.1.2.2.1 33-1.1.2.1.2.2.1.3.1 33-1.2.1.1.1.2 33-1.3.1.1.2 36-1.1.2.1.2.4.1.1 37-1.1.2.1.2.4.1 39-1.1.2.1.1 39-1.1.2.1.2 40-1.1.3 42-1.1.3.1 43-1.1.3.1.1
# ::id pmid_1563_0473.347
# ::preferred 
(a / and
      :op1 (i / immunohistochemistry~e.3
            :ARG1-of (d2 / describe-01
                  :ARG0 (a2 / and~e.6
                        :op1 (f2 / figure :mod "I"~e.5)
                        :op2 (f6 / figure :mod "J"~e.7)))
            :mod~e.14 (s / section-01~e.15
                  :ARG1 (a3 / and~e.23,26,32
                        :op1 (s2 / skin~e.39
                              :mod (w / wild-type)
                              :ARG1-of (d5 / describe-01
                                    :ARG0 (a4 / and~e.23,26,32
                                          :op1 (f4 / figure :mod "I"~e.20)
                                          :op2 (f7 / figure :mod "K")
                                          :op3 (f8 / figure :mod "M"~e.24)))
                              :ARG1-of (a9 / age-01
                                    :ARG2 (t2 / temporal-quantity
                                          :quant "30"
                                          :unit (d4 / day))))
                        :op2 (s3 / skin~e.39
                              :mod (t / transgenic)
                              :ARG1-of (d6 / describe-01
                                    :ARG0 (a5 / and~e.26,32
                                          :op1 (f5 / figure :mod "J"~e.29)
                                          :op2 (f9 / figure :mod "L")
                                          :op3 (f10 / figure :mod "N"~e.33)))
                              :ARG1-of (a10 / age-01
                                    :ARG2 t2)
                              :ARG1-of (d7 / describe-01
                                    :ARG2 (a6 / area~e.37
                                          :ARG1-of (a7 / affect-01~e.36))))))
            :manner (u / use-01~e.40
                  :ARG1 (a8 / antibody~e.42
                        :ARG1-of (i3 / indicate-01~e.43))))
      :op2 (i2 / immunofluorescence~e.10
            :ARG1-of (d3 / describe-01
                  :ARG0 (f3 / figure
                        :mod (v2 / value-interval :op1 "K" :op2 "N"~e.33)))
            :mod s
            :manner a8)
      :ARG1-of (d / describe-01
            :ARG0 (f / figure
                  :mod (v / value-interval :op1 "I"~e.5 :op2 "N"~e.33))))

# ::tok Note that with age , affected areas of the Tg epidermis became increasingly undulating , often exhibiting papilloma @-@ like invaginations ( J ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 2-1.3.r 3-1.3.1.3.1 5-1.3.1.1.2 6-1.3.1.1 10-1.3.1.1.1 11-1.3.1 12-1.3.1.2.2 13-1.3.1.2 15-1.3.2.3 16-1.3.2 17-1.3.2.2.1.1 19-1.3.2.2.1 20-1.3.2.2 22-1.3.2.1
# ::id pmid_1563_0473.348
# ::preferred 
(n / note-02~e.0
      :mode "imperative"
      :ARG0 (y / you)
      :ARG1~e.2 (a5 / and
            :op1 (b / become-01~e.11
                  :ARG1 (a / area~e.6
                        :part-of (e / epidermis~e.10
                              :mod (t / transgenic))
                        :ARG1-of (a2 / affect-01~e.5)
                        :ARG1-of (d / describe-01
                              :ARG0 (f / figure :mod "J")))
                  :ARG2 (u2 / undulate-00~e.13
                        :ARG1 a
                        :degree (i / increase-01~e.12))
                  :ARG1-of (c / cause-01
                        :ARG0 (a3 / age-01~e.3)))
            :op2 (e2 / exhibit-01~e.16
                  :ARG0 a~e.22
                  :ARG1 (i2 / invaginate-00~e.20
                        :ARG1-of (r / resemble-01~e.19
                              :ARG2 (p / papilloma~e.17)))
                  :frequency (o / often~e.15))))

# ::tok Insets in I and J are magnified views of the boxed areas , illustrating the absence ( Wt ) or presence ( Tg ) of nuclear anti @-@ cyclin D staining .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.3.1.1.1 3-1.3.1 4-1.3.1.2.1 5-1.3.r 6-1.2 7-1 8-1.1.r 10-1.1.1 11-1.1 13-1.4 15-1.4.1.1 17-1.4.1.1.2.1.1 19-1.4.1 20-1.4.1.2 22-1.4.1.2.1.1.1 24-1.4.1.1.1.r 25-1.4.1.1.1.1 26-1.4.1.1.1.2.1 28-1.4.1.1.1.2.1.1.1.1 29-1.4.1.1.1.2.1.1.1.2 30-1.4.1.1.1
# ::id pmid_1563_0473.349
# ::preferred 
(v / view-01~e.7
      :ARG1~e.8 (a2 / area~e.11
            :ARG1-of (b / box-02~e.10))
      :ARG1-of (m / magnify-01~e.6)
      :domain~e.5 (i / inset
            :location (a / and~e.3
                  :op1 (f / figure :mod "I"~e.2)
                  :op2 (f2 / figure :mod "J"~e.4)))
      :ARG0-of (i2 / illustrate-01~e.13
            :ARG1 (o / or~e.19
                  :op1 (a3 / absent-01~e.15
                        :ARG1~e.24 (s / stain-01~e.30
                              :mod (n5 / nucleus~e.25)
                              :instrument (a4 / antibody
                                    :ARG0-of (c / counter-01~e.26
                                          :ARG1 (p2 / protein
                                                :name (n6 / name :op1 "cyclin"~e.28 :op2 "D"~e.29)))))
                        :ARG1-of (d / describe-01
                              :ARG2 (n / name :op1 "Wt"~e.17)))
                  :op2 (p / present~e.20
                        :ARG1-of (d2 / describe-01
                              :ARG2 (n3 / name :op1 "Tg"~e.22))
                        :domain s))))

# ::tok With age , affected areas of the Tg epidermis also displayed perturbations within the basement membrane , as judged by antibody labeling against either basement membrane ( K and L ) or hemidesmosomal ( M and N ) components .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.5.1.2.r 1-1.6.1 3-1.1.1 4-1.1 8-1.1.2 9-1.4 10-1 11-1.2 14-1.3.1 15-1.3 18-1.5 20-1.5.1.2 21-1.5.1 24-1.5.1.1.1.1 25-1.5.1.1.1 27-1.5.1.1.1.2.1.1.1 28-1.5.1.1.1.2.1 29-1.5.1.1.1.2.1.2.1 31-1.5.1.1 32-1.5.1.1.2.1 34-1.5.1.1.2.2.1.1.1 35-1.5.1.1.2.2.1 36-1.5.1.1.2.2.1.2.1 38-1.5.1.1.2
# ::id pmid_1563_0473.350
# ::preferred 
(d / display-01~e.10
      :ARG0 (a / area~e.4
            :ARG1-of (a2 / affect-01~e.3)
            :part-of (e / epidermis~e.8
                  :mod (t / transgenic)))
      :ARG1 (p / perturb-01~e.11
            :ARG1 a)
      :ARG2 (m / membrane~e.15
            :mod (b / basement~e.14))
      :mod (a3 / also~e.9)
      :ARG2-of (j / judge-01~e.18
            :ARG3 (l / label-01~e.21
                  :ARG1 (o / or~e.31
                        :op1 (m2 / membrane~e.25
                              :mod (b2 / basement~e.24)
                              :ARG1-of (d2 / describe-01
                                    :ARG0 (a6 / and~e.28
                                          :op1 (f / figure :mod "K"~e.27)
                                          :op2 (f3 / figure :mod "L"~e.29))))
                        :op2 (c / component~e.38
                              :mod (h / hemidesmosomal~e.32)
                              :ARG1-of (d3 / describe-01
                                    :ARG0 (a7 / and~e.35
                                          :op1 (f2 / figure :mod "M"~e.34)
                                          :op2 (f4 / figure :mod "N"~e.36)))))
                  :instrument~e.0 (a5 / antibody~e.20)))
      :ARG1-of (c2 / cause-01
            :ARG0 (a4 / age-01~e.1)))

# ::tok Double arrows in L demarcate mosaic zones , revealing that perturbations were restricted to hyperthickened , i.e. , Snail @-@ positive zones ( to left of double arrows ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1 3-1.1.2.1 4-1 5-1.2.1 6-1.2 8-1.1.3 9-1.1.3.1.r 10-1.1.3.1.1 12-1.1.3.1 18-1.1.3.1.2.1.2.1.1.1.1 20-1.1.3.1.2.1.2.1 21-1.1.3.1.2 24-1.1.3.1.2.2.2 26-1.1.1 27-1.1
# ::id pmid_1563_0473.351
# ::preferred 
(d2 / demarcate-01~e.4
      :ARG0 (a / arrow~e.1,27
            :quant (d / double~e.0,26)
            :location (f / figure :mod "L"~e.3)
            :ARG0-of (r / reveal-01~e.8
                  :ARG1~e.9 (r2 / restrict-01~e.12
                        :ARG1 (p / perturb-01~e.10)
                        :ARG2 (z2 / zone~e.21
                              :ARG1-of (t / thicken-01
                                    :degree (h / hyper)
                                    :ARG1-of (m2 / mean-01
                                          :ARG2 (p2 / positive~e.20
                                                :mod (p3 / protein
                                                      :name (n / name :op1 "Snail"~e.18)))))
                              :location (r3 / relative-position
                                    :op1 a
                                    :direction (l / left~e.24))))))
      :ARG1 (z / zone~e.6
            :mod (m / mosaic~e.5)))

# ::tok Other abbreviations are as noted in the legend to <xref ref-type="fig" rid="pbio-0030011-g002"> Figure 2 </xref>@ .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2 1-1.1 1-1.1.1 1-1.1.1.r 4-1.2 5-1.2.1.r 7-1.2.1 12-1.2.1.1 13-1.2.1.1.1
# ::id pmid_1563_0473.352
# ::preferred 
(r / resemble-01
      :ARG1 (t / thing~e.1
            :ARG1-of~e.1 (a / abbreviate-01~e.1)
            :mod (o / other~e.0))
      :ARG2 (n / note-01~e.4
            :location~e.5 (l / legend~e.7
                  :mod (f / figure~e.12 :mod "2"~e.13))))

# ::tok Figure 4
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.1
# ::id pmid_1563_0473.353
# ::preferred 
(f / figure~e.0 :mod "4"~e.1)

# ::tok ( A ) Immunofluorescence of skin sections from P30 Wt and Tg mice .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1.1 3-1 4-1.2.r 5-1.2.1 6-1.2 7-1.2.1.1.r 10-1.2.1.1 12-1.2.1.1.1 12-1.2.1.1.2
# ::id pmid_1563_0473.354
# ::preferred 
(i / immunofluorescence~e.3
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "A"~e.1))
      :mod~e.4 (s / section-01~e.6
            :ARG1 (s2 / skin~e.5
                  :source~e.7 (a / and~e.10
                        :op1 (m / mouse~e.12
                              :mod (w / wild-type)
                              :age (t2 / temporal-quantity
                                    :quant "30"
                                    :unit (d2 / day)))
                        :op2 (m2 / mouse~e.12
                              :mod (t / transgenic)
                              :age t2)))))

# ::tok Shown are affected areas of Tg skin ; in areas where Snail protein was not expressed , stainings were normal .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 2-1.1.1.1 3-1.1.1 6-1.1.1.2 9-1.1.1 9-1.2.2 10-1.2.2.r 11-1.2.2.1.2.1.1 12-1.2.2.1.2 14-1.2.2.1.1 14-1.2.2.1.1.r 15-1.2.2.1 17-1.2.1 18-1.2.1.r 19-1.2
# ::id pmid_1563_0473.355
# ::preferred 
(m / multi-sentence
      :snt1 (s / show-01~e.0
            :ARG1 (a / area~e.3,9
                  :ARG1-of (a2 / affect-01~e.2)
                  :mod (s2 / skin~e.6
                        :mod (t / transgenic))))
      :snt2 (n / normal~e.19
            :domain~e.18 (s3 / stain-01~e.17)
            :location~e.10 (a3 / area~e.9
                  :ARG3-of (e / express-03~e.15
                        :polarity~e.14 "-"~e.14
                        :ARG2 (p / protein~e.12
                              :name (n2 / name :op1 "Snail"~e.11))))))

# ::tok Antibodies used are against AJ proteins and include E @-@ cadherin ( E @-@ cad ) , the transmembrane core protein ; β-catenin (β-cat ) , which binds E @-@ cadherin at AJs and which can also participate as a transcription cofactor when associated with LEF @-@ 1/TCF proteins in the nucleus ; α-catenin (α-cat ) which binds to both β-catenin and Ajuba , a close relative of zyxin ; and Ajuba , which can associate with proteins that bind to the actin cytoskeleton , as well as with Grb @-@ 2 , a mediator of the GTP nucleotide @-@ exchange protein Sos , involved in activation of the Ras @-@ MAPK signaling cascade .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.3 2-1.1.1.1 3-1.1 5-1.1.1 5-1.2.1.4.3.1.1 6-1.2.1 7-1.2 8-1.2.1.1.1.1 10-1.2.1.1.1.1 12-1.2.1.1.1.1 18-1.2.1.1.2 19-1.2.1.1.3 20-1.2.1.1 22-1.2.1.2.1.1 27-1.2.1.2 27-1.2.1.2.2 27-1.2.1.2.2.r 28-1.2.1.2.2.1 29-1.2.1.2.2.1 30-1.2.1.2.2.1 31-1.1.1.1 33-1.2.1.3.2.1 35-1.2.1.2.3.1 36-1.2.1.2.3.4 37-1.2.1.2.3 38-1.2.1.2.3.2.r 40-1.2.1.2.3.2.1 41-1.2.1.2.3.2 43-1.2.1.2.3.3 45-1.2.1.2.3.3.2.1.1 48-1.2.1.4.3.1.2.2.1.3 49-1.2.1.2.3.3.3.r 51-1.2.1.2.3.3.3 53-1.2.1.3.1.1 57-1.2.1.3 57-1.2.1.3.2 57-1.2.1.3.2.r 60-1.2.1.3.2.1.1 61-1.2.1.3.2.1 62-1.2.1.4.1.1 65-1.2.1.4.2.2 68-1.2.1.4.2.1.1.1 71-1.2.1.4.1.1 74-1.2.1.4.3.2 75-1.2.1.4.3 77-1.2.1.2.3.3.2 77-1.2.1.4.2.1 79-1.2.1.4.3.1.1.1 80-1.2.1.4.3.1.1.1.1.r 82-1.2.1.4.3.1.1.1.1.1 83-1.2.1.4.3.1.1.1.1 89-1.2.1.4.3.1.2.1.1 91-1.2.1.4.3.1.2.1.1 94-1.2.1.4.3.1.2 94-1.2.1.4.3.1.2.2 94-1.2.1.4.3.1.2.2.r 97-1.2.1.4.3.1.2.2.1.3.1.1 98-1.2.1.4.3.1.2.2.1.3.1.2 100-1.2.1.4.3.1.2.2.1.3.1.3 101-1.2.1.4.3.1.2.2.1 101-1.2.1.4.3.1.2.2.1.3 101-1.2.1.4.3.1.2.2.1.3.r 102-1.2.1.4.3.1.2.2.1.1.1 104-1.2.1.4.3.1.2.2.1.2 105-1.2.1.4.3.1.2.2.1.2.1.r 106-1.2.1.4.3.1.2.2.1.2.1 107-1.2.1.4.3.1.2.2.1.2.1.1.r 109-1.2.1.4.3.1.2.2.1.2.1.1.1.1 111-1.2.1.4.3.1.2.2.1.2.1.1.1.2 112-1.2.1.4.3.1.2.2.1.2.1.1.2.1 113-1.2.1.4.3.1.2.2.1.2.1.1.2
# ::id pmid_1563_0473.356
# ::preferred 
(a / antibody~e.0
      :ARG0-of (c / counter-01~e.3
            :ARG1 (p2 / protein~e.5
                  :ARG1-of (b4 / be-located-at-91~e.2,31
                        :ARG2 (l / location
                              :name (n2 / name :op1 "adherens" :op2 "junction")))))
      :ARG2-of (i / include-01~e.7
            :ARG1 (a2 / and~e.6
                  :op1 (p3 / protein~e.20
                        :name (n3 / name :op1 "E-cadherin"~e.8,10,12)
                        :mod (t / transmembrane~e.18)
                        :mod (c2 / core~e.19))
                  :op2 (p4 / protein~e.27
                        :name (n4 / name :op1 "β-catenin"~e.22)
                        :ARG0-of~e.27 (b / bind-01~e.27
                              :ARG1 p3~e.28,29,30
                              :ARG2 l)
                        :ARG0-of (p7 / participate-01~e.37
                              :mod (p8 / possible~e.35)
                              :mod~e.38 (c3 / cofactor~e.41
                                    :mod (t2 / transcribe-01~e.40))
                              :condition (a3 / associate-01~e.43
                                    :ARG1 p4
                                    :ARG2 (p16 / protein~e.77
                                          :name (n14 / name :op1 "LEF-1"~e.45 :op2 "TCF"))
                                    :location~e.49 (n8 / nucleus~e.51))
                              :mod (a8 / also~e.36)))
                  :op3 (p5 / protein~e.57
                        :name (n5 / name :op1 "α-catenin"~e.53)
                        :ARG0-of~e.57 (b2 / bind-01~e.57
                              :ARG2 (a4 / and~e.33,61
                                    :op1 p4~e.60
                                    :op2 (p6 / protein
                                          :name (n6 / name :op1 "Ajuba"~e.62,71)
                                          :ARG1-of (r / relate-01
                                                :ARG2 (p10 / protein~e.77
                                                      :name (n9 / name :op1 "zyxin"~e.68))
                                                :degree (c4 / close~e.65))
                                          :ARG1-of (a5 / associate-01~e.75
                                                :ARG2 (a6 / and
                                                      :op1 (p12 / protein~e.5
                                                            :ARG1-of (b3 / bind-01~e.79
                                                                  :ARG2~e.80 (c5 / cytoskeleton~e.83
                                                                        :mod (a9 / actin~e.82))))
                                                      :op2 (p13 / protein~e.94
                                                            :name (n11 / name :op1 "Grb-2"~e.89,91)
                                                            :ARG0-of~e.94 (m2 / mediate-01~e.94
                                                                  :ARG1 (p / protein~e.101
                                                                        :name (n7 / name :op1 "Sos"~e.102)
                                                                        :ARG1-of (i2 / involve-01~e.104
                                                                              :ARG2~e.105 (a7 / activate-01~e.106
                                                                                    :ARG1~e.107 (p15 / pathway
                                                                                          :name (n13 / name :op1 "Ras"~e.109 :op2 "MAPK"~e.111)
                                                                                          :mod (c6 / cascade~e.113
                                                                                                :subevent (s / signal-07~e.112)))))
                                                                        :mod~e.101 (p9 / protein~e.48,101
                                                                              :name (n / name
                                                                                    :op1 "GTP"~e.97
                                                                                    :op2 "nucleotide"~e.98
                                                                                    :op3 "exchange"~e.100
                                                                                    :op4 "factor"))))))
                                                :mod (p11 / possible~e.74))))))
                  :op4 p6))
      :ARG1-of (u / use-01~e.1))

# ::tok In Snail @-@ expressing Tg regions , there was a reduced staining with anti @-@ E @-@ cad and anti-α-cat and a more diffuse staining with anti @-@ Ajuba .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3.1.1.1.1 3-1.3.1 5-1.3 10-1.1.2 11-1.1 13-1.1.1.1.1 13-1.1.1.2.1 15-1.1.1.1.1.1.1.1 18-1 18-1.1.1 20-1 22-1.2.2.1 23-1.2.2 24-1.2 26-1.2.1.1 28-1.2.1.1.1.1.1
# ::id pmid_1563_0473.357
# ::preferred 
(a / and~e.18,20
      :op1 (s / stain-01~e.11
            :ARG2 (a2 / and~e.18
                  :op1 (a3 / antibody
                        :ARG0-of (c / counter-01~e.13
                              :ARG1 (p / protein
                                    :name (n / name :op1 "E-cadherin"~e.15))))
                  :op2 (a4 / antibody
                        :ARG0-of (c2 / counter-01~e.13
                              :ARG1 (p2 / protein
                                    :name (n2 / name :op1 "α-catenin")))))
            :ARG1-of (r2 / reduce-01~e.10))
      :op2 (s2 / stain-01~e.24
            :ARG2 (a5 / antibody
                  :ARG0-of (c3 / counter-01~e.26
                        :ARG1 (p4 / protein
                              :name (n4 / name :op1 "Ajuba"~e.28))))
            :mod (d / diffuse~e.23
                  :degree (m / more~e.22)))
      :location (r / region~e.5
            :ARG3-of (e / express-03~e.3
                  :ARG2 (p3 / protein
                        :name (n3 / name :op1 "Snail"~e.1)))
            :mod (t / transgenic)))

# ::tok Insets in the panels for β-catenin and Ajuba staining are magnified views of the boxed areas .
# ::amr-annotator SDL-AMR-09
# ::alignments 3-1.2.1.1 3-1.2.1.2 5-1.2.1.1.1.1.1.1 6-1.2.1 7-1.2.1.2.1.1.1.1 8-1.2.1.1.1 8-1.2.1.2.1 9-1.2.r 10-1.3 11-1 12-1.1.r 14-1.1.1 15-1.1
# ::id pmid_1563_0473.358
# ::preferred 
(v / view-01~e.11
      :ARG1~e.12 (a2 / area~e.15
            :ARG1-of (b / box-02~e.14))
      :domain~e.9 (i / inset
            :location (a / and~e.6
                  :op1 (p4 / panel~e.3
                        :purpose (s / stain-01~e.8
                              :ARG2 (p2 / protein
                                    :name (n / name :op1 "β-catenin"~e.5))))
                  :op2 (p5 / panel~e.3
                        :purpose (s2 / stain-01~e.8
                              :ARG2 (p3 / protein
                                    :name (n2 / name :op1 "Ajuba"~e.7))))))
      :ARG1-of (m / magnify-01~e.10))

# ::tok Arrows mark membrane localization of the protein and asterisks mark cells with elevated levels of cytoplasmic β-catenin or Ajuba .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1 2-1.1.2.2 6-1.1.2.1 7-1 8-1.2.1 9-1.2 10-1.2.2 12-1.2.2.1.1.1 13-1.2.2.1.1 14-1.2.2.1.1.2.r 15-1.2.2.1.1.2.1.2 16-1.2.2.1.1.2.1.1.1 17-1.2.2.1.1.2 18-1.2.2.1.1.2.2.1.1
# ::id pmid_1563_0473.359
# ::preferred 
(a / and~e.7
      :op1 (m / mark-01~e.1
            :ARG0 (a2 / arrow~e.0)
            :ARG1 (b / be-located-at-91
                  :ARG1 (p / protein~e.6)
                  :ARG2 (m3 / membrane~e.2)))
      :op2 (m2 / mark-01~e.9
            :ARG0 (a3 / asterisk~e.8)
            :ARG1 (c / cell~e.10
                  :ARG0-of (h / have-03
                        :ARG1 (l / level~e.13
                              :ARG1-of (e / elevate-01~e.12)
                              :quant-of~e.14 (o / or~e.17
                                    :op1 (p2 / protein
                                          :name (n / name :op1 "β-catenin"~e.16)
                                          :mod (c2 / cytoplasm~e.15))
                                    :op2 (p3 / protein
                                          :name (n2 / name :op1 "Ajuba"~e.18)
                                          :mod c2)))))))

# ::tok ( B ) Western blot analyses of protein extracts from P30 Wt and Tg back and ear skins .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3.1.1 3-1.2.1.1 4-1.2.1.2 5-1 5-1.2 5-1.2.r 6-1.1.r 7-1.1.1 8-1.1 12-1.1.2.1.2 14-1.1.2.1.2.1 15-1.1.2.1.2 16-1.1.2.1.2.2 17-1.1.2.1 17-1.1.2.2
# ::id pmid_1563_0473.360
# ::preferred 
(a / analyze-01~e.5
      :ARG1~e.6 (e / extract-01~e.8
            :ARG1 (p / protein~e.7)
            :ARG2 (a4 / and
                  :op1 (s2 / skin~e.17
                        :mod (w2 / wild-type)
                        :part-of (a3 / and~e.12,15
                              :op1 (b / back~e.14)
                              :op2 (e2 / ear~e.16))
                        :ARG1-of (a5 / age-01
                              :ARG2 (t2 / temporal-quantity
                                    :quant "30"
                                    :unit (d2 / day))))
                  :op2 (s3 / skin~e.17
                        :mod (t / transgenic)
                        :part-of a3
                        :ARG1-of (a6 / age-01
                              :ARG2 t2))))
      :instrument~e.5 (a2 / analysis~e.5
            :name (n2 / name :op1 "Western"~e.3 :op2 "blot"~e.4))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "B"~e.1)))

# ::tok Antibodies are as in ( A ) except anti @-@ P @-@ cad , which detects P @-@ cadherin , whose expression in the hair follicle was not affected , and anti @-@ tubulin , which detects tubulin , a control for equal protein loadings .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 0-1.2 0-1.3.1.1 0-1.3.1.2 5-1.2.1.1 7-1.3 8-1.3.1.1.1 8-1.3.1.2.1 10-1.3.1.1.2.1 15-1.3.1.1.2 16-1.3.1.1.1.1.1.1 18-1.3.1.1.1.1.1.1 21-1.3.1.1.1.1 21-1.3.1.1.1.1.2 21-1.3.1.1.1.1.2.r 22-1.3.1.1.1.1.2.1.r 24-1.3.1.1.1.1.2.1.1 25-1.3.1.1.1.1.2.1 27-1.3.1.1.1.1.2.2.1 27-1.3.1.1.1.1.2.2.1.r 28-1.3.1.1.1.1.2.2 31-1.3.1.1.1 33-1.3.1.2.2.1 36-1.3.1.2.2 37-1.3.1.2.2.1 38-1.3.1.2.2.1 39-1.3.1.2.2.1 40-1.3.1.2.2.1 41-1.3.1.2.2.1 42-1.3.1.2.2.1 43-1.3.1.2.2.1 44-1.3.1.2.2.1
# ::id pmid_1563_0473.361
# ::preferred 
(r / resemble-01
      :ARG1 (a / antibody~e.0)
      :ARG2 (a6 / antibody~e.0
            :location (f / figure :mod "A"~e.5))
      :ARG2-of (e / except-01~e.7
            :ARG1 (a2 / and
                  :op1 (a3 / antibody~e.0
                        :ARG0-of (c / counter-01~e.8,31
                              :ARG1 (p / protein~e.21
                                    :name (n / name :op1 "P-cadherin"~e.16,18)
                                    :ARG2-of~e.21 (e2 / express-03~e.21
                                          :ARG3~e.22 (f2 / follicle~e.25
                                                :mod (h / hair~e.24))
                                          :ARG1-of (a5 / affect-01~e.28 :polarity~e.27 "-"~e.27))))
                        :ARG0-of (d / detect-01~e.15
                              :ARG1 p~e.10))
                  :op2 (a4 / antibody~e.0
                        :ARG0-of (c2 / counter-01~e.8
                              :ARG1 (p2 / protein
                                    :name (n2 / name :op1 "tubulin")
                                    :ARG0-of (c3 / control-01
                                          :ARG1 (l2 / load-01
                                                :ARG1 (p3 / protein)
                                                :ARG1-of (e3 / equal-01)))))
                        :ARG0-of (d2 / detect-01~e.36
                              :ARG1 p2~e.33,37,38,39,40,41,42,43,44)))))

# ::tok Note that the reductions seen in E @-@ cadherin and α-catenin are likely to be underestimates of the actual differences in affected regions , since the Tg skin expressed Snail mosaically .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.3.r 3-1.3.1.2 4-1.3.1.2.2 5-1.3.1.2.1.r 6-1.3.1.2.1.1.1.1 8-1.3.1.2.1.1.1.1 9-1.3.1.2.1 10-1.3.1.2.1.2.1.1 11-1.3.1.r 12-1.3 13-1.3.2 14-1.3.1.2.r 14-1.3.1.r 15-1.3.1 16-1.3.1.1.r 18-1.3.1.1.1 19-1.3.1.1 20-1.3.1.1.2.r 21-1.3.1.1.2.1 22-1.3.1.1.2 24-1.3.2 27-1.3.2.1.2 28-1.3.2.1 29-1.3.2.1.1.1.1
# ::id pmid_1563_0473.362
# ::preferred 
(n / note-02~e.0
      :mode "imperative"
      :ARG0 (y / you)
      :ARG1~e.1 (l / likely~e.12
            :domain~e.11,14 (u / underestimate-01~e.15
                  :ARG1~e.16 (d / differ-02~e.19
                        :mod (a2 / actual~e.18)
                        :location~e.20 (r2 / region~e.22
                              :ARG1-of (a3 / affect-01~e.21)))
                  :domain~e.14 (r / reduce-01~e.3
                        :ARG1~e.5 (a / and~e.9
                              :op1 (p / protein
                                    :name (n2 / name :op1 "E-cadherin"~e.6,8))
                              :op2 (p2 / protein
                                    :name (n3 / name :op1 "α-catenin"~e.10)))
                        :ARG1-of (s2 / see-01~e.4)))
            :ARG1-of (c / cause-01~e.13,24
                  :ARG0 (e / express-03~e.28
                        :ARG2 (p3 / protein
                              :name (n4 / name :op1 "Snail"~e.29))
                        :ARG3 (s / skin~e.27
                              :mod (t / transgenic))
                        :manner (m / mosaical)))))

# ::tok ( C ) In the presence of elevated Snail , α-catenin levels can be restored by overexpression of E @-@ cadherin .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3.1.1 5-1.2 6-1.2.1.r 7-1.2.1.2 8-1.2.1.1.1 10-1.1.1.1.1.1 11-1.1.1 12-1 13-1.1.r 14-1.1 18-1.1.2.1.1.1 20-1.1.2.1.1.1
# ::id pmid_1563_0473.363
# ::preferred 
(p / possible~e.12
      :domain~e.13 (r / restore-01~e.14
            :ARG1 (l / level~e.11
                  :quant-of (p2 / protein
                        :name (n / name :op1 "α-catenin"~e.10)))
            :manner (o / overexpress-00
                  :ARG2 (p3 / protein
                        :name (n2 / name :op1 "E-cadherin"~e.18,20))))
      :condition (p4 / present~e.5
            :mod~e.6 (p5 / protein
                  :name (n3 / name :op1 "Snail"~e.8)
                  :ARG1-of (e2 / elevate-01~e.7)))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "C"~e.1)))

# ::tok Keratinocytes were transfected with either HA @-@ tagged Snail ( Snail[HA]; images on the left ) or Snail( HA ) and Ecad( HA ) ( images on the right ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1 5-1.2.1.2.1.1.1 7-1.2.1.2 7-1.2.2.1.2 7-1.2.2.2.2 8-1.2.1.1.1 8-1.2.2.1.1.1 11-1.2.1.3.1 12-1.2.1.3.1.1.r 14-1.2.1.3.1.1 16-1.2 18-1.2.1.2.1.1.1 22-1.2.1.2.1.1.1 25-1.2.2.3.1 26-1.2.2.3.1.1.r 28-1.2.2.3.1.1
# ::id pmid_1563_0473.364
# ::preferred 
(t / transfect-00~e.2
      :ARG1 (c / cell
            :name (n / name :op1 "keratinocyte"))
      :ARG2 (o2 / or~e.16
            :op1 (p / protein
                  :name (n2 / name :op1 "Snail"~e.8)
                  :ARG1-of (t2 / tag-01~e.7
                        :ARG2 (p2 / protein
                              :name (n3 / name :op1 "HA"~e.5,18,22)))
                  :ARG1-of (d / describe-01
                        :ARG0 (i / image~e.11
                              :location~e.12 (l / left~e.14))))
            :op2 (a / and
                  :op1 (p3 / protein
                        :name (n4 / name :op1 "Snail"~e.8)
                        :ARG1-of (t3 / tag-01~e.7
                              :ARG2 p2))
                  :op2 (p4 / protein
                        :name (n5 / name :op1 "E-cadherin")
                        :ARG1-of (t4 / tag-01~e.7
                              :ARG2 p2))
                  :ARG1-of (d2 / describe-01
                        :ARG0 (i2 / image~e.25
                              :location~e.26 (r / right~e.28))))))

# ::tok 2 d after transfection , cells were switched from low @-@ calcium growth medium to high @-@ calcium medium for 6 h to induce AJ formation .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.6.2.1 2-1.6 3-1.6.1 5-1.1 7-1 9-1.3.2 11-1.2.2 11-1.3.2.1 12-1.2.1 12-1.3.1 13-1.2 13-1.3 15-1.2.2.1 17-1.2.2 18-1.2 19-1.4.r 20-1.4.1 23-1.5 24-1.5.1.1.1.1 25-1.5.1
# ::id pmid_1563_0473.365
# ::preferred 
(s / switch-01~e.7
      :ARG1 (c / cell~e.5)
      :ARG2 (m2 / medium~e.13,18
            :mod (g2 / grow-01~e.12)
            :mod (c3 / calcium~e.11,17
                  :quant (h / high~e.15)))
      :ARG3 (m / medium~e.13
            :mod (g / grow-01~e.12)
            :ARG1-of (l / low-04~e.9
                  :ARG2 (c2 / calcium~e.11)))
      :duration~e.19 (t / temporal-quantity
            :quant "6"~e.20
            :unit (h2 / hour))
      :purpose (i / induce-01~e.23
            :ARG1 (f / form-01~e.25
                  :ARG1 (p / protein
                        :name (n / name :op1 "AJ"~e.24))))
      :time (a / after~e.2
            :op1 (t2 / transfect-00~e.3)
            :quant (t3 / temporal-quantity
                  :quant "2"~e.0
                  :unit (d / day))))

# ::tok Cells were stained with antibodies as indicated on the panels .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 2-1 3-1.2.r 4-1.2 5-1.3.r 6-1.3 7-1.3.1.r 9-1.3.1
# ::id pmid_1563_0473.366
# ::preferred 
(s / stain-01~e.2
      :ARG1 (c / cell~e.0)
      :ARG2~e.3 (a / antibody~e.4)
      :ARG1-of~e.5 (i / indicate-01~e.6
            :location~e.7 (p / panel~e.9)))

# ::tok Arrowheads point to sites of intercellular contact between a Snail @-@ transfected keratinocyte and its neighboring untransfected cell .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1 2-1.2.r 3-1.2 4-1.2.1.r 5-1.2.1.3 6-1.2.1 9-1.2.1.1.2.1.1.1 11-1.2.1.1.2 11-1.2.1.2.1 12-1.2.1.1.1.1 15-1.2.1.2.2 17-1.2.1.2
# ::id pmid_1563_0473.367
# ::preferred 
(p / point-01~e.1
      :ARG0 (a / arrowhead~e.0)
      :ARG2~e.2 (s / site~e.3
            :location-of~e.4 (c / contact-01~e.6
                  :ARG0 (c2 / cell
                        :name (n / name :op1 "keratinocyte"~e.12)
                        :ARG1-of (t / transfect-00~e.11
                              :ARG2 (p2 / protein
                                    :name (n2 / name :op1 "Snail"~e.9))))
                  :ARG1 (c3 / cell~e.17
                        :ARG1-of (t2 / transfect-00~e.11 :polarity "-")
                        :ARG1-of (n3 / neighbor-01~e.15))
                  :mod (i / intercellular~e.5))))

# ::tok ( D ) Reintroduction <i> of E @-@ cadherin </i> in keratinocytes expressing Snail returns pMAPK to basal levels .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.4.1.1 6-1.1.1.1.1 8-1.1.1.1.1 12-1.1.2.2 13-1.1.2.2.1.1.1 14-1 16-1.3.r 17-1.3.1 18-1.3
# ::id pmid_1563_0473.368
# ::preferred 
(r / return-04~e.14
      :ARG0 (r3 / reintroduce-01
            :ARG1 (p / protein
                  :name (n / name :op1 "E-cadherin"~e.6,8))
            :ARG2 (c / cell
                  :name (n2 / name :op1 "keratinocyte")
                  :ARG1-of (e / express-03~e.12
                        :ARG2 (p2 / protein
                              :name (n3 / name :op1 "Snail"~e.13)))))
      :ARG1 (p3 / pathway
            :name (n4 / name :op1 "MAPK")
            :ARG1-of (p4 / phosphorylate-01))
      :ARG2~e.16 (l / level~e.18
            :mod (b / basal~e.17))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "D"~e.1)))

# ::tok Keratinocytes were transfected with control vector ( K14 ) , or <i> Snail( HA ) , </i> or <i> Snail( HA ) </i> + <i> E @-@ cad( HA ) </i>@ .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1 3-1.2.r 4-1.2.1.2 5-1.2.1 7-1.2.1.1.1 10-1.2 17-1.2 25-1.2.3.2.1.1
# ::id pmid_1563_0473.369
# ::preferred 
(t / transfect-00~e.2
      :ARG1 (c / cell
            :name (n / name :op1 "keratinocyte"))
      :ARG2~e.3 (o / or~e.10,17
            :op1 (v2 / vector~e.5
                  :name (n2 / name :op1 "K14"~e.7)
                  :ARG0-of (c2 / control-01~e.4))
            :op2 (p / protein
                  :name (n3 / name :op1 "Snail(HA)"))
            :op3 (a / and
                  :op1 p
                  :op2 (p2 / protein
                        :name (n4 / name :op1 "E-cad(HA)"~e.25)))))

# ::tok After 2 d , cells were serum starved for 4 h and whole cell lysates were made and Western blotted with antibodies to pMAPK , HA to recognize the HA @-@ tagged Snail and E @-@ cadherin protein , 20 or tubulin as a loading control .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.4 1-1.4.1.1 4-1.1.1 4-1.2.1.2 6-1.1.2 7-1.1 8-1.1.3.r 9-1.1.3.1 11-1 12-1.2.1.1 13-1.2.1.2 16-1.2 17-1 18-1.3.3 19-1.3 20-1.3.1.3.r 20-1.3.1.r 21-1.3.1.1 25-1.3.1.2.1.1 27-1.3.1.2.2 29-1.3.1.2.1.1 31-1.3.1.2.2.1.1.2 32-1.3.1.2.2.1.1.1.1 33-1.3.1.2.2.1 34-1.3.1.2.2.1.2.1.1 36-1.3.1.2.2.1.2.1.1 37-1.3.1.2 37-1.3.1.2.2.1.1 37-1.3.1.2.2.1.2 37-1.3.1.3 41-1.3.1.3.1.1 42-1.3.1.3.2.r 42-1.4.r 44-1.3.1.3.2.1 45-1.3.1.3.2
# ::id pmid_1563_0473.370
# ::preferred 
(a / and~e.11,17
      :op1 (s / starve-01~e.7
            :ARG1 (c / cell~e.4)
            :ARG2 (s2 / serum~e.6)
            :duration~e.8 (t / temporal-quantity
                  :quant "4"~e.9
                  :unit (h / hour)))
      :op2 (m / make-01~e.16
            :ARG1 (l / lysate
                  :mod (w2 / whole~e.12)
                  :mod (c2 / cell~e.4,13)))
      :op3 (b / blot-01~e.19
            :ARG0~e.20 (a2 / and
                  :op1 (a3 / antibody~e.21
                        :ARG0-of (o / oppose-01
                              :ARG1 (p / pathway
                                    :name (n2 / name :op1 "MAPK")
                                    :ARG1-of (p2 / phosphorylate-01))))
                  :op2 (p6 / protein~e.37
                        :name (n3 / name :op1 "HA"~e.25,29)
                        :purpose (r / recognize-01~e.27
                              :ARG1 (a4 / and~e.33
                                    :op1 (p3 / protein~e.37
                                          :name (n4 / name :op1 "Snail"~e.32)
                                          :ARG1-of (t2 / tag-01~e.31
                                                :ARG2 p6))
                                    :op2 (p4 / protein~e.37
                                          :name (n5 / name :op1 "E-cadherin"~e.34,36)
                                          :ARG1-of t2))))
                  :accompanier~e.20 (p5 / protein~e.37
                        :name (n6 / name :op1 "tubulin"~e.41)
                        :ARG0-of~e.42 (c3 / control-01~e.45
                              :ARG0-of (l2 / load-01~e.44))))
            :ARG1 l
            :mod (w / western~e.18))
      :time~e.42 (a5 / after~e.0
            :quant (t3 / temporal-quantity
                  :quant "2"~e.1
                  :unit (d2 / day))))

# ::tok ( E ) Ajuba interacts with Grb @-@ 2 under conditions where α-catenin levels are reduced .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.4.1.1 3-1.1.1.1 4-1 5-1.2.r 6-1.2.1.1 8-1.2.1.1 10-1.3.r 12-1.3.1.1.1.1 13-1.3.1 15-1.3
# ::id pmid_1563_0473.371
# ::preferred 
(i / interact-01~e.4
      :ARG0 (p3 / protein
            :name (n / name :op1 "Ajuba"~e.3))
      :ARG1~e.5 (p / protein
            :name (n2 / name :op1 "Grb-2"~e.6,8))
      :condition~e.10 (r / reduce-01~e.15
            :ARG1 (l / level~e.13
                  :quant-of (p2 / protein
                        :name (n3 / name :op1 "α-catenin"~e.12))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "E"~e.1)))

# ::tok Protein extracts were made from skins of P30 Wt and <i> K14 @-@ Snail </i> Tg P30 mice ( blots on the left ) and of newborn Wt and <i> K14 @-@ Cre/α-catenin ( fl/fl ) </i> conditionally null animals ( blots on the right ) [ @<xref ref-type="bibr" rid="pbio-0030011-b07"> 7 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1 4-1.2.r 5-1.2.1.1 5-1.2.1.2 5-1.2.2.1 5-1.2.2.2 9-1.2 9-1.2.1 9-1.2.1.r 9-1.2.2 9-1.2.2.r 11-1.2.1.2.1.2.1.1 11-1.2.2.2.1.1.1.1.1 13-1.2.1.2.1.2.1.1 17-1.2.1.1.1 17-1.2.1.2.1 19-1.2.1.3.1 20-1.2.1.3.1.1.r 22-1.2.1.3.1.1 24-1.2 28-1.2 30-1.2.2.2.1.1.1.1.1 37-1.2.2.2.1.1.3.2 39-1.2.2.1.1 39-1.2.2.2.1 41-1.2.2.3.1 42-1.2.2.3.1.1.r 44-1.2.2.3.1.1 50-1.3.1.1.1
# ::id pmid_1563_0473.372
# ::preferred 
(e / extract-01~e.1
      :ARG1 (p / protein~e.0)
      :ARG2~e.4 (a2 / and~e.9,24,28
            :op1~e.9 (a6 / and~e.9
                  :op1 (s / skin~e.5
                        :part-of (m / mouse~e.17
                              :mod (w / wild-type)
                              :ARG1-of (a / age-01
                                    :ARG2 (t / temporal-quantity
                                          :quant "30"
                                          :unit (d / day)))))
                  :op2 (s2 / skin~e.5
                        :part-of (m2 / mouse~e.17
                              :mod (t2 / transgenic)
                              :mod (p2 / protein
                                    :name (n / name :op1 "K14-Snail"~e.11,13))
                              :ARG1-of (a3 / age-01
                                    :ARG2 (t3 / temporal-quantity
                                          :quant "30"
                                          :unit (d2 / day)))))
                  :ARG1-of (d4 / describe-01
                        :ARG0 (b2 / blot-01~e.19
                              :location~e.20 (l / left~e.22))))
            :op2~e.9 (a7 / and~e.9
                  :op1 (s3 / skin~e.5
                        :part-of (a4 / animal~e.39
                              :mod (w2 / wild-type)
                              :ARG1-of (b / bear-02
                                    :time (r / recent))))
                  :op2 (s4 / skin~e.5
                        :part-of (a5 / animal~e.39
                              :mod (m3 / macro-molecular-complex
                                    :part (p3 / protein
                                          :name (n2 / name :op1 "K14-Cre"~e.11,30))
                                    :part (p4 / protein
                                          :name (n3 / name :op1 "α-catenin"))
                                    :ARG2-of (m4 / mutate-01
                                          :mod "−/−"
                                          :mod (c2 / conditional~e.37)))))
                  :ARG1-of (d5 / describe-01
                        :ARG0 (b3 / blot-01~e.41
                              :location~e.42 (r2 / right~e.44)))))
      :ARG1-of (d3 / describe-01
            :ARG0 (p5 / publication
                  :ARG1-of (c / cite-01 :ARG2 "7"~e.50))))

# ::tok Equal amounts of protein extracts were treated with anti @-@ Grb @-@ 2 antibody (+) or control isotype antibody (–), and following centrifugation , immunoprecipitates were subjected to SDS @-@ PAGE and Western blot analysis with anti @-@ Ajuba and anti @-@ Grb @-@ 2 antibodies .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 1-1.1.1 2-1.1.1.2.r 3-1.1.1.2.1.1 4-1.1.1.2 4-1.1.1.2.1 4-1.1.1.2.1.r 6-1.1 7-1.2.2.3.r 8-1.1.2.1.1 8-1.2.2.3.1.1 8-1.2.2.3.2.1 10-1.1.2.1.1.1.1.1 12-1.1.2.1.1.1.1.1 13-1.1.2.1 13-1.1.2.2 15-1.1.2 16-1.1.2.2.1.1 17-1.1.2.2.1 18-1.1.2.2 18-1.2.2.3.1 18-1.2.2.3.2 20-1.2.2 20-1.2.2.3 21-1.2.3 22-1.2.3.1 26-1.2 28-1.2.2.1.2.1.1 30-1.2.2.1.2.1.1 31-1.2.2 32-1.2.2.2.2.1.1 33-1.2.2.2.2.1.2 34-1.2.2.1 34-1.2.2.2 35-1.2.2.3.r 36-1.2.2.3.1.1 38-1.2.2.3.1.1.1.1.1 40-1.2.2.3.1.1 42-1.1.2.1.1.1.1.1 44-1.1.2.1.1.1.1.1 45-1.2.2.3.1
# ::id pmid_1563_0473.373
# ::preferred 
(a4 / and
      :op1 (t / treat-04~e.6
            :ARG1 (a / amount~e.1
                  :mod (e2 / equal~e.0)
                  :quant-of~e.2 (t2 / thing~e.4
                        :ARG1-of~e.4 (e / extract-01~e.4
                              :ARG2 (p4 / protein~e.3))))
            :ARG2 (o2 / or~e.15
                  :op1 (a2 / antibody~e.13
                        :ARG0-of (o / oppose-01~e.8
                              :ARG1 (p2 / protein
                                    :name (n2 / name :op1 "Grb-2"~e.10,12,42,44))))
                  :op2 (a3 / antibody~e.13,18
                        :mod (i / isotype~e.17
                              :ARG1-of (c / control-01~e.16)))))
      :op2 (s / subject-01~e.26
            :ARG1 (m / molecular-physical-entity
                  :ARG1-of (i2 / immunoprecipitate-00))
            :ARG2 (a9 / and~e.20,31
                  :op1 (a5 / analyze-01~e.34
                        :ARG1 m
                        :mod (t5 / thing
                              :name (n / name :op1 "SDS-PAGE"~e.28,30)))
                  :op2 (a8 / analyze-01~e.34
                        :ARG1 m
                        :mod (t6 / thing
                              :name (n4 / name :op1 "Western"~e.32 :op2 "blot"~e.33)))
                  :instrument~e.7,35 (a10 / and~e.20
                        :op1 (a6 / antibody~e.18,45
                              :ARG0-of (o3 / oppose-01~e.8,36,40
                                    :ARG1 (p3 / protein
                                          :name (n3 / name :op1 "Ajuba"~e.38))))
                        :op2 (a7 / antibody~e.18
                              :ARG0-of (o4 / oppose-01~e.8
                                    :ARG1 p2))))
            :ARG1-of (f / follow-01~e.21
                  :ARG2 (c2 / centrifugate~e.22))))

# ::tok Note the presence of Ajuba only under conditions where levels of α-catenin and other AJ proteins were aberrantly low or absent .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 2-1.2 4-1.2.1.1.1 5-1.2.3 7-1.2.2.r 9-1.2.2.1.1.1 9-1.2.2.1.1.2 11-1.2.2.1.1.1.1.1.1 12-1.2.2.1.1 13-1.2.2.1.1.2.1.2 14-1.2.2.1.1.2.1.1.1 15-1.2.1 15-1.2.2.1.1.1.1 15-1.2.2.1.1.2.1 18-1.2.2.1 19-1.2.2 20-1.2.2.2
# ::id pmid_1563_0473.374
# ::preferred 
(n / note-02~e.0
      :ARG0 (y / you)
      :ARG1 (p / present~e.2
            :domain (p2 / protein~e.15
                  :name (n2 / name :op1 "Ajuba"~e.4))
            :condition~e.7 (o / or~e.19
                  :op1 (l / low-04~e.18
                        :ARG1 (a4 / and~e.12
                              :op1 (l2 / level~e.9
                                    :quant-of (p3 / protein~e.15
                                          :name (n3 / name :op1 "α-catenin"~e.11)))
                              :op2 (l3 / level~e.9
                                    :quant-of (p4 / protein~e.15
                                          :name (n4 / name :op1 "AJ"~e.14)
                                          :mod (o2 / other~e.13))))
                        :mod (a2 / aberrant))
                  :op2 (a / absent-01~e.20
                        :ARG1 a4))
            :mod (o3 / only~e.5)))

# ::tok ( F ) Transgene expression of excess Ajuba or the Grb @-@ 2 @-@ interacting domain ( pre @-@ LIM ) of Ajuba in keratinocytes results in the activation of the Ras @-@ MAPK pathway .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3.1.1 3-1.1.2 4-1.1 5-1.1.1.r 6-1.1.1.1 6-1.1.1.1.2 6-1.1.1.1.2.r 7-1.1.1.1.1.1 8-1.1.1 10-1.1.1.2.2.1.1.1 12-1.1.1.2.2.1.1.1 14-1.1.1.2.2 17-1.1.1.2.1.1 19-1.1.1.2.1.1 22-1.1.1.2.4 25-1 26-1.2.r 28-1.2 29-1.2.1.r 31-1.2.1.1.1 33-1.2.1.1.1 34-1.2.1
# ::id pmid_1563_0473.375
# ::preferred 
(r / result-01~e.25
      :ARG1 (e / express-03~e.4
            :ARG2~e.5 (o / or~e.8
                  :op1 (p / protein~e.6
                        :name (n / name :op1 "Ajuba"~e.7)
                        :ARG0-of~e.6 (e3 / exceed-01~e.6))
                  :op2 (p5 / protein-segment
                        :name (n6 / name :op1 "pre-LIM"~e.17,19)
                        :ARG0-of (i2 / interact-01~e.14
                              :ARG1 (p2 / protein
                                    :name (n2 / name :op1 "Grb-2"~e.10,12)))
                        :ARG1-of (b2 / be-located-at-91
                              :ARG2 (c / cell
                                    :name (n3 / name :op1 "keratinicyte")))
                        :part-of p~e.22))
            :mod (t / transgene~e.3))
      :ARG2~e.26 (a / activate-01~e.28
            :ARG1~e.29 (p3 / pathway~e.34
                  :name (n4 / name :op1 "Ras-MAPK"~e.31,33)))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure :mod "F"~e.1)))

# ::tok Primary newborn mouse keratinocytes were transfected with either the empty K14 expression vector ( K14 ) , or the expression vector driving Snail , full length Ajuba , or the pre @-@ LIM domain of Ajuba in the absence or presence of a peptide inhibitor ( inh ) that disrupts the interaction between Grb @-@ 2 and Sos .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2.1 2-1.1.2 5-1 9-1.2.1.1.2 10-1.2.1.1.1.1.1 11-1.2.2.1 12-1.2.2 14-1.2.1.1.1.1.1 17-1.2 19-1.2.1.1 19-1.2.2.1 20-1.2.1 20-1.2.2 21-1.2.2.2 22-1.2.2.2.1.1.1 24-1.2.3.2.1 25-1.2.3.2 26-1.2.3.1.1 28-1.2 30-1.2.4.1.1 32-1.2.4.1.1 35-1.2.4.2 36-1.3.r 38-1.3.1 39-1.3 40-1.3.2 41-1.3.1.1.r 43-1.3.1.1.1.1.1.1 44-1.3.1.1 44-1.3.1.1.1 44-1.3.1.1.1.r 49-1.3.1.1.1.2 51-1.3.1.1.1.2.1 53-1.3.1.1.1.2.1.1.1.1 55-1.3.1.1.1.2.1.1.1.1 57-1.3.1.1.1.2.1.2.1.1
# ::id pmid_1563_0473.376
# ::preferred 
(t2 / transfect-00~e.5
      :ARG1 (c / cell
            :name (n / name :op1 "keratinocyte")
            :part-of (m / mouse~e.2
                  :mod (p / primary~e.0)
                  :ARG1-of (b / bear-02
                        :time (r / recent))))
      :ARG2 (o / or~e.17,28
            :op1 (v / vector~e.20
                  :ARG1-of (e / express-03~e.19
                        :ARG2 (e2 / enzyme
                              :name (n3 / name :op1 "K14"~e.10,14))
                        :manner (e3 / empty~e.9)))
            :op2 (v2 / vector~e.12,20
                  :ARG1-of (e4 / express-03~e.11,19)
                  :ARG0-of (d / drive-02~e.21
                        :ARG1 (p2 / protein
                              :name (n4 / name :op1 "Snail"~e.22))))
            :op3 (p7 / protein
                  :name (n5 / name :op1 "Ajuba"~e.26)
                  :mod (l2 / length~e.25
                        :mod (f2 / full~e.24)))
            :op4 (p6 / protein-segment
                  :name (n10 / name :op1 "pre-LIM"~e.30,32)
                  :part-of p7~e.35))
      :condition~e.36 (o2 / or~e.39
            :op1 (a / absence~e.38
                  :domain~e.41 (m2 / molecular-physical-entity~e.44
                        :ARG0-of~e.44 (i2 / inhibit-01~e.44
                              :ARG1 (s / small-molecule
                                    :name (n7 / name :op1 "peptide"~e.43))
                              :ARG0-of (d3 / disrupt-01~e.49
                                    :ARG1 (i3 / interact-01~e.51
                                          :ARG0 (p4 / protein
                                                :name (n8 / name :op1 "Grb-2"~e.53,55))
                                          :ARG1 (p5 / protein
                                                :name (n9 / name :op1 "Sos"~e.57)))))))
            :op2 (p3 / presence~e.40
                  :domain m2)))

# ::tok 48 h posttransfection , protein extracts were prepared and subjected to SDS @-@ PAGE and Western blot analyses with antibodies against pMAPK , total MAPK , Ajuba ( also recognizing the smaller , pre @-@ LIM domain ) , and Snail .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3.2.1 4-1.1.1.1.1 5-1.1.1 5-1.1.1.1 5-1.1.1.1.r 7-1.1 8-1 9-1.2 10-1.2.2.r 11-1.2.2.1.1.1.1 13-1.2.2.1.1.1.1 14-1.2.2 15-1.2.2.2.1.1.1 16-1.2.2.2.1.1.2 17-1.2.2.1 17-1.2.2.2 18-1.2.2.3.r 19-1.2.2.3 20-1.2.2.3.1 23-1.2.2.3.1.1.2.2 24-1.2.2.3.1.1.1.1.1 24-1.2.2.3.1.1.2.1.1 26-1.2.2.3.1.1.3.1.1 28-1.2.2.3.2.2 29-1.2.2.3.2 31-1.2.2.3.2.1.2 31-1.2.2.3.2.1.2.1 31-1.2.2.3.2.1.2.1.r 33-1.2.2.3.2.1.1.1 35-1.2.2.3.2.1.1.1 40-1.2.2.3.1.1.4.1.1
# ::id pmid_1563_0473.377
# ::preferred 
(a / and~e.8
      :op1 (p2 / prepare-02~e.7
            :ARG1 (t4 / thing~e.5
                  :ARG1-of~e.5 (e2 / extract-01~e.5
                        :ARG2 (p8 / protein~e.4))))
      :op2 (s / subject-01~e.9
            :ARG1 t4
            :ARG2~e.10 (a2 / and~e.14
                  :op1 (a3 / analyze-01~e.17
                        :mod (t5 / thing
                              :name (n / name :op1 "SDS-PAGE"~e.11,13)))
                  :op2 (a4 / analyze-01~e.17
                        :mod (t6 / thing
                              :name (n3 / name :op1 "Western"~e.15 :op2 "blot"~e.16)))
                  :instrument~e.18 (a5 / antibody~e.19
                        :ARG0-of (o / oppose-01~e.20
                              :ARG1 (a6 / and
                                    :op1 (p / pathway
                                          :name (n2 / name :op1 "MAPK"~e.24)
                                          :ARG1-of (p4 / phosphorylate-01))
                                    :op2 (p5 / pathway
                                          :name (n5 / name :op1 "MAPK"~e.24)
                                          :mod (t / total~e.23))
                                    :op3 (p6 / protein
                                          :name (n6 / name :op1 "Ajuba"~e.26))
                                    :op4 (p7 / protein
                                          :name (n7 / name :op1 "Snail"~e.40))))
                        :ARG0-of (r / recognize-01~e.29
                              :ARG1 (p9 / protein-segment
                                    :name (n9 / name :op1 "pre-LIM"~e.33,35)
                                    :mod (s2 / small~e.31
                                          :degree~e.31 (m / more~e.31)))
                              :mod (a8 / also~e.28)))))
      :time (a7 / after
            :op1 (t2 / transfect-00)
            :quant (t3 / temporal-quantity
                  :quant "48"~e.0
                  :unit (h / hour))))

# ::tok Figure 5
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.1
# ::id pmid_1563_0473.378
# ::preferred 
(f / figure~e.0 :mod "5"~e.1)

# ::tok ( A ) Failure of Wnt and noggin signaling to induce Snail in cultured keratinocytes .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3.1.1 3-1 4-1.1.r 5-1.1.1.1.1.1 6-1.1 7-1.1.2.1.1.1 8-1.1.1 8-1.1.2 10-1.2 11-1.2.2.1.1 12-1.2.3.r 13-1.2.3.2
# ::id pmid_1563_0473.379
# ::preferred 
(f / fail-01~e.3
      :ARG1~e.4 (a / and~e.6
            :op1 (s / signal-07~e.8
                  :ARG0 (p / pathway
                        :name (n / name :op1 "Wnt"~e.5)))
            :op2 (s2 / signal-07~e.8
                  :ARG0 (p2 / protein
                        :name (n2 / name :op1 "noggin"~e.7))))
      :ARG2 (i / induce-01~e.10
            :ARG0 a
            :ARG1 (p3 / protein
                  :name (n3 / name :op1 "Snail"~e.11))
            :location~e.12 (c / cell
                  :name (n4 / name :op1 "keratinocyte")
                  :ARG1-of (c2 / culture-01~e.13)))
      :ARG1-of (d / describe-01
            :ARG0 (f2 / figure :mod "A"~e.1)))

# ::tok Primary mouse keratinocytes were treated with Wnt @- and @/@ or noggin @-@ conditioned medium (+) or the corresponding control medium (–).
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.3 1-1.1.2 4-1 5-1.2.r 6-1.2.1.1.1.1.1.1 8-1.2.1.1.1 10-1.2.1.1.1 11-1.2.1.1.1.2.1.1 13-1.2.1.1 14-1.2.1 16-1.2 18-1.2.2.1 19-1.2.2.2 20-1.2.2
# ::id pmid_1563_0473.380
# ::preferred 
(t / treat-04~e.4
      :ARG1 (c / cell
            :name (n / name :op1 "keratinocyte")
            :part-of (m / mouse~e.1)
            :mod (p / primary~e.0))
      :ARG2~e.5 (o3 / or~e.16
            :op1 (m2 / medium~e.14
                  :ARG1-of (c2 / condition-02~e.13
                        :ARG2 (a2 / and-or~e.8,10
                              :op1 (p2 / pathway
                                    :name (n2 / name :op1 "Wnt"~e.6))
                              :op2 (p3 / protein
                                    :name (n3 / name :op1 "noggin"~e.11)))))
            :op2 (m3 / medium~e.20
                  :ARG2-of (c3 / correspond-02~e.18)
                  :ARG0-of (c4 / control-01~e.19))))

# ::tok These conditions are known to activate the LEF @-@ 1/β-catenin reporter TOPGal and down @-@ regulate the <i> E @-@ cadherin </i> promoter ( see [ @<xref ref-type="bibr" rid="pbio-0030011-b04"> 4 </xref>@ ] for details ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1.1 1-1.1.1.1 3-1 5-1.1.1 7-1.1.1.2.2.1.1.1.1 10-1.1.1.2 10-1.1.1.2.2 10-1.1.1.2.2.r 11-1.1.1.2.1.1 12-1.1 18-1.1.2.1.1.1.1.1 20-1.1.2.1.1.1.1.1 24-1.2 29-1.2.3.1.1 32-1.2.2.r 33-1.2.2
# ::id pmid_1563_0473.381
# ::preferred 
(k / know-01~e.3
      :ARG1 (a2 / and~e.12
            :op1 (a / activate-01~e.5
                  :ARG0 (c / condition~e.1
                        :mod (t / this~e.0))
                  :ARG1 (m2 / molecular-physical-entity~e.10
                        :name (n3 / name :op1 "TOPGal"~e.11)
                        :ARG0-of~e.10 (r2 / report-01~e.10
                              :ARG1 (m3 / macro-molecular-complex
                                    :part (p2 / protein
                                          :name (n / name :op1 "LEF-1"~e.7))
                                    :part (p3 / protein
                                          :name (n2 / name :op1 "β-catenin"))))))
            :op2 (d4 / downregulate-01
                  :ARG1 (m / molecular-physical-entity
                        :ARG0-of (p4 / promote-01
                              :ARG1 (p5 / protein
                                    :name (n4 / name :op1 "E-cadherin"~e.18,20))))))
      :ARG1-of (s2 / see-01~e.24
            :ARG0 (y / you)
            :purpose~e.32 (d / detail-01~e.33)
            :location (p6 / publication
                  :ARG1-of (c2 / cite-01 :ARG2 "4"~e.29))))

# ::tok Using Western blot analyses , cellular proteins were then analyzed for Snail , LEF @-@ 1 , β-catenin , and tubulin .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.r 0-1.3.1 1-1.3.1.1.1.1.1 2-1.3.1.1.1.1.2 3-1 3-1.3.1.1 5-1.1.1 6-1.1 9-1 11-1.2.1.1.1.1 13-1.2.1.2.1.1 15-1.2.1.2.1.1 17-1.2.1.3.1.1 19-1.2.1 20-1.2.1.4.1.1
# ::id pmid_1563_0473.382
# ::preferred 
(a / analyze-01~e.3,9
      :ARG1 (p / protein~e.6
            :mod (c / cell~e.5))
      :purpose~e.0 (f / find-01
            :ARG1 (a2 / and~e.19
                  :op1 (p2 / protein
                        :name (n2 / name :op1 "Snail"~e.11))
                  :op2 (p3 / protein
                        :name (n3 / name :op1 "LEF-1"~e.13,15))
                  :op3 (p4 / protein
                        :name (n4 / name :op1 "β-catenin"~e.17))
                  :op4 (p5 / protein
                        :name (n5 / name :op1 "tubulin"~e.20))))
      :time (a3 / after
            :op1 (u / use-01~e.0
                  :ARG1 (a4 / analyze-01~e.3
                        :mod (t / thing
                              :name (n / name :op1 "Western"~e.1 :op2 "blot"~e.2))))))

# ::tok Proteins from keratinocytes transfected with K14 @- @<i> Snail </i> were used as a positive control for Snail expression .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1.1.1.r 3-1.1.1.2 4-1.1.1.2.1.r 5-1.1.1.2.1.1.1 8-1.1.1.2.1.1.1 11-1 12-1.2.r 14-1.2.3 15-1.2 16-1.2.2.r 17-1.2.2.1.1.1 18-1.2.2
# ::id pmid_1563_0473.383
# ::preferred 
(u / use-01~e.11
      :ARG1 (p / protein~e.0
            :source~e.1 (c / cell
                  :name (n / name :op1 "keratinocyte")
                  :ARG1-of (t / transfect-00~e.3
                        :ARG2~e.4 (p2 / protein
                              :name (n2 / name :op1 "K14-Snail"~e.5,8)))))
      :ARG2~e.12 (c2 / control-01~e.15
            :ARG0 p
            :ARG1~e.16 (e2 / express-03~e.18
                  :ARG2 (p4 / protein
                        :name (n4 / name :op1 "Snail"~e.17)))
            :mod (p3 / positive~e.14)))

# ::tok ( B ) TGF-β2 can induce Snail protein .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.2.1.1 3-1.1.1.1.1 4-1 5-1.1 6-1.1.2.1.1 7-1.1.1 7-1.1.2
# ::id pmid_1563_0473.384
# ::preferred 
(p / possible~e.4
      :domain (i / induce-01~e.5
            :ARG0 (p2 / protein~e.7
                  :name (n / name :op1 "TGF-β2"~e.3))
            :ARG1 (p3 / protein~e.7
                  :name (n2 / name :op1 "Snail"~e.6)))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "B"~e.1)))

# ::tok Primary keratinocytes were treated for the indicated times with recombinant TGF-β2 (+) or heat inactivated TGF-β2 (–).
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2 3-1 6-1.3 7-1.3.r 10-1.2.1.1.1 10-1.2.2.1.1 12-1.2 13-1.2.2.2.2 14-1.2.2.2.1 15-1.2.1.1.1 15-1.2.2.1.1
# ::id pmid_1563_0473.385
# ::preferred 
(t / treat-04~e.3
      :ARG1 (c / cell
            :name (n / name :op1 "keratinocyte")
            :mod (p / primary~e.0))
      :ARG2 (o / or~e.12
            :op1 (p2 / protein
                  :name (n2 / name :op1 "TGF-β2"~e.10,15)
                  :ARG1-of (r / recombine-01))
            :op2 (p3 / protein
                  :name (n3 / name :op1 "TGF-β2"~e.10,15)
                  :ARG1-of (a2 / activate-01
                        :polarity "-"~e.14
                        :ARG0 (h / heat~e.13))))
      :time~e.7 (i / indicate-01~e.6))

# ::tok Total cellular proteins were then isolated and analyzed by Western blot for Snail , pSMAD2 ( reflective of activated TGF @- signaling ) , and tubulin .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.2 1-1.1.1.1 2-1.1.1 4-1.3 5-1.1 6-1 7-1.2 8-1.2.3.r 9-1.2.3.1.1 10-1.2.3.1.2 12-1.2.2.1.1.1.1 18-1.2.2.1.2.3.1.2 19-1.2.2.1.2.3.1.1.1.1 21-1.2.2.1.2.3.1 25-1.2.2.1.3.1.1
# ::id pmid_1563_0473.386
# ::preferred 
(a / and~e.6
      :op1 (i / isolate-01~e.5
            :ARG1 (p / protein~e.2
                  :mod (c / cell~e.1)
                  :mod (t / total~e.0)))
      :op2 (a2 / analyze-01~e.7
            :ARG1 p
            :purpose (f / find-01
                  :ARG1 (a3 / and
                        :op1 (p2 / protein
                              :name (n2 / name :op1 "Snail"~e.12))
                        :op2 (p5 / protein
                              :name (n3 / name :op1 "SMAD2")
                              :ARG1-of (p3 / phosphorylate-01)
                              :ARG1-of (r / reflect-01
                                    :ARG2 (s / signal-07~e.21
                                          :ARG1 (m / molecular-physical-entity
                                                :name (n4 / name :op1 "TGF"~e.19))
                                          :ARG1-of (a5 / activate-01~e.18))))
                        :op3 (p4 / protein
                              :name (n5 / name :op1 "tubulin"~e.25))))
            :instrument~e.8 (t3 / thing
                  :name (n / name :op1 "Western"~e.9 :op2 "blot"~e.10)))
      :time (t2 / then~e.4))

# ::tok Note the activation of Snail expression , peaking at 2 h post @-@ TGF-β2 treatment and then disappearing thereafter .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 2-1.2.1.1 3-1.2.1.1.1.r 4-1.2.1.1.1.1.1.1 5-1.2.1.1.1 7-1.2.1 9-1.2.1.2.2.1 13-1.2.1.2.1.1.1.1 14-1.2.1.2.1 15-1.2 16-1.2.2.2 17-1.2.2
# ::id pmid_1563_0473.387
# ::preferred 
(n2 / note-02~e.0
      :ARG0 (y / you)
      :ARG1 (a / and~e.15
            :op1 (p / peak-01~e.7
                  :ARG1 (a2 / activate-01~e.2
                        :ARG1~e.3 (e / express-03~e.5
                              :ARG1 (p2 / protein
                                    :name (n / name :op1 "Snail"~e.4))))
                  :time (a3 / after
                        :op1 (t / treat-04~e.14
                              :ARG2 (p3 / protein
                                    :name (n3 / name :op1 "TGF-β2"~e.13)))
                        :quant (t3 / temporal-quantity
                              :quant "2"~e.9
                              :unit (h / hour))))
            :op2 (d / disappear-01~e.17
                  :ARG1 a2
                  :time (t2 / then~e.16))))

# ::tok ( C ) <i> Snail </i> mRNA expression is transiently induced by TGF-β2 .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.4.1.1 4-1.2.1.2.1.1 6-1.2.1.1.1 7-1.2 9-1.3 9-1.3.r 10-1 11-1.1.r 12-1.1.1.1
# ::id pmid_1563_0473.388
# ::preferred 
(i / induce-01~e.10
      :ARG0~e.11 (p2 / protein
            :name (n3 / name :op1 "TGF-β2"~e.12))
      :ARG1 (e / express-03~e.7
            :ARG2 (r / rna
                  :name (n / name :op1 "mRNA"~e.6)
                  :part (p / protein
                        :name (n2 / name :op1 "Snail"~e.4))))
      :manner~e.9 (t / transient~e.9)
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "C"~e.1)))

# ::tok The experiment in ( B ) was repeated , and this time , total RNAs were isolated from keratinocytes treated with TGF-β2 for the indicated times .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1 4-1.1.1.1.1.1 7-1.1 9-1 10-1.2.3.1 11-1.2.3 11-1.2.3.r 13-1.2.1.2 16-1.2 19-1.2.2.2 20-1.2.2.2.1.r 21-1.2.2.2.1.1.1 22-1.2.2.2.2.r 24-1.2.2.2.2.1 25-1.2.2.2.2
# ::id pmid_1563_0473.389
# ::preferred 
(a / and~e.9
      :op1 (r / repeat-01~e.7
            :ARG1 (e / experiment-01~e.1
                  :ARG1-of (d / describe-01
                        :ARG0 (f / figure :mod "B"~e.4))))
      :op2 (i / isolate-01~e.16
            :ARG1 (r2 / rna
                  :name (n / name :op1 "RNA")
                  :mod (t / total~e.13))
            :ARG2 (c / cell
                  :name (n2 / name :op1 "keratinocyte")
                  :ARG1-of (t2 / treat-04~e.19
                        :ARG2~e.20 (p / protein
                              :name (n3 / name :op1 "TGF-β2"~e.21))
                        :duration~e.22 (t3 / time~e.25
                              :ARG1-of (i2 / indicate-01~e.24))))
            :time~e.11 (t4 / time~e.11
                  :mod (t5 / this~e.10))))

# ::tok RT @-@ PCR was then used with (+) or without (–) reverse transcriptase ( RT ) and with primer sets specific for <i> Snail </i> and GAPDH mRNAs .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 2-1.1.1.1 4-1.2 5-1 8-1.1.2.1 9-1.1.2.1.2.1 9-1.1.2.1.2.1.r 11-1.1.2.1.1.1 11-1.1.2.1.1.1.2 11-1.1.2.1.1.1.2.r 12-1.1.2.1.1.1.1.1 14-1.1.1.1 16-1.1.2 18-1.1.2.2.1.1.1.1 19-1.1.2.2.1 20-1.1.2.2.1.2 23-1.1.2.2.1.2.1.1.1.1 25-1.1.2.2.1.2.1 26-1.1.2.2.1.2.1.2.2.1.1 27-1.1.2.2.1.2.1.2.1.1
# ::id pmid_1563_0473.390
# ::preferred 
(u / use-01~e.5
      :ARG1 (m / molecular-physical-entity
            :name (n / name :op1 "RT-PCR"~e.0,2,14)
            :manner (a6 / and~e.16
                  :op1 (o / or~e.8
                        :op1 (a / accompany-01
                              :ARG0 (e / enzyme~e.11
                                    :name (n2 / name :op1 "transcriptase"~e.12)
                                    :ARG1-of~e.11 (r / reverse-01~e.11)))
                        :op2 (a2 / accompany-01
                              :polarity~e.9 "-"~e.9
                              :ARG0 e))
                  :op2 (a3 / accompany-01
                        :ARG0 (s / set~e.19
                              :mod (d / dna-sequence
                                    :name (n3 / name :op1 "primer"~e.18))
                              :mod (s2 / specific~e.20
                                    :topic (a4 / and~e.25
                                          :op1 (p / protein
                                                :name (n4 / name :op1 "Snail"~e.23))
                                          :op2 (r2 / rna
                                                :name (n5 / name :op1 "mRNA"~e.27)
                                                :part-of (e2 / enzyme
                                                      :name (n6 / name :op1 "GAPDH"~e.26)))))))))
      :time (t / then~e.4))

# ::tok Note that <i> Snail </i> mRNA expression also peaked at 2 h , paralleling Snail protein .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 3-1.2.1.1.2.1.1 5-1.2.1.1.1.1 6-1.2.1 6-1.2.1.2.1 7-1.2.2 8-1.2 10-1.3.1.1 13-1.2.1.2 14-1.2.1.2.1.1 15-1.2.1.2.1.1
# ::id pmid_1563_0473.391
# ::preferred 
(n3 / note-02~e.0
      :ARG0 (y / you)
      :ARG1 (p / peak-01~e.8
            :ARG1 (e / express-03~e.6
                  :ARG2 (r / rna
                        :name (n / name :op1 "mRNA"~e.5)
                        :part (p2 / protein
                              :name (n2 / name :op1 "Snail"~e.3)))
                  :ARG0-of (p3 / parallel-01~e.13
                        :ARG1 (e2 / express-03~e.6
                              :ARG2 p2~e.14,15)))
            :mod (a / also~e.7))
      :time (a2 / after
            :op1 (t / temporal-quantity
                  :quant "2"~e.10
                  :unit (h / hour))))

# ::tok ( D ) TGF-β2 treatment results in enhanced activity of a <i> Snail </i> promoter-β-galactosidase reporter .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3.1.1 3-1.1.1.1.1 4-1.1 5-1 6-1.2.r 7-1.2.2 8-1.2 12-1.2.1.1.1.1.1 15-1.2.1 15-1.2.1.2 15-1.2.1.2.r
# ::id pmid_1563_0473.392
# ::preferred 
(r2 / result-01~e.5
      :ARG1 (t / treat-04~e.4
            :ARG2 (p2 / protein
                  :name (n / name :op1 "TGF-β2"~e.3)))
      :ARG2~e.6 (a / act-02~e.8
            :ARG1 (m / molecular-physical-entity~e.15
                  :ARG0-of (p3 / promote-01
                        :ARG1 (p4 / protein
                              :name (n2 / name :op1 "Snail"~e.12)))
                  :ARG0-of~e.15 (r3 / report-01~e.15
                        :ARG1 (e2 / enzyme
                              :name (n3 / name :op1 "β-galactosidase")
                              :ARG0-of p3)))
            :ARG1-of (e / enhance-01~e.7))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "D"~e.1)))

# ::tok Keratinocytes were transfected with a β-galactosidase reporter driven by a <i> Snail </i> promoter that is either WT ( wt prom ) or harbors a mutation in a putative pSMAD2 @/@ pSMAD4 binding site ( mt prom ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1 3-1.2.r 5-1.2.1.1.1.1 6-1.2 6-1.2.1 6-1.2.1.r 7-1.2.2 11-1.2.2.1.1.1.1.1.1 17-1.2.2.1.1.1.1.2 22-1.2.2.1 23-1.2.2.1.1 23-1.2.2.1.1.2 23-1.2.2.1.1.2.r 25-1.2.2.1.1.2.1 26-1.2.2.1.1.2.1.1.r 28-1.2.2.1.1.2.1.1.3 32-1.2.2.1.1.2.1.1.1 33-1.2.2.1.1.2.1.1
# ::id pmid_1563_0473.393
# ::preferred 
(t / transfect-00~e.2
      :ARG1 (c / cell
            :name (n / name :op1 "keratinocyte"))
      :ARG2~e.3 (m2 / molecular-physical-entity~e.6
            :ARG0-of~e.6 (r2 / report-01~e.6
                  :ARG1 (e / enzyme
                        :name (n2 / name :op1 "β-galactosidase"~e.5)))
            :ARG1-of (d / drive-02~e.7
                  :ARG0 (o / or~e.22
                        :op1 (m3 / molecular-physical-entity~e.23
                              :ARG0-of (p2 / promote-01
                                    :ARG1 (p3 / protein
                                          :name (n3 / name :op1 "Snail"~e.11)
                                          :mod (w / wild-type~e.17)))
                              :ARG0-of~e.23 (h / harbor-01~e.23
                                    :ARG1 (m / mutate-01~e.25
                                          :ARG2~e.26 (p6 / protein-segment~e.33
                                                :ARG1-of (b / bind-01~e.32
                                                      :ARG2 (p8 / protein
                                                            :name (n5 / name :op1 "SMAD4")
                                                            :ARG1-of (p5 / phosphorylate-01)))
                                                :part-of (p7 / protein
                                                      :name (n6 / name :op1 "SMAD2")
                                                      :ARG1-of (p4 / phosphorylate-01))
                                                :ARG1-of (t2 / think-01~e.28)))))
                        :op2 (m4 / molecular-physical-entity
                              :ARG0-of (p / promote-01
                                    :ARG1 p3)
                              :ARG0-of h)))))

# ::tok At 2 d posttransfection , cells were treated with either TGF-β or heat @-@ inactivated TGF-β2 ( inact ) for the times indicated .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.4.2.1 5-1.1 7-1 10-1.2.1.1.1 10-1.2.2.1.1 11-1.2 12-1.2.2.2.2 14-1.2.2.2.1 21-1.3 21-1.4.2 21-1.4.r 22-1.3.1
# ::id pmid_1563_0473.394
# ::preferred 
(t / treat-04~e.7
      :ARG1 (c / cell~e.5)
      :ARG2 (o / or~e.11
            :op1 (p / protein
                  :name (n / name :op1 "TGF-β"~e.10))
            :op2 (p2 / protein
                  :name (n2 / name :op1 "TGF-β"~e.10)
                  :ARG1-of (a3 / activate-01
                        :polarity "-"~e.14
                        :ARG0 (h / heat~e.12))))
      :duration (t2 / time~e.21
            :ARG1-of (i / indicate-01~e.22))
      :time~e.21 (a2 / after
            :op1 (t3 / transfect-00)
            :quant (t4 / temporal-quantity~e.21
                  :quant "2"~e.1
                  :unit (d / day))))

# ::tok β-galactosidase assays were then conducted , and results are reported as fold increase over a basal level of activity of 1 .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1.1.1 1-1.1.1 3-1.1.2 4-1.1 6-1 7-1.2.1 7-1.2.1.1 7-1.2.1.1.r 9-1.2 10-1.1.2.r 10-1.2.2.r 11-1.2.2.2 12-1.2.2 15-1.2.2.1.1 16-1.2.2.1 17-1.2.2.1.2.r 18-1.2.2.1.2 20-1.2.2.1.3.1
# ::id pmid_1563_0473.395
# ::preferred 
(a / and~e.6
      :op1 (c / conduct-01~e.4
            :ARG1 (a2 / assay-00~e.1
                  :ARG2 (e / enzyme
                        :name (n / name :op1 "β-galactosidase"~e.0)))
            :time~e.10 (t / then~e.3))
      :op2 (r / report-01~e.9
            :ARG1 (t2 / thing~e.7
                  :ARG2-of~e.7 (r2 / result-01~e.7))
            :manner~e.10 (i / increase-01~e.12
                  :ARG3 (l / level~e.16
                        :mod (b / basal~e.15)
                        :degree-of~e.17 (a3 / act-02~e.18)
                        :ARG1-of (e2 / equal-01 :ARG2 "1"~e.20))
                  :mod (f / fold~e.11))))

# ::tok The experiment was repeated three times in triplicate , and error bars reflect variations in the results .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.2 3-1.1 4-1.1.2.1 4-1.1.1 9-1 10-1.2.1.1 11-1.2.1 12-1.2 13-1.2.2 14-1.2.2.1.r 16-1.2.2.1 16-1.2.2.1.1 16-1.2.2.1.1.r
# ::id pmid_1563_0473.396
# ::preferred 
(a / and~e.9
      :op1 (r / repeat-01~e.3
            :ARG3 "3"~e.4
            :ARG1 (e / experiment-01~e.1 :quant "3"~e.4))
      :op2 (r2 / reflect-01~e.12
            :ARG1 (b / bar~e.11
                  :mod (e2 / error~e.10))
            :ARG2 (v / vary-01~e.13
                  :ARG1~e.14 (t / thing~e.16
                        :ARG2-of~e.16 (r3 / result-01~e.16)))))

# ::tok Figure 6
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.1
# ::id pmid_1563_0473.397
# ::preferred 
(f / figure~e.0 :mod "6"~e.1)

# ::tok ( A–D ) Skins from TGF-β2 WT or KO E17.5 embryos were analyzed for expression of TGF-β2 protein ( A ) , which is present in the epidermis and dermis as previously described [ @<xref ref-type="bibr" rid="pbio-0030011-b33"> 33 </xref>@ ] and in the hair bud , pSMAD2 ( B ) , Snail ( C ) , and <i> Snail </i> mRNA ( D ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 3-1.1.1.1 3-1.1.1.2 4-1.1.1.1.1.r 4-1.1.1.2.1.r 5-1.1.1.1.1.1.1.1 6-1.1.1.1.1.1.2 7-1.1.1 8-1.1.1.2.1.1.1.1 10-1.1.1.1.1 10-1.1.1.2.1 12-1.1 14-1.1.2.1 15-1.1.2.1.1.r 16-1.1.2.1.1.1.1.1 17-1.1.1.1.1.1 17-1.1.2.1.1.1 17-1.1.2.1.1.2.1 17-1.1.2.1.1.2.2 19-1.1.3.1.1 19-1.2.1.1.1 25-1.1.2.1.1.1.2.r 27-1.1.2.1.1.1.2.1 28-1.1.2.1.1.1.2 29-1.1.2.1.1.1.2.2 30-1.1.2.1.1.1.2.3.2.r 31-1.1.2.1.1.1.2.3.2 32-1.1.2.1.1.1.2.3 32-1.1.2.1.1.2.1.3 32-1.1.2.1.1.2.2.2 32-1.1.2.1.1.2.3.3 32-1.1.3 32-1.2 37-1.1.2.1.1.1.2.3.1.1.1 40-1.1.2.1.1 40-1.1.2.1.1.2 41-1.1.2.1.1.2.r 43-1.1.2.1.1.2.4.1 44-1.1.2.1.1.2.4 48-1.1.2.1.1.2.1.3.1.1 51-1.1.2.1.1.2.2.1.1 53-1.1.2.1.1.2.2.2.1.1 58-1.1.2.1.1.2.2.1.1 60-1.1.2.1.1.2.3.1.1 62-1.1.2.1.1.2.3.3.1.1 62-1.2.1.1.2
# ::id pmid_1563_0473.398
# ::preferred 
(a3 / and
      :op1 (a / analyze-01~e.12
            :ARG1 (o2 / or~e.7
                  :op1 (s / skin~e.3
                        :source~e.4 (e / embryo~e.10
                              :mod (p / protein~e.17
                                    :name (n / name :op1 "TGF-β2"~e.5)
                                    :mod (w / wild-type~e.6))))
                  :op2 (s3 / skin~e.3
                        :source~e.4 (e5 / embryo~e.10
                              :mod (e3 / enzyme
                                    :name (n2 / name :op1 "KO"~e.8))
                              :ARG1-of (a7 / age-01
                                    :ARG2 (t / temporal-quantity
                                          :quant "17.5"
                                          :unit (d4 / day))))))
            :purpose (f / find-01
                  :ARG1 (e4 / express-03~e.14
                        :ARG2~e.15 (a4 / and~e.40
                              :op1 (p2 / protein~e.17
                                    :name (n3 / name :op1 "TGF-β2"~e.16)
                                    :location~e.25 (a2 / and~e.28
                                          :op1 (e2 / epidermis~e.27)
                                          :op2 (d / dermis~e.29)
                                          :ARG1-of (d2 / describe-01~e.32
                                                :ARG0 (p4 / publication
                                                      :ARG1-of (c / cite-01 :ARG2 "33"~e.37))
                                                :time~e.30 (p3 / previous~e.31))))
                              :op2~e.41 (a6 / and~e.40
                                    :op1 (p7 / protein~e.17
                                          :name (n4 / name :op1 "SMAD2")
                                          :ARG1-of (p5 / phosphorylate-01)
                                          :ARG1-of (d6 / describe-01~e.32
                                                :ARG0 (f4 / figure :mod "B"~e.48)))
                                    :op2 (p6 / protein~e.17
                                          :name (n5 / name :op1 "Snail"~e.51,58)
                                          :ARG1-of (d7 / describe-01~e.32
                                                :ARG0 (f5 / figure :mod "C"~e.53)))
                                    :op3 (r / rna
                                          :name (n6 / name :op1 "mRNA"~e.60)
                                          :part p6
                                          :ARG1-of (d8 / describe-01~e.32
                                                :ARG0 (f6 / figure :mod "D"~e.62)))
                                    :location (b / bud~e.44
                                          :mod (h / hair~e.43))))))
            :ARG1-of (d5 / describe-01~e.32
                  :ARG0 (f3 / figure :mod "A"~e.19)))
      :ARG1-of (d3 / describe-01~e.32
            :ARG0 (f2 / figure
                  :mod (v / value-interval :op1 "A"~e.19 :op2 "D"~e.62))))

# ::tok Arrows point to the hair buds .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1 2-1.2.r 4-1.2.1 5-1.2
# ::id pmid_1563_0473.399
# ::preferred 
(p / point-01~e.1
      :ARG0 (a / arrow~e.0)
      :ARG2~e.2 (b / bud~e.5
            :mod (h / hair~e.4)))

# ::tok ( E ) Western blot analyses of Snail expression in the skins of 2 @-@ wk @-@ old <i> K14 @-@ Smad2 </i> transgenic ( SMAD2 TG ) and WT littermate ( WT ) mice .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3.1.1 3-1.2.1.1 4-1.2.1.2 5-1 6-1.1.r 7-1.1.1.1.1 8-1.1 9-1.1.2.r 11-1.1.2.1 11-1.1.2.2 13-1.1.2.1.1.2.1.1 17-1.1.2.1.1.2 19-1.1.2.1.1.1.1.1 21-1.1.2.1.1.1.1.1 23-1.1.2.1.1.3 28-1.1.2 29-1.1.2.2.1.2 30-1.1.2.2.1.1 32-1.1.2.2.1.2 34-1.1.2.1.1 34-1.1.2.2.1
# ::id pmid_1563_0473.400
# ::preferred 
(a3 / analyze-01~e.5
      :ARG1~e.6 (e / express-03~e.8
            :ARG2 (p / protein
                  :name (n2 / name :op1 "Snail"~e.7))
            :location~e.9 (a / and~e.28
                  :op1 (s / skin~e.11
                        :mod (m / mouse~e.34
                              :mod (e2 / enzyme
                                    :name (n3 / name :op1 "K14-Smad2"~e.19,21))
                              :ARG1-of (a2 / age-01~e.17
                                    :ARG2 (t / temporal-quantity
                                          :quant "2"~e.13
                                          :unit (w2 / week)))
                              :mod (t2 / transgenic~e.23)))
                  :op2 (s2 / skin~e.11
                        :mod (m2 / mouse~e.34
                              :mod (l / littermate~e.30)
                              :mod (w / wild-type~e.29,32)))))
      :mod (t3 / thing
            :name (n / name :op1 "Western"~e.3 :op2 "blot"~e.4))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "E"~e.1)))

# ::tok Antibody to tubulin was used as a control for equal protein loadings .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 2-1.1.1.1.1.1 4-1 5-1.2.r 7-1.2 8-1.2.1.r 9-1.2.1.2 10-1.2.1.1 11-1.2.1
# ::id pmid_1563_0473.401
# ::preferred 
(u / use-01~e.4
      :ARG1 (a / antibody~e.0
            :ARG0-of (o / oppose-01
                  :ARG1 (p / protein
                        :name (n / name :op1 "tubulin"~e.2))))
      :ARG2~e.5 (c / control-01~e.7
            :ARG1~e.8 (l / load-01~e.11
                  :ARG1 (p2 / protein~e.10)
                  :ARG1-of (e / equal-01~e.9))
            :ARG2 a))

# ::tok The K14 @-@ Smad2 Tg mouse was previously shown to possess activated TGF-β signaling [ @<xref ref-type="bibr" rid="pbio-0030011-b35"> 35 </xref>@ ].
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1.1.1.1 3-1.1.1.1.1.1 5-1.1.1 7-1.3 8-1 10-1.1 11-1.1.2.1.2 12-1.1.2.1.1.1 13-1.1.2 18-1.2.1.1.1
# ::id pmid_1563_0473.402
# ::preferred 
(s / show-01~e.8
      :ARG1 (p / possess-01~e.10
            :ARG0 (m / mouse~e.5
                  :mod (e / enzyme
                        :name (n2 / name :op1 "K14-Smad2"~e.1,3))
                  :mod (t / transgenic))
            :ARG1 (s2 / signal-07~e.13
                  :ARG0 (p2 / protein
                        :name (n3 / name :op1 "TGF-β"~e.12)
                        :ARG1-of (a / activate-01~e.11))))
      :ARG1-of (d / describe-01
            :ARG0 (p3 / publication
                  :ARG1-of (c / cite-01 :ARG2 "35"~e.18)))
      :time (p4 / previous~e.7))

# ::tok ( F–G ) Proliferation markers Ki67 ( F ) and pMAPK ( G ) are diminished in <i> TGF-β2 </i>@ -@ null hair relative to its WT counterpart .
# ::amr-annotator SDL-AMR-09
# ::alignments 3-1.1.1.3 3-1.1.2.4 4-1.1.1 4-1.1.2 5-1.1.1.1.1 7-1.1.1.2.1.1 7-1.4.1.1.1 9-1.1 12-1.1.2.3.1.1 12-1.4.1.1.2 15-1 18-1.2.1.1.1 22-1.2 26-1.3.1.1 27-1.3.1
# ::id pmid_1563_0473.403
# ::preferred 
(d / diminish-01~e.15
      :ARG1 (a2 / and~e.9
            :op1 (m2 / marker~e.4
                  :name (n5 / name :op1 "Ki67"~e.5)
                  :ARG1-of (d3 / describe-01
                        :ARG0 (f2 / figure :mod "F"~e.7))
                  :mod (p2 / proliferate-01~e.3))
            :op2 (m3 / marker~e.4
                  :name (n6 / name :op1 "MAPK")
                  :ARG1-of (p4 / phosphorylate-01)
                  :ARG1-of (d4 / describe-01
                        :ARG0 (f3 / figure :mod "G"~e.12))
                  :mod (p3 / proliferate-01~e.3)))
      :location (h / hair~e.22
            :mod (p5 / protein
                  :name (n3 / name :op1 "TGF-β2"~e.18)
                  :ARG2-of (m / mutate-01 :mod "−/−")))
      :ARG1-of (c / compare-01
            :ARG2 (c2 / counterpart~e.27
                  :mod (w / wild-type~e.26)))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure
                  :mod (v / value-interval :op1 "F"~e.7 :op2 "G"~e.12))))

# ::tok ( H–J ) <i> TGF-β2 </i>@ -@ null hair fails to down @-@ regulate E @-@ cadherin ( H ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 4-1.2.1.1.1 8-1.2 14-1.3.1.1 16-1.3.1.1 18-1.4.1.1.1
# ::id pmid_1563_0473.404
# ::preferred 
(d3 / downregulate-01
      :polarity "-"
      :ARG0 (h / hair~e.8
            :mod (p / protein
                  :name (n / name :op1 "TGF-β2"~e.4)
                  :ARG2-of (m / mutate-01 :mod "−/−")))
      :ARG1 (p2 / protein
            :name (n2 / name :op1 "E-cadherin"~e.14,16))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure
                  :mod (v / value-interval :op1 "H"~e.18 :op2 "J"))))

# ::tok Wnt and noggin signaling pathways are still intact in the TGF-β2 null hair as nuclear LEF @-@ 1 ( I ) and nuclear β-catenin ( J ) are still expressed .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3.1.1.1 1-1.3 2-1.3.2.1.1 3-1.3.1.2 4-1.3.1 4-1.3.2 5-1.3.r 6-1.3.3 7-1 8-1.1.r 10-1.1.1.1.1 12-1.1 14-1.2.1.1.1.2 14-1.2.1.1.2.2 15-1.2.1.1.1.1.1 17-1.2.1.1.1.1.1 19-1.2.1.1.1.1.1 19-1.2.1.1.1.3.1.1 21-1.2.1.1 22-1.2.1.1.1.2 22-1.2.1.1.2.2 23-1.2.1.1.2.1.1 25-1.2.1.1.2.3.1.1 27-1.3.r 28-1.2.1.2 29-1.2.1
# ::id pmid_1563_0473.405
# ::preferred 
(i / intact~e.7
      :location~e.8 (h / hair~e.12
            :mod (p2 / protein
                  :name (n / name :op1 "TGF-β2"~e.10)
                  :ARG2-of (m / mutate-01 :mod "−/−")))
      :ARG1-of (c / cause-01
            :ARG0 (e / express-03~e.29
                  :ARG2 (a2 / and~e.21
                        :op1 (p3 / protein
                              :name (n2 / name :op1 "LEF-1"~e.15,17,19)
                              :mod (n3 / nucleus~e.14,22)
                              :ARG1-of (d / describe-01
                                    :ARG0 (f / figure :mod "I"~e.19)))
                        :op2 (p4 / protein
                              :name (n4 / name :op1 "β-catenin"~e.23)
                              :mod (n5 / nucleus~e.14,22)
                              :ARG1-of (d2 / describe-01
                                    :ARG0 (f2 / figure :mod "J"~e.25))))
                  :mod s2~e.28))
      :domain~e.5,27 (a3 / and~e.1
            :op1 (p5 / pathway~e.4
                  :name (n7 / name :op1 "Wnt"~e.0)
                  :ARG0-of (s3 / signal-07~e.3))
            :op2 (p6 / pathway~e.4
                  :name (n8 / name :op1 "noggin"~e.2)
                  :ARG0-of s3)
            :mod (s2 / still~e.6)))

# ::tok Dragging Ras Back in the Ring ( PMID : 24651010 )
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1.1.1.1.1 2-1.1.3 3-1.1.2.r 5-1.1.2 7-1.2 9-1.2.1
# ::id pmid_2465_1010.1
# ::preferred 
(p / publication-91
      :ARG1 (d / drag-01~e.0
            :ARG1 (e / enzyme
                  :name (n / name :op1 "Ras"~e.1))
            :ARG2~e.3 (r / ring~e.5)
            :direction (b / back~e.2))
      :ARG8 (p3 / PMID~e.7 :mod "24651010"~e.9))

# ::tok Ras proteins play a major role in human cancers but have not yielded to therapeutic attack .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1.1 2-1.1 4-1.1.3 6-1.1.2.r 7-1.1.2.2 8-1.1.2.1.1 9-1 11-1.2.1 11-1.2.1.r 12-1.2 14-1.2.3.1 15-1.2.3
# ::id pmid_2465_1010.2
# ::preferred 
(c / contrast-01~e.9
      :ARG1 (p / play-08~e.2
            :ARG0 (e / enzyme
                  :name (n / name :op1 "Ras"~e.0))
            :ARG1~e.6 (d / disease
                  :name (n2 / name :op1 "cancer"~e.8)
                  :mod (h / human~e.7))
            :mod (m / major~e.4))
      :ARG2 (y / yield-02~e.12
            :polarity~e.11 "-"~e.11
            :ARG0 e
            :ARG2 (a / attack-01~e.15
                  :ARG0 (t / therapy~e.14)
                  :ARG1 e)))

# ::tok Ras @-@ driven cancers are among the most difficult to treat and often excluded from therapies .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.2.1.1.1 2-1.1.1 2-1.1.1.2 2-1.1.1.2.r 3-1.1.1.1.1 3-1.1.2.1.1 5-1.1 7-1.1.2.2.1.1 8-1.1.2.2.1 10-1.1.2 10-1.1.2.2 10-1.1.2.2.r 11-1 12-1.2.3 13-1.2 14-1.2.2.r 15-1.2.2
# ::id pmid_2465_1010.3
# ::preferred 
(a / and~e.11
      :op1 (i / include-91~e.5
            :ARG1 (d / disease~e.2
                  :name (n / name :op1 "cancer"~e.3)
                  :ARG1-of~e.2 (d2 / drive-02~e.2
                        :ARG0 (e / enzyme
                              :name (n2 / name :op1 "Ras"~e.0))))
            :ARG2 (d3 / disease~e.10
                  :name (n3 / name :op1 "cancer"~e.3)
                  :ARG2-of~e.10 (t / treat-03~e.10
                        :manner (d4 / difficult~e.8
                              :degree (m / most~e.7)))))
      :op2 (e2 / exclude-01~e.13
            :ARG1 d
            :ARG2~e.14 (t2 / therapy~e.15)
            :frequency (o / often~e.12)))

# ::tok The Ras proteins have been termed “ undruggable , ” based on failures from an era in which understanding of signaling transduction , feedback loops , redundancy , tumor heterogeneity , and Ras’ oncogenic role was poor .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1.1 4-1.2.2.r 5-1 10-1.3 11-1.3.1.r 12-1.3.1 13-1.3.1.1.r 15-1.3.1.1 18-1.3.1.1.1.1 19-1.3.1.1.1.1.1.r 20-1.3.1.1.1.1.1.1.1 23-1.3.1.1.1.1.1.2.1 24-1.3.1.1.1.1.1.2 26-1.3.1.1.1.1.1.3 28-1.3.1.1.1.1.1.4.1 29-1.3.1.1.1.1.1.4 31-1.3.1.1.1.1.1 33-1.3.1.1.1.1.1.5 33-1.3.1.1.1.1.1.5.2.1.1 35-1.3.1.1.1.1.r 36-1.3.1.1.1
# ::id pmid_2465_1010.4
# ::preferred 
(t / term-01~e.5
      :ARG1 (e / enzyme
            :name (n / name :op1 "Ras"~e.1))
      :ARG3 (p / possible
            :polarity "-"
            :domain~e.4 (d / drug-01
                  :ARG1 e))
      :ARG1-of (b / base-02~e.10
            :ARG2~e.11 (f / fail-01~e.12
                  :time~e.13 (e2 / era~e.15
                        :time-of (p2 / poor~e.36
                              :domain~e.35 (u / understand-01~e.18
                                    :ARG1~e.19 (a / and~e.31
                                          :op1 (t2 / transduct-00
                                                :ARG0-of (s / signal-07~e.20))
                                          :op2 (l / loop~e.24
                                                :mod (f2 / feedback~e.23))
                                          :op3 (r / redundancy~e.26)
                                          :op4 (h / heterogeneous~e.29
                                                :domain (t3 / tumor~e.28))
                                          :op5 (c / cause-01~e.33
                                                :ARG0 e
                                                :ARG1 (d2 / disease
                                                      :name (n2 / name :op1 "cancer"~e.33))))))))))

# ::tok Structures of Ras oncoproteins bound to their effectors or regulators are unsolved , and it is unknown precisely how Ras proteins activate their downstream targets .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2 1-1.1.2.1.r 2-1.1.2.1.1.1 4-1.1.2.1 4-1.1.2.1.3 4-1.1.2.1.3.r 5-1.1.2.1.3.1.r 6-1.1.2.1.3.1.1.1 6-1.1.2.1.3.1.1.1.r 7-1.1.2.1.3.1.1 8-1.1.2.1.3.1 9-1.1.2.1.3.1.2 9-1.1.2.1.3.1.2.1 9-1.1.2.1.3.1.2.1.r 11-1.1 11-1.1.1 11-1.1.1.r 11-1.2.1 13-1 16-1.1.1 16-1.2.1 17-1.2.3 18-1.2.2.1.r 18-1.2.3.r 19-1.2.2.1.1.1.1 21-1.2.2.1 23-1.2.2.1.2.2 24-1.2.2.1.2 24-1.2.2.1.2.1 24-1.2.2.1.2.1.r
# ::id pmid_2465_1010.5
# ::preferred 
(a / and~e.13
      :op1 (s / solve-01~e.11
            :polarity~e.11 "-"~e.11,16
            :ARG1 (s2 / structure~e.0
                  :consist-of~e.1 (e / enzyme~e.4
                        :name (n / name :op1 "Ras"~e.2)
                        :ARG0-of (c / cause-01
                              :ARG1 (c2 / cancer))
                        :ARG1-of~e.4 (b / bind-01~e.4
                              :ARG2~e.5 (o2 / or~e.8
                                    :op1 (e2 / effector~e.7
                                          :poss~e.6 e~e.6)
                                    :op2 (m / molecular-physical-entity~e.9
                                          :ARG0-of~e.9 (r / regulate-01~e.9
                                                :ARG1 e)))))))
      :op2 (k / know-01
            :polarity "-"~e.11,16
            :ARG1 (t / thing
                  :manner-of~e.18 (a2 / activate-01~e.21
                        :ARG0 (e3 / enzyme
                              :name (n2 / name :op1 "Ras"~e.19))
                        :ARG1 (m2 / molecular-physical-entity~e.24
                              :ARG1-of~e.24 (t2 / target-01~e.24
                                    :ARG0 e3)
                              :location (d / downstream~e.23))))
            :manner~e.18 (p / precise~e.17)))

# ::tok These knowledge gaps have impaired development of therapeutic strategies .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1.2 2-1.1 4-1 5-1.2 6-1.2.1.r 7-1.2.1.1 8-1.2.1
# ::id pmid_2465_1010.6
# ::preferred 
(i / impair-01~e.4
      :ARG0 (g / gap~e.2
            :mod (t2 / this~e.0)
            :topic (k / know-03~e.1))
      :ARG1 (d / develop-02~e.5
            :ARG1~e.6 (s / strategy~e.8
                  :mod (t / therapy~e.7))))

# ::tok A better understanding of Ras biology and biochemistry , coupled with new ways of targeting undruggable proteins , is likely to lead to new ways of defeating Ras @-@ driven cancers .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1.2 1-1.1.1.2.1 1-1.1.1.2.1.r 2-1.1.1 4-1.1.1.1.1.1.1.1 5-1.1.1.1.1 6-1.1.1.1 7-1.1.1.1.2 9-1.1.1.3 10-1.1.1.3.1.r 11-1.1.1.3.1.1 12-1.1.1.3.1 13-1.1.1.3.1.2.r 14-1.1.1.3.1.2 16-1.1.1.3.1.2.1 18-1.1.r 19-1 20-1.1.1 21-1.1 22-1.1.1 22-1.1.2.r 23-1.1.2.1 24-1.1.2 25-1.1.2.2.r 26-1.1.2.2 27-1.1.2.2.1.2.1 29-1.1.2.2.1 29-1.1.2.2.1.2 29-1.1.2.2.1.2.r 30-1.1.2.2.1.1.1
# ::id pmid_2465_1010.7
# ::preferred 
(l / likely~e.19
      :domain~e.18 (l2 / lead-03~e.21
            :ARG0 (u / understand-01~e.2,20,22
                  :ARG1 (a / and~e.6
                        :op1 (b / biology~e.5
                              :mod (e / enzyme
                                    :name (n / name :op1 "Ras"~e.4)))
                        :op2 (b2 / biochemistry~e.7
                              :mod e))
                  :mod (g / good~e.1
                        :degree~e.1 (m / more~e.1))
                  :ARG1-of (c / couple-01~e.9
                        :ARG2~e.10 (w2 / way~e.12
                              :mod (n4 / new~e.11)
                              :manner-of~e.13 (t / target-01~e.14
                                    :ARG1 (p / protein~e.16
                                          :ARG1-of (d4 / drug-01
                                                :mod (p2 / possible :polarity "-")))))))
            :ARG2~e.22 (w / way~e.24
                  :mod (n2 / new~e.23)
                  :manner-of~e.25 (d / defeat-01~e.26
                        :ARG1 (d2 / disease~e.29
                              :name (n3 / name :op1 "cancer"~e.30)
                              :ARG1-of~e.29 (d3 / drive-02~e.29
                                    :ARG0 e~e.27))))))

# ::tok Main Text
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1
# ::id pmid_2465_1010.8
# ::preferred 
(t / text~e.1
      :mod (m / main~e.0))

# ::tok Fifty years have passed since the transforming power of Ras genes was first recognized .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1.2 3-1 4-1.2 6-1.2.1.1.1 8-1.2.1.1.1.1.r 9-1.2.1.1.1.1.1.1 11-1.2.1.1.1.r 12-1.2.1.2 12-1.2.1.2.1 12-1.2.1.2.1.r 13-1.2.1
# ::id pmid_2465_1010.9
# ::preferred 
(p / pass-03~e.3
      :ARG1 (t / temporal-quantity
            :quant "50"~e.0
            :unit (y / year~e.1))
      :time (s / since~e.4
            :op1 (r / recognize-02~e.13
                  :ARG1 (p2 / possible
                        :domain~e.11 (t2 / transform-01~e.6
                              :ARG0~e.8 (e / enzyme
                                    :name (n / name :op1 "Ras"~e.9))))
                  :ord (o / ordinal-entity~e.12 :value~e.12 "1"~e.12))))

# ::tok Harvey sarcoma virus , Kirsten sarcoma virus , and Rasheed sarcoma virus contain Ras genes ( so named for their role in forming <i> ra </i>@ t <i> s </i>@ arcomas ; reviewed in <ce:cross-refs id="crosrefs0010" refid="bib3 bib31"> Barbacid , 1987; Karnoub and Weinberg , 2008 </ce:cross-refs> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1.1 1-1.1.1.1.2 2-1.1.1 4-1.1.2.1.1 5-1.1.1.1.2 6-1.1.1 6-1.1.2 6-1.1.3 8-1.1 9-1.1.3.1.1 10-1.1.3.1.2 11-1.1.3.1.3 12-1 13-1.2.1.1 14-1.2 16-1.2.2.1 17-1.2.2 18-1.2.2.1.1.r 19-1.2.2.1.1.1 19-1.2.2.1.1.1.r 22-1.2.2.1.1 32-1.3 38-1.3.1.1.1.1.1 41-1.3.1.2.1.1.1.1 42-1.3.1.2.1 43-1.3.1.2.1.2.1.1 45-1.3.1.2.2.1
# ::id pmid_2465_1010.10
# ::preferred 
(c / contain-01~e.12
      :ARG0 (a / and~e.8
            :op1 (v / virus~e.2,6
                  :name (n2 / name
                        :op1 "Harvey"~e.0
                        :op2 "sarcoma"~e.1,5
                        :op3 "virus"))
            :op2 (v2 / virus~e.6
                  :name (n3 / name
                        :op1 "Kirsten"~e.4
                        :op2 "sarcoma"
                        :op3 "virus"))
            :op3 (v3 / virus~e.6
                  :name (n4 / name
                        :op1 "Rasheed"~e.9
                        :op2 "sarcoma"~e.10
                        :op3 "virus"~e.11)))
      :ARG1 (g / gene~e.14
            :name (n / name :op1 "Ras"~e.13)
            :ARG1-of (n5 / name-01~e.17
                  :ARG1-of (c2 / cause-01~e.16
                        :ARG0~e.18 (f / form-01~e.22
                              :ARG0~e.19 g~e.19
                              :ARG1 (s / sarcoma
                                    :mod (r / rat))))))
      :ARG1-of (r2 / review-01~e.32
            :ARG0 (a2 / and
                  :op1 (p / publication-91
                        :ARG0 (p3 / person
                              :name (n6 / name :op1 "Barbacid"~e.38))
                        :time (d / date-entity :year "1987"))
                  :op2 (p2 / publication-91
                        :ARG0 (a3 / and~e.42
                              :op1 (p4 / person
                                    :name (n7 / name :op1 "Karnoub"~e.41))
                              :op2 (p5 / person
                                    :name (n8 / name :op1 "Weinberg"~e.43)))
                        :time (d2 / date-entity :year "2008"~e.45)))))

# ::tok These retroviruses initiated tumors efficiently and , using temperature @-@ sensitive mutants , were shown to be necessary for tumor maintenance ( <ce:cross-ref id="crosref0040" refid="bib62"> Shih et al. , 1979 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 2-1.1 3-1.1.2 4-1.1.3 5-1 5-1.3.1.1 7-1.2.2 8-1.2.2.1.2.1 10-1.2.2.1.2 11-1.2.2.1.1 14-1.2 17-1.2.1 18-1.2.1.1.r 19-1.2.1.1.1 20-1.2.1.1 25-1.3.1.1.1.1.1 26-1.3.1.1 27-1.3.1.1.2.1 29-1.3.1.2.1
# ::id pmid_2465_1010.11
# ::preferred 
(a / and~e.5
      :op1 (i / initiate-01~e.2
            :ARG0 (r / retrovirus
                  :mod (t / this~e.0))
            :ARG1 (t2 / tumor~e.3)
            :ARG2-of (e / efficient-01~e.4
                  :ARG1 r))
      :op2 (s / show-01~e.14
            :ARG1 (n / need-01~e.17
                  :ARG0~e.18 (m / maintain-01~e.20
                        :ARG1 t2~e.19)
                  :ARG1 r)
            :manner (u / use-01~e.7
                  :ARG1 (v / virus
                        :ARG2-of (m2 / mutate-01~e.11)
                        :ARG0-of (s2 / sensitive-03~e.10
                              :ARG1 (t3 / temperature~e.8)))))
      :ARG1-of (d / describe-01
            :ARG0 (p / publication-91
                  :ARG0 (a2 / and~e.5,26
                        :op1 (p2 / person
                              :name (n2 / name :op1 "Shih"~e.25))
                        :op2 (p3 / person
                              :mod (o / other~e.27)))
                  :time (d2 / date-entity :year "1979"~e.29))))

# ::tok They formed part of a fascinating collection of retroviruses that was assembled in the 1970 s , each able to transform cells in culture and in avian and rodent models .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 5-1.2.1 6-1.2 11-1.2.3 12-1.2.3.1.r 14-1.2.3.1.1 15-1.2.3.1.1.r 17-1.2.2.2 18-1.2.2.1.2 20-1.2.2.1 21-1.2.2.1.1 22-1.2.2.1.1.1.r 23-1.2.2.1.1.1.1 24-1.2.2.1.1.1 26-1.2.2.1.1.1.2.1 27-1.2.2.1.1.1 28-1.2.2.1.1.1.3.1 29-1.2.2.1.1.1.2 29-1.2.2.1.1.1.3
# ::id pmid_2465_1010.12
# ::preferred 
(i / include-91
      :ARG1 (t / they~e.0)
      :ARG2 (c / collection~e.6
            :ARG0-of (f2 / fascinate-01~e.5)
            :consist-of (r / retrovirus
                  :ARG0-of (t2 / transform-01~e.20
                        :ARG1 (c2 / cell~e.21
                              :source~e.22 (a2 / and~e.24,27
                                    :op1 (c3 / culture~e.23)
                                    :op2 (m / model~e.29
                                          :mod (b / bird~e.26))
                                    :op3 (m2 / model~e.29
                                          :mod (r2 / rodent~e.28))))
                        :mod (p2 / possible~e.18))
                  :mod (e / each~e.17))
            :ARG1-of (a / assemble-02~e.11
                  :time~e.12 (d / date-entity :decade~e.15 "1970"~e.14))))

# ::tok These experiments were , essentially , unbiased screens for genes that cause cancer ; the nature of the proteins that the genes encoded was completely unknown .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.3.1 1-1.1.3 2-1.1.3.r 4-1.1.4 6-1.1.2 6-1.1.2.1 6-1.1.2.1.r 7-1.1 8-1.1.1.r 9-1.1.1 11-1.1.1.1 12-1.1.1.1.1.1.1 15-1.2.2 16-1.2.2.1.r 18-1.2.2.1 21-1.2.2.1.1.1 22-1.2.2.1.1 24-1.2.3 25-1.1.2.1 25-1.2.1
# ::id pmid_2465_1010.13
# ::preferred 
(m / multi-sentence
      :snt1 (s / screen-01~e.7
            :ARG2~e.8 (g / gene~e.9
                  :ARG0-of (c / cause-01~e.11
                        :ARG1 (d / disease
                              :name (n / name :op1 "cancer"~e.12))))
            :ARG1-of (b / bias-01~e.6 :polarity~e.6 "-"~e.6,25)
            :domain~e.2 (e / experiment-01~e.1
                  :mod (t / this~e.0))
            :mod (e2 / essential~e.4))
      :snt2 (k / know-01
            :polarity "-"~e.25
            :ARG1 (n2 / nature~e.15
                  :mod~e.16 (p / protein~e.18
                        :ARG1-of (e3 / encode-01~e.22
                              :ARG0 (g2 / gene~e.21))))
            :degree (c2 / complete~e.24)))

# ::tok Remarkably , the majority of these viruses encoded proteins that were later identified as components of the tyrosine kinase @-@ Ras signaling pathway ( <ce:cross-ref id="crosref0045" refid="bib75"> Vogt , 2012 </ce:cross-ref> ) , even though the biochemical nature of these proteins was unknown , and tyrosine kinase activity had not been discovered ( <ce:cross-ref id="crosref0050" refid="bib17"> Eckhart et al. , 1979 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3 0-1.3.r 3-1.1.1.2 5-1.1.1.1.1 6-1.1 6-1.1.1.1 7-1 8-1.2 11-1.2.1.2 11-1.2.1.2.1 11-1.2.1.2.1.r 12-1.2.1 13-1.2.1.1.r 13-1.2.1.2.r 14-1.2.1.1 15-1.2.1.1.1.r 17-1.2.1.1.1.1.1 18-1.2.1.1.1.1.2 20-1.2.1.1.1.1.2 21-1.2.1.1.1.2 22-1.2.1.1.1 33-1.2.1.3 34-1.2.1.3 36-1.2.1.3.1.1.2.1 37-1.2.1.3.1.1.2 39-1.1.1.1.1 40-1.2 42-1.2.1.3.1.1.1 42-1.2.1.3.1.2.1 44-1.2.1.3.1 45-1.2.1.3.1.2.2.1.1.1 46-1.2.1.3.1.2.2.1.1.2 47-1.2.1.3.1.2.2 49-1.2.1.3.1.2.1 49-1.2.1.3.1.2.1.r 51-1.2.1.3.1.2 56-1.4.1.1.1.1.1 57-1.4.1.1 58-1.4.1.1.2.1
# ::id pmid_2465_1010.14
# ::preferred 
(e / encode-01~e.7
      :ARG0 (v / virus~e.6
            :ARG1-of (i / include-91
                  :ARG2 (v2 / virus~e.6
                        :mod (t / this~e.5,39))
                  :ARG3 (m / majority~e.3)))
      :ARG1 (p / protein~e.8,40
            :ARG1-of (i2 / identify-01~e.12
                  :ARG2~e.13 (c / component~e.14
                        :part-of~e.15 (p2 / pathway~e.22
                              :name (n / name :op1 "tyrosine"~e.17 :op2 "kinase-Ras"~e.18,20)
                              :ARG0-of (s / signal-07~e.21)))
                  :time~e.13 (l / late~e.11
                        :degree~e.11 (m2 / more~e.11))
                  :ARG1-of (h / have-concession-91~e.33,34
                        :ARG2 (a / and~e.44
                              :op1 (k / know-01
                                    :polarity "-"~e.42
                                    :ARG1 (n2 / nature~e.37
                                          :mod (b / biochemical~e.36)
                                          :poss p))
                              :op2 (d / discover-01~e.51
                                    :polarity~e.49 "-"~e.42,49
                                    :ARG1 (a2 / act-02~e.47
                                          :ARG0 (p3 / protein
                                                :name (n3 / name :op1 "tyrosine"~e.45 :op2 "kinase"~e.46))))))))
      :manner~e.0 (r / remarkable~e.0)
      :ARG1-of (d2 / describe-01
            :ARG0 (p4 / publication-91
                  :ARG0 (a3 / and~e.57
                        :op1 (p5 / person
                              :name (n4 / name :op1 "Eckhart"~e.56))
                        :op2 (p6 / person
                              :mod (o / other~e.58))))))

# ::tok Of the hundreds of mutant proteins now known to contribute to cancer that could have been identified in these assays , including those involved in DNA repair , cellular metabolism , RNA splicing , and the other hallmarks of cancer ( <ce:cross-ref id="crosref0055" refid="bib25"> Hanahan and Weinberg , 2011 </ce:cross-ref> ) , those in the tyrosine kinase @-@ Ras pathway stand out as the major drivers and have been the richest source of targets of successful cancer therapies ( Abl , epidermal growth factor receptor [EGFR], Her2/neu , B @-@ Raf , Kit , ALK , etc.).
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.2.1 3-1.2.1 4-1.2.1 5-1.2.1 6-1.2.1 7-1.2.1 8-1.2.1 9-1.2.1 10-1.1.2 11-1.1.1.2.1.3.1 13-1.1.1.2.1.4.2 16-1.1.1.2.1.4 17-1.1.1.2.1.4.1.r 18-1.1.1.2.1.4.1.1 19-1.1.1.2.1.4.1 21-1.1.1.2 21-1.1.1.2.1.5 23-1.1.1.2.1.5.1.1.1 24-1.1.1.2.1.5.1.1.1.1.r 25-1.1.1.2.1.5.1.1.1.1.1.1 26-1.1.1.2.1.5.1.1.1.1.1 28-1.1.1.2.1.5.1.1.1.1.2.1 29-1.1.1.2.1.5.1.1.1.1.2 31-1.1.1.2.1.5.1.1.1.1.3.1 32-1.1.1.2.1.5.1.1.1.1.3 34-1.1.1.2.1.5.1.1.1.1 36-1.1.1.2.1.5.1.1.1.1.4.1 37-1.1.1.2.1.5.1.1.1.1.4 38-1.1.1.2.1.5.1.1.1.1.4.2.r 39-1.1.1.2.1.5.1.1.1.1.4.2 44-1.1.1.2.2.1.1.1.1.1 45-1.1.1.2.2.1.1 46-1.1.1.2.2.1.1.2.1.1 48-1.1.1.2.2.1.2.1 55-1.1.1.1.1.1 56-1.1.1.1.1.2 58-1.1.1.1.1.2 59-1.1.1.1 60-1.1 61-1.1 62-1.1.2.1.1 64-1.1.2.1.2 66-1 66-1.2.2.1.2 67-1.2.2.1.1.2 70-1.2.3 70-1.2.3.1 70-1.2.3.1.r 71-1.2 72-1.2.2.r 73-1.2.2 73-1.2.2.1 73-1.2.2.1.r 74-1.2.2.1.1.r 75-1.2.2.1.1.2 76-1.2.2.1.1.1.1.1 77-1.2.2.1.1 79-1.2.2.1.2.1.1.1 81-1.2.2.1.2.2.1.1 82-1.2.2.1.2.2.1.2 83-1.2.2.1.2.2.1.3 84-1.2.2.1.2.2.1.4 86-1.2.2.1.2.3.1.1 88-1.2.2.1.2.4.1.1 90-1.2.2.1.2.4.1.1 92-1.2.2.1.2.5.1.1 94-1.2.2.1.2.6.1.1
# ::id pmid_2465_1010.15
# ::preferred 
(a / and~e.66
      :op1 (s / stand-out-06~e.60,61
            :ARG1 (p / protein
                  :location (p2 / pathway~e.59
                        :name (n / name :op1 "tyrosine"~e.55 :op2 "kinase-Ras"~e.56,58))
                  :ARG1-of (i / include-91~e.21
                        :ARG2 (p4 / protein
                              :ARG2-of (m2 / mutate-01)
                              :quant (m3 / multiple :op1 "100")
                              :ARG0-of (c2 / contribute-01
                                    :ARG2 d2~e.11
                                    :ARG1-of (k / know-01
                                          :time (n9 / now)))
                              :ARG1-of (i2 / identify-01~e.16
                                    :ARG0~e.17 (a3 / assay-00~e.19
                                          :mod (t4 / this~e.18))
                                    :mod (p5 / possible~e.13))
                              :ARG2-of (i3 / include-91~e.21
                                    :ARG1 (a4 / and
                                          :op1 (p6 / protein
                                                :ARG1-of (i4 / involve-01~e.23
                                                      :ARG2~e.24 (a5 / and~e.34
                                                            :op1 (r / repair-01~e.26
                                                                  :ARG1 (d3 / DNA~e.25))
                                                            :op2 (m4 / metabolism~e.29
                                                                  :mod (c3 / cell~e.28))
                                                            :op3 (s5 / splice-01~e.32
                                                                  :ARG1 (r2 / RNA~e.31))
                                                            :op4 (h / hallmark~e.37
                                                                  :mod (o / other~e.36)
                                                                  :mod~e.38 d2~e.39)))))))
                        :ARG1-of (d4 / describe-01
                              :ARG0 (p7 / publication-91
                                    :ARG0 (a6 / and~e.45
                                          :op1 (p8 / person
                                                :name (n10 / name :op1 "Hanahan"~e.44))
                                          :op2 (p9 / person
                                                :name (n11 / name :op1 "Weinberg"~e.46)))
                                    :time (d5 / date-entity :year "2011"~e.48)))))
            :ARG1-of (c / cause-01~e.10
                  :ARG0 (d / drive-02
                        :ARG0 p~e.62
                        :mod (m / major~e.64))))
      :op2 (s2 / source-02~e.71
            :ARG0 p~e.2,3,4,5,6,7,8,9
            :ARG1~e.72 (t / thing~e.73
                  :ARG1-of~e.73 (t2 / target-01~e.73
                        :ARG0~e.74 (t3 / therapy~e.77
                              :mod (d2 / disease
                                    :name (n2 / name :op1 "cancer"~e.76))
                              :ARG0-of (s3 / succeed-01~e.67,75))
                        :example (a2 / and~e.66
                              :op1 (e4 / enzyme
                                    :name (n3 / name :op1 "Abl"~e.79))
                              :op2 (e / enzyme
                                    :name (n4 / name
                                          :op1 "epidermal"~e.81
                                          :op2 "growth"~e.82
                                          :op3 "factor"~e.83
                                          :op4 "receptor"~e.84))
                              :op3 (p3 / protein
                                    :name (n5 / name :op1 "Her2/neu"~e.86))
                              :op4 (e2 / enzyme
                                    :name (n6 / name :op1 "B-Raf"~e.88,90))
                              :op5 (e5 / enzyme
                                    :name (n7 / name :op1 "Kit"~e.92))
                              :op6 (e6 / enzyme
                                    :name (n8 / name :op1 "ALK"~e.94))
                              :op7 (e3 / et-cetera))))
            :mod (r3 / rich~e.70
                  :degree~e.70 (m5 / most~e.70))))

# ::tok These successes can therefore be attributed to the central , dominant role of this pathway in cancer , as well as the fortuitous abundance of druggable targets .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1.1 1-1.1.1.1 2-1.1 2-1.1.1.2.2.3.1 3-1 4-1.1.1.r 5-1.1.1 8-1.1.1.2.1.4 10-1.1.1.2.1.3 13-1.1.1.2.1.1.1 14-1.1.1.2.1.1 16-1.1.1.2.1.2.1.1 20-1.1.1.2.r 22-1.1.1.2.2.2.1 23-1.1.1.2.2.2 26-1.1.1.2.2 26-1.1.1.2.2.1 26-1.1.1.2.2.1.r
# ::id pmid_2465_1010.16
# ::preferred 
(i / infer-01~e.3
      :ARG1 (p / possible~e.2
            :domain~e.4 (a / attribute-01~e.5
                  :ARG1 (s / succeed-01~e.1
                        :mod (t / this~e.0))
                  :ARG2~e.20 (a2 / and
                        :op1 (p2 / play-08
                              :ARG0 (p3 / pathway~e.14
                                    :mod t~e.13)
                              :ARG1 (d / disease
                                    :name (n / name :op1 "cancer"~e.16))
                              :ARG0-of (d2 / dominate-01~e.10)
                              :mod (c / central~e.8))
                        :op2 (t2 / thing~e.26
                              :ARG1-of~e.26 (t3 / target-01~e.26)
                              :mod (a3 / abundance~e.23
                                    :mod (f / fortuity~e.22))
                              :ARG1-of (d3 / drug-01
                                    :mod (p4 / possible~e.2)))))))

# ::tok However , specific therapies have not been developed for mutant Ras proteins themselves or for the cancers that they drive .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 2-1.1.2.1 3-1.1.2 5-1.1.1 5-1.1.1.r 7-1.1 8-1.1.3.r 9-1.1.3.1 9-1.1.3.1.2 9-1.1.3.1.2.r 10-1.1.3.1.1.1 13-1.1.3 16-1.1.3.2.1.1 18-1.1.3.2.2.1 19-1.1.3.2 19-1.1.3.2.2 19-1.1.3.2.2.r
# ::id pmid_2465_1010.17
# ::preferred 
(h / have-concession-91~e.0
      :ARG1 (d / develop-02~e.7
            :polarity~e.5 "-"~e.5
            :ARG1 (t / therapy~e.3
                  :mod (s / specific~e.2))
            :ARG3~e.8 (o / or~e.13
                  :op1 (e / enzyme~e.9
                        :name (n / name :op1 "Ras"~e.10)
                        :ARG2-of~e.9 (m / mutate-01~e.9))
                  :op2 (d2 / disease~e.19
                        :name (n2 / name :op1 "cancer"~e.16)
                        :ARG1-of~e.19 (d3 / drive-02~e.19
                              :ARG0 e~e.18)))))

# ::tok Worse yet , tumors driven by Ras genes are excluded from treatment with other targeted therapies .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 0-1.2 0-1.2.r 1-1.3 3-1.1.1 4-1.1.1.1 5-1.1.1.1.1.r 6-1.1.1.1.1.1.1 9-1.1 10-1.1.2.r 11-1.1.2 12-1.1.2.2.r 13-1.1.2.2.1 14-1.1.2.2.2 15-1.1.2.2
# ::id pmid_2465_1010.18
# ::preferred 
(b / bad-05~e.0
      :ARG1 (e / exclude-01~e.9
            :ARG1 (t / tumor~e.3
                  :ARG1-of (d / drive-01~e.4
                        :ARG0~e.5 (e2 / enzyme
                              :name (n / name :op1 "Ras"~e.6))))
            :ARG2~e.10 (t2 / treat-03~e.11
                  :ARG2 t
                  :ARG3~e.12 (t3 / therapy~e.15
                        :mod (o / other~e.13)
                        :ARG2-of (t4 / target-01~e.14))))
      :degree~e.0 (m / more~e.0)
      :mod (y / yet~e.1))

# ::tok Early efforts to block Ras cancers by preventing Ras farnesylation , once thought to be an essential posttranslational modification for Ras activity , were thwarted by the unexpected presence of a backup system ( geranylgeranyltransferase ) that restored activity of K @-@ Ras and N @-@ Ras after farnesyltransferase treatment .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.1 1-1.2 2-1.2.2.1 2-1.2.2.1.2 2-1.2.2.1.2.r 3-1.2.2 4-1.2.2.1.2.1.1.1 5-1.2.2.1.1.1 6-1.2.2.2.r 7-1.2.2.2 8-1.2.2.2.1.1 11-1.2.2.2.1.2.2 12-1.2.2.2.1.2 16-1.2.2.2.1.2.1.3 18-1.2.2.2.1.2.1 19-1.2.2.2.1.2.1.1.r 20-1.2.2.2.1.2.1.1.1 21-1.2.2.2.1.2.1.1 24-1 25-1.1.r 27-1.1.1.1 28-1.1 34-1.1.2.1.1 37-1.1.2.3 38-1.1.2.3.1 39-1.1.2.3.1.1.r 40-1.1.2.3.1.1.1.1.1 42-1.1.2.3.1.1.1.1.1 42-1.1.2.3.1.1.2.1.1 43-1.1.2.3.1.1 44-1.1.2.3.1.1.2.1.1 46-1.1.2.3.1.1.2.1.1 47-1.1.2.3.2 47-1.2.2.2.1.2.1.2 48-1.1.2.3.2.1.1.1.1 49-1.1.2.3.2.1
# ::id pmid_2465_1010.19
# ::preferred 
(t / thwart-01~e.24
      :ARG0~e.25 (p / present~e.28
            :ARG1-of (e / expect-01 :polarity "-"~e.27)
            :domain (e2 / enzyme
                  :name (n / name :op1 "geranylgeranyltransferase"~e.34)
                  :ARG0-of (b / back-04)
                  :ARG0-of (r / restore-01~e.37
                        :ARG1 (a / act-02~e.38
                              :ARG0~e.39 (a2 / and~e.43
                                    :op1 (e3 / enzyme
                                          :name (n2 / name :op1 "K-Ras"~e.40,42))
                                    :op2 (e4 / enzyme
                                          :name (n3 / name :op1 "N-Ras"~e.42,44,46))))
                        :time (a3 / after~e.47
                              :op1 (t2 / treat-04~e.49
                                    :ARG1 (e5 / enzyme
                                          :name (n4 / name :op1 "farnesyltransferase"~e.48)))))))
      :ARG1 (e6 / effort~e.1
            :mod (e7 / early~e.0)
            :purpose (b2 / block-01~e.3
                  :ARG1 (d / disease~e.2
                        :name (n5 / name :op1 "cancer"~e.5)
                        :ARG1-of~e.2 (c / cause-01~e.2
                              :ARG0 (e8 / enzyme
                                    :name (n6 / name :op1 "Ras"~e.4))))
                  :ARG3~e.6 (p2 / prevent-01~e.7
                        :ARG1 (f / farnesylate-00
                              :ARG1 e8~e.8
                              :ARG1-of (t3 / think-01~e.12
                                    :ARG2 (m / modify-01~e.18
                                          :ARG1~e.19 (a5 / act-02~e.21
                                                :ARG0 e8~e.20)
                                          :time (a4 / after~e.47
                                                :op1 (t4 / translate-01))
                                          :mod (e9 / essential~e.16))
                                    :time (o / once~e.11)))))))

# ::tok Likewise , efforts to kill Ras cancers by blocking one of Ras’ major downstream effectors , Raf kinase ( <ce:cross-ref id="crosref0060" refid="fig1"> Figure 1 </ce:cross-ref>@ <ce:float-anchor refid="fig1" /> ) , ran into the unexpected discovery that , in Ras @-@ transformed cells , Raf inhibitors activate the pathway rather than inhibit it ( see below and discussion in <ce:cross-ref id="crosref0065" refid="bib27"> Holderfield et al. , 2013 </ce:cross-ref> and <ce:cross-ref id="crosref0070" refid="bib39"> Lito et al. , 2013 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3 2-1.1 3-1.1.1.1.1 4-1.1.1 5-1.1.1.1.1.1.1.1 6-1.1.1.1 7-1.1.1.2.r 8-1.1.1.2 9-1.1.1.2.1.3.1.1 12-1.1.1.2.1.2.1.2 13-1.1.1.2.1.2.1.1 14-1.1.1.2.1.2.1 16-1.1.1.2.1.1.1 17-1.1.1.2.1 22-1.1.1.2.1.3.1 23-1.1.1.2.1.3.1.1 30-1 31-1.2.r 33-1.2.2.1 34-1.2 37-1.2.1.r 38-1.2.1.4.1.1 40-1.2.1.4.1 41-1.2.1.4 43-1.1.1.2.1.1.1 44-1.2.1.1 44-1.2.1.1.1 44-1.2.1.1.1.r 44-1.2.1.3.1 45-1.2.1 47-1.2.1.2 50-1.2.1.3.1 51-1.2.1.3.1.1 53-1.4 54-1.4.1 55-1.5.1 55-1.5.1.1.1 56-1.5 61-1.5.1.1.1.1.1.1 62-1.5.1.1.1 63-1.5.1.1.1.2.1 65-1.5.1.2.2 67-1.5.1 67-1.5.1.1.1 71-1.5.1.2.1.1.1 72-1.5.1 72-1.5.1.1.1 73-1.5.1.1.1.2.1 75-1.5.1.1.2.1
# ::id pmid_2465_1010.20
# ::preferred 
(r / run-07~e.30
      :ARG0 (e / effort~e.2
            :purpose (k / kill-01~e.4
                  :ARG1 (c / cancer~e.6
                        :ARG1-of (c2 / cause-01~e.3
                              :ARG0 (e2 / enzyme
                                    :name (n / name :op1 "Ras"~e.5))))
                  :ARG2~e.7 (b / block-01~e.8
                        :ARG1 (k2 / kinase~e.17
                              :name (n2 / name :op1 "Raf"~e.16,43)
                              :ARG1-of (i / include-91
                                    :ARG2 (e4 / effector~e.14
                                          :location (d2 / downstream~e.13)
                                          :mod (m / major~e.12)
                                          :poss e2))
                              :ARG1-of (d3 / describe-01
                                    :ARG0 (f / figure~e.22 :mod "1"~e.9,23))))))
      :ARG1~e.31 (d / discover-01~e.34
            :ARG1~e.37 (a / activate-01~e.45
                  :ARG0 (m2 / molecular-physical-entity~e.44
                        :ARG0-of~e.44 (i2 / inhibit-01~e.44
                              :ARG1 k2))
                  :ARG1 (p / pathway~e.47)
                  :ARG1-of (i3 / instead-of-91
                        :ARG2 (i4 / inhibit-01~e.44,50
                              :ARG1 p~e.51))
                  :location (c3 / cell~e.41
                        :ARG2-of (t / transform-01~e.40
                              :ARG0 e2~e.38)))
            :ARG1-of (e3 / expect-01 :polarity "-"~e.33))
      :manner (l / likewise~e.0)
      :ARG1-of (s / see-01~e.53
            :location (b2 / below~e.54))
      :ARG1-of (d4 / discuss-01~e.56
            :ARG0 (a2 / and~e.55,67,72
                  :op1 (p2 / publication-91
                        :ARG0 (a3 / and~e.55,62,67,72
                              :op1 (p4 / person
                                    :name (n4 / name :op1 "Holderfield"~e.61))
                              :op2 (p5 / person
                                    :mod (o / other~e.63,73)))
                        :time (d5 / date-entity :year "2013"~e.75))
                  :op2 (p3 / publication-91
                        :ARG0 (p6 / person
                              :name (n5 / name :op1 "Lito"~e.71))
                        :time d5~e.65))))

# ::tok MAP kinase kinase ( MEK ) inhibitors and phosphatidylinositol 3 @-@ kinase ( PI3K ) inhibitors have not yet shown significant clinical activity in Ras cancers , for reasons relating to feedback loops and poor therapeutic windows , among other issues discussed below .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.1.1.1.1.1.1 1-1.2.1.1.1.1.1.2 2-1.2.1.1.1.1.1.3 6-1.2.1.1 6-1.2.1.1.1 6-1.2.1.1.1.r 6-1.2.1.2 6-1.2.1.2.1 6-1.2.1.2.1.r 8-1.2.1.2.1.1.1.1 9-1.2.1.2.1.1.1.2 11-1.2.1.2.1.1.1.2 15-1.2.1.1 15-1.2.1.1.1 15-1.2.1.1.1.r 15-1.2.1.2 15-1.2.1.2.1 15-1.2.1.2.1.r 17-1.1 17-1.1.r 18-1.3 19-1 20-1.2.4 21-1.2.2 22-1.2 23-1.2.3.r 24-1.2.3.1.1.1.1 25-1.2.3 28-1.4.1 29-1.4.1.1 30-1.4.1.1.1.r 31-1.4.1.1.1.1.1 32-1.4.1.1.1.1 33-1.4.1.1.1 34-1.4.1.1.1.2.2 35-1.4.1.1.1.2.1 36-1.4.1.1.1.2 38-1.4.1.1.1.3 39-1.4.1.1.1.3.1.1 40-1.4.1.1.1.3.1 41-1.4.1.1.1.3.2 42-1.4.1.1.1.3.2.1
# ::id pmid_2465_1010.21
# ::preferred 
(s / show-01~e.19
      :polarity~e.17 "-"~e.17
      :ARG1 (a2 / act-02~e.22
            :ARG0 (a / and
                  :op1 (m / molecular-physical-entity~e.6,15
                        :ARG0-of~e.6,15 (i / inhibit-01~e.6,15
                              :ARG1 (p / protein
                                    :name (n / name
                                          :op1 "MAP"~e.0
                                          :op2 "kinase"~e.1
                                          :op3 "kinase"~e.2))))
                  :op2 (m2 / molecular-physical-entity~e.6,15
                        :ARG0-of~e.6,15 (i2 / inhibit-01~e.6,15
                              :ARG1 (e / enzyme
                                    :name (n2 / name :op1 "phosphatidylinositol"~e.8 :op2 "3-kinase"~e.9,11)))))
            :mod (c / clinic~e.21)
            :mod~e.23 (c2 / cancer~e.25
                  :ARG1-of (c3 / cause-01
                        :ARG0 (e2 / enzyme
                              :name (n3 / name :op1 "Ras"~e.24))))
            :ARG1-of (s2 / significant-02~e.20))
      :time (y / yet~e.18)
      :ARG1-of (c4 / cause-01
            :ARG0 (r / reason~e.28
                  :ARG1-of (r2 / relate-01~e.29
                        :ARG2~e.30 (a3 / and~e.33
                              :op1 (l / loop~e.32
                                    :mod (f / feedback~e.31))
                              :op2 (w / window~e.36
                                    :mod (t / therapy~e.35)
                                    :mod (p2 / poor~e.34))
                              :ARG1-of (i3 / include-91~e.38
                                    :ARG2 (i4 / issue~e.40
                                          :mod (o / other~e.39))
                                    :ARG1-of (d / discuss-01~e.41
                                          :location (b / below~e.42))))))))

# ::tok A convergence of urgent unmet clinical needs and advances in drug discovery has energized new efforts to target Ras cancers within academic centers and in the biopharmaceutical industry .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1 2-1.1.1.r 3-1.1.1.2 5-1.1.1.3 6-1.1.1 8-1.1.2 9-1.1.2.1.r 10-1.1.2.1.1 11-1.1.2.1 13-1 14-1.2.1 15-1.2 16-1.2.2.1.1 17-1.2.2 18-1.2.2.1.1.1.1.1 19-1.2.2.1 22-1.2.2.2.1 23-1.2.2.2 24-1.2.2.2.r 26-1.2.2.2.2.1 27-1.2.2.2.2
# ::id pmid_2465_1010.22
# ::preferred 
(e / energize-01~e.13
      :ARG0 (c / converge-01~e.1
            :ARG0~e.2 (n / need-01~e.6
                  :ARG1-of (m / meet-01 :polarity "-")
                  :mod (u / urgent~e.3)
                  :mod (c2 / clinical~e.5))
            :ARG1 (a / advance-01~e.8
                  :ARG1~e.9 (d / discover-01~e.11
                        :ARG1 (d2 / drug~e.10))))
      :ARG1 (e2 / effort~e.15
            :mod (n2 / new~e.14)
            :purpose (t / target-01~e.17
                  :ARG1 (c3 / cancer~e.19
                        :ARG1-of (c4 / cause-01~e.16
                              :ARG0 (e3 / enzyme
                                    :name (n3 / name :op1 "Ras"~e.18))))
                  :location~e.24 (a2 / and~e.23
                        :op1 (c5 / center~e.22
                              :mod (a3 / academy))
                        :op2 (i / industry~e.27
                              :mod (b / biopharmaceutical~e.26))))))

# ::tok To catalyze these renewed efforts , the National Cancer Institute recently launched a national Ras program at Frederick National Laboratory for Cancer ( see <ce:inter-ref> http : //webdefence.global.blackspider.com/urlwrap/?q=AXicY2Rn8FrCwHB9AQNDUU6 liXmKXnFRmV5 uYmZOcn5 eSVF @-@ jl5 yfi5DiaGJuaeHSY6Bgam5 mRFDUlJiSmJRYqlDcQpEPqOkpMBKXz8osdg5FagrMUcvvyidAQIA65QdsA&Z </ce:inter-ref> ) , whose goal is to fill critical knowledge gaps that are essential to target Ras cancers effectively and to engage the research community toward solving the Ras problem .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.3.1.1.1.2.1.1 1-1.4 2-1.4.2.2 3-1.4.2.1 4-1.4.2 7-1.1.1.1 8-1.1.1.2 9-1.1.1.3 10-1.3 11-1 13-1.2.1 14-1.2.2.1.1 15-1.2 16-1.5.r 17-1.5.1.1 18-1.5.1.2 19-1.5.1.3 20-1.5.1.4 21-1.5.1.5 23-1.6 25-1.6.1.1 41-1.2.3.1.1.1.2.1.1 42-1.2.3.1 43-1.2.3.1.1.2 44-1.2.3.1.1.1 45-1.2.3.1.1 48-1.2.3.1.1.1.1 49-1.2.3.1.1.1.2.1.1 50-1.2.3.1.1.1.2 51-1.2.3.1.1.1.2.1.1.1 52-1.2.3.1.1.1.2.1 53-1.2.3.1.1.1.2.2 53-1.2.3.1.1.1.2.2.r 55-1.2.3.1.1.1.2.1.1 56-1.2.3.2 58-1.2.3.2.1.1 59-1.2.3.2.1 61-1.2.3.2.2 63-1.2.3.2.2.2.1 64-1.2.3.2.2.2
# ::id pmid_2465_1010.23
# ::preferred 
(l / launch-01~e.11
      :ARG0 (r / research-institute
            :name (n / name
                  :op1 "National"~e.7
                  :op2 "Cancer"~e.8
                  :op3 "Institute"~e.9))
      :ARG1 (p / program~e.15
            :mod (n2 / nation~e.13)
            :topic (e2 / enzyme
                  :name (n3 / name :op1 "Ras"~e.14))
            :purpose (a / and
                  :op1 (f2 / fill-01~e.42
                        :ARG1 (g / gap~e.45
                              :topic (k / know-03~e.44
                                    :mod (e3 / essential~e.48)
                                    :purpose (t2 / target-01~e.50
                                          :ARG1 (c3 / cancer~e.52
                                                :ARG1-of (c4 / cause-01~e.0,41,49,55
                                                      :ARG0 e2~e.51))
                                          :manner~e.53 (e4 / effective~e.53)))
                              :mod (c2 / critical~e.43)))
                  :op2 (e5 / engage-01~e.56
                        :ARG1 (c5 / community~e.59
                              :ARG0-of (r4 / research-01~e.58))
                        :ARG2 (s / solve-01~e.61
                              :ARG0 c5
                              :ARG1 (p2 / problem~e.64
                                    :mod e2~e.63)))))
      :time (r2 / recent~e.10)
      :purpose (c / catalyze-01~e.1
            :ARG0 r
            :ARG1 (e / effort~e.4
                  :ARG1-of (r3 / renew-01~e.3)
                  :mod (t / this~e.2)))
      :location~e.16 (f / facility
            :name (n4 / name
                  :op1 "Frederick"~e.17
                  :op2 "National"~e.18
                  :op3 "Laboratory"~e.19
                  :op4 "for"~e.20
                  :op5 "Cancer"~e.21))
      :ARG1-of (s2 / see-01~e.23
            :medium (u / url-entity :value "http://RasCentral.org"~e.25)))

# ::tok Here , we will discuss some of these knowledge gaps , as well as recent advances and the challenges that lie ahead .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3 2-1.1 4-1 6-1.2.r 7-1.2.1.1.1.2 8-1.2.1.1.1.1 9-1.2.1 9-1.2.1.1.1 11-1.2.2.1.r 13-1.2.2.1.r 14-1.2.2.1 15-1.2.2 16-1.2 18-1.2.3 20-1.2.3.1 21-1.2.3.1.1
# ::id pmid_2465_1010.24
# ::preferred 
(d / discuss-01~e.4
      :ARG0 (w / we~e.2)
      :ARG1~e.6 (a / and~e.16
            :op1 (g / gap~e.9
                  :ARG1-of (i / include-91
                        :ARG2 (g2 / gap~e.9
                              :topic (k / know-03~e.8)
                              :mod (t / this~e.7))))
            :op2 (a2 / advance-01~e.15
                  :time~e.11,13 (r / recent~e.14))
            :op3 (c / challenge-01~e.18
                  :ARG1-of (l / lie-01~e.20
                        :ARG2 (a3 / ahead~e.21))))
      :medium (h / here~e.0))

# ::tok Ras Mutations in Cancer
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 1-1 2-1.2.r 3-1.2
# ::id pmid_2465_1010.25
# ::preferred 
(m / mutate-01~e.1
      :ARG2 (e / enzyme
            :name (n / name :op1 "Ras"~e.0))
      :location~e.2 (c / cancer~e.3))

# ::tok Ras genes were the first oncogenes identified in human cancer cells .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3.1.1 1-1.3 2-1.3.r 4-1.2 4-1.2.1 4-1.2.1.r 5-1 6-1.1 7-1.1.1.r 8-1.1.1.2 9-1.1.1.1 10-1.1.1
# ::id pmid_2465_1010.26
# ::preferred 
(o / oncogene~e.5
      :ARG1-of (i / identify-01~e.6
            :location~e.7 (c / cell~e.10
                  :mod (c2 / cancer~e.9)
                  :part-of (h / human~e.8)))
      :ord (o2 / ordinal-entity~e.4 :value~e.4 "1"~e.4)
      :domain~e.2 (g / gene~e.1
            :name (n / name :op1 "Ras"~e.0)))

# ::tok In a series of classic experiments , the groups of Weinberg , Cooper , Barbacid , and Wigler independently identified the transforming genes from T24 @/@ EJ bladder carcinoma cells as H @-@ Ras ( <ce:cross-refs id="crosrefs0015" refid="bib15 bib50 bib58 bib69"> Der et al. , 1982; Parada et al. , 1982; Santos et al. , 1982; Taparowsky et al. , 1982 </ce:cross-refs> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.4 3-1.4.1.r 4-1.4.1.1 5-1.4.1 8-1.1.1 8-1.1.2 8-1.1.3 8-1.1.4 10-1.1.1.1.1.1.1 12-1.1.2.1.1.1.1 14-1.1.3.1.1.1.1 16-1.1 17-1.1.4.1.1.1.1 18-1.5.1 19-1 21-1.2.1 22-1.2 23-1.2.2.r 24-1.2.2.1.1 26-1.2.2.1.1 27-1.2.2.2.1 28-1.2.2.2 29-1.2.2 30-1.3.r 30-1.6.1.2.2.r 30-1.6.1.3.2.r 30-1.6.1.4.2.r 31-1.3.1.1 33-1.3.1.1 41-1.6.1.1.1.1.1.1 42-1.6.1.1.1 43-1.6.1.1.1.2.1 46-1.6.1.2.1.1.1.1 47-1.6.1 47-1.6.1.1.1 47-1.6.1.2.1 47-1.6.1.3.1 47-1.6.1.4.1 48-1.6.1.3.1.2 51-1.6.1.3.1.1.1.1 52-1.6.1 52-1.6.1.1.1 52-1.6.1.2.1 52-1.6.1.3.1 52-1.6.1.4.1 53-1.6.1.4.1.2 56-1.6.1.4.1.1.1.1 57-1.6.1 57-1.6.1.1.1 57-1.6.1.2.1 57-1.6.1.3.1 57-1.6.1.4.1 58-1.6.1.1.1.2.1 60-1.6.1.1.2.1
# ::id pmid_2465_1010.27
# ::preferred 
(i / identify-01~e.19
      :ARG0 (a / and~e.16
            :op1 (g / group~e.8
                  :ARG1-of (l / lead-02
                        :ARG0 (p / person
                              :name (n / name :op1 "Weinberg"~e.10))))
            :op2 (g2 / group~e.8
                  :ARG1-of (l2 / lead-02
                        :ARG0 (p2 / person
                              :name (n2 / name :op1 "Cooper"~e.12))))
            :op3 (g3 / group~e.8
                  :ARG1-of (l3 / lead-02
                        :ARG0 (p3 / person
                              :name (n3 / name :op1 "Barbacid"~e.14))))
            :op4 (g4 / group~e.8
                  :ARG1-of (l4 / lead-02
                        :ARG0 (p4 / person
                              :name (n4 / name :op1 "Wigler"~e.17)))))
      :ARG1 (g5 / gene~e.22
            :ARG0-of (t / transform-01~e.21)
            :part-of~e.23 (c2 / cell-line~e.29
                  :name (n5 / name :op1 "T24/EJ"~e.24,26)
                  :mod (c3 / carcinoma~e.28
                        :mod (b / bladder~e.27))))
      :ARG2~e.30 (e2 / enzyme
            :name (n6 / name :op1 "H-Ras"~e.31,33))
      :manner (s / series~e.2
            :consist-of~e.3 (e / experiment-01~e.5
                  :mod (c / classic~e.4)))
      :ARG0-of (d3 / depend-01 :polarity "-"~e.18)
      :ARG1-of (d / describe-01
            :ARG0 (a2 / and~e.47,52,57
                  :op1 (p5 / publication-91
                        :ARG0 (a3 / and~e.42,47,52,57
                              :op1 (p9 / person
                                    :name (n7 / name :op1 "Der"~e.41))
                              :op2 (p10 / person
                                    :mod (o / other~e.43,58)))
                        :time (d2 / date-entity :year "1982"~e.60))
                  :op2 (p6 / publication-91
                        :ARG0 (a4 / and~e.47,52,57
                              :op1 (p11 / person
                                    :name (n8 / name :op1 "Parada"~e.46))
                              :op2 p10)
                        :time~e.30 d2)
                  :op3 (p7 / publication-91
                        :ARG0 (a5 / and~e.47,52,57
                              :op1 (p12 / person
                                    :name (n9 / name :op1 "Santos"~e.51))
                              :op2 p10~e.48)
                        :time~e.30 d2)
                  :op4 (p8 / publication-91
                        :ARG0 (a6 / and~e.47,52,57
                              :op1 (p13 / person
                                    :name (n10 / name :op1 "Taparowsky"~e.56))
                              :op2 p10~e.53)
                        :time~e.30 d2))))

# ::tok More than 30 years later , Ras genes are well established as the most frequently mutated oncogenes in human cancer ( <ce:cross-ref id="crosref0075" refid="tbl1"> Table 1 </ce:cross-ref>@ <ce:float-anchor refid="tbl1" /> ) , though H @-@ Ras itself is rarely one of them .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.4.1 1-1.4.1 2-1.4.1.1.1 3-1.4.1.1.2 4-1.4 6-1.1.1.1 7-1.1 7-1.5.1.1 9-1.3 10-1 11-1.2.r 11-1.4.r 13-1.2.1.1.1 14-1.2.1.1 15-1.2.1 16-1.2 17-1.2.2.r 18-1.2.2.1 19-1.2.2 24-1.6.1 25-1.6.1.1 32-1.5 33-1.5.1.1.1.1 35-1.5.1.1.1.1 38-1.5.1.3 39-1.6.1.1
# ::id pmid_2465_1010.28
# ::preferred 
(e3 / establish-01~e.10
      :ARG1 (g / gene~e.7
            :name (n / name :op1 "Ras"~e.6))
      :ARG2~e.11 (o / oncogene~e.16
            :ARG1-of (m2 / mutate-01~e.15
                  :frequency (f / frequent~e.14
                        :degree (m3 / most~e.13)))
            :location~e.17 (c / cancer~e.19
                  :mod (h / human~e.18)))
      :mod (w / well~e.9)
      :time~e.11 (l / late~e.4
            :op1 (m / more-than~e.0,1
                  :op1 (t / temporal-quantity
                        :quant "30"~e.2
                        :unit (y / year~e.3))))
      :ARG1-of (h2 / have-concession-91~e.32
            :ARG2 (i / include-91
                  :ARG1 (g2 / gene~e.7
                        :name (n2 / name :op1 "H-Ras"~e.33,35))
                  :ARG2 g
                  :frequency (r / rare~e.38)))
      :ARG1-of (d / describe-01
            :ARG0 (t2 / table~e.24 :mod "1"~e.25,39)))

# ::tok Although these numbers are , by now , painfully familiar , they underscore major gaps in our knowledge of Ras biology .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3.r 1-1.1.1 2-1.1 5-1.3.3 6-1.3.3 8-1.3.2 9-1.3 11-1.3.1 12-1 13-1.2.1 14-1.2 15-1.2.2.r 16-1.2.2.1 16-1.2.2.1.r 17-1.2.2 18-1.2.2.2.r 19-1.2.2.2.1.1.1 20-1.2.2.2
# ::id pmid_2465_1010.29
# ::preferred 
(u / underscore-01~e.12
      :ARG0 (n2 / number~e.2
            :mod (t / this~e.1))
      :ARG1 (g / gap~e.14
            :mod (m / major~e.13)
            :topic~e.15 (k / know-03~e.17
                  :ARG0~e.16 (w / we~e.16)
                  :ARG1~e.18 (b / biology~e.20
                        :mod (e2 / enzyme
                              :name (n3 / name :op1 "Ras"~e.19)))))
      :concession~e.0 (f / familiarize-01~e.9
            :ARG1 n2~e.11
            :degree (p / pain-01~e.8)
            :time (b2 / by-now~e.5,6)))

# ::tok Most obviously , we do not understand why K @-@ Ras mutation is much more frequent in human cancer than N @-@ Ras or H @-@ Ras , even though each of these is a powerful transforming gene in model systems , and all forms are expressed widely in adult tissues and in tumors .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.4.1 1-1.4 3-1.2 5-1.1 5-1.1.r 6-1 7-1.3 7-1.3.1 7-1.3.1.r 8-1.3.1.1.2.1.1.1 10-1.3.1.1.2.1.1.1 11-1.3.1.1.2 11-1.3.1.1.4.1 11-1.3.1.1.4.2 12-1.3.1.1.2.r 13-1.3.1.1.1.1 14-1.3.1.1.1 15-1.3.1.1 16-1.3.1.1.3.r 17-1.3.1.1.3.3 18-1.3.1.1.3.2.1 19-1.3.1.1.4.r 20-1.3.1.1.4.1.1.1.1 22-1.3.1.1.4.1.1.1.1 22-1.3.1.1.4.2.1.1.1 23-1.3.1.1.4 24-1.3.1.1.4.2.1.1.1 26-1.3.1.1.4.2.1.1.1 28-1.5.r 29-1.5.r 33-1.5.1.1.r 35-1.5.1.4 36-1.5.1.2 37-1.5.1 38-1.5.1.3.r 39-1.5.1.3.1 40-1.5.1.3 42-1.5 42-1.5.1.1 43-1.5.2.1.1 44-1.5.2.1 46-1.5.2 47-1.5.2.3 47-1.5.2.3.r 48-1.5.2.2.r 49-1.5.2.2.1.1 50-1.5.2.2.1 51-1.5.2.2 53-1.5.2.2.2
# ::id pmid_2465_1010.30
# ::preferred 
(u2 / understand-01~e.6
      :polarity~e.5 "-"~e.5
      :ARG0 (w / we~e.3)
      :ARG1 (t / thing~e.7
            :ARG0-of~e.7 (c / cause-01~e.7
                  :ARG1 (f / frequent~e.15
                        :degree (m / more~e.14
                              :quant (m2 / much~e.13))
                        :domain~e.12 (m3 / mutate-01~e.11
                              :ARG1 (e3 / enzyme
                                    :name (n4 / name :op1 "K-Ras"~e.8,10)))
                        :location~e.16 (d / disease
                              :wiki "Cancer"
                              :name (n2 / name :op1 "cancer"~e.18)
                              :mod (h / human~e.17))
                        :compared-to~e.19 (o3 / or~e.23
                              :op1 (m5 / mutate-01~e.11
                                    :ARG1 (e4 / enzyme
                                          :name (n5 / name :op1 "N-Ras"~e.20,22)))
                              :op2 (m7 / mutate-01~e.11
                                    :ARG1 (e5 / enzyme
                                          :name (n6 / name :op1 "H-Ras"~e.22,24,26)))))))
      :mod (o2 / obvious~e.1
            :degree (m4 / most~e.0))
      :concession~e.28,29 (a2 / and~e.42
            :op1 (g / gene~e.37
                  :domain~e.33 (a / and~e.42
                        :op1 e3
                        :op2 e4
                        :op3 e5)
                  :ARG0-of (t2 / transform-01~e.36)
                  :location~e.38 (s / system~e.40
                        :mod (m6 / model~e.39))
                  :mod (p / powerful~e.35))
            :op2 (e / express-03~e.46
                  :ARG1 (f2 / form~e.44
                        :mod (a3 / all~e.43))
                  :ARG3~e.48 (a4 / and~e.51
                        :op1 (t3 / tissue~e.50
                              :mod (a5 / adult~e.49))
                        :op2 (t4 / tumor~e.53))
                  :manner~e.47 (w2 / wide~e.47))))

# ::tok A simple explanation for the high frequency of K @-@ Ras mutations , relative to H @-@ Ras and N @-@ Ras , is that the K @-@ Ras protein has unique properties that favor oncogenesis .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3 2-1 3-1.2.r 5-1.2.2 6-1.2 7-1.1.r 8-1.1.2.1.1 10-1.1.2.1.1 10-1.2.3.1.1.1.1 11-1.2.1 11-1.2.3.1 11-1.2.3.2 14-1.2.3.1.1.r 14-1.2.3.r 15-1.2.3.1.1.1.1 17-1.2.3.1.1.1.1 17-1.2.3.2.1.1.1 18-1.2.3 19-1.2.3.2.1.1.1 21-1.2.3.2.1.1.1 23-1.2.1.r 26-1.1.2.1.1 28-1.1.2.1.1 31-1.1.1 32-1.1 34-1.1.3
# ::id pmid_2465_1010.31
# ::preferred 
(e3 / explain-01~e.2
      :ARG0~e.7 (p / property~e.32
            :mod (u / unique~e.31)
            :poss (e / enzyme
                  :name (n / name :op1 "K-Ras"~e.8,10,26,28))
            :ARG0-of (f / favor-01~e.34
                  :ARG1 (g / genesis
                        :mod (c / cancer))))
      :ARG1~e.3 (f2 / frequent~e.6
            :domain~e.23 (m / mutate-01~e.11
                  :ARG1 e)
            :degree (h / high~e.5)
            :compared-to~e.14 (a2 / and~e.18
                  :op1 (m2 / mutate-01~e.11
                        :ARG1~e.14 (e2 / enzyme
                              :name (n2 / name :op1 "H-Ras"~e.10,15,17)))
                  :op2 (m3 / mutate-01~e.11
                        :ARG1 (e4 / enzyme
                              :name (n3 / name :op1 "N-Ras"~e.17,19,21)))))
      :mod (s / simple~e.1))

# ::tok At first sight , this seems unlikely because the Ras proteins are highly conserved , especially in their effector @-@ binding regions where they are actually identical .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3.1 1-1.3.1.1 1-1.3.1.1.r 4-1.1.2.1 5-1 6-1.1 6-1.1.1 6-1.1.1.r 7-1.2 9-1.2.1.1.1.1 10-1.2.1.3 12-1.2.1.2 13-1.2.1 15-1.2.1.3.4 16-1.2.1.3.2.r 17-1.2.1.3.2 18-1.2.1.3.1.1 20-1.2.1.3.1 22-1.2.1.3.r 25-1.2.1.3.3.1 26-1.2.1.3.3
# ::id pmid_2465_1010.32
# ::preferred 
(s / seem-01~e.5
      :ARG1 (l / likely~e.6
            :polarity~e.6 "-"~e.6
            :domain (t / thing
                  :mod (t2 / this~e.4)))
      :ARG1-of (c / cause-01~e.7
            :ARG0 (c2 / conserve-01~e.13
                  :ARG1 (e2 / enzyme
                        :name (n2 / name :op1 "Ras"~e.9))
                  :degree (h / high~e.12)
                  :location~e.22 (p / protein-segment~e.10
                        :ARG1-of (b / bind-01~e.20
                              :ARG2 (e / effector~e.18))
                        :part-of~e.16 e2~e.17
                        :mod (i / identical~e.26
                              :mod (a2 / actual~e.25))
                        :degree (e4 / especially~e.15))))
      :time (s2 / see-01
            :ord (o / ordinal-entity~e.1 :value~e.1 "1"~e.1)))

# ::tok However , K @-@ Ras , but not N @-@ Ras or H @-@ Ras , confers stem @-@ like properties on certain cell types ( <ce:cross-ref id="crosref0080" refid="bib54"> Quinlan and Settleman , 2009 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.4 2-1.1.1.1.1 4-1.1.1.1.1 6-1 6-1.1.4 7-1.1.4.1.1 7-1.1.4.1.1.r 8-1.1.4.1.2.1.1.1 10-1.1.4.1.2.1.1.1 10-1.1.4.1.2.2.1.1 11-1.1.4.1.2 12-1.1.4.1.2.2.1.1 14-1.1.1.1.1 14-1.1.4.1.2.2.1.1 16-1.1 16-1.1.4.1 17-1.1.2.1.1.1.1 19-1.1.2.1 20-1.1.2 20-1.1.2.1.1 21-1.1.3.r 22-1.1.3.2 23-1.1.2.1.1.1 23-1.1.3.1 24-1.1.3 29-1.1.5.1.1.1.1.1 30-1.1.5.1.1 31-1.1.5.1.1.2.1.1 33-1.1.5.1.2.1
# ::id pmid_2465_1010.33
# ::preferred 
(c4 / contrast-01~e.6
      :ARG2 (c / confer-02~e.16
            :ARG0 (e / enzyme
                  :name (n / name :op1 "K-Ras"~e.2,4,14))
            :ARG1 (p / property~e.20
                  :ARG1-of (r / resemble-01~e.19
                        :ARG2 (p5 / property~e.20
                              :poss (c5 / cell~e.23
                                    :mod (s / stem~e.17)))))
            :ARG2~e.21 (t / type~e.24
                  :mod (c2 / cell~e.23)
                  :mod (c3 / certain~e.22))
            :ARG1-of (c6 / contrast-01~e.0,6
                  :ARG0 (c7 / confer-02~e.16
                        :polarity~e.7 "-"~e.7
                        :ARG0 (o / or~e.11
                              :op1 (e3 / enzyme
                                    :name (n3 / name :op1 "N-Ras"~e.8,10))
                              :op2 (e2 / enzyme
                                    :name (n2 / name :op1 "H-Ras"~e.10,12,14)))
                        :ARG1 p
                        :ARG2 t))
            :ARG1-of (d2 / describe-01
                  :ARG0 (p2 / publication-91
                        :ARG0 (a / and~e.30
                              :op1 (p3 / person
                                    :name (n4 / name :op1 "Quinlan"~e.29))
                              :op2 (p4 / person
                                    :name (n5 / name :op1 "Settleman"~e.31)))
                        :time (d / date-entity :year "2009"~e.33)))))

# ::tok K @-@ Ras @-@ 4B , the most highly expressed splice variant of K @-@ Ras , binds calmodulin ; H @-@ Ras and N @- Ras do not ( <ce:cross-ref id="crosref0085" refid="bib74"> Villalonga et al. , 2001 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1.1 2-1.1.1.1.1 2-1.1.1.2.2.1.1.1.1 4-1.1.1.1.1 7-1.1.1.2.1.1.1 8-1.1.1.2.1.1 9-1.1.1.2.1 10-1.1.1.2.2.1 11-1.1.1.2 13-1.1.1.1.1 15-1.2.2.1.1.1 17-1.1 17-1.2 18-1.1.2.1.1 18-1.2.3.1.1 20-1.2.2.1.1.1 22-1.2.2.1.1.1 22-1.2.2.2.1.1 23-1.2.2 24-1.2.2.2.1.1 26-1.2.2.2.1.1 28-1.2.1 28-1.2.1.r 33-1.3.1.1.1.1.1 34-1.3.1.1 35-1.3.1.1.2.1 37-1.3.1.2.1
# ::id pmid_2465_1010.34
# ::preferred 
(m / multi-sentence
      :snt1 (b / bind-01~e.17
            :ARG1 (e / enzyme
                  :name (n / name :op1 "K-Ras-4B"~e.0,2,4,13)
                  :mod (v2 / variant~e.11
                        :ARG1-of (e5 / express-03~e.9
                              :degree (h / high~e.8
                                    :degree (m2 / most~e.7))
                              :compared-to (r / result-01
                                    :ARG1 (s / splice-01~e.10
                                          :ARG1 (e4 / enzyme
                                                :name (n4 / name :op1 "K-Ras"~e.2)))))
                        :ARG2-of r))
            :ARG2 (p / protein
                  :name (n5 / name :op1 "calmodulin"~e.18)))
      :snt2 (b2 / bind-01~e.17
            :polarity~e.28 "-"~e.28
            :ARG1 (a / and~e.23
                  :op1 (e2 / enzyme
                        :name (n2 / name :op1 "H-Ras"~e.15,20,22))
                  :op2 (e3 / enzyme
                        :name (n3 / name :op1 "N-Ras"~e.22,24,26)))
            :ARG2 (p5 / protein
                  :name (n7 / name :op1 "calmodulin"~e.18)))
      :ARG1-of (d2 / describe-01
            :ARG0 (p2 / publication-91
                  :ARG0 (a2 / and~e.34
                        :op1 (p3 / person
                              :name (n6 / name :op1 "Villalonga"~e.33))
                        :op2 (p4 / person
                              :mod (o / other~e.35)))
                  :time (d / date-entity :year "2001"~e.37))))

# ::tok We believe that this unique property of K @-@ Ras @-@ 4B confers stem @-@ like properties to cells expressing oncogenic K @-@ Ras @-@ 4B proteins ( M . Wang and F.M . , unpublished data ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1 2-1.2.r 3-1.2.1.1 4-1.2.1.2 5-1.2.1 6-1.2.1.3.r 7-1.2.1.3.1.1 9-1.2.1.3.1.1 11-1.2.1.3.1.1 12-1.2 13-1.2.2.1.1.1.1 15-1.2.2.1 16-1.2.2 16-1.2.2.1.1 18-1.2.2.1.1.1 18-1.2.3 19-1.2.3.1 20-1.2.3.1.1 20-1.2.3.1.1.2 20-1.2.3.1.1.2.1 20-1.2.3.1.1.2.1.r 20-1.2.3.1.1.2.r 21-1.2.1.3.1.1 21-1.2.3.1.1.1.1 23-1.2.1.3.1.1 23-1.2.3.1.1.1.1 25-1.2.1.3.1.1 25-1.2.3.1.1.1.1 30-1.3.1.1.2.1.1.2 31-1.3.1.1.2 35-1.3.1.1.1 36-1.3.1
# ::id pmid_2465_1010.35
# ::preferred 
(b / believe-01~e.1
      :ARG0 (w / we~e.0)
      :ARG1~e.2 (c / confer-02~e.12
            :ARG0 (p / property~e.5
                  :mod (t / this~e.3)
                  :mod (u / unique~e.4)
                  :poss~e.6 (e / enzyme
                        :name (n / name :op1 "K-Ras-4B"~e.7,9,11,21,23,25)))
            :ARG1 (p2 / property~e.16
                  :ARG1-of (r / resemble-01~e.15
                        :ARG2 (p6 / property~e.16
                              :poss (c5 / cell~e.18
                                    :mod (s / stem~e.13)))))
            :ARG2 (c2 / cell~e.18
                  :ARG3-of (e2 / express-03~e.19
                        :ARG2 (e3 / enzyme~e.20
                              :name (n2 / name :op1 "K-Ras-4B"~e.21,23,25)
                              :ARG0-of~e.20 (c3 / cause-01~e.20
                                    :ARG1~e.20 (c4 / cancer~e.20))))))
      :ARG1-of (d / describe-01
            :ARG0 (d2 / data~e.36
                  :ARG1-of (p3 / publish-01
                        :polarity "-"~e.35
                        :ARG0 (a / and~e.31
                              :op1 (p4 / person
                                    :name (n3 / name :op1 "M." :op2 "Wang"~e.30))
                              :op2 (p5 / person
                                    :name (n4 / name :op1 "F.M.")))))))

# ::tok Analysis of human syndromes caused by germline mutations in H @-@ Ras or K @-@ Ras supports the idea that K @-@ Ras is a stronger oncogene .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1.1.1.r 2-1.1.1.1 3-1.1.1 4-1.1.1.2 5-1.1.1.2.1.r 6-1.1.1.2.1.1 7-1.1.1.2.1 8-1.1.1.2.1.2.r 9-1.1.1.2.1.2.1.1.1 11-1.1.1.2.1.2.1.1.1 11-1.1.1.2.1.2.2.1.1 12-1.1.1.2.1.2 13-1.1.1.2.1.2.2.1.1 15-1.1.1.2.1.2.1.1.1 15-1.1.1.2.1.2.2.1.1 16-1 18-1.2 20-1.1.1.2.1.2.2.1.1 22-1.1.1.2.1.2.1.1.1 22-1.1.1.2.1.2.2.1.1 23-1.2.1.1.r 25-1.2.1.3 25-1.2.1.3.1 25-1.2.1.3.1.r 26-1.2.1
# ::id pmid_2465_1010.36
# ::preferred 
(s / support-01~e.16
      :ARG0 (a / analyze-01~e.0
            :ARG1~e.1 (s2 / syndrome~e.3
                  :mod (h / human~e.2)
                  :ARG1-of (c / cause-01~e.4
                        :ARG0~e.5 (m / mutate-01~e.7
                              :ARG1 (g / germline~e.6)
                              :location~e.8 (o / or~e.12
                                    :op1 (e / enzyme
                                          :name (n / name :op1 "H-Ras"~e.9,11,15,22))
                                    :op2 (e2 / enzyme
                                          :name (n2 / name :op1 "K-Ras"~e.11,13,15,20,22)))))))
      :ARG1 (i / idea~e.18
            :mod (o2 / oncogene~e.26
                  :domain~e.23 e2
                  :compared-to e
                  :mod (s3 / strong~e.25
                        :degree~e.25 (m2 / more~e.25)))))

# ::tok Unexpectedly , humans can tolerate germline @-@ activating mutations in H @-@ Ras—the same activating mutations that drive somatic mutations .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.1 2-1.1.1 3-1 4-1.1 5-1.1.2.1.1 7-1.1.2.1 8-1.1.2 9-1.1.2.2.r 10-1.1.2.2.1.1 13-1.1.2.3 14-1.1.2.3.1.2 15-1.1.2.3.1 17-1.1.2.3.1.1 18-1.1.2.3.1.1.1.1 19-1.1.2.3.1.1.1
# ::id pmid_2465_1010.37
# ::preferred 
(p / possible~e.3
      :domain (t / tolerate-01~e.4
            :ARG0 (h / human~e.2)
            :ARG1 (m / mutate-01~e.8
                  :ARG0-of (a / activate-01~e.7
                        :ARG1 (g / germline~e.5))
                  :location~e.9 (e / enzyme
                        :name (n / name :op1 "H-Ras"~e.10))
                  :ARG1-of (s2 / same-01~e.13
                        :ARG2 (m2 / mutate-01~e.15
                              :ARG0 (d / drive-02~e.17
                                    :ARG1 (m3 / mutate-01~e.19
                                          :mod (s / somatic~e.18)))
                              :ARG0-of (a2 / activate-01~e.14)))))
      :ARG1-of (e2 / expect-01 :polarity "-"~e.0))

# ::tok Costello syndrome , which is characterized by germline H @-@ Ras mutations , is associated with a broad spectrum of developmental abnormalities and a high risk for rhabdomyosarcomas and neuroblastomas ( reviewed in <ce:cross-ref id="crosref0090" refid="bib55"> Rauen , 2013 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 1-1.1.1.2 5-1.1.2 6-1.1.2.1.r 7-1.1.2.1.2.1.1 8-1.1.2.1.1.1.1 10-1.1.2.1.1.1.1 11-1.1.2.1 14-1 15-1.2.r 17-1.2.1.1.1 18-1.2.1.1 19-1.2.1.1.r 20-1.2.1.2 21-1.2.1 22-1.2 24-1.2.2.2 25-1.2.2 26-1.2.2.1.r 27-1.2.2.1.1.1.1 28-1.2.2.1 29-1.2.2.1.2.1.1 31-1.3 36-1.3.1.1.1.1 38-1.3.1.2.1
# ::id pmid_2465_1010.38
# ::preferred 
(a / associate-01~e.14
      :ARG1 (d2 / disease
            :name (n2 / name :op1 "Costello"~e.0 :op2 "syndrome"~e.1)
            :ARG1-of (c / characterize-01~e.5
                  :ARG2~e.6 (m / mutate-01~e.11
                        :ARG1 (e / enzyme
                              :name (n / name :op1 "H-Ras"~e.8,10))
                        :location (g2 / germline
                              :name (n6 / name :op1 "germline"~e.7)))))
      :ARG2~e.15 (a3 / and~e.22
            :op1 (a2 / abnormality~e.21
                  :quant~e.19 (s / spectrum~e.18
                        :mod (b / broad~e.17))
                  :mod (g / growth~e.20))
            :op2 (r / risk-01~e.25
                  :ARG2~e.26 (a4 / and~e.28
                        :op1 (d3 / disease
                              :name (n3 / name :op1 "rhabdomyosarcomas"~e.27))
                        :op2 (d4 / disease
                              :name (n4 / name :op1 "neuroblastomas"~e.29)))
                  :mod (h / high~e.24)))
      :ARG1-of (r2 / review-01~e.31
            :ARG0 (p2 / publication-91
                  :ARG0 (p3 / person
                        :name (n5 / name :op1 "Rauen"~e.36))
                  :time (d / date-entity :year "2013"~e.38))))

# ::tok It is puzzling that these individuals do not succumb to malignancies associated with sporadic H @-@ Ras mutations ( <ce:cross-ref id="crosref0095" refid="tbl1"> Table 1 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1 4-1.1.2.1 5-1.1.2 7-1.1.1 7-1.1.1.r 8-1.1 9-1.1.3.r 10-1.1.3 11-1.1.3.1 12-1.1.3.1.1.r 13-1.1.3.1.1.2 14-1.1.3.1.1.1.1.1 16-1.1.3.1.1.1.1.1 17-1.1.3.1.1 22-1.2.1 23-1.2.1.1
# ::id pmid_2465_1010.39
# ::preferred 
(p / puzzle-01~e.2
      :ARG0 (s / succumb-01~e.8
            :polarity~e.7 "-"~e.7
            :ARG0 (i / individual~e.5
                  :mod (t / this~e.4))
            :ARG1~e.9 (m / malignancy~e.10
                  :ARG1-of (a / associate-01~e.11
                        :ARG2~e.12 (m2 / mutate-01~e.17
                              :ARG1 (e / enzyme
                                    :name (n / name :op1 "H-Ras"~e.14,16))
                              :time (s2 / sporadic~e.13)))))
      :ARG1-of (d / describe-01
            :ARG0 (t2 / table~e.22 :mod "1"~e.23)))

# ::tok Although fully activating alleles of H @-@ Ras can be tolerated , fully activated alleles of K @-@ Ras may not .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3.r 1-1.2.1.1.1 2-1.2.1.1 3-1.2.1 5-1.3.1.1.2.1.1 7-1.2.1.2.1.1 7-1.3.1.1.2.1.1 8-1 8-1.3 9-1.2.r 9-1.3.1.r 10-1.2 10-1.3.1 12-1.2.1.1.1 13-1.2.1.1 13-1.3.1.1.1 14-1.2.1 14-1.3.1.1 15-1.2.1.2.r 16-1.2.1.2.1.1 18-1.2.1.2.1.1 18-1.3.1.1.2.1.1 19-1 20-1.1 20-1.1.r
# ::id pmid_2465_1010.40
# ::preferred 
(p / possible~e.8,19
      :polarity~e.20 "-"~e.20
      :domain~e.9 (t / tolerate-01~e.10
            :ARG1 (a / allele~e.3,14
                  :ARG1-of (a2 / activate-01~e.2,13
                        :manner (f / full~e.1,12))
                  :mod~e.15 (e2 / enzyme
                        :name (n2 / name :op1 "K-Ras"~e.7,16,18))))
      :concession~e.0 (p2 / possible~e.8
            :domain~e.9 (t2 / tolerate-01~e.10
                  :ARG1 (a3 / allele~e.14
                        :ARG0-of (a4 / activate-01~e.13
                              :manner f)
                        :mod (e / enzyme
                              :name (n / name :op1 "H-Ras"~e.5,7,18))))))

# ::tok Variant alleles of K @-@ Ras that account for a small fraction of Noonan’s syndrome and cardiofaciocutaneous syndrome are weakly activated relative to their sporadic oncogenic counterparts ( <ce:cross-ref id="crosref0100" refid="bib61"> Schubbert et al. , 2007 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1 2-1.1.2.r 3-1.1.2.1.1 5-1.1.2.1.1 7-1.1.3 10-1.1.3.1.3.1 11-1.1.3.1.3 12-1.1.3.1.r 13-1.1.3.1.1.1.1 14-1.1.3.1.1.1.2 15-1.1.3.1 16-1.1.3.1.2.1.1 17-1.1.3.1.2.1.2 19-1.2 19-1.2.r 20-1 22-1.3.3 23-1.3.2 23-1.3.2.r 24-1.3.1 25-1.3.3 25-1.3.3.1 25-1.3.3.1.r 26-1.3 31-1.4.1.1.1.1.1 32-1.4.1.1 33-1.4.1.1.2.1 35-1.4.1.2.1
# ::id pmid_2465_1010.41
# ::preferred 
(a / activate-01~e.20
      :ARG1 (a2 / allele~e.1
            :mod (v2 / variant~e.0)
            :mod~e.2 (e / enzyme
                  :name (n / name :op1 "K-Ras"~e.3,5))
            :ARG0-of (a3 / account-01~e.7
                  :ARG1~e.12 (a4 / and~e.15
                        :op1 (d2 / disease
                              :name (n2 / name :op1 "Noonan’s"~e.13 :op2 "syndrome"~e.14))
                        :op2 (d3 / disease
                              :name (n3 / name :op1 "cardiofaciocutaneous"~e.16 :op2 "syndrome"~e.17))
                        :quant (f / fraction~e.11
                              :mod (s / small~e.10)))))
      :manner~e.19 (w / weak~e.19)
      :compared-to (c / counterpart~e.26
            :mod (s2 / sporadic~e.24)
            :poss~e.23 v2~e.23
            :ARG0-of (c2 / cause-01~e.22,25
                  :ARG1~e.25 (c3 / cancer~e.25)))
      :ARG1-of (d4 / describe-01
            :ARG0 (p / publication-91
                  :ARG0 (a5 / and~e.32
                        :op1 (p2 / person
                              :name (n4 / name :op1 "Schubbert"~e.31))
                        :op2 (p3 / person
                              :mod (o / other~e.33)))
                  :time (d / date-entity :year "2007"~e.35))))

# ::tok Further support for the idea that K @-@ Ras has functions distinct from H @-@ Ras and N @-@ Ras comes from analyses of the roles of Ras genes in development .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3 1-1 2-1.2.r 4-1.2 6-1.2.1.1.1.1 8-1.2.1.1.1.1 10-1.2.1 10-1.2.1.2.1.1 10-1.2.1.2.1.2 11-1.2.1.2 12-1.2.1.2.1.1.1.r 12-1.2.1.2.1.r 13-1.2.1.2.1.1.1.1.1 15-1.2.1.2.1.1.1.1.1 15-1.2.1.2.1.2.1.1.1 16-1.2.1.2.1 17-1.2.1.2.1.2.1.1.1 19-1.2.1.2.1.2.1.1.1 21-1.1.r 22-1.1 23-1.1.1.r 25-1.1.1 26-1.1.1.1.r 27-1.1.1.1.1.1 28-1.1.1.1 29-1.1.2.r 30-1.1.2
# ::id pmid_2465_1010.42
# ::preferred 
(s / support-01~e.1
      :ARG0~e.21 (a / analyze-01~e.22
            :ARG1~e.23 (r / role~e.25
                  :mod~e.26 (g / gene~e.28
                        :name (n3 / name :op1 "Ras"~e.27)))
            :ARG1-of~e.29 (d / develop-02~e.30))
      :ARG1~e.2 (i / idea~e.4
            :mod (f2 / function-01~e.10
                  :ARG0 (e / enzyme
                        :name (n / name :op1 "K-Ras"~e.6,8))
                  :mod (d2 / distinct~e.11
                        :compared-to~e.12 (a2 / and~e.16
                              :op1 (f3 / function-01~e.10
                                    :ARG0~e.12 (e2 / enzyme
                                          :name (n2 / name :op1 "H-Ras"~e.13,15)))
                              :op2 (f4 / function-01~e.10
                                    :ARG0 (e4 / enzyme
                                          :name (n4 / name :op1 "N-Ras"~e.15,17,19)))))))
      :degree (f / further~e.0))

# ::tok Mice that lack K @-@ Ras die during embryogenesis , whereas mice lacking H @-@ Ras and @/@ or N @-@ Ras are viable ( <ce:cross-ref id="crosref0105" refid="bib30"> Johnson et al. , 1997 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 2-1.1.1.1 3-1.1.1.1.1.1.1 5-1.1.1.1.1.1.1 6-1.1 7-1.1.2.r 10-1 11-1.2.1 12-1.2.1.1 13-1.2.1.1.1.1.1.1 15-1.2.1.1.1.1.1.1 15-1.2.1.1.1.2.1.1 16-1.2.1.1.1 18-1.2.1.1.1 19-1.2.1.1.1.2.1.1 21-1.2.1.1.1.2.1.1 22-1.2.1.r 23-1.2 28-1.3.1.1.1.1.1 29-1.3.1.1 30-1.3.1.1.2.1 32-1.3.1.2.1
# ::id pmid_2465_1010.43
# ::preferred 
(c2 / contrast-01~e.10
      :ARG1 (d2 / die-01~e.6
            :ARG1 (m / mouse~e.0
                  :ARG0-of (l / lack-01~e.2
                        :ARG1 (e / enzyme
                              :name (n / name :op1 "K-Ras"~e.3,5))))
            :time~e.7 (g / genesis
                  :mod (e3 / embryo)))
      :ARG2 (v / viable~e.23
            :domain~e.22 (m2 / mouse~e.11
                  :ARG0-of (l2 / lack-01~e.12
                        :ARG1 (a / and-or~e.16,18
                              :op1 (e2 / enzyme
                                    :name (n2 / name :op1 "H-Ras"~e.13,15))
                              :op2 (e4 / enzyme
                                    :name (n3 / name :op1 "N-Ras"~e.15,19,21))))))
      :ARG1-of (d3 / describe-01
            :ARG0 (p / publication-91
                  :ARG0 (a2 / and~e.29
                        :op1 (p2 / person
                              :name (n4 / name :op1 "Johnson"~e.28))
                        :op2 (p3 / person
                              :mod (o / other~e.30)))
                  :time (d / date-entity :year "1997"~e.32))))

# ::tok However , replacing K @-@ Ras with H @-@ Ras at the K @-@ Ras genomic locus allows mice to develop , suggesting that differential regulation of K @-@ Ras and H @-@ Ras gene expression determines their relative importance in development rather than the properties of the proteins themselves ( <ce:cross-ref id="crosref0110" refid="bib51"> Potenza et al. , 2005 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 2-1.1.1 3-1.1.1.1.1.1 5-1.1.1.1.1.1 5-1.1.1.2.1.1 7-1.1.1.2.1.1 9-1.1.1.1.1.1 9-1.1.1.2.1.1 12-1.1.1.1.1.1 14-1.1.1.1.1.1 14-1.1.1.2.1.1 15-1.1.1.3.1 16-1.1.1.3 17-1.1 18-1.1.2.1 20-1.1.2 22-1.1.3 23-1.1.3.1.r 24-1.1.3.1.1.2 25-1.1.3.1.1 26-1.1.3.1.3 27-1.1.1.1.1.1 29-1.1.1.1.1.1 29-1.1.1.2.1.1 31-1.1.1.2.1.1 33-1.1.1.1.1.1 33-1.1.1.2.1.1 34-1.1.1.1 34-1.1.1.2 35-1.1.3.1.1.1 36-1.1.3.1 37-1.1.3.1.2.2 37-1.1.3.1.2.2.r 38-1.1.3.1.2.1 39-1.1.3.1.2 40-1.1.3.1.2.3.r 41-1.1.3.1.2.3 45-1.1.3.1.3.1 46-1.1.3.1.3 54-1.2.1.1.1.1.1 55-1.1.3.1.1.1.1 55-1.2.1.1 56-1.2.1.1.2.1 58-1.2.1.2.1
# ::id pmid_2465_1010.44
# ::preferred 
(h / have-concession-91~e.0
      :ARG1 (a / allow-01~e.17
            :ARG0 (r / replace-01~e.2
                  :ARG1 (g2 / gene~e.34
                        :name (n / name :op1 "K-Ras"~e.3,5,9,12,14,27,29,33))
                  :ARG2 (g3 / gene~e.34
                        :name (n2 / name :op1 "H-Ras"~e.5,7,9,14,29,31,33))
                  :location (l / locus~e.16
                        :mod (g / genomic~e.15)
                        :ARG0-of (c2 / contain-01
                              :ARG1 g2)))
            :ARG1 (d2 / develop-02~e.20
                  :ARG1 (m / mouse~e.18))
            :ARG0-of (s / suggest-01~e.22
                  :ARG1~e.23 (d3 / determine-01~e.36
                        :ARG0 (r2 / regulate-01~e.25
                              :ARG1 (e3 / express-03~e.35
                                    :ARG1 (a2 / and~e.55
                                          :op1 g2
                                          :op2 g3))
                              :mod (d4 / differential~e.24))
                        :ARG1 (i / importance~e.39
                              :mod (r3 / relative~e.38)
                              :poss~e.37 a2~e.37
                              :purpose~e.40 (d5 / develop-02~e.41))
                        :ARG1-of (i2 / instead-of-91~e.26,46
                              :ARG2 (p2 / property~e.45
                                    :poss a2)))))
      :ARG1-of (d6 / describe-01
            :ARG0 (p3 / publication-91
                  :ARG0 (a3 / and~e.55
                        :op1 (p4 / person
                              :name (n3 / name :op1 "Potenza"~e.54))
                        :op2 (p / person
                              :mod (o / other~e.56)))
                  :time (d / date-entity :year "2005"~e.58))))

# ::tok Furthermore , Balmain and colleagues discovered that these H @-@ Ras knock @-@ in mice develop tumors in response to carcinogens at normal frequencies , except that they are now driven by H @-@ Ras instead of K @-@ Ras ( <ce:cross-ref id="crosref0115" refid="bib70"> To et al. , 2008 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1.1.1.1.1 3-1.1.1 4-1.1.1.2 5-1.1 6-1.1.2.r 7-1.1.2.1.2 8-1.1.2.1.1.1.1.1 10-1.1.2.1.1.1.1.1 14-1.1.2.1 15-1.1.2 16-1.1.2.2 17-1.1.2.3.r 18-1.1.2.3 19-1.1.2.3.1.r 20-1.1.2.3.1 21-1.1.2.4.r 22-1.1.2.4 25-1.1.2.5 29-1.1.2.5.1.3 30-1.1.2.5.1 30-1.1.2.5.1.4.1 31-1.1.2.5.1.1.r 32-1.1.2.5.1.1 33-1.1.2.5.1.1 34-1.1.2.5.1.1 35-1.1.2.5.1.4 36-1.1.2.5.1.4 36-1.1.2.5.1.4.1.1.r 37-1.1.2.5.1.4.1.1.1.1 39-1.1.2.1.1.1.1.1 39-1.1.2.5.1.4.1.1.1.1 44-1.2.1.1.1.1.1 45-1.2.1.1 46-1.2.1.1.2.1 48-1.2.1.2.1
# ::id pmid_2465_1010.45
# ::preferred 
(a / and
      :op2 (d2 / discover-01~e.5
            :ARG0 (a2 / and~e.3
                  :op1 (p / person
                        :name (n3 / name :op1 "Balmain"~e.2))
                  :op2 (c / colleague~e.4
                        :poss p))
            :ARG1~e.6 (d3 / develop-01~e.15
                  :ARG1 (m / mouse~e.14
                        :ARG3-of (e4 / express-03
                              :ARG2 (e / enzyme
                                    :name (n / name :op1 "H-Ras"~e.8,10,39)))
                        :mod (t2 / this~e.7))
                  :ARG2 (t / tumor~e.16)
                  :ARG2-of~e.17 (r / respond-01~e.18
                        :ARG1~e.19 (c3 / carcinogen~e.20))
                  :frequency~e.21 (n4 / normal~e.22)
                  :ARG1-of (e3 / except-01~e.25
                        :ARG2 (d4 / drive-02~e.30
                              :ARG0~e.31 e~e.32,33,34
                              :ARG1 c3
                              :time (n5 / now~e.29)
                              :ARG1-of (i / instead-of-91~e.35,36
                                    :ARG2 (d5 / drive-02~e.30
                                          :ARG0~e.36 (e2 / enzyme
                                                :name (n2 / name :op1 "K-Ras"~e.37,39))
                                          :ARG1 c3))))))
      :ARG1-of (d6 / describe-01
            :ARG0 (p2 / publication-91
                  :ARG0 (a3 / and~e.45
                        :op1 (p3 / person
                              :name (n6 / name :op1 "To"~e.44))
                        :op2 (p4 / person
                              :mod (o / other~e.46)))
                  :time (d / date-entity :year "2008"~e.48))))

# ::tok These data argue strongly that the locus is critical and that the specific Ras paralog encoded at that locus does not affect the frequency at which tumors arise .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1 2-1 3-1.3 3-1.3.r 4-1.2.r 6-1.2.1.1 7-1.2.1.1.r 8-1.2.1 9-1.2 10-1.2.r 12-1.2.2.2.2 13-1.2.2.2.1.1.1 14-1.2.2.2 15-1.2.2.2.3 18-1.2.2.2.3.1 20-1.2.2.1 20-1.2.2.1.r 21-1.2.2 23-1.2.2.3 26-1.2.2.3.1.1 27-1.2.2.3.1
# ::id pmid_2465_1010.46
# ::preferred 
(a / argue-01~e.2
      :ARG0 (d / data~e.1
            :mod (t / this~e.0))
      :ARG1~e.4,10 (a2 / and~e.9
            :op1 (c / critical~e.8
                  :domain~e.7 (l / locus~e.6))
            :op2 (a3 / affect-01~e.21
                  :polarity~e.20 "-"~e.20
                  :ARG0 (p / paralog~e.14
                        :mod (e / enzyme
                              :name (n / name :op1 "Ras"~e.13))
                        :mod (s2 / specific~e.12)
                        :ARG1-of (e2 / encode-01~e.15
                              :location l~e.18))
                  :ARG1 (h / have-frequency-91~e.23
                        :ARG1 (a4 / arise-01~e.27
                              :ARG1 (t3 / tumor~e.26)))))
      :manner~e.3 (s / strong~e.3))

# ::tok Equally important , they find that K @-@ Ras @-@ 4A , not K @-@ Ras @-@ 4B , is necessary for lung tumor initiation , although K @-@ Ras @-@ 4B is much more highly expressed during progression .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3.1 1-1.3 3-1.1 4-1 5-1.2.r 6-1.2.1.1.1 8-1.2.1.1.1 10-1.2.1.1.1 12-1.2.4.1.1 12-1.2.4.1.1.r 13-1.2.4.1.2.1.1 15-1.2.4.1.2.1.1 17-1.2.4.1.2.1.1 20-1.2 20-1.2.4.1 21-1.2.2.r 22-1.2.2.1.1 23-1.2.2.1 24-1.2.2 26-1.2.3.r 27-1.2.1.1.1 27-1.2.4.1.2.1.1 29-1.2.1.1.1 29-1.2.4.1.2.1.1 31-1.2.3.1 33-1.2.3.2.1.1 34-1.2.3.2.1 35-1.2.3.2 36-1.2.3 37-1.2.3.3.r 38-1.2.3.3
# ::id pmid_2465_1010.47
# ::preferred 
(f / find-01~e.4
      :ARG0 (t / they~e.3)
      :ARG1~e.5 (n2 / need-01~e.20
            :ARG1 (e / enzyme
                  :name (n3 / name :op1 "K-Ras-4A"~e.6,8,10,27,29))
            :purpose~e.21 (i2 / initiate-01~e.24
                  :ARG1 (t2 / tumor~e.23
                        :mod (l / lung~e.22)))
            :concession~e.26 (e4 / express-03~e.36
                  :ARG2 e2~e.31
                  :degree (h / high~e.35
                        :degree (m / more~e.34
                              :quant (m2 / much~e.33)))
                  :time~e.37 (p / progress-01~e.38
                        :ARG1 t2))
            :ARG1-of (c / contrast-01
                  :ARG2 (n / need-01~e.20
                        :polarity~e.12 "-"~e.12
                        :ARG1 (e2 / enzyme
                              :name (n4 / name :op1 "K-Ras-4B"~e.13,15,17,27,29))
                        :purpose i2)))
      :mod (i3 / important~e.1
            :degree (e3 / equal~e.0)))

# ::tok This supports the idea that K @-@ Ras @-@ 4B is the more important target in established tumors but raises the concern that K @-@ Ras @-@ 4A may have an important role in minor stem @-@ like populations of established tumors .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 1-1.1 3-1.1.2 5-1.1.2.1.1.1.1 7-1.1.2.1.1.1.1 9-1.1.2.1.1.1.1 12-1.1.2.1.2.1 13-1.1.2.1.2 14-1.1.2.1 15-1.1.2.1.2.2.r 16-1.1.2.1.2.2.1 17-1.1.2.1.2.2 18-1 21-1.2 23-1.2.1.1.1.1.1 25-1.2.1.1.1.1.1 27-1.2.1.1.1.1.1 28-1.2.1 29-1.2.1.1.2 31-1.2.1.1.2 32-1.2.1.1 33-1.2.1.1.3.r 34-1.2.1.1.3.1 35-1.2.1.1.3.2.1.1.1.1 37-1.2.1.1.3.2.1 37-1.2.1.1.3.2.1.1 37-1.2.1.1.3.2.1.1.r 38-1.2.1.1.3 39-1.2.1.1.3.3.r 40-1.2.1.1.3.3 41-1.2.1.1.3.3
# ::id pmid_2465_1010.48
# ::preferred 
(c / contrast-01~e.18
      :ARG1 (s / support-01~e.1
            :ARG0 (t / thing
                  :mod (t2 / this~e.0))
            :ARG1 (i / idea~e.3
                  :mod (t3 / target-01~e.14
                        :ARG1 (e / enzyme
                              :name (n / name :op1 "K-Ras-4B"~e.5,7,9))
                        :mod (i2 / important~e.13
                              :degree (m / more~e.12)
                              :location~e.15 (t4 / tumor~e.17
                                    :ARG1-of (e2 / establish-01~e.16))))))
      :ARG2 (c2 / concern-01~e.21
            :ARG0 (p / possible~e.28
                  :domain (r2 / role~e.32
                        :poss (e3 / enzyme
                              :name (n2 / name :op1 "K-Ras-4A"~e.23,25,27))
                        :mod (i3 / important~e.29,31)
                        :topic~e.33 (p2 / population~e.38
                              :mod (m2 / minor~e.34)
                              :ARG1-of (c3 / consist-01
                                    :ARG2 (c4 / cell~e.37
                                          :ARG1-of~e.37 (r / resemble-01~e.37
                                                :ARG2 (c5 / cell
                                                      :mod (s2 / stem~e.35)))))
                              :part-of~e.39 t4~e.40,41)))))

# ::tok These findings point toward an urgent need to validate K @-@ Ras @-@ 4A and K @-@ Ras @-@ 4B as drug targets , a major issue that has not yet been addressed .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2 1-1.1 1-1.1.1 1-1.1.1.r 2-1 5-1.2.2 6-1.2 8-1.2.1 9-1.2.1.1.1.1.1 9-1.2.1.1.2.1.1 11-1.2.1.1.1.1.1 11-1.2.1.1.2.1.1 13-1.2.1.1.1.1.1 14-1.2.1.1 15-1.2.1.1.1.1.1 15-1.2.1.1.2.1.1 17-1.2.1.1.1.1.1 17-1.2.1.1.2.1.1 19-1.2.1.1.2.1.1 20-1.2.1.1.r 20-1.2.3.2.2.r 21-1.2.1.1.3.1 22-1.2.1.1.3 25-1.2.3.1 26-1.2.3 29-1.2.3.2.1 29-1.2.3.2.1.r 30-1.2.3.2.2 32-1.2.3.2
# ::id pmid_2465_1010.49
# ::preferred 
(p / point-01~e.2
      :ARG0 (t / thing~e.1
            :ARG1-of~e.1 (f / find-01~e.1)
            :mod (t2 / this~e.0))
      :ARG2 (n / need-01~e.6
            :ARG1 (v / validate-01~e.8
                  :ARG1~e.20 (a / and~e.14
                        :op1 (e / enzyme
                              :name (n2 / name :op1 "K-Ras-4A"~e.9,11,13,15,17))
                        :op2 (e2 / enzyme
                              :name (n3 / name :op1 "K-Ras-4B"~e.9,11,15,17,19))
                        :ARG1-of (t3 / target-01~e.22
                              :ARG0 (d / drug~e.21))))
            :mod (u / urgent~e.5)
            :mod (i / issue~e.26
                  :mod (m / major~e.25)
                  :ARG1-of (a2 / address-02~e.32
                        :polarity~e.29 "-"~e.29
                        :time~e.20 (y / yet~e.30)))))

# ::tok Different frequencies of K @-@ Ras , N @-@ Ras , and H @-@ Ras mutations in human tumors may also reflect differences in gene expression resulting from differential codon usage ; rare codons limit K @-@ Ras expression and thus allow more efficient oncogenesis by preventing oncogene @-@ induced senescence ( <ce:cross-ref id="crosref0120" refid="bib35"> Lampson et al. , 2013 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1.2 1-1.1.1.1 3-1.1.1.1.1.1.1.1.1 5-1.1.1.1.1.1.1.1.1 5-1.1.1.1.1.1.2.1.1 7-1.1.1.1.1.1.2.1.1 9-1.1.1.1.1.1.1.1.1 9-1.1.1.1.1.1.2.1.1 9-1.1.1.1.1.1.3.1.1 11-1.1.1.1.1.1 12-1.1.1.1.1.1.3.1.1 14-1.1.1.1.1.1.1.1.1 14-1.1.1.1.1.1.3.1.1 15-1.1.1.1.1 17-1.1.1.1.3.1 18-1.1.1.1.3 19-1.1 20-1.1.2 21-1.1.1 22-1.1.1.2 23-1.1.1.2.1.r 24-1.1.1.2.1.1 25-1.1.1.2.1 26-1.1.1.2.2 27-1.1.1.2.2.1.r 28-1.1.1.2.2.1.2 29-1.2.1.1.1.1 30-1.1.1.2.2.1 32-1.2.1.1.2 34-1.2.1 35-1.2.1.2.1.1.1 37-1.2.1.2.1.1.1 38-1.2.1.2 39-1.2 40-1.2.2.3 41-1.2.2 42-1.2.2.2.2 43-1.2.2.2 45-1.2.2.4.r 46-1.2.2.4 47-1.2.2.4.2.1.1 49-1.2.2.4.2.1 50-1.2.2.4.2 55-1.3.1.1.1.1.1 56-1.3.1.1 57-1.3.1.1.2.1 59-1.3.1.2.1
# ::id pmid_2465_1010.50
# ::preferred 
(m / multi-sentence
      :snt1 (p / possible~e.19
            :domain (r / reflect-01~e.21
                  :ARG1 (h / have-frequency-91~e.1
                        :ARG1 (m2 / mutate-01~e.15
                              :ARG1 (a / and~e.11
                                    :op1 (e / enzyme
                                          :name (n / name :op1 "K-Ras"~e.3,5,9,14))
                                    :op2 (e2 / enzyme
                                          :name (n2 / name :op1 "N-Ras"~e.5,7,9))
                                    :op3 (e3 / enzyme
                                          :name (n3 / name :op1 "H-Ras"~e.9,12,14))))
                        :ARG1-of (d3 / differ-02~e.0)
                        :location (t / tumor~e.18
                              :mod (h2 / human~e.17)))
                  :ARG2 (d4 / differ-02~e.22
                        :ARG1~e.23 (e4 / express-03~e.25
                              :ARG1 (g / gene~e.24))
                        :ARG2-of (r3 / result-01~e.26
                              :ARG1~e.27 (u / use-01~e.30
                                    :ARG1 (c / codon)
                                    :mod (d5 / differential~e.28)))))
            :mod (a3 / also~e.20))
      :snt2 (a2 / and~e.39
            :op1 (l / limit-01~e.34
                  :ARG0 (d7 / dna-sequence
                        :name (n7 / name :op1 "codon"~e.29)
                        :mod (r2 / rare~e.32))
                  :ARG1 (e5 / express-03~e.38
                        :ARG1 (e7 / enzyme
                              :name (n8 / name :op1 "K-Ras"~e.35,37))))
            :op2 (a4 / allow-01~e.41
                  :ARG0 d7
                  :ARG1 (e6 / efficient-01~e.43
                        :ARG2 (o / originate-01
                              :ARG1 (c2 / cancer))
                        :degree (m3 / more~e.42))
                  :mod (t2 / thus~e.40)
                  :manner~e.45 (p2 / prevent-01~e.46
                        :ARG0 d7
                        :ARG1 (s / senescence~e.50
                              :ARG1-of (i / induce-01~e.49
                                    :ARG0 (o2 / oncogene~e.47))))))
      :ARG1-of (d6 / describe-01
            :ARG0 (p3 / publication-91
                  :ARG0 (a5 / and~e.56
                        :op1 (p4 / person
                              :name (n4 / name :op1 "Lampson"~e.55))
                        :op2 (p5 / person
                              :mod (o3 / other~e.57)))
                  :time (d2 / date-entity :year "2013"~e.59))))

# ::tok In addition , different rates of DNA repair have been reported for the K @-@ Ras gene relative to N @-@ Ras and H @-@ Ras ( <ce:cross-ref id="crosref0125" refid="bib18"> Feng et al. , 2002 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.1.1 1-1 1-1.1.1.2 1-1.2.1.1 3-1.1.1 4-1.1.1.3 5-1.1.1.3.1.r 6-1.1.1.3.1.1 7-1.1.1.3.1 10-1.1 11-1.1.1.1.r 13-1.1.1.1.1.1 15-1.1.1.1.1.1 16-1.1.1.1 18-1.1.1.2.r 19-1.1.1.2.2.1.1 21-1.1.1.2.1.1.1 21-1.1.1.2.2.1.1 23-1.1.1.2.1.1.1 25-1.1.1.2.1.1.1 30-1.2.1.1.1.1.1 31-1.2.1.1 32-1.2.1.1.2.1 34-1.2.1.2.1
# ::id pmid_2465_1010.51
# ::preferred 
(a / and~e.1
      :op2 (r / report-01~e.10
            :ARG1 (d2 / differ-02~e.3
                  :ARG1~e.11 (g / gene~e.16
                        :name (n / name :op1 "K-Ras"~e.13,15))
                  :ARG2~e.18 (a2 / and~e.1
                        :op1 (e2 / enzyme
                              :name (n2 / name :op1 "H-Ras"~e.21,23,25))
                        :op2 (e3 / enzyme
                              :name (n3 / name :op1 "N-Ras"~e.19,21)))
                  :ARG3 (r2 / rate~e.4
                        :mod~e.5 (r3 / repair-01~e.7
                              :ARG1 (d4 / DNA~e.6)))))
      :ARG1-of (d3 / describe-01
            :ARG0 (p / publication-91
                  :ARG0 (a3 / and~e.0,1,31
                        :op1 (p2 / person
                              :name (n4 / name :op1 "Feng"~e.30))
                        :op2 (p3 / person
                              :mod (o / other~e.32)))
                  :time (d / date-entity :year "2002"~e.34))))

# ::tok The underlying reasons for different frequencies of specific activating mutations are not well understood either .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.2.1 2-1.2 4-1.2.1.1.2 5-1.2.1.1 7-1.2.1.1.1.1 8-1.2.1.1.1.2 9-1.2.1.1.1 11-1.1 11-1.1.r 12-1.4 13-1 14-1.3
# ::id pmid_2465_1010.52
# ::preferred 
(u / understand-01~e.13
      :polarity~e.11 "-"~e.11
      :ARG1 (r / reason~e.2
            :ARG0-of (u2 / underlie-01~e.1
                  :ARG1 (h2 / have-frequency-91~e.5
                        :ARG1 (m2 / mutate-01~e.9
                              :mod (s2 / specific~e.7)
                              :ARG0-of (a2 / activate-01~e.8))
                        :ARG1-of (d2 / differ-02~e.4))))
      :mod (e / either~e.14)
      :manner (g / good~e.12))

# ::tok Some of these differences reflect different mutagenic insults to the genome ; the G12C mutation , for example , is a hallmark of exposure to tobacco smoke and , accordingly , is the most common mutation in K @-@ Ras in lung cancer ( reviewed in <ce:cross-ref id="crosref0130" refid="bib52"> Prior et al. , 2012 </ce:cross-ref> ; <ce:cross-ref id="crosref0135" refid="tbl2"> Table 2 </ce:cross-ref>@ <ce:float-anchor refid="tbl2" /> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.1.1 2-1.2.1.2.1.1.1 3-1.2.1.2.1 3-1.2.1.2.1.1 3-1.2.1.2.1.1.r 4-1.2 5-1.2.2.2 7-1.2.2 8-1.2.2.1.r 10-1.2.2.1 13-1.1.1.2.1 14-1.1.1.2 14-1.2.2.3.1 16-1 17-1 23-1.1.1.1 25-1.1.1.1.1.1 26-1.1.1.1.1 27-1.1 29-1.1.2.4 33-1.1.2.2.1 34-1.1.2.2 35-1.1.2 36-1.1.1.2.2.r 37-1.1.1.2.2.1.1 39-1.1.1.2.2.1.1 40-1.1.2.3.r 41-1.1.2.3.1 42-1.1.2.3 44-1.3 49-1.3.1.1.1.1.1 50-1.3.1.1 51-1.3.1.1.2.1 53-1.3.1.2.1 59-1.3.1.3 60-1.3.1.3.1
# ::id pmid_2465_1010.53
# ::preferred 
(e / exemplify-01~e.16,17
      :ARG0 (a / and~e.27
            :op1 (c / characteristic-02
                  :ARG1 (e2 / expose-01~e.23
                        :ARG2 (s2 / smoke-02~e.26
                              :ARG1 (t4 / tobacco~e.25)))
                  :ARG2 (m4 / mutate-01~e.14
                        :value "G12C"~e.13
                        :ARG2~e.36 (e3 / enzyme
                              :name (n / name :op1 "K-Ras"~e.37,39))))
            :op2 (m3 / mutate-01~e.35
                  :ARG2 e3
                  :mod (c2 / common~e.34
                        :degree (m5 / most~e.33))
                  :location~e.40 (c3 / cancer~e.42
                        :mod (l / lung~e.41))
                  :manner (a2 / accordingly~e.29)))
      :ARG1 (r / reflect-01~e.4
            :ARG1 (t / thing
                  :quant (s / some~e.0)
                  :ARG1-of (i / include-91
                        :ARG2 (t2 / thing~e.3
                              :ARG1-of~e.3 (d / differ-02~e.3
                                    :mod (t3 / this~e.2)))))
            :ARG2 (i2 / insult-01~e.7
                  :ARG1~e.8 (g / genome~e.10)
                  :ARG1-of (d2 / differ-02~e.5)
                  :ARG0-of (g2 / generate-01
                        :ARG1 (m2 / mutate-01~e.14
                              :ARG1 (d3 / DNA)))))
      :ARG1-of (r2 / review-01~e.44
            :ARG0 (p / publication-91
                  :ARG0 (a3 / and~e.50
                        :op1 (p2 / person
                              :name (n2 / name :op1 "Prior"~e.49))
                        :op2 (p3 / person
                              :mod (o / other~e.51)))
                  :time (d5 / date-entity :year "2012"~e.53)
                  :part (t5 / table~e.59 :mod "2"~e.60))))

# ::tok Other differences in frequency may reflect different biological properties of mutant proteins .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.2 1-1.1.1 3-1.1.1.1 4-1 5-1.1 6-1.1.1 6-1.1.2.2 7-1.1.2.3 8-1.1.2 10-1.1.2.1.1.1 11-1.1.2.1.1
# ::id pmid_2465_1010.54
# ::preferred 
(p / possible~e.4
      :domain (r / reflect-01~e.5
            :ARG1 (d2 / differ-02~e.1,6
                  :ARG3 (f / frequency~e.3)
                  :mod (o / other~e.0))
            :ARG2 (p2 / property~e.8
                  :ARG1-of (h / have-03
                        :ARG0 (p3 / protein~e.11
                              :ARG2-of (m / mutate-01~e.10)))
                  :ARG1-of (d / differ-02~e.6)
                  :mod (b / biology~e.7))))

# ::tok For example , G12C and G12V K @-@ Ras mutations in lung adenocarcinoma preferentially activate the RalGDS pathway , whereas G12D prefers the Raf @/@ mitogen @-@ activated protein kinase ( MAPK ) and PI3K pathways ( <ce:cross-ref id="crosref0140" refid="bib29"> Ihle et al. , 2012 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.4.2 1-1.4.2 3-1.1.1.1 4-1.1 5-1.1.2.1 6-1.1.1.2.1.1 8-1.1.1.2.1.1 9-1.1.1 9-1.1.2 9-1.4.1.1 11-1.1.3.1 12-1.1.3 13-1.3 14-1 16-1.2.1.1 17-1.2 19-1.4 20-1.4.1.1.1 21-1.4.1 23-1.4.1.2.1.2.1.1.1 25-1.4.1.2.2.2.1 27-1.4.1.2.1.2 27-1.4.1.2.2.2 29-1.4.1.2.1 29-1.4.1.2.2 31-1.4.1.2.1.1.1 31-1.4.1.2.2.1.1 33-1.4.1.2 34-1.4.1.2.3.1.1 35-1.4.1.2.3 40-1.5.1.1.1.1.1 41-1.5.1.1 42-1.5.1.1.2.1 44-1.5.1.2.1
# ::id pmid_2465_1010.55
# ::preferred 
(a / activate-01~e.14
      :ARG0 (a2 / and~e.4
            :op1 (m / mutate-01~e.9
                  :value "G12C"~e.3
                  :ARG2 (e2 / enzyme
                        :name (n2 / name :op1 "K-Ras"~e.6,8)))
            :op2 (m2 / mutate-01~e.9
                  :value "G12V"~e.5
                  :ARG2 e2)
            :location (a4 / adenocarcinoma~e.12
                  :mod (l2 / lung~e.11)))
      :ARG1 (p3 / pathway~e.17
            :name (n / name :op1 "RalGDS"~e.16))
      :ARG1-of (p2 / prefer-01~e.13)
      :ARG1-of (c / contrast-01~e.19
            :ARG2 (p / prefer-01~e.21
                  :ARG0 (m3 / mutate-01~e.9
                        :value "G12D"~e.20
                        :ARG2 e2)
                  :ARG1 (a3 / and~e.33
                        :op1 (k / kinase~e.29
                              :name (n8 / name :op1 "MAPK"~e.31)
                              :ARG1-of (a8 / activate-01~e.27
                                    :ARG0 (e4 / enzyme
                                          :name (n9 / name :op1 "Raf"~e.23))))
                        :op2 (k2 / kinase~e.29
                              :name (n10 / name :op1 "MAPK"~e.31)
                              :ARG1-of (a9 / activate-01~e.27
                                    :ARG0 (m5 / mitogen~e.25)))
                        :op3 (p7 / pathway~e.35
                              :name (n6 / name :op1 "PI3K"~e.34))))
            :ARG0-of (e3 / exemplify-01~e.0,1))
      :ARG1-of (d / describe-01
            :ARG0 (p6 / publication-91
                  :ARG0 (a7 / and~e.41
                        :op1 (p8 / person
                              :name (n7 / name :op1 "Ihle"~e.40))
                        :op2 (p9 / person
                              :mod (o / other~e.42)))
                  :time (d2 / date-entity :year "2012"~e.44))))

# ::tok In addition , mutations at codon 61 have a more profound effect on intrinsic GTPase when these Ras proteins are bound to Raf kinase .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1 3-1.1.1 4-1.1.1.1.r 5-1.1.1.1 6-1.1.1.1.1 9-1.1.3.1 10-1.1.3 11-1.1 12-1.1.2.r 13-1.1.2.2 14-1.1.2.1.1 17-1.1.1.1.2.1.1 20-1.1.4 21-1.1.4.2.r 22-1.1.4.2.1.1 23-1.1.4.2
# ::id pmid_2465_1010.56
# ::preferred 
(a / and~e.0,1
      :op2 (a2 / affect-01~e.11
            :ARG0 (m / mutate-01~e.3
                  :ARG1~e.4 (c2 / codon~e.5
                        :mod "61"~e.6
                        :part-of (e3 / enzyme
                              :name (n3 / name :op1 "Ras"~e.17))))
            :ARG1~e.12 (e2 / enzyme
                  :name (n2 / name :op1 "GTPase"~e.14)
                  :mod (i / intrinsic~e.13))
            :mod (p / profound~e.10
                  :degree (m2 / more~e.9))
            :condition (b / bind-01~e.20
                  :ARG1 e3
                  :ARG2~e.21 (k / kinase~e.23
                        :name (n6 / name :op1 "Raf"~e.22)))))

# ::tok This may drive a stronger signal through this effector pathway and account for higher frequency of N @-@ Ras position 61 mutations in melanoma , a disease frequently driven by hyperactivation of Raf kinase through B @-@ Raf mutations ( <ce:cross-ref id="crosref0145" refid="bib8"> Buhrman et al. , 2010 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 1-1 2-1.1.1 4-1.1.1.2.2 4-1.1.1.2.2.1 4-1.1.1.2.2.1.r 5-1.1.1.2 7-1.1.1.1 8-1.1.1.2.1.1 9-1.1.1.2.1 10-1.1 11-1.1.2 13-1.1.2.2.2 13-1.1.2.2.2.1 13-1.1.2.2.2.1.r 14-1.1.2.2 16-1.1.2.2.1.2.1.1 18-1.1.2.2.1.2.1.1 20-1.1.2.2.1.1 21-1.1.2.2.1 22-1.1.2.2.1.3.r 23-1.1.2.2.1.3.1.1 26-1.1.2.2.1.3 27-1.1.2.2.1.3.2.2 28-1.1.2.2.1.3.2 32-1.1.2.2.1.3.2.1.2.1.1 33-1.1.2.2.1.3.2.1.1.1 33-1.1.2.2.1.3.2.1.2 35-1.1.2.2.1.3.2.1.1.1.1.1 37-1.1.2.2.1.3.2.1.1.1.1.1 38-1.1.2.2.1.3.2.1.1 43-1.2.1.1.1.1.1 44-1.2.1.1 45-1.2.1.1.2.1 47-1.2.1.2.1
# ::id pmid_2465_1010.57
# ::preferred 
(p / possible~e.1
      :domain (a / and~e.10
            :op1 (d3 / drive-02~e.2
                  :ARG0 (t / this~e.0,7)
                  :ARG1 (s / signal-07~e.5
                        :ARG0 (p4 / pathway~e.9
                              :mod (e / effector~e.8))
                        :mod (s2 / strong~e.4
                              :degree~e.4 (m / more~e.4))))
            :op2 (a3 / account-01~e.11
                  :ARG0 t
                  :ARG1 (h / have-frequency-91~e.14
                        :ARG1 (m2 / mutate-01~e.21
                              :value "61"~e.20
                              :ARG2 (e2 / enzyme
                                    :name (n / name :op1 "N-Ras"~e.16,18))
                              :location~e.22 (d4 / disease~e.26
                                    :name (n5 / name :op1 "melanoma"~e.23)
                                    :ARG1-of (d5 / drive-02~e.28
                                          :ARG0 (h4 / hyperactivate-00
                                                :ARG0 (m6 / mutate-01~e.38
                                                      :ARG2 (k3 / kinase~e.33
                                                            :name (n6 / name :op1 "B-Raf"~e.35,37)))
                                                :ARG1 (k4 / kinase~e.33
                                                      :name (n7 / name :op1 "Raf"~e.32)))
                                          :frequency (f / frequent~e.27))))
                        :ARG2 (h3 / high~e.13
                              :degree~e.13 (m5 / more~e.13)))))
      :ARG1-of (d / describe-01
            :ARG0 (p2 / publication-91
                  :ARG0 (a2 / and~e.44
                        :op1 (p3 / person
                              :name (n2 / name :op1 "Buhrman"~e.43))
                        :op2 (p5 / person
                              :mod (o / other~e.45)))
                  :time (d2 / date-entity :year "2010"~e.47))))

# ::tok From a clinical viewpoint , lung adenocarcinomas driven by K @-@ Ras mutations at G12C and G12V have a worse outcome than G12D , possibly because these mutations engage different downstream effectors as described above ( <ce:cross-ref id="crosref0150" refid="fig1"> Figure 1 </ce:cross-ref> ; <ce:cross-ref id="crosref0155" refid="bib29"> Ihle et al. , 2012 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.5.1 5-1.1.1 6-1.1 7-1.1.2 8-1.1.2.1.r 9-1.1.2.1.1.2.1.1 11-1.1.2.1.1.2.1.1 12-1.1.2.1.1 12-1.1.2.1.2 14-1.1.2.1.1.1 15-1.1.2.1 16-1.1.2.1.2.1 17-1 19-1.2.1 19-1.2.1.1 19-1.2.1.1.r 20-1.2 21-1.2.1.2.r 22-1.2.1.2.1 24-1.3.2 25-1.3 27-1.2.1.2 28-1.3.1 29-1.3.1.2.2 30-1.3.1.2.1 31-1.3.1.2 32-1.4.1.2.r 33-1.4 34-1.4.2 39-1.4.1.3 40-1.4.1.3.1 46-1.4.1.1.1.1.1 47-1.4.1.1 48-1.4.1.1.2.1 50-1.4.1.2.1
# ::id pmid_2465_1010.58
# ::preferred 
(h / have-03~e.17
      :ARG0 (a / adenocarcinoma~e.6
            :mod (l / lung~e.5)
            :ARG1-of (d4 / drive-02~e.7
                  :ARG0~e.8 (a2 / and~e.15
                        :op1 (m2 / mutate-01~e.12
                              :value "G12C"~e.14
                              :ARG2 (e / enzyme
                                    :name (n / name :op1 "K-Ras"~e.9,11)))
                        :op2 (m3 / mutate-01~e.12
                              :value "G12V"~e.16
                              :ARG2 e))))
      :ARG1 (o / outcome~e.20
            :ARG1-of (b / bad-07~e.19
                  :degree~e.19 (m / more~e.19)
                  :compared-to~e.21 (m4 / mutate-01~e.27
                        :value "G12D"~e.22
                        :ARG2 e)))
      :ARG1-of (c3 / cause-01~e.25
            :ARG0 (e2 / engage-01~e.28
                  :ARG0 a2
                  :ARG1 (e3 / effector~e.31
                        :location (d / downstream~e.30)
                        :ARG1-of (d2 / differ-02~e.29)))
            :mod (p / possible~e.24))
      :ARG1-of (d3 / describe-01~e.33
            :ARG0 (p2 / publication-91
                  :ARG0 (a4 / and~e.47
                        :op1 (p3 / person
                              :name (n2 / name :op1 "Ihle"~e.46))
                        :op2 (p4 / person
                              :mod (o2 / other~e.48)))
                  :time~e.32 (d5 / date-entity :year "2012"~e.50)
                  :part (f / figure~e.39 :mod "1"~e.40))
            :medium (a3 / above~e.34))
      :ARG1-of (v2 / view-02
            :mod (c2 / clinic~e.2)))

# ::tok As MEK and PI3K inhibitors are tested in the clinic , it will be important to ask whether Ras alleles respond differently to these treatments .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.2.1.1.1.1.1.1.1 2-1.2.1.1 3-1.2.1.1.2.1.1.1.1 4-1.2.1.1.1 4-1.2.1.1.1.1 4-1.2.1.1.1.1.r 4-1.2.1.1.2 4-1.2.1.1.2.1 4-1.2.1.1.2.1.r 6-1.2.1 7-1.2.1.2.r 9-1.2.1.2 13-1.1.r 14-1 15-1.2 16-1.1 17-1.1.1.1 17-1.1.1.1.r 18-1.1.1.2.1.1 19-1.1.1.2 20-1.1.1 21-1.1.1.4 22-1.1.1.3.r 23-1.1.1.3.2 24-1.1.1.3
# ::id pmid_2465_1010.59
# ::preferred 
(i / important~e.14
      :domain~e.13 (a / ask-01~e.16
            :ARG1 (r / respond-01~e.20
                  :mode~e.17 "interrogative"~e.17
                  :ARG0 (a2 / allele~e.19
                        :name (n / name :op1 "Ras"~e.18))
                  :ARG1~e.22 (t / treat-03~e.24
                        :ARG1 a2
                        :mod (t2 / this~e.23))
                  :ARG1-of (d / differ-02~e.21)))
      :ARG1-of (c / cause-01~e.15
            :ARG0 (t3 / test-01~e.6
                  :ARG1 (a3 / and~e.2
                        :op1 (m / molecular-physical-entity~e.4
                              :ARG0-of~e.4 (i2 / inhibit-01~e.4
                                    :ARG1 (e / enzyme
                                          :name (n2 / name :op1 "MEK"~e.1))))
                        :op2 (m2 / molecular-physical-entity~e.4
                              :ARG0-of~e.4 (i3 / inhibit-01~e.4
                                    :ARG1 (e2 / enzyme
                                          :name (n3 / name :op1 "PI3K"~e.3)))))
                  :location~e.7 (c2 / clinic~e.9))))

# ::tok Patients suffering from cancers driven by any of these Ras mutations are excluded from treatment with cetuximab ( colorectal cancer ) or erlotinib ( lung adenocarcinoma ) because these treatments are ineffective for cancers with these Ras mutations and may even increase rates of progression .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1.1.1 2-1.1.1.1.r 3-1.1.1.1 4-1.1.1.1.1 6-1.1.1.1.1.1.2 8-1.1.1.1.1.1.3 9-1.1.1.1.1.1.1.1.1 10-1.1.1.1.1.1 11-1.3.1.1.2.r 12-1 13-1.2.r 14-1.2.1 14-1.2.2 15-1.2.1.2.r 16-1.2.1.2.1.1 18-1.2.1.2.2.1 19-1.2.1.2.2 21-1.2 22-1.2.2.2.1.1 24-1.2.2.2.2.1 25-1.2.2.2.2 27-1.3 27-1.3.1.1.3.1 28-1.2.1.1 29-1.3.1.1.2 30-1.3.1.1.2.r 31-1.3.1.1 31-1.3.1.1.1 31-1.3.1.1.1.r 32-1.3.1.1.3.r 33-1.3.1.1.3 35-1.1.1.1.1.1.3 36-1.1.1.1.1.1.1.1.1 37-1.1.1.1.1.1 37-1.3.1.1.3.1.1 38-1.3.1 39-1.3.1.2 40-1.3.1.2.1.3 41-1.3.1.2.1 42-1.3.1.2.1.2 43-1.3.1.2.1.2.1.r 44-1.3.1.2.1.2.1
# ::id pmid_2465_1010.60
# ::preferred 
(e / exclude-01~e.12
      :ARG1 (p / patient~e.0
            :ARG0-of (s / suffer-01~e.1
                  :ARG1~e.2 (c3 / cancer~e.3
                        :ARG1-of (d / drive-02~e.4
                              :ARG0 (m / mutate-01~e.10,37
                                    :ARG1 (e5 / enzyme
                                          :name (n3 / name :op1 "Ras"~e.9,36))
                                    :mod (a6 / any~e.6
                                          :ARG1-of (i3 / include-91))
                                    :mod (t2 / this~e.8,35))))))
      :ARG2~e.13 (o / or~e.21
            :op1 (t / treat-03~e.14
                  :ARG1 p~e.28
                  :ARG3~e.15 (s2 / small-molecule
                        :name (n / name :op1 "cetuximab"~e.16)
                        :condition (c / cancer~e.19
                              :mod (c2 / colorectal~e.18))))
            :op2 (t5 / treat-03~e.14
                  :ARG1 p
                  :ARG3 (s3 / small-molecule
                        :name (n2 / name :op1 "erlotinib"~e.22)
                        :condition (a4 / adenocarcinoma~e.25
                              :mod (l / lung~e.24)))))
      :ARG1-of (c5 / cause-01~e.27
            :ARG0 (a3 / and~e.38
                  :op1 (e2 / effective~e.31
                        :polarity~e.31 "-"~e.31
                        :domain~e.11,30 o~e.29
                        :condition~e.32 (c4 / cancer~e.33
                              :ARG1-of (c6 / cause-01~e.27
                                    :ARG0 (m3 / mutate-01~e.37))))
                  :op2 (p2 / possible~e.39
                        :domain (i2 / increase-01~e.41
                              :ARG0 o
                              :ARG1 (r2 / rate~e.42
                                    :degree-of~e.43 (p4 / progress-01~e.44
                                          :ARG1 c4))
                              :mod (e4 / even~e.40))))))

# ::tok Likewise , malignant melanomas with mutant N @-@ Ras are excluded from treatment with vemurafenib .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3 2-1.1.1 3-1.1 5-1.1.2.1 5-1.1.2.1.2 5-1.1.2.1.2.r 6-1.1.2.1.1.1 8-1.1.2.1.1.1 10-1 11-1.2.r 12-1.2 13-1.2.2.r 14-1.2.2.1.1
# ::id pmid_2465_1010.61
# ::preferred 
(e / exclude-01~e.10
      :ARG1 (m / melanoma~e.3
            :mod (m2 / malignant~e.2)
            :ARG0-of (h / have-03
                  :ARG1 (e2 / enzyme~e.5
                        :name (n2 / name :op1 "N-Ras"~e.6,8)
                        :ARG2-of~e.5 (m3 / mutate-01~e.5))))
      :ARG2~e.11 (t / treat-03~e.12
            :ARG1 m
            :ARG3~e.13 (s / small-molecule
                  :name (n / name :op1 "vemurafenib"~e.14)))
      :manner (l / likewise~e.0))

# ::tok However , surprisingly , K @-@ Ras @-@ G13D @-@ bearing colorectal cancers may show clinical benefit when treated with cetuximab .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 2-1.1.2 4-1.1.1.1.2.1.1.1 6-1.1.1.1.2.1.1.1 8-1.1.1.1.2.2.1 10-1.1.1.1.2 11-1.1.1.1.1 12-1.1.1.1 13-1.1 14-1.1.1 15-1.1.1.2.2 16-1.1.1.2 18-1.1.1.2.1 19-1.1.1.2.1.2.r 20-1.1.1.2.1.2.1.1
# ::id pmid_2465_1010.62
# ::preferred 
(c4 / contrast-01~e.0
      :ARG2 (p / possible~e.13
            :domain (s2 / show-01~e.14
                  :ARG0 (c / cancer~e.12
                        :mod (c3 / colorectal~e.11)
                        :ARG0-of (b2 / bear-01~e.10
                              :ARG1 (e / enzyme
                                    :name (n2 / name :op1 "K-Ras"~e.4,6))
                              :ARG2-of (m2 / mutate-01 :value "G13D"~e.8)))
                  :ARG1 (b / benefit-01~e.16
                        :ARG0 (t / treat-03~e.18
                              :ARG1 c
                              :ARG3~e.19 (s / small-molecule
                                    :name (n / name :op1 "cetuximab"~e.20)))
                        :mod (c2 / clinic~e.15)))
            :ARG0-of (s3 / surprise-01~e.2)))

# ::tok This result challenges our understanding of how these Ras mutations actually function in clinical situations ( <ce:cross-ref id="crosref0160" refid="bib16"> De Roock et al. , 2010 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2 1-1.1 1-1.1.1 1-1.1.1.r 2-1 3-1.2.1 3-1.2.1.r 4-1.2 5-1.2.2.r 6-1.2.2.1.r 7-1.2.2.1.1.2 8-1.2.2.1.1.1.1.1 9-1.2.2.1.1 10-1.2.2.1.2 11-1.2.2.1 12-1.2.2.1.3.r 13-1.2.2.1.3.1 14-1.2.2.1.3 19-1.3.1.1.1.1.1 20-1.3.1.1.1.1.2 21-1.3.1.1 22-1.3.1.1.2.1 24-1.3.1.1.2.2.1
# ::id pmid_2465_1010.63
# ::preferred 
(c / challenge-01~e.2
      :ARG0 (t4 / thing~e.1
            :ARG2-of~e.1 (r2 / result-01~e.1)
            :mod (t6 / this~e.0))
      :ARG1 (u / understand-01~e.4
            :ARG0~e.3 (w / we~e.3)
            :ARG1~e.5 (t / thing
                  :manner-of~e.6 (f / function-01~e.11
                        :ARG0 (m2 / mutate-01~e.9
                              :ARG1 (e2 / enzyme
                                    :name (n3 / name :op1 "Ras"~e.8))
                              :mod (t3 / this~e.7))
                        :mod (a / actual~e.10)
                        :condition~e.12 (s / situation~e.14
                              :mod (c2 / clinic~e.13)))))
      :ARG1-of (d / describe-01
            :ARG0 (p / publication-91
                  :ARG0 (a2 / and~e.21
                        :op1 (p2 / person
                              :name (n2 / name :op1 "De"~e.19 :op2 "Roock"~e.20))
                        :op2 (p3 / person
                              :mod (o / other~e.22)
                              :time (d2 / date-entity :year "2010"~e.24))))))

# ::tok Even the prototypic oncogenes of Harvey and Kirsten sarcoma viruses are not fully understood ; each has a codon 12 mutation , but each also carries a mutation of alanine 59 to threonine , which becomes phosphorylated by guanosine triphosphate ( GTP ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2.5 2-1.1.2.3 3-1.2.1.1.2 5-1.1.2.1.1.1.1 6-1.1.2 7-1.1.2.2.1.1.1 8-1.1.2.1.1 8-1.1.2.2.1 9-1.1.2.1.1 9-1.1.2.2.1 11-1.1.1 11-1.1.1.r 12-1.1.3 13-1.1 15-1.2.1.1.2.1 18-1.2.1.1 19-1.2.1.1.1 20-1.2.1 22-1.2 23-1.2.2.1 24-1.2.2.3 25-1.2.2 27-1.2.2.2 28-1.2.2.2.2.r 29-1.2.2.2.2.2.1 30-1.2.2.2.2.1 31-1.2.2.2.1.r 32-1.2.2.2.1.1.1 36-1.2.2.2.1.2 37-1.2.2.2.1.2.1.r 38-1.2.2.2.1.2.1.1.1 39-1.2.2.2.1.2.1.1.2
# ::id pmid_2465_1010.64
# ::preferred 
(m / multi-sentence
      :snt1 (u / understand-01~e.13
            :polarity~e.11 "-"~e.11
            :ARG1 (a / and~e.6
                  :op1 (g3 / gene
                        :part-of (s / sarcoma-virus~e.8,9
                              :name (n / name :op1 "Harvey"~e.5)))
                  :op2 (g4 / gene
                        :part-of (s2 / sarcoma-virus~e.8,9
                              :name (n2 / name :op1 "Kirsten"~e.7)))
                  :mod (p / prototypic~e.2)
                  :ARG0-of (c / cause-01
                        :ARG1 (c2 / cancer))
                  :mod (e / even~e.0))
            :degree (f / full~e.12))
      :snt2 (c3 / contrast-01~e.22
            :ARG1 (m2 / mutate-01~e.20
                  :ARG1 (c5 / codon~e.18
                        :mod "12"~e.19
                        :part-of (o / oncogene~e.3
                              :mod (e2 / each~e.15))))
            :ARG2 (c4 / carry-01~e.25
                  :ARG0 e2~e.23
                  :ARG1 (m3 / mutate-01~e.27
                        :ARG2~e.31 (a4 / amino-acid
                              :name (n8 / name :op1 "threonine"~e.32)
                              :ARG1-of (p2 / phosphorylate-01~e.36
                                    :ARG2~e.37 (s3 / small-molecule
                                          :name (n9 / name
                                                :op1 "guanosine"~e.38
                                                :op2 (t / triphosphate~e.39)))))
                        :ARG3~e.28 (a3 / amino-acid
                              :mod "59"~e.30
                              :name (n7 / name :op1 "alanine"~e.29)))
                  :mod (a5 / also~e.24))))

# ::tok This must have helped Scolnick and colleagues ( <ce:cross-ref id="crosref0165" refid="bib62"> Shih et al. , 1979 </ce:cross-ref> ) identify Ras’ crucial guanosine diphosphate ( GDP )/GTP properties ; without covalent phosphorylation , association with these nucleotides would have been very hard to detect .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 1-1.1 3-1.1.1 4-1.1.1.3.1.1.1 5-1.1.1.3 6-1.1.1.3.2 11-1.1.2.1.1.1.1.1 12-1.1.2.1.1 13-1.1.2.1.1.2.1 15-1.1.2.1.2.1 18-1.1.1.2 20-1.1.1.2.2.3 21-1.1.1.2.2.2.1.1.1 22-1.1.1.2.2.2.1.1.2 28-1.2.3.1 28-1.2.3.1.r 29-1.2.3.3 30-1.2.3 32-1.2.1.1 34-1.1.1.1 35-1.1.1.2.2.2.1 35-1.1.1.2.2.2.2 38-1.2.1.r 39-1.2.2 40-1.2 42-1.2.1
# ::id pmid_2465_1010.65
# ::preferred 
(a3 / and
      :op1 (i / infer-01~e.1
            :ARG1 (h / help-01~e.3
                  :ARG0 (t / this~e.0,34)
                  :ARG1 (i2 / identify-01~e.18
                        :ARG0 (a / and~e.5
                              :op1 (p2 / person
                                    :name (n / name :op1 "Scolnick"~e.4))
                              :op2 (c / colleague~e.6))
                        :ARG1 (c3 / characteristic-02
                              :ARG1 (e / enzyme
                                    :name (n2 / name :op1 "Ras"))
                              :ARG2 (s / slash
                                    :op1 (n5 / nucleotide~e.35
                                          :name (n3 / name :op1 "guanosine"~e.21 :op2 "diphosphate"~e.22))
                                    :op2 (n6 / nucleotide~e.35
                                          :name (n4 / name :op1 "GTP")))
                              :mod (c4 / crucial~e.20)))
                  :ARG2 a)
            :ARG1-of (d / describe-01
                  :ARG0 (p / publication-91
                        :ARG0 (a4 / and~e.12
                              :op1 (p4 / person
                                    :name (n7 / name :op1 "Shih"~e.11))
                              :op2 (p5 / person
                                    :mod (o / other~e.13)))
                        :time (d3 / date-entity :year "1979"~e.15))))
      :op2 (h2 / hard~e.40
            :domain~e.38 (d2 / detect-01~e.42
                  :ARG1 (a2 / associate-01~e.32
                        :ARG0 e
                        :ARG2 s))
            :degree (v / very~e.39)
            :condition (p3 / phosphorylate-01~e.30
                  :polarity~e.28 "-"~e.28
                  :ARG1 e
                  :mod (c5 / covalent~e.29))))

# ::tok However , how phosphorylation at threonine 59 contributes to Ras’ potent oncogenicity is unclear .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 3-1.1.2.1.1 4-1.1.2.1.1.1.r 5-1.1.2.1.1.1.2.1 6-1.1.2.1.1.1.1 7-1.1.2 7-1.1.2.1 7-1.1.2.1.r 8-1.1.2.1.2 10-1.1.2.1.2.3 12-1.1.2.r 13-1.1 13-1.1.1 13-1.1.1.r
# ::id pmid_2465_1010.66
# ::preferred 
(h / have-concession-91~e.0
      :ARG1 (c / clear~e.13
            :polarity~e.13 "-"~e.13
            :domain~e.12 (t / thing~e.7
                  :ARG1-of~e.7 (c2 / contribute-01~e.7
                        :ARG0 (p2 / phosphorylate-01~e.3
                              :ARG1~e.4 (a / amino-acid
                                    :mod "59"~e.6
                                    :name (n2 / name :op1 "threonine"~e.5)
                                    :part-of (e / enzyme
                                          :name (n / name :op1 "Ras"))))
                        :ARG2 (c3 / cause-01~e.8
                              :ARG0 e
                              :ARG1 (c4 / cancer)
                              :mod (p3 / potent~e.10))))))

# ::tok This A59T mutation inhibits Ras @-@ Raf interaction ( <ce:cross-ref id="crosref0170" refid="bib63"> Shirouzu et al. , 1994 </ce:cross-ref> ) and is extremely rare in human cancer .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.2 1-1.1.1.1 2-1.1.1 3-1.1 4-1.1.2.1.1.1 6-1.1.2.2.1.1 7-1.1.2 12-1.1.3.1.1.1.1.1 13-1.1.3.1.1 14-1.1.3.1.1.2.1 16-1.1.3.1.2.1 19-1 20-1.2.3.r 21-1.2.1 22-1.2 23-1.2.2.r 24-1.2.2.1 25-1.2.2
# ::id pmid_2465_1010.67
# ::preferred 
(a / and~e.19
      :op1 (i / inhibit-01~e.3
            :ARG0 (m / mutate-01~e.2
                  :value "A59T"~e.1
                  :mod (t / this~e.0))
            :ARG1 (i2 / interact-01~e.7
                  :ARG0 (e2 / enzyme
                        :name (n / name :op1 "Ras"~e.4))
                  :ARG1 (e3 / enzyme
                        :name (n2 / name :op1 "Raf"~e.6)))
            :ARG1-of (d / describe-01
                  :ARG0 (p / publication-91
                        :ARG0 (a2 / and~e.13
                              :op1 (p2 / person
                                    :name (n3 / name :op1 "Shirouzu"~e.12))
                              :op2 (p3 / person
                                    :mod (o / other~e.14)))
                        :time (d2 / date-entity :year "1994"~e.16))))
      :op2 (r / rare~e.22
            :degree (e / extreme~e.21)
            :location~e.23 (c / cancer~e.25
                  :mod (h / human~e.24))
            :domain~e.20 m))

# ::tok These anecdotes simply remind us that after 50 years , we still have a lot to learn about the biological and biochemical functions of Ras proteins .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1 2-1.4 3-1 4-1.3 6-1.2.4 7-1.2.4.1.1 8-1.2.4.1.2 10-1.2.1 11-1.2.3 14-1.2.2.3 16-1.2.2 17-1.2.2.2.r 19-1.2.2.2.1.2 20-1.2.2.2 21-1.2.2.2.2.2 22-1.2.2.2.1 22-1.2.2.2.2 23-1.2.2.2.1.1.r 24-1.2.2.2.1.1.1.1
# ::id pmid_2465_1010.68
# ::preferred 
(r / remind-01~e.3
      :ARG0 (a / anecdote~e.1
            :mod (t / this~e.0))
      :ARG1 (n / need-01
            :ARG0 (w3 / we~e.10)
            :ARG1 (l / learn-01~e.16
                  :ARG0 w3
                  :ARG1~e.17 (a2 / and~e.20
                        :op1 (f2 / function-01~e.22
                              :ARG0~e.23 (e / enzyme
                                    :name (n3 / name :op1 "Ras"~e.24))
                              :mod (b / biology~e.19))
                        :op2 (f / function-01~e.22
                              :ARG0 e
                              :mod (b2 / biochemical~e.21)))
                  :quant (l2 / lot~e.14))
            :mod (s2 / still~e.11)
            :time (a3 / after~e.6
                  :op1 (t2 / temporal-quantity
                        :quant "50"~e.7
                        :unit (y / year~e.8))))
      :ARG2 (w / we~e.4)
      :mod (s / simple~e.2))

# ::tok Although K @-@ Ras has emerged as by far the major Ras gene mutated in human cancer , it is surprising that other activating mutations in other members of the Ras superfamily , such as R @-@ Ras or Rap proteins , occur very rarely .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.r 1-1.2.1.1.1 3-1.2.2.1.1 5-1.2 6-1.2.3.r 7-1.2.3 8-1.2.3 10-1.2.2.2 11-1.2.2.1.1 12-1.2.2 13-1.2.2.3 14-1.2.2.4.r 15-1.2.2.4.2 16-1.2.2.4.1.1 20-1 22-1.1.4 23-1.1.1 24-1.1 26-1.1.3.1 26-1.1.4 27-1.1.3 30-1.1.3.2.1.1.1 31-1.1.3.2.1.3 33-1.1.3.2.1.2.r 34-1.1.3.2.1.2.r 35-1.1.3.2.1.2.1.1.1 37-1.1.3.2.1.2.1.1.1 38-1.1.3.2.1.2 39-1.1.3.2.1.2.2.1.1 40-1.1.3.2.1 43-1.1.2.1 44-1.1.2
# ::id pmid_2465_1010.69
# ::preferred 
(s / surprise-01~e.20
      :ARG0 (m / mutate-01~e.24
            :ARG0-of (a / activate-01~e.23)
            :frequency (r / rare~e.44
                  :degree (v / very~e.43))
            :location (m2 / member~e.27
                  :mod (o3 / other~e.26)
                  :ARG1-of (i / include-91
                        :ARG2 (p3 / protein~e.40
                              :name (n / name :op1 "Ras"~e.30)
                              :example~e.33,34 (o2 / or~e.38
                                    :op1 (e3 / enzyme
                                          :name (n6 / name :op1 "R-Ras"~e.35,37))
                                    :op2 (e4 / enzyme
                                          :name (n7 / name :op1 "Rap"~e.39)))
                              :mod (s2 / superfamily~e.31))))
            :mod (o / other~e.22,26))
      :concession~e.0 (e / emerge-02~e.5
            :ARG0 (e2 / enzyme
                  :name (n2 / name :op1 "K-Ras"~e.1))
            :ARG1 (g / gene~e.12
                  :name (n3 / name :op1 "Ras"~e.3,11)
                  :mod (m3 / major~e.10)
                  :ARG1-of (m4 / mutate-01~e.13)
                  :location~e.14 (d / disease
                        :name (n4 / name :op1 "cancer"~e.16)
                        :mod (h / human~e.15)))
            :degree~e.6 (b / by-far~e.7,8)))

# ::tok This is surprising because these proteins share identical or near @-@ identical effector @-@ binding regions .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 2-1 3-1.2 4-1.2.1.1.1 5-1.2.1.1 6-1.2.1 7-1.2.1.2.2.2 8-1.2.1.2 9-1.2.1.2.2.2.1 11-1.2.1.2.1.2 11-1.2.1.2.2.2 12-1.2.1.2.1.1.1 14-1.2.1.2.1.1 15-1.2.1.2.1 15-1.2.1.2.2
# ::id pmid_2465_1010.70
# ::preferred 
(s / surprise-01~e.2
      :ARG0 (t / this~e.0)
      :ARG1-of (c / cause-01~e.3
            :ARG0 (s2 / share-01~e.6
                  :ARG0 (p / protein~e.5
                        :mod (t2 / this~e.4))
                  :ARG1 (o / or~e.8
                        :op1 (r / region~e.15
                              :ARG0-of (b / bind-01~e.14
                                    :ARG1 (e / effector~e.12))
                              :ARG1-of (i / identical-01~e.11))
                        :op1 (r2 / region~e.15
                              :ARG0-of b
                              :ARG1-of (i2 / identical-01~e.7,11
                                    :mod (n / near~e.9)))))))

# ::tok However , only H @-@ Ras , N @-@ Ras , and K @-@ Ras are capable of binding and activating Raf kinases , and this unique property may well account for their predominance as human oncogenes .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 2-1.1.1.1.1.4 3-1.1.1.1.1.1.1.1 5-1.1.1.1.1.1.1.1 5-1.1.1.1.1.2.1.1 5-1.1.1.1.1.3.1.1 7-1.1.1.1.1.2.1.1 9-1.1.1.1.1.1.1.1 9-1.1.1.1.1.2.1.1 9-1.1.1.1.1.3.1.1 11-1.1.1.1.1 12-1.1.1.1.1.3.1.1 14-1.1.1.1.1.1.1.1 14-1.1.1.1.1.2.1.1 14-1.1.1.1.1.3.1.1 15-1.1.1.1.r 16-1.1.1.1 17-1.1.1.1.2.r 18-1.1.1.1.2.1 19-1.1.1.1.2 20-1.1.1.1.2.2 21-1.1.1.1.2.1.2.1.1 22-1.1.1.1.2.1.2 24-1 25-1.2.1.1.2 26-1.2.1.1.1 27-1.2.1.1 28-1.1.1 28-1.2 29-1.2.1.3 30-1.2.1 32-1.2.1.2.1 32-1.2.1.2.1.r 35-1.2.1.2.2.1 36-1.2.1.2.2
# ::id pmid_2465_1010.71
# ::preferred 
(a / and~e.24
      :op1 (h2 / have-concession-91~e.0
            :ARG2 (p / possible~e.28
                  :domain~e.15 (c2 / capable-01~e.16
                        :ARG1 (a2 / and~e.11
                              :op1 (e / enzyme
                                    :name (n / name :op1 "H-Ras"~e.3,5,9,14))
                              :op2 (e2 / enzyme
                                    :name (n2 / name :op1 "N-Ras"~e.5,7,9,14))
                              :op3 (e3 / enzyme
                                    :name (n3 / name :op1 "K-Ras"~e.5,9,12,14))
                              :mod (o / only~e.2))
                        :ARG2~e.17 (a3 / and~e.19
                              :op1 (b / bind-01~e.18
                                    :ARG0 a2
                                    :ARG1 (k / kinase~e.22
                                          :name (n4 / name :op1 "RAF"~e.21)))
                              :op2 (a4 / activate-01~e.20
                                    :ARG0 a2
                                    :ARG1 k)))))
      :op2 (p3 / possible~e.28
            :domain (a5 / account-01~e.30
                  :ARG0 (p5 / property~e.27
                        :mod (u / unique~e.26)
                        :mod (t / this~e.25))
                  :ARG1 (p4 / predominate-01
                        :ARG1~e.32 a2~e.32
                        :ARG2 (o2 / oncogene~e.36
                              :mod (h / human~e.35)))
                  :mod (w / well~e.29))))

# ::tok In contrast , the closely related R @-@ Ras proteins bind and activate PI3Ks but are rarely mutated in human cancer ( <ce:cross-ref id="crosref0175" refid="bib56"> Rodriguez @-@ Viciana et al. , 2004 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1 1-1.1 1-1.1.r 4-1.1.1.1.1.2.1 4-1.1.1.1.1.2.1.r 5-1.1.1.1.1.2 6-1.1.1.1.1.1.1 8-1.1.1.1.1.1.1 10-1.1.1.1 11-1.1.1 12-1.1.1.2 14-1.1 16-1.1.2.3 17-1.1.2 18-1.1.2.2.r 19-1.1.2.2.2 20-1.1.2.2.1.1 25-1.2.1.1.1.1.1 27-1.2.1.1.1.1.1 28-1.2.1.1 29-1.2.1.1.2.1 31-1.2.1.2.1
# ::id pmid_2465_1010.72
# ::preferred 
(c / contrast-01~e.1
      :ARG2~e.1 (c3 / contrast-01~e.1,14
            :ARG1 (a / and~e.11
                  :op1 (b / bind-01~e.10
                        :ARG0 (e / enzyme
                              :name (n2 / name :op1 "R-Ras"~e.6,8)
                              :ARG1-of (r / relate-01~e.5
                                    :manner~e.4 (c2 / close~e.4)))
                        :ARG1 (e2 / enzyme
                              :name (n4 / name :op1 "PI3K")))
                  :op2 (a2 / activate-01~e.12
                        :ARG0 e
                        :ARG1 e2))
            :ARG2 (m / mutate-01~e.17
                  :ARG1 e
                  :location~e.18 (d3 / disease
                        :name (n3 / name :op1 "cancer"~e.20)
                        :mod (h / human~e.19))
                  :frequency (r2 / rare~e.16)))
      :ARG1-of (d2 / describe-01
            :ARG0 (p / publication-91
                  :ARG0 (a3 / and~e.28
                        :op1 (p3 / person
                              :name (n5 / name :op1 "Rodriguez-Viciana"~e.25,27))
                        :op2 (p2 / person
                              :mod (o / other~e.29)))
                  :time (d / date-entity :year "2004"~e.31))))

# ::tok Activating mutations in Ras genes , coupled with a long history of Ras biology , implicate these mutant Ras proteins as major drivers in many cancers .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1.1.2 2-1.1.2.1.r 3-1.1.2.1.1.1 4-1.1.2.1 6-1.1.3 7-1.1.3.1.r 9-1.1.3.1.2 10-1.1.3.1 11-1.1.3.1.1.r 12-1.1.3.1.1.1.1.1 13-1.1.3.1.1 15-1 16-1.2.1.3 17-1.2.1.2 18-1.2.1.1.1 19-1.2.1 21-1.2.2 24-1.2.3.2 25-1.2.3.1.1
# ::id pmid_2465_1010.73
# ::preferred 
(i / implicate-01~e.15
      :ARG0 (a / activate-01~e.0
            :ARG0 (p2 / protein~e.19
                  :name (n2 / name :op1 "Ras"~e.18)
                  :ARG1-of (m / mutate-01~e.17)
                  :mod (t / this~e.16))
            :ARG1 (m2 / mutate-01~e.1
                  :ARG1~e.2 (g / gene~e.4
                        :name (n3 / name :op1 "Ras"~e.3)))
            :ARG1-of (c / couple-01~e.6
                  :ARG2~e.7 (h / history~e.10
                        :topic~e.11 (b / biology~e.13
                              :mod (e / enzyme
                                    :name (n / name :op1 "Ras"~e.12)))
                        :duration (l / long~e.9))))
      :ARG2 (d2 / drive-02
            :ARG0 p2
            :mod (m3 / major~e.21)
            :location (d3 / disease
                  :name (n4 / name :op1 "cancer"~e.25)
                  :quant (m4 / many~e.24))))

# ::tok Loss of the Ras GTPase @-@ activating protein ( GAP ) neurofibromin inculpates hyperactive wild @-@ type Ras proteins as drivers in many more cancers .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1.1.1.r 3-1.1.1.2.1.1 4-1.1.1.2.1.2 6-1.1.1 7-1.1.1.1 7-1.1.1.2 11-1.1.1.1.1.1 12-1 13-1.2.2.1 14-1.2.2 16-1.2.2 17-1.2.1.1 18-1.1.1.1 22-1.2.3.1.2.1 23-1.2.3.1.2 24-1.2.3.1.1.1
# ::id pmid_2465_1010.74
# ::preferred 
(i / inculpate-00~e.12
      :ARG0 (l / lose-02~e.0
            :ARG0~e.1 (a / activate-01~e.6
                  :ARG0 (p2 / protein~e.7,18
                        :name (n2 / name :op1 "neurofibromin"~e.11))
                  :ARG1 (p / protein~e.7
                        :name (n / name :op1 "Ras"~e.3 :op2 "GTPase"~e.4))))
      :ARG1 (e / enzyme
            :name (n3 / name :op1 "Ras"~e.17)
            :mod (w / wild-type~e.14,16
                  :mod (h / hyperactive~e.13))
            :ARG0-of (d3 / drive-02
                  :ARG1 (d2 / disease
                        :name (n4 / name :op1 "cancer"~e.24)
                        :mod (m / more~e.23
                              :mod (m2 / many~e.22))))))

# ::tok Somatic loss of neurofibromin expression by mutation , deletion , or by other means occurs in about 14 % glioblastoma , 13 %–14 % melanoma , 8 %–10 % lung adenocarcinoma , and at single @-@ digit frequency in most other cancers ( E.A . Collisson , personal communication ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2 1-1 2-1.1.r 3-1.1.1.1.1 4-1.1 5-1.1.2.r 6-1.1.2.1 8-1.1.2.2 10-1.1.2 12-1.1.2.3.1 13-1.1.2.3 17-1.1.3.1.2.1 17-1.1.3.2.2.1.2 18-1.1.3.1.2 19-1.1.3.1.1.1 21-1.1.3.2.2.1.1 23-1.1.3.1.2 24-1.1.3.2.1.1 26-1.1.3.3.2.1.1 28-1.1.3.2.2 28-1.1.3.3.2 29-1.1.3.3.1.1 30-1.1.3.3.1.2 32-1.1.3 33-1.1.3.r 34-1.1.3.4.3 36-1.1.3.4.3 39-1.1.3.4.2.1 40-1.1.3.4.2 41-1.1.3.4.1.1 45-1.3.1.1.1.2 47-1.3.1.2 48-1.3.1
# ::id pmid_2465_1010.75
# ::preferred 
(l / lose-01~e.1
      :ARG1~e.2 (e / express-03~e.4
            :ARG2 (p3 / protein
                  :name (n / name :op1 "neurofibromin"~e.3))
            :manner~e.5 (o2 / or~e.10
                  :op1 (m / mutate-01~e.6)
                  :op2 (d / delete-01~e.8)
                  :op3 (m2 / mean~e.13
                        :mod (o / other~e.12)))
            :location~e.33 (a2 / and~e.32
                  :op1 (d4 / disease
                        :name (n4 / name :op1 "glioblastoma"~e.19)
                        :mod (p2 / percentage-entity~e.18,23 :value "14"~e.17))
                  :op2 (d3 / disease
                        :name (n2 / name :op1 "melanoma"~e.24)
                        :mod (p5 / percentage-entity~e.28
                              :value (b / between :op1 "13"~e.21 :op2 "14"~e.17)))
                  :op3 (d2 / disease
                        :name (n3 / name :op1 "lung"~e.29 :op2 "adenocarcinoma"~e.30)
                        :mod (p6 / percentage-entity~e.28
                              :value (b2 / between :op1 "8"~e.26 :op2 "10")))
                  :op4 (d6 / disease
                        :name (n6 / name :op1 "cancer"~e.41)
                        :mod (o3 / other~e.40
                              :degree (m3 / most~e.39))
                        :frequency (s2 / single-digit~e.34,36))))
      :mod (s / somatic~e.0)
      :ARG1-of (d5 / describe-01
            :ARG0 (c2 / communicate-01~e.48
                  :ARG0 (p / person
                        :name (n5 / name :op1 "E.A." :op2 "Collisson"~e.45))
                  :mod (p4 / personal~e.47))))

# ::tok Neurofibromin must now be considered as a major tumor suppressor , along with p53 and phosphatase and tensin homolog , in human cancers .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1.1.1 1-1 2-1.1.2 4-1.1 5-1.1.2.r 7-1.1.1.5.2 8-1.1.1.5.1 12-1.1.1.r 13-1.1.1.2.1.1 14-1.1.1 15-1.1.1.3.1.1 16-1.1.1 17-1.1.1.4.1.1 18-1.1.1.4.1.2 21-1.1.1.5.3.1 22-1.1.1.5.3
# ::id pmid_2465_1010.76
# ::preferred 
(o2 / obligate-01~e.1
      :ARG2 (c / consider-01~e.4
            :ARG1~e.12 (a / and~e.14,16
                  :op1 (p2 / protein
                        :name (n / name :op1 "Neurofibromin"~e.0))
                  :op2 (p3 / protein
                        :name (n2 / name :op1 "p53"~e.13))
                  :op3 (p4 / protein
                        :name (n3 / name :op1 "phosphatase"~e.15))
                  :op4 (p / protein
                        :name (n5 / name :op1 "tensin"~e.17 :op2 "homolog"~e.18))
                  :ARG0-of (s / suppress-01
                        :ARG1 (t / tumor~e.8)
                        :mod (m / major~e.7)
                        :location (c2 / cancer~e.22
                              :mod (h / human~e.21))))
            :time~e.5 (n4 / now~e.2)))

# ::tok Loss of neurofibromin is usually mutually exclusive with Ras mutation and receptor tyrosine kinase ( RTK ) activation , suggesting that these genetic events represent different ways of activating similar pathways .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1.1.1.r 2-1.1.1.1.1.1 4-1.1.4 5-1.1.3 5-1.1.3.r 8-1.1.2.1.1.1.1 9-1.1.2.1 10-1.1.2 11-1.1.2.2.1.1.1 12-1.1.2.2.1.1.2 13-1.1.2.2.1.1.3 17-1.1.2.2 19-1 20-1.2.r 21-1.2.1.2 23-1.2.1 24-1.2 25-1.2.2.2 26-1.2.2 27-1.2.2.1.r 28-1.2.2.1 29-1.2.2.1.2.1 30-1.2.2.1.2
# ::id pmid_2465_1010.77
# ::preferred 
(s2 / suggest-01~e.19
      :ARG0 (e2 / exclude-01
            :ARG0 (l / lose-01~e.0
                  :ARG1~e.1 (p / protein
                        :name (n2 / name :op1 "neurofibromin"~e.2)))
            :ARG1 (a2 / and~e.10
                  :op1 (m2 / mutate-01~e.9
                        :ARG1 (e / enzyme
                              :name (n / name :op1 "Ras"~e.8)))
                  :op2 (a3 / activate-01~e.17
                        :ARG1 (p4 / protein
                              :name (n3 / name
                                    :op1 "receptor"~e.11
                                    :op2 "tyrosine"~e.12
                                    :op3 "kinase"~e.13))))
            :manner~e.5 (m / mutual~e.5)
            :mod (u / usual~e.4))
      :ARG1~e.20 (r / represent-01~e.24
            :ARG0 (e4 / event~e.23
                  :mod (g / gene)
                  :mod (t / this~e.21))
            :ARG1 (w / way~e.26
                  :manner-of~e.27 (a / activate-01~e.28
                        :ARG0 e4
                        :ARG1 (p3 / pathway~e.30
                              :ARG1-of (r2 / resemble-01~e.29)))
                  :ARG1-of (d / differ-02~e.25))))

# ::tok However , the precise consequences of losing neurofibromin are not entirely clear .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 3-1.1.3.1 4-1.1.3 4-1.1.3.2 4-1.1.3.2.r 5-1.1.3.2.1.r 6-1.1.3.2.1 7-1.1.3.2.1.1.1.1 8-1.1.3.r 9-1.1.1 9-1.1.1.r 10-1.1.2 11-1.1
# ::id pmid_2465_1010.78
# ::preferred 
(h / have-concession-91~e.0
      :ARG2 (c3 / clear~e.11
            :polarity~e.9 "-"~e.9
            :degree (e / entire~e.10)
            :domain~e.8 (c / consequence~e.4
                  :mod (p2 / precise~e.3)
                  :ARG1-of~e.4 (c2 / cause-01~e.4
                        :ARG0~e.5 (l / lose-01~e.6
                              :ARG1 (p / protein
                                    :name (n / name :op1 "neurofibromin"~e.7)))))))

# ::tok Levels of Ras @-@ GTP are high in cells lacking neurofibromin , but which forms of hyperactive wild @-@ type Ras proteins are most important to the malignant phenotype is a more difficult question .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1.1.1.r 2-1.1.1.1.2 4-1.1.1.1.1.1.1 5-1.1.1.r 6-1.1 7-1.1.2.r 8-1.1.2 9-1.1.2.1 10-1.1.2.1.1.2.1 12-1 14-1.2.2 15-1.2.2.1.r 16-1.2.2.1.3 17-1.2.2.1.2 19-1.2.2.1.2 20-1.2.2.1.1.1 21-1.1.2.1.1 22-1.2.2.r 23-1.2.4 23-1.2.6 24-1.2 25-1.2.3.r 27-1.2.3.1 28-1.2.3 29-1.2.2.r 31-1.2.5.1.1 32-1.2.5.1 33-1.2.5
# ::id pmid_2465_1010.79
# ::preferred 
(c / contrast-01~e.12
      :ARG1 (h / high~e.6
            :domain~e.5 (l / level~e.0
                  :mod~e.1 (m3 / macro-molecular-complex
                        :part (s / small-molecule
                              :name (n4 / name :op1 "GTP"~e.4))
                        :part e~e.2))
            :location~e.7 (c2 / cell~e.8
                  :ARG0-of (l2 / lack-01~e.9
                        :ARG1 (p / protein~e.21
                              :polarity "-"
                              :name (n2 / name :op1 "neurofibromin"~e.10)))))
      :ARG2 (i2 / important~e.24
            :mode "interrogative"
            :domain~e.22,29 (f / form~e.14
                  :mod~e.15 (e / enzyme
                        :name (n / name :op1 "Ras"~e.20)
                        :mod (w / wild-type~e.17,19)
                        :mod (h2 / hyperactive~e.16)))
            :beneficiary~e.25 (p4 / phenotype~e.28
                  :mod (m2 / malignant~e.27))
            :degree (m5 / most~e.23)
            :ARG1-of (q / question-01~e.33
                  :mod (d / difficult~e.32
                        :degree (m / more~e.31)))
            :degree (m4 / most~e.23)))

# ::tok Perhaps elevated H @-@ Ras , N @-@ Ras , K @-@ Ras @-@ 4A , and K @-@ Ras @-@ 4B all contribute to some extent .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.1.1.5 2-1.1.1.1.1.1 4-1.1.1.1.1.1 4-1.1.1.2.1.1 4-1.1.1.3.1.1 4-1.1.1.4.1.1 6-1.1.1.2.1.1 8-1.1.1.1.1.1 8-1.1.1.2.1.1 8-1.1.1.3.1.1 8-1.1.1.4.1.1 10-1.1.1.3.1.1 10-1.1.1.4.1.1 12-1.1.1.1.1.1 12-1.1.1.2.1.1 12-1.1.1.3.1.1 12-1.1.1.4.1.1 14-1.1.1.3.1.1 16-1.1.1 17-1.1.1.3.1.1 17-1.1.1.4.1.1 19-1.1.1.1.1.1 19-1.1.1.2.1.1 19-1.1.1.3.1.1 19-1.1.1.4.1.1 21-1.1.1.4.1.1 22-1.1.1.6 23-1.1 24-1.1.2.r 25-1.1.2.1 26-1.1.2
# ::id pmid_2465_1010.80
# ::preferred 
(p / possible~e.0
      :domain (c / contribute-01~e.23
            :ARG1 (a / and~e.16
                  :op1 (e / enzyme
                        :name (n / name :op1 "H-Ras"~e.2,4,8,12,19))
                  :op2 (e2 / enzyme
                        :name (n2 / name :op1 "N-Ras"~e.4,6,8,12,19))
                  :op3 (e3 / enzyme
                        :name (n3 / name :op1 "K-Ras-4A"~e.4,8,10,12,14,17,19))
                  :op4 (e4 / enzyme
                        :name (n4 / name :op1 "K-Ras-4B"~e.4,8,10,12,17,19,21))
                  :ARG1-of (e5 / elevate-01~e.1)
                  :mod (a2 / all~e.22))
            :degree~e.24 (e6 / extent~e.26
                  :mod (s2 / some~e.25))))

# ::tok However , neurofibromin is also a GAP for R @-@ Ras proteins , and hyperactivation of these proteins can also contribute to the malignant phenotype because R @-@ Ras proteins activate p110α, p110γ, and p110δ isoforms of PI3Ks ( <ce:cross-refs id="crosrefs0020" refid="bib42 bib28"> Marte et al. , 1997; Huang et al. , 2004 </ce:cross-refs> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 2-1.1.1.2.1.1 3-1.1.1.2.r 4-1.1.1.2.2 6-1.1.1.1.1 8-1.1.1.3.1.1 10-1.1.1.3.1.1 11-1.1.1.2 17-1.1.1.2 18-1.1.2 19-1.1.1.4 20-1.1.2.1 21-1.1.2.1.2.r 23-1.1.2.1.2.1 24-1.1.2.1.2 25-1.1.2.2 26-1.1.1.3.1.1 28-1.1.1.3.1.1 29-1.1.1.3 30-1.1.2.1.1 30-1.1.2.2.1 33-1.1.2.2.1.2.1 34-1.1.2.2.1.2.1.3.1.1 43-1.2.1.1.1.1.1.1 44-1.2.1 44-1.2.1.1.1 44-1.2.1.2.1 45-1.2.1.1.1.2.1 45-1.2.1.2.1.2.1 48-1.2.1.2.1.1.1.1 49-1.1 49-1.2.1.2.1 50-1.2.1.2.1.2.1 52-1.2.1.2.2.1
# ::id pmid_2465_1010.81
# ::preferred 
(h2 / have-concession-91~e.0
      :ARG2 (a / and~e.49
            :op1 (m / molecular-physical-entity
                  :name (n / name :op1 "GAP"~e.6)
                  :domain~e.3 (p / protein~e.11,17
                        :name (n2 / name :op1 "neurofibromin"~e.2)
                        :mod (a2 / also~e.4))
                  :beneficiary (p2 / protein~e.29
                        :name (n3 / name :op1 "R-Ras"~e.8,10,26,28))
                  :mod (a8 / also~e.19))
            :op2 (p3 / possible~e.18
                  :domain (c2 / contribute-01~e.20
                        :ARG0 (a3 / activate-01~e.30
                              :ARG1 (a5 / and~e.33
                                    :op1 (i2 / isoform
                                          :name (n4 / name :op1 "p110α"))
                                    :op2 (i3 / isoform
                                          :name (n5 / name :op1 "p110γ"))
                                    :op3 (i4 / isoform
                                          :name (n6 / name :op1 "p110δ"~e.34))
                                    :mod (e / enzyme
                                          :name (n7 / name :op1 "PI3K")))
                              :degree (h3 / hyper))
                        :ARG2~e.21 (p4 / phenotype~e.24
                              :mod (m3 / malignant~e.23))
                        :mod a8)
                  :ARG1-of (c3 / cause-01~e.25
                        :ARG0 (a4 / activate-01~e.30
                              :ARG0 p2
                              :ARG1 (i / include-91
                                    :ARG1 a5)))))
      :ARG1-of (d3 / describe-01
            :ARG0 (a6 / and~e.44
                  :op1 (p6 / publication-91
                        :ARG0 (a9 / and~e.44
                              :op1 (p5 / person
                                    :name (n9 / name :op1 "Marte"~e.43))
                              :op2 (p8 / person
                                    :mod (o / other~e.45)))
                        :time (d / date-entity :year "1997"))
                  :op2 (p7 / publication-91
                        :ARG0 (a7 / and~e.44,49
                              :op1 (p9 / person
                                    :name (n10 / name :op1 "Huang"~e.48))
                              :op2 (p10 / person
                                    :mod (o2 / other~e.45,50)))
                        :time (d2 / date-entity :year "2004"~e.52)))))

# ::tok Recently , Legius and colleagues ( <ce:cross-ref id="crosref0180" refid="bib7"> Brems et al. , 2007 </ce:cross-ref> ) discovered mutations in the Sprouty @-@ related protein , SPRED1 , in a form of neurofibromatosis type I ( NF1 ) in which the neurofibromin gene is wild @-@ type .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3 2-1.1.1.1.1 3-1.1 3-1.1.3.1.1 4-1.1.2 9-1.1.3.1.1.1.1.1 10-1.1.3.1.1 11-1.1.3.1.1.2.1 13-1.1.3.1.2.1 16-1 17-1.2 18-1.2.1.r 20-1.2.1.2.1.1.1 22-1.2.1.2 23-1.2.1 23-1.2.1.2.1 23-1.2.2.1.2.1.1 25-1.2.1.1.1 27-1.2.2.r 29-1.2.2 30-1.2.2.1.r 31-1.2.2.1.1.1 32-1.2.2.1.1.2 33-1.2.2.1.1.3 40-1.2.2.1.2.1.1.1.1 41-1.2.2.1.2 43-1.2.2.1.2.2 45-1.2.2.1.2.2
# ::id pmid_2465_1010.82
# ::preferred 
(d2 / discover-01~e.16
      :ARG0 (a / and~e.3
            :op1 (p / person
                  :name (n / name :op1 "Legius"~e.2))
            :op2 (c / colleague~e.4)
            :ARG1-of (d3 / describe-01
                  :ARG0 (p5 / publication-91
                        :ARG0 (a2 / and~e.3,10
                              :op1 (p6 / person
                                    :name (n6 / name :op1 "Brems"~e.9))
                              :op2 (p7 / person
                                    :mod (o2 / other~e.11)))
                        :time (d / date-entity :year "2007"~e.13))))
      :ARG1 (m / mutate-01~e.17
            :ARG1~e.18 (p2 / protein~e.23
                  :name (n2 / name :op1 "SPRED1"~e.25)
                  :ARG1-of (r2 / relate-01~e.22
                        :ARG2 (p3 / protein~e.23
                              :name (n3 / name :op1 "Sprouty"~e.20))))
            :location~e.27 (f / form~e.29
                  :mod~e.30 (d4 / disease
                        :name (n4 / name
                              :op1 "neurofibromatosis"~e.31
                              :op2 "type"~e.32
                              :op3 "I"~e.33)
                        :location-of (g / gene~e.41
                              :ARG0-of (e / encode-01
                                    :ARG1 (p4 / protein~e.23
                                          :name (n5 / name :op1 "neurofibromin"~e.40)))
                              :mod (w / wild-type~e.43,45)))))
      :time (r / recent~e.0))

# ::tok This disease is now called Legius syndrome ( <ce:cross-ref id="crosref0185" refid="bib7"> Brems et al. , 2007 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1 3-1.3 4-1 4-1.4.1.1.1.1.r 5-1.2.1 6-1.2.2 11-1.4.1.1.1.1.1 12-1.4.1.1 13-1.4.1.1.2.1 15-1.4.1.2.1
# ::id pmid_2465_1010.83
# ::preferred 
(c / call-01~e.4
      :ARG1 (d2 / disease~e.1
            :mod (t / this~e.0))
      :ARG2 (n / name :op1 "Legius"~e.5 :op2 "syndrome"~e.6)
      :time (n2 / now~e.3)
      :ARG1-of (d4 / describe-01
            :ARG0 (p / publication-91
                  :ARG0 (a / and~e.12
                        :op1 (p2 / person
                              :name~e.4 (n3 / name :op1 "Brems"~e.11))
                        :op2 (p3 / person
                              :mod (o / other~e.13)))
                  :time (d / date-entity :year "2007"~e.15))))

# ::tok SPRED1 has a well @-@ established pedigree as a negative regulator of the Raf @/@ MAPK pathway , though the mechanism has been unclear .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 1-1 3-1.2.1.1 5-1.2.1 6-1.2 13-1.1.2.1.1.1 15-1.1.2.1.1.1 16-1.1.2.1 18-1.3 20-1.3.1.2 22-1.3.1.2.r 23-1.3.1 23-1.3.1.1 23-1.3.1.1.r
# ::id pmid_2465_1010.84
# ::preferred 
(h / have-03~e.1
      :ARG0 (p / protein
            :name (n / name :op1 "SPRED1"~e.0)
            :ARG2-of (d / downregulate-01
                  :ARG1 (p3 / pathway~e.16
                        :name (n2 / name :op1 "Raf/MAPK"~e.13,15))))
      :ARG1 (p2 / pedigree~e.6
            :ARG1-of (e / establish-01~e.5
                  :manner (g / good~e.3)))
      :ARG1-of (h2 / have-concession-91~e.18
            :ARG2 (c / clear~e.23
                  :polarity~e.23 "-"~e.23
                  :domain~e.22 (m2 / mechanism~e.20))))

# ::tok However , the fact that loss of neurofibromin is , to a significant extent , phenocopied by loss of SPRED1 , supports the idea that NF1 is a disease of hyperactive Ras and that the major function of neurofibromin is to turn Ras off .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 5-1.1.1.1 5-1.1.1.2 7-1.1.1.2.1.1.1 12-1.1.1.3 17-1.1.1.1 17-1.1.1.2 18-1.1.1.1.1.r 19-1.1.1.1.1.1.1 21-1.1 23-1.1.2 25-1.1.2.1.1.2.1.1 26-1.1.2.1.1.2.r 28-1.1.2.1.1 30-1.1.2.1.1.1.1.2 31-1.1.2.1.1.1.1.1.1 32-1.1.2.1 35-1.1.2.1.2.3 36-1.1.2.1.2 37-1.1.2.1.2.2.r 38-1.1.2.1.2.2.1 39-1.1.2.1.1.2.r 40-1.1.2.1.1.1 41-1.1.2.1.2.2 42-1.1.2.1.2.2.2.1.1 43-1.1.2.1.2.2
# ::id pmid_2465_1010.85
# ::preferred 
(h2 / have-concession-91~e.0
      :ARG1 (s / support-01~e.21
            :ARG0 (p / phenocopy-00
                  :ARG0 (l / lose-01~e.5,17
                        :ARG1~e.18 (p2 / protein
                              :name (n2 / name :op1 "SPRED1"~e.19)))
                  :ARG1 (l2 / lose-01~e.5,17
                        :ARG1 (p3 / protein
                              :name (n3 / name :op1 "neurofibromin"~e.7)))
                  :ARG1-of (s2 / significant-02~e.12))
            :ARG1 (i / idea~e.23
                  :topic (a / and~e.32
                        :op1 (d / disease~e.28
                              :ARG1-of (c2 / cause-01~e.40
                                    :ARG0 (e / enzyme
                                          :name (n / name :op1 "Ras"~e.31)
                                          :mod (h / hyperactive~e.30)))
                              :domain~e.26,39 (d2 / disease
                                    :name (n4 / name :op1 "NF1"~e.25)))
                        :op1 (f / function-01~e.36
                              :ARG0 p3
                              :ARG1~e.37 (t / turn-off-07~e.41,43
                                    :ARG0 p3~e.38
                                    :ARG1 (e2 / enzyme
                                          :name (n5 / name :op1 "Ras"~e.42)))
                              :mod (m / major~e.35))))))

# ::tok The neurofibromin protein itself is over 2,800 amino acids in length , and the GAP domain only accounts for about 300 amino acids , raising the possibility that neurofibromin has other functions that are not directly related to negative regulation of Ras .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.2.1.1 2-1.1.2 2-1.2.1 4-1.1.2.r 5-1.1.1.1 6-1.1.1.1.1 7-1.1.1 8-1.1.1 10-1.1 12-1 14-1.2.1.1.1 15-1.2.1.1.2 16-1.2.3 17-1.2 18-1.2.2.r 19-1.2.2.1 20-1.2.2.1.1 21-1.2.2 22-1.2.2 24-1.3 26-1.3.1 28-1.3.1.1.1 30-1.3.1.1.2 31-1.3.1.1 33-1.3.1.1.r 34-1.3.1.1.2.1.1 34-1.3.1.1.2.1.1.r 35-1.3.1.1.2.1.3 35-1.3.1.1.2.1.3.r 36-1.3.1.1.2.1 41-1.3.1.1.2.1.2.1.1.1
# ::id pmid_2465_1010.86
# ::preferred 
(a2 / and~e.12
      :op1 (l2 / long~e.10
            :mod (a3 / amino-acid~e.7,8
                  :quant (o / over~e.5 :op1 "2800"~e.6))
            :domain~e.4 (p / protein~e.2
                  :name (n2 / name :op1 "neurofibromin"~e.1)))
      :op2 (a4 / account-01~e.17
            :ARG0 (p2 / protein-segment~e.2
                  :name (n3 / name :op1 "GAP"~e.14 :op2 "domain"~e.15))
            :ARG1~e.18 (a5 / amino-acid~e.21,22
                  :quant (a / about~e.19 :op1 "300"~e.20))
            :mod (o3 / only~e.16))
      :ARG0-of (r / raise-01~e.24
            :ARG1 (p3 / possible~e.26
                  :domain~e.33 (f / function-01~e.31
                        :ARG0 p~e.28
                        :ARG1 (o2 / other~e.30
                              :ARG1-of (r2 / relate-01~e.36
                                    :polarity~e.34 "-"~e.34
                                    :ARG2 (d4 / downregulate-01
                                          :ARG1 (e / enzyme
                                                :name (n / name :op1 "Ras"~e.41)))
                                    :manner~e.35 (d5 / direct~e.35)))))))

# ::tok Most attempts to identify additional functions have failed , however , and it seems most likely that neurofibromin senses an unidentified cellular metabolite and downregulates Ras accordingly , just as p120 Ras @-@ GAP senses phosphotyrosine residues , and downregulates Ras when it binds to these residues on activated receptors in the plasma membrane ( reviewed in <ce:cross-ref id="crosref0190" refid="bib6"> Bos et al. , 2007 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1.2 1-1.1.1.1 3-1.1.1.1.1 4-1.1.1.1.1.1.1 5-1.1.1.1.1.1 7-1.1.1 9-1.1 11-1 13-1.2.2 14-1.2.1 15-1.2 16-1.2.2.1.r 17-1.2.2.1.1.1.1.1 18-1.2.2.1.1 20-1.2.2.1.1.2.2 20-1.2.2.1.1.2.2.1 20-1.2.2.1.1.2.2.1.r 21-1.2.2.1.1.2.1 22-1.2.2.1.1.2 23-1.2.2.1 25-1.2.2.1.2.1.1.1 26-1.2.2.1.2.3 28-1.2.2.1.3.2 30-1.2.2.1.3.1.1.1.1.1 31-1.2.2.1.3.1.1.1.1.2 33-1.2.2.1.3.1.1.1.1.2 34-1.2.2.1.3.1.1 36-1.2.2.1.3.1.1.2 38-1.2.2.1.3.1 40-1.2.2.1.3.1.2.3.1 41-1.2.2.1.3.1.2.3.r 43-1.2.2.1.3.1.2.3 46-1.2.2.1.3.1.2.3.2 47-1.2.2.1.3.1.2.3.3.r 48-1.2.2.1.3.1.2.3.3.1 49-1.2.2.1.3.1.2.3.3 50-1.2.2.1.3.1.2.3.4.r 52-1.2.2.1.3.1.2.3.4.1 53-1.2.2.1.3.1.2.3.4 55-1.3 60-1.3.1.1.1.1.1 61-1.3.1.1 62-1.3.1.1.2.1 64-1.3.1.2.1
# ::id pmid_2465_1010.87
# ::preferred 
(a / and~e.11
      :op1 (h / have-concession-91~e.9
            :ARG1 (f / fail-01~e.7
                  :ARG1 (a2 / attempt-01~e.1
                        :ARG1 (i2 / identify-01~e.3
                              :ARG1 (f2 / function-01~e.5
                                    :mod (a3 / additional~e.4)))
                        :quant (m2 / most~e.0))))
      :op2 (l / likely~e.15
            :degree (m / most~e.14)
            :domain (s / seem-01~e.13
                  :ARG1~e.16 (a4 / and~e.23
                        :op1 (s2 / sense-01~e.18
                              :ARG0 (p / protein
                                    :name (n2 / name :op1 "neurofibromin"~e.17))
                              :ARG1 (m4 / metabolite~e.22
                                    :mod (c2 / cell~e.21)
                                    :ARG1-of (i / identify-01~e.20 :polarity~e.20 "-"~e.20)))
                        :op2 (d2 / downregulate-01
                              :ARG1 (e / enzyme
                                    :name (n / name :op1 "Ras"~e.25))
                              :ARG2 p
                              :manner (a5 / accordingly~e.26))
                        :ARG1-of (r / resemble-01
                              :ARG2 (a7 / and~e.38
                                    :op1 (s3 / sense-01~e.34
                                          :ARG0 (p2 / protein
                                                :name (n3 / name :op1 "p120"~e.30 :op2 "Ras-GAP"~e.31,33))
                                          :ARG1 (r2 / residue~e.36
                                                :mod (a6 / amino-acid
                                                      :name (n4 / name :op1 "threonine")
                                                      :ARG3-of (p3 / phosphorylate-01))))
                                    :op2 (d3 / downregulate-01
                                          :ARG1 e
                                          :ARG2 p2
                                          :time~e.41 (b / bind-01~e.43
                                                :ARG1 p2~e.40
                                                :ARG2 r2~e.46
                                                :ARG3~e.47 (r3 / receptor~e.49
                                                      :ARG1-of (a8 / activate-01~e.48))
                                                :location~e.50 (m3 / membrane~e.53
                                                      :part-of (p4 / plasma~e.52)))))
                              :mod (j / just~e.28)))))
      :ARG1-of (r4 / review-01~e.55
            :ARG0 (p5 / publication-91
                  :ARG0 (a9 / and~e.61
                        :op1 (p6 / person
                              :name (n5 / name :op1 "Bos"~e.60))
                        :op2 (p7 / person
                              :mod (o / other~e.62)))
                  :time (d / date-entity :year "2007"~e.64))))

# ::tok Whatever neurofibromin senses ( if this model is correct ) is likely to be conserved between <i> S . cerevisiae </i> and humans because the <i> S . cerevisiae </i> IRA1 and IRA2 proteins look very much like neurofibromin .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1.1.1.1.1 2-1.1.1 2-1.1.1.1 2-1.1.1.1.r 4-1.2.r 5-1.2.1.1 6-1.2.1 7-1.2.1.r 8-1.2 10-1.1.r 11-1 12-1.3 13-1.1.r 14-1.1 15-1.1.2 19-1.1.2.1.1.2 21-1.1.2 22-1.1.2.2 23-1.3 28-1.3.1.1.1.2 30-1.3.1.1.1.1.1 31-1.3.1.1 32-1.3.1.1.2.1.1 33-1.1.1.1.1 33-1.3.1.1.1 33-1.3.1.1.2 35-1.3.1.3.1 36-1.3.1.3 37-1.3.1 38-1.3.1.2
# ::id pmid_2465_1010.88
# ::preferred 
(l / likely~e.11
      :domain~e.10,13 (c / conserve-01~e.14
            :ARG1 (t / thing~e.2
                  :ARG1-of~e.2 (s / sense-01~e.2
                        :ARG0 (p / protein~e.33
                              :name (n / name :op1 "neurofibromin"~e.1))))
            :location (b / between~e.15,21
                  :op1 (o / organism
                        :name (n2 / name :op1 "S." :op2 "cerevisiae"~e.19))
                  :op2 (h / human~e.22)))
      :condition~e.4 (c2 / correct~e.8
            :domain~e.7 (m2 / model~e.6
                  :mod (t2 / this~e.5)))
      :ARG1-of (c3 / cause-01~e.12,23
            :ARG0 (r / resemble-01~e.37
                  :ARG1 (a / and~e.31
                        :op1 (p2 / protein~e.33
                              :name (n3 / name :op1 "IRA1"~e.30)
                              :mod o~e.28)
                        :op2 (p3 / protein~e.33
                              :name (n4 / name :op1 "IRA2"~e.32)
                              :mod o))
                  :ARG2 p~e.38
                  :degree (m / much~e.36
                        :degree (v / very~e.35)))))

# ::tok Unfortunately , the complete lack of any recognizable domains or motifs outside the GAP domain and a SEC14 domain has not helped in identifying what these proteins recognize .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.4 0-1.4.1 3-1.2.2 4-1.2 5-1.2.1.r 6-1.2.1.1.1 8-1.2.1.1 9-1.2.1 10-1.2.1.2 10-1.3.1.1.1.2 11-1.2.3 13-1.2.3.1.1.1.1 14-1.2.3.1.1.1.2 15-1.2.3.1 17-1.2.3.1.2.1.1 18-1.2.3.1.2.1.2 20-1.1 20-1.1.r 20-1.4.1.r 21-1 22-1.3.r 23-1.3 24-1.3.1 26-1.2.3.1.1 27-1.2.1.3 27-1.3.1.1
# ::id pmid_2465_1010.89
# ::preferred 
(h / help-01~e.21
      :polarity~e.20 "-"~e.20
      :ARG0 (l / lack-01~e.4
            :ARG1~e.5 (o / or~e.9
                  :op1 (d / domain~e.8
                        :mod (a / any~e.6))
                  :op2 (m / motif~e.10
                        :mod a)
                  :ARG1-of (r / recognize-01~e.27
                        :mod (p / possible)))
            :degree (c / complete~e.3)
            :location (o2 / outside~e.11
                  :op1 (a2 / and~e.15
                        :op1 (p2 / protein-segment~e.26
                              :name (n / name :op1 "GAP"~e.13 :op2 "domain"~e.14))
                        :op2 (p4 / protein-segment
                              :name (n2 / name :op1 "SEC14"~e.17 :op2 "domain"~e.18)))))
      :ARG1~e.22 (i / identify-01~e.23
            :ARG1 (t / thing~e.24
                  :ARG1-of (r2 / recognize-01~e.27
                        :ARG0 (a3 / and
                              :op1 p2
                              :op2 (p3 / protein-segment~e.10)))))
      :ARG2-of (f / fortunate-01~e.0 :polarity~e.20 "-"~e.0))

# ::tok By comparing proteins that bind to wild @-@ type SPRED1 versus mutants from Legius syndrome , we found that neurofibromin binds directly to SPRED proteins , via their EVH1 domains , and that SPRED proteins bring neurofibromin to the plasma membrane ( <ce:cross-ref id="crosref0195" refid="bib67"> Stowe et al. , 2012 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3 2-1.3.1 2-1.3.2 4-1.3.1.1 5-1.3.1.1.1.r 6-1.3.1.1.1.2 8-1.3.1.1.1.2 9-1.3.1.1.1.1.1 11-1.3.2.1 12-1.3.2.2.r 13-1.3.2.2.1.1 14-1.3.2.2.1.2 16-1.1 17-1 18-1.2.r 19-1.2.1.1.1.1 20-1.2.1 21-1.2.1.4 21-1.2.1.4.r 23-1.2.1.2.1.1 24-1.2.1.1 28-1.2.1.3.1.1.1 28-1.2.1.3.2.1.1 29-1.2.1.3.1.1.2 29-1.2.1.3.2.1.2 31-1.2.1.3 33-1.2.1.2.1.1 34-1.2.1.1 34-1.2.1.2 34-1.2.1.3.1 34-1.2.1.3.2 35-1.2.2 36-1.2.2.2 37-1.2.2.3.r 39-1.2.2.3.1 40-1.2.2.3 45-1.4.1.1.1.1.1 46-1.4.1.1 47-1.4.1.1.2.1 49-1.4.1.2.1
# ::id pmid_2465_1010.90
# ::preferred 
(f / find-01~e.17
      :ARG0 (w / we~e.16)
      :ARG1~e.18 (a2 / and
            :op1 (b / bind-01~e.20
                  :ARG1 (p / protein~e.24,34
                        :name (n / name :op1 "neurofibromin"~e.19))
                  :ARG2 (p2 / protein~e.34
                        :name (n2 / name :op1 "SPRED"~e.23,33))
                  :ARG3 (a / and~e.31
                        :op1 (p10 / protein-segment~e.34
                              :name (n3 / name :op1 "EVH1"~e.28 :op2 "domain"~e.29)
                              :part-of p)
                        :op1 (p3 / protein-segment~e.34
                              :name (n7 / name :op1 "EVH1"~e.28 :op2 "domain"~e.29)
                              :part-of p2))
                  :manner~e.21 (d4 / direct~e.21))
            :op2 (b2 / bring-01~e.35
                  :ARG0 p2
                  :ARG1 p~e.36
                  :ARG2~e.37 (m / membrane~e.40
                        :part-of (p4 / plasma~e.39))))
      :manner (c / compare-01~e.1
            :ARG1 (p5 / protein~e.2
                  :ARG1-of (b3 / bind-01~e.4
                        :ARG2~e.5 (p6 / protein
                              :name (n4 / name :op1 "SPRED1"~e.9)
                              :mod (w2 / wild-type~e.6,8))))
            :ARG2 (p11 / protein~e.2
                  :ARG2-of (m2 / mutate-01~e.11)
                  :source~e.12 (d5 / disease
                        :name (n5 / name :op1 "Legius"~e.13 :op2 "syndrome"~e.14))))
      :ARG1-of (d6 / describe-01
            :ARG0 (p7 / publication-91
                  :ARG0 (a3 / and~e.46
                        :op1 (p8 / person
                              :name (n6 / name :op1 "Stowe"~e.45))
                        :op2 (p9 / person
                              :mod (o / other~e.47)))
                  :time (d / date-entity :year "2012"~e.49))))

# ::tok SPRED proteins also bind to c @-@ Kit , and perhaps to other RTKs , suggesting that neurofibromin regulates Ras locally in response to specific receptor signaling , rather than simply suppressing Ras throughout the plasma membrane .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 1-1.1 1-1.4.1.1 2-1.3 3-1 4-1.2.r 5-1.2.1.1.1 7-1.2.1.1.1 9-1.2 10-1.2.2.3 12-1.2.2.2 15-1.4 16-1.4.1.r 17-1.4.1.1.1.1 18-1.4.1 19-1.4.1.2.1.1 20-1.4.1.3 21-1.4.1.4.r 22-1.4.1.4 23-1.4.1.4.1.r 24-1.4.1.4.1.1.1 25-1.4.1.4.1.1 26-1.4.1.4.1 30-1.4.1.5.1.4 31-1.4.1.5.1 32-1.4.1.5.1.2 35-1.4.1.5.1.3.1 36-1.4.1.5.1.3
# ::id pmid_2465_1010.91
# ::preferred 
(b / bind-01~e.3
      :ARG1 (p2 / protein~e.1
            :name (n2 / name :op1 "SPRED"~e.0))
      :ARG2~e.4 (a / and~e.9
            :op1 (e2 / enzyme
                  :name (n3 / name :op1 "c-Kit"~e.5,7))
            :op2 (k / kinase
                  :name (n4 / name :op1 "RTK")
                  :mod (o / other~e.12)
                  :mod (p / possible~e.10)))
      :mod (a2 / also~e.2)
      :ARG0-of (s / suggest-01~e.15
            :ARG1~e.16 (r / regulate-01~e.18
                  :ARG0 (p4 / protein~e.1
                        :name (n5 / name :op1 "neurofibromin"~e.17))
                  :ARG1 (e / enzyme
                        :name (n / name :op1 "Ras"~e.19))
                  :mod (l / local~e.20)
                  :ARG2-of~e.21 (r2 / respond-01~e.22
                        :ARG1~e.23 (s2 / signal-07~e.26
                              :ARG0 (r3 / receptor~e.25
                                    :mod (s3 / specific~e.24))))
                  :ARG1-of (i / instead-of-91
                        :ARG2 (s4 / suppress-01~e.31
                              :ARG0 p4
                              :ARG1 e~e.32
                              :location (m / membrane~e.36
                                    :part-of (p5 / plasma~e.35))
                              :mod (s5 / simple~e.30))))))

# ::tok In this case , loss of neurofibromin may lead to local activation of Ras that is coupled to specific receptors , suggesting that inhibitors of these receptors might reverse the effects of neurofibromin loss .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.r 1-1.2.1 2-1.2 4-1.1.1 5-1.1.1.1.r 6-1.1.1.1.1.1 7-1 8-1.1 9-1.1.2.r 10-1.1.2.2 11-1.1.2 12-1.1.2.1.r 13-1.1.2.1.1.1 16-1.1.2.3 17-1.1.2.3.1.r 18-1.1.2.3.1.1 19-1.1.2.3.1 21-1.1.3 22-1.1.3.1.r 23-1.1.3.1.1.1 23-1.1.3.1.1.1.1 23-1.1.3.1.1.1.1.r 25-1.2.1 26-1.1.2.3.1 27-1.1.3.1 28-1.1.3.1.1 30-1.1.3.1.1.2 31-1.1.3.1.1.2.1.r 32-1.1.3.1.1.2.1 33-1.1.3.1.1.2.1
# ::id pmid_2465_1010.92
# ::preferred 
(p / possible~e.7
      :domain (l / lead-03~e.8
            :ARG0 (l2 / lose-01~e.4
                  :ARG1~e.5 (p2 / protein
                        :name (n2 / name :op1 "neurofibromin"~e.6)))
            :ARG2~e.9 (a / activate-01~e.11
                  :ARG1~e.12 (e / enzyme
                        :name (n / name :op1 "Ras"~e.13))
                  :mod (l3 / local~e.10)
                  :ARG1-of (c / couple-01~e.16
                        :ARG2~e.17 (r / receptor~e.19,26
                              :mod (s / specific~e.18))))
            :ARG0-of (s2 / suggest-01~e.21
                  :ARG1~e.22 (p3 / possible~e.27
                        :domain (r2 / reverse-01~e.28
                              :ARG0 (m / molecular-physical-entity~e.23
                                    :ARG0-of~e.23 (i / inhibit-01~e.23
                                          :ARG1 r))
                              :ARG1 (a2 / affect-01~e.30
                                    :ARG0~e.31 l2~e.32,33)))))
      :prep-in~e.0 (c2 / case~e.2
            :mod (t / this~e.1,25)))

# ::tok The recent Cancer Genome Atlas analysis of mutations in lung cancer revealed an intriguing overlap between neurofibromin loss and Met amplification , suggesting a functional connection that merits further investigation ( E.A . Collisson , personal communication ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.3 2-1.1.1.1.1 3-1.1.1.1.2 4-1.1.1.1.3 5-1.1 6-1.1.2.r 7-1.1.2 8-1.1.2.1.r 9-1.1.2.1.2.1 10-1.1.2.1.2.2 11-1 13-1.2.3 14-1.2 16-1.2.1.1.1.1 17-1.2.1 19-1.2.2.1.1.1 20-1.2.2 22-1.3 24-1.3.1.1 25-1.3.1 27-1.3.1.2 28-1.3.1.2.1.2 29-1.3.1.2.1 31-1.4.1.1.1 33-1.4.1.1.2 35-1.4.2 36-1.4
# ::id pmid_2465_1010.93
# ::preferred 
(r / reveal-01~e.11
      :ARG0 (a / analyze-01~e.5
            :ARG0 (t / thing
                  :name (n3 / name
                        :op1 "Cancer"~e.2
                        :op2 "Genome"~e.3
                        :op3 "Atlas"~e.4))
            :ARG1~e.6 (m / mutate-01~e.7
                  :ARG0~e.8 (d2 / disease
                        :wiki "Lung_cancer"
                        :name (n2 / name :op1 "lung"~e.9 :op2 "cancer"~e.10)))
            :time (r2 / recent~e.1))
      :ARG1 (o / overlap-01~e.14
            :ARG0 (l2 / lose-01~e.17
                  :ARG1 (p2 / protein
                        :name (n4 / name :op1 "neurofibromin"~e.16)))
            :ARG1 (a2 / amplify-01~e.20
                  :ARG1 (p3 / protein
                        :name (n5 / name :op1 "Met"~e.19)))
            :ARG0-of (i2 / intrigue-01~e.13))
      :ARG0-of (s / suggest-01~e.22
            :ARG1 (c / connect-01~e.25
                  :mod (f / function~e.24)
                  :ARG0-of (m2 / merit-01~e.27
                        :ARG1 (i / investigate-01~e.29
                              :ARG1 c
                              :degree (f2 / further~e.28)))))
      :ARG1-of (c2 / communicate-01~e.36
            :ARG0 (p4 / person
                  :name (n / name :op1 "E.A"~e.31 :op2 "Collisson"~e.33))
            :manner (p5 / personal~e.35)))

# ::tok Validation of Ras as a Target
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.1.r 2-1.1.1.1.1 5-1.1
# ::id pmid_2465_1010.94
# ::preferred 
(v / validate-01~e.0
      :ARG1~e.1 (t / target-01~e.5
            :ARG1 (e / enzyme
                  :name (n / name :op1 "Ras"~e.2))))

# ::tok Ras oncogenes can certainly initiate cancer in model organisms and probably do so in humans .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1.1.1 1-1.1.1.1 2-1.1 3-1.1.2 4-1.1.1 4-1.2.1 5-1.1.1.2.2.1 6-1.1.1.3.r 7-1.1.1.3.1 8-1.1.1.3 9-1 10-1.2 13-1.2.1.3.r 14-1.2.1.3
# ::id pmid_2465_1010.95
# ::preferred 
(a / and~e.9
      :op1 (p / possible~e.2
            :domain (i / initiate-01~e.4
                  :ARG0 (o / oncogene~e.1
                        :name (n / name :op1 "Ras"~e.0))
                  :ARG1 (d / disease
                        :wiki "Cancer"
                        :name (n2 / name :op1 "cancer"~e.5))
                  :location~e.6 (o2 / organism~e.8
                        :mod (m / model~e.7)))
            :mod (c / certain~e.3))
      :op2 (p2 / probable~e.10
            :domain (i2 / initiate-01~e.4
                  :ARG0 o
                  :ARG1 d
                  :location~e.13 (h / human~e.14))))

# ::tok However , their role in maintaining tumors is less clear .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 2-1.1.2.1 2-1.1.2.1.r 3-1.1.2 4-1.1.2.2.r 5-1.1.2.2 6-1.1.2.2.1 7-1.1.2.r 8-1.1.1 9-1.1
# ::id pmid_2465_1010.96
# ::preferred 
(h / have-concession-91~e.0
      :ARG1 (c2 / clear~e.9
            :degree (l / less~e.8)
            :domain~e.7 (r / role~e.3
                  :poss~e.2 (t / they~e.2)
                  :topic~e.4 (m / maintain-01~e.5
                        :ARG1 (t2 / tumor~e.6)))))

# ::tok There is significant evidence that supports K @-@ Ras as a continued candidate for direct therapeutic targeting , dating back to the classic studies of temperature @-@ sensitive mutants of Ras , by Scolnick , Lowy , and colleagues and including microinjection studies with antibodies that block Ras activity ( <ce:cross-ref id="crosref0200" refid="bib34"> Kung et al. , 1986 </ce:cross-ref> ) or block specific mutant alleles of Ras ( <ce:cross-ref id="crosref0205" refid="bib19"> Feramisco et al. , 1985 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1 3-1 5-1.2 6-1.2.1.3.1.1 8-1.2.1.3.1.1 11-1.2.1.2 12-1.2.1 13-1.2.1.1.r 14-1.2.1.1.1.1 15-1.2.1.1.1 16-1.2.1.1 18-1.3 18-1.4.1.2.1.1.2.1.2 18-1.4.1.2.2.1.2.1.2 19-1.3.2 20-1.3.1.r 22-1.3.1.3 23-1.3.1 24-1.3.1.2.r 25-1.3.1.2.3.1 27-1.3.1.2.3 28-1.3.1.2 28-1.3.1.2.2 28-1.3.1.2.2.r 30-1.3.1.2.1.1 32-1.3.1.1.r 33-1.3.1.1.1.1.1 35-1.3.1.1.2.1.1 37-1.3.1.1 38-1.3.1.1.3 39-1.3.1.1 40-1.4 42-1.4.1 43-1.4.1.2.r 44-1.4.1.2.1 44-1.4.1.2.2 46-1.4.1.2.1.1 46-1.4.1.2.2.1 47-1.4.1.2.1.1.1.1.1.1 48-1.4.1.2.1.1.1 53-1.4.1.2.1.1.2.1.1.1.1.1 54-1.4.1.2.1.1.2.1.1 55-1.4.1.2.1.1.2.1.1.2.1 57-1.4.1.2.1.1.2.1.2.1 60-1.4.1.2 61-1.4.1.2.2.1 62-1.4.1.2.2.1.1.3 63-1.4.1.2.2.1.1.2 64-1.4.1.2.2.1.1 65-1.4.1.2.2.1.1.1.r 66-1.4.1.2.2.1.1.1 71-1.4.1.2.2.1.2.1.1.1.1.1 72-1.4.1.2.1.1.2.1.1 72-1.4.1.2.2.1.2.1.1 73-1.4.1.2.1.1.2.1.1.2.1 75-1.4.1.2.2.1.2.1.2.1
# ::id pmid_2465_1010.97
# ::preferred 
(e3 / evidence-01~e.3
      :ARG1-of (s / significant-02~e.2)
      :ARG0-of (s2 / support-01~e.5
            :ARG1 (c / candidate~e.12
                  :purpose~e.13 (t / target-01~e.16
                        :ARG0 (t2 / therapy~e.15
                              :mod (d3 / direct~e.14)))
                  :ARG1-of (c2 / continue-01~e.11)
                  :domain (e / enzyme
                        :name (n / name :op1 "K-Ras"~e.6,8))))
      :ARG1-of (d4 / date-01~e.18
            :ARG2~e.20 (s3 / study-01~e.23
                  :ARG0~e.32 (a / and~e.37,39
                        :op1 (p / person
                              :name (n3 / name :op1 "Scolnick"~e.33))
                        :op2 (p2 / person
                              :name (n4 / name :op1 "Lowy"~e.35))
                        :op3 (c3 / colleague~e.38))
                  :ARG1~e.24 (e2 / enzyme~e.28
                        :name (n2 / name :op1 "Ras"~e.30)
                        :ARG2-of~e.28 (m / mutate-01~e.28)
                        :ARG0-of (s4 / sensitive-03~e.27
                              :ARG1 (t3 / temperature~e.25)))
                  :mod (c4 / classic~e.22))
            :direction (b / back~e.19))
      :ARG2-of (i / include-01~e.40
            :ARG1 (s5 / study-01~e.42
                  :ARG1 (i2 / inject-01
                        :mod (m3 / micro))
                  :instrument~e.43 (o / or~e.60
                        :op1 (a2 / antibody~e.44
                              :ARG0-of (b2 / block-01~e.46
                                    :ARG1 (a3 / act-02~e.48
                                          :ARG0 (e4 / enzyme
                                                :name (n5 / name :op1 "Ras"~e.47)))
                                    :ARG1-of (d5 / describe-01
                                          :ARG0 (p3 / publication-91
                                                :ARG0 (a4 / and~e.54,72
                                                      :op1 (p4 / person
                                                            :name (n6 / name :op1 "Kung"~e.53))
                                                      :op2 (p5 / person
                                                            :mod (o2 / other~e.55,73)))
                                                :time (d / date-entity~e.18 :year "1986"~e.57)))))
                        :op2 (a5 / antibody~e.44
                              :ARG0-of (b3 / block-01~e.46,61
                                    :ARG1 (a6 / allele~e.64
                                          :mod~e.65 e4~e.66
                                          :ARG2-of (m2 / mutate-01~e.63)
                                          :mod (s6 / specific~e.62))
                                    :ARG1-of (d6 / describe-01
                                          :ARG0 (p6 / publication-91
                                                :ARG0 (a7 / and~e.72
                                                      :op1 (p7 / person
                                                            :name (n7 / name :op1 "Feramisco"~e.71))
                                                      :op2 (p8 / person
                                                            :mod o2))
                                                :time (d2 / date-entity~e.18 :year "1985"~e.75)))))))))

# ::tok Ablation of K @-@ Ras in mouse models of lung adenocarcinoma ( <ce:cross-ref id="crosref0210" refid="bib20"> Fisher et al. , 2001 </ce:cross-ref> ) or pancreas cancer ( <ce:cross-ref id="crosref0215" refid="bib83"> Ying et al. , 2012 </ce:cross-ref> ) led to dramatic tumor regression , just as ablation of H @-@ Ras leads to tumor regression in mouse models of melanoma ( <ce:cross-ref id="crosref0220" refid="bib10"> Chin et al. , 1999 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 2-1.1.1.1.1 4-1.1.1.1.1 6-1.1.2.1.1 7-1.1.2.1 7-1.1.2.2 8-1.1.2.1.3.r 9-1.1.2.1.3.1.1 10-1.1.2.1.3.1.2 15-1.1.2.1.2.1.1.1.1.1 16-1.1.2.1.2.1.1 17-1.1.2.1.2.1.1.2.1 19-1.1.2.1.2.1.2.1 22-1.1.2 23-1.1.2.2.3.1.1 24-1.1.2.2.3.1.2 29-1.1.2.2.2.1.1.1.1.1 30-1.1.2.1.2.1.1 30-1.1.2.2.2.1.1 31-1.1.2.1.2.1.1.2.1 33-1.1.2.2.2.1.2.1 36-1 38-1.2.2 39-1.2.1 43-1.1.2.1.2.1.2.r 43-1.1.2.2.2.1.2.r 44-1.1 44-1.3.1.1 45-1.3.1.1.1.r 46-1.3.1.1.1.1.1 48-1.3.1.1.1.1.1 49-1.3.1 51-1.3.1.2.1 54-1.3.1.2.2.1 55-1.3.1.2.2 56-1.3.1.2.2.2.r 57-1.3.1.2.2.2.1.1 62-1.3.1.3.1.1.1.1.1 63-1.1.2.1.2.1.1 63-1.3.1.3.1.1 64-1.1.2.1.2.1.1.2.1 66-1.3.1.3.1.2.1
# ::id pmid_2465_1010.98
# ::preferred 
(l / lead-03~e.36
      :ARG0 (a / ablate-00~e.0,44
            :ARG1 (e / enzyme
                  :name (n / name :op1 "K-Ras"~e.2,4))
            :location (o / or~e.22
                  :op1 (m / model~e.7
                        :mod (m2 / mouse~e.6)
                        :ARG1-of (d4 / describe-01
                              :ARG0 (p2 / publication-91
                                    :ARG0 (a3 / and~e.16,30,63
                                          :op1 (p3 / person
                                                :name (n2 / name :op1 "Fisher"~e.15))
                                          :op2 (p4 / person
                                                :mod (o2 / other~e.17,31,64)))
                                    :time~e.43 (d / date-entity :year "2001"~e.19)))
                        :topic~e.8 (d8 / disease
                              :name (n6 / name :op1 "lung"~e.9 :op2 "adenocarcinoma"~e.10)))
                  :op2 (m3 / model~e.7
                        :mod m2
                        :ARG1-of (d5 / describe-01
                              :ARG0 (p5 / publication-91
                                    :ARG0 (a4 / and~e.30
                                          :op1 (p6 / person
                                                :name (n4 / name :op1 "Ying"~e.29))
                                          :op2 (p7 / person
                                                :mod o2))
                                    :time~e.43 (d2 / date-entity :year "2012"~e.33)))
                        :topic (d9 / disease
                              :name (n7 / name :op1 "pancreas"~e.23 :op2 "cancer"~e.24)))))
      :ARG2 (r / regress-01
            :ARG1 (t / tumor~e.39)
            :degree (d6 / dramatic~e.38))
      :ARG1-of (r2 / resemble-01
            :ARG2 (l3 / lead-03~e.49
                  :ARG0 (a5 / ablate-00~e.44
                        :ARG1~e.45 (e2 / enzyme
                              :name (n3 / name :op1 "H-Ras"~e.46,48)))
                  :ARG2 (r3 / regress-01
                        :ARG1 (t2 / tumor~e.51)
                        :location (m4 / model~e.55
                              :mod (m5 / mouse~e.54)
                              :topic~e.56 (d10 / disease
                                    :name (n8 / name :op1 "melanoma"~e.57))))
                  :ARG1-of (d7 / describe-01
                        :ARG0 (p8 / publication-91
                              :ARG0 (a6 / and~e.63
                                    :op1 (p9 / person
                                          :name (n5 / name :op1 "Chin"~e.62))
                                    :op2 (p10 / person
                                          :mod o2))
                              :time (d3 / date-entity :year "1999"~e.66))))))

# ::tok On the other hand , K @-@ Ras knockdown in human cell lines resulted in a spectrum of responses , revealing a range of K @-@ Ras dependencies ( <ce:cross-ref id="crosref0225" refid="bib64"> Singh et al. , 2009 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.2.1.1.2.1 5-1.1.1.1.1.1 7-1.1.1.1.1.1 10-1.1.1.2.1 11-1.1.1.2 12-1.1.1.2 13-1.1 14-1.1.2.r 16-1.1.2.2 17-1.1.2.2.r 18-1.1.2 18-1.1.2.1 18-1.1.2.1.r 20-1.1.2.3 22-1.1.2.3.1.2 23-1.1.2.3.1.2.r 24-1.1.2.3.1.1 25-1.1.2.3.1.1 26-1.1.2.3.1.1 27-1.1.2.3.1 32-1.2.1.1.1.1.1 33-1.2.1.1 34-1.2.1.1.2.1 36-1.2.1.2.1
# ::id pmid_2465_1010.99
# ::preferred 
(c / contrast-01
      :ARG2 (r / result-01~e.13
            :ARG1 (k / knock-02
                  :ARG1 (e / enzyme
                        :name (n / name :op1 "K-Ras"~e.5,7))
                  :location (c2 / cell-line~e.11,12
                        :mod (h / human~e.10)))
            :ARG2~e.14 (t / thing~e.18
                  :ARG2-of~e.18 (r2 / respond-01~e.18)
                  :quant~e.17 (s / spectrum~e.16)
                  :ARG0-of (r3 / reveal-01~e.20
                        :ARG1 (d2 / depend-01~e.27
                              :ARG1 e~e.24,25,26
                              :quant~e.23 (r4 / range~e.22)))))
      :ARG1-of (d3 / describe-01
            :ARG0 (p / publication-91
                  :ARG0 (a / and~e.33
                        :op1 (p2 / person
                              :name (n2 / name :op1 "Singh"~e.32))
                        :op2 (p3 / person
                              :mod (o / other~e.2,34)))
                  :time (d / date-entity :year "2009"~e.36))))

# ::tok Assessment of Ras dependency in 3D culture systems suggests that this assay system is a more stringent measure of Ras dependency .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1.1.1.r 2-1.1.1.1.1.1 3-1.1.1 4-1.1.2.r 5-1.1.2.2 6-1.1.2.1 7-1.1.2 8-1 9-1.2.r 10-1.2.1.1 11-1.2.1.2 12-1.2.1 15-1.2.3.1 16-1.2.3 17-1.2 18-1.2.2.r 19-1.2.2 20-1.2.2
# ::id pmid_2465_1010.100
# ::preferred 
(s / suggest-01~e.8
      :ARG0 (a / assess-01~e.0
            :ARG1~e.1 (d / depend-01~e.3
                  :ARG1 (e / enzyme
                        :name (n / name :op1 "Ras"~e.2)))
            :location~e.4 (s2 / system~e.7
                  :mod (c / culture~e.6)
                  :mod (x / 3D~e.5)))
      :ARG1~e.9 (m / measure-01~e.17
            :ARG0 (s3 / system~e.12
                  :mod (t / this~e.10)
                  :ARG0-of (a2 / assay-00~e.11))
            :ARG1~e.18 d~e.19,20
            :mod (s4 / stringent~e.16
                  :degree (m2 / more~e.15))))

# ::tok These studies raise the question of what is the most relevant system to measure this essential parameter and , in general , responses to candidate therapeutics targeting K @-@ Ras .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2 1-1.1.1 2-1 4-1.2 6-1.1 6-1.2.1.1.1.1.2 9-1.2.1.1.2 10-1.2.1.1 11-1.2.1 13-1.2.1.1.1 14-1.2.1.1.1.1.1.2 15-1.2.1.1.1.1.1.1 16-1.2.1.1.1.1.1 17-1.2.1.1.1.1 19-1.2.1.1.1.1.2.1.r 20-1.2.1.1.1.1.2.1.2 22-1.2.1.1.1.1.2.1 23-1.2.1.1.1.1.2.1.1.r 24-1.2.1.1.1.1.2.1.1.1 25-1.2.1.1.1.1.2.1.1 26-1.2.1.1.1.1.2.1.1.2 27-1.2.1.1.1.1.2.1.1.2.1.1.1 29-1.2.1.1.1.1.2.1.1.2.1.1.1
# ::id pmid_2465_1010.101
# ::preferred 
(r / raise-01~e.2
      :ARG0 (t / thing~e.6
            :ARG1-of (s / study-01~e.1)
            :mod (t2 / this~e.0))
      :ARG1 (q / question-01~e.4
            :ARG1 (s2 / system~e.11
                  :ARG1-of (r2 / relevant-01~e.10
                        :ARG2 (m2 / measure-01~e.13
                              :ARG1 (a / and~e.17
                                    :op1 (p / parameter~e.16
                                          :mod (e2 / essential~e.15)
                                          :mod t2~e.14)
                                    :op2 (t3 / thing~e.6
                                          :ARG2-of~e.19 (r3 / respond-01~e.22
                                                :ARG1~e.23 (t4 / therapeutics~e.25
                                                      :mod (c / candidate~e.24)
                                                      :ARG0-of (t5 / target-01~e.26
                                                            :ARG1 (e / enzyme
                                                                  :name (n / name :op1 "K-Ras"~e.27,29))))
                                                :mod (g / general-02~e.20)))))
                        :degree (m / most~e.9)))))

# ::tok Furthermore , the degree to which Ras genes are knocked down may be critical .
# ::amr-annotator SDL-AMR-09
# ::alignments 3-1.1.1.1 3-1.1.1.1.1.r 6-1.1.1.1.1.1.1.1.1.1 7-1.1.1.1.1.1 9-1.1.1.1.1 10-1.1.1.1.1 11-1.1 12-1.1.1.1.r 12-1.1.1.r 13-1.1.1
# ::id pmid_2465_1010.102
# ::preferred 
(a / and
      :op2 (p / possible~e.11
            :domain~e.12 (c / critical~e.13
                  :domain~e.12 (d2 / degree~e.3
                        :degree-of~e.3 (k / knock-02~e.9,10
                              :ARG1 (g / gene~e.7
                                    :ARG0-of (e2 / encode-01
                                          :ARG1 (e / enzyme
                                                :name (n / name :op1 "Ras"~e.6)))))))))

# ::tok Genetic ablation is obviously different than small interfering RNA @- or small hairpin RNA ( shRNA )-mediated knockdown .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1 3-1.3 4-1 6-1.2.1.1.1.1.1 7-1.2.1.1.1.1.2 8-1.2.1.1.1.1.3 10-1.2.1.1 11-1.2.1.1.2.1.1 12-1.2.1.1.2.1.2 13-1.2.1.1.2.1.3
# ::id pmid_2465_1010.103
# ::preferred 
(d / differ-02~e.4
      :ARG1 (a / ablate-00~e.1
            :ARG1 (g / gene))
      :ARG2 (k / knock-02
            :ARG1-of (m / mediate-01
                  :ARG0 (o / or~e.10
                        :op1 (r / rna
                              :name (n2 / name
                                    :op1 "small"~e.6
                                    :op2 "interfering"~e.7
                                    :op3 "RNA"~e.8))
                        :op2 (r2 / rna
                              :name (n / name
                                    :op1 "small"~e.11
                                    :op2 "hairpin"~e.12
                                    :op3 "RNA"~e.13)))))
      :ARG1-of (o2 / obvious-01~e.3))

# ::tok It is also clear that knocking down activated Ras can lead to hyperactivation of upstream pathways , such as EGFR signaling ( <ce:cross-ref id="crosref0230" refid="bib84"> Young et al. , 2013 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.2.1.r 1-1.2.r 2-1.1 3-1 5-1.2.1.1 6-1.2.1.1 7-1.2.1.1.1.2 7-1.2.1.2 8-1.2.1.1.1.1.1 9-1.2 10-1.2.1 13-1.2.1.2.2.r 14-1.2.1.2.2.1 15-1.2.1.2.2 18-1.2.1.3.1.2.r 19-1.2.1.2.2.2.1.1.1.1 20-1.2.1.2.2.2.1 25-1.2.1.3.1.1.1.1.1 26-1.2.1.3.1.1 27-1.2.1.3.1.1.2.1 29-1.2.1.3.1.2.1
# ::id pmid_2465_1010.104
# ::preferred 
(c / clear~e.3
      :mod (a / also~e.2)
      :domain~e.1 (p / possible~e.9
            :domain~e.1 (l / lead-03~e.10
                  :ARG0 (k / knock-02~e.5,6
                        :ARG1 (e / enzyme
                              :name (n / name :op1 "Ras"~e.8)
                              :ARG1-of (a2 / activate-01~e.7)))
                  :ARG2 (a3 / activate-01~e.7
                        :ARG0 k
                        :ARG1~e.13 (p2 / pathway~e.15
                              :location (u / upstream~e.14)
                              :ARG1-of (e3 / exemplify-01
                                    :ARG0 (s / signal-07~e.20
                                          :ARG0 (e2 / enzyme
                                                :name (n2 / name :op1 "EGFR"~e.19)))))
                        :degree (h / hyper))
                  :ARG1-of (d2 / describe-01
                        :ARG0 (p3 / publication-91
                              :ARG0 (a4 / and~e.26
                                    :op1 (p4 / person
                                          :name (n3 / name :op1 "Young"~e.25))
                                    :op2 (p5 / person
                                          :mod (o / other~e.27)))
                              :time~e.18 (d / date-entity :year "2013"~e.29))))))

# ::tok Presumably , these pathways are suppressed in cells with activated Ras and rebound when the suppressor is removed .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3 2-1.1.1.1 3-1.1.1 5-1.1 6-1.1.2.r 7-1.1.2 9-1.1.2.1.1.2 10-1.1.2.1.1.1.1 11-1 12-1.2 13-1.2.2.r 17-1.2.2
# ::id pmid_2465_1010.105
# ::preferred 
(a / and~e.11
      :op1 (s / suppress-01~e.5
            :ARG1 (p / pathway~e.3
                  :mod (t / this~e.2))
            :location~e.6 (c / cell~e.7
                  :ARG0-of (c2 / contain-01
                        :ARG1 (e / enzyme
                              :name (n / name :op1 "Ras"~e.10)
                              :ARG1-of (a2 / activate-01~e.9)))))
      :op2 (r / rebound-01~e.12
            :ARG1 p
            :time~e.13 (r2 / remove-01~e.17
                  :ARG1 (m / molecular-physical-entity
                        :ARG0-of s)))
      :ARG1-of (p2 / presume-01~e.0))

# ::tok Although this rebound effect may not be sufficient to sustain a malignant phenotype , it may offset proapoptotic effects associated with oncogene inactivation .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.2.1.2.2 2-1.2.1.2.1 3-1.2.1.2 4-1.2 5-1.2.1.1 5-1.2.1.1.r 6-1.2.1.r 7-1.2.1 9-1.2.1.3 11-1.2.1.3.2.1 12-1.2.1.3.2 14-1.2.1.3.1 15-1.1 16-1.1.1 18-1.1.1.2 19-1.1.1.2.1 20-1.1.1.2.1.1.r 21-1.1.1.2.1.1.2 22-1.1.1.2.1.1 22-1.1.1.2.1.1.1 22-1.1.1.2.1.1.1.r
# ::id pmid_2465_1010.106
# ::preferred 
(h / have-concession-91~e.0
      :ARG1 (p3 / possible~e.15
            :domain (o / offset-01~e.16
                  :ARG0 (a / affect-01~e.3
                        :ARG1 (r / rebound-01~e.2)
                        :mod (t / this~e.1))
                  :ARG1 (a2 / affect-01~e.18
                        :ARG1-of (a3 / associate-01~e.19
                              :ARG2~e.20 (a4 / activate-01~e.22
                                    :polarity~e.22 "-"~e.22
                                    :ARG1 (o2 / oncogene~e.21)))
                        :ARG0-of (f / favor-01
                              :ARG1 (a5 / apoptosis)))))
      :ARG2 (p / possible~e.4
            :domain~e.6 (s / suffice-01~e.7
                  :polarity~e.5 "-"~e.5
                  :ARG0 a
                  :purpose (s2 / sustain-01~e.9
                        :ARG0 a~e.14
                        :ARG1 (p2 / phenotype~e.12
                              :mod (m / malignant~e.11))))))

# ::tok Do K @-@ Ras Therapies Have to Be Allele Specific ?
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.2.2.1.1.1 3-1.2.2.1.1.1 4-1.2.2 7-1.2.2.r 8-1.2.1 9-1.2 10-1.1 10-1.1.r
# ::id pmid_2465_1010.107
# ::preferred 
(o / obligate-01
      :mode~e.10 "interrogative"~e.10
      :ARG2 (s / specific~e.9
            :topic (a / allele~e.8)
            :domain~e.7 (t / therapy~e.4
                  :mod (e / enzyme
                        :name (n / name :op1 "K-Ras"~e.1,3)))))

# ::tok The most specific way to block oncogenic Ras would be to target the activating substitution itself .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1 2-1.1 3-1 3-1.2.r 4-1.2.1 4-1.2.1.2 4-1.2.1.2.r 5-1.2 6-1.2.1 6-1.2.1.2 6-1.2.1.2.1 6-1.2.1.2.1.r 6-1.2.1.2.r 7-1.2.1.1.1 11-1.3 13-1.3.1.1 14-1.3.1
# ::id pmid_2465_1010.108
# ::preferred 
(w / way~e.3
      :mod (s2 / specific~e.2
            :degree (m / most~e.1))
      :manner-of~e.3 (b / block-01~e.5
            :ARG1 (e / enzyme~e.4,6
                  :name (n / name :op1 "Ras"~e.7)
                  :ARG0-of~e.4,6 (c / cause-01~e.4,6
                        :ARG1~e.6 (c2 / cancer~e.6))))
      :domain (t / target-01~e.11
            :ARG1 (s / substitute-01~e.14
                  :ARG0-of (a / activate-01~e.13))))

# ::tok The first example was recently published by Shokat and colleagues , who identified electrophilic compounds that react covalently with cysteine @-@ 12 in G12C mutant K @-@ Ras ( <ce:cross-ref id="crosref0235" refid="bib49"> Ostrem et al. , 2013 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.2.1 1-1.2.1.1 1-1.2.1.1.r 2-1.2 4-1.3 5-1 5-1.4.1 6-1.1.r 7-1.1.1.1.1 8-1.1 9-1.1.2 12-1.1.3 14-1.1.3.1 16-1.1.3.1.2 18-1.1.3.1.2.1.r 19-1.1.3.1.2.1.2.1 21-1.1.3.1.2.1.1 22-1.1.3.1.2.3.r 23-1.1.3.1.2.3.2.1 24-1.1.3.1.2.3 24-1.1.3.1.2.3.2 24-1.1.3.1.2.3.2.r 25-1.1.3.1.2.3.1.1 27-1.1.3.1.2.3.1.1 32-1.4.1.1.1.1.1 33-1.1 34-1.4.1.1.2.1 36-1.4.1.2.1
# ::id pmid_2465_1010.109
# ::preferred 
(p / publish-01~e.5
      :ARG0~e.6 (a / and~e.8,33
            :op1 (p2 / person
                  :name (n / name :op1 "Shokat"~e.7))
            :op2 (c / colleague~e.9)
            :ARG0-of (i / identify-01~e.12
                  :ARG1 (c2 / compound~e.14
                        :mod (e2 / electrophile)
                        :ARG0-of (r2 / react-01~e.16
                              :ARG1~e.18 (a2 / amino-acid
                                    :mod "12"~e.21
                                    :name (n2 / name :op1 "cysteine"~e.19))
                              :manner (c3 / covalent)
                              :location~e.22 (e3 / enzyme~e.24
                                    :name (n3 / name :op1 "K-Ras"~e.25,27)
                                    :ARG2-of~e.24 (m / mutate-01~e.24 :value "G12C"~e.23))))))
      :ARG1 (e / exemplify-01~e.2
            :ord (o / ordinal-entity~e.1 :value~e.1 "1"~e.1))
      :time (r / recent~e.4)
      :ARG1-of (d / describe-01
            :ARG0 (p3 / publication-91~e.5
                  :ARG0 (a3 / and
                        :op1 (p4 / person
                              :name (n4 / name :op1 "Ostrem"~e.32))
                        :op2 (p5 / person
                              :mod (o2 / other~e.34)))
                  :time (d2 / date-entity :year "2013"~e.36))))

# ::tok These compounds interact selectively with the GDP form of K @-@ Ras @-@ G12C protein ( <ce:cross-ref id="crosref0240" refid="fig2"> Figure 2 </ce:cross-ref>@ <ce:float-anchor refid="fig2" /> ) and bind at a pocket near switch 2 that had not been apparent from analysis of crystal structures .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 1-1.1.1 2-1.1 3-1.1.3 3-1.1.3.r 4-1.1.2.r 6-1.1.2.2.1.1 9-1.1.2.1.1.1 11-1.1.2.1.1.1 13-1.1.2.1.2.1 19-1.1.4.1 20-1.1.4.1.1 26-1 27-1.2 28-1.2.2.r 30-1.2.2 31-1.2.2.1 32-1.2.2.1.1 33-1.2.2.1.1.1 36-1.2.2.2.1 36-1.2.2.2.1.r 40-1.2.2.2.2 41-1.2.2.2.2.1.r 42-1.2.2.2.2.1.1 43-1.2.2.2.2.1
# ::id pmid_2465_1010.110
# ::preferred 
(a / and~e.26
      :op1 (i / interact-01~e.2
            :ARG0 (c / compound~e.1
                  :mod (t / this~e.0))
            :ARG1~e.4 (m2 / macro-molecular-complex
                  :part (e / enzyme
                        :name (n / name :op1 "K-Ras"~e.9,11)
                        :ARG2-of (m / mutate-01 :value "G12C"~e.13))
                  :part (s2 / small-molecule
                        :name (n2 / name :op1 "GDP"~e.6)))
            :manner~e.3 (s / selective~e.3)
            :ARG1-of (d / describe-01
                  :ARG0 (f / figure~e.19 :mod "2"~e.20)))
      :op2 (b / bind-01~e.27
            :ARG1 c
            :location~e.28 (p / pocket~e.30
                  :location (n3 / near~e.31
                        :op1 (s3 / switch~e.32 :mod "2"~e.33))
                  :ARG1-of (a2 / appear-01
                        :polarity~e.36 "-"~e.36
                        :manner (a3 / analyze-01~e.40
                              :ARG1~e.41 (s4 / structure~e.43
                                    :poss (c2 / crystal~e.42)))))))

# ::tok A similar approach led to the identification of a GDP analog that covalently and specifically binds G12C and renders this oncogenic protein inactive ( <ce:cross-ref id="crosref0245" refid="bib38"> Lim et al. , 2014 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1 2-1.1 3-1 4-1.2.r 6-1.2 7-1.2.1.r 9-1.2.1.1.1 10-1.2.1.2 14-1.2.1.3.3 15-1.2.1 15-1.2.1.3 15-1.2.1.3.r 16-1.2.1.3.1.2.1 20-1.2.1.3.1 20-1.2.1.3.1.3 20-1.2.1.3.1.3.1 20-1.2.1.3.1.3.1.r 20-1.2.1.3.1.3.r 27-1.3.1.1.1.1.1 28-1.3.1.1 29-1.3.1.1.2.1 31-1.3.1.2.1
# ::id pmid_2465_1010.111
# ::preferred 
(l / lead-03~e.3
      :ARG0 (a / approach-02~e.2
            :ARG1-of (r / resemble-01~e.1))
      :ARG1~e.4 (i / identify-01~e.6
            :ARG1~e.7 (s / small-molecule~e.15
                  :name (n / name :op1 "GDP"~e.9)
                  :mod (a2 / analog~e.10)
                  :ARG1-of~e.15 (b / bind-01~e.15
                        :ARG2 (e / enzyme~e.20
                              :name (n2 / name :op1 "Ras")
                              :ARG2-of (m / mutate-01 :value "G12C"~e.16)
                              :ARG0-of~e.20 (c2 / cause-01~e.20
                                    :ARG1~e.20 (c3 / cancer~e.20)))
                        :manner (c / covalent)
                        :mod (s2 / specific~e.14))
                  :ARG0-of (d3 / deactivate-01
                        :ARG1 e)))
      :ARG1-of (d / describe-01
            :ARG0 (p3 / publication-91
                  :ARG0 (a4 / and~e.28
                        :op1 (p / person
                              :name (n3 / name :op1 "Lim"~e.27))
                        :op2 (p2 / person
                              :mod (o / other~e.29)))
                  :time (d2 / date-entity :year "2014"~e.31))))

# ::tok Perhaps other compounds could be identified that interact specifically with the G12D and G13D mutant forms using similar strategies .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.1.1.1 2-1.1.1 3-1 4-1.1.r 5-1.1 7-1.1.1.2 8-1.1.1.2.2 9-1.1.1.2.1.r 11-1.1.1.2.1.1.2.1 12-1.1.1.2.1 13-1.1.1.2.1.2.2.1 14-1.1.1.2.1.1 14-1.1.1.2.1.1.2 14-1.1.1.2.1.1.2.r 14-1.1.1.2.1.2 14-1.1.1.2.1.2.2 14-1.1.1.2.1.2.2.r 16-1.1.2 17-1.1.2.1.1 18-1.1.2.1
# ::id pmid_2465_1010.112
# ::preferred 
(p / possible~e.0,3
      :domain~e.4 (i / identify-01~e.5
            :ARG1 (c / compound~e.2
                  :mod (o / other~e.1)
                  :ARG0-of (i2 / interact-01~e.7
                        :ARG1~e.9 (a / and~e.12
                              :op1 (e / enzyme~e.14
                                    :name (n / name :op1 "Ras")
                                    :ARG1-of~e.14 (m / mutate-01~e.14 :value "G12D"~e.11))
                              :op2 (e2 / enzyme~e.14
                                    :name (n2 / name :op1 "Ras")
                                    :ARG1-of~e.14 (m2 / mutate-01~e.14 :value "G13D"~e.13)))
                        :mod (s / specific~e.8)))
            :ARG2-of (u / use-01~e.16
                  :ARG1 (s2 / strategy~e.18
                        :ARG1-of (r / resemble-01~e.17)))))

# ::tok These brilliant experiments remind us that these proteins are in dynamic and flexible states that might present more opportunities for small molecule attack than was previously realized .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1.2 2-1.1 3-1 4-1.3 5-1.2.r 6-1.2.1.1.3.1 7-1.2.1.1.3 10-1.2.1.1.1 12-1.2.1.1.2 13-1.2.1.1 15-1.2 16-1.2.1 17-1.2.1.2.2 18-1.2.1.2 19-1.2.1.2.1.r 20-1.2.1.2.1.1.1 21-1.2.1.2.1.1 22-1.2.1.2.1 23-1.2.1.2.2 25-1.2.1.2.2.1.1 26-1.2.1.2.2.1
# ::id pmid_2465_1010.113
# ::preferred 
(r / remind-01~e.3
      :ARG0 (e / experiment-01~e.2
            :mod (t / this~e.0)
            :ARG1-of (b / brilliant-01~e.1))
      :ARG1~e.5 (p / possible~e.15
            :domain (p2 / present-01~e.16
                  :ARG0 (s / state~e.13
                        :mod (d / dynamic~e.10)
                        :mod (f / flexible~e.12)
                        :poss (p3 / protein~e.7
                              :mod (t2 / this~e.6)))
                  :ARG1 (o / opportunity~e.18
                        :mod~e.19 (a / attack-01~e.22
                              :ARG0 (m / molecule~e.21
                                    :mod (s2 / small~e.20)))
                        :quant (m2 / more-than~e.17,23
                              :op1 (r2 / realize-01~e.26
                                    :time (p4 / previous~e.25))))))
      :ARG2 (w / we~e.4))

# ::tok Indeed , it is well established that Ras @-@ GTP exists in two states , only one of which is active and each with distinct binding properties for effectors , GAPs , and nucleotide ( <ce:cross-refs id="crosrefs0025" refid="bib21 bib36"> Geyer et al. , 1996; Liao et al. , 2008 </ce:cross-refs> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3 4-1.2 5-1 6-1.1.r 7-1.1.1.1.1.1 9-1.1.1.2.1.1 10-1.1 11-1.1.2.r 12-1.1.2.1 13-1.1.2 13-1.1.2.2.1 15-1.1.2.2.1.2 16-1.1.2.2.1.1 20-1.1.2.2.1.3 23-1.1.2.3.r 24-1.1.2.3.2 25-1.1.2.3.1 26-1.1.2.3 27-1.1.2.3.1.1.r 28-1.1.2.3.1.1.1 30-1.1.2.3.1.1.2.1.1 32-1.1.2.3.1.1 33-1.1.2.3.1.1.3 39-1.4.1.1.1.1.1.1 40-1.4.1 40-1.4.1.1.1 40-1.4.1.2.1 41-1.4.1.1.1.2.1 41-1.4.1.2.1.2.1 44-1.4.1.2.1.1.1.1 45-1.4.1.2.1 46-1.4.1.2.1.2.1 48-1.4.1.2.2.1
# ::id pmid_2465_1010.114
# ::preferred 
(e / establish-01~e.5
      :ARG1~e.6 (e2 / exist-01~e.10
            :ARG1 (m / macro-molecular-complex
                  :part (e4 / enzyme
                        :name (n3 / name :op1 "Ras"~e.7))
                  :part (s3 / small-molecule
                        :name (n4 / name :op1 "GTP"~e.9)))
            :ARG2~e.11 (s / state~e.13
                  :quant "2"~e.12
                  :ARG2-of (i / include-91
                        :ARG1 (s2 / state~e.13
                              :quant "1"~e.16
                              :mod (o / only~e.15)
                              :mod (a / active~e.20)))
                  :poss-of~e.23 (p / property~e.26
                        :mod (b / bind-01~e.25
                              :ARG1~e.27 (a2 / and~e.32
                                    :op1 (e3 / effector~e.28)
                                    :op2 (p2 / protein
                                          :name (n / name :op1 "GAP"~e.30))
                                    :op3 (n2 / nucleotide~e.33)))
                        :mod (d / distinct~e.24))))
      :manner (g / good~e.4)
      :mod (i2 / indeed~e.0)
      :ARG1-of (d2 / describe-01
            :ARG0 (a3 / and~e.40
                  :op1 (p3 / publication-91
                        :ARG0 (a4 / and~e.40
                              :op1 (p4 / person
                                    :name (n5 / name :op1 "Geyer"~e.39))
                              :op2 (p5 / person
                                    :mod (o2 / other~e.41)))
                        :time (d3 / date-entity :year "1996"))
                  :op2 (p6 / publication-91
                        :ARG0 (a5 / and~e.40,45
                              :op1 (p7 / person
                                    :name (n6 / name :op1 "Liao"~e.44))
                              :op2 (p8 / person
                                    :mod (o3 / other~e.41,46)))
                        :time (d4 / date-entity :year "2008"~e.48)))))

# ::tok The idea of targeting the GDP @-@ bound form of an oncogenic mutant seems counterintuitive because we often think of oncogenic mutants as being locked in their GTP @-@ bound states , signaling persistently downstream .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.2 2-1.1.2.1.r 3-1.1.2.1 5-1.1.2.1.1.2.1.1 7-1.2.1.3.1.2.2 7-1.2.1.3.1.2.2.2 7-1.2.1.3.1.2.2.2.r 11-1.1.2.1.1.1.2 11-1.1.2.1.1.1.2.1 11-1.1.2.1.1.1.2.1.r 12-1.1.2.1.1.1 12-1.1.2.1.1.1.1 12-1.1.2.1.1.1.1.r 13-1 15-1.2 16-1.2.1.1 17-1.2.1.4 18-1.2.1 20-1.1.2.1.1.1.2 20-1.1.2.1.1.1.2.1 20-1.1.2.1.1.1.2.1.r 21-1.1.2.1.1.1 21-1.1.2.1.1.1.1 21-1.1.2.1.1.1.1.r 23-1.1.2.r 24-1.2.1.3.1 27-1.2.1.3.1.2.2.1.1 29-1.2.1.3.1.2.2 29-1.2.1.3.1.2.2.2 29-1.2.1.3.1.2.2.2.r 32-1.2.1.3.2 33-1.2.1.3.2.3 34-1.2.1.3.2.2
# ::id pmid_2465_1010.115
# ::preferred 
(s / seem-01~e.13
      :ARG1 (i3 / intuitive
            :polarity "-"
            :domain~e.23 (i2 / idea~e.1
                  :mod~e.2 (t / target-01~e.3
                        :ARG1 (m2 / macro-molecular-complex
                              :part (e / enzyme~e.12,21
                                    :ARG1-of~e.12,21 (m / mutate-01~e.12,21)
                                    :ARG0-of (c3 / cause-01~e.11,20
                                          :ARG1~e.11,20 (c4 / cancer~e.11,20)))
                              :part (s2 / small-molecule
                                    :name (n / name :op1 "GDP"~e.5))))))
      :ARG1-of (c2 / cause-01~e.15
            :ARG0 (t2 / think-01~e.18
                  :ARG0 (w / we~e.16)
                  :ARG1 e
                  :ARG2 (a / and
                        :op1 (l / lock-01~e.24
                              :ARG1 e
                              :ARG3 (m3 / macro-molecular-complex
                                    :part e
                                    :part (s4 / small-molecule~e.7,29
                                          :name (n2 / name :op1 "GTP"~e.27)
                                          :ARG2-of~e.7,29 (b2 / bind-01~e.7,29))))
                        :op2 (s5 / signal-07~e.32
                              :ARG0 e
                              :location (d / downstream~e.34)
                              :ARG1-of (p / persist-01~e.33)))
                  :frequency (o / often~e.17))))

# ::tok However , codon 12 mutants retain measurable intrinsic GTPase activity , even though they are all refractory to GAP @-@ mediated GTPase stimulation .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 2-1.1.1.1 3-1.1.1.1.1 4-1.1.1.1.2 5-1.1 6-1.1.2.3 7-1.1.2.2 8-1.1.2.1.1.1 11-1 12-1 13-1.2.2.2 14-1.2.2.r 15-1.2.2.1 16-1.2 17-1.2.1.r 18-1.2.1.2.1.1.1 20-1.2.1.2 21-1.2.1.1 22-1.2.1
# ::id pmid_2465_1010.116
# ::preferred 
(h / have-concession-91~e.0,11,12
      :ARG1 (r / retain-01~e.5
            :ARG0 (e2 / enzyme
                  :part (c / codon~e.2
                        :mod "12"~e.3
                        :ARG2-of (m / mutate-01~e.4)))
            :ARG1 (a / act-01
                  :ARG1 (e / enzyme
                        :name (n / name :op1 "GTPase"~e.8))
                  :mod (i / intrinsic~e.7)
                  :ARG1-of (m2 / measure-01~e.6
                        :mod (p / possible))))
      :ARG2 (r2 / refractory~e.16
            :prep-to~e.17 (s / stimulate-01~e.22
                  :ARG1 e~e.21
                  :ARG1-of (m3 / mediate-01~e.20
                        :ARG0 (p2 / protein
                              :name (n2 / name :op1 "GAP"~e.18))))
            :domain~e.14 (e3 / enzyme
                  :mod (a2 / all~e.15)
                  :part c~e.13)))

# ::tok Although GTP hydrolysis rates are slow , the GDP off rates are also slow , and indeed , oncogenic mutants often exist with similar levels of GTP and GDP : if intrinsic GTPase and GDP off rates were identical , Ras proteins would be 50 % GTP bound and 50 % GDP bound .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1.1.2.1.1.1.1.1 2-1.1.1.2.1.1 3-1.1.1.1.1 3-1.1.1.2.1 5-1.1.1.1 5-1.1.1.2 8-1.1.1.1.1.1.1.1 10-1.1.1.1.1 12-1.1.1.1.2 13-1.1.1.1 15-1.1 16-1.1.2.4 18-1.1.2.1.1.2.2 18-1.1.2.1.1.2.2.1 18-1.1.2.1.1.2.2.1.r 19-1.1.2.1.1.2 19-1.1.2.1.1.2.1 19-1.1.2.1.1.2.1.r 20-1.1.2.3 23-1.1.2 24-1.1.2.1 24-1.1.2.2 26-1.2.1.1.1.2.1.1.1 27-1.1 28-1.1.2.2.1.1.1 30-1.2 31-1.2.2.1.2 32-1.2.2.1.1.1.1 34-1.2.2.2.1.1.1 36-1.2.2.1 36-1.2.2.2 38-1.2.2 40-1.2.1.1.1.1.1 40-1.2.1.1.2.1.1 40-1.2.1.2.1.1 44-1.2.1.1.1.3.1 45-1.2.1.1.1.3 46-1.1.2.1.1.1.1 46-1.2.1.1.1.2.1.1.1 47-1.2.1.1.1 47-1.2.1.1.1.2 47-1.2.1.1.1.2.r 49-1.2.1.1.1.3.1 50-1.2.1.1.1.3 51-1.2.1.1.2.2.1.1.1 52-1.2.1.1.1 52-1.2.1.1.1.2 52-1.2.1.1.1.2.r 52-1.2.1.1.2 52-1.2.1.1.2.2 52-1.2.1.1.2.2.r
# ::id pmid_2465_1010.117
# ::preferred 
(m / multi-sentence
      :snt1 (a / and~e.15,27
            :op1 (h / have-concession-91~e.0
                  :ARG1 (s / slow-05~e.5,13
                        :ARG1 (r / rate~e.3,10
                              :degree-of (s2 / small-molecule
                                    :name (n / name :op1 "GDP"~e.8)
                                    :ARG1-of (d / deactivate-01)))
                        :mod (a2 / also~e.12))
                  :ARG2 (s3 / slow-05~e.5
                        :ARG1 (r2 / rate~e.3
                              :degree-of (h2 / hydrolyze-01~e.2
                                    :ARG1 (s4 / small-molecule
                                          :name (n2 / name :op1 "GTP"~e.1))))))
            :op2 (r3 / resemble-01~e.23
                  :ARG1 (l / level~e.24
                        :degree-of (s9 / small-molecule
                              :name (n11 / name :op1 "GTP"~e.46)
                              :part-of (e2 / enzyme~e.19
                                    :ARG2-of~e.19 (m2 / mutate-01~e.19)
                                    :ARG0-of (c / cause-01~e.18
                                          :ARG1~e.18 (c2 / cancer~e.18)))))
                  :ARG2 (l2 / level~e.24
                        :degree-of (s5 / small-molecule
                              :name (n3 / name :op1 "GDP"~e.28)
                              :part-of e2))
                  :frequency (o / often~e.20)
                  :mod (i4 / indeed~e.16)))
      :snt2 (h3 / have-condition-91~e.30
            :ARG1 (i2 / include-91
                  :ARG1 (a3 / and
                        :op1 (e5 / enzyme~e.47,52
                              :name (n7 / name :op1 "Ras"~e.40)
                              :ARG1-of~e.47,52 (b2 / bind-01~e.47,52
                                    :ARG2 (s7 / small-molecule
                                          :name (n9 / name :op1 "GTP"~e.26,46)))
                              :quant (p / percentage-entity~e.45,50 :value "50"~e.44,49))
                        :op2 (e6 / enzyme~e.52
                              :name (n8 / name :op1 "Ras"~e.40)
                              :ARG1-of~e.52 (b / bind-01~e.52
                                    :ARG2 (s8 / small-molecule
                                          :name (n10 / name :op1 "GDP"~e.51)))
                              :quant p))
                  :ARG2 (e4 / enzyme
                        :name (n6 / name :op1 "Ras"~e.40)))
            :ARG2 (i / identical-01~e.38
                  :ARG1 (r4 / rate~e.36
                        :degree-of (e3 / enzyme
                              :name (n4 / name :op1 "GTPase"~e.32))
                        :mod (i5 / intrinsic~e.31))
                  :ARG2 (r5 / rate~e.36
                        :degree-of (s6 / small-molecule
                              :name (n5 / name :op1 "GDP"~e.34)
                              :ARG1-of (d2 / deactivate-01))
                        :mod i5))))

# ::tok This presents an opportunity for targeting the GDP @-@ bound state and trapping it in the off state and so preventing recharging with GTP .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1 3-1.2 4-1.2.1.r 5-1.2.1 7-1.2.1.1.1.1.1 9-1.2.1.1.1 9-1.2.1.1.1.2 9-1.2.1.1.1.2.r 12-1.2.2 13-1.2.2.1 20-1.2.2.3 21-1.2.2.3.1 22-1.2.2.3.1.1.r 23-1.2.2.3.1.1.1.1
# ::id pmid_2465_1010.118
# ::preferred 
(p / present-01~e.1
      :ARG0 (t3 / this~e.0)
      :ARG1 (o / opportunity~e.3
            :mod~e.4 (t / target-01~e.5
                  :ARG1 (m / macro-molecular-complex
                        :part (s / small-molecule~e.9
                              :name (n / name :op1 "GDP"~e.7)
                              :ARG1-of~e.9 (b2 / bind-01~e.9))))
            :mod (t2 / trap-01~e.12
                  :ARG1 m~e.13
                  :ARG2 (d / deactivate-01
                        :ARG1 m)
                  :purpose (p2 / prevent-01~e.20
                        :ARG1 (r / recharge-01~e.21
                              :ARG2~e.22 (s2 / small-molecule
                                    :name (n2 / name :op1 "GTP"~e.23)))))))

# ::tok As an alternative to targeting specific Ras mutants , such as G12C , compounds could be developed that target individual Ras isoforms but do not discriminate between wild @-@ type and mutant Ras proteins .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1.2 3-1.1.2.1.r 4-1.1.2.1 5-1.1.2.1.1.3 6-1.1.1.1.2.1.3.1.1.1 6-1.1.2.1.1.1.1 6-1.1.2.1.1.4.1.1.1 7-1.1.2.1.1 7-1.1.2.1.1.2 7-1.1.2.1.1.2.r 7-1.1.2.1.1.4.1 7-1.1.2.1.1.4.1.2 7-1.1.2.1.1.4.1.2.r 11-1.1.2.1.1.4.1.2.1 13-1.1.1 14-1 15-1.1.r 16-1.1 18-1.1.1.1 19-1.1.1.1.1.2 20-1.1.1.1.1.1.1.1 22-1.1.1.1.2 24-1.1.1.1.2.1.1 24-1.1.1.1.2.1.1.r 25-1.1.1.1.2.1 26-1.1.1.1.2.1.3 27-1.1.1.1.2.1.3.1.2 29-1.1.1.1.2.1.3.1.2 30-1.1.1.1.2.1.3 31-1.1.1.1.2.1.3.2 32-1.1.1.1.2.1.3.2
# ::id pmid_2465_1010.119
# ::preferred 
(p / possible~e.14
      :domain~e.15 (d / develop-02~e.16
            :ARG1 (c / compound~e.13
                  :ARG0-of (t / target-01~e.18
                        :ARG1 (i / isoform
                              :mod (e / enzyme
                                    :name (n / name :op1 "Ras"~e.20))
                              :mod (i2 / individual~e.19))
                        :ARG1-of (c2 / contrast-01~e.22
                              :ARG2 (d2 / discriminate-01~e.25
                                    :polarity~e.24 "-"~e.24
                                    :ARG0 c
                                    :ARG1 (b / between~e.26,30
                                          :op1 (e3 / enzyme
                                                :name (n3 / name :op1 "Ras"~e.6)
                                                :mod (w / wild-type~e.27,29))
                                          :op2 e2~e.31,32)))))
            :ARG4 (a / alternative~e.2
                  :prep-to~e.3 (t2 / target-01~e.4
                        :ARG1 (e2 / enzyme~e.7
                              :name (n2 / name :op1 "Ras"~e.6)
                              :ARG2-of~e.7 (m / mutate-01~e.7)
                              :mod (s / specific~e.5)
                              :ARG1-of (e5 / exemplify-01
                                    :ARG0 (e6 / enzyme~e.7
                                          :name (n5 / name :op1 "Ras"~e.6)
                                          :ARG2-of~e.7 (m2 / mutate-01~e.7 :value "G12C"~e.11))))))))

# ::tok This could be achieved by targeting specific hypervariable regions at the C terminus where the Ras proteins differ most widely ( <ce:cross-ref id="crosref0250" refid="fig3"> Figure 3 </ce:cross-ref>@ <ce:float-anchor refid="fig3" /> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1 2-1.1.r 3-1.1 4-1.1.2.r 5-1.1.2 6-1.1.2.1.1 7-1.1.2.1.2 8-1.1.2.1 9-1.1.2.1.4.r 11-1.1.2.1.4.1.1 12-1.1.2.1.4.1.2 13-1.1.2.1.3.r 15-1.1.2.1.3.1.1.1 16-1.1.2.1.4 17-1.1.2.1.3 18-1.1.2.1.3.2.1 19-1.1.2.1.3.2 24-1.2.1 25-1.2.1.1
# ::id pmid_2465_1010.120
# ::preferred 
(p / possible~e.1
      :domain~e.2 (a / achieve-01~e.3
            :ARG1 (t / this~e.0)
            :manner~e.4 (t2 / target-01~e.5
                  :ARG1 (r / region~e.8
                        :mod (s / specific~e.6)
                        :mod (h / hypervariable~e.7)
                        :location-of~e.13 (d / differ-02~e.17
                              :ARG1 (e / enzyme
                                    :name (n2 / name :op1 "Ras"~e.15))
                              :degree (w / wide~e.19
                                    :degree (m / most~e.18)))
                        :part-of~e.9 (p2 / protein-segment~e.16
                              :name (n / name :op1 "C"~e.11 :op2 "terminus"~e.12)))))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure~e.24 :mod "3"~e.25)))

# ::tok The C @-@ terminal hypervariable region of K @-@ Ras @-@ 4B is very different from the hypervariable regions of other Ras proteins and is involved in the specific interaction of K @-@ Ras @-@ 4B with calmodulin ( <ce:cross-ref id="crosref0255" refid="bib40"> Lopez @-@ Alcalá et al. , 2008 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1.2.1.1 3-1.1.1.2.1.1 4-1.1.1.1 5-1.1.1 7-1.1.1.2.2.1.1 9-1.1.1.2.2.1.1 11-1.1.1.2.2.1.1 13-1.1.3 14-1.1 17-1.1.1.1 18-1.1.1 18-1.1.2 19-1.1.2.2.r 20-1.1.2.2.2 21-1.1.2.2.1.1 22-1.2.1 23-1 23-1.3.1.1 25-1.2 26-1.2.2.r 28-1.2.2.3 29-1.2.2 30-1.2.2.1.r 31-1.2.2.1 32-1.2.2.1 33-1.2.2.1 34-1.2.2.1 35-1.2.2.1 36-1.2.2.2.r 37-1.2.2.2 42-1.3.1.1.1.1.1 44-1.3.1.1.1.1.1 45-1.3.1.1 46-1.3.1.1.2.1 48-1.3.1.2.1
# ::id pmid_2465_1010.121
# ::preferred 
(a / and~e.23
      :op1 (d / differ-02~e.14
            :ARG1 (r2 / region~e.5,18
                  :mod (h / hypervariable~e.4,17)
                  :part-of (p / protein-segment
                        :name (n / name :op1 "C-terminus"~e.1,3)
                        :part-of (e / enzyme
                              :name (n2 / name :op1 "K-Ras-4B"~e.7,9,11))))
            :ARG2 (r / region~e.18
                  :mod h
                  :part-of~e.19 (e2 / enzyme
                        :name (n3 / name :op1 "Ras"~e.21)
                        :mod (o / other~e.20)))
            :degree (v / very~e.13))
      :op2 (i / involve-01~e.25
            :ARG1 p~e.22
            :ARG2~e.26 (i2 / interact-01~e.29
                  :ARG0~e.30 e~e.31,32,33,34,35
                  :ARG1~e.36 (c / calmodulin~e.37)
                  :mod (s / specific~e.28)))
      :ARG1-of (d2 / describe-01
            :ARG0 (p2 / publication-91
                  :ARG0 (a3 / and~e.23,45
                        :op1 (p3 / person
                              :name (n4 / name :op1 "Lopez-Alcalá"~e.42,44))
                        :op2 (p4 / person
                              :mod (o2 / other~e.46)))
                  :time (d3 / date-entity :year "2008"~e.48))))

# ::tok Because K @-@ Ras @-@ 4B seems to be the major form of K @-@ Ras in established tumors , these specific biochemical properties may afford unique opportunities for therapeutic attack .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.1.1.1.1.1 1-1.1.1.3.1.1 3-1.1.1.1.1.1 3-1.1.1.3.1.1 5-1.1.1.3.1.1 6-1.1 8-1.1.1.3.r 10-1.1.1.2 11-1.1.1 13-1.1.1.1.1.1 13-1.1.1.3.1.1 15-1.1.1.1.1.1 15-1.1.1.3.1.1 16-1.1.1.4.r 17-1.1.1.4.1 18-1.1.1.4 20-1.2.1.1.1 21-1.2.1.1.2 22-1.2.1.1.3 23-1.2.1.1 24-1.2 25-1.2.1 26-1.2.1.2.1 27-1.2.1.2 28-1.2.1.2.2.r 29-1.2.1.2.2.1 30-1.2.1.2.2
# ::id pmid_2465_1010.122
# ::preferred 
(c / cause-01~e.0
      :ARG0 (s / seem-01~e.6
            :ARG1 (f / form~e.11
                  :mod (e / enzyme
                        :name (n / name :op1 "K-Ras"~e.1,3,13,15))
                  :mod (m / major~e.10)
                  :domain~e.8 (e2 / enzyme
                        :name (n2 / name :op1 "K-Ras-4B"~e.1,3,5,13,15))
                  :location~e.16 (t / tumor~e.18
                        :ARG1-of (e3 / establish-01~e.17))))
      :ARG1 (p / possible~e.24
            :domain (a / afford-02~e.25
                  :ARG0 (p2 / property~e.23
                        :mod (t2 / this~e.20)
                        :mod (s2 / specific~e.21)
                        :mod (b / biochemical~e.22))
                  :ARG1 (o / opportunity~e.27
                        :mod (u / unique~e.26)
                        :mod~e.28 (a2 / attack-01~e.30
                              :ARG0 (t3 / therapy~e.29))))))

# ::tok Mouse models suggest that such compounds would be well tolerated because animals lacking any single isoform of Ras are viable ( A . Balmain , personal communication ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1 2-1 3-1.2.r 4-1.2.1.1 5-1.2.1 8-1.2.2 9-1.2 10-1.3 11-1.3.1.1 12-1.3.1.1.1 13-1.3.1.1.1.1.2 14-1.3.1.1.1.1.1 15-1.3.1.1.1.1 16-1.3.1.1.1.1.3.r 17-1.3.1.1.1.1.3.1.1 18-1.3.1.1.r 19-1.3.1 23-1.4.1.1.2 25-1.4.2 26-1.4
# ::id pmid_2465_1010.123
# ::preferred 
(s / suggest-01~e.2
      :ARG0 (m / model~e.1
            :mod (m2 / mouse~e.0))
      :ARG1~e.3 (t / tolerate-01~e.9
            :ARG1 (c / compound~e.5
                  :mod (s2 / such~e.4))
            :manner (g / good~e.8))
      :ARG1-of (c2 / cause-01~e.10
            :ARG0 (v / viable~e.19
                  :domain~e.18 (a / animal~e.11
                        :ARG0-of (l / lack-01~e.12
                              :ARG1 (i / isoform~e.15
                                    :mod (s3 / single~e.14)
                                    :mod (a2 / any~e.13)
                                    :mod~e.16 (e / enzyme
                                          :name (n / name :op1 "Ras"~e.17)))))))
      :ARG1-of (c3 / communicate-01~e.26
            :ARG0 (p / person
                  :name (n2 / name :op1 "A." :op2 "Balmain"~e.23))
            :mod (p2 / personal~e.25)))

# ::tok Targeting GDP @/@ GTP Binding and Exchange
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.1.1.1.1.1.1 3-1.1.1.1.2.1.1 4-1.1.1 5-1.1 6-1.1.2
# ::id pmid_2465_1010.124
# ::preferred 
(t / target-01~e.0
      :ARG1 (a / and~e.5
            :op1 (b / bind-01~e.4
                  :ARG2 (s3 / slash
                        :op1 (s / small-molecule
                              :name (n / name :op1 "GDP"~e.1))
                        :op2 (s2 / small-molecule
                              :name (n2 / name :op1 "GTP"~e.3))))
            :op2 (e / exchange-01~e.6
                  :ARG1 s
                  :ARG3 s2)))

# ::tok Ras proteins bind GDP and GTP with picomolar affinity .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 2-1 3-1.2.1.1.1 4-1.2 5-1.2.2.1.1 7-1.2.1.2.1 8-1.2.1.2
# ::id pmid_2465_1010.125
# ::preferred 
(b / bind-01~e.2
      :ARG1 (e / enzyme
            :name (n / name :op1 "Ras"~e.0))
      :ARG2 (a2 / and~e.4
            :op1 (s / small-molecule
                  :name (n2 / name :op1 "GDP"~e.3)
                  :mod (a / affinity~e.8
                        :mod (p / picomolar~e.7)))
            :op2 (s2 / small-molecule
                  :name (n3 / name :op1 "GTP"~e.5)
                  :mod a)))

# ::tok It is generally accepted that oncogenic Ras proteins cannot be attacked with nucleotide analogs because high GTP concentrations make competition impossible .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.2 3-1 4-1.1.r 5-1.1.2.2 5-1.1.2.2.2 5-1.1.2.2.2.1 5-1.1.2.2.2.1.r 5-1.1.2.2.2.r 5-1.1.3 6-1.1.2.2.1.1 8-1.1 8-1.1.1 8-1.1.1.r 9-1.1.2.r 10-1.1.2 11-1.1.2.1.r 12-1.1.2.1.1 13-1.1.2.1 14-1.1.3 15-1.1.3.1.1.2 16-1.1.3.1.1.1.1.1 17-1.1.3.1.1 18-1.1.3.1 19-1.1.3.1.2.2 20-1.1.3.1.2 20-1.1.3.1.2.1 20-1.1.3.1.2.1.r
# ::id pmid_2465_1010.126
# ::preferred 
(a / accept-01~e.3
      :ARG1~e.4 (p / possible~e.8
            :polarity~e.8 "-"~e.8
            :domain~e.9 (a2 / attack-01~e.10
                  :ARG0~e.11 (a3 / analog~e.13
                        :mod (n2 / nucleotide~e.12))
                  :ARG1 (e / enzyme~e.5
                        :name (n / name :op1 "Ras"~e.6)
                        :ARG0-of~e.5 (c / cause-01~e.5
                              :ARG1~e.5 (c2 / cancer~e.5))))
            :ARG1-of (c3 / cause-01~e.5,14
                  :ARG0 (m / make-02~e.18
                        :ARG0 (c4 / concentrate-02~e.17
                              :ARG1 (s / small-molecule
                                    :name (n3 / name :op1 "GTP"~e.16))
                              :mod (h / high~e.15))
                        :ARG1 (p2 / possible~e.20
                              :polarity~e.20 "-"~e.20
                              :domain (c5 / compete-01~e.19)))))
      :manner (g / general-02~e.2))

# ::tok The high affinity for GTP is also considered a barrier , though it is easy to imagine that analogs could be developed with equally high affinity .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1.1.1 2-1.1.1.1 3-1.1.1.1.2.r 4-1.1.1.1.2.1.1 5-1.1.1.1.r 6-1.1.2 7-1.1 9-1.1.1 11-1 13-1.2.1.r 14-1.2 16-1.2.1 17-1.2.1.1.r 18-1.2.1.1.1.1 19-1.2.1.1 20-1.2.1.1.1.r 21-1.2.1.1.1 22-1.2.1.1.1.1.1.r 23-1.2.1.1.1.1.1.1.1 24-1.2.1.1.1.1.1.1 25-1.2.1.1.1.1.1
# ::id pmid_2465_1010.127
# ::preferred 
(h / have-concession-91~e.11
      :ARG1 (c / consider-01~e.7
            :ARG1 (b / barrier~e.9
                  :domain~e.5 (a / affinity~e.2
                        :mod (h2 / high~e.1)
                        :topic~e.3 (s / small-molecule
                              :name (n / name :op1 "GTP"~e.4))))
            :mod (a4 / also~e.6))
      :ARG2 (e / easy~e.14
            :domain~e.13 (i / imagine-01~e.16
                  :ARG1~e.17 (p / possible~e.19
                        :domain~e.20 (d / develop-02~e.21
                              :ARG1 (a2 / analog~e.18
                                    :poss-of~e.22 (a3 / affinity~e.25
                                          :mod (h3 / high~e.24
                                                :degree (e2 / equal~e.23)))))))))

# ::tok This approach to targeting Ras has therefore been abandoned .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.2 1-1.1.1 2-1.1.1.1.r 3-1.1.1.1 4-1.1.1.1.1.1.1 6-1 8-1.1
# ::id pmid_2465_1010.128
# ::preferred 
(c / cause-01~e.6
      :ARG1 (a / abandon-01~e.8
            :ARG1 (a2 / approach-02~e.1
                  :ARG1~e.2 (t2 / target-01~e.3
                        :ARG1 (e / enzyme
                              :name (n / name :op1 "Ras"~e.4)))
                  :mod (t / this~e.0))))

# ::tok However , Ras proteins in their GTP state exist in complexes with effectors ( Raf kinases , RalGDS , PI3K , other Ras @-@ binding proteins ) , as well as regulators ( GAPs and guanine nucleotide exchange factors [GEFs]).
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 2-1.1.1.1.1.1.1.4.2.1.1.1 2-1.1.1.2.1.1 3-1.1.1.1.1.1.1.4 6-1.1.1.2.2.1.1.1 10-1.1.1.1 10-1.1.2.1 12-1.1.1.1.1 14-1.1.1.1.1.1.1.1.1.1 15-1.1.1.1.1.1.1.1 17-1.1.1.1.1.1.1.2.1.1 19-1.1.1.1.1.1.1.3.1.1 21-1.1.1.1.1.1.1.4.1 22-1.1.1.1.1.1.1.4.2.1.1.1 22-1.1.1.2.1.1 24-1.1.1.1.1.1.1.4.2 24-1.1.1.2.2 25-1.1.1.1.1.1.1.2 25-1.1.2.1.1.1.1.1 25-1.1.2.1.1.1.1.2 30-1.1.2.1.1.r 31-1.1.2.1.1 31-1.1.2.1.1.2 31-1.1.2.1.1.2.r 33-1.1.2.1.1.1.1.1.1.1 34-1.1.2.1.1.1.1 35-1.1.2.1.1.1.1.2.1.1 36-1.1.2.1.1.1.1.2.1.2 37-1.1.2.1.1.1.1.2.1.3 38-1.1.2.1.1.1.1.2.1.4
# ::id pmid_2465_1010.129
# ::preferred 
(h / have-concession-91~e.0
      :ARG1 (a3 / and
            :op1 (h2 / have-part-91
                  :ARG1 (m / macro-molecular-complex~e.10
                        :part (e3 / effector~e.12
                              :ARG1-of (e4 / exemplify-01
                                    :ARG0 (a / and
                                          :op1 (k / kinase~e.15
                                                :name (n3 / name :op1 "Raf"~e.14))
                                          :op2 (p4 / protein~e.25
                                                :name (n5 / name :op1 "RalGDS"~e.17))
                                          :op3 (e5 / enzyme
                                                :name (n4 / name :op1 "PI3K"~e.19))
                                          :op4 (p / protein~e.3
                                                :mod (o / other~e.21)
                                                :ARG1-of (b2 / bind-01~e.24
                                                      :ARG2 (e6 / enzyme
                                                            :name (n6 / name :op1 "Ras"~e.2,22))))))))
                  :ARG2 (e2 / enzyme
                        :name (n / name :op1 "Ras"~e.2,22)
                        :ARG1-of (b / bind-01~e.24
                              :ARG2 (s / small-molecule
                                    :name (n2 / name :op1 "GTP"~e.6)))))
            :op2 (h3 / have-part-91
                  :ARG1 (m3 / macro-molecular-complex~e.10
                        :part~e.30 (m2 / molecular-physical-entity~e.31
                              :ARG1-of (e7 / exemplify-01
                                    :ARG0 (a2 / and~e.34
                                          :op1 (p2 / protein~e.25
                                                :name (n7 / name :op1 "GAP"~e.33))
                                          :op2 (p3 / protein~e.25
                                                :name (n8 / name
                                                      :op1 "guanine"~e.35
                                                      :op2 "nucleotide"~e.36
                                                      :op3 "exchange"~e.37
                                                      :op4 "factor"~e.38))))
                              :ARG0-of~e.31 (r / regulate-01~e.31)))
                  :ARG2 e2)))

# ::tok The effects of most of these proteins on nucleotide binding have not been measured .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.2 2-1.2.1.r 3-1.2.1.1.2 5-1.2.1.1.1.1 6-1.2.1 6-1.2.1.1.1 7-1.2.2.r 8-1.2.2.1 9-1.2.2 11-1.1 11-1.1.r 13-1
# ::id pmid_2465_1010.130
# ::preferred 
(m / measure-01~e.13
      :polarity~e.11 "-"~e.11
      :ARG1 (e / effect-03~e.1
            :ARG0~e.2 (p / protein~e.6
                  :ARG1-of (i / include-91
                        :ARG2 (p2 / protein~e.6
                              :mod (t / this~e.5))
                        :ARG3 (m2 / most~e.3)))
            :ARG1~e.7 (b / bind-01~e.9
                  :ARG1 (n / nucleotide~e.8))))

# ::tok GEFs , of course , greatly reduce the affinity for nucleotides , allowing GDP to be released rapidly and replaced by GTP .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 2-1.3 3-1.3 5-1.4 6-1 8-1.2 9-1.2.1.r 10-1.2.1 12-1.5 13-1.5.1.1.1.1.1 16-1.5.1.1 17-1.5.1.1.2 17-1.5.1.1.2.r 18-1.5.1 19-1.5.1.2 20-1.5.1.2.2.r 21-1.5.1.2.2.1.1
# ::id pmid_2465_1010.131
# ::preferred 
(r / reduce-01~e.6
      :ARG0 (p / protein
            :name (n / name :op1 "GEF"~e.0))
      :ARG1 (a / affinity~e.8
            :topic~e.9 (n2 / nucleotide~e.10))
      :mod (o / of-course~e.2,3)
      :degree (g / great~e.5)
      :ARG0-of (a2 / allow-01~e.12
            :ARG1 (a3 / and~e.18
                  :op1 (r2 / release-01~e.16
                        :ARG1 (s / small-molecule
                              :name (n3 / name :op1 "GDP"~e.13))
                        :manner~e.17 (r3 / rapid~e.17))
                  :op2 (r4 / replace-01~e.19
                        :ARG1 s
                        :ARG2~e.20 (s2 / small-molecule
                              :name (n4 / name :op1 "GTP"~e.21))))))

# ::tok Although oncogenic mutants do not need GEFs to put them in the active state , they are still sensitive to GEF @-@ mediated exchange and cycle through a complex state in which nucleotide @-@ free Ras protein is bound to the GEF ; this may provide a potential opportunity for a mutant @-@ specific nucleotide analog to bind .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.2.2 1-1.2.2.1 1-1.2.2.1.1 1-1.2.2.1.1.r 1-1.2.2.1.r 2-1.2.2.2 4-1.2.1 4-1.2.1.r 5-1.2 6-1.2.3.1.1.1 7-1.2.2 7-1.2.2.1 7-1.2.2.1.r 9-1.1.1.1 17-1.1.1.3 18-1.1.1 19-1.2.2 19-1.2.2.1 19-1.2.2.1.r 20-1.1.1.2.1.1 22-1.1.1.2.1 23-1.1.1.2 24-1.1 25-1.1.2 26-1.1.2.2.r 28-1.1.2.2 32-1.1.2.2.1.2.1 34-1.1.2.2.1 34-1.1.2.2.1.2 34-1.1.2.2.1.2.r 35-1.1.2.2.1.1.1 36-1.1.2.2.1.3.1 38-1.1.2.2.1.3 39-1.2.2 39-1.2.2.1 39-1.2.2.1.r 41-1.1.2.2.1.3.1 44-1.1.3.2 45-1.1.3 47-1.1.3.1.2 48-1.1.3.1 51-1.1.3.1.1.1.2.1 53-1.1.3.1.1.1.2 54-1.1.3.1.1.1.1 55-1.1.3.1.1.1 57-1.1.2.2.1.3 57-1.1.3.1.1
# ::id pmid_2465_1010.132
# ::preferred 
(h / have-concession-91~e.0
      :ARG1 (a2 / and~e.24
            :op1 (s / sensitive-03~e.18
                  :ARG0 e~e.9
                  :ARG1 (e2 / exchange-01~e.23
                        :ARG1-of (m2 / mediate-01~e.22
                              :ARG0 p~e.20))
                  :mod (s2 / still~e.17))
            :op2 (c3 / cycle-01~e.25
                  :ARG0 (e / enzyme~e.1,7,19,39
                        :ARG0-of~e.1,7,19,39 (c / cause-01~e.1,7,19,39
                              :ARG1~e.1 (c2 / cancer~e.1))
                        :ARG2-of (m / mutate-01~e.2))
                  :path~e.26 (m4 / macro-molecular-complex~e.28
                        :part (e3 / enzyme~e.34
                              :name (n3 / name :op1 "Ras"~e.35)
                              :ARG1-of~e.34 (f / free-04~e.34
                                    :ARG2 (n4 / nucleotide~e.32))
                              :ARG1-of (b / bind-01~e.38,57
                                    :ARG2 p~e.36,41))))
            :ARG0-of (p2 / provide-01~e.45
                  :ARG1 (o / opportunity~e.48
                        :mod (b2 / bind-01~e.57
                              :ARG1 (a3 / analog~e.55
                                    :mod (n5 / nucleotide~e.54)
                                    :mod (s3 / specific~e.53
                                          :topic (m3 / mutate-01~e.51))))
                        :mod (p4 / potential~e.47))
                  :mod (p3 / possible~e.44)))
      :ARG2 (n / need-01~e.5
            :polarity~e.4 "-"~e.4
            :ARG0 e
            :ARG1 (a / activate-01
                  :ARG0 (p / protein
                        :name (n2 / name :op1 "GEF"~e.6))
                  :ARG1 e)))

# ::tok In support of this , we noted many years ago that antibodies directed against specific codon 12 mutants were effective at reversing transformation in cells , as cited above , yet these antibodies do not bind to nucleotide @-@ loaded Ras ( <ce:cross-ref id="crosref0260" refid="bib11"> Clark et al. , 1985 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.4 2-1.4.1.r 3-1.4.1 5-1.1 6-1 7-1.3.2 8-1.3.2.1.2 9-1.3 9-1.3.1 9-1.3.1.r 11-1.2.2.1 12-1.2.2.1.1 13-1.2.2.1.1.1 14-1.2.2.1.1.1.1.2 15-1.2.2.1.1.1.1.1 16-1.2.2.1.1.1.1.1.1 17-1.2.2.1.1.1.1.1.2 18-1.2.2.1.r 19-1.2.2 20-1.2.2.2.r 21-1.2.2.2 22-1.2.2.2.2 23-1.2.2.2.2.1.r 24-1.2.2.2.2.1 26-1.3.r 26-1.5.r 27-1.5 28-1.5.1 31-1.4.1 32-1.2.1.2 34-1.2.1.1 34-1.2.1.1.r 35-1.2.1 36-1.2.1.3.r 37-1.2.1.3.2.1 39-1.2.1.3.2 40-1.2.1.3.1.1 45-1.6.1.1.1.1.1 46-1.6.1.1 47-1.6.1.1.2.1 49-1.6.1.2.1
# ::id pmid_2465_1010.133
# ::preferred 
(n / note-01~e.6
      :ARG0 (w / we~e.5)
      :ARG1 (h / have-concession-91
            :ARG1 (b2 / bind-01~e.35
                  :polarity~e.34 "-"~e.34
                  :ARG1 a~e.32
                  :ARG2~e.36 (e2 / enzyme
                        :name (n3 / name :op1 "Ras"~e.40)
                        :ARG1-of (l / load-01~e.39
                              :ARG2 (n4 / nucleotide~e.37))))
            :ARG2 (e / effective~e.19
                  :domain~e.18 (a / antibody~e.11
                        :ARG1-of (d / direct-01~e.12
                              :ARG2 (a2 / against~e.13
                                    :op1 (e3 / enzyme
                                          :part (c / codon~e.15
                                                :mod "12"~e.16
                                                :ARG2-of (m2 / mutate-01~e.17))
                                          :mod (s / specific~e.14)))))
                  :purpose~e.20 (r / reverse-01~e.21
                        :ARG0 a
                        :ARG1 (t2 / transform-01~e.22
                              :ARG1~e.23 (c2 / cell~e.24)))))
      :time~e.26 (b / before~e.9
            :op1~e.9 (n2 / now~e.9)
            :quant (m / many~e.7
                  :op1 (t / temporal-quantity
                        :quant "1"
                        :unit (y / year~e.8))))
      :ARG0-of (s2 / support-01~e.1
            :ARG1~e.2 (t3 / this~e.3,31))
      :ARG1-of~e.26 (c3 / cite-01~e.27
            :medium (a3 / above~e.28))
      :ARG1-of (d2 / describe-01
            :ARG0 (p / publication-91
                  :ARG0 (a4 / and~e.46
                        :op1 (p2 / person
                              :name (n5 / name :op1 "Clark"~e.45))
                        :op2 (p3 / person
                              :mod (o / other~e.47)))
                  :time (d3 / date-entity :year "1985"~e.49))))

# ::tok We therefore speculate that oncogenic Ras exists in a nucleotide @-@ free state frequently enough to make it vulnerable to attack .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1.3 2-1 3-1.2.r 4-1.2.1 4-1.2.1.2 4-1.2.1.2.1 4-1.2.1.2.1.r 4-1.2.1.2.r 5-1.2.1.1.1 6-1.2 7-1.2.2.r 9-1.2.2.1.1 11-1.2.2.1 12-1.2.2 13-1.2.3 14-1.2.3.1 15-1.2.4.1.2.r 16-1.2.4 16-1.2.4.1.2 17-1.2.4.1.1 18-1.2.1.3 18-1.2.4.1 19-1.2.4.1.2.r 20-1.2.4.1.2
# ::id pmid_2465_1010.134
# ::preferred 
(s / speculate-01~e.2
      :ARG0 (w / we~e.0)
      :ARG1~e.3 (e2 / exist-01~e.6
            :ARG1 (e / enzyme~e.4
                  :name (n / name :op1 "Ras"~e.5)
                  :ARG0-of~e.4 (c / cause-01~e.4
                        :ARG1~e.4 (c2 / cancer~e.4))
                  :mod (v / vulnerable~e.18))
            :ARG2~e.7 (s2 / state~e.12
                  :ARG1-of (f / free-04~e.11
                        :ARG2 (n2 / nucleotide~e.9)))
            :frequency (f2 / frequent~e.13
                  :degree (e3 / enough~e.14))
            :ARG0-of (m / make-02~e.16
                  :ARG1 (v2 / vulnerable~e.18
                        :domain e~e.17
                        :prep-to~e.15,19 (a / attack-01~e.16,20))))
      :ARG1-of (i / infer-01~e.1))

# ::tok Whether oncogenic Ras proteins are regulated at all by Sos and other GEFs has been surprisingly difficult to determine definitively , partly because there are many types of GEFs in mammalian cells .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 0-1.1.1.1.r 1-1.1.1.3 1-1.1.1.3.2 1-1.1.1.3.2.1 1-1.1.1.3.2.1.r 1-1.1.1.3.2.r 2-1.1.1.3.1.1 3-1.1.1.2.1 3-1.1.1.2.2 5-1.1.1 6-1.1.1.4 7-1.1.1.4 9-1.1.1.2.1.1.1 10-1.1.1.2 11-1.1.1.2.2.2 12-1.1.1.2.2.1.1 14-1.1.r 15-1.2 16-1 17-1.3 18-1.1 19-1.1.2 19-1.1.2.r 22-1.3 25-1.3.1.2 26-1.3.1 27-1.3.1.1.r 28-1.3.1.1 31-1.3.1.3
# ::id pmid_2465_1010.135
# ::preferred 
(d / difficult~e.16
      :domain~e.14 (d2 / determine-01~e.18
            :ARG1 (r / regulate-01~e.5
                  :mode~e.0 "interrogative"~e.0
                  :ARG0 (a3 / and~e.10
                        :op1 (p / protein~e.3
                              :name (n2 / name :op1 "Sos"~e.9))
                        :op2 (p2 / protein~e.3
                              :name (n3 / name :op1 "GEF"~e.12)
                              :mod (o / other~e.11)))
                  :ARG1 (e / enzyme~e.1
                        :name (n / name :op1 "Ras"~e.2)
                        :ARG0-of~e.1 (c / cause-01~e.1
                              :ARG1~e.1 (c2 / cancer~e.1)))
                  :degree (a2 / at-all~e.6,7))
            :manner~e.19 (d3 / definitive~e.19))
      :ARG0-of (s / surprise-01~e.15)
      :ARG1-of (c3 / cause-01~e.17,22
            :ARG0 (t / type~e.26
                  :mod~e.27 p2~e.28
                  :quant (m / many~e.25)
                  :location (c4 / cell~e.31
                        :mod (m2 / mammal)))
            :degree (p3 / part)))

# ::tok Furthermore , GEFs such as Sos have allosteric sites for Ras binding as well as sites for GDP @/@ GTP exchange , and it is hard to measure GTP loading on individual Ras isoforms in cells .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1.1.1.1.1 3-1.1.1.1.2.r 4-1.1.1.1.2.r 5-1.1.1.1.2.1.1 6-1.1.1 7-1.1.1.2.1.1 8-1.1.1.2.1 10-1.1.1.2.1.2.1.1.1 11-1.1.1.2.1.2 15-1.1.1.2.1 15-1.1.1.2.2 16-1.1.1.2.2.1.r 17-1.1.1.2.2.1.2.1.1 19-1.1.1.2.2.1.1.1.1 20-1.1.1.2.2.1 22-1.1 22-1.1.1.2 24-1.1.2.1.r 25-1.1.2 27-1.1.2.1 28-1.1.2.1.1.2 29-1.1.2.1.1 31-1.1.2.1.1.1.2 32-1.1.2.1.1.1.1 34-1.1.2.1.2.r 35-1.1.2.1.2
# ::id pmid_2465_1010.136
# ::preferred 
(a / and
      :op2 (a2 / and~e.22
            :op1 (h / have-03~e.6
                  :ARG0 (p / protein
                        :name (n3 / name :op1 "GEF"~e.2)
                        :example~e.3,4 (p2 / protein
                              :name (n4 / name :op1 "Sos"~e.5)))
                  :ARG1 (a4 / and~e.22
                        :op1 (s2 / site~e.8,15
                              :mod (a3 / allosteric~e.7)
                              :purpose (b / bind-01~e.11
                                    :ARG1 (e / enzyme
                                          :name (n / name :op1 "Ras"~e.10))))
                        :op2 (s3 / site~e.15
                              :purpose~e.16 (e2 / exchange-01~e.20
                                    :ARG1 (s / small-molecule
                                          :name (n2 / name :op1 "GTP"~e.19))
                                    :ARG2 (s4 / small-molecule
                                          :name (n5 / name :op1 "GDP"~e.17))))))
            :op2 (h2 / hard~e.25
                  :domain~e.24 (m / measure-01~e.27
                        :ARG1 (l / load-01~e.29
                              :ARG1 (i / isoform
                                    :mod e~e.32
                                    :mod (i2 / individual~e.31))
                              :ARG2 s~e.28)
                        :location~e.34 (c / cell~e.35)))))

# ::tok However , it is clear that mutant Ras proteins are not 100 % GTP bound , and GEFs could increase the fraction of Ras @-@ GTP to some extent .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 3-1.1.1.1.r 4-1.1.1 6-1.1.1.1.2 6-1.1.1.1.2.2 6-1.1.1.1.2.2.r 7-1.1.1.1.2.1.1 8-1.1.2.1.1 9-1.1.1.1.r 9-1.1.2.1.r 10-1.1.1.1.1 10-1.1.1.1.1.r 11-1.1.1.1.4.1 12-1.1.1.1.4 13-1.1.1.1.3.1.1 14-1.1.1.1 16-1.1 17-1.1.2.1.1.1.1 18-1.1.2 19-1.1.2.1 21-1.1.2.1.2 22-1.1.2.1.2.1.r 23-1.1.2.1.2.1.1 25-1.1.1.1.3.1.1 26-1.1.2.1.3.r 27-1.1.2.1.3 28-1.1.1.1.4.r
# ::id pmid_2465_1010.137
# ::preferred 
(h / have-concession-91~e.0
      :ARG1 (a / and~e.16
            :op1 (c / clear~e.4
                  :domain~e.3,9 (b / bind-01~e.14
                        :polarity~e.10 "-"~e.10
                        :ARG1 (e / enzyme~e.6
                              :name (n / name :op1 "Ras"~e.7)
                              :ARG1-of~e.6 (m / mutate-01~e.6))
                        :ARG2 (s / small-molecule
                              :name (n2 / name :op1 "GTP"~e.13,25))
                        :extent~e.28 (p3 / percentage-entity~e.12 :value "100"~e.11)))
            :op2 (p4 / possible~e.18
                  :domain~e.9 (i / increase-01~e.19
                        :ARG0 (p5 / protein~e.8
                              :name (n3 / name :op1 "GEF"~e.17))
                        :ARG1 (f / fraction~e.21
                              :mod~e.22 (m2 / macro-molecular-complex
                                    :part e~e.23
                                    :part s))
                        :ARG2~e.26 (s3 / some~e.27)))))

# ::tok However , targeting Sos or other GEFs for treating mutant Ras cancers does not appear an attractive proposition .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 2-1.1.2 3-1.1.2.1.1.1.1 4-1.1.2.1 5-1.1.2.1.2.2 6-1.1.2.1.2.1.1 7-1.1.2.2.r 8-1.1.2.2 9-1.1.2.2.1.1 10-1.1.2.2.1.1.1.1.1 11-1.1.2.2.1 13-1.1.1 13-1.1.1.r 14-1.1 16-1.1.2.3.1 17-1.1.2.3
# ::id pmid_2465_1010.138
# ::preferred 
(h / have-concession-91~e.0
      :ARG1 (a / appear-02~e.14
            :polarity~e.13 "-"~e.13
            :ARG1 (t / target-01~e.2
                  :ARG1 (o / or~e.4
                        :op1 (p / protein
                              :name (n2 / name :op1 "Sos"~e.3))
                        :op2 (p2 / protein
                              :name (n3 / name :op1 "GEF"~e.6)
                              :mod (o2 / other~e.5)))
                  :purpose~e.7 (t2 / treat-03~e.8
                        :ARG2 (c / cancer~e.11
                              :location-of (m / mutate-01~e.9
                                    :ARG1 (e / enzyme
                                          :name (n / name :op1 "Ras"~e.10)))))
                  :ARG1-of (p3 / propose-01~e.17
                        :ARG0-of (a2 / attract-01~e.16)))))

# ::tok Oncogenic mutants may or may not depend on GEFs , to some degree , but wild @-@ type Ras proteins most certainly do .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2.2 1-1.1.2.2 2-1.1.2 3-1.1 4-1.1.1 4-1.1.2 5-1.1.2.1 5-1.1.2.1.r 6-1.1.1.1 6-1.2 7-1.1.1.1.2.r 8-1.1.1.1.2.1.1 11-1.1.3 12-1.1.3.r 14-1 15-1.2.1.2 17-1.2.1.2 18-1.2.1.1.1 19-1.1.1.1.1 20-1.2.3.1 21-1.2.3
# ::id pmid_2465_1010.139
# ::preferred 
(c / contrast-01~e.14
      :ARG1 (o / or~e.3
            :op1 (p / possible~e.4
                  :domain (d / depend-01~e.6
                        :ARG0 (p2 / protein~e.19
                              :ARG2-of (m / mutate-01
                                    :ARG0-of (c2 / cause-01
                                          :ARG1 (c3 / cancer))))
                        :ARG1~e.7 (p3 / protein
                              :name (n2 / name :op1 "GEF"~e.8))))
            :op2 (p4 / possible~e.2,4
                  :polarity~e.5 "-"~e.5
                  :domain d~e.0,1)
            :degree~e.12 (s / some~e.11))
      :ARG2 (d2 / depend-01~e.6
            :ARG0 (e / enzyme
                  :name (n / name :op1 "Ras"~e.18)
                  :mod (w / wild-type~e.15,17))
            :ARG1 p3
            :mod (c4 / certain~e.21
                  :degree (m2 / most~e.20))))

# ::tok For these reasons , recent efforts to target mutant Ras that led to compounds that bind at the Sos @-@ binding site may seem disappointing ( <ce:cross-refs id="crosrefs0030" refid="bib44 bib68"> Maurer et al. , 2012; Sun et al. , 2012 </ce:cross-refs> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.2.1.1 2-1.2.1 4-1.1.1.1.1 5-1.1.1.1 7-1.1.1.1.2 8-1.1.1.1.2.1 8-1.1.1.1.2.1.2 8-1.1.1.1.2.1.2.r 9-1.1.1.1.2.1.1.1 11-1.1.1.1.2.1.3 12-1.1.1.1.2.1.3.1.r 13-1.1.1.1.2.1.3.1 15-1.1.1.1.2.1.3.1.1 16-1.1.1.1.2.1.3.1.1.1.r 18-1.1.1.1.2.1.3.1.1.1.1.1.1.1 20-1.1.1.1.2.1.3.1.1.1.1 21-1.1.1.1.2.1.3.1.1.1 22-1 23-1.1 24-1.1.1 30-1.3.1.1.1.1.1.1 31-1.3.1 31-1.3.1.1.1 31-1.3.1.2.1 32-1.3.1.1.1.2.1 32-1.3.1.2.1.2.1 35-1.3.1.2.1.1.1.1 36-1.3.1 36-1.3.1.1.1 36-1.3.1.2.1 37-1.3.1.1.1.2.1 37-1.3.1.2.1.2.1 39-1.3.1.1.2.1 39-1.3.1.2.2.1
# ::id pmid_2465_1010.140
# ::preferred 
(p / possible~e.22
      :domain (s / seem-01~e.23
            :ARG1 (d3 / disappoint-01~e.24
                  :ARG0 (e2 / effort~e.5
                        :time (r / recent~e.4)
                        :purpose (t / target-01~e.7
                              :ARG1 (e / enzyme~e.8
                                    :name (n / name :op1 "Ras"~e.9)
                                    :ARG1-of~e.8 (m / mutate-01~e.8)
                                    :ARG0-of (l / lead-03~e.11
                                          :ARG2~e.12 (c / compound~e.13
                                                :ARG0-of (b / bind-01~e.15
                                                      :location~e.16 (s2 / site~e.21
                                                            :location-of (b2 / bind-01~e.20
                                                                  :ARG2 (p2 / protein
                                                                        :name (n2 / name :op1 "Sos"~e.18))))))))))))
      :ARG1-of (c2 / cause-01
            :ARG0 (r2 / reason~e.2
                  :mod (t2 / this~e.1)))
      :ARG1-of (d4 / describe-01
            :ARG0 (a / and~e.31,36
                  :op1 (p3 / publication-91
                        :ARG0 (a2 / and~e.31,36
                              :op1 (p4 / person
                                    :name (n3 / name :op1 "Maurer"~e.30))
                              :op2 (p5 / person
                                    :mod (o2 / other~e.32,37)))
                        :time (d2 / date-entity :year "2012"~e.39))
                  :op2 (p6 / publication-91
                        :ARG0 (a3 / and~e.31,36
                              :op1 (p7 / person
                                    :name (n5 / name :op1 "Sun"~e.35))
                              :op2 (p8 / person
                                    :mod (o / other~e.32,37)))
                        :time (d / date-entity :year "2012"~e.39)))))

# ::tok However , the compounds that these groups discovered could be excellent starting points toward the discovery of compounds that have selectivity for mutant forms of K @-@ Ras or block effector interactions .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 3-1.1.1.3 5-1.1.1.3.1.1.1 6-1.1.1.3.1.1 7-1.1.1.3.1 8-1.1 9-1.1.1.3.r 9-1.1.1.r 10-1.1.1.2 11-1.1.1.1 12-1.1.1 13-1.1.1.4.r 15-1.1.1.4.1 15-1.1.1.4.2 17-1.1.1.4.1.1 17-1.1.1.4.2.1 22-1.1.1.4.1.1.1.1.2 23-1.1.1.4.1.1.1.1 24-1.1.1.4.1.1.1.1.1.r 25-1.1.1.4.1.1.1.1.1.1.1 27-1.1.1.4.1.1.1.1.1.1.1 28-1.1.1.4 29-1.1.1.4.2.1.1 30-1.1.1.4.2.1.1.1.1 31-1.1.1.4.2.1.1.1
# ::id pmid_2465_1010.141
# ::preferred 
(h / have-concession-91~e.0
      :ARG1 (p2 / possible~e.8
            :domain~e.9 (p3 / point~e.12
                  :source-of (s / start-01~e.11)
                  :mod (e2 / excellent~e.10)
                  :domain~e.9 (c / compound~e.3
                        :ARG1-of (d / discover-01~e.7
                              :ARG0 (g / group~e.6
                                    :mod (t / this~e.5))))
                  :direction~e.13 (o / or~e.28
                        :op1 (d2 / discover-01~e.15
                              :ARG1 (c2 / compound~e.17
                                    :ARG0-of (s2 / select-01
                                          :ARG1 (f / form~e.23
                                                :mod~e.24 (e / enzyme
                                                      :name (n / name :op1 "K-Ras"~e.25,27))
                                                :ARG2-of (m / mutate-01~e.22)))))
                        :op2 (d3 / discover-01~e.15
                              :ARG1 (c3 / compound~e.17
                                    :ARG0-of (b / block-01~e.29
                                          :ARG1 (i / interact-01~e.31
                                                :ARG0 (e3 / effector~e.30)))))))))

# ::tok Restoring GTP Hydrolysis
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.1.1.1.1 2-1.1
# ::id pmid_2465_1010.142
# ::preferred 
(r / restore-01~e.0
      :ARG1 (h / hydrolyze-01~e.2
            :ARG1 (s / small-molecule
                  :name (n / name :op1 "GTP"~e.1))))

# ::tok Mutations at codons 12 , 13 , and 61 inhibit GAP @-@ mediated GTP hydrolysis .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 3-1.1.1.1.1 5-1.1.1.2.1 7-1.1.1 8-1.1.1.3.1 9-1 10-1.2.2.1.1.1 12-1.2.2 13-1.2.1.1.1 14-1.2
# ::id pmid_2465_1010.143
# ::preferred 
(i / inhibit-01~e.9
      :ARG0 (m / mutate-01~e.0
            :location (a / and~e.7
                  :op1 (c / codon :mod "12"~e.3)
                  :op2 (c2 / codon :mod "13"~e.5)
                  :op3 (c3 / codon :mod "61"~e.8)))
      :ARG1 (h / hydrolyze-01~e.14
            :ARG1 (s / small-molecule
                  :name (n / name :op1 "GTP"~e.13))
            :ARG1-of (m2 / mediate-01~e.12
                  :ARG0 (p / protein
                        :name (n5 / name :op1 "GAP"~e.10)))))

# ::tok As a result , mutant Ras proteins accumulate with elevated GTP @-@ bound proportion .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.2 4-1.1.1 4-1.1.1.2 4-1.1.1.2.r 5-1.1.1.1.1 7-1 8-1.1.r 9-1.1.2.2 10-1.1.2.1.2.1.1 12-1.1.2.1 13-1.1.2
# ::id pmid_2465_1010.144
# ::preferred 
(a / accumulate-01~e.7
      :ARG1~e.8 (a2 / and
            :op1 (e / enzyme~e.4
                  :name (n / name :op1 "Ras"~e.5)
                  :ARG1-of~e.4 (m / mutate-01~e.4))
            :op2 (p / proportion~e.13
                  :mod (b / bind-01~e.12
                        :ARG1 e
                        :ARG2 (s / small-molecule
                              :name (n2 / name :op1 "GTP"~e.10)))
                  :ARG1-of (e2 / elevate-01~e.9)))
      :ARG2-of (r / result-01~e.2))

# ::tok Trahey and McCormick discovered GAP while seeking to explain how relatively small changes in intrinsic GTPase between wild @-@ type and mutant Ras proteins accounted for profound differences in transforming activity ( <ce:cross-ref id="crosref0265" refid="bib71"> Trahey and McCormick , 1987 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1.1 1-1.1 2-1.1.2.1.1 3-1 4-1.2.1.1 5-1.3.1.2.r 5-1.4.r 6-1.4 8-1.4.2 10-1.4.2.2.1.2.1 11-1.4.2.2.1.2 12-1.4.2.2.1 13-1.4.2.2.1.1.r 14-1.4.2.2.1.1.2 15-1.4.2.2.1.1.1.1 17-1.4.2.2.1.3.2 19-1.4.2.2.1.3.2 21-1.4.2.2.1.3.3 21-1.4.2.2.1.3.3.2 21-1.4.2.2.1.3.3.2.r 22-1.4.2.2.1.3.1.1 22-1.4.2.2.1.3.3.1.1 23-1.2 24-1.4.2.2 25-1.4.2.2.2.r 26-1.4.2.2.2.3.2 27-1.4.2.2.2 29-1.4.2.2.2.3.1 30-1.4.2.2.2.3 35-1.1.1.1.1 36-1.1 37-1.1.2.1.1 39-1.3.1.2.1
# ::id pmid_2465_1010.145
# ::preferred 
(d2 / discover-01~e.3
      :ARG0 (a / and~e.1,36
            :op1 (p / person
                  :name (n3 / name :op1 "Trahey"~e.0,35))
            :op2 (p2 / person
                  :name (n4 / name :op1 "McCormick"~e.2,37)))
      :ARG1 (p3 / protein~e.23
            :name (n5 / name :op1 "GAP"~e.4))
      :ARG1-of (d4 / describe-01
            :ARG0 (p5 / publication-91
                  :ARG0 a
                  :time~e.5 (d / date-entity :year "1987"~e.39)))
      :time~e.5 (s / seek-01~e.6
            :ARG0 a
            :ARG1 (e3 / explain-01~e.8
                  :ARG0 a
                  :ARG1 (a2 / account-01~e.24
                        :ARG0 (c / change-01~e.12
                              :ARG1~e.13 (e / enzyme
                                    :name (n / name :op1 "GTPase"~e.15)
                                    :mod (i / intrinsic~e.14))
                              :mod (s2 / small~e.11
                                    :degree (r / relative~e.10))
                              :location (e2 / enzyme
                                    :name (n2 / name :op1 "Ras"~e.22)
                                    :mod (w / wild-type~e.17,19)
                                    :compared-to (e4 / enzyme~e.21
                                          :name (n6 / name :op1 "Ras"~e.22)
                                          :ARG1-of~e.21 (m / mutate-01~e.21))))
                        :ARG1~e.25 (d3 / differ-02~e.27
                              :ARG1 e2
                              :ARG2 e4
                              :ARG3 (a3 / act-02~e.30
                                    :ARG0-of (t / transform-01~e.29)
                                    :mod (p4 / profound~e.26)))))))

# ::tok Intrinsic rates of GTP hydrolysis are five orders of magnitude slower than rates catalyzed by GAPs and therefore do not contribute significantly to steady @-@ state levels of Ras @-@ GTP .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1 2-1.1.2.r 3-1.1.2.1.1.1 4-1.1.2 5-1.1.r 6-1.2.1.1 7-1.2.1 8-1.2.1.2.r 9-1.2.1.2 10-1 10-1.2 10-1.2.r 11-1.3.r 12-1.3 13-1.3.1 14-1.3.1.1.r 15-1.3.1.1.1.1 17-1.4 19-1.4.1.1 19-1.4.1.1.r 20-1.4.1 21-1.4.1.4 22-1.4.1.3.r 23-1.4.1.3.1 25-1.4.1.3.1 26-1.4.1.3 27-1.4.1.3.2.r 28-1.4.1.3.2.1.1.1 30-1.4.1.3.2.2
# ::id pmid_2465_1010.146
# ::preferred 
(s3 / slow~e.10
      :domain~e.5 (r / rate~e.1
            :mod (i / intrinsic~e.0)
            :degree-of~e.2 (h / hydrolyze-01~e.4
                  :ARG1 (s / small-molecule
                        :name (n / name :op1 "GTP"~e.3))))
      :degree~e.10 (m / more~e.10
            :degree (o / order~e.7
                  :quant "5"~e.6
                  :mod~e.8 (m2 / magnitude~e.9)))
      :compared-to~e.11 (r2 / rate~e.12
            :degree-of (c / catalyze-01~e.13
                  :ARG0~e.14 (p / protein
                        :name (n2 / name :op1 "GAP"~e.15))))
      :ARG0-of (c2 / cause-01~e.17
            :ARG1 (c3 / contribute-01~e.20
                  :polarity~e.19 "-"~e.19
                  :ARG0 r
                  :ARG2~e.22 (l / level~e.26
                        :mod (s2 / steady-state~e.23,25)
                        :quant-of~e.27 (m3 / macro-molecular-complex
                              :part (e / enzyme
                                    :name (n3 / name :op1 "Ras"~e.28))
                              :part s~e.30))
                  :ARG1-of (s4 / significant-02~e.21))))

# ::tok However , once Ras proteins bind effectors , GAPs can no longer interact , and intrinsic GTPase may become important in determining how long Ras and its effectors remain engaged .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 3-1.1.2.1.2.1.1.1.1.1.1.1 4-1.1.1.1.2 5-1.1.3 6-1.1.3.2 8-1.1.1.1.2.1.1 9-1.1.1 10-1.1.1.1.1 10-1.1.1.1.1.r 11-1.1.1.2 12-1.1.1.1 14-1.1 15-1.1.2.1.1.2 16-1.1.2.1.1.1.1 17-1.1.2 18-1.1.2.1 19-1.1.2.1.2 21-1.1.2.1.2.1 24-1.1.2.1.2.1.1.1.1.1.1.1 25-1.1.2.1.2.1.1.1.1 26-1.1.2.1.2.1.1.1.1.2.1 26-1.1.2.1.2.1.1.1.1.2.1.r 27-1.1.2.1.2.1.1.1.1.2 28-1.1.2.1.2.1.1.1 29-1.1.2.1.2.1.1.1.2
# ::id pmid_2465_1010.147
# ::preferred 
(h / have-concession-91~e.0
      :ARG1 (a / and~e.14
            :op1 (p / possible~e.9
                  :domain (i / interact-01~e.12
                        :polarity~e.10 "-"~e.10
                        :ARG0 (p2 / protein~e.4
                              :name (n4 / name :op1 "GAP"~e.8)))
                  :time (a4 / any-longer~e.11))
            :op2 (p3 / possible~e.17
                  :domain (b / become-01~e.18
                        :ARG1 (e2 / enzyme
                              :name (n3 / name :op1 "GTPase"~e.16)
                              :mod (i2 / intrinsic~e.15))
                        :ARG2 (i3 / important~e.19
                              :purpose (d2 / determine-01~e.21
                                    :ARG1 (t / temporal-quantity
                                          :time-of (r / remain-01~e.28
                                                :ARG1 (a2 / and~e.25
                                                      :op1 (e / enzyme
                                                            :name (n / name :op1 "Ras"~e.3,24))
                                                      :op2 (e5 / effector~e.27
                                                            :poss~e.26 e~e.26))
                                                :ARG3 (e4 / engage-01~e.29
                                                      :ARG1 e5)))))))
            :time (b2 / bind-01~e.5
                  :ARG1 e
                  :ARG2 (e3 / effector~e.6))))

# ::tok Indeed , effector binding may well affect intrinsic GTPase activity of Ras as it does for heterotrimeric G proteins .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2 2-1.1.1.1 3-1.1.1 4-1 5-1.1.4 6-1.1 6-1.1.3.1 7-1.1.2.3 8-1.1.2.2.1.1 11-1.1.2.1.1.1 12-1.1.3.1.1.r 13-1.1.3.1.1 15-1.1.3.1.2.r 16-1.1.3.1.2.2 17-1.1.3.1.2.1.1 18-1.1.3.1.2
# ::id pmid_2465_1010.148
# ::preferred 
(p / possible~e.4
      :domain (a / affect-01~e.6
            :ARG0 (b / bind-01~e.3
                  :ARG1 (e3 / effector~e.2))
            :ARG1 (a2 / act-01
                  :ARG0 (e2 / enzyme
                        :name (n2 / name :op1 "Ras"~e.11))
                  :ARG1 (e / enzyme
                        :name (n / name :op1 "GTPase"~e.8))
                  :mod (i / intrinsic~e.7))
            :ARG1-of (s / same-01
                  :ARG2 (a3 / affect-01~e.6
                        :ARG0~e.12 b~e.13
                        :ARG1~e.15 (p2 / protein~e.18
                              :name (n3 / name :op1 "G"~e.17)
                              :mod (h / heterotrimeric~e.16))))
            :degree (w / well~e.5))
      :mod (i2 / indeed~e.0))

# ::tok If indeed intrinsic GTPase limits signal output , perhaps assays for compounds that stimulate intrinsic GTPase of Ras effector complexes may merit consideration .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3.r 1-1.3.3 2-1.3.1 3-1.3.1 4-1.3 5-1.3.2.1 6-1.3.2 8-1 8-1.2 8-1.2.r 9-1.1.1 10-1.1.1.1.r 11-1.1.1.1 13-1.1.1.1.1 14-1.1.1.1.1.1.2.2 15-1.1.1.1.1.1.2.1.1 17-1.1.1.1.1.1.1.1.1.1.1 18-1.1.1.1.1.1.1.1 19-1.1.1.1.1.1.1 20-1 21-1.1 22-1.1.2
# ::id pmid_2465_1010.149
# ::preferred 
(p2 / possible~e.8,20
      :domain (m / merit-01~e.21
            :ARG0 (a / assay-00~e.9
                  :ARG1~e.10 (c2 / compound~e.11
                        :ARG0-of (s / stimulate-01~e.13
                              :ARG1 (a2 / act-01
                                    :ARG0 (c3 / complex~e.19
                                          :part (e4 / effector~e.18
                                                :mod (e3 / enzyme
                                                      :name (n2 / name :op1 "Ras"~e.17))))
                                    :ARG1 (e / enzyme
                                          :name (n / name :op1 "GTPase"~e.15)
                                          :mod (i / intrinsic~e.14))))))
            :ARG1 (c / consider-01~e.22))
      :mod~e.8 (p3 / perhaps~e.8)
      :condition~e.0 (l / limit-01~e.4
            :ARG0 e~e.2,3
            :ARG1 (o2 / output~e.6
                  :mod (s2 / signal~e.5))
            :mod (i2 / indeed~e.1)))

# ::tok Mattos and colleagues recently showed that the Ras @-@ binding domain of Raf ( the RBD ) has a profound effect on suppressing intrinsic hydrolysis rates of Ras Q61 mutants , but not wild @-@ type Ras or G12V mutants ( <ce:cross-ref id="crosref0270" refid="bib8"> Buhrman et al. , 2010 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1.1 1-1.1 2-1.1.2 3-1.3 4-1 5-1.2.r 7-1.2.1.3.1.1.1 9-1.2.1.3 12-1.2.1.2.1.1 15-1.2.1.1.1 19-1.2.3 20-1.2 20-1.2.4.1 22-1.2.2 22-1.2.4.1.3 23-1.2.2.1.2 24-1.2.2.1.1 25-1.2.2.1 26-1.2.2.1.1.1.r 27-1.2.2.1.1.1.1.1 28-1.2.2.1.1.1.2.1 29-1.2.2.1.1.1 29-1.2.2.1.1.1.2 29-1.2.2.1.1.1.2.r 31-1.2.4 32-1.2.4.1.1 32-1.2.4.1.1.r 32-1.2.4.1.3.1 32-1.2.4.1.3.1.r 33-1.2.4.1.3.2.1.2 35-1.2.4.1.3.2.1.2 36-1.2.4.1.3.2.1.1.1 36-1.2.4.1.3.2.2.1.1 37-1.2.4.1.3.2 38-1.2.4.1.3.2.2.2.1 39-1.2.4.1.3.2.2 39-1.2.4.1.3.2.2.2 39-1.2.4.1.3.2.2.2.r 44-1.4.1.1.1.1.1 45-1.4.1.1 46-1.4.1.1.2.1 48-1.4.1.2.1
# ::id pmid_2465_1010.150
# ::preferred 
(s / show-01~e.4
      :ARG0 (a / and~e.1
            :op1 (p / person
                  :name (n3 / name :op1 "Mattos"~e.0))
            :op2 (c / colleague~e.2
                  :poss p))
      :ARG1~e.5 (a2 / affect-01~e.20
            :ARG0 (p7 / protein-segment
                  :name (n9 / name :op1 "RBD"~e.15)
                  :part-of (e / enzyme
                        :name (n / name :op1 "Raf"~e.12))
                  :ARG0-of (b / bind-01~e.9
                        :ARG1 (e2 / enzyme
                              :name (n2 / name :op1 "Ras"~e.7))))
            :ARG1 (s2 / suppress-01~e.22
                  :ARG1 (r2 / rate~e.25
                        :degree-of (h / hydrolyze-01~e.24
                              :ARG1~e.26 (e3 / enzyme~e.29
                                    :name (n4 / name :op1 "Ras"~e.27)
                                    :ARG2-of~e.29 (m / mutate-01~e.29 :value "Q61"~e.28)))
                        :mod (i / intrinsic~e.23)))
            :degree (p2 / profound~e.19)
            :ARG1-of (c3 / contrast-01~e.31
                  :ARG2 (a4 / affect-01~e.20
                        :polarity~e.32 "-"~e.32
                        :ARG0 p7
                        :ARG1 (s3 / suppress-01~e.22
                              :polarity~e.32 "-"~e.32
                              :ARG1 (o / or~e.37
                                    :op1 (e4 / enzyme
                                          :name (n5 / name :op1 "Ras"~e.36)
                                          :mod (w / wild-type~e.33,35))
                                    :op2 (e5 / enzyme~e.39
                                          :name (n6 / name :op1 "Ras"~e.36)
                                          :ARG2-of~e.39 (m2 / mutate-01~e.39 :value "G12V"~e.38))))
                        :mod p2)))
      :time (r / recent~e.3)
      :ARG1-of (d3 / describe-01
            :ARG0 (p3 / publication-91
                  :ARG0 (a3 / and~e.45
                        :op1 (p5 / person
                              :name (n8 / name :op1 "Buhrman"~e.44))
                        :op2 (p4 / person
                              :mod (o2 / other~e.46)))
                  :time (d / date-entity :year "2010"~e.48))))

# ::tok They propose that suppression of intrinsic GTPase stabilizes Ras @-@ Raf complexes and increases signal output to the MAPK pathway selectively ; this accounts for the preference of Q61 mutants over G12 mutants in melanoma , a disease that is clearly Raf @-@ MAPK driven ( <ce:cross-ref id="crosref0275" refid="bib8"> Buhrman et al. , 2010 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1 2-1.1.2.r 3-1.1.2.1.1 4-1.1.2.1.1.1.r 5-1.1.2.1.1.1.2 6-1.1.2.1.1.1.1.1 7-1.1.2.1 8-1.1.2.1.2.1.1.1 10-1.1.2.1.2.2.1.1 11-1.1.2.1.2 12-1.1.2 13-1.1.2.2 14-1.1.2.2.2.1 15-1.1.2.2.2 18-1.1.2.2.2.2.1.1 19-1.1.2.2.2.2 19-1.2.2.3.2.1 22-1.2.1 23-1.2 24-1.2.2.r 26-1.2.2 27-1.2.2.1.r 28-1.2.2.1.1.1 29-1.2.2.1 29-1.2.2.1.1 29-1.2.2.1.1.r 31-1.2.2.2.1.1 32-1.2.2.2 32-1.2.2.2.1 32-1.2.2.2.1.r 33-1.2.2.3.r 34-1.2.2.3.1.1 37-1.2.2.3 40-1.2.2.3.2.2 40-1.2.2.3.2.2.r 41-1.2.2.3.2.1.1.1 43-1.2.2.3.2.1.1.1 44-1.2.2.3.2 49-1.3.1.1.1.1.1 50-1.3.1.1 51-1.3.1.1.2.1 53-1.3.1.2.1
# ::id pmid_2465_1010.151
# ::preferred 
(m / multi-sentence
      :snt1 (p2 / propose-01~e.1
            :ARG0 (t / they~e.0)
            :ARG1~e.2 (a / and~e.12
                  :op1 (s / stabilize-01~e.7
                        :ARG0 (s2 / suppress-01~e.3
                              :ARG1~e.4 (e / enzyme
                                    :name (n / name :op1 "GTPase"~e.6)
                                    :mod (i / intrinsic~e.5)))
                        :ARG1 (m2 / macro-molecular-complex~e.11
                              :part (e2 / enzyme
                                    :name (n3 / name :op1 "Ras"~e.8))
                              :part (e3 / enzyme
                                    :name (n4 / name :op1 "Raf"~e.10))))
                  :op2 (i2 / increase-01~e.13
                        :ARG0 s2
                        :ARG1 (o2 / output~e.15
                              :mod (s3 / signal~e.14)
                              :direction (p / pathway~e.19
                                    :name (n2 / name :op1 "MAPK"~e.18))))
                  :manner (s4 / select-01)))
      :snt2 (a2 / account-01~e.23
            :ARG0 (t2 / this~e.22)
            :ARG1~e.24 (p3 / prefer-01~e.26
                  :ARG1~e.27 (e4 / enzyme~e.29
                        :ARG2-of~e.29 (m3 / mutate-01~e.29 :value "Q61"~e.28))
                  :ARG2 (e5 / enzyme~e.32
                        :ARG2-of~e.32 (m4 / mutate-01~e.32 :value "G12"~e.31))
                  :location~e.33 (d2 / disease~e.37
                        :name (n5 / name :op1 "melanoma"~e.34)
                        :ARG1-of (d3 / drive-02~e.44
                              :ARG0 (p4 / pathway~e.19
                                    :name (n6 / name :op1 "Raf-MAPK"~e.41,43))
                              :manner~e.40 (c / clear~e.40)))))
      :ARG1-of (d4 / describe-01
            :ARG0 (p5 / publication-91
                  :ARG0 (a3 / and~e.50
                        :op1 (p6 / person
                              :name (n7 / name :op1 "Buhrman"~e.49))
                        :op2 (p7 / person
                              :mod (o / other~e.51)))
                  :time (d / date-entity :year "2010"~e.53))))

# ::tok In the 1980 s , several groups , including those at Cetus and Hoffmann La Roche , screened for compounds that restore GTP hydrolysis to mutant Ras , in the presence or absence of GAP .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.3.1 3-1.3.1.r 5-1.1.1 6-1.1 6-1.1.2.1.1 6-1.1.2.1.2 8-1.1.2 9-1.1.2.1.3 10-1.1.2.1.1.1.r 11-1.1.2.1.1.1.1.1 12-1.1.2.1 13-1.1.2.1.2.1.1.1 14-1.1.2.1.2.1.1.2 15-1.1.2.1.2.1.1.3 17-1 18-1.2.r 19-1.2 20-1.1.2.1.3 21-1.2.1 22-1.2.1.1.1.1.1 23-1.2.1.1 24-1.2.1.1.2.r 25-1.2.1.1.2 25-1.2.1.1.2.2 25-1.2.1.1.2.2.r 26-1.2.1.1.2.1.1 28-1.2.1.2.r 30-1.2.1.2.1 31-1.2.1.2 32-1.2.1.2.2 33-1.2.1.2.1.1.r 34-1.2.1.2.1.1.1.1
# ::id pmid_2465_1010.152
# ::preferred 
(s2 / screen-01~e.17
      :ARG0 (g / group~e.6
            :quant (s3 / several~e.5)
            :ARG2-of (i / include-01~e.8
                  :ARG1 (a2 / and~e.12
                        :op1 (g2 / group~e.6
                              :location~e.10 (c / company
                                    :name (n3 / name :op1 "Cetus"~e.11)))
                        :op2 (g3 / group~e.6
                              :location (c2 / company
                                    :name (n4 / name
                                          :op1 "Hoffmann"~e.13
                                          :op2 "La"~e.14
                                          :op3 "Roche"~e.15)))
                        :mod (t / that~e.9,20))))
      :ARG2~e.18 (c3 / compound~e.19
            :ARG0-of (r / restore-01~e.21
                  :ARG1 (h / hydrolyze-01~e.23
                        :ARG1 (s / small-molecule
                              :name (n / name :op1 "GTP"~e.22))
                        :ARG2~e.24 (e / enzyme~e.25
                              :name (n2 / name :op1 "Ras"~e.26)
                              :ARG1-of~e.25 (m / mutate-01~e.25)))
                  :condition~e.28 (o / or~e.31
                        :op1 (p2 / present~e.30
                              :domain~e.33 (p / protein
                                    :name (n5 / name :op1 "GAP"~e.34)))
                        :op2 (a / absent-01~e.32
                              :ARG1 p))))
      :time (d / date-entity :decade~e.3 "1980"~e.2))

# ::tok These screens failed to find compounds that increased GTPase rates .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1 2-1 4-1.2 5-1.2.2 7-1.2.2.1 8-1.2.2.1.1.1.1.1 9-1.2.2.1.1
# ::id pmid_2465_1010.153
# ::preferred 
(f / fail-01~e.2
      :ARG1 (s / screen-01~e.1
            :mod (t / this~e.0))
      :ARG2 (f2 / find-01~e.4
            :ARG0 s
            :ARG1 (c / compound~e.5
                  :ARG0-of (i / increase-01~e.7
                        :ARG1 (r / rate~e.9
                              :degree-of (e / enzyme
                                    :name (n / name :op1 "GTPase"~e.8)))))))

# ::tok Furthermore , as structures of Ras proteins emerged , mostly from Wittinghofer’s group , it became clear that codon 12 substitutions presented a steric block to GAP @-@ mediated GTP hydrolysis that could not be overcome by a small molecule .
# ::amr-annotator SDL-AMR-09
# ::alignments 3-1.1.3.1.1 4-1.1.3.1.1.1.r 5-1.1.3.1.1.1.1.1 6-1.1.1.2.1.2.1 7-1.1.3.1 9-1.1.3.1.2.2 10-1.1.3.1.2.r 12-1.1.3.1.2 15-1.1 16-1.1.2 18-1.1.1.1.1 19-1.1.1.1.1.1 20-1.1.1.1 21-1.1.1 23-1.1.1.2.2 24-1.1.1.2 26-1.1.1.2.1.2.1.1.1 28-1.1.1.2.1.2 29-1.1.1.2.1.1.1.1 30-1.1.1.2.1 32-1.1.1.2.3.2 33-1.1.1.2.3.2.1 33-1.1.1.2.3.2.1.r 35-1.1.1.2.3 36-1.1.1.2.3.1.r 38-1.1.1.2.3.1 39-1.1.1.2.3.1
# ::id pmid_2465_1010.154
# ::preferred 
(a / and
      :op2 (b / become-01~e.15
            :ARG1 (p2 / present-01~e.21
                  :ARG0 (s2 / substitute-01~e.20
                        :ARG2 (c2 / codon~e.18 :mod "12"~e.19))
                  :ARG1 (b2 / block-01~e.24
                        :ARG1 (h / hydrolyze-01~e.30
                              :ARG1 (s / small-molecule
                                    :name (n2 / name :op1 "GTP"~e.29))
                              :ARG1-of (m / mediate-01~e.28
                                    :ARG0 (p3 / protein~e.6
                                          :name (n3 / name :op1 "GAP"~e.26))))
                        :manner (s3 / steric~e.23)
                        :ARG1-of (o / overcome-01~e.35
                              :ARG0~e.36 (s4 / small-molecule~e.38,39)
                              :mod (p / possible~e.32 :polarity~e.33 "-"~e.33))))
            :ARG2 (c / clear~e.16)
            :ARG1-of (c3 / cause-01
                  :ARG0 (e2 / emerge-02~e.7
                        :ARG0 (s5 / structure~e.3
                              :poss~e.4 (e / enzyme
                                    :name (n / name :op1 "Ras"~e.5)))
                        :source~e.10 (g / group~e.12
                              :poss (p4 / person
                                    :name (n4 / name :op1 "Wittinghofer"))
                              :degree (m2 / most~e.9))))))

# ::tok These studies were mostly based on G12V mutations because these were the most widely used at that time .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1 3-1.3 4-1 5-1.2.r 6-1.2.1 7-1.2 8-1.4 9-1.1.1 12-1.4.1.2.1 13-1.4.1.2 14-1.4.1 16-1.4.1.3 17-1.4.1.3.r
# ::id pmid_2465_1010.155
# ::preferred 
(b / base-02~e.4
      :ARG1 (s / study~e.1
            :mod (t / this~e.0,9))
      :ARG2~e.5 (m2 / mutate-01~e.7 :value "G12V"~e.6)
      :degree (m / most~e.3)
      :ARG1-of (c / cause-01~e.8
            :ARG0 (u / use-01~e.14
                  :ARG1 m2
                  :extent (w / wide~e.13
                        :degree (m3 / most~e.12))
                  :time~e.17 (t2 / that~e.16))))

# ::tok Whether the same conclusion can be applied to other mutations such as G12D or G13D remains to be seen because structures of these proteins bound to GAP have not been solved .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 0-1.1.1.1.r 2-1.1.1.2.1.1 3-1.1.1.2.1 4-1.1.1 5-1.1.1.2.r 6-1.1.1.2 7-1.1.1.2.2.r 8-1.1.1.2.2.1 9-1.1.1.2.2 9-1.1.1.2.2.2.1 9-1.1.1.2.2.2.2 10-1.1.1.2.2.2.r 11-1.1.1.2.2.2.r 12-1.1.1.2.2.2.1.1 13-1.1.1.2.2.2 14-1.1.1.2.2.2.2.1 15-1 16-1.2 17-1.1.1.2.r 18-1.1 19-1.2 20-1.2.1.2 21-1.2.1.2.1.r 22-1.2.1.2.1.1 23-1.2.1.2.1 24-1.2.1.2.2 25-1.2.1.2.2.1.r 26-1.2.1.2.2.1.1.1 28-1.2.1.1 28-1.2.1.1.r 30-1.2.1
# ::id pmid_2465_1010.156
# ::preferred 
(r / remain-01~e.15
      :ARG1 (s2 / see-01~e.18
            :ARG1 (p / possible~e.4
                  :mode~e.0 "interrogative"~e.0
                  :domain~e.5,17 (a / apply-02~e.6
                        :ARG1 (c / conclude-01~e.3
                              :ARG1-of (s / same-01~e.2))
                        :ARG2~e.7 (m / mutate-01~e.9
                              :mod (o / other~e.8)
                              :example~e.10,11 (o2 / or~e.13
                                    :op1 (m2 / mutate-01~e.9 :value "G12D"~e.12)
                                    :op2 (m3 / mutate-01~e.9 :value "G13D"~e.14))))))
      :ARG1-of (c2 / cause-01~e.16,19
            :ARG0 (s3 / solve-01~e.30
                  :polarity~e.28 "-"~e.28
                  :ARG1 (s4 / structure~e.20
                        :poss~e.21 (p2 / protein~e.23
                              :mod (t / this~e.22))
                        :ARG1-of (b / bind-01~e.24
                              :ARG2~e.25 (p3 / protein
                                    :name (n / name :op1 "GAP"~e.26)))))))

# ::tok The approach of restoring GTP hydrolysis to mutant proteins received a brief infusion of hope when Scheffzek and colleagues showed that G12V H @-@ Ras could indeed hydrolyze a GTP analog diaminobenzophenone @-@ phosphoroamidate @-@ GTP in which the aromatic amino group mimics the catalytic effects of GAP’s arginine finger ( <ce:cross-ref id="crosref0280" refid="bib2"> Ahmadian et al. , 1999 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1 2-1.1.1.r 3-1.1.1 4-1.1.1.1.1.1.1 5-1.1.1.1 7-1.1.1.2.1 7-1.3.2.1.2 7-1.3.2.1.2.2 7-1.3.2.1.2.2.r 8-1.1.1.2 9-1 11-1.2.2 12-1.2 13-1.2.1.r 14-1.2.1 15-1.3.r 16-1.3.1.1.1.1 17-1.3.1 18-1.3.1.2 19-1.3 20-1.3.2.r 21-1.3.2.1.2.2.1 22-1.3.2.1.2.1.1 24-1.3.2.1.2.1.1 25-1.3.2 26-1.3.2.2 27-1.3.2.1 29-1.3.2.1.1.1.1 30-1.3.2.1.1.2 31-1.3.2.1.1.1.1 33-1.3.2.1.1.1.1 35-1.3.2.1.1.1.1 39-1.3.2.1.1.3.1.1 40-1.3.2.1.1.3.1.2 41-1.3.2.1.1.3.1 42-1.3.2.1.1.3 44-1.3.2.1.1.3.2.2 45-1.3.2.1.1.3.2 48-1.3.2.1.1.3.2.1.2.1.1 49-1.3.2.1.1.3.2.1 54-1.4.1.1.1.1.1 55-1.4.1.1 56-1.4.1.1.2.1 58-1.4.1.2.1
# ::id pmid_2465_1010.157
# ::preferred 
(r / receive-01~e.9
      :ARG0 (a / approach~e.1
            :topic~e.2 (r2 / restore-01~e.3
                  :ARG1 (h / hydrolyze-01~e.5
                        :ARG1 (s / small-molecule
                              :name (n / name :op1 "GTP"~e.4)))
                  :ARG2 (p2 / protein~e.8
                        :ARG1-of (m / mutate-01~e.7))))
      :ARG1 (i / infuse-01~e.12
            :ARG1~e.13 (h2 / hope~e.14)
            :duration (b / brief~e.11))
      :time~e.15 (s2 / show-01~e.19
            :ARG0 (a2 / and~e.17
                  :op1 (p3 / person
                        :name (n3 / name :op1 "Scheffzek"~e.16))
                  :op2 (c / colleague~e.18))
            :ARG1~e.20 (p / possible~e.25
                  :domain (h3 / hydrolyze-01~e.27
                        :ARG1 (s3 / small-molecule
                              :name (n4 / name :op1 "diaminobenzophenone-phosphoroamidate-GTP"~e.29,31,33,35)
                              :mod (a3 / analog~e.30
                                    :domain s)
                              :location-of (m3 / mimic-01~e.42
                                    :ARG0 (g / group~e.41
                                          :mod (a4 / aromatic~e.39)
                                          :mod (a5 / amine~e.40))
                                    :ARG1 (e2 / effect-03~e.45
                                          :ARG0 (f / finger~e.49
                                                :part-of (p4 / protein
                                                      :name (n5 / name :op1 "GAP"))
                                                :mod (a6 / amino-acid
                                                      :name (n6 / name :op1 "arginine"~e.48)))
                                          :ARG1 (c2 / catalyze-01~e.44))))
                        :ARG2 (e / enzyme~e.7
                              :name (n2 / name :op1 "H-Ras"~e.22,24)
                              :ARG2-of~e.7 (m2 / mutate-01~e.7 :value "G12V"~e.21)))
                  :mod (i2 / indeed~e.26)))
      :ARG1-of (d2 / describe-01
            :ARG0 (p5 / publication-91
                  :ARG0 (a7 / and~e.55
                        :op1 (p6 / person
                              :name (n7 / name :op1 "Ahmadian"~e.54))
                        :op2 (p7 / person
                              :mod (o / other~e.56)))
                  :time (d / date-entity :year "1999"~e.58))))

# ::tok A small molecule that provided this local charge might therefore trick mutant Ras into GTP hydrolysis .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1 2-1.1.1 4-1.1.1.1 5-1.1.1.1.1.2 6-1.1.1.1.1.1 7-1.1.1.1.1 8-1 9-1.2 10-1.1 11-1.1.2 11-1.1.2.2 11-1.1.2.2.r 12-1.1.2.1.1 13-1.1.3.r 14-1.1.3.1.1.1 15-1.1.3
# ::id pmid_2465_1010.158
# ::preferred 
(p2 / possible~e.8
      :domain (t / trick-01~e.10
            :ARG0 (s2 / small-molecule~e.1,2
                  :ARG0-of (p3 / provide-01~e.4
                        :ARG1 (c / charge~e.7
                              :mod (l / local~e.6)
                              :mod (t2 / this~e.5))))
            :ARG1 (e / enzyme~e.11
                  :name (n / name :op1 "Ras"~e.12)
                  :ARG1-of~e.11 (m / mutate-01~e.11))
            :purpose~e.13 (h / hydrolyze-01~e.15
                  :ARG1 (s / small-molecule
                        :name (n2 / name :op1 "GTP"~e.14))))
      :ARG1-of (i / infer-01~e.9))

# ::tok At first sight , the GTD-/GTP @-@ binding site of Ras does not offer any room for such a molecule to bind .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.2.1 1-1.2.1.1 1-1.2.1.1.r 7-1.1.2 10-1.1.2.1.1.1 12-1.1.1 12-1.1.1.r 13-1.1 14-1.1.3.1 15-1.1.3 19-1.1.2.2.1 19-1.1.2.2.2 21-1.1.2
# ::id pmid_2465_1010.159
# ::preferred 
(s / seem-01
      :ARG1 (o2 / offer-01~e.13
            :polarity~e.12 "-"~e.12
            :ARG0 (b / bind-01~e.7,21
                  :ARG1 (e / enzyme
                        :name (n / name :op1 "Ras"~e.10))
                  :ARG2 (s2 / slash
                        :op1 (s3 / small-molecule~e.19
                              :name (n2 / name :op1 "GTD"))
                        :op2 (s4 / small-molecule~e.19
                              :name (n3 / name :op1 "GTP"))))
            :ARG1 (r / room~e.15
                  :mod (a / any~e.14))
            :purpose b)
      :time (s5 / see-01
            :ord (o / ordinal-entity~e.1 :value~e.1 "1"~e.1)))

# ::tok However , these issues deserve rethinking—perhaps G12D offers more possibilities for this kind of attack than G12V , for example .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 2-1.1.1.1.1 3-1.1.1.1 4-1.1.1 6-1.1.2.1.1.1 7-1.1.2.1 8-1.1.2.1.2.1 9-1.1.2 9-1.1.2.1.2 10-1.1.2.1.2.2.r 11-1.1.2.1.2.2.1.1 12-1.1.2.1.2.2.1 13-1.1.2.1.2.2.1.r 14-1.1.2.1.2.2 15-1.1.2.1.2.1.1.r 16-1.1.2.1.2.1.1.1 18-1.1.2.2 19-1.1.2.2
# ::id pmid_2465_1010.160
# ::preferred 
(c / contrast-01~e.0
      :ARG2 (a / and
            :op1 (d / deserve-01~e.4
                  :ARG0 (i / issue~e.3
                        :mod (t2 / this~e.2))
                  :ARG1 (r / rethink-01
                        :ARG1 i))
            :op2 (p / possible~e.9
                  :domain (o / offer-01~e.7
                        :ARG0 (m / mutate-01 :value "G12D"~e.6)
                        :ARG1 (p2 / possibility~e.9
                              :mod (m2 / more~e.8
                                    :compared-to~e.15 (m3 / mutate-01 :value "G12V"~e.16))
                              :mod~e.10 (a2 / attack-01~e.14
                                    :mod~e.13 (k / kind~e.12
                                          :mod (t / this~e.11)))))
                  :ARG0-of (e / exemplify-01~e.18,19
                        :ARG1 i))))

# ::tok Targeting Ras Posttranslational Modification Pathways
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.1.1.1 3-1.1.2 4-1.1
# ::id pmid_2465_1010.161
# ::preferred 
(t / target-01~e.0
      :ARG1 (p / pathway~e.4
            :name (n / name :op1 "Ras"~e.1)
            :ARG1-of (m / modify-01~e.3
                  :time (a / after
                        :op1 (t2 / translate-00)))))

# ::tok Ras proteins are processed in several steps ( reviewed in <ce:cross-ref id="crosref0285" refid="bib24"> Gysin et al. , 2011 </ce:cross-ref> ) , including farnesylation , proteolytic cleavage at the C terminus by RCE1 , and carboxymethylation by isoprenylcysteine carboxyl methyltransferase ( ICMT ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 1-1.2.2.1.2.2 3-1 5-1.2.1 6-1.2 8-1.3 13-1.3.1.1.1.1.1 14-1.3.1.1 15-1.3.1.1.2.1 17-1.3.1.2.1 21-1.2.2 24-1.2.2.1.2.3 28-1.2.2.1.2.2.1.1 29-1.2.2.1.2.2.1.1 31-1.2.2.1.2.1.1.1 33-1.2.2.1 36-1.2.2.1.3.2.1.1 37-1.2.2.1.3.2.1.2 38-1.2.2.1.3.2.1.3
# ::id pmid_2465_1010.162
# ::preferred 
(p / process-01~e.3
      :ARG1 (e / enzyme
            :name (n / name :op1 "Ras"~e.0))
      :manner (s / step-01~e.6
            :quant (s2 / several~e.5)
            :ARG2-of (i / include-91~e.21
                  :ARG1 (a2 / and~e.33
                        :op1 (f / farnesylate-00
                              :ARG1 e)
                        :op2 (c / cleave-01
                              :ARG0 (e2 / enzyme
                                    :name (n3 / name :op1 "RCE1"~e.31))
                              :ARG1 (p6 / protein-segment~e.1
                                    :name (n4 / name :op1 "C-terminus"~e.28,29)
                                    :part-of e)
                              :mod (p5 / proteolytic~e.24))
                        :op3 (c2 / carboxymethylate-00
                              :ARG1 e
                              :ARG2 (e3 / enzyme
                                    :name (n5 / name
                                          :op1 "isoprenylcysteine"~e.36
                                          :op2 "carboxyl"~e.37
                                          :op3 "methyltransferase"~e.38))))))
      :ARG1-of (r / review-01~e.8
            :ARG0 (p2 / publication-91
                  :ARG0 (a / and~e.14
                        :op1 (p3 / person
                              :name (n2 / name :op1 "Gysin"~e.13))
                        :op2 (p4 / person
                              :mod (o / other~e.15)))
                  :time (d / date-entity :year "2011"~e.17))))

# ::tok K @-@ Ras @-@ 4A , H @-@ Ras , and N @-@ Ras are further processed by palmitoylation ( <ce:cross-ref id="crosref0290" refid="fig3"> Figure 3 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.1.1.1 2-1.2.1.1.1 4-1.2.1.1.1 6-1.2.2.1.1 8-1.2.1.1.1 8-1.2.2.1.1 8-1.2.3.1.1 10-1.2 11-1.2.3.1.1 13-1.2.1.1.1 13-1.2.2.1.1 13-1.2.3.1.1 15-1.3 16-1 23-1.4.1 24-1.4.1.1
# ::id pmid_2465_1010.163
# ::preferred 
(p / process-01~e.16
      :ARG0 (p2 / palmitoylate-00)
      :ARG1 (a / and~e.10
            :op1 (e / enzyme
                  :name (n / name :op1 "K-Ras-4A"~e.0,2,4,8,13))
            :op2 (e2 / enzyme
                  :name (n2 / name :op1 "H-Ras"~e.6,8,13))
            :op3 (e3 / enzyme
                  :name (n3 / name :op1 "N-Ras"~e.8,11,13)))
      :degree (f / further~e.15)
      :ARG1-of (d / describe-01
            :ARG0 (f2 / figure~e.23 :mod "3"~e.24)))

# ::tok These reactions are not only essential for plasma membrane localization but also for Raf kinase activation .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.1 1-1.2 2-1.1.1 2-1.2.r 5-1 7-1.1.1.1.1 8-1.1.1.1 12-1.1.r 13-1.1.2.1.1.1 14-1.1.2.1 15-1.1.2
# ::id pmid_2465_1010.164
# ::preferred 
(e / essential~e.5
      :purpose~e.12 (a / and
            :op1 (b / be-located-at-91~e.2
                  :ARG2 (m / membrane~e.8
                        :mod (p / plasma~e.7)))
            :op2 (a2 / activate-01~e.15
                  :ARG1 (k / kinase~e.14
                        :name (n / name :op1 "Raf"~e.13))))
      :domain~e.2 (r / react-01~e.1
            :mod (t / this~e.0)))

# ::tok The failure of farnesyltransferase inhibitors has been well documented .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1 2-1.1.1.r 3-1.1.1.1.1.1.1 4-1.1.1 4-1.1.1.1 4-1.1.1.1.r 7-1.2 8-1
# ::id pmid_2465_1010.165
# ::preferred 
(d / document-01~e.8
      :ARG1 (f / fail-01~e.1
            :ARG1~e.2 (m / molecular-physical-entity~e.4
                  :ARG0-of~e.4 (i / inhibit-01~e.4
                        :ARG1 (e / enzyme
                              :name (n / name :op1 "farnesyltransferase"~e.3)))))
      :manner (g / good~e.7))

# ::tok By sheer bad luck , the forms of Ras that play the major roles in human cancer , K @-@ Ras and N @-@ Ras , can be geranylgeranylated when farnesyltransferase is inhibited , allowing newly synthesized Ras proteins to be inserted correctly in the membrane and to function normally .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.2.1.2 2-1.1.2.1.1 3-1.1.2.1 8-1.1.3.1.1.1.1.1 10-1.1.1.3 12-1.1.1.3.2 14-1.1.1.3.1.r 15-1.1.1.3.1.1 16-1.1.1.3.1 18-1.1.1.1.1.1 20-1.1.1.1.1.1 20-1.1.1.2.1.1 21-1.1.1 22-1.1.1.2.1.1 24-1.1.1.2.1.1 26-1 27-1.1.r 30-1.2.1.1.1 32-1.2 34-1.1.3 35-1.1.3.1.1.1.2.1 36-1.1.3.1.1.1.2 37-1.1.3.1.1.1.1.1 41-1.1.3.1.1 42-1.1.3.1.1.3 42-1.1.3.1.1.3.r 43-1.1.3.1.1.2.r 45-1.1.3.1.1.2 46-1.1.3.1 48-1.1.3.1.2 49-1.1.3.1.2.2 49-1.1.3.1.2.2.r
# ::id pmid_2465_1010.166
# ::preferred 
(p / possible~e.26
      :domain~e.27 (g / geranylgeranylate-00
            :ARG1 (a / and~e.21
                  :op1 (e / enzyme
                        :name (n / name :op1 "K-Ras"~e.18,20))
                  :op2 (e2 / enzyme
                        :name (n2 / name :op1 "N-Ras"~e.20,22,24))
                  :ARG0-of (p2 / play-08~e.10
                        :ARG1~e.14 (c / cancer~e.16
                              :mod (h / human~e.15))
                        :mod (m / major~e.12)))
            :ARG1-of (c2 / cause-01
                  :ARG0 (l / luck~e.3
                        :ARG1-of (b / bad-07~e.2)
                        :mod (s / sheer~e.1)))
            :ARG0-of (a4 / allow-01~e.34
                  :ARG1 (a3 / and~e.46
                        :op1 (i2 / insert-01~e.41
                              :ARG1 (e4 / enzyme
                                    :name (n5 / name :op1 "Ras"~e.8,37)
                                    :ARG1-of (s2 / synthesize-01~e.36
                                          :mod (n6 / new~e.35)))
                              :ARG2~e.43 (m2 / membrane~e.45)
                              :manner~e.42 (c4 / correct~e.42))
                        :op2 (f / function-01~e.48
                              :ARG0 e4
                              :manner~e.49 (n4 / normal~e.49)))))
      :condition (i / inhibit-01~e.32
            :ARG1 (e3 / enzyme
                  :name (n3 / name :op1 "farnesyltransferase"~e.30))))

# ::tok H @-@ Ras , on the other hand , is not geranylgeranylated , suggesting that tumors driven by mutant H @-@ Ras , such as bladder cancer or thyroid cancer , might be susceptible to farnesyltransferase inhibition .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2.1.1 2-1.1.2.1.1 10-1.1.1 10-1.1.1.r 13-1.1.3 14-1.1.3.1.r 15-1.1.3.1.1.1 16-1.1.3.1.1.1.1 17-1.1.3.1.1.1.1.1.r 18-1.1.3.1.1.1.1.1 18-1.1.3.1.1.1.1.1.2 18-1.1.3.1.1.1.1.1.2.r 19-1.1.3.1.1.1.1.1.1.1 21-1.1.3.1.1.1.1.1.1.1 23-1.1.3.1.1.1.2.r 24-1.1.3.1.1.1.2.r 25-1.1.3.1.1.1.2.1.1 26-1.1.3.1.1.1.2.1 26-1.1.3.1.1.1.2.2 27-1.1.3.1.1.1.2 28-1.1.3.1.1.1.2.2.1 29-1.1.3.1.1.1.2.2 31-1.1.3.1 32-1.1.3.1.1.1.r 32-1.1.3.1.1.r 33-1.1.3.1.1 34-1.1.3.1.1.2.r 35-1.1.3.1.1.2.1.1.1 36-1.1.3.1.1.2
# ::id pmid_2465_1010.167
# ::preferred 
(c3 / contrast-01
      :ARG2 (g / geranylgeranylate-00
            :polarity~e.10 "-"~e.10
            :ARG1 (e3 / enzyme
                  :name (n3 / name :op1 "H-Ras"~e.0,2))
            :ARG0-of (s2 / suggest-01~e.13
                  :ARG1~e.14 (p / possible~e.31
                        :domain~e.32 (s / susceptible~e.33
                              :domain~e.32 (t / tumor~e.15
                                    :ARG1-of (d / drive-02~e.16
                                          :ARG0~e.17 (e2 / enzyme~e.18
                                                :name (n2 / name :op1 "H-Ras"~e.19,21)
                                                :ARG2-of~e.18 (m / mutate-01~e.18)))
                                    :example~e.23,24 (o / or~e.27
                                          :op1 (c / cancer~e.26
                                                :mod (b / bladder~e.25))
                                          :op2 (c2 / cancer~e.26,29
                                                :op2 (t2 / thyroid~e.28))))
                              :prep-to~e.34 (i2 / inhibit-01~e.36
                                    :ARG1 (e / enzyme
                                          :name (n / name :op1 "farnesyltransferase"~e.35))))))))

# ::tok Targeting RCE1 or ICMT has also been evaluated , though the consequences of blocking these enzymes are difficult to predict or understand .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1.1.1.1.1.1 2-1.1.1.1 3-1.1.1.1.2.1.1 5-1.1.2 7-1.1 11-1.2.1.1.1 11-1.2.1.1.1.1 11-1.2.1.1.1.1.r 12-1.2.1.1.1.1.1.r 13-1.2.1.1.1.1.1 15-1.2.1.1.1.1.1.1 16-1.2.1.r 17-1.2 18-1.2.1.2 19-1.2.1.1 20-1.2.1 21-1.2.1.2
# ::id pmid_2465_1010.168
# ::preferred 
(c / contrast-01
      :ARG1 (e / evaluate-01~e.7
            :ARG1 (t / target-01~e.0
                  :ARG1 (o / or~e.2
                        :op1 (e2 / enzyme
                              :name (n / name :op1 "RCE1"~e.1))
                        :op2 (e3 / enzyme
                              :name (n2 / name :op1 "ICMT"~e.3))))
            :mod (a / also~e.5))
      :ARG2 (d / difficult~e.17
            :domain~e.16 (o3 / or~e.20
                  :op1 (p / predict-01~e.19
                        :ARG1 (c2 / consequence~e.11
                              :ARG1-of~e.11 (c3 / cause-01~e.11
                                    :ARG0~e.12 (b / block-01~e.13
                                          :ARG1 o~e.15))))
                  :op2 (u / understand-01~e.18,21
                        :ARG1 c2))))

# ::tok For example , inhibition of either enzyme can actually lead to increased Ras @-@ mediated tumorigenesis ( <ce:cross-refs id="crosrefs0035" refid="bib13 bib76"> Court et al. , 2013; Wahlstrom et al. , 2007 </ce:cross-refs> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2 1-1.2 3-1.1.1 4-1.1.1.1.r 5-1.1.1.1.1 6-1.1.1.1 7-1 8-1.1.3 9-1.1 11-1.1.2.2 12-1.1.2.3.1.1.1 14-1.1.2.3 21-1.3.1.1.1.1.1.1 22-1.3.1 22-1.3.1.1.1 22-1.3.1.2.1 23-1.3.1.1.1.2.1 23-1.3.1.2.1.2.1 26-1.3.1.2.1.1.1.1 27-1.3.1.2.1 28-1.3.1.2.1.2.1 30-1.3.1.2.2.1
# ::id pmid_2465_1010.169
# ::preferred 
(p / possible~e.7
      :domain (l / lead-03~e.9
            :ARG0 (i2 / inhibit-01~e.3
                  :ARG1~e.4 (e2 / enzyme~e.6
                        :mod (e3 / either~e.5)))
            :ARG2 (c / create-01
                  :ARG1 (t / tumor)
                  :ARG1-of (i / increase-01~e.11)
                  :ARG1-of (m / mediate-01~e.14
                        :ARG0 (e / enzyme
                              :name (n / name :op1 "Ras"~e.12))))
            :mod (a / actual~e.8))
      :ARG0-of (e4 / exemplify-01~e.0,1)
      :ARG1-of (d / describe-01
            :ARG0 (a2 / and~e.22
                  :op1 (p4 / publication-91
                        :ARG0 (a4 / and~e.22
                              :op1 (p2 / person
                                    :name (n2 / name :op1 "Court"~e.21))
                              :op2 (p3 / person
                                    :mod (o2 / other~e.23)))
                        :time (d2 / date-entity :year "2013"))
                  :op2 (p5 / publication-91
                        :ARG0 (a3 / and~e.22,27
                              :op1 (p6 / person
                                    :name (n3 / name :op1 "Wahlstrom"~e.26))
                              :op2 (p7 / person
                                    :mod (o / other~e.23,28)))
                        :time (d3 / date-entity :year "2007"~e.30)))))

# ::tok Palmitoylation and depalmitoylation of H @-@ Ras , K @-@ Ras @-@ 4A , and N @-@ Ras proteins provide dynamic aspects to membrane localization and may present therapeutic opportunities for these proteins .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1 4-1.1.1.1.1.1.1.1 6-1.1.1.1.1.1.1.1 6-1.1.1.1.1.2.1.1 6-1.1.1.1.1.3.1.1 8-1.1.1.1.1.2.1.1 10-1.1.1.1.1.2.1.1 12-1.1.1.1.1.2.1.1 15-1.1.1.1.1.3.1.1 17-1.1.1.1.1.1.1.1 17-1.1.1.1.1.2.1.1 17-1.1.1.1.1.3.1.1 19-1.1 20-1.1.2.1 21-1.1.2 23-1.1.3.2 25-1 26-1.2 27-1.2.1 28-1.2.1.2.1 29-1.2.1.2
# ::id pmid_2465_1010.170
# ::preferred 
(a / and~e.1,25
      :op1 (p / provide-01~e.19
            :ARG0 (a2 / and
                  :op1 (p3 / palmitoylate-00
                        :ARG1 (a3 / and
                              :op1 (e / enzyme
                                    :name (n / name :op1 "H-Ras"~e.4,6,17))
                              :op2 (e2 / enzyme
                                    :name (n2 / name :op1 "K-Ras-4A"~e.6,8,10,12,17))
                              :op3 (e3 / enzyme
                                    :name (n3 / name :op1 "N-Ras"~e.6,15,17))))
                  :op2 (d / depalmitoylate-00
                        :ARG1 a3))
            :ARG1 (a4 / aspect~e.21
                  :mod (d2 / dynamic~e.20))
            :ARG2 (b / be-located-at-91
                  :ARG1 a3
                  :ARG2 (m / membrane~e.23)))
      :op2 (p2 / possible~e.26
            :domain (p4 / present-01~e.27
                  :ARG0 a2
                  :ARG1 (o / opportunity~e.29
                        :mod (t / therapy~e.28))
                  :ARG2 a3)))

# ::tok Recent work demonstrated that acyl protein thioesterase 1 ( APT1 ) , which is responsible for Ras depalmitoylation , could be targeted by palmostatin B to selectively inhibit the growth of N @-@ Ras mutant leukemia cells ( <ce:cross-ref id="crosref0295" refid="bib80"> Xu et al. , 2012 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.1.1 1-1.2.1 2-1.2 4-1.1.2.1.1 5-1.1.2.1.2 6-1.1.2.1.3 7-1.1.2.1.4 14-1.1.2 14-1.1.2.2 14-1.1.2.2.r 16-1.1.2.2.1.1.1.1 19-1 20-1.1.r 21-1.1 22-1.1.1.r 23-1.1.1.1.1 24-1.1.1.1.2 26-1.1.3.2 26-1.1.3.2.r 27-1.1.3 29-1.1.3.1 30-1.1.3.1.1.r 31-1.1.3.1.1.2.1.1.1.1 33-1.1.3.1.1.2.1.1.1.1 34-1.1.3.1.1.2.1.1 34-1.1.3.1.1.2.1.1.2 34-1.1.3.1.1.2.1.1.2.r 35-1.1.3.1.1.1 36-1.1.3.1.1 41-1.3.1.1.1.1.1 42-1.3.1.1 43-1.3.1.1.2.1 45-1.3.1.2.1
# ::id pmid_2465_1010.171
# ::preferred 
(p / possible~e.19
      :domain~e.20 (t / target-01~e.21
            :ARG0~e.22 (s / small-molecule
                  :name (n3 / name :op1 "palmostatin"~e.23 :op2 "B"~e.24))
            :ARG1 (e4 / enzyme~e.14
                  :name (n6 / name
                        :op1 "acyl"~e.4
                        :op2 "protein"~e.5
                        :op3 "thioesterase"~e.6
                        :op4 "1"~e.7)
                  :ARG0-of~e.14 (r2 / responsible-01~e.14
                        :ARG1 (d / depalmitoylate-00
                              :ARG1 (e / enzyme
                                    :name (n2 / name :op1 "Ras"~e.16)))))
            :purpose (i / inhibit-01~e.27
                  :ARG1 (g / grow-01~e.29
                        :ARG1~e.30 (c2 / cell~e.36
                              :source (l / leukemia~e.35)
                              :ARG1-of (e2 / encode-01
                                    :ARG0 (d5 / DNA
                                          :part (g2 / gene~e.34
                                                :name (n4 / name :op1 "N-Ras"~e.31,33)
                                                :ARG0-of~e.34 (m / mutate-01~e.34))))))
                  :manner~e.26 (s2 / selective~e.26)))
      :ARG1-of (d2 / demonstrate-01~e.2
            :ARG0 (w / work~e.1
                  :mod (r / recent~e.0)))
      :ARG1-of (d3 / describe-01
            :ARG0 (p3 / publication-91
                  :ARG0 (a / and~e.42
                        :op1 (p4 / person
                              :name (n5 / name :op1 "Xu"~e.41))
                        :op2 (p5 / person
                              :mod (o / other~e.43)))
                  :time (d4 / date-entity :year "2012"~e.45))))

# ::tok In contrast , K @-@ Ras @-@ 4B localization seemed relatively static and stable : specific localization of K @-@ Ras @-@ 4B to plasma membranes is based on electrostatic interactions between lysine residues in the hypervariable region and phospholipids in the membrane .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.2.2 3-1.1.1.1.1.1 5-1.1.1.1.1.1 7-1.1.1.1.1.1 9-1.2 10-1.2.1.1.1 11-1.2.1.1 12-1.2.1 13-1.2.1.2 15-1.1.1.3 18-1.1.1.1.1.1 20-1.1.1.1.1.1 22-1.1.1.1.1.1 24-1.1.1.2.1 25-1.1.1.2 25-1.1.2.2.1 26-1.1.1 27-1.1 28-1.1.2.r 29-1.1.2.3 30-1.1.2 32-1.1.2.1.1.1.1 33-1.1.2.1 34-1.1.2.1.2.r 36-1.1.2.1.2.1 37-1.1.2.1.2 42-1.1.1.2 42-1.1.2.2.1
# ::id pmid_2465_1010.172
# ::preferred 
(c2 / cause-01
      :ARG0 (b / base-02~e.27
            :ARG1 (b3 / be-located-at-91~e.26
                  :ARG1 (e2 / enzyme
                        :name (n / name :op1 "K-Ras-4B"~e.3,5,7,18,20,22))
                  :ARG2 (m / membrane~e.25,42
                        :mod (p / plasma~e.24))
                  :mod (s4 / specific~e.15))
            :ARG2~e.28 (i / interact-01~e.30
                  :ARG0 (r2 / residue~e.33
                        :mod (a2 / amino-acid
                              :name (n2 / name :op1 "lysine"~e.32))
                        :location~e.34 (r3 / region~e.37
                              :mod (h / hypervariable~e.36)))
                  :ARG1 (p2 / phospholipid
                        :location (m3 / membrane~e.25,42))
                  :mod (e3 / electrostatic~e.29)))
      :ARG1 (s / seem-01~e.9
            :ARG1 (a / and~e.12
                  :op1 (s2 / static~e.11
                        :degree (r / relative~e.10))
                  :op2 (s3 / stable~e.13)
                  :domain b3)
            :ARG2-of (c3 / contrast-01~e.1)))

# ::tok However , another therapeutic opportunity has been presented by the discovery that PDE6δ acts as a solubilizing factor that modulates Ras proteins by sustaining their dynamic distribution in cellular membranes .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 2-1.1.2.2 3-1.1.2.1 4-1.1.2 7-1.1 8-1.1.1.r 10-1.1.1 11-1.1.1.1.r 12-1.1.1.1.1.1.1 13-1.1.1.1 17-1.1.1.1.2 19-1.1.1.1.2.2 20-1.1.1.1.2.2.1.1.1 21-1.1.1.1.1 22-1.1.1.1.2.2.2.r 23-1.1.1.1.2.2.2 25-1.1.1.1.2.2.2.2.3 26-1.1.1.1.2.2.2.2 27-1.1.1.1.2.2.2.2.2.r 28-1.1.1.1.2.2.2.2.2.1 29-1.1.1.1.2.2.2.2.2
# ::id pmid_2465_1010.173
# ::preferred 
(c / contrast-01~e.0
      :ARG2 (p / present-01~e.7
            :ARG0~e.8 (d / discover-01~e.10
                  :ARG1~e.11 (a2 / act-01~e.13
                        :ARG0 (p2 / protein~e.21
                              :name (n / name :op1 "PDE6δ"~e.12))
                        :ARG1 (f / factor~e.17
                              :ARG0-of (s / solubilize-00
                                    :ARG1 (e / enzyme
                                          :name (n2 / name :op1 "Ras"~e.20)))
                              :ARG0-of (m / modulate-01~e.19
                                    :ARG1 e
                                    :manner~e.22 (s2 / sustain-01~e.23
                                          :ARG0 f
                                          :ARG1 (d2 / distribute-01~e.26
                                                :ARG1 e
                                                :ARG2~e.27 (m2 / membrane~e.29
                                                      :location (c2 / cell~e.28))
                                                :manner (d3 / dynamic~e.25)))))))
            :ARG1 (o / opportunity~e.4
                  :mod (t / therapy~e.3)
                  :mod (a / another~e.2))))

# ::tok A small molecule was identified that prevents association of K @-@ Ras @-@ 4B , and other proteins , with PDEδ and so delocalizes these proteins and inhibits downstream signaling ( <ce:cross-ref id="crosref0300" refid="bib86"> Zimmermann et al. , 2013 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1 2-1.1 4-1 6-1.1.1 7-1.1.1.1 8-1.1.1.1.1.r 9-1.1.1.1.1.1.1.1 11-1.1.1.1.1.1.1.1 13-1.1.1.1.1.1.1.1 15-1.1.1.1.1 16-1.1.1.1.1.2.1 17-1.1.1.1.1.2 19-1.1.1.1.2.r 20-1.1.1.1.2.1.1 21-1.1.1.2 22-1.1.1.2 25-1.1.1.1.1.2 26-1.1.1.1.1 26-1.1.1.2.1 27-1.1.1.2.1.2 28-1.1.1.2.1.2.2.1 29-1.1.1.2.1.2.2 34-1.2.1.1.1.1.1 35-1.2.1.1 36-1.2.1.1.2.1 38-1.2.1.2.1
# ::id pmid_2465_1010.174
# ::preferred 
(i / identify-01~e.4
      :ARG1 (s / small-molecule~e.1,2
            :ARG0-of (p / prevent-01~e.6
                  :ARG1 (a / associate-01~e.7
                        :ARG1~e.8 (a2 / and~e.15,26
                              :op1 (e / enzyme
                                    :name (n / name :op1 "K-Ras-4B"~e.9,11,13))
                              :op2 (p3 / protein~e.17,25
                                    :mod (o / other~e.16)))
                        :ARG2~e.19 (p4 / protein
                              :name (n2 / name :op1 "PDEδ"~e.20)))
                  :ARG0-of (c2 / cause-01~e.21,22
                        :ARG1 (a4 / and~e.26
                              :op1 (d2 / delocalize-00
                                    :ARG0 s
                                    :ARG1 a2)
                              :op2 (i2 / inhibit-01~e.27
                                    :ARG0 s
                                    :ARG1 (s2 / signal-07~e.29
                                          :source (d / downstream~e.28)))))))
      :ARG1-of (d3 / describe-01
            :ARG0 (p5 / publication-91
                  :ARG0 (a5 / and~e.35
                        :op1 (p6 / person
                              :name (n3 / name :op1 "Zimmermann"~e.34))
                        :op2 (p7 / person
                              :mod (o2 / other~e.36)))
                  :time (d4 / date-entity :year "2013"~e.38))))

# ::tok Little is still known about the trafficking of Ras to and from the membrane , and there are likely to be additional factors or chaperones involved in the movement of the proteins that could serve as targets for small molecules .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 2-1.1.2 3-1.1 4-1.1.1.1.r 6-1.1.1.1.1 6-1.1.1.1.2 7-1.1.1.1.1.1.r 8-1.1.1.1.1.1.1.1 9-1.1.1.1.1.2.r 10-1.1.1.1 11-1.1.1.1.2.2.r 13-1.1.1.1.1.2 13-1.1.1.1.2.2 15-1 17-1.2.1.r 18-1.2 20-1.2.1.r 21-1.2.1.1.1.1 22-1.2.1.1.1 23-1.2.1.1 24-1.2.1.1.2 25-1.2.1 26-1.2.1.2.r 28-1.2.1.2 29-1.2.1.2.1.r 31-1.2.1.2.1 33-1.2.1.2.1.1.2 34-1.2.1.2.1.1 35-1.2.1.2.1.1.1.r 36-1.2.1.2.1.1.1 37-1.2.1.2.1.1.1.1.r 38-1.2.1.2.1.1.1.1 39-1.2.1.2.1.1.1.1
# ::id pmid_2465_1010.175
# ::preferred 
(a / and~e.15
      :op1 (k / know-01~e.3
            :ARG1 (l2 / little~e.0
                  :topic~e.4 (a2 / and~e.10
                        :op1 (t2 / traffic-01~e.6
                              :ARG1~e.7 (e / enzyme
                                    :name (n / name :op1 "Ras"~e.8))
                              :destination~e.9 (m / membrane~e.13))
                        :op2 (t3 / traffic-01~e.6
                              :ARG1 e
                              :source~e.11 (m2 / membrane~e.13))))
            :mod (s / still~e.2))
      :op2 (l / likely~e.18
            :domain~e.17,20 (i / involve-01~e.25
                  :ARG1 (o / or~e.23
                        :op1 (f / factor~e.22
                              :mod (a3 / additional~e.21))
                        :op2 (c / chaperone~e.24))
                  :ARG2~e.26 (m3 / move-01~e.28
                        :ARG1~e.29 (p / protein~e.31
                              :ARG0-of (s2 / serve-01~e.34
                                    :ARG1~e.35 (t / target-01~e.36
                                          :ARG0~e.37 (s3 / small-molecule~e.38,39)
                                          :ARG1 p)
                                    :mod (p2 / possible~e.33)))))))

# ::tok In a related study , K @-@ Ras @-@ 4B was shown to undergo retrograde trafficking from the plasma membrane to endomembranes .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.2.1 3-1.2 5-1.1.1.1.1 7-1.1.1.1.1 9-1.1.1.1.1 11-1 13-1.1 14-1.1.2.1 15-1.1.2 16-1.1.2.2.r 18-1.1.2.2.1 19-1.1.2.2
# ::id pmid_2465_1010.176
# ::preferred 
(s / show-01~e.11
      :ARG1 (u / undergo-01~e.13
            :ARG1 (e2 / enzyme
                  :name (n / name :op1 "K-Ras-4B"~e.5,7,9))
            :ARG2 (t / traffic-01~e.15
                  :ARG1-of (r2 / retrograde-01~e.14)
                  :source~e.16 (m / membrane~e.19
                        :mod (p2 / plasma~e.18))
                  :direction (e / endomembrane)))
      :medium (s2 / study~e.3
            :ARG1-of (r / relate-01~e.2)))

# ::tok This may serve as an additional pathway to specifically disrupt for therapeutic benefit ( <ce:cross-ref id="crosref0305" refid="bib4"> Bivona et al. , 2006 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1 2-1.1 3-1.1.2.r 3-1.2.1.2.r 5-1.1.2.1 6-1.1.2 8-1.1.3.2 9-1.1.3 10-1.1.3.3.r 11-1.1.3.3.2 12-1.1.3.3 17-1.2.1.1.1.1.1 18-1.2.1.1 19-1.2.1.1.2.1 21-1.2.1.2.1
# ::id pmid_2465_1010.177
# ::preferred 
(p / possible~e.1
      :domain (s / serve-01~e.2
            :ARG0 (t / this~e.0)
            :ARG1~e.3 (p2 / pathway~e.6
                  :mod (a / additional~e.5))
            :purpose (d / disrupt-01~e.9
                  :ARG0 p2
                  :manner (s2 / specific~e.8)
                  :purpose~e.10 (b / benefit-01~e.12
                        :ARG0 p2
                        :mod (t2 / therapy~e.11))))
      :ARG1-of (d2 / describe-01
            :ARG0 (p3 / publication-91
                  :ARG0 (a2 / and~e.18
                        :op1 (p4 / person
                              :name (n / name :op1 "Bivona"~e.17))
                        :op2 (p5 / person
                              :mod (o / other~e.19)))
                  :time~e.3 (d3 / date-entity :year "2006"~e.21))))

# ::tok In addition to these processing events , several recent papers have highlighted other posttranslational modifications of K @-@ Ras that could serve as therapeutic targets .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2 1-1.2 3-1.2.1.1 4-1.2.1.2 5-1.2.1 7-1.1.1 8-1.1.2 9-1.1 11-1 12-1.2.2.2 14-1.2.2 15-1.2.2.1.r 16-1.2.2.1.1.1 18-1.2.2.1.1.1 20-1.2.2.4.2 21-1.2.2.4 22-1.2.2.3.r 22-1.2.2.4.1.r 23-1.2.2.4.1.1 24-1.2.2.4.1
# ::id pmid_2465_1010.178
# ::preferred 
(h / highlight-01~e.11
      :ARG0 (p / paper~e.9
            :quant (s / several~e.7)
            :mod (r / recent~e.8))
      :ARG1 (a / and~e.0,1
            :op1 (e / event~e.5
                  :mod (t / this~e.3)
                  :topic (p2 / process-01~e.4))
            :op2 (m / modify-01~e.14
                  :ARG1~e.15 (e2 / enzyme
                        :name (n / name :op1 "K-Ras"~e.16,18))
                  :mod (o / other~e.12)
                  :time~e.22 (a2 / after
                        :op1 (t2 / translate-00))
                  :ARG0-of (s2 / serve-01~e.21
                        :ARG1~e.22 (t3 / target-01~e.24
                              :ARG0 (t4 / therapy~e.23)
                              :ARG1 m)
                        :mod (p3 / possible~e.20)))))

# ::tok Mono @-@ ubiquitination at Lys147 has been shown to enhance GTP loading and effector @-@ binding affinity of K @-@ Ras ( <ce:cross-ref id="crosref0310" refid="bib59"> Sasaki et al. , 2011 </ce:cross-ref> ) , suggesting that targeting of ubiquitin pathway enzymes might have an effect on K @-@ Ras activity .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 0-1.1.1.1.r 2-1.1.1 7-1 9-1.1 10-1.1.2.1.1.1.1 11-1.1.2.1 12-1.1.2 13-1.1.2.2.2.1 15-1.1.2.2.2 16-1.1.2.2 17-1.1.2.2.1.r 18-1.1.2.2.1.1.1 20-1.1.2.2.1.1.1 25-1.2.1.1.1.1.1 26-1.2.1.1 27-1.2.1.1.2.1 29-1.2.1.2.1 33-1.3 34-1.3.1.r 35-1.3.1.1 36-1.3.1.1.1.r 37-1.3.1.1.1.1.1.1 38-1.3.1.1.1.1 39-1.3.1.1.1 40-1.3.1.3 43-1.3.1 44-1.3.1.2.r 45-1.3.1.2.1 46-1.3.1.2.1 47-1.3.1.2.1 48-1.3.1.2
# ::id pmid_2465_1010.179
# ::preferred 
(s / show-01~e.7
      :ARG1 (e / enhance-01~e.9
            :ARG0 (u / ubiquitinate-01~e.2
                  :quant~e.0 "1"~e.0
                  :ARG1 (a / amino-acid
                        :mod "147"
                        :name (n / name :op1 "lysine")))
            :ARG1 (a2 / and~e.12
                  :op1 (l / load-01~e.11
                        :ARG2 (s2 / small-molecule
                              :name (n2 / name :op1 "GTP"~e.10)))
                  :op2 (a3 / affinity~e.16
                        :poss~e.17 (e2 / enzyme
                              :name (n3 / name :op1 "K-Ras"~e.18,20))
                        :topic (b / bind-01~e.15
                              :ARG2 (e3 / effector~e.13)))))
      :ARG1-of (d / describe-01
            :ARG0 (p / publication-91
                  :ARG0 (a4 / and~e.26
                        :op1 (p2 / person
                              :name (n4 / name :op1 "Sasaki"~e.25))
                        :op2 (p3 / person
                              :mod (o / other~e.27)))
                  :time (d2 / date-entity :year "2011"~e.29)))
      :ARG0-of (s3 / suggest-01~e.33
            :ARG1~e.34 (a5 / affect-01~e.43
                  :ARG0 (t / target-01~e.35
                        :ARG1~e.36 (e4 / enzyme~e.39
                              :part-of (p5 / pathway~e.38
                                    :name (n5 / name :op1 "ubiquitin"~e.37))))
                  :ARG1~e.44 (a6 / act-02~e.48
                        :ARG0 e2~e.45,46,47)
                  :mod (p4 / possible~e.40))))

# ::tok Acetylation of Lys104 was shown to decrease GEF @-@ induced nucleotide exchange , leading to reduced transformation efficiency in cells , and the deacetylases SIRT2 and HDAC6 were shown to regulate the level of acetylation of K @-@ Ras ( <ce:cross-ref id="crosref0315" refid="bib81"> Yang et al. , 2013 </ce:cross-ref> ) , suggesting that inhibitors of these enzymes might have an effect on the oncogenic potential of mutant K @-@ Ras tumors .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 4-1.1 6-1.1.1 7-1.1.1.2.2.1.1.1 9-1.1.1.2.2 10-1.1.1.2.1 11-1.1.1.2 13-1.1.1.1.2 14-1.1.1.1.2.1.r 15-1.1.1.1.2.1 16-1.1.1.1.2.1.1.1 17-1.1.1.1.2.1.1 18-1.1.1.1.2.1.1.1.1.r 19-1.1.1.1.2.1.1.1.1 21-1 21-1.3.1.1 24-1.2.1.1.1.1.1 25-1.2.1.1 26-1.2.1.1.2.1.1 28-1.2 30-1.2.1 32-1.2.1.2 33-1.2.1.2.1.r 34-1.2.1.2.1 43-1.3.1.1.1.1.1 44-1.3.1.1 45-1.3.1.1.2.1 47-1.3.1.2.1 51-1.2.2 52-1.2.2.1.r 53-1.2.2.1.1 56-1.1.1.2.2.1 56-1.2.1.1.1 56-1.2.1.1.2 57-1.2.2.1.2 57-1.2.2.1.3 60-1.2.2.1 61-1.2.2.1.2.1.r 63-1.2.2.1.2.1 63-1.2.2.1.2.1.2 63-1.2.2.1.2.1.2.r 65-1.2.2.1.2.1.1.r 66-1.2.2.1.2.1.1.1 70-1.2.2.1.2.1.1
# ::id pmid_2465_1010.180
# ::preferred 
(a / and~e.21
      :op1 (s / show-01~e.4
            :ARG1 (d / decrease-01~e.6
                  :ARG0 (a2 / acetylate-01~e.0
                        :ARG1 (a3 / amino-acid
                              :mod "104"
                              :name (n / name :op1 "lysine"))
                        :ARG0-of (l / lead-03~e.13
                              :ARG2~e.14 (r / reduce-01~e.15
                                    :ARG1 (e2 / efficient-01~e.17
                                          :ARG2 (t / transform-01~e.16
                                                :ARG1~e.18 (c / cell~e.19))))))
                  :ARG1 (e / exchange-01~e.11
                        :ARG1 (n2 / nucleotide~e.10)
                        :ARG1-of (i / induce-01~e.9
                              :ARG0 (p / protein~e.56
                                    :name (n3 / name :op1 "GEF"~e.7))))))
      :op2 (s2 / show-01~e.28
            :ARG1 (r2 / regulate-01~e.30
                  :ARG0 (a4 / and~e.25
                        :op1 (e4 / enzyme~e.56
                              :name (n4 / name :op1 "SIRT2"~e.24))
                        :op2 (e5 / enzyme~e.56
                              :name (n5 / name :op1 "HDAC6"~e.26))
                        :ARG2-of (d2 / deacetylate-01 :polarity "-"))
                  :ARG1 (l2 / level~e.32
                        :mod~e.33 (a5 / acetylate-01~e.34
                              :ARG1 (t2 / tumor~e.70
                                    :ARG2-of (m / mutate-01~e.66)))))
            :ARG0-of (s3 / suggest-01~e.51
                  :ARG1~e.52 (a7 / affect-01~e.60
                        :ARG0 (i2 / inhibit-01~e.53
                              :ARG1 a4)
                        :ARG1 (p6 / possible~e.57
                              :domain~e.61 (c2 / cause-01~e.63
                                    :ARG0~e.65 t2
                                    :ARG1~e.63 (c3 / cancer~e.63)))
                        :mod (p5 / possible~e.57))))
      :ARG1-of (d4 / describe-01
            :ARG0 (p2 / publication-91
                  :ARG0 (a6 / and~e.21,44
                        :op1 (p3 / person
                              :name (n7 / name :op1 "Yang"~e.43))
                        :op2 (p4 / person
                              :mod (o / other~e.45)))
                  :time (d5 / date-entity :year "2013"~e.47))))

# ::tok Finally , nitrosylation of Cys118 in H @-@ Ras has been shown to activate Ras by enhancing nucleotide dissociation , leading to higher levels of GTP @-@ bound protein .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2 6-1.1.1.2.1.1 8-1.1.2.1.1 11-1 13-1.1 14-1.1.2.1.1 15-1.1.3.r 16-1.1.3 17-1.1.3.2.1 18-1.1.3.2 20-1.1.3.3 21-1.1.3.3.1.r 22-1.1.3.3.1.1 22-1.1.3.3.1.1.1 22-1.1.3.3.1.1.1.r 23-1.1.3.3.1 24-1.1.3.3.1.2.r 25-1.1.3.3.1.2.1.1.1.1 27-1.1.3.3.1.2.1 28-1.1.3.3.1.2
# ::id pmid_2465_1010.181
# ::preferred 
(s / show-01~e.11
      :ARG1 (a / activate-01~e.13
            :ARG0 (n3 / nitrosylate-00
                  :ARG1 (a2 / amino-acid
                        :mod "118"
                        :name (n6 / name :op1 "Cysteine"))
                  :location (e / enzyme
                        :name (n / name :op1 "H-Ras"~e.6)))
            :ARG1 (e2 / enzyme
                  :name (n2 / name :op1 "Ras"~e.8,14))
            :manner~e.15 (e3 / enhance-01~e.16
                  :ARG0 n3
                  :ARG1 (d / dissociate-01~e.18
                        :ARG1 (n4 / nucleotide~e.17))
                  :ARG0-of (l / lead-03~e.20
                        :ARG2~e.21 (l2 / level~e.23
                              :mod (h / high~e.22
                                    :degree~e.22 (m / more~e.22))
                              :degree-of~e.24 (p / protein~e.28
                                    :ARG1-of (b / bind-01~e.27
                                          :ARG0 (s2 / small-molecule
                                                :name (n5 / name :op1 "GTP"~e.25))))))))
      :time (f / final~e.0))

# ::tok The eNos protein was identified as a strong enhancer of nitrosylation and therefore could also be a therapeutic target to attack mutant Ras ( <ce:cross-ref id="crosref0320" refid="bib37"> Lim et al. , 2008 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1.1.1 2-1.1.1 4-1.1 5-1.3.1.2.r 7-1.1.2.3 11-1.3.1.1 12-1 13-1.2 14-1.2.1.3 15-1.2.1.r 17-1.2.1.1 18-1.2.1 20-1.2.1.4 21-1.2.1.4.2 21-1.2.1.4.2.2 21-1.2.1.4.2.2.r 22-1.2.1.4.2.1.1 27-1.3.1.1.1.1.1 28-1.3.1.1 29-1.3.1.1.2.1 31-1.3.1.2.1
# ::id pmid_2465_1010.182
# ::preferred 
(c / cause-01~e.12
      :ARG0 (i / identify-01~e.4
            :ARG1 (p2 / protein~e.2
                  :name (n2 / name :op1 "eNos"~e.1))
            :ARG2 (e2 / enhance-01
                  :ARG1 (n3 / nitrosylate-00)
                  :ARG2 p2
                  :mod (s / strong~e.7)))
      :ARG1 (p / possible~e.13
            :domain~e.15 (t2 / target-01~e.18
                  :ARG0 (t / therapy~e.17)
                  :ARG1 p2
                  :mod (a3 / also~e.14)
                  :purpose (a / attack-01~e.20
                        :ARG0 p2
                        :ARG1 (e / enzyme~e.21
                              :name (n / name :op1 "Ras"~e.22)
                              :ARG1-of~e.21 (m / mutate-01~e.21)))))
      :ARG0-of (d2 / describe-01
            :ARG1 (p3 / publication-91
                  :ARG0 (a2 / and~e.11,28
                        :op1 (p4 / person
                              :name (n4 / name :op1 "Lim"~e.27))
                        :op2 (p5 / person
                              :mod (o / other~e.29)))
                  :time~e.5 (d / date-entity :year "2008"~e.31))))

# ::tok Downstream Pathways and Drug Targets
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1 2-1 3-1.2.1 4-1.2
# ::id pmid_2465_1010.183
# ::preferred 
(a / and~e.2
      :op1 (p / pathway~e.1
            :mod (d / downstream~e.0))
      :op2 (t / target-01~e.4
            :ARG0 (d2 / drug~e.3)))

# ::tok When it became clear that targeting mutant Ras proteins directly was technically impossible with the tools available at that time , the search for drugs that block Ras activity moved downstream .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3.r 3-1.3 4-1.3.1.2.3.1.1.1 5-1.3.1.2 6-1.3.1.2.1 6-1.3.1.2.1.2 6-1.3.1.2.1.2.r 7-1.3.1.2.1.1.1 9-1.3.1.2.2 9-1.3.1.2.2.r 10-1.3.1.2.r 10-1.3.1.r 11-1.3.1.3 12-1.3.1 12-1.3.1.1 12-1.3.1.1.r 13-1.3.1.2.3.r 15-1.3.1.2.3 16-1.3.1.2.3.1 18-1.3.1.2.3.1.1.1 19-1.3.1.2.3.1.1 19-1.3.1.2.3.1.1.r 19-1.3.r 22-1 23-1.1.r 24-1.1 25-1.3.1.2.3.1.1.1 26-1.1.1 27-1.1.1.1.1 28-1.1.1.1 29-1.2 30-1.2.1
# ::id pmid_2465_1010.184
# ::preferred 
(s / search-01~e.22
      :ARG2~e.23 (d / drug~e.24
            :ARG0-of (b / block-01~e.26
                  :ARG1 (a / act-02~e.28
                        :ARG0 e~e.27)))
      :ARG0-of (m / move-01~e.29
            :ARG2 (d2 / downstream~e.30))
      :time~e.0,19 (c / clear~e.3
            :domain~e.10 (p / possible~e.12
                  :polarity~e.12 "-"~e.12
                  :domain~e.10 (t / target-01~e.5
                        :ARG1 (e / enzyme~e.6
                              :name (n / name :op1 "Ras"~e.7)
                              :ARG1-of~e.6 (m2 / mutate-01~e.6))
                        :manner~e.9 (d3 / direct~e.9)
                        :instrument~e.13 (t3 / tool~e.15
                              :mod (a2 / available~e.16
                                    :time~e.19 (t4 / time~e.19
                                          :mod (t5 / that~e.4,18,25)))))
                  :mod (t2 / technical~e.11))))

# ::tok In the early 1990 s , the MAPK pathway and the PI3K pathway were known to be downstream of Ras ( <ce:cross-ref id="crosref0325" refid="fig1"> Figure 1 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.2 3-1.2.1.1 4-1.2.1.1.r 7-1.1.1.1.1.1 8-1.1.1.1 8-1.1.1.2 9-1.1.1 11-1.1.1.2.1.1 12-1.1.1.1 13-1.1 14-1 16-1.1 17-1.1.2.2 19-1.1.2.1.1.1 24-1.3.1 25-1.3.1.1
# ::id pmid_2465_1010.185
# ::preferred 
(k / know-01~e.14
      :ARG1 (b / be-located-at-91~e.13,16
            :ARG1 (a / and~e.9
                  :op1 (p / pathway~e.8,12
                        :name (n / name :op1 "MAPK"~e.7))
                  :op2 (p2 / pathway~e.8
                        :name (n3 / name :op1 "PI3K"~e.11)))
            :ARG2 (r / relative-position
                  :op1 (e2 / enzyme
                        :name (n2 / name :op1 "Ras"~e.19))
                  :direction (d3 / downstream~e.17)))
      :time (e / early~e.2
            :op1 (d / date-entity :decade~e.4 "1990"~e.3))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure~e.24 :mod "1"~e.25)))

# ::tok In 1993 , four groups showed that Ras binds directly to Raf kinase ( <ce:cross-refs id="crosrefs0040" refid="bib47 bib73 bib77 bib85"> Moodie et al. , 1993; Van Aelst et al. , 1993; Warne et al. , 1993; Zhang et al. , 1993 </ce:cross-refs> ) , and later , activation of Raf kinase by Ras was achieved in vitro ( <ce:cross-ref id="crosref0330" refid="bib66"> Stokoe and McCormick , 1997 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.3.1 1-1.1.3.1 1-1.1.4.1.1.2.1 3-1.1.1.1 4-1.1.1 5-1.1 6-1.1.2.r 7-1.1.2.1.1.1 8-1.1.2 9-1.1.2.3 10-1.1.2.2.r 11-1.1.2.2.1.1 12-1.1.2.2 20-1.1.4.1.1.1.1.1.1 21-1.1.4.1 21-1.1.4.1.1.1 21-1.1.4.1.2.1 21-1.1.4.1.3.1 21-1.1.4.1.4.1 22-1.1.4.1.1.1.2.1 22-1.1.4.1.2.1.2.1 22-1.1.4.1.3.1.2.1 22-1.1.4.1.4.1.2.1 25-1.1.4.1.2.1.1.1.1 26-1.1.4.1.2.1.1.1.2 27-1.1.4.1 27-1.1.4.1.1.1 27-1.1.4.1.2.1 27-1.1.4.1.3.1 27-1.1.4.1.4.1 28-1.1.4.1.1.1.2.1 28-1.1.4.1.2.1.2.1 28-1.1.4.1.3.1.2.1 28-1.1.4.1.4.1.2.1 31-1.1.4.1.3.1.1.1.1 32-1.1.4.1 32-1.1.4.1.1.1 32-1.1.4.1.2.1 32-1.1.4.1.3.1 32-1.1.4.1.4.1 33-1.1.4.1.1.1.2.1 33-1.1.4.1.2.1.2.1 33-1.1.4.1.3.1.2.1 33-1.1.4.1.4.1.2.1 36-1.1.4.1.4.1.1.1.1 37-1.1.4.1 37-1.1.4.1.1.1 37-1.1.4.1.2.1 37-1.1.4.1.3.1 37-1.1.4.1.4.1 38-1.1.4.1.1.1.2.1 38-1.1.4.1.2.1.2.1 38-1.1.4.1.3.1.2.1 38-1.1.4.1.4.1.2.1 40-1.1.3.1 44-1 44-1.1.4.1 44-1.2.5.1.1 45-1.2.4 45-1.2.4.1 45-1.2.4.1.r 47-1.2 49-1.1.2.2.1.1 50-1.1.2.2 52-1.1.2.1.1.1 54-1.2.3 55-1.2.3.1 56-1.2.3.1 61-1.2.5.1.1.1.1.1 62-1.2.5.1.1 63-1.2.5.1.1.2.1.1 65-1.2.5.1.2.1
# ::id pmid_2465_1010.186
# ::preferred 
(a / and~e.44
      :op1 (s / show-01~e.5
            :ARG0 (g / group~e.4 :quant "4"~e.3)
            :ARG1~e.6 (b / bind-01~e.8
                  :ARG0 (e / enzyme
                        :name (n / name :op1 "Ras"~e.7,52))
                  :ARG1~e.10 (k / kinase~e.12,50
                        :name (n2 / name :op1 "Raf"~e.11,49))
                  :mod (d2 / direct~e.9))
            :time (d / date-entity :year "1993"~e.1,40)
            :ARG1-of (d3 / describe-01
                  :ARG0 (a5 / and~e.21,27,32,37,44
                        :op1 (p / publication-91
                              :ARG0 (a4 / and~e.21,27,32,37
                                    :op1 (p2 / person
                                          :name (n3 / name :op1 "Moodie"~e.20))
                                    :op2 (p3 / person
                                          :mod (o / other~e.22,28,33,38)))
                              :time (d4 / date-entity :year "1993"~e.1))
                        :op2 (p4 / publication-91
                              :ARG0 (a6 / and~e.21,27,32,37
                                    :op1 (p5 / person
                                          :name (n4 / name :op1 "Van"~e.25 :op2 "Aelst"~e.26))
                                    :op2 (p6 / person
                                          :mod (o2 / other~e.22,28,33,38)))
                              :time d4)
                        :op3 (p7 / publication-91
                              :ARG0 (a7 / and~e.21,27,32,37
                                    :op1 (p8 / person
                                          :name (n5 / name :op1 "Warne"~e.31))
                                    :op2 (p9 / person
                                          :mod (o3 / other~e.22,28,33,38)))
                              :time d4)
                        :op4 (p10 / publication-91
                              :ARG0 (a8 / and~e.21,27,32,37
                                    :op1 (p11 / person
                                          :name (n6 / name :op1 "Zhang"~e.36))
                                    :op2 (p12 / person
                                          :mod (o4 / other~e.22,28,33,38)))
                              :time d4))))
      :op2 (a2 / activate-01~e.47
            :ARG0 e
            :ARG1 k
            :ARG1-of (a3 / achieve-01~e.54
                  :manner (i / in-vitro~e.0,55,56))
            :time (l / late~e.45
                  :degree~e.45 (m / more~e.45))
            :ARG1-of (d5 / describe-01
                  :ARG0 (p13 / publication-91
                        :ARG0 (a9 / and~e.44,62
                              :op1 (p14 / person
                                    :name (n7 / name :op1 "Stokoe"~e.61))
                              :op2 (p15 / person
                                    :name (n8 / name :op1 "McCormick"~e.63)))
                        :time (d6 / date-entity :year "1997"~e.65)))))

# ::tok This was unexpectedly difficult ; for one thing , Raf activation by Ras required fully processed Ras in a lipid environment , and direct binding of unprocessed Ras failed to activate the kinase .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1.1.r 2-1.1.2.1 3-1.1 6-1.2.3 9-1.2.1.1.2.1.1 10-1.2.1.1 12-1.2.2.1.1.1.1 13-1.2.1 14-1.2.1.2.2 15-1.2.1.2 16-1.2.1.2.1 17-1.2.1.3.r 19-1.2.1.3.1 20-1.2.1.3 22-1.2 23-1.2.2.1.2 24-1.2.2.1 26-1.2.2.1.1.2 26-1.2.2.1.1.2.1 26-1.2.2.1.1.2.1.r 27-1.2.2.1.1.1.1 28-1.2.2 30-1.2.1.1 30-1.2.2.2 32-1.2.1.1.2
# ::id pmid_2465_1010.187
# ::preferred 
(m / multi-sentence
      :snt1 (d / difficult~e.3
            :domain~e.1 (t / this~e.0)
            :ARG1-of (e3 / expect-01 :polarity "-"~e.2))
      :snt2 (a3 / and~e.22
            :op1 (r / require-01~e.13
                  :ARG0 (a / activate-01~e.10,30
                        :ARG0 (e2 / enzyme
                              :name (n2 / name :op1 "Ras"~e.12,27)
                              :ARG1-of (p2 / process-01~e.26 :polarity~e.26 "-"~e.26))
                        :ARG1 (k / kinase~e.32
                              :name (n / name :op1 "Raf"~e.9)))
                  :ARG1 (p / process-01~e.15
                        :ARG1 e2~e.16
                        :manner (f / full~e.14))
                  :location~e.17 (e4 / environment~e.20
                        :mod (l / lipid~e.19)))
            :op2 (f2 / fail-01~e.28
                  :ARG1 (b / bind-01~e.24
                        :ARG1 e2
                        :manner (d2 / direct~e.23))
                  :ARG2 (a2 / activate-01~e.30
                        :ARG0 b
                        :ARG1 k))
            :li (x / 1~e.6)))

# ::tok Furthermore , autophosphorylation rapidly shut down Raf kinase in vitro ; we had to preincubate processed Ras with Raf in the absence of ATP before measuring Raf kinase activity .
# ::amr-annotator SDL-AMR-09
# ::alignments 3-1.1.1.3 3-1.1.1.3.r 4-1.1.1 5-1.1.1 6-1.1.1.1.1.1 7-1.1.1.1 8-1.1.1.1.2 9-1.1.1.1.2 11-1.1.2.1 12-1.1.2 13-1.1.2 14-1.1.2.2 15-1.1.2.2.2.1.2 16-1.1.2.2.2.1.1.1 18-1.1.1.1.1.1 18-1.1.2.2.2.2.1.1 19-1.1.1.1.2 19-1.1.2.2.3.r 21-1.1.2.2.3 22-1.1.2.2.3.1.r 23-1.1.2.2.3.1.1.1 24-1.1.2.3 25-1.1.2.3.1 26-1.1.1.1.1.1 27-1.1.1.1 28-1.1.2.3.1.2
# ::id pmid_2465_1010.188
# ::preferred 
(a4 / and
      :op2 (c / cause-01
            :ARG0 (s2 / shut-down-05~e.4,5
                  :ARG1 (k / kinase~e.7,27
                        :name (n3 / name :op1 "Raf"~e.6,18,26)
                        :manner (i / in-vitro~e.8,9,19))
                  :ARG2 (p / phosphorylate-01
                        :ARG1 k
                        :ARG2 k)
                  :manner~e.3 (r / rapid~e.3))
            :ARG1 (o / obligate-01~e.12,13
                  :ARG1 (w / we~e.11)
                  :ARG2 (p4 / preincubate-00~e.14
                        :ARG0 w
                        :ARG1 (a / and
                              :op1 (e2 / enzyme
                                    :name (n2 / name :op1 "Ras"~e.16)
                                    :ARG1-of (p3 / process-01~e.15))
                              :op2 (e / enzyme
                                    :name (n / name :op1 "Raf"~e.18)))
                        :condition~e.19 (a5 / absent~e.21
                              :domain~e.22 (s / small-molecule
                                    :name (n4 / name :op1 "ATP"~e.23))))
                  :time (b / before~e.24
                        :op1 (m2 / measure-01~e.25
                              :ARG0 w
                              :ARG1 (a2 / act-02~e.28
                                    :ARG1 (p2 / protein)))))))

# ::tok This autophosphorylation accounts , at least in part , for paradoxical activation of Raf kinase by Raf inhibitors , a phenomenon that was discovered 16 years later ( reviewed in <ce:cross-ref id="crosref0335" refid="bib27"> Holderfield et al. , 2013 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2 2-1 4-1.3.1 5-1.3.1 7-1.3 11-1.2 12-1.2.2.r 13-1.2.2.1.1 14-1.2.2 16-1.2.2.1.1 17-1.2.1 17-1.2.1.1 17-1.2.1.1.r 23-1.4 24-1.4.1.1.1.1 25-1.4.1.1.1.2 26-1.4.1 26-1.4.1.1 26-1.4.1.1.r 28-1.5 33-1.5.1.1.1.1.1 34-1.5.1.1 35-1.5.1.1.2.1 37-1.5.1.2.1
# ::id pmid_2465_1010.189
# ::preferred 
(a4 / account-01~e.2
      :ARG0 (p / phosphorylate-01
            :mod (s / self)
            :mod (t3 / this~e.0))
      :ARG1 (a2 / activate-01~e.11
            :ARG0 (m2 / molecular-physical-entity~e.17
                  :ARG0-of~e.17 (i2 / inhibit-01~e.17
                        :ARG1 (k / kinase~e.14
                              :name (n2 / name :op1 "Raf"~e.13,16))))
            :ARG1~e.12 k
            :manner (p3 / paradox))
      :extent (p7 / part~e.7
            :mod (a / at-least~e.4,5))
      :ARG1-of (d2 / discover-01~e.23
            :mod (l / late~e.26
                  :degree~e.26 (m / more~e.26
                        :op1 (t / temporal-quantity
                              :quant "16"~e.24
                              :unit (y / year~e.25)))))
      :ARG1-of (r / review-01~e.28
            :ARG0 (p4 / publication-91
                  :ARG0 (a3 / and~e.34
                        :op1 (p5 / person
                              :name (n3 / name :op1 "Holderfield"~e.33))
                        :op1 (p6 / person
                              :mod (o / other~e.35)))
                  :time (d / date-entity :year "2013"~e.37))))

# ::tok These issues complicate the development of in vitro assays for compounds that prevent Ras @-@ dependent activation of Raf kinase , an obvious system for therapeutic intervention .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1 2-1 4-1.2 5-1.2.1.r 6-1.2.1.2 7-1.2.1.2 8-1.2.1 9-1.2.1.1.r 10-1.2.1.1 12-1.2.1.1.1 13-1.2.1.1.1.1.2.1.1.1 15-1.2.1.1.1.1.2 16-1.2.1.1.1.1 17-1.2.1.1.1.1.1.r 18-1.2.1.1.1.1.1.1.1 19-1.2.1.1.1.1.1 22-1.2.2.1 23-1.2.2 24-1.2.2.2.r 25-1.2.2.2.1 26-1.2.2.2
# ::id pmid_2465_1010.190
# ::preferred 
(c / complicate-01~e.2
      :ARG0 (i / issue~e.1
            :mod (t / this~e.0))
      :ARG1 (d / develop-02~e.4
            :ARG1~e.5 (a / assay-00~e.8
                  :ARG1~e.9 (c2 / compound~e.10
                        :ARG0-of (p / prevent-01~e.12
                              :ARG1 (a2 / activate-01~e.16
                                    :ARG1~e.17 (k / kinase~e.19
                                          :name (n / name :op1 "Raf"~e.18))
                                    :ARG0-of (d2 / depend-01~e.15
                                          :ARG1 (e2 / enzyme
                                                :name (n2 / name :op1 "Ras"~e.13))))))
                  :manner (i2 / in-vitro~e.6,7))
            :mod (s / system~e.23
                  :mod (o / obvious~e.22)
                  :ARG0-of~e.24 (i3 / intervene-01~e.26
                        :ARG1 (t2 / therapy~e.25)))))

# ::tok Direct blocking of Ras @-@ Raf binding with small molecules does not appear to be a promising approach because the binding surface ( two antiparallel β strands ) offers no foothold in which a compound could bind .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.1.1.3 1-1.2.1.1 2-1.2.1.1.2.r 3-1.2.1.1.2.1.1.1 5-1.2.1.1.2.2.1.1 6-1.2.1.1.2 7-1.2.1.1.1.r 8-1.2.1.1.1 9-1.2.1.1.1 11-1.1 11-1.1.r 12-1 13-1.3 14-1.2.1.1.r 16-1.2 17-1.2.1 18-1.3 20-1.3.1.2 21-1.3.1.2.1 23-1.3.1.3.1.1.2.1.1 24-1.3.1.3.1.1.2.1.3 25-1.3.1.3.1.1.2.1.2.1 26-1.3.1.3.1.1.2.1 28-1.3.1 29-1.3.1.1 29-1.3.1.1.r 30-1.3.1.3 34-1.3.1.3.1.1.1 35-1.3.1.3.1 36-1.3.1.3.1.1
# ::id pmid_2465_1010.191
# ::preferred 
(a / appear-02~e.12
      :polarity~e.11 "-"~e.11
      :ARG1 (p2 / promise-01~e.16
            :ARG2 (a2 / approach~e.17
                  :domain~e.14 (b / block-01~e.1
                        :ARG0~e.7 (s / small-molecule~e.8,9)
                        :ARG1~e.2 (b2 / bind-01~e.6
                              :ARG1 (e / enzyme
                                    :name (n / name :op1 "Ras"~e.3))
                              :ARG2 (e2 / enzyme
                                    :name (n2 / name :op1 "Raf"~e.5)))
                        :manner (d / direct~e.0))))
      :ARG1-of (c / cause-01~e.13,18
            :ARG0 (o / offer-01~e.28
                  :polarity~e.29 "-"~e.29
                  :ARG0 (b4 / bind-01~e.20
                        :ARG3 (s2 / surface~e.21))
                  :ARG1 (f / foothold~e.30
                        :location-of (p3 / possible~e.35
                              :domain (b3 / bind-01~e.36
                                    :ARG1 (c3 / compound~e.34)
                                    :ARG1-of (m / mean-01
                                          :ARG2 (s3 / strand~e.26
                                                :quant "2"~e.23
                                                :name (n3 / name :op1 "β"~e.25)
                                                :mod (a3 / antiparallel~e.24)))))))))

# ::tok However , for example , preventing binding using peptides or by indirect allosteric approaches has been considered ( see <ce:cross-ref id="crosref0340" refid="bib79"> Wu et al. , 2013 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 2-1.1 3-1.1 5-1.1.1.1 6-1.1.1.1.1 7-1.1.1.1.2.1 8-1.1.1.1.2.1.1 9-1.1.1.1.2 10-1.1.1.1.2.r 11-1.1.1.1.2.2.1.1 12-1.1.1.1.2.2.1.2 13-1.1.1.1.2.2 16-1.1.1 18-1.2 22-1.2.1.1.1.1.1 23-1.2.1.1 24-1.2.1.1.2.1 26-1.2.1.2.1
# ::id pmid_2465_1010.192
# ::preferred 
(h2 / have-concession-91~e.0
      :ARG1 (e2 / exemplify-01~e.2,3
            :ARG0 (c2 / consider-01~e.16
                  :ARG1 (p / prevent-01~e.5
                        :ARG1 (b / bind-01~e.6)
                        :manner~e.10 (o3 / or~e.9
                              :op1 (u / use-01~e.7
                                    :ARG1 (p5 / peptide~e.8))
                              :op2 (a / approach-02~e.13
                                    :ARG0 (m2 / molecular-physical-entity
                                          :mod (i / indirect~e.11)
                                          :mod (a3 / allosteric~e.12)))))))
      :ARG1-of (s / see-01~e.18
            :location (p2 / publication-91
                  :ARG0 (a2 / and~e.23
                        :op1 (p3 / person
                              :name (n3 / name :op1 "Wu"~e.22))
                        :op2 (p4 / person
                              :mod (o2 / other~e.24)))
                  :time (d / date-entity :year "2013"~e.26))))

# ::tok The drug discovery group at Onyx Pharmaceuticals began screening for Raf kinase inhibitors in 1992 after it was able produce active c @-@ Raf kinase in baculovirus ( by coinfection with v @-@ Src ) and to reconstitute the MAPK pathway in vitro ( <ce:cross-ref id="crosref0345" refid="bib41"> Macdonald et al. , 1993 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1.2.1 2-1.1.1.2 3-1.1.1 4-1.1.1.1.r 5-1.1.1.1.1.1 6-1.1.1.1.1.2 7-1 8-1.1 9-1.1.2.r 10-1.1.2.1.1.1.1 11-1.1.4.1.2.1.2 12-1.1.2 12-1.1.2.1 12-1.1.2.1.r 13-1.1.3.r 13-1.1.4.1.2.2.3 14-1.1.3.1 15-1.1.4 18-1.1.4.1 19-1.1.4.1.2.1 20-1.1.4.1.2.1.2.2 21-1.1.4.1.2.1.2.1.1 23-1.1.4.1.2.1.2.1.1 24-1.1.4.1.2.1.2 25-1.1.4.1.2.2.3 26-1.1.4.1.2.1.4.1.1 31-1.1.4.1.2.1.3.1.1.1 33-1.1.4.1.2.1.3.1.1.1 35-1.1.4.1.2 37-1.1.4.1.2.2 39-1.1.4.1.2.2.2.1.1 40-1.1.4.1.2.2.2 41-1.1.4.1.2.2.3 42-1.1.4.1.2.2.3 47-1.2.1.1.1.1.1 48-1.2.1.1 49-1.2.1.1.2.1 51-1.2.2.1
# ::id pmid_2465_1010.193
# ::preferred 
(b / begin-01~e.7
      :ARG1 (s / screen-01~e.8
            :ARG0 (g / group~e.3
                  :part-of~e.4 (c / company
                        :name (n5 / name :op1 "Onyx"~e.5 :op2 "Pharmaceuticals"~e.6))
                  :ARG0-of (d3 / discover-01~e.2
                        :ARG1 (d4 / drug~e.1)))
            :ARG1~e.9 (m / molecular-physical-entity~e.12
                  :ARG0-of~e.12 (i / inhibit-01~e.12
                        :ARG1 (e / enzyme
                              :name (n4 / name :op1 "Raf"~e.10))))
            :time~e.13 (d / date-entity :year "1992"~e.14)
            :time (a / after~e.15
                  :op1 (c2 / capable-01~e.18
                        :ARG1 g
                        :ARG2 (a4 / and~e.35
                              :op1 (p / produce-01~e.19
                                    :ARG0 g
                                    :ARG1 (k / kinase~e.11,24
                                          :name (n2 / name :op1 "c-Raf"~e.21,23)
                                          :mod (a2 / active~e.20))
                                    :manner (c3 / coinfect-00
                                          :ARG0 (v2 / virus
                                                :name (n7 / name :op1 "v-Src"~e.31,33)))
                                    :location (o / organism
                                          :name (n3 / name :op1 "baculovirus"~e.26)))
                              :op2 (r / reconstitute-01~e.37
                                    :ARG0 g
                                    :ARG1 (p2 / pathway~e.40
                                          :name (n / name :op1 "MAPK"~e.39))
                                    :manner (i3 / in-vitro~e.13,25,41,42))))))
      :ARG1-of (d2 / describe-01
            :ARG0 (p3 / publication-91
                  :ARG0 (a3 / and~e.48
                        :op1 (p4 / person
                              :name (n6 / name :op1 "Macdonald"~e.47))
                        :op2 (p5 / person
                              :mod (o2 / other~e.49))))
            :time (d5 / date-entity :year "1993"~e.51)))

# ::tok It was then assumed that in cancer cells with mutant Ras , the Raf @/@ MAPK pathway would be hyperactive and that drugs that inhibit Raf would be effective ways of treating Ras mutant cancers .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.3 3-1 5-1.1.r 6-1.1.2.2.2.1 7-1.2 8-1.2.2.r 9-1.1.2.2.3 9-1.2.2 10-1.1.2.2.3.1.1.1 13-1.1.1.1.1.1 15-1.1.1.1.1.2 16-1.1.1.1 18-1.1.1.1.r 19-1.1.1 20-1.1 22-1.1.2.1 24-1.1.2.1.1 25-1.1.2.1.1.1.1.1 28-1.1.2.3 29-1.1.2.3.r 31-1.1.2 32-1.1.2.2.3.1.1.1 33-1.1.2.2.3 33-1.2.2 34-1.2.1
# ::id pmid_2465_1010.194
# ::preferred 
(a / assume-02~e.3
      :ARG1~e.5 (a2 / and~e.20
            :op1 (h / hyperactive~e.19
                  :domain~e.18 (p / pathway~e.16
                        :name (n4 / name :op1 "Raf"~e.13 :op2 "MAPK"~e.15)))
            :op2 (t / treat-04~e.31
                  :ARG0 (d2 / drug~e.22
                        :ARG0-of (i / inhibit-01~e.24
                              :ARG1 (e2 / enzyme
                                    :name (n3 / name :op1 "Raf"~e.25))))
                  :ARG1 (d / disease
                        :wiki "Cancer"
                        :name (n / name :op1 "cancer"~e.6)
                        :mod (m / mutate-01~e.9,33
                              :ARG1 (e / enzyme
                                    :name (n2 / name :op1 "Ras"~e.10,32))))
                  :manner~e.29 (e3 / effective~e.28)))
      :location (c / cell~e.7
            :mod (c2 / cancer~e.34)
            :prep-with~e.8 (m2 / mutate-01~e.9,33
                  :ARG1 e))
      :time (t2 / then~e.2))

# ::tok It was also assumed that MEK and extracellular signal @-@ regulated kinase ( ERK ) inhibitors would have the same effect .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1.r 2-1.2 3-1 5-1.1.1.1.1.1.1 6-1.1.1.1 7-1.1.1.1.2.1.1.1.1 8-1.1.1.1.2.1.1.1.2 10-1.1.1.1.2.1.1.1.2 11-1.1.1.1.2.1.1.1.3 15-1.1.1.1.2 15-1.1.1.1.2.1 15-1.1.1.1.2.1.r 19-1.1.1.2 20-1.1.1
# ::id pmid_2465_1010.195
# ::preferred 
(a / assume-02~e.3
      :ARG1 (p / possible
            :domain~e.1 (a2 / affect-01~e.20
                  :ARG0 (a3 / and~e.6
                        :op1 (e / enzyme
                              :name (n / name :op1 "MEK"~e.5))
                        :op2 (t / thing~e.15
                              :ARG0-of~e.15 (i / inhibit-01~e.15
                                    :ARG1 (e2 / enzyme
                                          :name (n2 / name
                                                :op1 "extracellular"~e.7
                                                :op2 "signal-regulated"~e.8,10
                                                :op3 "kinase"~e.11)))))
                  :ARG1-of (s / same-01~e.19)))
      :mod (a4 / also~e.2))

# ::tok In hindsight , most of the assumptions were incorrect : the Raf @/@ MAPK pathway is not often hyperactive in human cancer cells with mutant Ras , as measured by steady @-@ state levels of phospho @-@ MEK or phospho @-@ ERK .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.4.r 1-1.4 3-1.2.1 4-1.2.1.r 6-1.2 7-1.2.r 8-1 8-1.1 8-1.1.r 11-1.3.1.2.1.1 13-1.3.1.2.1.2 14-1.3.1.2 15-1.3.1.2.r 16-1.3.1.1.1 16-1.3.1.1.1.r 17-1.3.1.1 18-1.3.1 19-1.3.1.3.r 19-1.4.r 20-1.3.1.3.1.3 21-1.3.1.3.1.2.1 22-1.3.1.3 23-1.3.1.3.2.r 24-1.3.1.3.2 24-1.3.1.3.2.2 24-1.3.1.3.2.2.r 25-1.3.1.3.2.1.1 27-1.3.1.4.r 28-1.3.1.4 29-1.3.1.4.1.r 30-1.3.1.4.1.2 32-1.3.1.4.1.2.1 33-1.3.1.4.1 37-1.3.1.4.1.1.1.1.1.1 38-1.3.1.4.1.1 41-1.3.1.4.1.1.2.1.1.1
# ::id pmid_2465_1010.196
# ::preferred 
(c2 / correct~e.8
      :polarity~e.8 "-"~e.8
      :domain~e.7 (a / assume-02~e.6
            :quant~e.4 (m / most~e.3))
      :ARG1-of (e2 / exemplify-01
            :ARG0 (h / hyperactive~e.18
                  :frequency (o / often~e.17 :polarity~e.16 "-"~e.16)
                  :domain~e.15 (p / pathway~e.14
                        :name (n3 / name :op1 "Raf"~e.11 :op2 "MAPK"~e.13))
                  :location~e.19 (c / cell~e.22
                        :mod (d / disease
                              :wiki "Cancer"
                              :name (n / name :op1 "cancer"~e.21)
                              :mod (h2 / human~e.20))
                        :prep-with~e.23 (e / enzyme~e.24
                              :name (n2 / name :op1 "Ras"~e.25)
                              :ARG1-of~e.24 (m3 / mutate-01~e.24)))
                  :ARG1-of~e.27 (m2 / measure-01~e.28
                        :ARG2~e.29 (l / level~e.33
                              :degree-of (o2 / or~e.38
                                    :op1 (p2 / phosphorylate-01
                                          :ARG2 (e4 / enzyme
                                                :name (n4 / name :op1 "MEK"~e.37)))
                                    :op2 (p3 / phosphorylate-01
                                          :ARG2 (e3 / enzyme
                                                :name (n5 / name :op1 "ERK"~e.41))))
                              :ARG1-of (s / steady-01~e.30
                                    :mod (s2 / state~e.32))))))
      :prep-in~e.0,19 (h3 / hindsight~e.1))

# ::tok Raf inhibitors lead to paradoxical activation of Raf kinase following exposure to Raf inhibitors , especially in Ras mutant cancers ( reviewed in <ce:cross-ref id="crosref0350" refid="bib39"> Lito et al. , 2013 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1.1.1 1-1.1 1-1.1.1 1-1.1.1.r 2-1 5-1.2 6-1.2.1.r 7-1.2.1 8-1.2.1 9-1.5 10-1.5.1 11-1.5.1.1.r 12-1.5.1.1 13-1.5.1.1 15-1.3.3 17-1.3.2.1.1.1 18-1.3.2 19-1.3.1.1 21-1.4 26-1.4.1.1.1.1.1 27-1.4.1.1 28-1.4.1.1.2.1 30-1.4.1.2.1
# ::id pmid_2465_1010.197
# ::preferred 
(l / lead-03~e.2
      :ARG0 (m2 / molecular-physical-entity~e.1
            :ARG0-of~e.1 (i2 / inhibit-01~e.1
                  :ARG1 (k2 / kinase
                        :name (n6 / name :op1 "Raf"~e.0))))
      :ARG2 (a / activate-01~e.5
            :ARG1~e.6 k2~e.7,8
            :manner (p / paradox))
      :location (d2 / disease
            :name (n4 / name :op1 "cancer"~e.19)
            :mod (m / mutate-01~e.18
                  :ARG1 (e / enzyme
                        :name (n2 / name :op1 "Ras"~e.17)))
            :mod (e2 / especially~e.15))
      :ARG1-of (r / review-01~e.21
            :ARG0 (p3 / publication-91
                  :ARG0 (a2 / and~e.27
                        :op1 (p4 / person
                              :name (n5 / name :op1 "Lito"~e.26))
                        :op2 (p5 / person
                              :mod (o / other~e.28)))
                  :time (d / date-entity :year "2013"~e.30)))
      :time (f / follow-01~e.9
            :ARG2 (e3 / expose-01~e.10
                  :ARG2~e.11 m2~e.12,13)))

# ::tok MEK and ERK inhibitors do not show paradoxical activation but are generally ineffective on their own because they relieve feedback inhibition on upstream kinases , leading to activation of PI3K , among other effects ( <ce:cross-refs id="crosrefs0045" refid="bib45 bib12 bib72 bib46"> Mirzoeva et al. , 2009; Corcoran et al. , 2012; Turke et al. , 2012; Montero @-@ Conde et al. , 2013 </ce:cross-refs> ) , and because they lack a clear therapeutic window .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2.1.1.1.1.1 1-1.1.2.1.1 2-1.1.2.1.1.2.1.1 3-1.1.2 3-1.1.2.1 3-1.1.2.1.r 5-1.1.1 5-1.1.1.r 6-1.1 8-1.1.3 9-1 11-1.2.3 12-1.2 12-1.2.1 12-1.2.1.r 13-1.2.2 14-1.2.2 15-1.2.2 16-1.2.4 17-1.2.4.1.1.1 18-1.2.4.1.1 19-1.2.4.1.1.2.1 20-1.2.4.1.1.2 21-1.2.4.1.1.3.r 22-1.2.4.1.1.3.1 23-1.2.4.1.1.3 25-1.2.4.1.1.4 26-1.2.4.1.1.4.1.r 27-1.2.4.1.1.4.1 28-1.2.4.1.1.4.1.1.r 29-1.2.4.1.1.4.1.1.1.1 31-1.2.4.1.1.4.1.2 32-1.2.4.1.1.4.1.2.1.1 33-1.2.4.1.1.4.1.2.1 41-1.2.4.1.1.5.1.1.1.1.1.1 42-1.2.4.1.1.5.1 42-1.2.4.1.1.5.1.1.1 42-1.2.4.1.1.5.1.2.1 42-1.2.4.1.1.5.1.3.1 42-1.2.4.1.1.5.1.4.1 43-1.2.4.1.1.5.1.1.1.2.1 46-1.2.4.1.1.5.1.2.1.1.1.1 47-1.2.4.1.1.5.1 47-1.2.4.1.1.5.1.1.1 47-1.2.4.1.1.5.1.2.1 47-1.2.4.1.1.5.1.3.1 47-1.2.4.1.1.5.1.4.1 48-1.2.4.1.1.5.1.3.1.2 51-1.2.4.1.1.5.1.3.1.1.1.1 52-1.2.4.1.1.5.1 52-1.2.4.1.1.5.1.1.1 52-1.2.4.1.1.5.1.2.1 52-1.2.4.1.1.5.1.3.1 52-1.2.4.1.1.5.1.4.1 53-1.2.4.1.1.5.1.4.1.2 56-1.2.4.1.1.5.1.4.1.1.1.1 58-1.2.4.1.1.5.1.4.1.1.1.1 59-1.2.4.1.1.5.1 59-1.2.4.1.1.5.1.1.1 59-1.2.4.1.1.5.1.2.1 59-1.2.4.1.1.5.1.3.1 59-1.2.4.1.1.5.1.4.1 60-1.2.4.1.1.5.1.1.1.2.1 62-1.2.4.1.1.5.1.4.2.1 66-1.2.4.1 66-1.2.4.1.1.5.1 67-1.2.4 68-1.2.4.1.2.1 69-1.2.4.1.2 71-1.2.4.1.2.2.1 72-1.2.4.1.2.2.2 73-1.2.4.1.2.2
# ::id pmid_2465_1010.198
# ::preferred 
(c / contrast-01~e.9
      :ARG1 (s / show-01~e.6
            :polarity~e.5 "-"~e.5
            :ARG0 (m / molecular-physical-entity~e.3
                  :ARG0-of~e.3 (i / inhibit-01~e.3
                        :ARG1 (a2 / and~e.1
                              :op1 (e2 / enzyme
                                    :name (n / name :op1 "MEK"~e.0))
                              :op2 (e3 / enzyme
                                    :name (n2 / name :op1 "ERK"~e.2)))))
            :ARG1 (a / activate-01~e.8
                  :mod (p / paradox)))
      :ARG2 (e / effective~e.12
            :polarity~e.12 "-"~e.12
            :mod (b / by-oneself~e.13,14,15)
            :mod (g / general-02~e.11)
            :ARG1-of (c2 / cause-01~e.16,67
                  :ARG0 (a5 / and~e.66
                        :op1 (r / relieve-01~e.18
                              :ARG0 m~e.17
                              :ARG1 (i2 / inhibit-01~e.20
                                    :subevent-of (f / feedback~e.19))
                              :ARG2~e.21 (k / kinase~e.23
                                    :location (u / upstream~e.22))
                              :ARG0-of (l / lead-03~e.25
                                    :ARG2~e.26 (a3 / activate-01~e.27
                                          :ARG1~e.28 (e4 / enzyme
                                                :name (n3 / name :op1 "PI3K"~e.29))
                                          :ARG1-of (i3 / include-91~e.31
                                                :ARG2 (a4 / affect-01~e.33
                                                      :mod (o / other~e.32)))))
                              :ARG1-of (d2 / describe-01
                                    :ARG0 (a6 / and~e.42,47,52,59,66
                                          :op1 (p2 / publication-91
                                                :ARG0 (a7 / and~e.42,47,52,59
                                                      :op1 (p6 / person
                                                            :name (n4 / name :op1 "Mirzoeva"~e.41))
                                                      :op2 (p7 / person
                                                            :mod (o2 / other~e.43,60)))
                                                :time (d3 / date-entity :year "2009"))
                                          :op2 (p3 / publication-91
                                                :ARG0 (a8 / and~e.42,47,52,59
                                                      :op1 (p8 / person
                                                            :name (n5 / name :op1 "Corcoran"~e.46))
                                                      :op2 p7)
                                                :time (d4 / date-entity :year "2012"))
                                          :op3 (p4 / publication-91
                                                :ARG0 (a9 / and~e.42,47,52,59
                                                      :op1 (p9 / person
                                                            :name (n6 / name :op1 "Turke"~e.51))
                                                      :op2 p7~e.48)
                                                :time d4)
                                          :op4 (p5 / publication-91
                                                :ARG0 (a10 / and~e.42,47,52,59
                                                      :op1 (p10 / person
                                                            :name (n7 / name :op1 "Montero-Conde"~e.56,58))
                                                      :op2 p7~e.53)
                                                :time (d5 / date-entity :year "2013"~e.62)))))
                        :op2 (l2 / lack-01~e.69
                              :ARG0 m~e.68
                              :ARG1 (w / window~e.73
                                    :mod (c3 / clear~e.71)
                                    :mod (t / therapy~e.72)))))))

# ::tok MEK1 @/@ MEK2 isoforms have a high degree of amino acid identity , suggesting redundant roles in signaling .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1.1.1 2-1.1.2.1.1.1 6-1.3 7-1.3.r 9-1.2 10-1.2 13-1.4 14-1.4.1.3 17-1.4.1.2
# ::id pmid_2465_1010.199
# ::preferred 
(i4 / identical-01
      :ARG1 (s / slash
            :op1 (i / isoform
                  :mod (e / enzyme
                        :name (n / name :op1 "MEK1"~e.0)))
            :op2 (i3 / isoform
                  :mod (e2 / enzyme
                        :name (n2 / name :op1 "MEK2"~e.2))))
      :ARG2 (a / amino-acid~e.9,10)
      :degree~e.7 (h2 / high~e.6)
      :ARG0-of (s2 / suggest-01~e.13
            :ARG1 (p / play-08
                  :ARG0 s
                  :ARG1 (s3 / signal-07~e.17)
                  :mod (r / redundant~e.14))))

# ::tok The same is true for ERK1/ERK2 .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1 3-1
# ::id pmid_2465_1010.200
# ::preferred 
(t / true-01~e.3
      :ARG1 (t2 / thing
            :mod (s / same~e.1))
      :ARG2 (s2 / slash
            :op1 (e / enzyme
                  :name (n / name :op1 "ERK1"))
            :op2 (e2 / enzyme
                  :name (n2 / name :op1 "ERK2"))))

# ::tok However , knocking out the gene encoding MEK1 , <i> Map2k1 </i> ( <ce:cross-ref id="crosref0355" refid="bib22"> Giroux et al. , 1999 </ce:cross-ref> ) , or the gene encoding ERK2 , <i> Mapk1 </i> ( <ce:cross-refs id="crosrefs0050" refid="bib26 bib57 bib82"> Hatano et al. , 2003; Saba @-@ El @-@ Leil et al. , 2003; Yao et al. , 2003 </ce:cross-refs> ) , is embryonic lethal , indicating a requirement for signaling from a particular isoform , at least in the context of embryogenesis .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 2-1.1.1 3-1.1.1 5-1.1.1.1.1 6-1.1.1.1.1.2 7-1.1.1.1.1.2.1.1.1 10-1.1.1.1.1.1.1 16-1.1.1.1.1.3.1.1.1.1.1 17-1.1.1.1.1.3.1.1 18-1.1.1.1.1.3.1.1.2.1 20-1.1.1.1.1.3.1.2.1 24-1.1.1.1 26-1.1.1.1.1 26-1.1.1.1.2 27-1.1.1.1.1.2 27-1.1.1.1.2.2 28-1.1.1.1.2.2.1.1.1 31-1.1.1.1.2.1.1 39-1.1.1.1.2.3.1.1.1.1.1.1 40-1.1.1.1.1.3.1.1 40-1.1.1.1.2.3.1 40-1.1.1.1.2.3.1.1.1 40-1.1.1.1.2.3.1.2.1 40-1.1.1.1.2.3.1.3.1 41-1.1.1.1.2.3.1.2.1.2 44-1.1.1.1.2.3.1.2.1.1.1.1 46-1.1.1.1.2.3.1.2.1.1.1.1 48-1.1.1.1.2.3.1.2.1.1.1.1 49-1.1.1.1.1.3.1.1 49-1.1.1.1.2.3.1 49-1.1.1.1.2.3.1.1.1 49-1.1.1.1.2.3.1.2.1 49-1.1.1.1.2.3.1.3.1 50-1.1.1.1.2.3.1.3.1.2 53-1.1.1.1.2.3.1.3.1.1.1.1 54-1.1.1.1.1.3.1.1 54-1.1.1.1.2.3.1 54-1.1.1.1.2.3.1.1.1 54-1.1.1.1.2.3.1.2.1 54-1.1.1.1.2.3.1.3.1 55-1.1.1.1.1.3.1.1.2.1 57-1.1.1.1.2.3.1.1.2.1 65-1.1.3 67-1.1.3.1 68-1.1.3.1.1.r 69-1.1.3.1.1 70-1.1.3.1.2.r 72-1.1.3.1.2.1 73-1.1.3.1.2 75-1.1.3.1.3.1 76-1.1.3.1.3.1 81-1.1.3.1.3
# ::id pmid_2465_1010.201
# ::preferred 
(c2 / contrast-01~e.0
      :ARG2 (c / cause-01
            :ARG0 (k / knock-03~e.2,3
                  :ARG1 (o / or~e.24
                        :op1 (g / gene~e.5,26
                              :name (n / name :op1 "Map2k1"~e.10)
                              :ARG0-of (e / encode-01~e.6,27
                                    :ARG1 (e2 / enzyme
                                          :name (n2 / name :op1 "MEK1"~e.7)))
                              :ARG1-of (d2 / describe-01
                                    :ARG0 (p2 / publication-91
                                          :ARG0 (a2 / and~e.17,40,49,54
                                                :op1 (p4 / person
                                                      :name (n5 / name :op1 "Giroux"~e.16))
                                                :op2 (p3 / person
                                                      :mod (o2 / other~e.18,55)))
                                          :time (d3 / date-entity :year "1999"~e.20))))
                        :op2 (g2 / gene~e.26
                              :name (n3 / name :op1 "Mapk1"~e.31)
                              :ARG0-of (e3 / encode-01~e.27
                                    :ARG1 (e4 / enzyme
                                          :name (n4 / name :op1 "ERK2"~e.28)))
                              :ARG1-of (d4 / describe-01
                                    :ARG0 (a3 / and~e.40,49,54
                                          :op1 (p5 / publication-91
                                                :ARG0 (a4 / and~e.40,49,54
                                                      :op1 (p8 / person
                                                            :name (n6 / name :op1 "Hatano"~e.39))
                                                      :op2 p3)
                                                :time (d5 / date-entity :year "2003"~e.57))
                                          :op2 (p6 / publication-91
                                                :ARG0 (a5 / and~e.40,49,54
                                                      :op1 (p9 / person
                                                            :name (n7 / name :op1 "Saba-El-Leil"~e.44,46,48))
                                                      :op2 p3~e.41)
                                                :time d5)
                                          :op3 (p7 / publication-91
                                                :ARG0 (a6 / and~e.40,49,54
                                                      :op1 (p10 / person
                                                            :name (n8 / name :op1 "Yao"~e.53))
                                                      :op2 p3~e.50)
                                                :time d5))))))
            :ARG1 (d / die-01
                  :ARG1 (e5 / embryo))
            :ARG0-of (i / indicate-01~e.65
                  :ARG1 (r / require-01~e.67
                        :ARG1~e.68 (s / signal-07~e.69
                              :ARG0 (i2 / isoform~e.73
                                    :mod (p / particular~e.72)))
                        :ARG2~e.70 i2
                        :condition (e6 / embryogenesis~e.81
                              :mod (a / at-least~e.75,76))))))

# ::tok Although <i> Map2k2 </i>@ <sup loc="post"> <i> −/− </i>@ </sup> ( MEK2 null ) and <i> Mapk3 </i>@ <sup loc="post"> <i> −/− </i>@ </sup> ( ERK1 null ) mice are viable , in vivo ablation of MEK1 in a <i> Map2k2 </i>@ <sup loc="post"> <i> −/− </i>@ </sup> background ( <ce:cross-refs id="crosrefs0055" refid="bib60 bib5"> Scholl et al. , 2007; Blasco et al. , 2011 </ce:cross-refs> ) or ERK2 in a <i> Mapk3 </i>@ <sup loc="post"> <i> −/− </i>@ </sup> background ( <ce:cross-ref id="crosref0360" refid="bib9"> Chan et al. , 2013 </ce:cross-ref> ) results in apoptosis and lethality in adult mice .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 11-1.2.1.1.1.2.2.1.1 14-1.2.1 25-1.2.1.2.1.2.2.1.1 28-1.2.1.1 29-1.2.1.r 30-1.2 32-1.1.1.1.2 33-1.1.1.1.2 34-1.1.1.1 34-1.1.1.2 35-1.1.1.1.1.r 36-1.1.1.1.1.1.1 37-1.1.1.1.2 48-1.1.1.1.3 48-1.1.1.2.3 54-1.1.1.1.4.1.1.1.1.1.1 55-1.1.1.1.4.1.1.1 56-1.1.1.1.4.1.1.1.2.1 59-1.1.1.1.4.1.2.1.1.1.1 60-1.1.1.1.4.1 60-1.1.1.1.4.1.1.1 60-1.1.1.1.4.1.2.1 61-1.1.1.1.4.1.1.1.2.1 63-1.1.1.1.4.1.2.2.1 66-1.1.1 67-1.1.1.2.1.1.1 68-1.1.1.2.2 79-1.1.1.1.3 84-1.1.1.2.4.1.1.1.1.1 85-1.1.1.1.4.1 85-1.1.1.1.4.1.1.1 85-1.1.1.2.4.1.1 86-1.1.1.1.4.1.1.1.2.1 88-1.1.1.2.4.1.2.1 91-1.1 92-1.1.1.1.2 92-1.1.2.r 93-1.1.2.1 94-1.1.1.1.4.1 94-1.1.1.1.4.1.1.1 94-1.1.2 96-1.1.1.1.2 97-1.1.2.2.1.1 98-1.1.2.2.1 98-1.2.1.2
# ::id pmid_2465_1010.202
# ::preferred 
(h / have-concession-91~e.0
      :ARG1 (r / result-01~e.91
            :ARG1 (o / or~e.66
                  :op1 (a2 / ablate-00~e.34
                        :ARG1~e.35 (e3 / enzyme
                              :name (n7 / name :op1 "MEK1"~e.36))
                        :manner (i / in-vivo~e.32,33,37,92,96)
                        :location (b / background~e.48,79
                              :mod (g / gene
                                    :name (n / name :op1 "Map2k2−/−")
                                    :ARG1-of (e5 / express-03
                                          :polarity "-"
                                          :ARG2 (e / enzyme
                                                :name (n3 / name :op1 "MEK2"~e.11)))))
                        :ARG1-of (d / describe-01
                              :ARG0 (a6 / and~e.60,85,94
                                    :op1 (p / publication-91
                                          :ARG0 (a7 / and~e.55,60,85,94
                                                :op1 (p3 / person
                                                      :name (n9 / name :op1 "Scholl"~e.54))
                                                :op2 (p4 / person
                                                      :mod (o2 / other~e.56,61,86)))
                                          :time (d2 / date-entity :year "2007"))
                                    :op2 (p2 / publication-91
                                          :ARG0 (a8 / and~e.60
                                                :op1 (p5 / person
                                                      :name (n10 / name :op1 "Blasco"~e.59))
                                                :op2 p4)
                                          :time (d3 / date-entity :year "2011"~e.63)))))
                  :op2 (a3 / ablate-00~e.34
                        :ARG1 (e4 / enzyme
                              :name (n8 / name :op1 "ERK2"~e.67))
                        :manner i~e.68
                        :location (b2 / background~e.48
                              :mod (g2 / gene
                                    :name (n2 / name :op1 "Mapk3−/−")
                                    :ARG1-of (e6 / express-03
                                          :polarity "-"
                                          :ARG2 (e2 / enzyme
                                                :name (n5 / name :op1 "ERK1"~e.25)))))
                        :ARG1-of (d4 / describe-01
                              :ARG0 (p7 / publication-91
                                    :ARG0 (a9 / and~e.85
                                          :op1 (p8 / person
                                                :name (n11 / name :op1 "Chan"~e.84))
                                          :op2 p4)
                                    :time (d5 / date-entity :year "2013"~e.88)))))
            :ARG2~e.92 (a4 / and~e.94
                  :op1 (a5 / apoptosis~e.93
                        :mod (m5 / mouse~e.98
                              :mod (a10 / adult~e.97)))
                  :op2 (d6 / die-01
                        :ARG1 m5)))
      :ARG2 (v / viable~e.30
            :domain~e.29 (a / and~e.14
                  :op1 (m / mouse~e.28
                        :mod g)
                  :op2 (m2 / mouse~e.98
                        :mod g2))))

# ::tok This may suggest a limited therapeutic window for any pan inhibitor of these kinases , and the clinical toxicity of potential drugs in this target class bears this out .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.2 1-1.2.2 2-1.2.2 3-1.2.2 4-1.2.2 5-1.2.2 6-1.2.2 7-1.2.2 8-1.2.2 9-1.2.2 10-1.2.2 11-1.2.2 12-1.2.2 13-1.2.2 15-1 17-1.2.1.1 20-1.2.1.2.1 21-1.2.1.2 23-1.1.1.2.3.2.1.1 24-1.2.1.2.2.1.1 25-1.2.1.2.2.1 26-1.2 27-1.2.2 28-1.2
# ::id pmid_2465_1010.203
# ::preferred 
(a / and~e.15
      :op1 (p / possible
            :domain (s / suggest-01
                  :ARG0 (t / this)
                  :ARG1 (w / window
                        :mod (t2 / therapy)
                        :ARG1-of (l / limit-01)
                        :poss (m / molecular-physical-entity
                              :mod (p2 / pan)
                              :ARG0-of (i / inhibit-01
                                    :ARG1 (k / kinase
                                          :mod (t3 / this~e.23)))))))
      :op2 (b / bear-05~e.26,28
            :ARG0 (t4 / toxic
                  :mod (c / clinic~e.17)
                  :domain (d / drug~e.21
                        :mod (p3 / potential~e.20)
                        :ARG1-of (i2 / include-91
                              :ARG2 (c2 / class~e.25
                                    :ARG1-of (t5 / target-01~e.24)))))
            :ARG1 p~e.0,1,2,3,4,5,6,7,8,9,10,11,12,13,27))

# ::tok The Onyx @/@ Bayer screen for c @-@ Raf inhibitors led to the discovery and development of sorafenib .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1.1.1.1 3-1.1.1.2.1.1 4-1.1 8-1.1.2.1.1.1.1 9-1.1.2 9-1.1.2.1 9-1.1.2.1.r 10-1 11-1.2.r 13-1.2.1 14-1.2 15-1.2.2 16-1.2.1.1.r 17-1.2.1.1.1.1
# ::id pmid_2465_1010.204
# ::preferred 
(l / lead-03~e.10
      :ARG0 (s / screen-01~e.4
            :ARG0 (s2 / slash
                  :op1 (c / company
                        :name (n / name :op1 "Onyx"~e.1))
                  :op2 (c2 / company
                        :name (n2 / name :op1 "Bayer"~e.3)))
            :ARG2 (m / molecular-physical-entity~e.9
                  :ARG0-of~e.9 (i / inhibit-01~e.9
                        :ARG1 (e / enzyme
                              :name (n3 / name :op1 "C-Raf"~e.8)))))
      :ARG2~e.11 (a / and~e.14
            :op1 (d / discover-01~e.13
                  :ARG1~e.16 (s3 / small-molecule
                        :name (n4 / name :op1 "sorafenib"~e.17)))
            :op2 (d2 / develop-02~e.15
                  :ARG1 s3)))

# ::tok However , it was disappointing when sorafenib failed to show clinical benefit in early clinical trials against Ras mutant cancers , and this lack of response was difficult to understand because sorafenib does indeed inhibit Raf kinase .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 3-1.1.2.1.r 4-1.1.1 5-1.1.1.1.4.3.r 5-1.1.1.1.4.r 6-1.1.1.1.2.1.1 9-1.1.1.1 10-1.1.1.1.3.2 11-1.1.1.1.3 13-1.1.1.1.4.3 14-1.1.1.1.4.2 15-1.1.1.1.4 16-1.1.1.1.4.1 17-1.1.1.1.4.1.1.1.1.1 18-1.1.1.1.4.1.1.1 18-1.1.1.1.4.1.1.1.2 18-1.1.1.1.4.1.1.1.2.r 19-1.1.1.1.4.1.1 21-1.1 22-1.1.2.1.1.2 23-1.1.2.1.1 24-1.1.2.1.1.1.r 25-1.1.2.1.1.1 26-1.1.2.1.r 27-1.1.2 28-1.1.2.1 28-1.1.2.2 29-1.1.2.1 30-1.1.2.2 31-1.1.2.2.1.1 33-1.1.2.2.1.3 34-1.1.2.2.1 35-1.1.2.2.1.2.1.1 36-1.1.2.2.1.2
# ::id pmid_2465_1010.205
# ::preferred 
(h / have-concession-91~e.0
      :ARG1 (a / and~e.21
            :op1 (d / disappoint-01~e.4
                  :ARG0 (s2 / show-01~e.9
                        :polarity "-"
                        :ARG0 (s3 / small-molecule
                              :name (n / name :op1 "sorafenib"~e.6))
                        :ARG1 (b / benefit-01~e.11
                              :ARG0 s3
                              :mod (c / clinic~e.10))
                        :time~e.5 (t / try-01~e.15
                              :ARG1 (a2 / against~e.16
                                    :op1 (c2 / cancer~e.19
                                          :mod (e2 / enzyme~e.18
                                                :name (n2 / name :op1 "Ras"~e.17)
                                                :ARG2-of~e.18 (m / mutate-01~e.18))))
                              :mod c~e.14
                              :time~e.5 (e / early~e.13))))
            :op2 (d2 / difficult~e.27
                  :domain~e.3,26 (u / understand-01~e.28,29
                        :ARG1 (l / lack-01~e.23
                              :ARG1~e.24 (r / respond-01~e.25)
                              :mod (t2 / this~e.22)))
                  :ARG1-of (c3 / cause-01~e.28,30
                        :ARG0 (i / inhibit-01~e.34
                              :ARG0 s3~e.31
                              :ARG1 (k / kinase~e.36
                                    :name (n3 / name :op1 "Raf"~e.35))
                              :mod (i2 / indeed~e.33))))))

# ::tok Despite this , sorafenib and fluoro @-@ sorafenib ( regorafenib ) have since been approved for the treatment of renal cell carcinoma , hepatocellular carcinoma , thyroid cancer , colorectal cancer , and gastrointestinal stromal cancer .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.2 3-1.1.1.1.1.1 4-1.1.1 5-1.1.1.2.1.1 7-1.1.1.2.1.1 9-1.1.1.2.2.1.1.1 12-1.1.3 14-1.1 15-1.1.2.r 17-1.1.2 18-1.1.2.1.r 19-1.1.2.1.1.1.1 20-1.1.2.1.1.1 21-1.1.2.1.1 23-1.1.2.1.2.1 24-1.1.2.1.2 26-1.1.2.1.3.1 27-1.1.2.1.3 29-1.1.2.1.4.1 30-1.1.2.1.4 30-1.1.2.1.5 32-1.1.2.1 33-1.1.2.1.5.1.1 35-1.1.2.1.4
# ::id pmid_2465_1010.206
# ::preferred 
(h / have-concession-91~e.0
      :ARG1 (a / approve-01~e.14
            :ARG1 (a2 / and~e.4
                  :op1 (s2 / small-molecule
                        :name (n / name :op1 "sorafenib"~e.3))
                  :op2 (s3 / small-molecule
                        :name (n2 / name :op1 "fluoro-sorafenib"~e.5,7)
                        :ARG1-of (m / mean-01
                              :ARG2 (s4 / small-molecule
                                    :name (n3 / name :op1 "regorafenib"~e.9)))))
            :ARG2~e.15 (t2 / treat-03~e.17
                  :ARG2~e.18 (a3 / and~e.32
                        :op1 (c / carcinoma~e.21
                              :mod (c2 / cell~e.20
                                    :mod (k / kidney~e.19)))
                        :op2 (c3 / carcinoma~e.24
                              :mod (h2 / hepatocellular~e.23))
                        :op3 (c4 / cancer~e.27
                              :mod (t3 / thyroid~e.26))
                        :op4 (c5 / cancer~e.30,35
                              :mod (c6 / colon~e.29))
                        :op5 (c7 / cancer~e.30
                              :mod (s5 / stroma
                                    :mod (g / gastrointestinal~e.33)))))
            :time (s / since~e.12))
      :ARG2 (t / this~e.1))

# ::tok In hepatocellular carcinoma , biomarker analysis in Phase II clinical trials showed a clear correlation between levels of phospho @-@ ERK and clinical response , suggesting that inhibition of Raf kinase is responsible for part of the clinical benefit ( <ce:cross-ref id="crosref0365" refid="bib1"> Abou @-@ Alfa et al. , 2006 </ce:cross-ref> ) , but in the other indications , it appears likely that inhibition of vascular endothelial growth factor receptor 2 or other kinases is responsible .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.6.1 2-1.1.6 4-1.1.1.1 5-1.1.1 7-1.1.3.2 8-1.1.3.2.1.1 9-1.1.3.1 10-1.1.3 11-1.1 13-1.1.2.3 14-1.1.2 16-1.1.2.1 20-1.1.2.1.1.1.1 21-1.1.5.1.1 22-1.1.2.2.1 23-1.1.2.2 25-1.1.4 26-1.1.4.1.r 27-1.1.4.1.1 28-1.1.4.1.1.1.r 29-1.1.4.1.1.1.1.1 30-1.1.4.1.1.1 32-1.1.4.1 33-1.1.4.1.2.r 34-1.1.4.1.2.2 37-1.1.4.1.2.1 38-1.1.4.1.2 43-1.1.5.1.1.1.1.1 45-1.1.5.1.1.1.1.1 46-1.1.5.1.1 47-1.1.5.1.1.2.1 49-1.1.5.1.2.1 53-1 54-1.2.r 56-1.2.2.1 57-1.2.2 60-1.2 61-1.2.1 63-1.2.1.1.1 64-1.2.1.1.1.1.r 65-1.2.1.1.1.1.1.1.1 66-1.2.1.1.1.1.1.1.2 67-1.2.1.1.1.1.1.1.3 68-1.2.1.1.1.1.1.1.4 69-1.2.1.1.1.1.1.1.5 70-1.2.1.1.1.1.1.1.6 71-1.2.1.1.1.1 72-1.2.1.1.1.1.2.1 73-1.2.1.1.1.1.1 73-1.2.1.1.1.1.2 74-1.2.1.1.r 75-1.2.1.1
# ::id pmid_2465_1010.207
# ::preferred 
(c / contrast-01~e.53
      :ARG1 (s / show-01~e.11
            :ARG0 (a / analyze-01~e.5
                  :ARG1 (b / biomarker~e.4))
            :ARG1 (c3 / correlate-01~e.14
                  :ARG1 (l / level~e.16
                        :degree-of (e / enzyme
                              :name (n / name :op1 "ERK"~e.20)
                              :ARG3-of (p2 / phosphorylate-01)))
                  :ARG2 (r / respond-01~e.23
                        :mod c2~e.22)
                  :mod (c4 / clear~e.13))
            :subevent-of (t / try-01~e.10
                  :mod (c2 / clinic~e.9)
                  :mod (p / phase~e.7
                        :ord (o / ordinal-entity :value "2"~e.8)))
            :ARG0-of (s2 / suggest-01~e.25
                  :ARG1~e.26 (r2 / responsible-01~e.32
                        :ARG0 (i / inhibit-01~e.27
                              :ARG1~e.28 (k / kinase~e.30
                                    :name (n2 / name :op1 "Raf"~e.29)))
                        :ARG1~e.33 (b2 / benefit-01~e.38
                              :mod (c5 / clinic~e.37)
                              :degree (p3 / part~e.34))))
            :ARG1-of (d / describe-01
                  :ARG0 (p4 / publication-91
                        :ARG0 (a2 / and~e.21,46
                              :op1 (p5 / person
                                    :name (n3 / name :op1 "Abou-Alfa"~e.43,45))
                              :op2 (p6 / person
                                    :mod (o2 / other~e.47)))
                        :time (d2 / date-entity :year "2006"~e.49)))
            :condition (c6 / carcinoma~e.2
                  :mod (h2 / hepatocellular~e.1)))
      :ARG2~e.54 (a3 / appear-02~e.60
            :ARG1 (l2 / likely~e.61
                  :domain~e.74 (r3 / responsible-01~e.75
                        :ARG0 (i3 / inhibit-01~e.63
                              :ARG1~e.64 (o4 / or~e.71
                                    :op1 (k2 / kinase~e.73
                                          :name (n4 / name
                                                :op1 "vascular"~e.65
                                                :op2 "endothelial"~e.66
                                                :op3 "growth"~e.67
                                                :op4 "factor"~e.68
                                                :op5 "receptor"~e.69
                                                :op6 "2"~e.70))
                                    :op2 (k3 / kinase~e.73
                                          :mod (o5 / other~e.72))))
                        :ARG1 b2))
            :condition (i2 / indicate-101~e.57
                  :mod (o3 / other~e.56))))

# ::tok Hopefully , a clearer picture will emerge through analysis of exceptional responders or through deciphering mechanisms of drug resistance .
# ::amr-annotator SDL-AMR-09
# ::alignments 3-1.1.1.1 3-1.1.1.1.1 3-1.1.1.1.1.r 4-1.1.1 6-1.1 8-1.1.2.1 9-1.1.2.1.1.r 10-1.1.2.1.1.2 12-1.1.2 14-1.1.2.2 15-1.1.2.2.1 16-1.1.2.2.1.1.r 17-1.1.2.2.1.1.1 18-1.1.2.2.1.1
# ::id pmid_2465_1010.208
# ::preferred 
(h / hope-01
      :ARG1 (e / emerge-01~e.6
            :ARG0 (p / picture~e.4
                  :mod (c / clear~e.3
                        :degree~e.3 (m / more~e.3)))
            :ARG1 (o / or~e.12
                  :op1 (a / analyze-01~e.8
                        :ARG1~e.9 (t / thing
                              :ARG0-of (r / respond-01)
                              :mod (e2 / exceptional~e.10)))
                  :op2 (d / decipher-01~e.14
                        :ARG1 (m2 / mechanism~e.15
                              :mod~e.16 (r2 / resist-01~e.18
                                    :ARG1 (d2 / drug~e.17)))))))

# ::tok Inhibitors of PI3K pathway have not yet fared much better in the clinic , also because of feedback mechanisms that activate upstream signaling , as well as poor therapeutic index .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.2 0-1.2.2.1 0-1.2.2.1.r 1-1.2.2.1.1.r 2-1.2.2.1.1.1.1 3-1.2.2.1.1 5-1.2.1 5-1.2.1.r 6-1.2.5 7-1.2 8-1.2.3.1.1 9-1.2.3 9-1.2.3.1 9-1.2.3.1.r 10-1.2.4.r 12-1.2.4 14-1.1.1.3 15-1 17-1.1.1.1 18-1.1.1 20-1.1.1.2 21-1.1.1.2.1.1 22-1.1.1.2.1 24-1.2.5.r 25-1.2.3 26-1.1.r 26-1.2.5.r 27-1.1.2.2 28-1.1.2.1 29-1.1.2
# ::id pmid_2465_1010.209
# ::preferred 
(c / cause-01~e.15
      :ARG0~e.26 (a / and
            :op1 (m4 / mechanism~e.18
                  :mod (f2 / feedback~e.17)
                  :ARG0-of (a2 / activate-01~e.20
                        :ARG1 (s / signal-07~e.22
                              :source (u / upstream~e.21)))
                  :mod (a3 / also~e.14))
            :op2 (i2 / index~e.29
                  :mod (t / therapy~e.28)
                  :mod (p2 / poor~e.27)))
      :ARG1 (f / fare-01~e.7
            :polarity~e.5 "-"~e.5
            :ARG0 (m3 / molecular-physical-entity~e.0
                  :ARG0-of~e.0 (i / inhibit-01~e.0
                        :ARG1~e.1 (p / pathway~e.3
                              :name (n / name :op1 "PI3K"~e.2))))
            :manner (g / good~e.9,25
                  :degree~e.9 (m / more~e.9
                        :quant (m2 / much~e.8)))
            :location~e.10 (c2 / clinic~e.12)
            :time~e.24,26 (y / yet~e.6)))

# ::tok However , the relative failure of these downstream approaches does not mean that they are not critical to Ras oncogenesis .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 3-1.1.2.2 4-1.1.2 5-1.1.2.1.r 6-1.1.2.1.1 7-1.1.2.1.2 8-1.1.2.1 10-1.1.1 10-1.1.1.r 11-1.1 13-1.1.3.3 14-1.1.3.3.r 15-1.1.3.1 15-1.1.3.1.r 16-1.1.3 17-1.1.3.2 18-1.1.3.2.1.1.1
# ::id pmid_2465_1010.210
# ::preferred 
(c2 / contrast-01~e.0
      :ARG2 (m / mean-01~e.11
            :polarity~e.10 "-"~e.10
            :ARG1 (f / fail-01~e.4
                  :ARG1~e.5 (a / approach-02~e.8
                        :mod (t / this~e.6)
                        :mod (d / downstream~e.7))
                  :mod (r / relative~e.3))
            :ARG2 (c / critical~e.16
                  :polarity~e.15 "-"~e.15
                  :topic (c3 / cause-01~e.17
                        :ARG0 (e / enzyme
                              :name (n / name :op1 "Ras"~e.18))
                        :ARG1 (c4 / cancer))
                  :domain~e.14 a~e.13)))

# ::tok Indeed , ablation of c @-@ Raf ( but not B @-@ Raf ) in mice inhibits development and delays progression of Ras @-@ driven tumors in a lung adenocarcinoma model ( <ce:cross-ref id="crosref0370" refid="bib5"> Blasco et al. , 2011 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3 2-1.1.1 2-1.1.1.3.1 6-1.1.1.1.1.1 8-1.1.1.3 9-1.1.1.3.1.1 9-1.1.1.3.1.1.r 10-1.1.1.3.1.2.1.1 12-1.1.1.1.1.1 12-1.1.1.3.1.2.1.1 14-1.1.1.2.r 15-1.1.1.2 16-1.1 17-1.1.2 18-1 18-1.4.1.1 19-1.2 20-1.2.2 21-1.2.2.1.r 22-1.2.2.1.1.1.1.1 24-1.2.2.1.1 25-1.2.2.1 26-1.2.2.2.r 28-1.2.2.2.1.1 29-1.2.2.2.1 30-1.2.2.2 35-1.4.1.1.1.1.1 36-1.4.1.1 37-1.4.1.1.2.1 39-1.4.1.2.1
# ::id pmid_2465_1010.211
# ::preferred 
(a / and~e.18
      :op1 (i / inhibit-01~e.16
            :ARG0 (a2 / ablate-00~e.2
                  :ARG1 (e / enzyme
                        :name (n / name :op1 "C-Raf"~e.6,12))
                  :location~e.14 (m / mouse~e.15)
                  :ARG1-of (c / contrast-01~e.8
                        :ARG2 (a5 / ablate-00~e.2
                              :polarity~e.9 "-"~e.9
                              :ARG1 (e2 / enzyme
                                    :name (n2 / name :op1 "B-Raf"~e.10,12)))))
            :ARG1 (d2 / develop-01~e.17
                  :ARG1 (m2 / model~e.30
                        :topic (a3 / adenocarcinoma~e.29
                              :mod (l / lung~e.28)))
                  :ARG2 (t / tumor~e.25
                        :ARG1-of (d3 / drive-02~e.24
                              :ARG0 (e3 / enzyme
                                    :name (n3 / name :op1 "Ras"~e.22))))))
      :op2 (d / delay-01~e.19
            :ARG0 a2
            :ARG1 (p / progress-01~e.20
                  :ARG1~e.21 t
                  :location~e.26 m2))
      :mod (i2 / indeed~e.0)
      :ARG1-of (d4 / describe-01
            :ARG0 (p2 / publication-91
                  :ARG0 (a4 / and~e.18,36
                        :op1 (p3 / person
                              :name (n4 / name :op1 "Blasco"~e.35))
                        :op2 (p4 / person
                              :mod (o / other~e.37)))
                  :time (d5 / date-entity :year "2011"~e.39))))

# ::tok However , in an in vivo pancreatic cancer mouse model , B @-@ Raf was shown to be required for tumor progression ( <ce:cross-ref id="crosref0375" refid="bib65"> Sobczak et al. , 2008 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 2-1.1.2.3 4-1.1.2.3 5-1.1.2.3 6-1.1.2.1.1 7-1.1.2.1 8-1.1.2.2 9-1.1.2 11-1.1.1.2.1.1 13-1.1.1.2.1.1 15-1.1 18-1.1.1 19-1.1.1.1.r 20-1.1.1.1.1 21-1.1.1.1 26-1.1.3.1.1.1.1.1 27-1.1.3.1.1 28-1.1.3.1.1.2.1 30-1.1.3.1.2.1
# ::id pmid_2465_1010.212
# ::preferred 
(c2 / contrast-01~e.0
      :ARG2 (s / show-01~e.15
            :ARG1 (r / require-01~e.18
                  :ARG0~e.19 (p / progress-01~e.21
                        :ARG1 (t / tumor~e.20))
                  :ARG1 (e / enzyme
                        :name (n / name :op1 "B-Raf"~e.11,13)))
            :condition (m / model~e.9
                  :topic (c / cancer~e.7
                        :mod (p2 / pancreas~e.6))
                  :mod (m2 / mouse~e.8)
                  :mod (i / in-vivo~e.2,4,5))
            :ARG1-of (d / describe-01
                  :ARG0 (p3 / publication-91
                        :ARG0 (a / and~e.27
                              :op1 (p4 / person
                                    :name (n2 / name :op1 "Sobczak"~e.26))
                              :op2 (p5 / person
                                    :mod (o / other~e.28)))
                        :time (d2 / date-entity :year "2008"~e.30)))))

# ::tok This suggests tissue @-@ specific signaling cascades and will require more investigation .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1 2-1.1.2.2.1 4-1.1.2.2 5-1.1.2.1 6-1.1.2 7-1 9-1.2 10-1.2.2.1 11-1.2.2
# ::id pmid_2465_1010.213
# ::preferred 
(a / and~e.7
      :op1 (s / suggest-01~e.1
            :ARG0 (t / this~e.0)
            :ARG1 (c / cascade~e.6
                  :subevent (s2 / signal-07~e.5)
                  :mod (s3 / specific~e.4
                        :topic (t2 / tissue~e.2))))
      :op2 (r / require-01~e.9
            :ARG0 t
            :ARG1 (i / investigate-01~e.11
                  :degree (m / more~e.10))))

# ::tok Genetic disruption of Ras binding to PI3K-α has a similar effect .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2 1-1.1 2-1.1.1.r 3-1.1.1.1.1.1 4-1.1.1 5-1.1.1.2.r 6-1.1.1.2.1.1 9-1.2 10-1
# ::id pmid_2465_1010.214
# ::preferred 
(a / affect-01~e.10
      :ARG0 (d / disrupt-01~e.1
            :ARG1~e.2 (b / bind-01~e.4
                  :ARG1 (e / enzyme
                        :name (n / name :op1 "Ras"~e.3))
                  :ARG2~e.5 (e2 / enzyme
                        :name (n2 / name :op1 "PI3K-α"~e.6)))
            :mod (g / genetic~e.0))
      :ARG1-of (r / resemble-01~e.9))

# ::tok We can therefore assume that small molecules that can block downstream signaling without triggering feedback and with the correct specificity and biochemical properties may still be effective , but more work needs to be done to develop such compounds effectively .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.1.1.1 1-1.2.1 1-1.2.1.1.2 2-1.2 3-1.2.1.1 5-1.2.1.1.2.1.1.1 6-1.2.1.1.2.1.1 8-1.2.1.1.2.1.1.2.3 9-1.2.1.1.2.1.1.2 10-1.2.1.1.2.1.1.2.1.1 11-1.2.1.1.2.1.1.2.1 12-1.2.1.1.2.1.1.2.2.1 12-1.2.1.1.2.1.1.2.2.1.r 13-1.2.1.1.2.1.1.2.2 14-1.2.1.1.2.1.1.2.2.3 15-1.2.1.1.2.1.1.3.1 18-1.2.1.1.2.1.1.3.1.1.1 19-1.2.1.1.2.1.1.3.1.1 20-1.2.1.1.2.1.1.3.1 21-1.2.1.1.2.1.1.3.1.2.1 22-1.2.1.1.2.1.1.3.1.2 23-1.2.1.1.2 24-1.2.1.1.2.1.2 25-1.2.1.1.2.1.1.r 25-1.2.1.1.2.1.r 26-1.2.1.1.2.1 28-1 29-1.1.1.1 30-1.1.1 31-1.1 34-1.1.1 36-1.1.1.2 37-1.1.1.2.1.1 38-1.1.1.2.1 39-1.1.1.2.2 39-1.1.1.2.2.r
# ::id pmid_2465_1010.215
# ::preferred 
(h / have-concession-91~e.28
      :ARG1 (n / need-01~e.31
            :ARG1 (w2 / work-01~e.30,34
                  :degree (m2 / more~e.29)
                  :purpose (d2 / develop-02~e.36
                        :ARG1 (c2 / compound~e.38
                              :mod (s5 / such~e.37))
                        :manner~e.39 (e2 / effective~e.39))))
      :ARG2 (i / infer-01~e.2
            :ARG1 (p / possible~e.1
                  :domain (a / assume-02~e.3
                        :ARG0 (w / we~e.0)
                        :ARG1 (p2 / possible~e.1,23
                              :domain~e.25 (e / effective~e.26
                                    :domain~e.25 (m / molecule~e.6
                                          :mod (s / small~e.5)
                                          :ARG0-of (b / block-01~e.9
                                                :ARG1 (s2 / signal-07~e.11
                                                      :source (d / downstream~e.10))
                                                :manner (t / trigger-01~e.13
                                                      :polarity~e.12 "-"~e.12
                                                      :ARG0 m
                                                      :ARG1 (f / feedback~e.14))
                                                :mod (p4 / possible~e.8))
                                          :ARG0-of (h2 / have-03
                                                :ARG1 (a2 / and~e.15,20
                                                      :op1 (s3 / specificity~e.19
                                                            :mod (c / correct~e.18))
                                                      :op2 (p3 / property~e.22
                                                            :mod (b2 / biochemical~e.21)
                                                            :mod c))))
                                    :mod (s4 / still~e.24)))))))

# ::tok The third direct effector arm of Ras signaling that plays a major role in human cancer is the RalGDS ( Ral guanine nucleotide dissociation stimulator ) pathway ( <ce:cross-ref id="crosref0380" refid="fig1"> Figure 1 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3 1-1.3.1 1-1.3.1.r 2-1.1.1 3-1.1 4-1 5-1.2.r 6-1.2.1.1.1 7-1.2 9-1.4 11-1.4.2 13-1.4.1.r 14-1.4.1.2 15-1.4.1.1.1 16-1.5.r 18-1.5.1.1 26-1.5 31-1.6.1 32-1.6.1.1
# ::id pmid_2465_1010.216
# ::preferred 
(a / arm~e.4
      :mod (e / effector~e.3
            :mod (d3 / direct~e.2))
      :poss~e.5 (s / signal-07~e.7
            :ARG0 (e2 / enzyme
                  :name (n2 / name :op1 "Ras"~e.6)))
      :ord (o / ordinal-entity~e.1 :value~e.1 "3"~e.1)
      :ARG0-of (p2 / play-08~e.9
            :ARG1~e.13 (d / disease
                  :name (n3 / name :op1 "cancer"~e.15)
                  :mod (h / human~e.14))
            :mod (m / major~e.11))
      :domain~e.16 (p / pathway~e.26
            :name (n / name :op1 "RalGDS"~e.18))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure~e.31 :mod "1"~e.32)))

# ::tok Perhaps the best evidence of the importance of this effector pathway comes from demonstration that mice null for RalGDS have reduced skin carcinogen @-@ induced tumor incidence , size , and progression to malignancy compared to wild @-@ type mice ( <ce:cross-ref id="crosref0385" refid="bib23"> González @-@ García et al. , 2005 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 2-1.2.3 2-1.2.3.1 2-1.2.3.1.r 3-1.2 4-1.2.2.r 6-1.2.2 7-1.2.2.1.r 8-1.2.2.1.2 9-1.2.2.1.1 10-1.2.2.1 12-1.2.1.r 13-1.2.1 14-1.2.1.1.r 15-1.2.1.1.1 16-1.2.1.1.1.1 17-1.2.1.1.1.1.1.r 18-1.2.1.1.1.1.1.1.1 19-1.2.1.1 20-1.2.1.1.2.4 21-1.2.1.1.2.1.1.2 22-1.2.1.1.2.1.1.1.1 24-1.2.1.1.2.1.1.1 25-1.2.1.1.2.1.1 26-1.2.1.1.2.1 28-1.2.1.1.2.2 30-1.2.1.1.2 31-1.2.1.1.2.3 32-1.2.1.1.2.3.2.r 33-1.2.1.1.2.3.2 34-1.2.1.1.2.4.1 35-1.2.1.1.2.4.1.1.r 36-1.2.1.1.2.4.1.1.1 38-1.2.1.1.2.4.1.1.1 39-1.2.1.1.2.4.1.1 44-1.1.1.1.1.1.1 46-1.1.1.1.1.1.1 47-1.1.1.1 48-1.1.1.1.2.1 50-1.1.1.2.1
# ::id pmid_2465_1010.217
# ::preferred 
(p / possible~e.0
      :ARG1-of (d2 / describe-01
            :ARG0 (p4 / publication-91
                  :ARG0 (a2 / and~e.47
                        :op1 (p5 / person
                              :name (n2 / name :op1 "González-García"~e.44,46))
                        :op2 (p6 / person
                              :mod (o / other~e.48)))
                  :time (d3 / date-entity :year "2005"~e.50)))
      :domain (e / evidence-01~e.3
            :ARG0~e.12 (d / demonstrate-01~e.13
                  :ARG1~e.14 (h / have-03~e.19
                        :ARG0 (m3 / mouse~e.15
                              :mod (n3 / null~e.16
                                    :mod~e.17 (g2 / gene
                                          :name (n / name :op1 "RalGDS"~e.18))))
                        :ARG1 (a / and~e.30
                              :op1 (i2 / incidence~e.26
                                    :frequency-of (t / tumor~e.25
                                          :ARG1-of (i3 / induce-01~e.24
                                                :ARG0 (c2 / carcinogen~e.22))
                                          :mod (s / skin~e.21)))
                              :op2 (s2 / size~e.28
                                    :mod t)
                              :op3 (p3 / progress-01~e.31
                                    :ARG1 t
                                    :ARG4~e.32 (m2 / malignancy~e.33))
                              :ARG1-of (r / reduce-01~e.20
                                    :ARG1-of (c3 / compare-01~e.34
                                          :ARG2~e.35 (m4 / mouse~e.39
                                                :mod (w / wild-type~e.36,38)))))))
            :ARG1~e.4 (i / importance~e.6
                  :domain~e.7 (p2 / pathway~e.10
                        :mod (e2 / effector~e.9)
                        :mod (t2 / this~e.8)))
            :manner (g / good~e.2
                  :degree~e.2 (m / most~e.2))))

# ::tok These data , and many others ( <ce:cross-refs id="crosrefs0060" refid="bib43 bib32"> Martin et al. , 2011; Kashatus , 2013 </ce:cross-refs> ) , support a role for RalGDS both in vitro and in vivo as an important effector pathway utilized by oncogenic Ras to drive tumorigenesis that could potentially be exploited for therapeutic intervention , although the absence of somatic mutations in this effector pathway makes its precise role less clear than the Raf @/@ MAPK and PI3K pathways .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 1-1.1.1 3-1.1 3-1.1.3.1 3-1.1.3.1.1.1 4-1.1.2.1 5-1.1.2 5-1.1.3.1.1.1.2.1 11-1.1.3.1.1.1.1.1.1 12-1.1.3.1 12-1.1.3.1.1.1 13-1.1.3.1.1.1.2.1 16-1.1.3.1.2.1.1.1 18-1.1.3.1.2.2.1 22-1 25-1.2.r 26-1.2.1.1.1.1 28-1.2.1.3 29-1.2.1.3 30-1.2 31-1.2.1.3 31-1.2.2.3 32-1.2.2.3 33-1.1.3.1.1.2.r 33-1.1.3.1.2.2.r 35-1.2.1.2.2 36-1.2.1.2.1 37-1.2.1.2 38-1.2.1.2.3 39-1.2.1.2.3.1.r 40-1.2.1.2.3.1 40-1.2.1.2.3.1.2 40-1.2.1.2.3.1.2.1 40-1.2.1.2.3.1.2.1.r 40-1.2.1.2.3.1.2.r 41-1.2.1.2.3.1.1.1 42-1.2.1.2.3.1 42-1.2.1.2.3.1.2 42-1.2.1.2.3.1.2.r 43-1.2.1.2.3.2 46-1.2.1.2.3.2.2.2.2 47-1.2.1.2.3.2.2.2.3 49-1.2.1.2.3.2.2.2 50-1.2.1.2.3.2.2.2.1.r 51-1.2.1.2.3.2.2.2.1.1 52-1.2.1.2.3.2.2.2.1 54-1.3 56-1.3.1.1 57-1.3.1.1.1.r 58-1.3.1.1.1.1 59-1.3.1.1.1 60-1.2.1.3 60-1.2.2.3 61-1.1.1.1 62-1.2.1.2.1 63-1.2.1.2 64-1.3.1 65-1.3.1.2.1 65-1.3.1.2.1.r 66-1.3.1.2.2 68-1.3.1.2.3.1 69-1.3.1.2.3 72-1.3.1.2.3.2.1.1.1.1 74-1.3.1.2.3.2.1.1.1.1 75-1.3.1.2.3.2.1 76-1.3.1.2.3.2.1.2.1.1 77-1.3.1.2.3.2.1.1 77-1.3.1.2.3.2.1.2
# ::id pmid_2465_1010.218
# ::preferred 
(s / support-01~e.22
      :ARG0 (a / and~e.3
            :op2 (d / data~e.1
                  :mod (t / this~e.0,61))
            :op2 (o / other~e.5
                  :quant (m / many~e.4))
            :ARG1-of (d2 / describe-01
                  :ARG0 (a2 / and~e.3,12
                        :op1 (p / publication-91
                              :ARG0 (a3 / and~e.3,12
                                    :op1 (p2 / person
                                          :name (n / name :op1 "Martin"~e.11))
                                    :op2 (p3 / person
                                          :mod (o2 / other~e.5,13)))
                              :time~e.33 (d3 / date-entity :year "2011"))
                        :op2 (p4 / publication-91
                              :ARG0 (p5 / person
                                    :name (n2 / name :op1 "Kashatus"~e.16))
                              :time~e.33 (d4 / date-entity :year "2013"~e.18)))))
      :ARG1~e.25 (a6 / and~e.30
            :op1 (p6 / play-02
                  :ARG0 (g / gene
                        :name (n3 / name :op1 "RalGDS"~e.26))
                  :ARG1 (p7 / pathway~e.37,63
                        :mod (e / effector~e.36,62)
                        :mod (i / important~e.35)
                        :ARG1-of (u / utilize-01~e.38
                              :ARG0~e.39 (e2 / enzyme~e.40,42
                                    :name (n4 / name :op1 "Ras"~e.41)
                                    :ARG0-of~e.40,42 (c / cause-01~e.40,42
                                          :ARG1~e.40 (c2 / cancer~e.40)))
                              :purpose (d5 / drive-02~e.43
                                    :ARG0 e2
                                    :ARG1 (c3 / create-01
                                          :ARG1 (t2 / tumor)
                                          :ARG1-of (e3 / exploit-01~e.49
                                                :ARG2~e.50 (i4 / intervene-01~e.52
                                                      :mod (t3 / therapy~e.51))
                                                :mod (p8 / possible~e.46)
                                                :mod (p9 / potential~e.47))))))
                  :mod (i2 / in-vitro~e.28,29,31,60))
            :op2 (p14 / play-02
                  :ARG0 g
                  :ARG1 p7
                  :mod (i3 / in-vivo~e.31,32,60)))
      :ARG1-of (h / have-concession-91~e.54
            :ARG2 (m2 / make-02~e.64
                  :ARG0 (a4 / absent-01~e.56
                        :ARG1~e.57 (m3 / mutate-01~e.59
                              :mod (s2 / somatic~e.58))
                        :ARG2 p7)
                  :ARG1 (p10 / play-02
                        :ARG0~e.65 g~e.65
                        :mod (p11 / precise~e.66)
                        :mod (c4 / clear~e.69
                              :degree (l / less~e.68)
                              :ARG1-of (c5 / compare-01
                                    :ARG2 (a5 / and~e.75
                                          :op1 (p12 / pathway~e.77
                                                :name (n5 / name :op1 "Raf/MAPK"~e.72,74))
                                          :op2 (p13 / pathway~e.77
                                                :name (n6 / name :op1 "PI3K"~e.76)))))))))

# ::tok On the other hand , Ral signaling is upstream of NF-κB and TBK1 , both of which have been implicated as essential genes downstream of K @-@ Ras ( <ce:cross-refs id="crosrefs0065" refid="bib48 bib32"> Neel et al. , 2011; Kashatus , 2013 </ce:cross-refs> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.2.1.1.1.2.1 5-1.1.1.1.1.1 6-1.1.1 7-1.1 8-1.1.2.2 10-1.1.2.1.1.1.1 11-1.1.2.1 12-1.1.2.1.2.1.1 19-1.1.2.1.3 20-1.1.2.1.3.2.r 21-1.1.2.1.3.2.1 22-1.1.2.1.3.2 23-1.1.2.1.3.1.2 25-1.1.2.1.3.1.1.1.1 27-1.1.2.1.3.1.1.1.1 33-1.2.1.1.1.1.1.1 34-1.2.1 34-1.2.1.1.1 35-1.2.1.1.1.2.1 38-1.2.1.2.1.1.1 40-1.2.1.2.2.1
# ::id pmid_2465_1010.219
# ::preferred 
(c / contrast-01
      :ARG2 (b / be-located-at-91~e.7
            :ARG1 (s / signal-07~e.6
                  :ARG0 (e / enzyme
                        :name (n / name :op1 "Ral"~e.5)))
            :ARG2 (r / relative-position
                  :op1 (a / and~e.11
                        :op1 (g / gene
                              :name (n2 / name :op1 "NF-κB"~e.10))
                        :op2 (g2 / gene
                              :name (n3 / name :op1 "TBK1"~e.12))
                        :ARG1-of (i / implicate-01~e.19
                              :location (r2 / relative-position
                                    :op1 (e2 / enzyme
                                          :name (n4 / name :op1 "K-Ras"~e.25,27))
                                    :direction (d / downstream~e.23))
                              :prep-as~e.20 (g3 / gene~e.22
                                    :mod (e3 / essential~e.21))))
                  :direction (u / upstream~e.8)))
      :ARG1-of (d2 / describe-01
            :ARG0 (a2 / and~e.34
                  :op1 (p / publication-91
                        :ARG0 (a3 / and~e.34
                              :op1 (p3 / person
                                    :name (n5 / name :op1 "Neel"~e.33))
                              :op2 (p4 / person
                                    :mod (o / other~e.2,35)))
                        :time (d3 / date-entity :year "2011"))
                  :op2 (p2 / publication-91
                        :ARG0 (p5 / person
                              :name (n6 / name :op1 "Kashatus"~e.38))
                        :time (d4 / date-entity :year "2013"~e.40)))))

# ::tok Other potential Ras effectors that could be important in cancer and therefore a source of potential therapeutic targets include phospholipase CE and Tiam1 , a GEF that stimulates the activation of Rac ( <ce:cross-ref id="crosref0390" refid="fig1"> Figure 1 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.3 1-1.2.1 2-1.2.2.1.1 3-1.2 5-1.2.4.1 7-1.2.4 8-1.2.4.2.r 9-1.2.4.2.1.1 11-1.2.4.3 13-1.2.4.3.1 14-1.2.4.3.1.2.r 15-1.2.4.3.1.2.3 16-1.2.4.3.1.2.1 17-1.2.4.3.1.2 18-1 19-1.1.1 20-1.1.1.1.1 21-1.1 22-1.1.2.1.1 25-1.1.2.2.1.1.1 27-1.1.2.2.1 27-1.1.2.2.1.2 27-1.1.2.2.1.2.r 29-1.1.2.2.1.2.1 30-1.1.2.2.1.2.1.1.r 31-1.1.2.2.1.2.1.1.1.1 36-1.3.1 37-1.3.1.1
# ::id pmid_2465_1010.220
# ::preferred 
(i / include-01~e.18
      :ARG1 (a / and~e.21
            :op1 (p4 / phospholipase~e.19
                  :name (n3 / name :op1 "CE"~e.20))
            :op2 (p7 / protein
                  :name (n4 / name :op1 "Tiam1"~e.22)
                  :ARG1-of (m / mean-01
                        :ARG2 (p5 / protein~e.27
                              :name (n5 / name :op1 "GEF"~e.25)
                              :ARG0-of~e.27 (s2 / stimulate-01~e.27
                                    :ARG1 (a2 / activate-01~e.29
                                          :ARG1~e.30 (p6 / protein
                                                :name (n6 / name :op1 "Rac"~e.31))))))))
      :ARG2 (e / effector~e.3
            :mod (p / potential~e.1)
            :mod (e2 / enzyme
                  :name (n / name :op1 "Ras"~e.2))
            :mod (o / other~e.0)
            :mod (i2 / important~e.7
                  :mod (p2 / possible~e.5)
                  :topic~e.8 (d / disease
                        :name (n2 / name :op1 "cancer"~e.9))
                  :ARG0-of (c / cause-01~e.11
                        :ARG1 (s / source-02~e.13
                              :ARG0 e
                              :ARG1~e.14 (t / target-01~e.17
                                    :ARG0 (t2 / therapy~e.16)
                                    :ARG1 e
                                    :mod (p3 / potential~e.15))))))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure~e.36 :mod "1"~e.37)))

# ::tok Rac1 is necessary for K @-@ Ras tumor initiation , further implicating the importance of this pathway in K @-@ Ras tumorigenesis , though not yet providing obvious therapeutic targets ( <ce:cross-ref id="crosref0395" refid="bib24"> Gysin et al. , 2011 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.1.1 1-1.3.1.1.r 2-1 3-1.1.r 4-1.1.1.1.1 6-1.1.1.1.1 7-1.1.2 7-1.3.1.2.2 8-1.1 10-1.3.3 11-1.3 13-1.3.1 16-1.3.1.1 18-1.1.1.1.1 20-1.1.1.1.1 23-1.3.2 24-1.3.2.1.1 24-1.3.2.1.1.r 25-1.3.2.1.4 26-1.3.2.1 27-1.3.2.1.3.2 28-1.3.2.1.3.1 29-1.3.2.1.3 34-1.4.1.1.1.1.1 35-1.4.1.1 36-1.4.1.1.2.1 38-1.4.1.2.1
# ::id pmid_2465_1010.221
# ::preferred 
(n / need-01~e.2
      :ARG0~e.3 (i / initiate-01~e.8
            :ARG0 (e / enzyme
                  :name (n3 / name :op1 "K-Ras"~e.4,6,18,20))
            :ARG1 (t / tumor~e.7))
      :ARG1 (p / pathway
            :name (n2 / name :op1 "Rac1"~e.0))
      :ARG0-of (i2 / implicate-01~e.11
            :ARG1 (i3 / important~e.13
                  :domain~e.1 p~e.16
                  :topic (c / create-01
                        :ARG0 e
                        :ARG1 (t2 / tumor~e.7)))
            :ARG1-of (h / have-concession-91~e.23
                  :ARG2 (p2 / provide-01~e.26
                        :polarity~e.24 "-"~e.24
                        :ARG0 p
                        :ARG1 (t3 / target-01~e.29
                              :ARG0 (t4 / therapy~e.28)
                              :mod (o / obvious~e.27))
                        :time (y / yet~e.25)))
            :mod (f / further~e.10))
      :ARG1-of (d / describe-01
            :ARG0 (p3 / publication-91
                  :ARG0 (a / and~e.35
                        :op1 (p4 / person
                              :name (n4 / name :op1 "Gysin"~e.34))
                        :op2 (p5 / person
                              :mod (o2 / other~e.36)))
                  :time (d2 / date-entity :year "2011"~e.38))))

# ::tok Likewise , cyclin D1 , NF-κB , and Myc are necessary for Ras tumorigenesis ; further analysis of the role of these pathways may lead to new therapeutic insights .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.3 2-1.1.2.1.1.1 3-1.1.2.1.1.2 5-1.1.2.2.1.1 7-1.1.2 8-1.1.2.3.1.1 12-1.1.1.1.1.1 15-1.2.1.1.2 16-1.2.1.1 17-1.2.1.1.1.r 19-1.2.1.1.1 20-1.2.1.1.1.1.r 21-1.2.1.1.1.1.1 22-1.2.1.1.1.1 23-1.2 24-1.2.1 25-1.2.1.2.r 26-1.2.1.2.2 27-1.2.1.2.1 28-1.2.1.2
# ::id pmid_2465_1010.222
# ::preferred 
(m / multi-sentence
      :snt1 (r / require-01
            :ARG0 (c / create-01
                  :ARG0 (e / enzyme
                        :name (n2 / name :op1 "Ras"~e.12))
                  :ARG1 (t / tumor))
            :ARG1 (a / and~e.7
                  :op1 (p / protein
                        :name (n / name :op1 "cyclin"~e.2 :op2 "D1"~e.3))
                  :op2 (p2 / protein
                        :name (n3 / name :op1 "NF-κB"~e.5))
                  :op3 (p3 / protein
                        :name (n4 / name :op1 "Myc"~e.8)))
            :mod (l2 / likewise~e.0))
      :snt2 (p4 / possible~e.23
            :domain (l / lead-03~e.24
                  :ARG0 (a2 / analyze-01~e.16
                        :ARG1~e.17 (r2 / role~e.19
                              :topic~e.20 (p5 / pathway~e.22
                                    :mod (t2 / this~e.21)))
                        :degree (f / further~e.15))
                  :ARG2~e.25 (i / insight~e.28
                        :mod (t3 / therapy~e.27)
                        :mod (n5 / new~e.26)))))

# ::tok For example , <ce:cross-ref id="crosref0400" refid="bib53"> Puyol et al. ( 2010 ) </ce:cross-ref> recently demonstrated that germline or conditional deletion of <i> Cdk4 </i> led to senescence in lung cells expressing activated K @-@ Ras .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3 1-1.3 6-1.1.1.1.1.1 7-1.1.1 8-1.1.1.2.1 10-1.1.2.1 13-1.4 14-1 15-1.2.r 16-1.2.1.1.1.1.1 17-1.2.1 18-1.2.1.2.2 19-1.2.1.1 19-1.2.1.2 22-1.2.1.1.2.1.1 24-1.2 25-1.2.2.r 26-1.2.2 27-1.2.3.r 28-1.2.3.2 29-1.2.3 30-1.2.3.1 31-1.2.3.1.1.2 32-1.2.3.1.1.1.1 34-1.2.3.1.1.1.1
# ::id pmid_2465_1010.223
# ::preferred 
(d2 / demonstrate-01~e.14
      :ARG0 (p / publication-91
            :ARG0 (a / and~e.7
                  :op1 (p2 / person
                        :name (n2 / name :op1 "Puyol"~e.6))
                  :op2 (p3 / person
                        :mod (o / other~e.8)))
            :time (d / date-entity :year "2010"~e.10))
      :ARG1~e.15 (l / lead-03~e.24
            :ARG0 (o2 / or~e.17
                  :op1 (d3 / delete-01~e.19
                        :ARG0 (c / cell-line
                              :name (n3 / name :op1 "germline"~e.16))
                        :ARG1 (e3 / enzyme
                              :name (n4 / name :op1 "Cdk4"~e.22)))
                  :op2 (d4 / delete-01~e.19
                        :ARG1 e3
                        :mod (c2 / conditional~e.18)))
            :ARG2~e.25 (s / senescence~e.26)
            :location~e.27 (c3 / cell~e.29
                  :ARG3-of (e4 / express-03~e.30
                        :ARG2 (e2 / enzyme
                              :name (n / name :op1 "K-Ras"~e.32,34)
                              :ARG1-of (a2 / activate-01~e.31)))
                  :mod (l2 / lung~e.28)))
      :ARG0-of (e / exemplify-01~e.0,1)
      :time (r / recent~e.13))

# ::tok Furthermore , treatment with a Cdk4 inhibitor reduced the growth of K @-@ Ras @-@ driven tumors .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1.1 3-1.1.1.1.r 5-1.1.1.1.1.1.1.1 6-1.1.1.1 6-1.1.1.1.1 6-1.1.1.1.1.r 7-1.1 9-1.1.2 10-1.1.2.1.r 11-1.1.2.1.1.1.1.1 13-1.1.2.1.1.1.1.1 15-1.1.2.1.1 16-1.1.2.1
# ::id pmid_2465_1010.224
# ::preferred 
(a / and
      :op2 (r / reduce-01~e.7
            :ARG0 (t2 / treat-04~e.2
                  :ARG2~e.3 (m / molecular-physical-entity~e.6
                        :ARG0-of~e.6 (i / inhibit-01~e.6
                              :ARG1 (p / protein
                                    :name (n / name :op1 "Cdk4"~e.5)))))
            :ARG1 (g / grow-01~e.9
                  :ARG1~e.10 (t3 / tumor~e.16
                        :ARG1-of (d / drive-02~e.15
                              :ARG0 (e / enzyme
                                    :name (n2 / name :op1 "K-Ras"~e.11,13)))))))

# ::tok Finally , unbiased shRNA screens have revealed potential targets for K @-@ Ras cancers .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3 2-1.1.2 2-1.1.2.1 2-1.1.2.1.r 3-1.1.1.1.1 4-1.1 6-1 7-1.2.2 8-1.2 9-1.2.1.r 10-1.2.1.2.1.1 12-1.2.1.2.1.1 13-1.2.1.1.1
# ::id pmid_2465_1010.225
# ::preferred 
(r / reveal-01~e.6
      :ARG0 (s / screen-01~e.4
            :ARG1 (r2 / rna
                  :name (n2 / name :op1 "shRNA"~e.3))
            :ARG1-of (b / bias-01~e.2 :polarity~e.2 "-"~e.2))
      :ARG1 (t / target-01~e.8
            :ARG1~e.9 (d / disease
                  :name (n3 / name :op1 "cancer"~e.13)
                  :mod (e / enzyme
                        :name (n / name :op1 "K-Ras"~e.10,12)))
            :mod (p / potential~e.7))
      :time (f / final~e.0))

# ::tok These include STK33 , TBK1 , and GATA @-@ 2 .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2 1-1 2-1.1.1.1.1 4-1.1.2.1.1 6-1.1 7-1.1.3.1.1 9-1.1.3.1.1
# ::id pmid_2465_1010.226
# ::preferred 
(i / include-01~e.1
      :ARG1 (a / and~e.6
            :op1 (p / protein
                  :name (n / name :op1 "STK33"~e.2))
            :op2 (p2 / protein
                  :name (n2 / name :op1 "TBK1"~e.4))
            :op3 (p3 / protein
                  :name (n3 / name :op1 "GATA-2"~e.7,9)))
      :ARG2 (t / this~e.0))

# ::tok So far , STK33 inhibition does not appear to be a useful approach to K @-@ Ras cancers ( <ce:cross-ref id="crosref0405" refid="bib78"> Weiwer et al. , 2012 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.3 1-1.3 3-1.2.1.1.1.1 4-1.2.1 6-1.1 6-1.1.r 7-1 11-1.2.3 12-1.2 13-1.2.2.r 14-1.2.2.2.1.1 16-1.2.2.2.1.1 17-1.2.2.1.1 22-1.4.1.1.1.1.1 23-1.4.1.1 24-1.4.1.1.2.1 26-1.4.1.2.1
# ::id pmid_2465_1010.227
# ::preferred 
(a / appear-02~e.7
      :polarity~e.6 "-"~e.6
      :ARG1 (a2 / approach-02~e.12
            :ARG0 (i / inhibit-01~e.4
                  :ARG1 (p / protein
                        :name (n3 / name :op1 "STK33"~e.3)))
            :ARG1~e.13 (d2 / disease
                  :name (n2 / name :op1 "cancer"~e.17)
                  :mod (e / enzyme
                        :name (n / name :op1 "K-Ras"~e.14,16)))
            :mod (u / useful~e.11))
      :time (s / so-far~e.0,1)
      :ARG1-of (d3 / describe-01
            :ARG0 (p2 / publication-91
                  :ARG0 (a3 / and~e.23
                        :op1 (p3 / person
                              :name (n4 / name :op1 "Weiwer"~e.22))
                        :op2 (p4 / person
                              :mod (o / other~e.24)))
                  :time (d / date-entity :year "2012"~e.26))))

# ::tok TBK1 inhibitors are still being investigated : this target is of particular interest because it is part of the well @-@ validated RalGDS pathway .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1.1.1.1 1-1.1.1 1-1.1.1.1 1-1.1.1.1.r 3-1.1.2 5-1.1 7-1.2.1.2 8-1.2.1 8-1.2.1.1 8-1.2.1.1.r 11-1.2.2 12-1.2 13-1.2.3 14-1.2.3.1.1 19-1.2.3.1.2.2.1 21-1.2.3.1.2.2 22-1.2.3.1.2.1.1 23-1.2.3.1.2
# ::id pmid_2465_1010.228
# ::preferred 
(m / multi-sentence
      :snt1 (i2 / investigate-01~e.5
            :ARG1 (m2 / molecular-physical-entity~e.1
                  :ARG0-of~e.1 (i / inhibit-01~e.1
                        :ARG1 (p / protein
                              :name (n / name :op1 "TBK1"~e.0))))
            :mod (s / still~e.3))
      :snt2 (i3 / interest-01~e.12
            :ARG2 (t / thing~e.8
                  :ARG1-of~e.8 (t2 / target-01~e.8)
                  :mod (t3 / this~e.7))
            :mod (p2 / particular~e.11)
            :ARG1-of (c / cause-01~e.13
                  :ARG0 (i4 / include-91
                        :ARG1 t~e.14
                        :ARG2 (p3 / pathway~e.23
                              :name (n2 / name :op1 "RalGDS"~e.22)
                              :ARG1-of (v / validate-01~e.21
                                    :manner (w / well~e.19)))))))

# ::tok GATA2 is also of considerable interest ; genetic ablation leads to tumor regression in mouse models of adenocarcinoma of the lung , and whereas this transcription factor may appear to be the least druggable of targets , its role in regulating the proteasome suggested therapeutic approaches that appear very promising ( <ce:cross-ref id="crosref0410" refid="bib33"> Kumar et al. , 2012 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1.1 2-1.1.2 4-1.1.3 5-1.1 7-1.2.1.1.1 8-1.2.1.1 9-1.2.1 11-1.2.1.2.1 14-1.2.1.2.2.2 15-1.2.1.2.2 16-1.2.1.2.2.1.r 17-1.2.1.2.2.1.1.1 20-1.2.1.2.2.1.2 22-1.2 24-1.2.2.2.1.1.1.1.2 25-1.2.2.2.1.1.1.1.1 26-1.2.2.2.1.1.1.1 27-1.2.2.2 27-1.2.2.2.1.1 28-1.2.2.2.1 30-1.2.2.2.1.1.1.r 30-1.2.2.2.1.r 32-1.2.2.2.1.1.1.2 35-1.2.2.2.1.1.1.3 35-1.2.2.2.1.1.1.3.1 35-1.2.2.2.1.1.1.3.1.r 37-1.2.2.1.1.1 37-1.2.2.1.1.1.r 38-1.2.2.1.1 39-1.2.2.1.1.2.r 40-1.2.2.1.1.2 42-1.2.2.1.1.2.2.1.1 43-1.2.2.1 44-1.2.2.1.2.1 45-1.2.2.1.2 47-1.2.2.1.2.2.2 48-1.2.2.1.2.2.1 49-1.2.2.1.2.2 54-1.2.2.3.1.1.1.1.1 55-1.2.2.3.1.1 56-1.2.2.3.1.1.2.1 58-1.2.2.3.1.2.1
# ::id pmid_2465_1010.229
# ::preferred 
(m / multi-sentence
      :snt1 (i / interest-01~e.5
            :ARG2 (p / protein
                  :name (n / name :op1 "GATA2"~e.0))
            :mod (a / also~e.2)
            :degree (c / considerable~e.4))
      :snt2 (a2 / and~e.22
            :op1 (l / lead-03~e.9
                  :ARG0 (a3 / ablate-00~e.8
                        :mod (g / genetic~e.7))
                  :ARG2 (r / regress-01
                        :ARG1 (t / tumor~e.11)
                        :location (m2 / model~e.15
                              :mod~e.16 (d3 / disease
                                    :name (n2 / name :op1 "adenocarcinoma"~e.17)
                                    :mod (l2 / lung~e.20))
                              :mod (m3 / mouse~e.14))))
            :op2 (h / have-concession-91
                  :ARG1 (s / suggest-01~e.43
                        :ARG0 (r2 / role~e.38
                              :poss~e.37 f~e.37
                              :topic~e.39 (r3 / regulate-01~e.40
                                    :ARG0 (f / factor~e.26
                                          :ARG0-of (t2 / transcribe-01~e.25)
                                          :mod (t3 / this~e.24))
                                    :ARG1 (m4 / macro-molecular-complex
                                          :name (n3 / name :op1 "proteasome"~e.42))))
                        :ARG1 (a5 / approach-02~e.45
                              :ARG2 (t6 / therapy~e.44)
                              :ARG0-of (p4 / promise-01~e.49
                                    :degree (v / very~e.48)
                                    :ARG1-of (a6 / appear-02~e.47))))
                  :ARG2 (p2 / possible~e.27
                        :domain~e.30 (a4 / appear-02~e.28
                              :ARG1 (p3 / possible~e.27
                                    :domain~e.30 (d4 / drug-01
                                          :ARG2 f
                                          :degree (l3 / least~e.32)
                                          :compared-to (t4 / thing~e.35
                                                :ARG0-of~e.35 (t5 / target-01~e.35))))))
                  :ARG1-of (d5 / describe-01
                        :ARG0 (p5 / publication-91
                              :ARG0 (a7 / and~e.55
                                    :op1 (p6 / person
                                          :name (n4 / name :op1 "Kumar"~e.54))
                                    :op2 (p7 / person
                                          :mod (o / other~e.56)))
                              :time (d / date-entity :year "2012"~e.58))))))

# ::tok Future Prospects
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1
# ::id pmid_2465_1010.230
# ::preferred 
(p / prospect-01~e.1
      :time (f / future~e.0))

# ::tok In this Review , we have summarized some of the challenges of targeting Ras cancers .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.3.1 2-1.3 4-1.1 6-1 7-1.2.1.2 10-1.2.1.1 10-1.2.1.1.1 10-1.2.1.1.1.r 11-1.2.1.1.1.1.r 12-1.2.1.1.1.1 13-1.2.1.1.1.1.1.2.1.1 14-1.2.1.1.1.1.1.1.1
# ::id pmid_2465_1010.231
# ::preferred 
(s / summarize-01~e.6
      :ARG0 (w / we~e.4)
      :ARG1 (t / thing
            :ARG1-of (i / include-91
                  :ARG2 (t2 / thing~e.10
                        :ARG0-of~e.10 (c / challenge-01~e.10
                              :ARG1~e.11 (t3 / target-01~e.12
                                    :ARG1 (d / disease
                                          :name (n2 / name :op1 "cancer"~e.14)
                                          :mod (e / enzyme
                                                :name (n / name :op1 "Ras"~e.13))))))
                  :ARG3 (s2 / some~e.7)))
      :medium (r / review-01~e.2
            :mod (t4 / this~e.1)))

# ::tok Despite the tremendous progress that has been made , we still have to learn a great deal about these cancers before we can be confident that we can treat them effectively .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 2-1.2.1 3-1.2 7-1.2 9-1.1.1.1 10-1.1.1.5 13-1.1.1 15-1.1.1.3.1 16-1.1.1.3 17-1.1.1.2.r 18-1.1.1.2.1 19-1.1.1.2 20-1.1.1.4 21-1.1.1.1 22-1.1.1.4.1 23-1.1.1.4.1.1.r 24-1.1.1.4.1.1 25-1.1.1.4.1.1.1.r 26-1.1.1.4.1.1.1 27-1.1.1.4.1.1.2 28-1.1.1.4.1.1.2.1 30-1.1.1.4.1.1.2.1.3 30-1.1.1.4.1.1.2.1.3.r
# ::id pmid_2465_1010.232
# ::preferred 
(h / have-concession-91~e.0
      :ARG1 (o / obligate-01
            :ARG2 (l / learn-01~e.13
                  :ARG0 (w / we~e.9,21)
                  :ARG1~e.17 (c / cancer~e.19
                        :mod (t / this~e.18))
                  :quant (d / deal~e.16
                        :mod (g / great~e.15))
                  :time (b / before~e.20
                        :op1 (p / possible~e.22
                              :domain~e.23 (c2 / confident-01~e.24
                                    :ARG1~e.25 w~e.26
                                    :ARG2 (p2 / possible~e.27
                                          :domain (t2 / treat-04~e.28
                                                :ARG0 w
                                                :ARG1 c
                                                :manner~e.30 (e / effective~e.30))))))
                  :mod (s / still~e.10)))
      :ARG2 (p3 / progress-01~e.3,7
            :degree (t3 / tremendous~e.2)))

# ::tok Recent experience in targeting Raf and MEK has underscored how a pathway that appeared simple and linear is extremely complex and poorly understood at the level of detail required to shut it down effectively .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2 1-1.1 3-1.1.1 4-1.1.1.1.1.1.1 5-1.1.1.1 6-1.1.1.1.2.1.1 7-1.1 8-1 9-1.2.2.2.1.1.1.2.r 11-1.2.1.2 13-1.2.1.2.3 14-1.2.1.2.1 16-1.2.1.2.2 17-1.2.1.2.r 18-1.2.1.1 19-1.2.1 20-1.2 21-1.2.2.3 22-1.2.2 25-1.2.2.2 27-1.2.2.2.1 28-1.2.2.2.1.1 30-1.2.2.2.1.1.1 32-1.2.2.2.1.1.1 33-1.2.2.2.1.1.1.2
# ::id pmid_2465_1010.233
# ::preferred 
(u / underscore-01~e.8
      :ARG0 (e3 / experience-01~e.1,7
            :ARG1 (t / target-01~e.3
                  :ARG1 (a / and~e.5
                        :op1 (e / enzyme
                              :name (n / name :op1 "Raf"~e.4))
                        :op2 (e2 / enzyme
                              :name (n2 / name :op1 "MEK"~e.6))))
            :time (r / recent~e.0))
      :ARG1 (a2 / and~e.20
            :op1 (c / complex~e.19
                  :degree (e4 / extreme~e.18)
                  :domain~e.17 (p / pathway~e.11
                        :mod (s / simple~e.14)
                        :mod (l / linear~e.16)
                        :ARG1-of (a3 / appear-02~e.13)))
            :op2 (u2 / understand-01~e.22
                  :ARG1 p
                  :ARG2 (l2 / level~e.25
                        :mod (d / detail-01~e.27
                              :ARG1-of (r2 / require-01~e.28
                                    :ARG0 (s2 / shut-down-05~e.30,32
                                          :ARG1 p
                                          :manner~e.9 (e5 / effective~e.33)))))
                  :degree (p2 / poor~e.21))))

# ::tok Nobody expected that Raf inhibitors would activate Raf kinase in Ras @-@ transformed cells , for example , or that inhibition of downstream kinases like MEK would lead to activation of upstream signaling .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 0-1.1.r 0-1.2 1-1 2-1.3.r 3-1.3.1.1.1.1.1.1 4-1.3.1.1 4-1.3.1.1.1 4-1.3.1.1.1.r 6-1.3.1.1.2 7-1.3.1.1.2.1.1.1 8-1.3.1.1.2.1 9-1.3.1.1.2.2.r 10-1.3.1.1.2.2.1.1.1.1 12-1.3.1.1.2.2.1 13-1.3.1.1.2.2 15-1.3.2.1.1.2 16-1.3.2.1.1.2 18-1.3 20-1.3.1.1 20-1.3.1.1.1 20-1.3.1.1.1.r 20-1.3.2.1 22-1.3.2.1.1.1 23-1.3.2.1.1 24-1.3.1.2 24-1.3.2.1.1.2 25-1.3.2.1.1.2.1.1.1 27-1.3.2 29-1.3.1 29-1.3.2.2 30-1.3.2.2.1.r 31-1.3.2.2.1.1 32-1.3.2.2.1
# ::id pmid_2465_1010.234
# ::preferred 
(e4 / expect-01~e.1
      :polarity~e.0 "-"~e.0
      :ARG0 (a / anybody~e.0)
      :ARG1~e.2 (o / or~e.18
            :op1 (a2 / activate-01~e.29
                  :ARG0 (m / molecular-physical-entity~e.4,20
                        :ARG0-of~e.4,20 (i / inhibit-01~e.4,20
                              :ARG1 (e / enzyme
                                    :name (n / name :op1 "Raf"~e.3)))
                        :ARG0-of (a3 / activate-01~e.6
                              :ARG1 (k / kinase~e.8
                                    :name (n3 / name :op1 "Raf"~e.7))
                              :location~e.9 (c / cell~e.13
                                    :ARG1-of (t2 / transform-01~e.12
                                          :ARG0 (e6 / enzyme
                                                :name (n4 / name :op1 "Ras"~e.10))))))
                  :ARG0-of (e2 / exemplify-01~e.24))
            :op2 (l / lead-03~e.27
                  :ARG0 (i2 / inhibit-01~e.20
                        :ARG1 (k2 / kinase~e.23
                              :mod (d / downstream~e.22)
                              :ARG1-of (e5 / exemplify-01~e.15,16,24
                                    :ARG0 (e3 / enzyme
                                          :name (n2 / name :op1 "MEK"~e.25)))))
                  :ARG2 (a4 / activate-01~e.29
                        :ARG1~e.30 (s / signal-07~e.32
                              :direction (u / upstream~e.31))))))

# ::tok We need a much deeper analysis of the molecular mechanisms underlying Ras regulation and effector engagement before we can expect to interfere with these mechanisms effectively .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1 3-1.2.2.1.1 4-1.2.2 4-1.2.2.1 4-1.2.2.1.r 5-1.2 6-1.2.1.r 8-1.2.1.1 9-1.2.1 10-1.2.1.2 11-1.2.1.2.1.1.1.1.1 12-1.2.1.2.1.1 13-1.2.1.2.1 14-1.2.1.2.1.2.1 15-1.2.1.2.1.2 16-1.2.3 17-1.1 18-1.2.3.1 19-1.2.3.1.1 21-1.2.3.1.1.2 24-1.2.3.1.1.2.2 25-1.2.3.1.1.2.3 25-1.2.3.1.1.2.3.r
# ::id pmid_2465_1010.235
# ::preferred 
(n3 / need-01~e.1
      :ARG0 (w / we~e.0,17)
      :ARG1 (a / analyze-01~e.5
            :ARG1~e.6 (m / mechanism~e.9
                  :mod (m2 / molecule~e.8)
                  :ARG0-of (u / underlie-01~e.10
                        :ARG1 (a2 / and~e.13
                              :op1 (r / regulate-01~e.12
                                    :ARG1 (e / enzyme
                                          :name (n2 / name :op1 "Ras"~e.11)))
                              :op2 (e2 / engage-01~e.15
                                    :ARG1 (e3 / effector~e.14)))))
            :mod (d / deep~e.4
                  :degree~e.4 (m3 / more~e.4
                        :mod (m4 / much~e.3)))
            :time (b / before~e.16
                  :op1 (p / possible~e.18
                        :domain (e4 / expect-01~e.19
                              :ARG0 w
                              :ARG1 (i / interfere-01~e.21
                                    :ARG0 w
                                    :ARG1 m~e.24
                                    :manner~e.25 (e5 / effective~e.25)))))))

# ::tok It seems to us more likely that these deeper insights will lead to productive approaches for intervention than to the conclusion that Ras is indeed undruggable .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1 2-1.2.r 3-1.2 4-1.1.1.1.1 4-1.3.1 5-1.3 6-1.1.r 7-1.1.1.2 8-1.1.1.1 8-1.1.1.1.1 8-1.1.1.1.1.r 9-1.1.1 11-1.1 14-1.1.2 15-1.1.2.2.r 16-1.1.2.2 20-1.1.2.3.1 22-1.1.2.3.1.1.2.1.1.1 23-1.1.2.3.1.1.2.r 24-1.1.2.3.1.1.3
# ::id pmid_2465_1010.236
# ::preferred 
(s / seem-01~e.1
      :ARG1~e.6 (l / lead-03~e.11
            :ARG0 (i / insight~e.9
                  :mod (d / deep~e.8
                        :degree~e.8 (m / more~e.4,8))
                  :mod (t / this~e.7))
            :ARG1 (a / approach-02~e.14
                  :ARG0-of (p / produce-01)
                  :purpose~e.15 (i2 / intervene-01~e.16)
                  :ARG1-of (i3 / instead-of-91
                        :ARG2 (c2 / conclude-01~e.20
                              :ARG1 (p2 / possible
                                    :polarity "-"
                                    :domain~e.23 (d2 / drug-01
                                          :ARG1 (e / enzyme
                                                :name (n2 / name :op1 "Ras"~e.22)))
                                    :mod (i4 / indeed~e.24))))))
      :ARG2~e.2 (w / we~e.3)
      :mod (l2 / likely~e.5
            :degree (m2 / more~e.4)))

# ::tok New technologies and insights and fresh eyes are likely to solve this problem .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 1-1.1.1 2-1.1 3-1.1.2 4-1.1 5-1.1.3.1 6-1.1.3 8-1.3 10-1 11-1.2.1 12-1.2
# ::id pmid_2465_1010.237
# ::preferred 
(s / solve-01~e.10
      :ARG0 (a / and~e.2,4
            :op1 (t2 / technology~e.1
                  :mod (n / new~e.0))
            :op2 (i / insight~e.3
                  :mod n)
            :op3 (e / eye~e.6
                  :mod (f / fresh~e.5)))
      :ARG1 (p / problem~e.12
            :mod (t / this~e.11))
      :mod (l / likely~e.8))

# ::tok We are also optimistic that completely different approaches to treating cancer will contribute to eliminating Ras cancers , including new ways of knocking down @/@ out genes using RNAi and CRISPR technologies and delivering these payloads to tumors ( <ce:cross-ref id="crosref0415" refid="bib14"> Davis et al. , 2010 </ce:cross-ref> ) , as well as new ways of deploying the immune system .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1.1.r 2-1.2 3-1 5-1.3.1.2.1 6-1.3.1.2 7-1.3.1 8-1.3.1.1.r 9-1.3.1.1 10-1.3.1.1.1.2.1 12-1.3 13-1.3.2.r 14-1.3.2 15-1.3.2.1.3.1.1 16-1.3.2.1.2.1 18-1.3.1.3 19-1.3.1.3.1.1.1 20-1.3.1.3.1.1 21-1.3.1.3.1.1.2.r 22-1.3.1.3.1.1.2.1.1 23-1.3.1.3.1.1.2.1.1 25-1.3.1.3.1.1.2.1.2 26-1.3.1.3.1.1.2.1.1.1 27-1.3.1.3.1.1.2.1.1.2 28-1.3.1.3.1.1.2.1.1.2.1.1.1.1.1 29-1.3.1.3.1.1.2.1.1.2.1 30-1.3.1.3.1.1.2.1.1.2.1.2.1.1.1 31-1.3.1.3.1.1.2.1.1.2.1.1 31-1.3.1.3.1.1.2.1.1.2.1.2 32-1.3.1.3.1.1.2 32-1.3.1.3.1.1.2.1.1.2.1 33-1.3.1.3.1.1.2.2 34-1.3.1.3.1.1.2.2.1.1 35-1.3.1.3.1.1.2.2.1 36-1.3.1.3.1.1.2.2.2.r 37-1.3.1.3.1.1.2.2.2 42-1.3.1.3.1.1.3.1.1.1.1.1 43-1.3.1.3.1.1.3.1.1 44-1.3.1.3.1.1.3.1.1.2.1 46-1.3.1.3.1.1.3.1.2.1 50-1.3.1.3.1.1.3.1.2.r 52-1.3.1.3.1.1.3.1.2.r 53-1.3.1.3.1.1.1 54-1.3.1.3.1.2 55-1.3.1.3.1.2.2.r 56-1.3.1.3.1.2.2 58-1.3.1.3.1.2.2.1.1 59-1.3.1.3.1.2.2.1
# ::id pmid_2465_1010.238
# ::preferred 
(o / optimistic~e.3
      :domain~e.1 (w / we~e.0)
      :mod (a / also~e.2)
      :topic (c / contribute-01~e.12
            :ARG0 (a2 / approach-02~e.7
                  :ARG1~e.8 (t / treat-04~e.9
                        :ARG1 (d2 / disease
                              :wiki "Cancer"
                              :name (n / name :op1 "cancer"~e.10)))
                  :ARG1-of (d3 / differ-02~e.6
                        :degree (c2 / complete~e.5))
                  :ARG2-of (i / include-01~e.18
                        :ARG1 (a3 / and
                              :op1 (w2 / way~e.20
                                    :mod (n4 / new~e.19,53)
                                    :manner-of~e.21 (a5 / and~e.32
                                          :op1 (s / slash
                                                :op1 (k / knock-02~e.22,23
                                                      :ARG1 (g / gene~e.26)
                                                      :ARG5 (u / use-01~e.27
                                                            :ARG1 (a4 / and~e.29,32
                                                                  :op1 (t2 / technology~e.31
                                                                        :mod (m / molecular-physical-entity
                                                                              :name (n5 / name :op1 "RNAi"~e.28)))
                                                                  :op2 (t3 / technology~e.31
                                                                        :mod (m2 / molecular-physical-entity
                                                                              :name (n6 / name :op1 "CRISPR"~e.30))))))
                                                :op2 (k2 / knock-03~e.25
                                                      :ARG1 g
                                                      :ARG2 u))
                                          :op2 (d5 / deliver-01~e.33
                                                :ARG1 (p / payload~e.35
                                                      :mod (t4 / this~e.34))
                                                :ARG2~e.36 (t5 / tumor~e.37)))
                                    :ARG1-of (d6 / describe-01
                                          :ARG0 (p2 / publication-91
                                                :ARG0 (a6 / and~e.43
                                                      :op1 (p3 / person
                                                            :name (n7 / name :op1 "Davis"~e.42))
                                                      :op2 (p4 / person
                                                            :mod (o2 / other~e.44)))
                                                :time~e.50,52 (d / date-entity :year "2010"~e.46))))
                              :op2 (w3 / way~e.54
                                    :mod n4
                                    :manner-of~e.55 (d7 / deploy-01~e.56
                                          :ARG1 (s2 / system~e.59
                                                :mod (i2 / immune~e.58)))))))
            :ARG2~e.13 (e2 / eliminate-01~e.14
                  :ARG1 (d4 / disease
                        :wiki "Cancer"
                        :name (n3 / name :op1 "cancer"~e.16)
                        :mod (e / enzyme
                              :name (n2 / name :op1 "Ras"~e.15))))))

# ::tok In this respect , it is noteworthy that anti @-@ CTLA @-@ 4 therapy appears to be equally effective in treating melanoma driven by N @-@ Ras or B @-@ Raf ; therefore , Ras cancers may not be excluded from these approaches as they have been from others .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2 1-1.1.2 2-1.1.2 5-1.1.1.1.1.1.r 8-1.1.1.1.1.1.1.1.1 10-1.1.1.1.1.1.1.1.1 12-1.1.1.1.1.1.1.1.1 13-1.1.1.1.1.1 14-1.1.1.1 16-1.1.1.1.1.1.r 17-1.1.1.1.1.2 18-1.1.1.1.1 19-1.1.1.1.1.3.r 19-1.1.2 20-1.1.1.1.1.3 21-1.1.1.1.1.3.1.1.1 22-1.1.1.1.1.3.1 22-1.1.1.1.1.3.1.2 22-1.1.1.1.1.3.1.2.r 23-1.1.1.1.1.3.1.2.1.r 24-1.1.1.1.1.3.1.2.1.1.1.1 26-1.1.1.1.1.3.1.2.1.1.1.1 27-1.1.1.1.1.3.1.2.1 28-1.1.1.1.1.3.1.2.1.2.1.1 30-1.1.1.1.1.3.1.2.1.2.1.1 32-1.2 34-1.2.1.2.1.2.1.1 35-1.2.1.2.1.1.1 36-1.2.1 37-1.2.1.1 37-1.2.1.1.r 38-1.2.1.2.r 39-1.2.1.2 39-1.2.1.2.3.1 41-1.2.1.2.2.1 42-1.2.1.2.2 42-1.2.1.2.3.1.2 43-1.2.1.2.3.1.1.r 44-1.2.1.2.3.1.1 46-1.2.1.2.r 47-1.2.1.2.3.1.2.1.r 48-1.2.1.2.3.1.2.1
# ::id pmid_2465_1010.239
# ::preferred 
(m / multi-sentence
      :snt1 (r / recommend-01
            :ARG1 (n4 / note-01
                  :ARG1 (a / appear-02~e.14
                        :ARG1 (e4 / effective~e.18
                              :domain~e.5,16 (t / therapy~e.13
                                    :mod (a2 / antibody
                                          :name (n5 / name :op1 "anti-CTLA-4"~e.8,10,12)))
                              :degree (e5 / equal~e.17)
                              :topic~e.19 (t2 / treat-04~e.20
                                    :ARG1 (d2 / disease~e.22
                                          :name (n6 / name :op1 "melanoma"~e.21)
                                          :ARG1-of~e.22 (d3 / drive-01~e.22
                                                :ARG0~e.23 (o / or~e.27
                                                      :op1 (e6 / enzyme
                                                            :name (n7 / name :op1 "N-Ras"~e.24,26))
                                                      :op2 (e2 / enzyme
                                                            :name (n2 / name :op1 "B-Raf"~e.28,30)))))))))
            :mod (i / in-this-respect~e.0,1,2,19))
      :snt2 (i2 / infer-01~e.32
            :ARG1 (p / possible~e.36
                  :polarity~e.37 "-"~e.37
                  :domain~e.38,46 (e7 / exclude-01~e.39
                        :ARG1 (d4 / disease
                              :name (n8 / name :op1 "cancer"~e.35)
                              :mod (e3 / enzyme
                                    :name (n3 / name :op1 "Ras"~e.34)))
                        :ARG2 (a3 / approach-02~e.42
                              :mod (t3 / this~e.41))
                        :ARG1-of (r2 / resemble-01
                              :ARG2 (e8 / exclude-01~e.39
                                    :ARG1~e.43 d4~e.44
                                    :ARG2 (a4 / approach-02~e.42
                                          :mod~e.47 (o2 / other~e.48))))))))

# ::tok All of these considerations lead us to be optimistic about future prospects of finally delivering the knockout punch .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2 1-1.1.2.r 2-1.1.1 3-1.1 4-1 5-1.2 6-1.3.r 7-1.3.1.r 8-1.3 9-1.3.2.r 10-1.3.2.2 11-1.3.2 12-1.3.2.1.r 13-1.3.2.1.2 14-1.3.2.1 17-1.3.2.1.1
# ::id pmid_2465_1010.240
# ::preferred 
(l / lead-03~e.4
      :ARG0 (c2 / consider-01~e.3
            :mod (t / this~e.2)
            :quant~e.1 (a / all~e.0))
      :ARG1 (w / we~e.5)
      :ARG2~e.6 (o / optimistic~e.8
            :domain~e.7 w
            :topic~e.9 (p / prospect~e.11
                  :mod~e.12 (d / deliver-01~e.14
                        :ARG1 (p2 / punch-01~e.17
                              :mod (k / knock-03))
                        :time (f2 / final~e.13))
                  :time (f / future~e.10))))

# ::tok Figure 1
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.1
# ::id pmid_2465_1010.241
# ::preferred 
(f / figure~e.0 :mod "1"~e.1)

# ::tok Simplified View of the Ras Pathway
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2 1-1 2-1.1.r 4-1.1.1.1 5-1.1
# ::id pmid_2465_1010.242
# ::preferred 
(v / view-02~e.1
      :ARG1~e.2 (p / pathway~e.5
            :name (n2 / name :op1 "Ras"~e.4))
      :ARG1-of (s / simplify-01~e.0))

# ::tok Ras proteins are converted from their GDP state to their GTP state by GEFs , in response to upstream signals ( <ce:cross-ref id="crosref0425" refid="bib6"> Bos et al. , 2007 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2.1.1 1-1.1 3-1 5-1.4.2 5-1.4.2.r 6-1.4.1.1.1 7-1.3 7-1.4 8-1.3.r 9-1.3.2 9-1.3.2.r 10-1.3.1.1.1 11-1.3 13-1.1.1.1 15-1.5.r 16-1.5 17-1.5.1.r 18-1.5.1.1 19-1.5.1 24-1.6.1.1.1.1.1 25-1.6.1.1 26-1.6.1.1.2.1 28-1.6.1.2.1
# ::id pmid_2465_1010.243
# ::preferred 
(c / convert-01~e.3
      :ARG0 (p2 / protein~e.1
            :name (n4 / name :op1 "GEF"~e.13))
      :ARG1 (e / enzyme
            :name (n / name :op1 "Ras"~e.0))
      :ARG2~e.8 (s4 / state~e.7,11
            :mod (s2 / small-molecule
                  :name (n3 / name :op1 "GTP"~e.10))
            :mod~e.9 e~e.9)
      :ARG3 (s3 / state~e.7
            :mod (s / small-molecule
                  :name (n2 / name :op1 "GDP"~e.6))
            :poss~e.5 e~e.5)
      :ARG2-of~e.15 (r / respond-01~e.16
            :ARG1~e.17 (s5 / signal-07~e.19
                  :direction (u / upstream~e.18)))
      :ARG1-of (d2 / describe-01
            :ARG0 (p / publication-91
                  :ARG0 (a / and~e.25
                        :op1 (p3 / person
                              :name (n5 / name :op1 "Bos"~e.24))
                        :op2 (p4 / person
                              :mod (o / other~e.26)))
                  :time (d / date-entity :year "2007"~e.28))))

# ::tok GAPs convert Ras @-@ GTP back to Ras @-@ GDP .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 1-1 2-1.2.1.1.1 4-1.2.2.1.1 5-1.4 6-1.3.r 7-1.3.1 9-1.3.2.1.1
# ::id pmid_2465_1010.244
# ::preferred 
(c / convert-01~e.1
      :ARG0 (p / protein
            :name (n / name :op1 "GAP"~e.0))
      :ARG1 (m / macro-molecular-complex
            :part (e / enzyme
                  :name (n2 / name :op1 "Ras"~e.2))
            :part (s / small-molecule
                  :name (n3 / name :op1 "GTP"~e.4)))
      :ARG3~e.6 (m2 / macro-molecular-complex
            :part e~e.7
            :part (s2 / small-molecule
                  :name (n4 / name :op1 "GDP"~e.9)))
      :direction (b / back~e.5))

# ::tok p120 GAP does this when recruited to activated RTKs .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 1-1.1.1.2 2-1 3-1.2 4-1.3.r 5-1.3 7-1.3.2.2
# ::id pmid_2465_1010.245
# ::preferred 
(d / do-02~e.2
      :ARG0 (p / protein
            :name (n / name :op1 "p120"~e.0 :op2 "GAP"~e.1))
      :ARG1 (t / this~e.3)
      :time~e.4 (r / recruit-01~e.5
            :ARG1 p
            :ARG2 (k / kinase
                  :name (n2 / name :op1 "RTK")
                  :ARG1-of (a / activate-01~e.7))))

# ::tok The signal that directs NF1 ( neurofibromin )/SPRED to inactivate Ras is not known .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.2 3-1.2.1 6-1.2.1.1.1.1.1 9-1.2.1.2.1 10-1.2.1.2.3.1.1 12-1.1 12-1.1.r 12-1.2.1.2.1 12-1.2.1.2.1.r 13-1
# ::id pmid_2465_1010.246
# ::preferred 
(k / know-01~e.13
      :polarity~e.12 "-"~e.12
      :ARG1 (s / signal-07~e.1
            :ARG0-of (d / direct-01~e.3
                  :ARG1 (s2 / slash
                        :op1 (p / protein
                              :name (n2 / name :op1 "neurofibromin"~e.6))
                        :op2 (p2 / protein
                              :name (n3 / name :op1 "SPRED")))
                  :ARG2 (a / activate-01
                        :polarity~e.12 "-"~e.9,12
                        :ARG0 s2
                        :ARG1 (e / enzyme
                              :name (n / name :op1 "Ras"~e.10))))))

# ::tok Several other GAPs are capable of downregulating Ras ( <ce:cross-ref id="crosref0430" refid="bib6"> Bos et al. , 2007 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2 1-1.1.3 2-1.1.1.1 4-1 7-1.2.1.1.1 12-1.3.1.1.1.1.1 13-1.3.1.1 14-1.1.3 16-1.3.1.2.1
# ::id pmid_2465_1010.247
# ::preferred 
(c / capable-01~e.4
      :ARG1 (p / protein
            :name (n2 / name :op1 "GAP"~e.2)
            :quant (s / several~e.0)
            :mod (o / other~e.1,14))
      :ARG2 (d2 / downregulate-01
            :ARG1 (e / enzyme
                  :name (n / name :op1 "Ras"~e.7))
            :ARG2 p)
      :ARG1-of (d3 / describe-01
            :ARG0 (p2 / publication-91
                  :ARG0 (a / and~e.13
                        :op1 (p3 / person
                              :name (n3 / name :op1 "Bos"~e.12))
                        :op2 (p4 / person
                              :mod o))
                  :time (d / date-entity :year "2007"~e.16))))

# ::tok Ras @-@ GTP binds and activates multiple downstream effectors .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1.1.1 2-1.1.1.2.1.1 3-1.1 4-1 5-1.2 6-1.1.2.2 7-1.1.2.1 8-1.1.2
# ::id pmid_2465_1010.248
# ::preferred 
(a / and~e.4
      :op1 (b / bind-01~e.3
            :ARG0 (m / macro-molecular-complex
                  :part (e / enzyme
                        :name (n / name :op1 "Ras"~e.0))
                  :part (s / small-molecule
                        :name (n2 / name :op1 "GTP"~e.2)))
            :ARG1 (e2 / effector~e.8
                  :mod (d / downstream~e.7)
                  :quant (m2 / multiple~e.6)))
      :op2 (a2 / activate-01~e.5
            :ARG0 m
            :ARG1 e))

# ::tok The group of proteins shown on the left includes potential effectors whose significance is less well understood relative to RalGDS , Raf kinases , and PI3Ks ( <ce:cross-ref id="crosref0435" refid="bib24"> Gysin et al. , 2011 </ce:cross-ref> ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1 2-1.1.1.r 3-1.1.1 4-1.1.2 5-1.1.2.1.r 7-1.1.2.1 8-1 8-1.1.3 9-1.1.3.1.1 10-1.1.3.1 14-1.1.3.1.2.1.1.1 15-1.1.3.1.2.1.1 16-1.1.3.1.2.1 18-1.1.3.1.2.1 18-1.1.3.1.2.1.1.2.r 19-1.1.3.1.2.1.1.2.1.1.1 21-1.1.3.1.2.1.1.2.2.1.1 22-1.1.3.1.2.1.1.2.2 24-1.1.3.1.2.1.1.2 24-1.2.1.1 30-1.2.1.1.1.1.1 31-1.2.1.1 32-1.2.1.1.2.1 34-1.2.1.2.1
# ::id pmid_2465_1010.249
# ::preferred 
(i / include-01~e.8
      :ARG2 (g / group~e.1
            :consist-of~e.2 (p / protein~e.3)
            :ARG1-of (s / show-01~e.4
                  :location~e.5 (l / left~e.7))
            :ARG2-of (i2 / include-01~e.8
                  :ARG1 (e2 / effector~e.10
                        :mod (p2 / potential~e.9)
                        :ARG0-of (s2 / signify-01
                              :ARG1-of (u / understand-01~e.16,18
                                    :mod (w / well~e.15
                                          :degree (l2 / less~e.14)
                                          :compared-to~e.18 (a / and~e.24
                                                :op1 (p3 / protein
                                                      :name (n2 / name :op1 "RalGDS"~e.19))
                                                :op2 (k / kinase~e.22
                                                      :name (n3 / name :op1 "Raf"~e.21))
                                                :op3 (e / enzyme
                                                      :name (n / name :op1 "PI3K")))))))))
      :ARG1-of (d2 / describe-01
            :ARG0 (p4 / publication-91
                  :ARG0 (a2 / and~e.24,31
                        :op1 (p5 / person
                              :name (n4 / name :op1 "Gysin"~e.30))
                        :op2 (p6 / person
                              :mod (o / other~e.32)))
                  :time (d / date-entity :year "2011"~e.34))))

# ::tok Protein families are represented as single proteins to simplify the schematic ; in addition , feedback loops are not included .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.2.1 1-1.1.2 3-1.1 4-1.1.1.r 5-1.1.1.1 6-1.1.1 8-1.1.3 10-1.1.3.2 12-1.2 13-1.2 15-1.2.1.2.1 16-1.2.1.2 18-1.2.1.1 18-1.2.1.1.r 19-1.2.1
# ::id pmid_2465_1010.250
# ::preferred 
(m / multi-sentence
      :snt1 (r / represent-01~e.3
            :ARG0~e.4 (p / protein~e.6
                  :mod (s / single~e.5))
            :ARG1 (f / family~e.1
                  :consist-of (p2 / protein~e.0))
            :purpose (s2 / simplify-01~e.8
                  :ARG0 r
                  :ARG1 (s3 / schematic~e.10)))
      :snt2 (a / and~e.12,13
            :op2 (i / include-01~e.19
                  :polarity~e.18 "-"~e.18
                  :ARG1 (l / loop-01~e.16
                        :mod (f2 / feedback~e.15)))))

# ::tok Figure 2
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.1
# ::id pmid_2465_1010.251
# ::preferred 
(f / figure~e.0 :mod "2"~e.1)

# ::tok Structure Showing Small Molecule @-@ Directed Electrophilic Attack of K @-@ Ras @-@ G12C
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 1-1 2-1.2.3.1 3-1.2.3.1 5-1.2.3 7-1.2 8-1.2.1.r 9-1.2.1.1.1 11-1.2.1.1.1 13-1.2.1.2.1
# ::id pmid_2465_1010.252
# ::preferred 
(s / show-01~e.1
      :ARG0 (s2 / structure-01~e.0)
      :ARG1 (a / attack-01~e.7
            :ARG1~e.8 (e2 / enzyme
                  :name (n / name :op1 "K-Ras"~e.9,11)
                  :ARG1-of (m / mutate-01 :value "G12C"~e.13))
            :mod (e / electrophile)
            :ARG1-of (d / direct-01~e.5
                  :ARG0 (s3 / small-molecule~e.2,3))))

# ::tok K @-@ Ras @-@ G12C ( Protein Data Bank <ce:inter-ref> 4LUC_A </ce:inter-ref> ) is displayed in surface representation .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1.1 2-1.1.1.1 4-1.1.2.1 6-1.1.3.2 7-1.1.3 8-1.1.3 10-1.1.3.1.1 14-1 15-1.2.r 16-1.2.1 17-1.2
# ::id pmid_2465_1010.253
# ::preferred 
(d / display-01~e.14
      :ARG1 (e / enzyme
            :name (n / name :op1 "K-Ras"~e.0,2)
            :ARG1-of (m / mutate-01 :value "G12C"~e.4)
            :part-of (d2 / data-bank~e.7,8
                  :name (n2 / name :op1 "4LUC_A"~e.10)
                  :mod (p / protein~e.6)))
      :ARG2~e.15 (r / represent-01~e.17
            :mod (s / surface~e.16)))

# ::tok The cocrystallized ligands , GDP and N-( 1-[( 2,4 @-@ dichlorophenoxy ) acetyl]piperidin @- 4 @-@ yl )-4 @-@ sulfanylbutanamide , are shown in stick mode .
# ::amr-annotator SDL-AMR-09
# ::alignments 2-1.1 2-1.1.2.1.1 2-1.1.2.1.2 4-1.1.2.1.1.1.1 5-1.1.2.1 14-1.1.2.1.2.1.2 19-1.1.2.1.2.1.2 22-1 23-1.2.r 24-1.2.1 25-1.2
# ::id pmid_2465_1010.254
# ::preferred 
(s2 / show-01~e.22
      :ARG1 (l / ligand~e.2
            :ARG1-of (c / co-crystallize-00)
            :ARG1-of (m / mean-01
                  :ARG2 (a / and~e.5
                        :op1 (l2 / ligand~e.2
                              :name (n2 / name :op1 "GDP"~e.4))
                        :op1 (l3 / ligand~e.2
                              :name (n3 / name :op1 "N-(1-[(2,4-dichlorophenoxy)acetyl]piperidin-" :op2 "4-yl)-4-sulfanylbutanamide"~e.14,19)))))
      :manner~e.23 (m2 / mode~e.25
            :mod (s / stick~e.24)))

# ::tok The location of calcium ion is shown as a green ball .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1 2-1.1.1.r 3-1.1.1.1 4-1.1.1 6-1 7-1.2.r 9-1.2.1 10-1.2
# ::id pmid_2465_1010.255
# ::preferred 
(s / show-01~e.6
      :ARG1 (l / location~e.1
            :location-of~e.2 (i / ion~e.4
                  :mod (c / calcium~e.3)))
      :manner~e.7 (b / ball~e.10
            :mod (g / green~e.9)))

# ::tok Switch 1 ( 28–38 ) and switch 2 ( 57–63 ) are highlighted by orange and red colors , respectively .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1.1.1.1 5-1 6-1.1.1 6-1.2.1 7-1.2.1.1.1 12-1.1 12-1.2 13-1.1.2.r 14-1.1.2 15-1 16-1.2.2
# ::id pmid_2465_1010.256
# ::preferred 
(a2 / and~e.5,15
      :op1 (h / highlight-01~e.12
            :ARG1 (s / switch~e.0,6
                  :ord (o / ordinal-entity :value "1"~e.1)
                  :mod (v / value-interval :op1 "28" :op2 "38"))
            :manner~e.13 (o2 / orange~e.14))
      :op2 (h2 / highlight-01~e.12
            :ARG1 (s2 / switch~e.6
                  :ord (o3 / ordinal-entity :value "2"~e.7)
                  :mod (v2 / value-interval :op1 "57" :op2 "63"))
            :manner (r / red~e.16)))

# ::tok Key ligand @-@ interacting residue ( C12 , V9 , V7 , F78 , I100 , M72 , Q99 , and R68 ) positions are colored green .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.10 1-1.1.9.1 3-1.1.9 4-1.1.1.1.1 4-1.1.2.1.1 4-1.1.3.1.1 4-1.1.4.1.1 4-1.1.5.1.1 4-1.1.6.1.1 4-1.1.7.1.1 4-1.1.8.1.1 20-1.1 23-1.1.1 23-1.1.2 23-1.1.3 23-1.1.4 23-1.1.5 23-1.1.6 23-1.1.7 23-1.1.8 24-1.1.1.1 24-1.1.2.1 24-1.1.3.1 24-1.1.4.1 24-1.1.5.1 24-1.1.6.1 24-1.1.7.1 24-1.1.8.1 25-1 26-1.2
# ::id pmid_2465_1010.257
# ::preferred 
(c / color-01~e.25
      :ARG1 (a / and~e.20
            :op1 (p / position~e.23
                  :ARG2-of (b / be-located-at-91~e.24
                        :ARG1 (r / residue~e.4
                              :mod (a2 / amino-acid
                                    :mod "12"
                                    :name (n / name :op1 "cysteine")))))
            :op2 (p2 / position~e.23
                  :ARG2-of (b2 / be-located-at-91~e.24
                        :ARG1 (r2 / residue~e.4
                              :mod (a3 / amino-acid
                                    :mod "9"
                                    :name (n2 / name :op1 "valine")))))
            :op3 (p3 / position~e.23
                  :ARG2-of (b3 / be-located-at-91~e.24
                        :ARG1 (r3 / residue~e.4
                              :mod (a4 / amino-acid
                                    :mod "7"
                                    :name (n3 / name :op1 "valine")))))
            :op4 (p4 / position~e.23
                  :ARG2-of (b4 / be-located-at-91~e.24
                        :ARG1 (r4 / residue~e.4
                              :mod "78"
                              :mod (a5 / amino-acid
                                    :name (n4 / name :op1 "phenylalanine")))))
            :op5 (p5 / position~e.23
                  :ARG2-of (b5 / be-located-at-91~e.24
                        :ARG1 (r5 / residue~e.4
                              :mod "100"
                              :mod (a6 / amino-acid
                                    :name (n5 / name :op1 "isoleucine")))))
            :op6 (p6 / position~e.23
                  :ARG2-of (b6 / be-located-at-91~e.24
                        :ARG1 (r6 / residue~e.4
                              :mod "72"
                              :mod (a7 / amino-acid
                                    :name (n6 / name :op1 "methionine")))))
            :op7 (p7 / position~e.23
                  :ARG2-of (b7 / be-located-at-91~e.24
                        :ARG1 (r7 / residue~e.4
                              :mod "99"
                              :mod (a8 / amino-acid
                                    :name (n7 / name :op1 "glutamine")))))
            :op8 (p8 / position~e.23
                  :ARG2-of (b8 / be-located-at-91~e.24
                        :ARG1 (r8 / residue~e.4
                              :mod "68"
                              :mod (a9 / amino-acid
                                    :name (n8 / name :op1 "arginine")))))
            :ARG0-of (i / interact-01~e.3
                  :ARG1 (l / ligand~e.1))
            :mod (k / key~e.0))
      :ARG2 (g / green~e.26))

# ::tok Position of C12 residue is shown in ball and stick ( green ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1 3-1.1.1 5-1 6-1.2.r 7-1.2.1 8-1.2 9-1.2.2 11-1.2.3.1
# ::id pmid_2465_1010.258
# ::preferred 
(s / show-01~e.5
      :ARG1 (p / position-01~e.0
            :ARG1 (r / residue~e.3
                  :mod (a / amino-acid
                        :mod "12"
                        :name (n / name :op1 "cysteine"))))
      :manner~e.6 (a2 / and~e.8
            :op1 (b / ball~e.7)
            :op2 (s2 / stick~e.9)
            :ARG1-of (r2 / represent-01
                  :ARG0 (g / green~e.11))))

# ::tok Note that residues 58 and 60 are part of both switch 2 and the key ligand @-@ interacting group ( shown in blue ) .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.1.r 2-1.1.1 2-1.1.2 3-1.1.1.1.1 4-1.1 4-1.1.3 5-1.1.2.1.1 7-1.1.3.r 10-1.1.3.1 11-1.1.3.1.1 12-1.1.3 14-1.1.3.2.2 15-1.1.3.2.1.1 17-1.1.3.2.1 18-1.1.3.2 20-1.2 21-1.2.1.r 22-1.2.1
# ::id pmid_2465_1010.259
# ::preferred 
(n / note-01~e.0
      :ARG1~e.1 (a / and~e.4
            :op1 (r / residue~e.2
                  :mod (a2 / amino-acid :mod "58"~e.3))
            :op2 (r2 / residue~e.2
                  :mod (a3 / amino-acid :mod "60"~e.5))
            :part-of~e.7 (a4 / and~e.4,12
                  :op1 (s / switch~e.10 :mod "2"~e.11)
                  :op2 (g / group~e.18
                        :ARG0-of (i / interact-01~e.17
                              :ARG1 (l / ligand~e.15))
                        :mod (k / key~e.14))))
      :ARG1-of (s2 / show-01~e.20
            :manner~e.21 (b / blue~e.22)))

# ::tok Figure 3
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1 1-1.1
# ::id pmid_2465_1010.260
# ::preferred 
(f / figure~e.0 :mod "3"~e.1)

# ::tok Schematic Representation of the Ras Isoforms
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.2 1-1 4-1.1.1.1
# ::id pmid_2465_1010.261
# ::preferred 
(r / representation-02~e.1
      :ARG1 (i / isoform
            :name (n2 / name :op1 "Ras"~e.4))
      :ARG2 (s / schematic~e.0))

# ::tok The structures of the G domain of H @-@ Ras , N @-@ Ras , and K @-@ Ras have been solved and are virtually identical , but the structure of processed hypervariable regions has not been solved and is therefore depicted as a linear sequence .
# ::amr-annotator SDL-AMR-09
# ::alignments 1-1.1.1.1 4-1.1.1.1.1.1.1 4-1.1.1.2.1.1.1 4-1.1.1.3.1.1.1 5-1.1.1.1.1.1.2 5-1.1.1.2.1.1.2 5-1.1.1.3.1.1.2 6-1.1.1.1.1.r 7-1.1.1.1.1.2.1.1 9-1.1.1.1.1.2.1.1 9-1.1.1.2.1.2.1.1 9-1.1.1.3.1.2.1.1 11-1.1.1.2.1.2.1.1 13-1.1.1.1.1.2.1.1 13-1.1.1.2.1.2.1.1 13-1.1.1.3.1.2.1.1 15-1.1.1 16-1.1.1.3.1.2.1.1 18-1.1.1.1.1.2.1.1 18-1.1.1.2.1.2.1.1 18-1.1.1.3.1.2.1.1 21-1.1 22-1 24-1.2.2 25-1.2 27-1.3 29-1.1.1.2 29-1.1.1.3 29-1.3.1.1.2 30-1.3.1.1.2.1.r 30-1.3.1.r 31-1.3.1.1.2.1.2 33-1.3.1.1.2.1 35-1.3.1.1.1 35-1.3.1.1.1.r 37-1.3.1.1 38-1.3.1 41-1.3.1.2 42-1.3.1.2.2.r 44-1.3.1.2.2.1 45-1.3.1.2.2
# ::id pmid_2465_1010.262
# ::preferred 
(a / and~e.22
      :op1 (s / solve-01~e.21
            :ARG1 (a2 / and~e.15
                  :op1 (s2 / structure-01~e.1
                        :ARG1~e.6 (p / protein-segment
                              :name (n3 / name :op1 "G"~e.4 :op2 "domain"~e.5)
                              :part-of (e / enzyme
                                    :name (n / name :op1 "H-Ras"~e.7,9,13,18))))
                  :op2 (s3 / structure-01~e.29
                        :ARG1 (p2 / protein-segment
                              :name (n4 / name :op1 "G"~e.4 :op2 "domain"~e.5)
                              :part-of (e3 / enzyme
                                    :name (n5 / name :op1 "N-Ras"~e.9,11,13,18))))
                  :op3 (s4 / structure-01~e.29
                        :ARG1 (p3 / protein-segment
                              :name (n6 / name :op1 "G"~e.4 :op2 "domain"~e.5)
                              :part-of (e2 / enzyme
                                    :name (n2 / name :op1 "K-Ras"~e.9,13,16,18))))))
      :op2 (i / identical-01~e.25
            :ARG1 a2
            :mod (v / virtual~e.24))
      :ARG1-of (c / contrast-01~e.27
            :ARG2~e.30 (a3 / and~e.38
                  :op1 (s5 / solve-01~e.37
                        :polarity~e.35 "-"~e.35
                        :ARG1 (s6 / structure-01~e.29
                              :ARG1~e.30 (r / region~e.33
                                    :ARG1-of (v2 / vary-01
                                          :degree (h / hyper))
                                    :ARG1-of (p4 / process-01~e.31))))
                  :op2 (d / depict-01~e.41
                        :ARG1 s6
                        :ARG2~e.42 (s7 / sequence~e.45
                              :mod (l / linear~e.44))))))

# ::tok Lipid modifications with farnesyl ( purple ) and palmitoyl ( orange ) chains are shown .
# ::amr-annotator SDL-AMR-09
# ::alignments 0-1.1.1 1-1.1 2-1.1.2.r 3-1.1.2.1.1.1.1 5-1.1.2.1.1.2.1 7-1.1.2 8-1.1.2.2.1.1.1 10-1.1.2.2.1.2.1 12-1.1.2.1 12-1.1.2.2 14-1
# ::id pmid_2465_1010.263
# ::preferred 
(s / show-01~e.14
      :ARG1 (m / modify-01~e.1
            :ARG1 (l / lipid~e.0)
            :instrument~e.2 (a / and~e.7
                  :op1 (c / chain~e.12
                        :mod (r / radical
                              :name (n / name :op1 "farnesyl"~e.3)
                              :ARG1-of (r2 / represent-01
                                    :ARG0 (p / purple~e.5))))
                  :op2 (c2 / chain~e.12
                        :mod (r3 / radical
                              :name (n2 / name :op1 "palmitoyl"~e.8)
                              :ARG1-of (r4 / represent-01
                                    :ARG0 (o / orange~e.10)))))))

